PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ARRIAGADA, R; RUTQVIST, LE				ARRIAGADA, R; RUTQVIST, LE			ADJUVANT CHEMOTHERAPY IN EARLY BREAST-CANCER AND INCIDENCE OF NEW PRIMARY MALIGNANCIES	LANCET			English	Article							RADIOTHERAPY; LEUKEMIA; TAMOXIFEN; CARCINOMA; RADIATION; THERAPY; TRIAL	Adjuvant chemotherapy is increasingly being given to patients with early breast cancer. Long-term follow-up studies suggest a higher frequency of secondary tumours, especially leukaemias, among women receiving such cytotoxic drugs. We studied the frequency of new primary malignancies in 1113 patients with early breast cancer who had been included in a randomised trial to compare chemotherapy as an adjunct to primary surgery with adjuvant locoregional radiotherapy. The estimated rate of new primary malignancies at ten years was significantly lower (p < 0.0003) in the chemotherapy group (1%) than in the radiotherapy group (6%). The corresponding rate among 1986 patients treated with surgery alone was 5%. Our findings suggest that adjuvant chemotherapy in early breast cancer may protect against the development of new primary tumours in the first ten years of follow-up.	KAROLINSKA HOSP,RADIUMHEMMET,CTR ONCOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital	ARRIAGADA, R (corresponding author), INST GUSTAVE ROUSSY,RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							ALPER JC, 1985, J AM ACAD DERMATOL, V13, P567, DOI 10.1016/S0190-9622(85)70198-3; BOIVIN JF, 1986, AM J EPIDEMIOL, V123, P993, DOI 10.1093/oxfordjournals.aje.a114351; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FISHER B, 1985, J CLIN ONCOL, V3, P1640, DOI 10.1200/JCO.1985.3.12.1640; FORNANDER T, 1989, LANCET, V1, P117; GELLER RB, 1989, CANCER, V64, P629, DOI 10.1002/1097-0142(19890801)64:3<629::AID-CNCR2820640311>3.0.CO;2-L; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HERRING M, AM J CLIN ONCOL-CANC, V9, P269; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HORN PL, 1988, YALE J BIOL MED, V1, P223; KALDOR J, 1990, ACTA ONCOL, V29, P647, DOI 10.3109/02841869009090070; KRAMAR A, 1987, STAT MED, V6, P785, DOI 10.1002/sim.4780060709; LAVEY RS, 1990, CANCER, V66, P874, DOI 10.1002/1097-0142(19900901)66:5<874::AID-CNCR2820660511>3.0.CO;2-6; MATTSON B, 1984, THESIS U STOCKHOLM S, P7; MEYSKENS FL, 1990, NEW ENGL J MED, V323, P825, DOI 10.1056/NEJM199009203231210; ROSNER F, 1978, AM J HEMATOL, V4, P151, DOI 10.1002/ajh.2830040207; RUTQVIST LE, 1987, BREAST CANCER RES TR, V10, P255, DOI 10.1007/BF01805762; RUTQVIST LE, 1989, INT J RADIAT ONCOL, V16, P629, DOI 10.1016/0360-3016(89)90478-1; TUBIANA M, 1988, INNOVATIONS RAD ONCO, P265; VALAGUSSA P, 1987, J CLIN ONCOL, V5, P1138, DOI 10.1200/JCO.1987.5.8.1138	22	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					535	538		10.1016/0140-6736(91)91100-9	http://dx.doi.org/10.1016/0140-6736(91)91100-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678800				2022-12-28	WOS:A1991GD00200004
J	HOEKMAN, K; VONBLOMBERGVANDERFLIER, BME; WAGSTAFF, J; DREXHAGE, HA; PINEDO, HM				HOEKMAN, K; VONBLOMBERGVANDERFLIER, BME; WAGSTAFF, J; DREXHAGE, HA; PINEDO, HM			REVERSIBLE THYROID-DYSFUNCTION DURING TREATMENT WITH GM-CSF	LANCET			English	Note							COLONY-STIMULATING FACTOR; ANTIGEN EXPRESSION; DENDRITIC CELLS; INDUCTION; INTERFERON; INVITRO; THERAPY	To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250-mu-g/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.	FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,DE BOELELAAN 1117,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,AMSTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam								ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; KUNG AWC, 1990, J CLIN ENDOCR METAB, V71, P1230, DOI 10.1210/jcem-71-5-1230; LIESCHKE GJ, 1989, ANN INTERN MED, V110, P357, DOI 10.7326/0003-4819-110-5-357; MARKOWICZ S, 1990, J CLIN INVEST, V85, P955, DOI 10.1172/JCI114525; MARTIN A, 1990, ENDOCRINOLOGY, V127, P651, DOI 10.1210/endo-127-2-651; SMITH PD, 1990, J IMMUNOL, V144, P3829; VOORBY HAM, 1990, CLIN IMMUNOL IMMUNOP, V55, P9, DOI 10.1016/0090-1229(90)90065-X; WEETMAN AP, 1985, J CLIN ENDOCR METAB, V61, P817, DOI 10.1210/jcem-61-5-817	10	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					541	542		10.1016/0140-6736(91)91103-2	http://dx.doi.org/10.1016/0140-6736(91)91103-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678803	Green Submitted			2022-12-28	WOS:A1991GD00200007
J	DAVIES, NJ; FARQUHARSON, RG; WALKINSHAW, SA				DAVIES, NJ; FARQUHARSON, RG; WALKINSHAW, SA			LOW-DOSE ASPIRIN AND NULLIPARAE	LANCET			English	Letter							PREGNANCY				DAVIES, NJ (corresponding author), LIVERPOOL MATERN HOSP,LIVERPOOL L7 7BN,ENGLAND.							DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; MURPHY JF, 1986, LANCET, V1, P992; TURNER MJ, 1990, OBSTET GYNECOL, V76, P159; UZAN, 1991, LANCET, V337, P1427	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					324	324		10.1016/0140-6736(91)90471-Z	http://dx.doi.org/10.1016/0140-6736(91)90471-Z			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677150				2022-12-28	WOS:A1991FZ56500058
J	EDWARDS, RG; MORCOS, S; MACNAMEE, M; BALMACEDA, JP; WALTERS, DE; ASCH, R				EDWARDS, RG; MORCOS, S; MACNAMEE, M; BALMACEDA, JP; WALTERS, DE; ASCH, R			HIGH FECUNDITY OF AMENORRHEIC WOMEN IN EMBRYO-TRANSFER PROGRAMS	LANCET			English	Article							OOCYTE DONATION; INVITRO FERTILIZATION; OVARIAN FAILURE; CYCLES	There is uncertainty over whether the steady decline in human fertility with increasing maternal age is due to quality of the oocyte or of the endometrium. To clarify the issue age-related implantation and pregnancy rates in two embryo-transfer programmes were examined in relation to embryo quality and type of menstrual cycle. In both the UK and the US programmes rates were higher in previously amenorrhoeic (acyclic) women than in eugonadal women, irrespective of age and number of embryos replaced. Oocyte quality, as determined by age of oocyte donor, in-vitro growth of embryo, and proportion of defective embryos in culture, did not contribute to the difference, nor did type of cycle during therapy. If a uterus that has not been subjected to regular menstrual cycles is a favourable factor, a period of induced amenorrhoea might be beneficial for infertile women.	UNIV CAMBRIDGE CHURCHILL COLL,CAMBRIDGE CB3 0DS,ENGLAND; UNIV CALIF IRVINE,DEPT OBSTET & GYNAECOL,DIV REPROD ENDOCRINOL,IRVINE,CA 92717	University of Cambridge; University of California System; University of California Irvine								ABDALLA HI, 1990, HUM REPROD, V5, P1018, DOI 10.1093/oxfordjournals.humrep.a137209; ASCH RH, 1988, FERTIL STERIL, V49, P263; EDWARDS R G, 1984, Journal of In Vitro Fertilization and Embryo Transfer, V1, P3, DOI 10.1007/BF01129615; ELLIS SA, 1990, J IMMUNOL, V144, P731; GERLI S, 1989, HUM REPROD, V4, P746, DOI 10.1093/oxfordjournals.humrep.a136977; GOSDEN RG, 1988, BIOL MENOPAUSE; HENDERSON SA, 1968, NATURE, V218, P22, DOI 10.1038/218022a0; HOWLES CM, 1987, HUM REPROD, V2, P17, DOI 10.1093/oxfordjournals.humrep.a136482; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; LASALLE B, 1985, FERTIL STERIL, V44, P645; LUTJEN P, 1984, NATURE, V307, P174, DOI 10.1038/307174a0; PLACHOT M, 1990, BRIT MED BULL, V46, P675, DOI 10.1093/oxfordjournals.bmb.a072424; PLACKETT RL, 1983, ANAL CATEGORICAL DAT; POLANI PE, IN PRESS HUM GENET; SATHANANDAN C, IN PRESS HUM REPROD; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; SERHAL P, 1990, BRIT MED BULL, V46, P796, DOI 10.1093/oxfordjournals.bmb.a072432; SERHAL PF, 1989, LANCET, V1, P1185	18	85	88	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					292	294						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677120				2022-12-28	WOS:A1991FZ56500013
J	MOLFINO, NA; WRIGHT, SC; KATZ, I; TARLO, S; SILVERMAN, F; MCCLEAN, PA; SZALAI, JP; RAIZENNE, M; SLUTSKY, AS; ZAMEL, N				MOLFINO, NA; WRIGHT, SC; KATZ, I; TARLO, S; SILVERMAN, F; MCCLEAN, PA; SZALAI, JP; RAIZENNE, M; SLUTSKY, AS; ZAMEL, N			EFFECT OF LOW CONCENTRATIONS OF OZONE ON INHALED ALLERGEN RESPONSES IN ASTHMATIC SUBJECTS	LANCET			English	Article							BRONCHIAL REACTIVITY; PULMONARY-FUNCTION; AIRWAY RESPONSIVENESS; EXPOSURE; HUMANS; INFLAMMATION; ADAPTATION; INHALATION; POLLUTION; HISTAMINE	The relation between inhalation of ambient concentrations of ozone and airway reactivity to inhaled allergens may be important in asthma, since both agents can produce inflammatory changes in the airways. Seven asthmatic patients (mean age 40 [SD 13] years), with seasonal symptoms of asthma and positive skin tests for ragweed or grass, took part in a study to investigate whether exposure to low concentrations of ozone potentiates the airway allergic response. The patients were studied during 4 separate weeks in the winter. In each week there were 3 study days: on days 1 and 3 methacholine challenges were carried out; and on day 2 the subject received one of four combined challenges in a single-blind design - air breathing followed by inhalation of allergen diluent (placebo); ozone followed by inhalation of allergen diluent air followed by allergen; or ozone followed by allergen. The ozone concentration was 0.12 ppm during 1 h of tidal breathing at rest, and allergens were inhaled until the forced expiratory volume in 1 s (FEV1) had fallen by 15% (PC15). There were no significant differences in baseline FEV, after exposure to ozone but PC15 was significantly reduced when allergen was preceded by ozone inhalation: the mean PC15 after air was 0.013 (SD 0.017) mg/ml compared with 0.0056 (0.0062) mg/ml after ozone (p = 0.042). Thus, low ozone concentrations, similar to those commonly occurring in urban areas, can increase the bronchial responsiveness to allergen in atopic asthmatic subjects. This effect does not seem to be the result of changes in baseline airway function.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO M5S 1A1,ONTARIO,CANADA; HLTH & WELF CANADA,OTTAWA K1A 0L2,ONTARIO,CANADA	University of Toronto; University of Toronto			Slutsky, Arthur/M-3325-2019; Slutsky, Arthur S/A-6013-2008	Slutsky, Arthur S/0000-0002-6063-3876; Tarlo, Susan/0000-0002-4746-5310				BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BATES DV, 1989, ENVIRON HEALTH PERSP, V79, P69, DOI 10.2307/3430531; BEL EH, 1990, J ALLERGY CLIN IMMUN, V85, P1067, DOI 10.1016/0091-6749(90)90052-6; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; DIMEO MJ, 1981, AM REV RESPIR DIS, V124, P245; GERSHWIN LJ, 1981, INT ARCH ALLER A IMM, V65, P266, DOI 10.1159/000232766; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GOLDSMITH J R, 1969, Journal of the Air Pollution Control Association, V19, P329; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; KERL HR, 1987, AM REV RESPIR DIS, V135, P1124; KOENIG JQ, 1985, AM REV RESPIR DIS, V132, P648; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; KULLE TJ, 1982, AM IND HYG ASSOC J, V43, P832, DOI 10.1202/0002-8894(1982)043<0832:DOPFAT>2.3.CO;2; LEVIN R, 1962, PUBLIC HLTH REP, V77, P947; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PHELPS HW, 1961, JAMA-J AM MED ASSOC, V175, P990, DOI 10.1001/jama.1961.03040110054012; PRIDE NB, 1979, BR J CLIN PHARM, V8, P109; SCHELEGLE ES, 1989, AM REV RESPIR DIS, V140, P211, DOI 10.1164/ajrccm/140.1.211; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SILVERMAN F, 1976, J APPL PHYSIOL, V41, P859, DOI 10.1152/jappl.1976.41.6.859; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; YANAI M, 1990, J APPL PHYSIOL, V68, P2267, DOI 10.1152/jappl.1990.68.6.2267; ZAMEL N, 1984, B EUR PHYSIOPATH RES, V20, P471; 1987, BR J DIS CHEST, V81, P30; 1980, ATS NEWS, V2, P11	30	329	333	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					199	203		10.1016/0140-6736(91)90346-Q	http://dx.doi.org/10.1016/0140-6736(91)90346-Q			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676776				2022-12-28	WOS:A1991FY50400001
J	DEGRAEFFMEEDER, ER; VANDERZEE, R; RIJKERS, GT; SCHUURMAN, HJ; KUIS, W; BIJLSMA, JWJ; ZEGERS, BJM; VANEDEN, W				DEGRAEFFMEEDER, ER; VANDERZEE, R; RIJKERS, GT; SCHUURMAN, HJ; KUIS, W; BIJLSMA, JWJ; ZEGERS, BJM; VANEDEN, W			RECOGNITION OF HUMAN 60 KD HEAT-SHOCK PROTEIN BY MONONUCLEAR-CELLS FROM PATIENTS WITH JUVENILE CHRONIC ARTHRITIS	LANCET			English	Article							65-KILODALTON MYCOBACTERIAL ANTIGEN; RHEUMATOID-ARTHRITIS; TUBERCULOSIS; REACTIVITY; PATHOGENESIS; LYMPHOCYTES; THERAPY; CLONES	A postulated mechanism for autoimmune disorders is that the immunoreactivity develops against bacterial antigens which show a high degree of sequence homology with mammalian proteins. The mycobacterial 65 kD heat shock protein (hsp) has been implicated in several forms of arthritis. Substantial amounts of the human 60 kD homologue (hsp60) were produced by insertion of the gene into Escherichia coli. To investigate the hypothesis that T-cell reactivity is directed against the endogenous hsp, T-cell proliferation of synovial-fluid and peripheral-blood mononuclear cells in response to hsp60 was studied in samples from six patients with juvenile chronic arthritis (JCA) and nine adult patients with rheumatoid arthritis (RA). There was no T-lymphocyte proliferative response to purified fractions of hsp60 in mononuclear cells from RA patients or healthy children and young adults. However, both synovial-fluid and peripheral-blood mononuclear cells from JCA patients showed significant correlation between the stimulation indices for human hsp60 and for mycobacterial hsp65 (r = 0.948, p < 0.02). A similar correlation for hsp60 and mycobacterial hsp70 did not achieve significance. Immunohistochemistry showed that hsp65 and hsp70 homologues were expressed in the synovial membrane in these patients but not in controls. These findings suggest a sequence of events in which hsps become expressed during synovial inflammation and function as autoantigens. In JCA this may be manifested by specific T-cell reactivity which apparently is lost in the more bone-eroding and non-remitting adult disease.	NATL INST PUBL HLTH & ENVIRONM PROTECT,BILTHOVEN,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT PATHOL,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT INTERNAL MED,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT HOSP,DEPT RHEUMATOL,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,FAC VET MED,INST INFECT DIS & IMMUNOL,UTRECHT,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University	DEGRAEFFMEEDER, ER (corresponding author), STATE UNIV UTRECHT,HET WILHELMINA KINDERZIEKENHUIS,DEPT IMMUNOL,POB 18009,3501 CA UTRECHT,NETHERLANDS.		Rijkers, Ger/AAW-6143-2020; van der Zee, Ruurd/O-5256-2015; Rijkers, Ger/R-7236-2019	van der Zee, Ruurd/0000-0002-4331-2755; Rijkers, Ger/0000-0001-6948-6123				ABRAHAMSEN TG, 1978, SCAND J IMMUNOL, V7, P81, DOI 10.1111/j.1365-3083.1978.tb00429.x; BAHR GM, 1988, CLIN EXP IMMUNOL, V74, P211; BILLINGHAM MEJ, 1990, J EXP MED, V171, P339, DOI 10.1084/jem.171.1.339; COHEN IR, 1986, IMMUNOL REV, V94, P5, DOI 10.1111/j.1600-065X.1986.tb01161.x; COHEN IR, 1985, ARTHRITIS RHEUM, V28, P841, DOI 10.1002/art.1780280802; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; DUDANI AK, 1989, INFECT IMMUN, V57, P2786, DOI 10.1128/IAI.57.9.2786-2793.1989; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831; GASTON JSH, 1989, J IMMUNOL, V143, P2492; HOLOSHITZ J, 1986, LANCET, V2, P305; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JONES DB, 1990, LANCET, P583; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; LYDYARD P, 1990, IMMUNOL TODAY, V2, P228; MEHLERT A, 1989, MOL MICROBIOL, V3, P125, DOI 10.1111/j.1365-2958.1989.tb01801.x; Munthe E, 1978, CARE RHEUMATIC CHILD, P47; OTTENHOFF THM, 1986, LANCET, V2, P310; PALACIOSBOIX AA, 1988, J IMMUNOL, V140, P1844; POPE RM, 1991, CELL IMMUNOL, V133, P95, DOI 10.1016/0008-8749(91)90182-B; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; RES PCM, 1990, LANCET, V336, P1406, DOI 10.1016/0140-6736(90)93104-W; STOKER NG, 1989, GENE, V78, P93, DOI 10.1016/0378-1119(89)90317-X; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; THOMPSON SJ, 1990, EUR J IMMUNOL, V20, P2479, DOI 10.1002/eji.1830201118; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VANDENBROEK MF, 1989, APMIS, V97, P861; VANEDEN W, 1990, IMMUNOL RES, V9, P157, DOI 10.1007/BF02918175; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VANEDENW, 1900, APMIS, V98, P383	30	173	180	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1368	1372		10.1016/0140-6736(91)93057-G	http://dx.doi.org/10.1016/0140-6736(91)93057-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674762				2022-12-28	WOS:A1991FP87000002
J	LITTLE, JM; AVRAMOVIC, J				LITTLE, JM; AVRAMOVIC, J			GALLSTONE FORMATION AFTER MAJOR ABDOMINAL-SURGERY	LANCET			English	Article							SLUDGE FORMATION; RISK-FACTORS; CHOLELITHIASIS; METABOLISM; COMPLICATION; VAGOTOMY; DISEASE	84 patients underwent multiple abdominal ultrasound examinations over a median of 36 months (range 6-140). 11 had gallstones at their first ultrasound examination, and were excluded from further analysis. Of the remaining 73 patients, 12 of 47 who underwent major abdominal surgery had gallstones within 14-36 months of operation, compared with 0 of 26 who did not undergo such surgery. The cumulative prevalence of new gallstones within 3 years of major surgery was 28%; no new gallstones were seen from 36 to up to 140 months postoperatively. By univariate and logistic regression analysis, age and major abdominal surgery were the only significant clinical determinants for the appearance of gallstones during follow-up. The findings of this retrospective study indicate that major abdominal surgery may accelerate the development of gallstones in some patients. If confirmed in a prospective study, it may be possible to define groups at high risk of gallstones after surgery and to institute prophylactic measures.	UNIV SYDNEY, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney	LITTLE, JM (corresponding author), WESTMEAD HOSP, DEPT SURG, WESTMEAD, NSW 2145, AUSTRALIA.							BENGMARK S, 1982, BILIARY TRACT, P270; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; COWIE AGA, 1972, BRIT J SURG, V59, P365, DOI 10.1002/bjs.1800590508; DEITEL M, 1987, SURG GYNECOL OBSTET, V164, P549; DOTY JE, 1985, ANN SURG, V201, P76, DOI 10.1097/00000658-198520110-00011; DUANE WC, 1976, J LIPID RES, V17, P211; GOSBINK BR, 1976, SEMIN RADIOL, V11, P185; HARRISON EC, 1978, AM HEART J, V95, P483, DOI 10.1016/0002-8703(78)90240-5; HAUTERS P, 1988, BRIT J SURG, V75, P899, DOI 10.1002/bjs.1800750923; HEATON KW, 1969, BMJ-BRIT MED J, V3, P494, DOI 10.1136/bmj.3.5669.494; IHASZ M, 1981, AM J SURG, V141, P48, DOI 10.1016/0002-9610(81)90010-6; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LINDSTROM CG, 1977, SCAND J GASTROENTERO, V12, P341, DOI 10.3109/00365527709180938; LORUSSO D, 1988, SURGERY, V103, P579; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MILLER MC, 1968, CAN MED ASSOC J, V98, P350; PITT HA, 1983, GASTROENTEROLOGY, V84, P1274; ROSLYN JJ, 1984, AM J SURG, V148, P58, DOI 10.1016/0002-9610(84)90289-7; SALEN G, 1975, GASTROENTEROLOGY, V69, P676; TOMPKINS RK, 1972, SURGERY, V71, P196	23	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1991	337	8750					1135	1137		10.1016/0140-6736(91)92796-5	http://dx.doi.org/10.1016/0140-6736(91)92796-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674022				2022-12-28	WOS:A1991FL12400013
J	LEE, KO; TAYLOR, EA; OH, VMS; CHEAH, JS; AW, SE				LEE, KO; TAYLOR, EA; OH, VMS; CHEAH, JS; AW, SE			HYPERINSULINEMIA IN THYROTOXIC HYPOKALEMIC PERIODIC PARALYSIS	LANCET			English	Note								To test the hypothesis that there is an abnormal serum insulin response to a carbohydrate load in thyrotoxic hypokalaemic periodic paralysis (THPP), 18 men with THPP and 15 with uncomplicated thyrotoxicosis were studied during an oral glucose tolerance test. The THPP group had significantly higher fasting insulin concentrations (27.6 [3.6] vs 13.4 [1.8] mU/l; p < 0.005) and a higher overall insulin response to oral glucose (p < 0.001 by ANOVA) than the thyrotoxicosis group. There were no significant differences in fasting or stimulated glucose. Hyperinsulinaemia may be an important factor in the precipitation of acute paralysis in THPP.	SINGAPORE GEN HOSP,DEPT CLIN RES,SINGAPORE,SINGAPORE	Singapore General Hospital	LEE, KO (corresponding author), NATL UNIV SINGAPORE,DEPT MED,KENT RIDGE,SINGAPORE 0511,SINGAPORE.		Lee, Kok-Onn/E-9874-2011; LIU, JIANG Jimmy/AHB-8921-2022	Lee, Kok-Onn/0000-0002-3040-1185; LIU, JIANG Jimmy/0000-0001-6281-6505				DOAR JWH, 1969, DIABETES, V18, P633, DOI 10.2337/diab.18.9.633; ERLIJ D, 1979, J PHYSL, V259, P13; HAY ID, 1975, BRIT MED J, V4, P761, DOI 10.1136/bmj.4.5999.761; LOOS U, 1986, 61ST P M AM THYR ASS, P24; MCFADZEAN AJ, 1967, BMJ-BRIT MED J, V1, P451, DOI 10.1136/bmj.1.5538.451; OH VMS, 1990, CLIN SCI, V78, P199, DOI 10.1042/cs0780199; SHISHIBA Y, 1972, METABOLISM, V21, P285, DOI 10.1016/0026-0495(72)90071-6; SWEADNER KJ, 1980, NEW ENGL J MED, V302, P777, DOI 10.1056/NEJM198004033021404; YEO PPB, 1988, PROGR ENDOCRINOLOGY, V2, P1341; YEUNG RTT, 1974, AM J MED, V57, P584, DOI 10.1016/0002-9343(74)90010-2	10	53	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1063	1064		10.1016/0140-6736(91)91710-C	http://dx.doi.org/10.1016/0140-6736(91)91710-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673496				2022-12-28	WOS:A1991FK20400007
J	COHEN, D; GREEN, M; BLOCK, C; SLEPON, R; AMBAR, R; WASSERMAN, SS; LEVINE, MM				COHEN, D; GREEN, M; BLOCK, C; SLEPON, R; AMBAR, R; WASSERMAN, SS; LEVINE, MM			REDUCTION OF TRANSMISSION OF SHIGELLOSIS BY CONTROL OF HOUSEFLIES (MUSCA-DOMESTICA)	LANCET			English	Article							ENTERIC PATHOGENS; EPIDEMIOLOGY; ANTIBODIES; FLIES	The effect of control of houseflies on the incidence of diarrhoea and shigellosis was evaluated in a prospective crossover intervention study at two military field bases several kilometres apart. In early summer, 1988, intensive fly control measures (mainly bait and trap strategy) were introduced on one base, while the other served as a control. After 11 weeks, as new cohorts arrived, the intervention was abruptly discontinued in the first base and instituted in the second for the next 11 weeks. The study was repeated the next summer. Overall, fly counts were 64% lower on the bases exposed to fly control measures (p = 0.024). Concomitantly, clinic visits dropped by 42% (p = 0.146) for diarrhoeal diseases and by 85% for shigellosis (p = 0.015), as did rates of seroconversion, by 76% (p = 0.024) for antibodies to Shigella and by 57% (p = 0.006) for antibodies to enterotoxigenic Escherichia coli. The findings indicate that houseflies, acting as mechanical vectors, transmit Shigella (and possibly enterotoxigenic E coli) diarrhoeal infections.	UNIV MARYLAND, SCH MED, DEPT MED, DIV GEOG MED, CTR VACCINE DEV, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	COHEN, D (corresponding author), ISRAEL DEF FORCES, MED CORPS, IL-02149 MIL POST, ISRAEL.			Green, Manfred S./0000-0002-9753-5612; Cohen, Daniel/0000-0003-2664-2303				BIDAWID SP, 1978, ANN TROP MED PARASIT, V72, P117, DOI 10.1080/00034983.1978.11719291; BLACK RE, 1978, AM J EPIDEMIOL, V108, P47; BOYD JSK, 1957, T R SOC TROP MED HYG, V51, P474; COHEN D, 1988, J INFECT DIS, V157, P1068, DOI 10.1093/infdis/157.5.1068; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; DUPONT HL, 1970, AM J EPIDEMIOL, V92, P172, DOI 10.1093/oxfordjournals.aje.a121195; ECHEVERRIA P, 1983, APPL ENVIRON MICROB, V46, P32, DOI 10.1128/AEM.46.1.32-36.1983; FLOYD T. M., 1953, Journal of the Egyptian Public Health Association, V28, P75; GEAR HS, 1944, BRIT MED J, V1, P4341; GREEN M, IN PRESS REV INFECT; GREEN MS, 1987, ISRAEL J MED SCI, V23, P811; Howard LO, 1900, P WASH ACAD SCI, V28, P541; HUTCHINSON R. IRENE, 1956, MONTH BULL MED RES COUNC [GT BRIT], V15, P110; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; KHAN M, 1980, T ROY SOC TROP MED H, V74, P528, DOI 10.1016/0035-9203(80)90071-1; Kuhns DM, 1944, AM J PUBLIC HEALTH N, V34, P750, DOI 10.2105/AJPH.34.7.750; Ledingham J. G., 1920, Journal of the Royal Army Medical Corps London, V34; LEVINE MM, 1985, J CLIN MICROBIOL, V21, P174, DOI 10.1128/JCM.21.2.174-179.1985; LEVINE O, IN PRESS REV INFECT; LINDSAY DR, 1953, PUBLIC HEALTH REP, V68, P361, DOI 10.2307/4588424; MANSONBAHR P, 1919, T R SOC TROP MED HYG, V13, P64; MARA DD, 1984, 13 TECHN ADV GROUP N; MATSUMURA F, 1975, TOXICOLOGY INSECTICI, P97; MER G. G., 1960, Rivista di Parassitologia, V21, P143; Morgan P R, 1977, Cent Afr J Med, V23, P1; PATTON WS, 1937, ANN TROP MED PARASIT, V27, P397; PEFFLY R. L., 1953, Journal of the Egyptian Public Health Association, V28, P55; PICKERING LK, 1986, REV INFECT DIS, V8, P539; RICHARDS CS, 1961, AM J TROP MED HYG, V10, P44, DOI 10.4269/ajtmh.1961.10.44; SCUDDER HI, 1947, PUBLIC HEALTH REP, V62, P681, DOI 10.2307/4586121; Simmons P, 1923, J ECON ENTOMOL, V16, P357, DOI 10.1093/jee/16.4.357; Sokal R. R, 1981, BIOMETRY; STEWART W., 1944, Journal of the Royal Army Medical Corps, V83, P42; WATT J, 1948, PUBLIC HEALTH REP, V63, P1319, DOI 10.2307/4586723	34	140	150	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1991	337	8748					993	997		10.1016/0140-6736(91)92657-N	http://dx.doi.org/10.1016/0140-6736(91)92657-N			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673210				2022-12-28	WOS:A1991FJ13500002
J	FORREST, BD				FORREST, BD			WOMEN, HIV, AND MUCOSAL IMMUNITY	LANCET			English	Editorial Material							HUMAN IMMUNODEFICIENCY VIRUS; SECRETIONS; INFECTION; SYSTEM; PROTECTION; ANTIBODIES; CELL				FORREST, BD (corresponding author), PUBL HLTH LAB SERV, CTR AIDS, CTR COMMUNICABLE DIS SURVEILLANCE, 61 COLINDALE AVE, LONDON NW9 5EQ, ENGLAND.							ALNOZHA M, 1990, J ACQ IMMUN DEF SYND, V3, P193; ARCHIBALD DW, 1987, J INFECT DIS, V156, P240, DOI 10.1093/infdis/156.1.240; BELEC L, 1989, J INFECT DIS, V160, P385, DOI 10.1093/infdis/160.3.385; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; DREW WL, 1990, SEX TRANSM DIS, V17, P110, DOI 10.1097/00007435-199004000-00014; FULTZ PN, 1986, J INFECT DIS, V154, P896, DOI 10.1093/infdis/154.5.896; HENRY JL, 1966, J HYG-CAMB, V64, P105, DOI 10.1017/S0022172400040389; HUSBAND AJ, 1984, AUST J EXP BIOL MED, V62, P687, DOI 10.1038/icb.1984.65; KUTTEH WH, 1988, OBSTET GYNECOL, V71, P56; MANOFF SB, 1989, PEDIATR INFECT DIS J, V8, P309; MERRIMAN H, 1984, J INFECT DIS, V149, P505, DOI 10.1093/infdis/149.4.505; MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; PARR MB, 1990, ADVANCES IN MUCOSAL IMMUNOLOGY, P608; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; SCHUMACHER GFB, 1988, HUM REPROD, V3, P289, DOI 10.1093/oxfordjournals.humrep.a136698; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; SUTJIPTO S, 1990, J VIROL, V64, P2290, DOI 10.1128/JVI.64.5.2290-2297.1990; WOLF JL, 1984, ANNU REV MED, V35, P95, DOI 10.1146/annurev.med.35.1.95; WOLFSY CB, 1986, LANCET, V1, P527	24	72	76	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1991	337	8745					835	836		10.1016/0140-6736(91)92527-9	http://dx.doi.org/10.1016/0140-6736(91)92527-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672924				2022-12-28	WOS:A1991FF22800015
J	HULBERT, MFG				HULBERT, MFG			EFFICACY OF EYEPAD IN CORNEAL HEALING AFTER CORNEAL FOREIGN-BODY REMOVAL	LANCET			English	Note								30 patients with corneal epithelial defect due to removal of corneal foreign bodies were randomly allocated to receive either chloramphenicol with continuous application of an eyepad or chloramphenicol without the eyepad. Almost all corneal defects were healed at 24 h, and all were healed by 48 h, with no statistically significant difference between the two groups. Discomfort at 24 h was greater in the eyepad group than in the control group. An eyepad seems to confer no benefit in healing and is uncomfortable.	ST JAMES UNIV HOSP,DEPT OPHTHALMOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital								ACHESON JF, 1987, BRIT J OPHTHALMOL, V71, P285, DOI 10.1136/bjo.71.4.285; JACKSON H, 1960, BRIT MED J, V2, P713, DOI 10.1136/bmj.2.5200.713; 1987, LANCET, V2, P1250	3	33	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					643	643		10.1016/0140-6736(91)92454-A	http://dx.doi.org/10.1016/0140-6736(91)92454-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671993				2022-12-28	WOS:A1991FB73000005
J	ROWLEY, G; FIELDING, K				ROWLEY, G; FIELDING, K			RELIABILITY AND ACCURACY OF THE GLASGOW COMA SCALE WITH EXPERIENCED AND INEXPERIENCED USERS	LANCET			English	Article							IMPAIRED CONSCIOUSNESS; LEVEL	To investigate whether the Glasgow Coma Scale (GCS) can be used reliably and accurately by inexperienced observers, ratings made by observers grouped by level of experience were examined for within-group interobserver disagreements and for discrepancies with scores given by an expert. The GCS was used accurately by experienced and highly trained users, but inexperienced users made consistent errors. The errors were such that they would not be detectable by studies that examine only interobserver agreement, and they were substantial, averaging in some cases more than one point on the four-point and five-point scales of the GCS. Also, the error rates were highest at the intermediate levels of consciousness, for which the detection of changes in condition is vital. The findings support the continued use of the GCS by appropriately qualified personnel, but call into question much of the conventional wisdom about its reliability when used by untrained or inexperienced staff. The findings also suggest that interobserver comparisons are insufficient for establishing the viability of the GCS.	ALFRED HOSP,NEUROL NEUROSURG UNIT,MELBOURNE,AUSTRALIA	Florey Institute of Neuroscience & Mental Health	ROWLEY, G (corresponding author), MONASH UNIV,FAC EDUC,SCH GRAD STUDIES,MELBOURNE,VIC 3168,AUSTRALIA.							ALLAN D, 1984, NURS MIRROR, V158, P31; CRONBACH LJ, 1972, DEPENDABILITY BEHAVI; Fielding K, 1990, Aust J Adv Nurs, V7, P13; Ingersoll G L, 1987, Crit Care Nurse, V7, P26; JENNETT B, 1977, LANCET, V1, P878; Jones C, 1979, J Neurosurg Nurs, V11, P192; Lord F. M., 1968, STAT THEORY MENTAL T; SHAVELSON RJ, 1989, AM PSYCHOL, V44, P922, DOI 10.1037/0003-066X.44.6.922; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1982, SCOT MED J, V27, P7, DOI 10.1177/003693308202700103; TEASDALE G, 1974, LANCET, V2, P81; TEASDLAE G, 1975, NURS TIMES, V72, P914	15	159	162	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					535	538		10.1016/0140-6736(91)91309-I	http://dx.doi.org/10.1016/0140-6736(91)91309-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671900				2022-12-28	WOS:A1991EZ87400015
J	WILCOCK, D; LANE, DP				WILCOCK, D; LANE, DP			LOCALIZATION OF P53, RETINOBLASTOMA AND HOST REPLICATION PROTEINS AT SITES OF VIRAL REPLICATION IN HERPES-INFECTED CELLS	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; DNA-BINDING-PROTEIN; LARGE TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; GENE-PRODUCT; SV40-TRANSFORMED CELLS; SUSCEPTIBILITY GENE; AUXILIARY PROTEIN; POLYMERASE-DELTA; NUCLEAR ANTIGEN	REPLICATION of DNA occurs at DNA occurs at discrete sites in eukaryotic cell nuclei, where replication proteins are clustered into large complexes, or 'replicases' 1-3. Similarly, viral DNA replication is a highly structured process, notably in herpes simplex virus type-1 (HSV-1; reviewed in ref. 4) in which large globular "replication compartments' containing the viral replication machinery exist. Replicating cellular DNA redistributes to these compartments upon HSV-1 infection 5. We have now used antibodies raised against several cellular proteins to detect changes in their subnuclear localization on HSV-1 infection. We found that various proteins involved in cellular DNA replication move to sites of viral DNA synthesis, whereas a selection of non-replication proteins do not. The retinoblastoma protein and p53 (the products of two putative anti-oncogenes 6.7) relocate to the same sites as known DNA replication proteins, suggesting that they may be associated with DNA replication complexes in normal, uninfected cells.			WILCOCK, D (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BERNS KI, 1978, REPLICATION MAMMALIA, P13; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BROWN SM, 1973, J GEN VIROL, V18, P329, DOI 10.1099/0022-1317-18-3-329; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2187; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOX E, 1990, VIROLOGY, V176, P403, DOI 10.1016/0042-6822(90)90010-O; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KNIPE DM, 1987, J VIROL, V61, P276, DOI 10.1128/JVI.61.2.276-284.1987; KNIPE DM, 1989, ADV VIRUS RES, V37, P85; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LERNER MR, 1980, NATURE, V283; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAO JCH, 1975, BIOCHEMISTRY-US, V14, P5475, DOI 10.1021/bi00696a015; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989; WASEEM NH, 1990, J CELL SCI, V96, P121; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLTER S, 1980, BIOCHIM BIOPHYS ACTA, V607, P420, DOI 10.1016/0005-2787(80)90152-5; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	42	249	252	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					429	431		10.1038/349429a0	http://dx.doi.org/10.1038/349429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1671528				2022-12-28	WOS:A1991EV51400056
J	MUNGER, RG; PRINEAS, RJ; CROW, RS; CHANGBUMRUNG, S; KEANE, V; WANGSUPHACHART, V; JONES, MP				MUNGER, RG; PRINEAS, RJ; CROW, RS; CHANGBUMRUNG, S; KEANE, V; WANGSUPHACHART, V; JONES, MP			PROLONGED QT INTERVAL AND RISK OF SUDDEN-DEATH IN SOUTH-EAST ASIAN MEN	LANCET			English	Note							SLEEP; REFUGEES	Sudden death in sleep occurs in substantial numbers among young men in South-East Asia. The frequencies of electrocardiographic abnormalities were measured in groups with varying risks of such sudden death. The mean heart-rate-corrected QT interval (QTc) was significantly (p < 0.05) greater among 123 Laotian refugees in Thailand at high risk (405 [95% confidence interval 397-413] ms) than in 77 Laotian refugees in the United States at lower risk (364 [359-369] ms) and 199 non-Asian US residents at negligible risk (358 [354-362] ms). Among refugees in Thailand, prolonged QTc interval was associated with poor thiamine status and a history of seizure-like episodes in sleep. Thiamine deficiency may be a cause of prolonged QT interval and sudden death in this region.	UNIV MIAMI, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33152 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; MAHIDOL UNIV, FAC TROP MED, DEPT TROP NUTR & FOOD SCI, BANGKOK 10700, THAILAND; MAHIDOL UNIV, FAC TROP MED, DEPT TROP HYG, BANGKOK 10700, THAILAND; INT ORG MIGRAT, BANGKOK, THAILAND	University of Miami; University of Minnesota System; University of Minnesota Twin Cities; Mahidol University; Mahidol University; International Organization for Migration	MUNGER, RG (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, 2830 STEINDLER BLDG, IOWA CITY, IA 52242 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019877] Funding Source: NIH RePORTER; NCRR NIH HHS [507RR-05548] Funding Source: Medline; NHLBI NIH HHS [R01-HL-19877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWNE KF, 1983, AM J CARDIOL, V52, P55, DOI 10.1016/0002-9149(83)90068-1; KEYS A, 1945, 21 U MINN SCH PUBL H, P1; MOSS A J, 1986, Journal of the American Medical Association, V256, P2985, DOI 10.1001/jama.256.21.2985; MUNGER RG, 1987, AM J PUBLIC HEALTH, V77, P1187, DOI 10.2105/AJPH.77.9.1187; MUNGER RG, 1990, LANCET, V335, P1154, DOI 10.1016/0140-6736(90)91154-3; NIMMANNIT S, 1990, LANCET, V336, P116, DOI 10.1016/0140-6736(90)91631-J; OTTO CM, 1984, ANN INTERN MED, V100, P45; TOMAN JEP, P SOC EXP BIOL MED, V58, P65; WAKABAYASHI A, 1979, JPN CIRC J, V43, P955; 1988, MMWR, V37, P568	10	31	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 3	1991	338	8762					280	281		10.1016/0140-6736(91)90419-P	http://dx.doi.org/10.1016/0140-6736(91)90419-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677112				2022-12-28	WOS:A1991FZ56500005
J	FRIBERG, L; OLESEN, J; IVERSEN, HK; SPERLING, B				FRIBERG, L; OLESEN, J; IVERSEN, HK; SPERLING, B			MIGRAINE PAIN ASSOCIATED WITH MIDDLE CEREBRAL-ARTERY DILATATION - REVERSAL BY SUMATRIPTAN	LANCET			English	Article							BLOOD-FLOW; CLASSIC MIGRAINE; 5-HT1-LIKE RECEPTOR; COMMON MIGRAINE; ATTACKS; GR43175; ISCHEMIA; TOMOGRAPHY; HEADACHE; AGONIST	The combination of measurements of regional cerebral blood flow (rCBF) and blood velocity in the middle cerebral arteries (MCA) by transcranial doppler sonography was used to investigate cerebrovascular involvement in migraine. Ten migraine patients with unilateral headache were studied during an attack and when they had been free of attacks for 5 days (non-attack). On both occasions they were given an intravenous infusion of sumatriptan (2 mg), a 5-HT1-like receptor agonist, which relieved the symptoms within 30 min without affecting rCBF. The MCA velocity was normal on both sides on the non-attack day and on the unaffected side during the attack. However, during the attack the MCA velocity on the headache side was significantly lower than that on the nonheadache side (45 vs 61 cm/s:mean difference 16.3 [95% confidence interval 10.3-22.3]; p = 0.02). The MCA velocity on the headache side returned to normal after treatment with sumatriptan and recovery. Since rCBF in the MCA supply territory was unaffected, the lower velocity can be explained only by dilatation of the MCA. The mean MCA diameter increase was estimated to be 20%. Thus, headache was associated with intracranial large arterial dilatation on the headache side. Sumatriptan predominantly had effects on the distended artery, which suggests that the 5-HT receptor system has a role in the pathogenesis of migraine.	GENTOFTE HOSP,DEPT NEUROL,DK-2900 COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	FRIBERG, L (corresponding author), BISWAS & ASSOCIATES,DEPT CLIN PHYSIOL & NUCL MED,OTTAWA K2H 5Y6,ONTARIO,CANADA.		Iversen, Helle Klingenberg/B-9154-2009; Iversen, Helle Klingenberg/P-5726-2019	Iversen, Helle Klingenberg/0000-0002-5880-6352; Olesen, Jes/0000-0002-6712-2702				AASLID R, TRANSCRANIAL DOPPLER, P19; ANDERSEN AR, 1988, ARCH NEUROL-CHICAGO, V45, P154, DOI 10.1001/archneur.1988.00520260040017; ATKINS HL, 1980, J NUCL MED, V21, P459; CELSIS P, 1981, J COMPUT ASSIST TOMO, V5, P641, DOI 10.1097/00004728-198110000-00006; DECLERCK F, 1985, SEROTONIN CARDIOVASC, P155; DOENICKE A, 1988, LANCET, V1, P1309; EDVINSSON L, 1989, CEPHALALGIA S10, V9, P39; FENIUK W, 1989, BRIT J PHARMACOL, V96, P83, DOI 10.1111/j.1476-5381.1989.tb11787.x; FRIBERG L, 1987, BRAIN, V110, P917, DOI 10.1093/brain/110.4.917; FRIBERG L, 1989, CEPHALALGIA S10, V9, P29; HARPER AM, 1977, J PHYSIOL-LONDON, V271, P735, DOI 10.1113/jphysiol.1977.sp012023; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HUMPHREY PPA, 1988, BRIT J PHARMACOL, V94, P1123, DOI 10.1111/j.1476-5381.1988.tb11630.x; IVERSEN HK, 1990, LANCET, V336, P837, DOI 10.1016/0140-6736(90)92339-J; JENSEN K, 1985, ACTA NEUROL SCAND, V72, P561; JENSEN K, 1987, ACTA NEUROL SCAND, V75, P310, DOI 10.1111/j.1600-0404.1987.tb05452.x; LASSEN NA, 1978, J COMPUT ASSIST TOMO, V2, P661, DOI 10.1097/00004728-197811000-00047; LAURITZEN M, 1983, ANN NEUROL, V13, P633, DOI 10.1002/ana.410130609; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Moskowitz M., 1988, BASIC MECH HEADACHE, P429; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLESEN J, 1981, LANCET, V2, P438; OLSEN TS, 1987, ARCH NEUROL-CHICAGO, V44, P156, DOI 10.1001/archneur.1987.00520140028013; PARSONS AA, 1989, BRIT J PHARMACOL, V96, P434, DOI 10.1111/j.1476-5381.1989.tb11835.x; SKINHOJ E, 1973, ARCH NEUROL-CHICAGO, V29, P95, DOI 10.1001/archneur.1973.00490260039007; TFELTHANSEN P, 1989, CEPHALALGIA, V9, P73; THIE A, 1990, HEADACHE, V30, P209, DOI 10.1111/j.1526-4610.1990.hed3004209.x; YOUNG AR, 1987, NEURONAL MESSENGERS, P57	29	337	337	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					13	17		10.1016/0140-6736(91)90005-A	http://dx.doi.org/10.1016/0140-6736(91)90005-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676084				2022-12-28	WOS:A1991FV29600004
J	DAVIDSON, RN; CROFT, SL; SCOTT, A; MAINI, M; MOODY, AH; BRYCESON, ADM				DAVIDSON, RN; CROFT, SL; SCOTT, A; MAINI, M; MOODY, AH; BRYCESON, ADM			LIPOSOMAL AMPHOTERICIN-B IN DRUG-RESISTANT VISCERAL LEISHMANIASIS	LANCET			English	Note							ANTILEISHMANIAL ACTIVITY; AGENTS	The treatment of visceral leishmaniasis (VL) may be complicated by drug toxicity or intolerance, and by drug resistance. 1 Amphotericin B (AmB) is effective, 1 but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common. Liposomes have been proposed as an effective way to target drugs at macrophages, which are the cells infected in visceral leishmaniasis. 2-7 In animals AmB incorporated into liposomes is highly effective against experimental leishmaniasis, with low toxicity. This report is of the successful treatment of a patient with multiply drug-resistant visceral leishmaniasis with a commercially prepared formulation of liposomal amphotericin B (L-AmB) ('AmBisome', Vestar, San Dimas, California, USA). We also report, for comparison, a patient treated with conventional AmB, and preliminary studies in mice comparing the two agents.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	DAVIDSON, RN (corresponding author), HOSP TROP DIS,4 ST PANCRAS WAY,LONDON NW1 0PE,ENGLAND.			Maini, Mala/0000-0001-6384-1462				ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6; ALVING CR, 1978, P NATL ACAD SCI USA, V75, P2959, DOI 10.1073/pnas.75.6.2959; BERMAN JD, 1986, ANTIMICROB AGENTS CH, V30, P847, DOI 10.1128/AAC.30.6.847; BRYCESON ADM, 1987, THERAPY MAN, pCH18; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; Croft S. L., 1989, Leishmaniasis: The current status and new strategies for control. Proceedings of a NATO Advanced Study Institute on leishmaniasis: The first centenary (1885-1985), new strategies for control, Zakinthos, Greece, 20-27 September 1987., P783; CROFT SL, 1986, PHARM INT, V7, P229; LOPEZBERESTEIN G, 1987, ANTIMICROB AGENTS CH, V31, P675, DOI 10.1128/AAC.31.5.675; NEW RRC, 1981, J ANTIMICROB CHEMOTH, V8, P371, DOI 10.1093/jac/8.5.371; NEW RRC, 1978, NATURE, V272, P55, DOI 10.1038/272055a0	10	156	159	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1061	1062		10.1016/0140-6736(91)91708-3	http://dx.doi.org/10.1016/0140-6736(91)91708-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673494				2022-12-28	WOS:A1991FK20400005
J	HUI, KP; BARNES, NC				HUI, KP; BARNES, NC			LUNG-FUNCTION IMPROVEMENT IN ASTHMA WITH A CYSTEINYL-LEUKOTRIENE RECEPTOR ANTAGONIST	LANCET			English	Note							LY171883; ANTIGEN	In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart. The increase in forced expiratory volume in 1 s (FEV1) above baseline was significantly greater after ICI 204,219 than after placebo. This effect persisted after nebulised salbutamol. These findings suggest that cysteinyl-leukotrienes are one of the causes of persistent bronchoconstriction in chronic asthma.	LONDON CHEST HOSP,DEPT THORAC MED,BONNER RD,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London								BARNES N, 1988, MECHANISMS ASTHMA PH, P393; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; CLOUD ML, 1989, AM REV RESPIR DIS, V140, P1336, DOI 10.1164/ajrccm/140.5.1336; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988	10	188	194	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1062	1063		10.1016/0140-6736(91)91709-4	http://dx.doi.org/10.1016/0140-6736(91)91709-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673495				2022-12-28	WOS:A1991FK20400006
J	WEITZ, ZW; BIRNBAUM, AJ; SOBOTKA, PA; ZARLING, EJ; SKOSEY, JL				WEITZ, ZW; BIRNBAUM, AJ; SOBOTKA, PA; ZARLING, EJ; SKOSEY, JL			HIGH BREATH PENTANE CONCENTRATIONS DURING ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							FREE-RADICAL GENERATION; LIPID-PEROXIDATION; ALKANES; OXYGEN	To investigate whether reperfusion after myocardial ischaemia leads to free-radical-mediated peroxidation of membrane lipids and cell damage, we measured pentane, a product of lipid peroxidation, in the breath of 10 healthy control subjects and in 20 consecutive patients with suspected acute myocardial infarction. 10 of these patients showed no myocardial damage on electrocardiography (patient control group) and 10 satisfied standard diagnostic criteria for acute myocardial infarction. The three groups were well matched for age, sex, underlying disease, and smoking habits. The time from onset of chest pain to breath collection was similar in the patient control and acute myocardial infarction groups. The breath pentane concentration was higher (p < 0.0001) in the acute myocardial infarction group (4.96 [1.15] nmol/l) than in the patient control (1.96 [1.04] nmol/l) and healthy control groups (1.71 [0.87] nmol/l). Lipid peroxidation during acute myocardial infarction reflects action of oxygen radicals and their potential for contribution to the pathogenesis of tissue damage.	LOYOLA UNIV,MED CTR,DEPT MED CARDIOL,MAYWOOD,IL 60153; LOYOLA UNIV,MED CTR,DEPT MED GASTROENTEROL,MAYWOOD,IL 60153; UNIV ILLINOIS,DEPT MED RHEUMATOL,CHICAGO,IL 60680	Loyola University Chicago; Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								ALONSO DR, 1973, CIRCULATION, V48, P588, DOI 10.1161/01.CIR.48.3.588; ARROYO CM, 1987, FREE RADICAL BIO MED, V3, P313, DOI 10.1016/S0891-5849(87)80037-0; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOLLI R, 1990, CIRCULATION, V82, P723, DOI 10.1161/01.CIR.82.3.723; BULKLEY G, CITED INDIRECTLY; DAVIES S W, 1989, European Heart Journal, V10, P274; DUMELIN EE, 1977, LIPIDS, V12, P894, DOI 10.1007/BF02533308; FRIDOVICH I, 1984, METHOD ENZYMOL, V105, P59; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; KAGEN L, 1977, AM J MED, V62, P86, DOI 10.1016/0002-9343(77)90353-9; LANDIS JR, 1976, COMPUT PROG BIOMED, V6, P196, DOI 10.1016/0010-468X(76)90037-4; LEUPRECHT H, 1982, J MICROCOMPUT APPL, V5, P31, DOI 10.1016/0745-7138(82)90041-0; METZ G, 1976, CLIN SCI MOL MED, V50, P237, DOI 10.1042/cs0500237; MICKEL HS, 1987, STROKE, V18, P426, DOI 10.1161/01.STR.18.2.426; ROBERTS MJD, 1990, LANCET, V336, P143, DOI 10.1016/0140-6736(90)91661-S; SHAH B, 1989, CIRCULATION S, V80, P33; TAPPEL AL, 1981, FED PROC, V40, P174; TAPPEL AL, 1979, BIOCH CLIN ASPECTS O, P679; VANGOSSUM A, 1989, EUR RESPIR J, V2, P787; ZARLING EJ, 1987, CLIN CHEM, V33, P140; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; 1983, PROPOSAL MULTINATION	23	103	106	2	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					933	935		10.1016/0140-6736(91)91569-G	http://dx.doi.org/10.1016/0140-6736(91)91569-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678029				2022-12-28	WOS:A1991FH13100002
J	WELLES, SL; MUELLER, N; TACHIBANA, N; SHISHIME, E; OKAYAMA, A; MURAI, K; TSUDA, K				WELLES, SL; MUELLER, N; TACHIBANA, N; SHISHIME, E; OKAYAMA, A; MURAI, K; TSUDA, K			DECREASED EOSINOPHIL NUMBERS IN HTLV-I CARRIERS	LANCET			English	Letter									MIYAZAKI MED COLL,DEPT MED 2,MIYAZAKI,JAPAN	University of Miyazaki	WELLES, SL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115, USA.							CHAVANCE M, 1988, LANCET, V2, P1309; ISHIZAKI J, 1988, J ACQ IMMUN DEF SYND, V1, P340; MATUTES E, 1986, INT J CANCER, V38, P41, DOI 10.1002/ijc.2910380108; MUELLER N, 1990, HUMAN RETROVIROLOGY : HTLV, P281; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; POPOVIC M, 1984, SCIENCE, V226, P459, DOI 10.1126/science.6093248; PRIN L, 1988, LANCET, V2, P569; TACHIBANA N, 1988, INT J CANCER, V42, P829, DOI 10.1002/ijc.2910420605	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					987	987		10.1016/0140-6736(91)91631-4	http://dx.doi.org/10.1016/0140-6736(91)91631-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678076				2022-12-28	WOS:A1991FH13100064
J	DIXON, J; WELCH, HG				DIXON, J; WELCH, HG			PRIORITY SETTING - LESSONS FROM OREGON	LANCET			English	Article								The state of Oregon has developed a unique method to set priorities for health services. The method is based on a cost-utility formula but also incorporates public attitudes and values. Using an explicit process, the Oregon Health Services Commission has completed the ranking of 714 condition-treatment pairs. The background, methods, and criticisms of the Oregon approach highlight key questions for managers and physicians in other health services when they allocate limited resources.	NW THAMES REG HLTH AUTHOR,LONDON,ENGLAND; WHITE RIVER JUNCT VET ADM,WHITE RIVER JCT,VT; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756	Dartmouth College; Dartmouth College	DIXON, J (corresponding author), COMMONWEALTH FUND,1 E 75TH ST,NEW YORK,NY 10021, USA.							BRINDLE D, 1991, GUARDIAN WEEKLY 0203; CALLAHAN D, 1990, NEW ENGL J MED, V322, P1810, DOI 10.1056/NEJM199006213222511; CRANSHAW R, 1990, W J MED, V152, P441; DEAN M, 1991, LANCET, V337, P480, DOI 10.1016/0140-6736(91)93408-2; DEAN M, 1991, LANCET, V337, P351, DOI 10.1016/0140-6736(91)90961-N; DUGGAN JM, 1989, LANCET, V1, P772; EGAN T, 1991, NY TIMES        0222; FORD S, 1991, BRIT MED J, V302, P288, DOI 10.1136/bmj.302.6771.288-a; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GORE A, 1990, ACAD MED, V65, P634, DOI 10.1097/00001888-199010000-00007; HOLLINGSBAUM F, 1991, BRIT MED J, V302, P288; KELLY G, 1991, BRIT MED J, V302, P288; KITZHABER J, 1989, LANCET, V2, P106; PACKWOOD B, 1990, ACAD MED, V65, P632, DOI 10.1097/00001888-199010000-00006; QUAM L, 1989, BRIT MED J, V299, P448, DOI 10.1136/bmj.299.6696.448; REAGAN MD, 1990, POLY STUD REV, V9, P219; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; SCHWARTZ WB, 1990, NY TIMES        0709; SHOEMAKER R, 1989, MED ETHICS ADVISOR, V5, P88; VLADECK BC, 1990, COMMUNICATION    SEP; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; WELCH WP, IN PRESS HLTH CARE F; 1990, OREGONIAN       0615; 1989, WORKING PATIENTS; 1989, OREGON MED PRIORITY; 1991, PRIORITESED HLTH SER	26	143	144	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					891	894		10.1016/0140-6736(91)90213-9	http://dx.doi.org/10.1016/0140-6736(91)90213-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672977				2022-12-28	WOS:A1991FG04800012
J	LONG, CC; MARKS, R				LONG, CC; MARKS, R			CALCIPOTRIOL AND BETAMETHASONE VALERATE FOR PSORIASIS	LANCET			English	Letter											LONG, CC (corresponding author), UNIV COLL CARDIFF,DEPT DERMATOL,CARDIFF CF4 4XN,S GLAM,WALES.							ALLENBY CF, 1975, BRIT MED J, V1, P619; BAKER H, PSORIASIS, P15; DYKES PJ, 1979, BRIT J DERMATOL, V101, P599, DOI 10.1111/j.1365-2133.1979.tb15108.x; HORWITZ SN, 1985, J AM ACAD DERMATOL, V13, P784, DOI 10.1016/S0190-9622(85)70224-1; IVE AF, 1969, BRIT MED J, V3, P149; KRAGBALLE, 1991, LANCET, V337, P193; STAUGHTON RCD, 1986, BRIT MED J, V2, P419	7	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					921	922		10.1016/0140-6736(91)90258-Q	http://dx.doi.org/10.1016/0140-6736(91)90258-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1673003				2022-12-28	WOS:A1991FG04800057
J	JOHANSEN, HK; NIR, M; HOIBY, N; KOCH, C; SCHWARTZ, M				JOHANSEN, HK; NIR, M; HOIBY, N; KOCH, C; SCHWARTZ, M			SEVERITY OF CYSTIC-FIBROSIS IN PATIENTS HOMOZYGOUS AND HETEROZYGOUS FOR DELTA-F508 MUTATION	LANCET			English	Article							INFECTION; GENE	To assess the relation between genotype and severity of disease in cystic fibrosis (CF) the frequencies and extent of several features of its phenotypic expression were investigated in the 235 patients who attend the Danish CF Centre. 14 patients who attend irregularly and 3 who do not carry the DELTA-F508 mutation at all were excluded. The case-reports of the remaining 218 patients (aged 4 months to 41 years) were carefully evaluated, and they were all analysed for the DELTA-F508 mutation. 172 (79%) were homozygous for DELTA-F508 and 46 (20%) were heterozygous. The mutation therefore occurs on 89% of the chromosomes analysed. There were no significant differences between the homozygous and heterozygous groups in the proportions with meconium ileus at birth, liver involvement, or chronic Pseudomonas aeruginosa infection. However, significantly more of the homozygous patients had onset of symptoms before the age of 6 months (p < 0.025); they were significantly younger at diagnosis (p = 0.013) and centre referral (p = 0.006); they required greater pancreatic enzyme substitution (p = 0.0002) and had poorer lung function; and the calculated yearly incidence of chronic Ps aeruginosa infection and yearly mortality rates were greater than in heterozygous patients (p = 0.0001).	RIGSHOSP,DANISH CYST FIBROSIS CTR,DEPT PEDIAT,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	JOHANSEN, HK (corresponding author), RIGSHOSP,DEPT CLIN MICROBIOL,AFSN 7806,TAGENSUEI 20,DK-2200 COPENHAGEN N,DENMARK.							BORGO G, 1990, J MED GENET, V27, P665, DOI 10.1136/jmg.27.11.665; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DEAN M, 1990, PEDIATR PULM S, V5, P203; DIEM K, 1975, SCI TABLES, V28, P69; DUARTE A, 1990, HUM GENET, V85, P404, DOI 10.1007/BF02428279; ESTIVILL X, 1989, LANCET, V2, P1404; HALLEY DJJ, 1990, HUM GENET, V85, P407, DOI 10.1007/BF02428281; HOIBY N, 1989, ACTA PAEDIATR SCAND, V78, P395, DOI 10.1111/j.1651-2227.1989.tb11099.x; HOIBY N, 1982, ACTA PAEDIATR SC   S, V301, P75; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; Krintel J J, 1985, Ugeskr Laeger, V147, P1184; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; PEDERSEN SS, 1987, ACTA PAEDIATR SCAND, V76, P955, DOI 10.1111/j.1651-2227.1987.tb17271.x; POLGAR G, 1971, PULMONARY FUNCTION T, P88; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; SCHWARTZ M, 1990, HUM GENET, V85, P427, DOI 10.1007/BF02428297; SCHWARZ MJ, 1990, HUM GENET, V85, P428, DOI 10.1007/BF02428298; SERRE JL, 1990, HUM GENET, V84, P449; STUHRMANN M, 1990, LANCET, V335, P738, DOI 10.1016/0140-6736(90)90862-Y; WOOD RE, 1976, AM REV RESPIR DIS, V113, P833; 1990, HUM GENET, V85, P436	23	154	156	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					631	634		10.1016/0140-6736(91)92449-C	http://dx.doi.org/10.1016/0140-6736(91)92449-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671990				2022-12-28	WOS:A1991FB73000002
J	SCOTT, NA; LEINHARDT, DJ; OHANRAHAN, T; FINNEGAN, S; SHAFFER, JL; IRVING, MH				SCOTT, NA; LEINHARDT, DJ; OHANRAHAN, T; FINNEGAN, S; SHAFFER, JL; IRVING, MH			SPECTRUM OF INTESTINAL FAILURE IN A SPECIALIZED UNIT	LANCET			English	Article							HOME PARENTERAL-NUTRITION; FISTULAS; MANAGEMENT; TRACT	300 consecutive admissions over 7 years to a purpose-built intestinal failure unit are reviewed. The commonest underlying condition was Crohn's disease (42%), and the commonest complication precipitating admission was intestinal fistula (42%). Total parenteral nutrition was used in 85% and surgery in 50%. A multidisciplinary approach to management gave a high success rate-90% of patients were discharged from hospital, although nearly 25% needed home parental nutrition. These results suggest that chronic intestinal failure should be managed in specialised units in the same manner as other types of organ failure.	UNIV MANCHESTER, HOPE HOSP, DEPT SURG, NUTR UNIT, ECCLES OLD RD, SALFORD M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT MED, SALFORD M6 8HD, LANCS, ENGLAND	University of Manchester; University of Manchester								BURY KD, 1971, AM J SURG, V121, P174, DOI 10.1016/0002-9610(71)90096-1; FISCHER JE, 1976, TOTAL PARENTERAL NUT, P127; FLEMING CR, 1981, CLIN SURGERY INT, P219; IRVING M, 1985, ANN ROY COLL SURG, V67, P2; KETTLEWELL MGW, 1983, BRIT MED J, V286, P1323; LEREBOURS E, 1988, JPEN-PARENTER ENTER, V12, P360, DOI 10.1177/0148607188012004360; LEVY E, 1988, BRIT J SURG, V75, P549, DOI 10.1002/bjs.1800750615; MCINTYRE PB, 1984, BRIT J SURG, V71, P293, DOI 10.1002/bjs.1800710416; MUGHAL M, 1986, LANCET, V2, P383; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; PADBERG FT, 1981, ANN SURG, V193, P264, DOI 10.1097/00000658-198103000-00002; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; ROSE D, 1986, SURG GYNECOL OBSTET, V163, P345; STOKES MA, 1988, BRIT J SURG, V75, P481, DOI 10.1002/bjs.1800750524	14	33	33	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 23	1991	337	8739					471	473		10.1016/0140-6736(91)93403-V	http://dx.doi.org/10.1016/0140-6736(91)93403-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671480				2022-12-28	WOS:A1991EY88700014
J	HOPPU, K; TIKANOJA, T; TAPANAINEN, P; REMES, M; SAARENPAAHEIKKILA, O; KOUVALAINEN, K				HOPPU, K; TIKANOJA, T; TAPANAINEN, P; REMES, M; SAARENPAAHEIKKILA, O; KOUVALAINEN, K			ACCIDENTAL ASTEMIZOLE OVERDOSE IN YOUNG-CHILDREN	LANCET			English	Note							TORSADE-DE-POINTES	6 cases of accidental astemizole poisoning in children have been reported to the Finnish Poison Information Center. The children were aged 1 year 7 months to 3 years 4 months and had taken doses of 2.5 to 16.7 mg/kg, at least twelve times that recommended. In 2 children the overdose was verified by measurement of drug concentrations. Despite measures to prevent drug absorption prolonged QT(c)-interval, a sign of cardiac toxicity, was found in all 5 children on whom an electrocardiogram was available for analysis, and severe ventricular arrhythmias developed in 1. Young children with accidental astemizole overdose should be carefully monitored in hospital. Similar precautions may be justified in cases of overdose with other selective H-1-histamine receptor antagonists.	UNIV KUOPIO,DEPT PAEDIAT,KUOPIO,FINLAND; UNIV OULU,DEPT PAEDIAT,SF-90100 OULU 10,FINLAND; UNIV TAMPERE,DEPT PAEDIAT,TAMPERE,FINLAND	University of Eastern Finland; University of Oulu; Tampere University	HOPPU, K (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DEPT PAEDIAT 2,SF-00290 HELSINKI 29,FINLAND.		Hoppu, Kalle/A-2811-2009	Hoppu, Kalle/0000-0001-6775-0453				Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CRAFT TM, 1986, BRIT MED J, V292, P660, DOI 10.1136/bmj.292.6521.660; DAVIES AJ, 1989, BRIT MED J, V298, P325, DOI 10.1136/bmj.298.6669.325; GARSON A, 1990, PEDIATRIC ARRHYTHMIA, P427; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; SIMONS FER, 1988, LANCET, V2, P624; SNOOK J, 1988, BRIT J CLIN PRACT, V42, P257; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; WOESTENBORGHS R, 1986, DRUG DEVELOP RES, V8, P63, DOI 10.1002/ddr.430080108	10	66	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					538	540		10.1016/0140-6736(91)91101-Y	http://dx.doi.org/10.1016/0140-6736(91)91101-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678801				2022-12-28	WOS:A1991GD00200005
J	OPELZ, G; MYTILINEOS, J; SCHERER, S; DUNCKLEY, H; TREJAUT, J; CHAPMAN, J; MIDDLETON, D; SAVAGE, D; FISCHER, O; BIGNON, JD; BENSA, JC; ALBERT, E; NOREEN, H				OPELZ, G; MYTILINEOS, J; SCHERER, S; DUNCKLEY, H; TREJAUT, J; CHAPMAN, J; MIDDLETON, D; SAVAGE, D; FISCHER, O; BIGNON, JD; BENSA, JC; ALBERT, E; NOREEN, H			SURVIVAL OF DNA HLA-DR TYPED AND MATCHED CADAVER KIDNEY-TRANSPLANTS	LANCET			English	Article							GRAFT-SURVIVAL	The clinical value of serological HLA matching for cadaver kidney transplantation remains uncertain because the success rate for HLA-matched cadaver transplants is lower than that of HLA-matched sibling grafts. Up to 25% of serological HLA-DR typings may be incorrect when compared with a more accurate DNA-RFLP method, and we have now examined whether incorrect HLA-DR typings account for the lower than expected success rates of HLA-matched cadaver transplants. 58 transplant centres took part in this study and DNA was extracted from over 4000 samples of frozen tissue at the study centre. 8 laboratories then completed blind RFLP typing for HLA-DR. Serological typing data were reported by individual transplant laboratories. 29 of 107 transplants (27%) that were reported as HLA A, B, DR compatible and 76 of 273 (28%) transplants that were reported as HLA B, DR compatible according to serological typing were found to be HLA-DR mismatched by DNA typing. The one-year transplant success rate for DNA-matched HLA, A, B, DR grafts was 87% compared with 69% for mismatched grafts (p < 0.02); the corresponding success rate for DNA-matched HLA B, DR grafts was 85% compared with 72% for mismatched grafts (p < 0.01). Many transplants that were previously thought to be HLA matched are mismatched, and this finding may account for previously unexplained graft failures.	RED CROSS BLOOD TRANSFUS SERV,SYDNEY,AUSTRALIA; REG TISSUE TYPING LAB,BELFAST,NORTH IRELAND; TRANSFUS & IMMUNOPATHOL CTR,GRENOBLE,FRANCE; UNIV MINNESOTA,DEPT LAB MED,MINNEAPOLIS,MN 55455; UNIV VIENNA,INST BLOOD GRP SEROL,A-1010 VIENNA,AUSTRIA; UNIV NANTES,CTR BLOOD TRANSFUS,F-44035 NANTES,FRANCE; UNIV MUNICH,DEPT PAEDIAT,W-8000 MUNICH 2,GERMANY	Australian Red Cross Blood Service; University of Minnesota System; University of Minnesota Twin Cities; University of Vienna; Nantes Universite; University of Munich	OPELZ, G (corresponding author), UNIV HEIDELBERG,INST IMMUNOL,DEPT TRANSPLANTAT IMMUNOL,W-6900 HEIDELBERG,GERMANY.			Trejaut, Jean/0000-0002-4245-0814				BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; GRAHAM DE, 1978, ANAL BIOCHEM, V85, P609, DOI 10.1016/0003-2697(78)90262-2; Lau M, 1989, Clin Transpl, P447; MATAS AJ, 1989, CLIN TRANSPLANT, V3, P22; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MYTILINEOS J, 1990, TRANSPLANTATION, V50, P870, DOI 10.1097/00007890-199011000-00024; OPELZ G, 1991, TRANSPLANT P, V23, P373; OPELZ G, 1985, TRANSPLANTATION, V40, P240, DOI 10.1097/00007890-198509000-00003; OPELZ G, 1991, TRANSPLANT P, V23, P46; OPELZ G, 1991, ETHICS JUSTICS COMME, P399; SCHREUDER GMT, 1990, EUROTRANSPLANT NEWSL, V70, P2; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; URYU N, 1990, TISSUE ANTIGENS, V35, P20, DOI 10.1111/j.1399-0039.1990.tb01751.x	14	190	196	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					461	463		10.1016/0140-6736(91)90540-6	http://dx.doi.org/10.1016/0140-6736(91)90540-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678443				2022-12-28	WOS:A1991GC15300001
J	DAVIDSON, DR; CRAWLEY, A; HILL, RE; TICKLE, C				DAVIDSON, DR; CRAWLEY, A; HILL, RE; TICKLE, C			POSITION-DEPENDENT EXPRESSION OF 2 RELATED HOMEOBOX GENES IN DEVELOPING VERTEBRATE LIMBS	NATURE			English	Article							CHICK WING BUD; PATTERN-FORMATION; POLARIZING REGION; RETINOIC ACID; MOUSE; DROSOPHILA	MANY genes that control pattern formation in insects contain a conserved homeobox region which encodes a domain involved in DNA binding 1. One approach to understanding pattern formation in vertebrates is to examine the role of homeobox-containing genes in the developing limb 2. Two such genes, Hox-7.1 and Hox-8.1, are expressed in distal mesoderm, but not in the proximal core, of mouse forelimb (refs 3,4, and D.R.D., manuscript in preparation). The proximodistal cartilage pattern in the chick wing is progressively determined in the distal mesoderm, which is maintained as a 'progress zone' by the overlying apical ectodermal ridge 5. Indeed, proximal cells are reprogrammed to form distal structures when placed in the progress zone 6 and we therefore expect that genes involved in controlling limb pattern should be activated in such grafts. We tested this requirement for Hox-7.1 and Hox-8.1 in mouse limb mesoderm placed in chick wing buds. Our results reported here indicate that both genes are rapidly activated by a signal from the apical ectoderm. These properties, taken with the DNA-binding properties of the homeodomain, strongly suggest that Hox-7.1 and Hox-8.1 have fundamental roles in limb-pattern formation.	UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND	University of London; University College London	DAVIDSON, DR (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,DEV GENET GRP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							CAIRNS JM, 1965, DEV BIOL, V12, P36, DOI 10.1016/0012-1606(65)90019-9; COTTRILL CP, 1990, CELL DIFFER DEV, V29, P67, DOI 10.1016/0922-3371(90)90025-R; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DOLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAMBURGER V, 1979, J MORPHOL, V50, P217; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JORQUERA B, 1971, CR ACAD SCI D NAT, V272, P1522; LYONS KM, 1990, DEVELOPMENT, V109, P833; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; SAUNDERS JW, 1959, DEV BIOL, V1, P281, DOI 10.1016/0012-1606(59)90030-2; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TICKLE C, 1976, NATURE, V259, P396, DOI 10.1038/259396a0; Wolpert L, 1975, Ciba Found Symp, V0, P95	20	188	191	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					429	431		10.1038/352429a0	http://dx.doi.org/10.1038/352429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1677742				2022-12-28	WOS:A1991FZ34600064
J	FRIEDMAN, GD; HIATT, RA; QUESENBERRY, CP; SELBY, JV				FRIEDMAN, GD; HIATT, RA; QUESENBERRY, CP; SELBY, JV			CASE-CONTROL STUDY OF SCREENING FOR PROSTATIC-CANCER BY DIGITAL RECTAL EXAMINATIONS	LANCET			English	Article							DIAGNOSIS; ADENOCARCINOMA; DEFINITION; CARCINOMA; EFFICACY; DISEASE	Although commonly thought to be an effective method of screening for prostatic cancer, digital rectal examinations have yet to be shown by controlled study to help prevent advanced forms of this disease. 139 men with metastatic (stage D) prostatic cancer (cases) were compared with an equal number of matched men free of this condition (controls), with respect to rectal examinations recorded in the medical records up to, on average, 23 years before the cases' initial diagnosis of prostatic cancer. Cases and controls were members of a large health maintenance organisation in northern California. In the 10 years before initial diagnosis (excluding the last three months) the average number of examinations for routine screening (2.45 vs 2.52) or to evaluate intestinal or rectal symptoms (0.44 in both) were similar in cases and controls, respectively. After adjustment for racial differences, the relative risk of metastatic prostatic cancer for men with one or more screening rectal examinations compared with men with none was 0.9 with a 95% confidence interval of 0.5-1.7. Screening by routine digital rectal examination appears to have little if any effect in preventing metastatic prostatic cancer. If there is a small benefit, it will be difficult to demonstrate by conventional epidemiological study.	KAISER PERMANENTE MED CARE PROGRAM, NO CALIF REG, DIV RES, OAKLAND, CA USA	Kaiser Permanente			Hiatt, Robert/AAQ-1537-2021					BRESLOW NE, 1980, IARC SCI PUBL, V32, P247; Chodak G W, 1988, Prog Clin Biol Res, V269, P87; CHODAK GW, 1986, J UROLOGY, V135, P951, DOI 10.1016/S0022-5347(17)45935-0; CLEMENTS R, 1988, CLIN RADIOL, V39, P87, DOI 10.1016/S0009-9260(88)80352-0; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FLANDERS WD, 1984, PROSTATE, V5, P621, DOI 10.1002/pros.2990050608; FRAME PS, 1986, J FAM PRACTICE, V22, P511; GILBERTSEN VA, 1971, J AMER MED ASSOC, V215, P81; GREENWALD P, 1982, CANCER EPIDEMIOL, P938; Guinan P, 1987, Prog Clin Biol Res, V243A, P551; GUINAN P, 1980, NEW ENGL J MED, V303, P499, DOI 10.1056/NEJM198008283030906; HIATT RA, 1982, KIDNEY INT, V22, P63, DOI 10.1038/ki.1982.133; KADMON D, 1987, GENITOURINARY CANCER, P77; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; MORRISON AS, 1982, AM J EPIDEMIOL, V115, P6; MORRISON AS, 1985, SCREENING CHRONIC DI, P109; SACKETT DL, 1975, LANCET, V2, P357, DOI 10.1016/S0140-6736(75)92790-7; SPIGELMAN SS, 1986, J UROLOGY, V136, P1228, DOI 10.1016/S0022-5347(17)45292-X; STAMEY TA, 1983, MONOGR UROL, V4, P65; SWINSCOW TDV, 1978, STATISTICS SQUARE ON; THOMPSON IM, 1984, J UROLOGY, V132, P690, DOI 10.1016/S0022-5347(17)49828-4; THOMPSON IM, 1987, J UROLOGY, V137, P424, DOI 10.1016/S0022-5347(17)44055-9; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; 1987, WORKING GUIDELINES E, P26; 1989, GUIDE CLIN PREVENTIV, P63	26	101	102	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	1991	337	8756					1526	1529		10.1016/0140-6736(91)93207-P	http://dx.doi.org/10.1016/0140-6736(91)93207-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675379				2022-12-28	WOS:A1991FT11600014
J	WEBER, GF; MAERTENS, P; MENG, X; PIPPENGER, CE				WEBER, GF; MAERTENS, P; MENG, X; PIPPENGER, CE			GLUTATHIONE-PEROXIDASE DEFICIENCY AND CHILDHOOD SEIZURES	LANCET			English	Note								4 children with intractable seizures, repeated infections, and intolerance to anticonvulsants had evidence of glutathione peroxidase deficiency. 2 had low intracellular enzyme activity but normal blood selenium and high plasma glutathione peroxidase concentrations. The other 2 had low intracellular glutathione peroxidase activity with low circulating glutathione peroxidase and selenium concentrations. The clinical state of the children improved after discontinuation of anticonvulsant medication and selenium substitution.	UNIV SO ALABAMA,MED CTR,DEPT NEUROL,MOBILE,AL 36617; CLEVELAND CLIN FDN,DEPT BIOCHEM,CLEVELAND,OH 44195	University of South Alabama; Cleveland Clinic Foundation	WEBER, GF (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.							BAKER SS, 1983, J IMMUNOL, V130, P2856; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; HOLMES B, 1970, NEW ENGL J MED, V283, P217, DOI 10.1056/NEJM197007302830501; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PIPPENGER CE, 1989, ANTIEPILEPTIC DRUG I, P293; WILMORE LJ, 1981, NEUROLOGY, V31, P63	6	99	102	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1443	1444		10.1016/0140-6736(91)93130-2	http://dx.doi.org/10.1016/0140-6736(91)93130-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675321				2022-12-28	WOS:A1991FR06000007
J	SUNDERLAND, R				SUNDERLAND, R			TREATMENT OF CHILDHOOD FEVERS	LANCET			English	Letter											SUNDERLAND, R (corresponding author), SELLY OAK HOSP,BIRMINGHAM B29 6JD,ENGLAND.							KRAMER, 1991, LANCET, V337, P591	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1347	1348		10.1016/0140-6736(91)93020-A	http://dx.doi.org/10.1016/0140-6736(91)93020-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674320				2022-12-28	WOS:A1991FP08400037
J	OCALLAGHAN, E; SHAM, P; TAKEI, N; GLOVER, G; MURRAY, RM				OCALLAGHAN, E; SHAM, P; TAKEI, N; GLOVER, G; MURRAY, RM			SCHIZOPHRENIA AFTER PRENATAL EXPOSURE TO 1957 A2-INFLUENZA EPIDEMIC	LANCET			English	Article							INFLUENZA; BIRTH	The birth dates of schizophrenic inpatients in eight health regions in England and Wales were reviewed for any effect of the 1957 A2 influenza epidemic. 5 months after the peak infection prevalence, the number of births of individuals who later developed schizophrenia was 88% higher than the average number of such births in the corresponding periods of the 2 previous and the next 2 years. This finding is in accordance with a study from Helsinki and with clinical and neuropathological evidence of aberrant fetal brain development in the pathogenesis of schizophrenia.	INST PSYCHIAT,DEPT PSYCHOL MED,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT COMMUNITY MED,LONDON SW1P 2AP,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	University of London; King's College London; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Murray, Robin M/F-8658-2012; Takei, Nori/AAC-8578-2019; Takei, Nori/GWZ-7464-2022	Murray, Robin M/0000-0003-0829-0519; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOWLER AE, 1990, ARCH GEN PSYCHIAT, V47, P877; COFFEY VP, 1959, LANCET, V2, P935; DEGREEF G, 1988, BIOL PSYCHIAT, V24, P461, DOI 10.1016/0006-3223(88)90186-2; GUY JD, 1983, SCHIZOPHRENIA BULL, V9, P571, DOI 10.1093/schbul/9.4.571; JAKOB H, 1989, J ROY SOC MED, V82, P466, DOI 10.1177/014107688908200808; JOHNSTONE EC, 1976, LANCET, V2, P924; KENDELL RE, 1989, ARCH GEN PSYCHIAT, V46, P878; LECK I, 1963, BRIT J PREV SOC MED, V17, P70; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; MCDONALD JC, 1958, P ROY SOC MED, V51, P1016; MEDNICK SA, 1990, ARCH GEN PSYCHIAT, V47, P875; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; MENINGER KA, 1926, AM J PSYCHIAT, V82, P469; MURRAY RM, 1988, SCHIZOPHRENIA MAJOR, P90; MURRAY RM, 1985, GENETICS ASPECTS HUM, P63; OCALLAGHAN E, IN PRESS BR J PSYCHI; WEINBERGER DR, 1980, AM J PSYCHIAT, V137, P1410; ZIPURSKY RB, 1987, BIOL PSYCHIAT, V22, P1288, DOI 10.1016/0006-3223(87)90040-0; [No title captured]; 1958, REPORT REGISTRAR GEN	22	329	332	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1248	1250		10.1016/0140-6736(91)92919-S	http://dx.doi.org/10.1016/0140-6736(91)92919-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN047	1674062				2022-12-28	WOS:A1991FN04700003
J	NEUMANN, HPH; WIESTLER, OD				NEUMANN, HPH; WIESTLER, OD			CLUSTERING OF FEATURES OF VONHIPPEL-LINDAU SYNDROME - EVIDENCE FOR A COMPLEX GENETIC-LOCUS	LANCET			English	Article							RENAL-CELL CARCINOMA; FAMILIAL PHEOCHROMOCYTOMA; DISEASE; MEMBERS; REGION; 3P	von Hippel-Lindau syndrome (HLS), an autosomal-dominant inherited disease, was studied in 92 affected subjects from 29 kindreds. In an initial survey to identify HLS gene carriers, all patients treated at the University of Freiburg for angiomatosis retinae (22), haemangioblastoma of the central nervous system (CNS) (63), and phaeochromocytoma (54) were examined as potential HLS gene carriers. HLS was diagnosed in 86% of the patients with angiomatosis retinae, 19% of the patients with haemangioblastoma of the CNS, and 19% of the patients with phaeochromocytoma. Based on these and on an additional 49 newly diagnosed cases (24 by clinical examination and 25 by pedigree analysis), the calculated prevalence of the disease in the district of Freiburg, Germany, with a population of 1.909 million is 1/38 951. There was a striking tendency for familial clustering of HLS features in affected kindreds. Both angiomatosis retinae and haemangioblastoma of the CNS occurred in most families, whereas renal lesions and/or pancreatic cysts and phaeochromatocytoma were mutually exclusive. This finding suggests that HLS is caused by different mutations within a complex genetic locus, or additional genetic lesions, which cooperate with the HLS gene on chromosome 3p. Te data point to a linear sequence of features as follows: phaeochromocytoma, angiomatosis retinae, haemangioblastoma of the CNS, renal lesions, pancreatic cysts, and epididymal cystadenoma.	UNIV ZURICH,DEPT PATHOL,CH-8006 ZURICH,SWITZERLAND	University of Zurich	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT MED,W-7800 FREIBURG,GERMANY.							ATUK NO, 1979, MEDICINE, V58, P209, DOI 10.1097/00005792-197905000-00001; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; DECKER HJH, 1989, CANCER GENET CYTOGEN, V39, P289, DOI 10.1016/0165-4608(89)90194-5; DECKER HJH, 1988, CANCER GENET CYTOGEN, V33, P59, DOI 10.1016/0165-4608(88)90050-7; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GOODMAN J, 1964, J NEUROSURG, V21, P97, DOI 10.3171/jns.1964.21.2.0097; GOODMAN MD, 1990, CANCER, V65, P1150, DOI 10.1002/1097-0142(19900301)65:5<1150::AID-CNCR2820650520>3.0.CO;2-P; GREEN JS, 1986, CAN MED ASSOC J, V134, P133; HOFFMAN RW, 1982, ARCH INTERN MED, V142, P1962, DOI 10.1001/archinte.142.10.1962; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; KIECHLESCHWARZ M, 1989, HUM GENET, V82, P127, DOI 10.1007/BF00284043; KING CR, 1987, CANCER GENET CYTOGEN, V27, P345, DOI 10.1016/0165-4608(87)90017-3; LAMIELL JM, 1989, MEDICINE, V68, P1; MACRAE HM, 1969, CAN J OPHTHALMOL, V3, P28; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MULHOLLAND SG, 1969, J AMER MED ASSOC, V207, P1709, DOI 10.1001/jama.207.9.1709; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P309; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NICOL AAM, 1957, ANN HUM GENET, V22, P7, DOI 10.1111/j.1469-1809.1957.tb01293.x; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHARP WV, 1971, ANGIOLOGY, V22, P141, DOI 10.1177/000331977102200305; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; WELCH R B, 1977, International Ophthalmology Clinics, V17, P137, DOI 10.1097/00004397-197701720-00012	23	241	256	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1052	1054		10.1016/0140-6736(91)91705-Y	http://dx.doi.org/10.1016/0140-6736(91)91705-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673491				2022-12-28	WOS:A1991FK20400002
J	TOZUN, N; FORBES, A; ANDERSON, MG; MURRAYLYON, IM				TOZUN, N; FORBES, A; ANDERSON, MG; MURRAYLYON, IM			SAFETY OF ALCOHOL AFTER VIRAL-HEPATITIS	LANCET			English	Article								To test the validity of the generally held belief that moderate consumption of alcohol during convalescence from acute viral hepatitis adversely affects outcome, 87 adults recovering from acute viral hepatitis (hepatitis A in 36, hepatitis B in 34, hepatitis non-A, non-B in 17) were studied. Criteria for entry to the study attempted to ensure that no patient was a chronic hepatitis B carrier. Patients were randomised either to a moderate alcohol intake, or to continued complete abstention. Drinkers consumed 26 g alcohol daily (mean) and none remained abstinent. At 3 months all patients were well, with normal liver function tests. There were no significant differences between the two groups at any time. The findings suggest that moderate alcohol intake during convalescence from acute viral hepatitis does not seem to be harmful.	CHARING CROSS HOSP,GASTROINTESTINAL UNIT,LONDON W6 8RF,ENGLAND	Imperial College London				Forbes, Alastair/0000-0001-7416-9843				CULLINAN ER, 1958, BRIT MED J, V1, P1315, DOI 10.1136/bmj.1.5083.1315; Damodaran K, 1944, Br Med J, V2, P587; GARDNER HT, 1949, ANN INTERN MED, V30, P1009, DOI 10.7326/0003-4819-30-5-1009; NELSON RS, 1954, AM J MED, V16, P780, DOI 10.1016/0002-9343(54)90442-8; SJOGREN MH, 1987, ANN INTERN MED, V101, P635; VILLA E, 1982, LANCET, V2, P1243; 1983, DRUG THER B, V21, P89	7	9	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1079	1080		10.1016/0140-6736(91)91719-B	http://dx.doi.org/10.1016/0140-6736(91)91719-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673505				2022-12-28	WOS:A1991FK20400016
J	YUKI, N; SATO, S; MIYATAKE, T; SUGIYAMA, K; KATAGIRI, T; SASAKI, H				YUKI, N; SATO, S; MIYATAKE, T; SUGIYAMA, K; KATAGIRI, T; SASAKI, H			MOTONEURON-DISEASE-LIKE DISORDER AFTER GANGLIOSIDE THERAPY	LANCET			English	Letter							GM1		YAMAGATA UNIV,DEPT INTERNAL MED 3,YAMAGATA 990,JAPAN	Yamagata University	YUKI, N (corresponding author), NIIGATA UNIV,BRAIN RES INST,DEPT NEUROL,NIIGATA 951,JAPAN.		Yuki, Nobuhiro/H-3187-2012					BRADLEY WG, 1990, MUSCLE NERVE, V13, P833, DOI 10.1002/mus.880130910; FREDDO L, 1986, NEUROLOGY, V36, P454, DOI 10.1212/WNL.36.4.454; HOROWITZ SH, 1989, MUSCLE NERVE, V12, P314, DOI 10.1002/mus.880120410; NAGAI Y, 1976, NEUROSCI LETT, V2, P107, DOI 10.1016/0304-3940(76)90033-1; PESTRONK A, 1988, ANN NEUROL, V24, P73, DOI 10.1002/ana.410240113; YUKI N, 1990, NEUROLOGY, V40, P1900, DOI 10.1212/WNL.40.12.1900	6	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1109	1110		10.1016/0140-6736(91)91767-O	http://dx.doi.org/10.1016/0140-6736(91)91767-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673540				2022-12-28	WOS:A1991FK20400070
J	BERAL, V; PETERMAN, T; BERKELMAN, R; JAFFE, H				BERAL, V; PETERMAN, T; BERKELMAN, R; JAFFE, H			AIDS-ASSOCIATED NON-HODGKIN LYMPHOMA	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; BURKITTS-LYMPHOMA; HOMOSEXUAL MEN	Non-Hodgkin lymphoma is associated with HIV infection. We investigated the epidemiology and aetiology of AIDS-related non-Hodgkin lymphoma by analysing data from cases reported to the Centers for Disease Control, Atlanta, USA, up to June 30, 1989. During this period 97 258 AIDS cases were reported, of whom 2824 (2.9%) had non-Hodgkin lymphoma. The condition was about 60 times more common in AIDS patients than in the general US population. 1686 cases were immunoblastic lymphoma, 548 primary lymphoma of the brain, and 590 Burkitt's lymphoma, a condition which is not normally associated with immunosuppression. The proportion of AIDS patients with immunoblastic lymphoma increased from 0% in those under 1 year old to 3.5% in those aged 50 or more. Primary lymphoma of the brain was constant at 0.6% for all ages. The frequency of Burkitt's lymphoma increased from zero in infants to a peak at 10-19 years of age (1.8%). Each type of lymphoma was twice as common in whites as in blacks and in men as in women. Lymphoma was most common in patients with haemophilia or clotting disorders and least common in those born in the Caribbean or Africa who had acquired HIV by heterosexual contact. Epidemiological data suggested that whilst infectious agents (eg, Epstein-Barr virus) may be associated with development of non-Hodgkin lymphomas in AIDS patients there was probably no single cause for all the types of lymphoma. Perhaps the most puzzling question is why Burkitt's lymphoma is commonly associated with HIV infection but not with other types of immunosuppression.	CTR DIS CONTROL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.			Garba, Mohammed Ashir/0000-0002-4183-7769				BECKHARDT RN, 1988, MT SINAI J MED, V55, P383; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CREMER KJ, 1990, J NATL CANCER I, V82, P1016, DOI 10.1093/jnci/82.12.1016; DOLL DC, 1982, LANCET, V1, P1026; EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO;2-M; EPSTEIN LG, 1988, PEDIATRICS, V82, P355; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KINLEN LJ, 1982, CANCER SURV, V1, P567; Lenoir GM, 1989, IMMUNE DISORDERS OPP, P173; LEVINE AM, 1990, SEMIN ONCOL, V17, P104; LEVINE PH, 1985, IARC SCI PUBL, V60, P217; NG VL, 1989, 4TH INT C AIDS MONTR, P688; PENN I, 1983, TRANSPLANT P, V15, P2790; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; THOMAS JA, IN PRESS ADV CANCER; WHANGPENG J, 1984, BLOOD, V63, P818; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; ZIEGLER JL, 1982, LANCET, V2, P631; 1982, MMWR, V31, P277; 1987, MMWR S1S, V36, pS1; 1988, 1987 ANN CANCER STAT; 1984, LANCET, V1, P601; 1985, IARC SCI PUBLICATION, V60; 1985, INT CLASSIFICATION D; 1989, LANCET, V1, P249; 1989, LANCET, V1, P1171; 1988, J NATL CANCER I, V80, P855	27	543	556	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					805	809		10.1016/0140-6736(91)92513-2	http://dx.doi.org/10.1016/0140-6736(91)92513-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672911				2022-12-28	WOS:A1991FF22800001
J	VU, TKH; HUNG, DT; WHEATON, VI; COUGHLIN, SR				VU, TKH; HUNG, DT; WHEATON, VI; COUGHLIN, SR			MOLECULAR-CLONING OF A FUNCTIONAL THROMBIN RECEPTOR REVEALS A NOVEL PROTEOLYTIC MECHANISM OF RECEPTOR ACTIVATION	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN-PLATELETS; LIGAND-BINDING; HOMOLOGOUS DESENSITIZATION; BOVINE TRYPSINOGEN; EXPRESSION SYSTEM; INDUCED RELEASE; CDNA; PROTEIN; CELL	We isolated a cDNA encoding a functional human thrombin receptor by direct expression cloning in Xenopus oocytes. mRNA encoding this receptor was detected in human platelets and vascular endothelial cells. The deduced amino acid sequence revealed a new member of the seven transmembrane domain receptor family with a large amino-terminal extracellular extension containing a remarkable feature. A putative thrombin cleavage site (LDPR/S) resembling the activation cleavage site in the zymogen protein C (LDPR/I) was noted 41 amino acids carboxyl to the receptor's start methionine. A peptide mimicking the new amino terminus created by cleavage at R41 was a potent agonist for both thrombin receptor activation and platelet activation. "Uncleavable" mutant thrombin receptors failed to respond to thrombin but were responsive to the new amino-terminal peptide. These data reveal a novel signaling mechanism in which thrombin cleaves its receptor's amino-terminal extension to create a new receptor amino terminus that functions as a tethered ligand and activates the receptor.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VU, TKH (corresponding author), UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043322, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43322, HL 43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Baenziger N L, 1974, Methods Enzymol, V31, P149; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAHLBACK B, 1986, J BIOL CHEM, V261, P5111; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P2462, DOI 10.1021/bi00737a015; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRASER CM, 1989, J BIOL CHEM, V264, P9266; GREENBERG SM, 1988, BLOOD, V72, P1968; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Muszbek L, 1984, THROMBIN, P83; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PAPAYANNOPOULOU T, 1987, J CLIN INVEST, V79, P859, DOI 10.1172/JCI112895; PARIS S, 1988, J BIOL CHEM, V263, P11250; PHILLIPS DR, 1974, THROMB DIATH HAEMOST, V32, P207, DOI 10.1055/s-0038-1647686; PIPILISYNETOS E, 1990, BIOCHEM BIOPH RES CO, V171, P913, DOI 10.1016/0006-291X(90)90770-N; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERAGA HA, 1977, CHEM BIOL THROMBIN, P145; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; STENFLO J, 1982, J BIOL CHEM, V257, P2180; SUMIKAWA K, 1982, NUCLEIC ACIDS RES, V10, P5809, DOI 10.1093/nar/10.19.5809; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; VANOBBERGHENSCHILLING E, 1990, FEBS LETT, V262, P330, DOI 10.1016/0014-5793(90)80221-4; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118	60	2845	2986	0	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1057	1068		10.1016/0092-8674(91)90261-V	http://dx.doi.org/10.1016/0092-8674(91)90261-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1672265				2022-12-28	WOS:A1991FD55800004
J	BENGSTON, K; NICHOLS, MM; SCHNADIG, V; ELLIS, MD				BENGSTON, K; NICHOLS, MM; SCHNADIG, V; ELLIS, MD			SUDDEN-DEATH IN A CHILD FOLLOWING JELLYFISH ENVENOMATION BY CHIROPSALMUS-QUADRUMANUS - CASE-REPORT AND AUTOPSY FINDINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							WAR	Sudden death following coelenterate envenomation is not uncommon in Australia where the Pacific box jellyfish is indigenous. However, few cases of sudden fatal reactions have been reported in the Northern Hemisphere, and those that have occurred have all been attributed to the Portuguese man-of-war, Physalia physalis. We report the case of a child who died within 40 minutes of accidental envenomation with tentacles of a jellyfish, Chiropsalmus quadrumanus, and describe the findings at autopsy. This coelenterate may be of special danger to small children.	UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								AUERBACH PS, 1991, NEW ENGL J MED, V325, P486, DOI 10.1056/NEJM199108153250707; BURNETT JW, 1985, TOXICON, V23, P681, DOI 10.1016/0041-0101(85)90373-3; BURNETT JW, 1989, TOXICON, V27, P823, DOI 10.1016/0041-0101(89)90050-0; BURNETT JW, 1987, ANN EMERG MED, V16, P1000, DOI 10.1016/S0196-0644(87)80748-5; HALSTEAD B, 1988, DANGEROUS VENOMOUS M, P99; HASTINGS SG, 1967, P SOC EXP BIOL MED, V125, P41; IOANNIDES G, 1965, ARCH DERMATOL, V91, P448, DOI 10.1001/archderm.1965.01600110034008; LUMLEY J, 1988, MED J AUSTRALIA, V148, P527, DOI 10.5694/j.1326-5377.1988.tb99466.x; MAHONEY LT, 1986, J PEDIATR, V107, P207; Noren G R, 1977, J Forensic Sci, V22, P188	10	24	24	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1404	1406		10.1001/jama.266.10.1404	http://dx.doi.org/10.1001/jama.266.10.1404			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1679136				2022-12-28	WOS:A1991GD80700037
J	GARCIA, HH; MARTINEZ, M; GILMAN, R; HERRERA, G; TSANG, VCW; PILCHER, JB; DIAZ, F; VERASTEGUI, M; GALLO, C; PORRAS, M; ALVARADO, M; NARANJO, J; MIRANDA, E				GARCIA, HH; MARTINEZ, M; GILMAN, R; HERRERA, G; TSANG, VCW; PILCHER, JB; DIAZ, F; VERASTEGUI, M; GALLO, C; PORRAS, M; ALVARADO, M; NARANJO, J; MIRANDA, E			DIAGNOSIS OF CYSTICERCOSIS IN ENDEMIC REGIONS	LANCET			English	Article							CEREBRAL CYSTICERCOSIS; NEUROCYSTICERCOSIS; ASSAY	Taenia solium cysticercosis is a frequent cause of neurological disease in developing countries. Specific diagnosis of cysticercosis is difficult. We obtained serum and/or CSF samples from 204 consecutive patients admitted to a neurological ward in Lima, Peru, and looked for antibodies specific for T solium with the enzyme-linked immunoelectrotransfer blot (EITB) assay. 21 (12%) of 173 serum samples from these patients were EITB-positive. In contrast, only 2 (1.5%) of 135 patients attending a public endoscopy clinic and 1 (1%) of 88 patients attending a private endoscopy clinic were seropositive. 1 (1%) of 98 pregnant women living in a Lima shanty town was EITB-positive. 15 (58%) of 26 neurology patients diagnosed clinically as having cysticercosis were seronegative. Routine screening by EITB of all patients with neurological symptoms from areas of endemic cysticercosis would avoid misdiagnosis of this common and treatable disease.	CTR DIS CONTROL,CTR INFECT DIS,DIV PARASIT DIS,1600 CLIFTON RD,ATLANTA,GA 30333; UNIV PERUANA CAYETANO HEREDIA,LIMA,PERU; INST NACL CIENCIAS NEUROL,LIMA,PERU; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Centers for Disease Control & Prevention - USA; Universidad Peruana Cayetano Heredia; Johns Hopkins University			Gallo, Carla/Q-4296-2019	Evans, Carlton/0000-0002-6873-5447; Gallo, Carla/0000-0001-8348-0473; Verastegui, Manuela/0000-0002-7500-1353	Wellcome Trust [057434] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS R, 1987, PEDIATR INFECT DIS J, V6, P942, DOI 10.1097/00006454-198710000-00019; CHOPRA JS, 1981, T ROY SOC TROP MED H, V75, P4; FLISSER A, 1988, PARASITOL TODAY, V4, P131, DOI 10.1016/0169-4758(88)90187-1; FLISSER A, 1983, CYSTICERCOSIS CENTRA, P7; LOO L, 1982, MEDICINE, V61, P341, DOI 10.1097/00005792-198211000-00001; Lozano-Elizondo D, 1983, CYSTICERCOSIS CENTRA, P84; Mahajan R.C., 1982, P39; MCCORMICK GF, 1982, ARCH NEUROL-CHICAGO, V39, P534, DOI 10.1001/archneur.1982.00510210004002; MOHAMMAD IN, 1984, J CLIN MICROBIOL, V20, P775, DOI 10.1128/JCM.20.4.775-779.1984; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; Nava Segura J, 1983, Salud Publica Mex, V25, P297; RANGEL R, 1987, AM J TROP MED HYG, V36, P387, DOI 10.4269/ajtmh.1987.36.387; SALAZAR A, 1983, J NEUROSURG, V59, P660, DOI 10.3171/jns.1983.59.4.0660; Schenone H., 1982, P25; Takayanagui O M, 1983, Arq Neuropsiquiatr, V41, P50; TRELLES JO, 1978, HDB CLIN NEUROLOGY 3, V35, P291; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; 1989, 38TH ANN M AM SOC TR; [No title captured]	19	81	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					549	551						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678809				2022-12-28	WOS:A1991GD00200013
J	ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM				ODARCEDERLOF, I; THEODORSSON, E; ERICSSON, F; KJELLSTRAND, CM			PLASMA-CONCENTRATIONS OF CALCITONIN GENE-RELATED PEPTIDE IN FLUID OVERLOAD	LANCET			English	Note							ATRIAL-NATRIURETIC-PEPTIDE	To investigate the hypothesis that calcitonin gene-related peptide (CGRP), a potent vasodilator, is an important physiological defence against fluid overload, plasma CGRP concentrations were measured in various degrees of fluid overload in 26 haemodialysis patients, for whom diuresis, mediated by atrial natriuretic peptide (ANP), is not a possible defence mechanism. Plasma CGRP concentrations were positively correlated with the degree of fluid excess (r = 0.815, p = 0.0001) and were significantly higher in 5 patients with severe fluid overload than in those less severely affected (143 [SE 14] vs 52 [11] pmol/l; p < 0.001). CGRP may be an effective defence against complications of fluid overload since if can increase capitance by vasodilatation.	KAROLINSKA HOSP,DEPT CLIN CHEM,S-10401 STOCKHOLM 60,SWEDEN; UNIV ALBERTA HOSP,DEPT MED,DIV NEPHROL,EDMONTON T6G 2B7,ALBERTA,CANADA	Karolinska Institutet; Karolinska University Hospital; University of Alberta	ODARCEDERLOF, I (corresponding author), KAROLINSKA HOSP,DEPT INTERNAL MED,DIV NEPHROL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Theodorsson, Elvar/H-2096-2011	Theodorsson, Elvar/0000-0003-0756-7723				BERGLUND H, 1990, BRIT HEART J, V64, P9; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; ERICSSON F, 1983, NEPHRON, V33, P173, DOI 10.1159/000182937; GENNARI C, 1990, CARDIOVASC RES, V3, P239; GREENBERG B, 1987, BRIT J PHARMACOL, V92, P789, DOI 10.1111/j.1476-5381.1987.tb11382.x; LANG RE, 1985, NATURE, V314, P264, DOI 10.1038/314264a0; ODARCEDERLOF I, 1989, J INTERN MED, V226, P177, DOI 10.1111/j.1365-2796.1989.tb01376.x; TALARTSCHIK J, 1988, Z KARDIOL, V77, P72; YAMAMOTO A, 1988, BIOCHEM BIOPH RES CO, V155, P1452, DOI 10.1016/S0006-291X(88)81304-4	10	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					411	412		10.1016/0140-6736(91)91035-S	http://dx.doi.org/10.1016/0140-6736(91)91035-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678085				2022-12-28	WOS:A1991GB44600006
J	SINGH, BM; WISE, PH; MARKS, V				SINGH, BM; WISE, PH; MARKS, V			DETECTION OF GLIBENCLAMIDE IN ORAL INSULIN CAPSULES	LANCET			English	Letter									ST LUKES HOSP,GUILDFORD,SURREY,ENGLAND		SINGH, BM (corresponding author), CHARING CROSS HOSP,DEPT ENDOCRINOL,LONDON W6 8RF,ENGLAND.							CHO YW, 1989, LANCET, V2, P1518	1	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					308	309		10.1016/0140-6736(91)90448-X	http://dx.doi.org/10.1016/0140-6736(91)90448-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677127				2022-12-28	WOS:A1991FZ56500025
J	CARRIGAN, DR; DROBYSKI, WR; RUSSLER, SK; TAPPER, MA; KNOX, KK; ASH, RC				CARRIGAN, DR; DROBYSKI, WR; RUSSLER, SK; TAPPER, MA; KNOX, KK; ASH, RC			INTERSTITIAL PNEUMONITIS ASSOCIATED WITH HUMAN HERPESVIRUS-6 INFECTION AFTER MARROW TRANSPLANTATION	LANCET			English	Note							CYTOMEGALO-VIRUS	Severe interstitial pneumonitis in 2 marrow-transplant recipients was associated with human herpesvirus-6 (HHV-6) infection. The virus was repeatedly detected in respiratory specimens from 1 patient, and HHV-6-infected cells were shown in lung tissue from both patients by immunohistochemical staining. The infected cells were primarily intra-alveolar macrophages, although infected lymphocytes were seen. HHV-6 should be considered as a cause of unexplained lung disease in marrow-transplant recipients and other immunocompromised patients.	MED COLL WISCONSIN,DEPT MED,DIV HEMATOL ONCOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT MED,DIV INFECT DIS,MILWAUKEE,WI 53226; MED COLL WISCONSIN,BONE MARROW TRANSPLANT PROGRAM,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	CARRIGAN, DR (corresponding author), MED COLL WISCONSIN,DEPT PATHOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.		Drobyski, William/R-6994-2019					ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; FRENKEL N, 1990, J VIROL, V64, P4598, DOI 10.1128/JVI.64.9.4598-4602.1990; GLEAVES CA, 1985, J CLIN MICROBIOL, V21, P217, DOI 10.1128/JCM.21.2.217-221.1985; HUANG LM, 1990, LANCET, V336, P60, DOI 10.1016/0140-6736(90)91580-4; LEVY JA, 1990, VIROLOGY, V178, P113, DOI 10.1016/0042-6822(90)90384-4; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; RUSSLER SK, 1989, LANCET, V2, P382; RUSSLER SK, IN PRESS AM J PATHOL; SPECTOR S, 1990, SEMIN HEMATOL, V27, P1; TOORKEY CB, 1989, J INFECT DIS, V160, P741, DOI 10.1093/infdis/160.5.741	10	258	260	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					147	149		10.1016/0140-6736(91)90137-E	http://dx.doi.org/10.1016/0140-6736(91)90137-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677066				2022-12-28	WOS:A1991FX42400005
J	SINHA, S; NEWSOMDAVIS, J; MILLS, K; BYRNE, N; LANG, B; VINCENT, A				SINHA, S; NEWSOMDAVIS, J; MILLS, K; BYRNE, N; LANG, B; VINCENT, A			AUTOIMMUNE ETIOLOGY FOR ACQUIRED NEUROMYOTONIA (ISAACS SYNDROME)	LANCET			English	Article							MUSCLE HYPERTROPHY; PATIENT; CHANNEL	Neuromyotonia is a rare disorder of unknown cause in which hyperexcitability of peripheral motor nerves leads to incapacitating muscle twitching, cramps, and weakness. We investigated an antibody-mediated mechanism for neuromyotonia in a 24-year-old man with a 7-year history of severe disease unresponsive to pharmacological treatment. Two periods of plasma exchange each produced almost complete disappearance of symptoms for 2-3 weeks, and a highly significant decrease in recorded neuromyotonic discharges. Injection of the patient's plasma or purified IgG into mice significantly enhanced in-vitro resistance to d-tubocurarine at the neuromuscular junction of phrenic nerve-diaphragm preparations. This finding suggests that an increase in neurotransmitter release might result from an antibody-mediated reduction in the number of functional potassium channels that normally regulate nerve excitability. The demonstration of pathogenic IgG autoantibodies in acquired neuromyotonia suggests that immunosuppressive treatment may be helpful in severe cases.	UNIV OXFORD,INST MOLEC MED,NEUROSCI GRP,OXFORD,ENGLAND; UNIV OXFORD,DEPT CLIN NEUROL,OXFORD,ENGLAND; UNIV OXFORD,DEPT NEUROPHYSIOL,OXFORD,ENGLAND	University of Oxford; University of Oxford; University of Oxford				Sinha, Saurabh/0000-0001-7453-9576				BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BOSTOCK H, 1988, BRAIN RES, V462, P354, DOI 10.1016/0006-8993(88)90564-1; HOREJSI J, 1956, ACTA MED SCAND, V155, P65; ISAACS H, 1961, J NEUROL NEUROSUR PS, V24, P319, DOI 10.1136/jnnp.24.4.319; LANG B, 1981, LANCET, V2, P224; NAGASHIMA T, 1985, J NEUROL SCI, V67, P269, DOI 10.1016/0022-510X(85)90151-0; PARTANEN VSJ, 1980, ACTA NEUROL SCAND, V61, P216; REEBACK J, 1979, BRIT MED J, V1, P1464, DOI 10.1136/bmj.1.6176.1464; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; TOYKA KV, 1977, NEW ENGL J MED, V296, P125, DOI 10.1056/NEJM197701202960301; VASILESCU C, 1984, J NEUROL, V231, P276, DOI 10.1007/BF00313668; ZISFEIN J, 1983, ARCH NEUROL-CHICAGO, V40, P241, DOI 10.1001/archneur.1983.04050040071012	13	178	186	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					75	77		10.1016/0140-6736(91)90073-X	http://dx.doi.org/10.1016/0140-6736(91)90073-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676468				2022-12-28	WOS:A1991FW16100003
J	OLIVER, MF				OLIVER, MF			MIGHT TREATMENT OF HYPERCHOLESTEROLEMIA INCREASE NONCARDIAC MORTALITY	LANCET			English	Editorial Material							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; PREVENTION; MEN; TRIALS				OLIVER, MF (corresponding author), WYNN INST METAB RES, 21 WELLINGTON RD, LONDON NW8 9SQ, ENGLAND.							CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CUTTS JL, 1989, INT J IMMUNOPHARMACO, V11, P863, DOI 10.1016/0192-0561(89)90107-0; DAYTON S, 1969, CIRCULATION S2, V39, P1; EDERER F, 1971, LANCET, V2, P203; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEADY JA, 1980, LANCET, V2, P379; HJERMANN I, 1990, ATHER REV, V21, P103; HJERMANN I, 1981, LANCET, V2, P1303; LEAF A, 1990, NEW ENGL J MED, V323, P1416, DOI 10.1056/NEJM199011153232011; LINTON AL, 1990, J CLIN EPIDEMIOL, V43, P1021, DOI 10.1016/0895-4356(90)90146-G; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; OLIVER MF, 1981, LANCET, V2, P1090; OLIVER MF, 1988, J AM COLL CARDIOL, V12, P814, DOI 10.1016/0735-1097(88)90327-0; PETO R, 1991, J AM COLL CARDIOL, V17, P451; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; VIRKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; WEDER AB, 1991, HYPERTENSION, V17, P203, DOI 10.1161/01.HYP.17.2.203; YUSUF S, 1988, ATHEROSCLEROSIS, P389	23	145	145	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	1991	337	8756					1529	1531		10.1016/0140-6736(91)93208-Q	http://dx.doi.org/10.1016/0140-6736(91)93208-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675380				2022-12-28	WOS:A1991FT11600015
J	SHEPHERD, GL; JENKINS, WJ; ALEXANDER, J				SHEPHERD, GL; JENKINS, WJ; ALEXANDER, J			ASTHMA EXACERBATIONS IN PATIENTS TAKING REGULAR SALMETEROL, OR SALBUTAMOL FOR SYMPTOMS	LANCET			English	Letter											SHEPHERD, GL (corresponding author), GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND.							SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; 1991, LANCET, V337, P913	2	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1424	1424		10.1016/0140-6736(91)93118-S	http://dx.doi.org/10.1016/0140-6736(91)93118-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674807				2022-12-28	WOS:A1991FP87000057
J	KAUFMAN, LD; GRUBER, BL; GREGERSEN, PK				KAUFMAN, LD; GRUBER, BL; GREGERSEN, PK			CLINICAL FOLLOW-UP AND IMMUNOGENETIC STUDIES OF 32 PATIENTS WITH EOSINOPHILIA-MYALGIA-SYNDROME	LANCET			English	Article								31 patients with L-tryptophan-associated eosinophilia-myalgia syndrome (EMS) that developed during the United States outbreak in 1989 were followed up prospectively at a university hospital outpatient rheumatology clinic for 16 to 24 months from the onset of their illness. Another patient with EMS associated with L-tryptophan in 1988 was followed up for 30 months. 93% of the 28 survivors from the 1989 cohort continue to have symptoms affecting 1-4 organ systems (median 3) and 3 have died, so the disorder produces considerable morbidity and mortality. The chronic sequelae most often associated with long-term disability are sclerodermatous skin thickening (54%), sensorimotor polyneuropathy (61%), proximal myopathy (36%), and severe episodic myalgias (64%). Thrombocytopenia developed in 1 patient. HLA-class II typing revealed a non-significant trend towards an association with HLA-DR4. Early therapy with corticosteroids did not seem to prevent the development of chronic manifestations.	CORNELL UNIV, N SHORE UNIV HOSP,COLL MED,DEPT MED,DIV MOLEC MED, MANHASSET, NY 11030 USA	Cornell University; Northwell Health; North Shore University Hospital	KAUFMAN, LD (corresponding author), SUNY STONY BROOK, HLTH SCI CTR T16040, DEPT MED, DIV ALLERGY RHEUMATOL & CLIN IMMUNOL, STONY BROOK, NY 11794 USA.							BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; CROFFORD LJ, 1990, J CLIN INVEST, V86, P1757, DOI 10.1172/JCI114902; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1990, J RHEUMATOL, V17, P795; KAUFMAN LD, 1990, MEDICINE, V69, P187, DOI 10.1097/00005792-199007000-00001; KAUFMAN LD, 1990, J AM ACAD DERMATOL, V23, P1063, DOI 10.1016/0190-9622(90)70334-E; KAUFMAN LD, IN PRESS RHEUM DIS C; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; LAKHANPAL S, 1988, SEMIN ARTHRITIS RHEU, V17, P221, DOI 10.1016/0049-0172(88)90008-X; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MEDSGER TA, 1968, ARTHRITIS RHEUM-US, V11, P554, DOI 10.1002/art.1780110405; SEIDMAN RJ, 1991, J NEUROPATH EXP NEUR, V50, P49, DOI 10.1097/00005072-199101000-00004; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAZELAAR HD, 1990, CHEST, V97, P1032, DOI 10.1378/chest.97.5.1032; TSOKOS GC, 1981, ARCH INTERN MED, V246, P766; VARGA J, 1990, SEMIN ARTHRITIS RHEU, V19, P313, DOI 10.1016/0049-0172(90)90069-R; VICARIO JL, 1982, LANCET, V1, P276; 1989, MMWR, V38, P765	20	71	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1071	1074		10.1016/0140-6736(91)91717-9	http://dx.doi.org/10.1016/0140-6736(91)91717-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673503				2022-12-28	WOS:A1991FK20400014
J	PINION, SB; KENNEDY, JH; MILLER, RW; MACLEAN, AB				PINION, SB; KENNEDY, JH; MILLER, RW; MACLEAN, AB			ONCOGENE EXPRESSION IN CERVICAL INTRAEPITHELIAL NEOPLASIA AND INVASIVE CANCER OF CERVIX	LANCET			English	Note							C-MYC ONCOGENE; UTERINE CERVIX; RAS ONCOGENE; PAPILLOMAVIRUS; PROGNOSIS; CARCINOMA	Expression of the oncogenes Ha-RAS, c-MYC, and ERB-2 was investigated with an automated image analysis system in 12 specimens of normal cervix, 10 of cervical intraepithelial neoplasia (CIN) grade 1, 24 of CIN 3, and 10 of invasive cancer of the cervix. There was amplification of all three oncogenes in CIN 3 and invasive cancer compared with normal cervix and CIN 1. The difference was most pronounced with an antibody to the RAS p21 protein, with no overlap between CIN 3 and the normal range. This method might be useful in screening for cervical neoplasia, and for the determination of which CIN lesions require treatment.	WESTERN INFIRM & ASSOCIATED HOSP,DEPT GYNAECOL,GLASGOW G11 6NT,SCOTLAND; UNIV STRATHCLYDE,DEPT BIOMED INSTRUMENTAT,GLASGOW G1 1XW,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT GYNAECOL,GLASGOW G4 0SF,SCOTLAND	University of Strathclyde; University of Glasgow	PINION, SB (corresponding author), ABERDEEN ROYAL INFIRM,DEPT GYNAECOL,ABERDEEN AB9 2ZB,SCOTLAND.							DILUCA D, 1989, INT J CANCER, V43, P570, DOI 10.1002/ijc.2910430407; HENDYIBBS P, 1987, BRIT J CANCER, V55, P275, DOI 10.1038/bjc.1987.53; HUGHES RG, 1989, J CLIN PATHOL, V42, P46, DOI 10.1136/jcp.42.1.46; LONG CA, 1988, AM J OBSTET GYNECOL, V159, P1512, DOI 10.1016/0002-9378(88)90586-8; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1985, PAPILLOMAVIRUSES MOL, P47; SAGAE S, 1989, CANCER-AM CANCER SOC, V63, P1577, DOI 10.1002/1097-0142(19890415)63:8<1577::AID-CNCR2820630822>3.0.CO;2-C; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SOWANI A, 1989, MOL CELL PROBE, V3, P117, DOI 10.1016/0890-8508(89)90022-4; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0	10	67	69	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					819	820		10.1016/0140-6736(91)92518-7	http://dx.doi.org/10.1016/0140-6736(91)92518-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672915				2022-12-28	WOS:A1991FF22800006
J	COX, IM; CAMPBELL, MJ; DOWSON, D				COX, IM; CAMPBELL, MJ; DOWSON, D			RED-BLOOD-CELL MAGNESIUM AND CHRONIC FATIGUE SYNDROME	LANCET			English	Article							MYALGIC ENCEPHALOMYELITIS; EPIDEMIC; INFECTION	The hypotheses that patients with chronic fatigue syndrome (CFS) have low red blood cell magnesium and that magnesium treatment would improve the wellbeing of such patients were tested in a case-control study and a randomised, double-blind, placebo-controlled trial, respectively. In the case-control study, 20 patients with CFS had lower red cell magnesium concentrations than did 20 healthy control subjects matched for age, sex, and social class (difference 0.1 mmol/l, 95% confidence interval [CI] 0.05 to 0.15). In the clinical trial, 32 patients with CFS were randomly allocated either to intramuscular magnesium sulphate every week for 6 weeks (15 patients) or to placebo (17). Patients treated with magnesium claimed to have improved energy levels, better emotional state, and less pain, as judged by changes in the Nottingham health profile. 12 of the 15 treated patients said that they had benefited from treatment, and in 7 patients energy score improved from the maximum to the minimum. By contrast, 3 of the 17 patients on placebo said that they felt better (difference 62%, 95% CI 35 to 90), and 1 patient had a better energy score. Red cell magnesium returned to normal in all patients on magnesium but in only 1 patient on placebo. The findings show that magnesium may have a role in CFS.	SOUTHAMPTON GEN HOSP,S ACAD BLOCK,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,SCH MED,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton; University of Southampton								ABRAHAM AS, 1980, BIOCHEM MED METAB B, V24, P21, DOI 10.1016/0006-2944(80)90082-4; ABRAHAM GE, 1981, AM J CLIN NUTR, V34, P1264; ALFREY AC, 1974, J LAB CLIN MED, V84, P153; BASTIEN S, 1990, APR CAMBR S MYALG EN; CALDER BD, 1984, J ROY COLL GEN PRACT, V34, P15; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DEVANE J, 1980, IRISH J MED SCI, V149, P73; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JOHANSSON BW, 1984, ACTA PHARMACOL TOX, V54, P125; JONES JP, 1985, ANN INTERN MED, V201, P1; KENDELL RE, 1991, LANCET, V337, P160; LLOYD AR, 1988, LANCET, V1, P1286; LLOYD AR, 1990, 1990 CAMBR S MYALG E, P1; MCEVEDY CP, 1973, BRIT J PSYCHIAT, V122, P141, DOI 10.1192/bjp.122.2.141; MCEVEDY CP, 1970, BRIT MED J, V1, P7, DOI 10.1136/bmj.1.5687.7; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; MILNER A, 1984, INTRO ATOMIC ABSORPT, P78; RAMSAY AM, 1957, LANCET, V2, P1196; SCHMIDT M, 1989, MAGNESIUM RES, V2, P281; Seelig M, 1980, MAGNESIUM DEFICIENCY; WEBB WL, 1981, PSYCHOSOMATICS, V22, P199; YOUSEF GE, 1988, LANCET, V1, P146; 1985, LANCET, V1, P1017	25	143	151	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					757	760		10.1016/0140-6736(91)91371-Z	http://dx.doi.org/10.1016/0140-6736(91)91371-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672392				2022-12-28	WOS:A1991FD88400004
J	HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; GREENWOOD, BM; MCMICHAEL, AJ				HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; GREENWOOD, BM; MCMICHAEL, AJ			HLA CLASS-I TYPING BY PCR - HLA-B27 AND AN AFRICAN B27 SUBTYPE	LANCET			English	Article							ANKYLOSING-SPONDYLITIS; POPULATION; ANTIGENS; DNA	We describe a rapid method of HLA class I typing using the polymerase chain reaction and oligonucleotide hybridisation that eliminates the requirements for viable lymphocytes and allows subtypes to be defined. We have used this to demonstrate that the predominant subtype of HLA-B27 in the Gambia, West Africa, is HLA-B*2703, which is very rare or absent in other racial groups. This subtype differs from the common Caucasian HLA-B27 subtypes in its recognition by cytotoxic T cells. We propose that HLA*B-2703, unlike other HLA-B27 subtypes, may not be associated with ankylosing spondylitis, thus accounting in part for the rarity of this condition in black populations.	MRC LABS,FAJARA,SENEGAMBIA		HILL, AVS (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353; BREWERTON DA, 1973, LANCET, V1, P904; CALVO V, 1990, J IMMUNOL, V144, P4038; Cave L, 1965, Rhumatologie, V17, P153; CHERTKOFF LP, 1988, HUM IMMUNOL, V23, P241, DOI 10.1016/0198-8859(88)90060-2; CHOO SY, 1988, HUM IMMUNOL, V21, P209; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DEWAAL L, 1987, J IMMUNOL, V139, P3396; DUTOIT ED, 1988, TISSUE ANTIGENS, V31, P109; FERNANDEZVINA M, 1990, HUM IMMUNOL, V28, P51, DOI 10.1016/0198-8859(90)90102-U; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTON JSH, 1990, CLIN EXP IMMUNOL, V82, P1; GREENWOOD BM, 1970, ANN RHEUM DIS, V29, P56, DOI 10.1136/ard.29.1.56; KALIDI I, 1988, TISSUE ANTIGENS, V31, P98, DOI 10.1111/j.1399-0039.1988.tb02070.x; KHAN MA, 1977, J RHEUMATOL, V4, P39; OKOYE RC, 1989, TISSUE ANTIGENS, V33, P445, DOI 10.1111/j.1399-0039.1989.tb01693.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SCARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0	24	151	161	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					640	642		10.1016/0140-6736(91)92452-8	http://dx.doi.org/10.1016/0140-6736(91)92452-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671992				2022-12-28	WOS:A1991FB73000004
J	KRAMER, MS; NAIMARK, LE; ROBERTSBRAUER, R; MCDOUGALL, A; LEDUC, DG				KRAMER, MS; NAIMARK, LE; ROBERTSBRAUER, R; MCDOUGALL, A; LEDUC, DG			RISKS AND BENEFITS OF PARACETAMOL ANTIPYRESIS IN YOUNG-CHILDREN WITH FEVER OF PRESUMED VIRAL ORIGIN	LANCET			English	Article							SURVIVAL; TEMPERATURE; PHOBIA	To examine whether antipyretic therapy in young children is associated with potential risks (interference with enhanced host defences at febrile temperatures) or benefits (improved comfort and behaviour), a randomised, double-blind, placebo-controlled trial of paracetamol was conducted among 225 children 6 months to 6 years of age who presented with acute (less-than-or-equal-to 4 days) fever (greater-than-or-equal-to 38-degrees-C per rectum) without evident bacterial focus of infection. Parents were asked to give paracetamol liquid 10-15 mg/kg or placebo every 4 h as needed for fever and to avoid bathing, sponging, or other pharmacological agents. Parents kept temperature and symptom diaries and recorded changes in child comfort and behaviour according to a pretested, 5-category Likert-type questionnaire 1-2 h after every dose. There were no significant differences between treated and placebo groups in mean duration of subsequent fever (34.7 vs 36.1 h) or other symptoms (72.9 vs 71.7 h). Paracetamol-treated children were more likely to be rated by their parents as having at least a 1-category improvement in activity (38 vs 11%; p = 0.005) and alertness (33 vs 12%; p = 0.036) but no significant differences were noted in mood, comfort, appetite, or fluid intake. That overall improvement in behaviour and comfort with paracetamol was not impressive is underscored by the inaccuracy of parents' "guess" at the end of the trial as to which agent their child had received - 45% correct guesses for paracetamol and 52% for placebo. The data suggest that the clinically relevant hazards and benefits of paracetamol antipyresis have been exaggerated.	MCGILL UNIV,FAC MED,DEPT PEDIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,FAC MED,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3A 2T5,QUEBEC,CANADA	McGill University; McGill University								AMEND DF, 1970, J FISH RES BOARD CAN, V27, P265, DOI 10.1139/f70-034; BERNARD C, 1976, LECONS CHALEUR ANIMA; BERNHEIM HA, 1976, SCIENCE, V193, P237, DOI 10.1126/science.935867; CARMICHAEL LE, 1969, J INFECT DIS, V120, P669, DOI 10.1093/infdis/120.6.669; COVERT JB, 1977, NATURE, V267, P43, DOI 10.1038/267043a0; DORAN TF, 1989, J PEDIATR-US, V114, P1045, DOI 10.1016/S0022-3476(89)80461-5; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; HANSON DF, 1983, J IMMUNOL, V130, P216; HO M, 1970, ARCH INTERN MED, V126, P134; JAMPEL HD, 1983, J EXP MED, V157, P1229, DOI 10.1084/jem.157.4.1229; KLUGER MJ, 1975, SCIENCE, V188, P166, DOI 10.1126/science.1114347; KRAMER MS, 1985, PEDIATRICS, V75, P1110; MCMAHON F, 1984, PEDIATRICS, V73, P600; MUZENBERGER JP, 1981, AM J HOSP PHARM, V38, P861; NULLBACKER A, 1984, J VIROL, V52, P928; Redman Coxe J., 1846, WRITINGS HIPPOCRATES; RON Y, 1984, J IMMUNOL, V133, P2037; SCHMITT BD, 1980, AM J DIS CHILD, V134, P176, DOI 10.1001/archpedi.1980.02130140050015; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; STROUSE S, 1909, J EXP MED, V111, P743; TEISNER B, 1974, NATURE, V147, P568	21	86	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					591	594		10.1016/0140-6736(91)91648-E	http://dx.doi.org/10.1016/0140-6736(91)91648-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671951				2022-12-28	WOS:A1991FA70200012
J	SMIRNE, S; IANNACCONE, S; FERINISTRAMBI, L; COMOLA, M; COLOMBO, E; NEMNI, R				SMIRNE, S; IANNACCONE, S; FERINISTRAMBI, L; COMOLA, M; COLOMBO, E; NEMNI, R			MUSCLE-FIBER TYPE AND HABITUAL SNORING	LANCET			English	Article							OBSTRUCTIVE SLEEP-APNEA; SKELETAL-MUSCLES; STIMULATION; AIRWAY	Although anatomical abnormalities of the upper airway have been recorded in some patients with obstructive sleep apnoea (OSA), a muscle tone dysregulation also seems to have an important role in this disorder. Since habitual snoring is the initial stage of OSA, the structural characteristics of upper airway muscles (medium pharyngeal constrictor muscle [MPCM]) from 13 men (9 non-snorers and 4 habitual snorers) were studied. MPCM fibre structure in non-snorers was broadly similar to that in normal limb muscles, with the exception that fibre diameters were smaller for all fibre types. Compared with limb muscles, MPCM had a smaller proportion of type IIb fibres and a higher proportion of types I and IIa fibres. MPCM in habitual snorers had an abnormal distribution of fibre types (low percentage of type I and type IIb fibres and high percentage of type IIa fibres) compared with non-snorers (p < 0.001) and the type IIa fibres were hypertrophic. No myopathic or neurogenic changes were seen. Two possible hypotheses explain the abnormal distribution of fibre types in snorers. First, a constitutionally determined reduction of slow alpha-motor neurons induces an adaptive transformation of type IIb to type IIa fibres and a hypertrophy of type IIa fibres; or, second, motor neurons change their patterns of discharge and, hence, of activation, and modify fibre-type distribution of MPCM as an adaptation to the anatomical characteristic of upper airway and habitual snoring.	UNIV MILAN,CTR SLEEP DISORDERS,I-20122 MILAN,ITALY; HOSP NIGUARDA CA GRANDA,DEPT OTOLARYNGOL,MILAN,ITALY	University of Milan	SMIRNE, S (corresponding author), UNIV MILAN,SCI INST HS RAFFAELE,DEPT NEUROL,VIA PRINETTI 29,I-20127 MILAN,ITALY.		STRAMBI, Luigi FERINI/K-3620-2018; Iannaccone, sandro/K-4252-2018	STRAMBI, Luigi FERINI/0000-0003-2867-5424; Iannaccone, sandro/0000-0002-8333-3972				ALAMOOD WS, 1987, J PHYSIOL-LONDON, V392, P377, DOI 10.1113/jphysiol.1987.sp016786; Astrom K.E., 1981, DISORDERS VOLUNTARY, P151; BARNARD RJ, 1970, J APPL PHYSIOL, V28, P762, DOI 10.1152/jappl.1970.28.6.762; BASMAJIAN JV, 1955, ARCH NEURO PSYCHIATR, V73, P224, DOI 10.1001/archneurpsyc.1955.02330080102019; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; Buller AJ, 1974, DISORDERS VOLUNTARY, P20; COTTER M, 1986, EXP NEUROL, V93, P531, DOI 10.1016/0014-4886(86)90173-1; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI, P82; GRIMBY G, 1983, CLIN PHYSIOL, V3, P209, DOI 10.1111/j.1475-097X.1983.tb00704.x; GRIMBY G, 1982, ACTA PHYSL SCAND, V115, P124; GUILLEMINAULT C, 1978, EXP NEUROL, V62, P48, DOI 10.1016/0014-4886(78)90040-7; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HISHIKAWA Y, 1965, ELECTROEN CLIN NEURO, V18, P487, DOI 10.1016/0013-4694(65)90129-X; HORNER RL, 1989, EUR RESPIR J, V2, P613; LEESE G, 1986, ACTA ANAT, V127, P77; LEXELL J, 1983, ACTA PHYSIOL SCAND, V117, P115, DOI 10.1111/j.1748-1716.1983.tb07185.x; LUGARESI E, 1983, B EUR PHYSIOPATH RES, V19, P590; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; ROJEWSKI TE, 1984, OTOLARYNG HEAD NECK, V92, P127, DOI 10.1177/019459988409200201; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SULLIVAN CE, 1987, SLEEP AGING RELATED, P47; SURATT PM, 1983, AM REV RESPIR DIS, V127, P487, DOI 10.1164/arrd.1983.127.4.487; TAUBER ES, 1977, ANN NEUROL, V2, P66, DOI 10.1002/ana.410020112; THORSTENSSON A, 1976, ACTA PHYSL SCAND S, V443, P7; WADE AJ, 1990, LANCET, V335, P805, DOI 10.1016/0140-6736(90)90933-V	25	89	92	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					597	599						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671953				2022-12-28	WOS:A1991FA70200014
J	STORCK, M; HARTL, WH; ZIMMERER, E; INTHORN, D				STORCK, M; HARTL, WH; ZIMMERER, E; INTHORN, D			COMPARISON OF PUMP-DRIVEN AND SPONTANEOUS CONTINUOUS HEMOFILTRATION IN POSTOPERATIVE ACUTE-RENAL-FAILURE	LANCET			English	Article							CONTINUOUS ARTERIOVENOUS HEMOFILTRATION; INTENSIVE-CARE UNIT; LEUKOTRIENES; MANAGEMENT; PROGNOSIS; LUNG	In a comparison of spontaneous continuous arteriovenous haemofiltration (CAVH) and pump-driven haemofiltration (PDHF) for acute renal failure after surgery, 116 patients admitted to a surgical intensive care unit were assigned CAVH (48) or PDHF (68). The method of assignment was that a patient was treated by PDHF if he or she was the only patient requiring treatment at that time (only one pump was available); any other patient coming to the unit would be treated by CAVH. The groups were slightly unbalanced because there were fewer simultaneous cases than expected. The main endpoints were survival rate, control of uraemia, and additional application of haemodialysis. There were no differences between the patient groups in age, duration of treatment, severity of illness, serum creatinine concentration at the start of treatment, or cause of acute renal failure. Both treatments adequately controlled uraemia and fluid overload. However, the survival rate was significantly higher with PDHF than with CAVH (6 [12.5%] vs 20 [29.4%]; p < 0.05). The daily ultrafiltrate volume was significantly higher with PDHF than with CAVH (15.7 [95% confidence interval 13.6-17.8] vs 7.0 [6.6-7.4] 1/day; p < 0.05). The volume of ultrafiltrate in patients with ischaemic or sepsis-induced acute renal failure was correlated with the survival rate. This finding suggests that the better survival rate in the PDHF group was due to faster elimination of toxic mediators (of molecular weight 800-1000 daltons) through the filter membrane by high-volume haemofiltration.			STORCK, M (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG,MARCHIONINISTR 15,W-8000 MUNICH 70,GERMANY.		hartl, Wolfgang/I-1981-2012; Storck, Martin/L-6893-2017					BADR KF, 1986, KIDNEY INT, V30, P474, DOI 10.1038/ki.1986.210; BALL HA, 1986, INTENS CARE MED, V12, P116; BARTLETT RH, 1986, SURGERY, V100, P400; BARTLETT RH, 1988, T AM SOC ART INT ORG, V34, P67; BINGEL M, 1987, LANCET, V1, P14; CERRA FB, 1990, ARCH SURG-CHICAGO, V125, P519; CHARLSON ME, 1989, ANN SURG, V209, P328, DOI 10.1097/00000658-198903000-00013; COHEN J, 1977, STATISTICAL POWER AN, P186; CORAIM F, 1985, CONTINUOUS ARTERIOVE, P103; DAVENPORT A, 1987, LANCET, V1, P216; DECAMP MM, 1988, JAMA-J AM MED ASSOC, V260, P530, DOI 10.1001/jama.260.4.530; GOTLOIB L, 1986, RESUSCITATION, V13, P123, DOI 10.1016/0300-9572(86)90016-X; KINDLER J, 1985, 1984 INT C CAVH AACH, P129; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KRAMAN S, 1979, CRIT CARE MED, V7, P263, DOI 10.1097/00003246-197906000-00002; KRAMER P, 1977, KLIN WOCHENSCHR, V55, P1121, DOI 10.1007/BF01477940; KRONFOL NO, 1986, T AM SOC ART INT ORG, V32, P85; KWAAN JH, 1980, AM SURGEON, V146, P295; LIANO F, 1989, NEPHRON, V51, P307, DOI 10.1159/000185314; LOPEZHERCE J, 1989, INTENS CARE MED, V15, P224, DOI 10.1007/BF00271055; MAHER ER, 1988, LANCET, V2, P129; MATSON J, 1990, FASEB Journal, V4, pA953; MAULT JR, 1987, SURGERY, V101, P478; MORGAN JM, 1988, INT J CARDIOL, V21, P259, DOI 10.1016/0167-5273(88)90103-9; MYERS BD, 1986, NEW ENGL J MED, V314, P97; PEACHEY TD, 1988, LANCET, V2, P878; SCHETZ M, 1989, INTENS CARE MED, V15, P349; SIVAK ED, 1986, CRIT CARE MED, V14, P48, DOI 10.1097/00003246-198601000-00011; SUSINI G, 1990, CRIT CARE MED, V18, P14, DOI 10.1097/00003246-199001000-00004; WENDON J, 1989, INTENS CARE MED, V15, P358; ZOBEL G, 1989, CRIT CARE MED, V17, P534, DOI 10.1097/00003246-198906000-00010	32	153	159	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					452	455		10.1016/0140-6736(91)93393-N	http://dx.doi.org/10.1016/0140-6736(91)93393-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671471				2022-12-28	WOS:A1991EY88700004
J	BROWN, PH; CROMPTON, GK; GREENING, AP				BROWN, PH; CROMPTON, GK; GREENING, AP			PROINFLAMMATORY CYTOKINES IN ACUTE ASTHMA	LANCET			English	Article							COLONY-STIMULATING FACTOR; SOLUBLE INTERLEUKIN-2 RECEPTOR; BRONCHIAL-ASTHMA; INTERFERON-GAMMA; CELLS INVITRO; ACTIVATION; MACROPHAGE; EXPRESSION; DISEASE; IONOPHORE-A23187	Cytokine-mediated interactions between monocytes/macrophages, lymphocytes, and eosinophils may be important in regulation of airway inflammation in asthma. Peripheral blood cytokine concentrations were measured in twenty adults with severe, acute asthma, ten with mild asthma (intermittent inhaled beta-agonists), twelve with chronic asthma (high-dose inhaled steroids), and in sixteen healthy subjects. Interleukin-1-beta, tumour necrosis factor, and interferon-gamma were not detected in most subjects. Granulocyte macrophage colony-stimulating factor concentrations were higher in patients with severe asthma than in healthy subjects (median 179 vs 80 pg/ml; 95% confidence interval for difference 16-168; p = 0.009). Plasma concentrations of soluble interleukin-2 receptor (sIL-2R) were similar in all asthma groups (geometric mean in severe acute group 570 U/ml, mild group 559 U/ml, and chronic group 560 U/ml) and higher than those in healthy controls (361 U/ml, p < 0.01). Sequential sIL-2R measurements were done in fifteen of the patients with severe acute asthma. There was no difference between baseline concentrations and those after 2 days of steroid treatment but by day 7 they had fallen significantly (ratio day 7/day 3 = 0.74, [95% CI 0.67=0.82]; p < 0.001); however, there was no correlation with improvement in peak expiratory flow. This study provides further evidence for T-lymphocyte activation in asthma but shows that plasma sIL-2R is not a useful marker of disease activity.			BROWN, PH (corresponding author), NO GEN HOSP,RESP UNIT,FERRY RD,EDINBURGH EH5 2DQ,MIDLOTHIAN,SCOTLAND.							ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BERMAN JS, 1990, AM REV RESPIR DIS, V142, P238, DOI 10.1164/ajrccm/142.1.238; CANNON JG, 1988, LYMPHOKINE RES, V7, P457; CHOW CC, 1990, CLIN ENDOCRINOL, V33, P317, DOI 10.1111/j.1365-2265.1990.tb00496.x; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; COLVER GB, 1989, BRIT MED J, V298, P1426, DOI 10.1136/bmj.298.6685.1426; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUFF GW, 1989, LANCET, V1, P1432; GIN W, 1985, J ALLERGY CLIN IMMUN, V76, P675, DOI 10.1016/0091-6749(85)90670-0; HERRMANN F, 1988, J CLIN INVEST, V81, P1415, DOI 10.1172/JCI113471; HOLTER W, 1987, J IMMUNOL, V138, P2917; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; HUNNINGHAKE GW, 1987, AM REV RESPIR DIS, V135, P66; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KUS J, 1990, CLIN EXP ALLERGY, V20, P165, DOI 10.1111/j.1365-2222.1990.tb02662.x; LEE TH, 1990, RESP MED, V84, P259, DOI 10.1016/S0954-6111(08)80049-2; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MACDONALD HR, 1986, ANNU REV CELL BIOL, V2, P231; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; ROUBIN R, 1987, CLIN EXP IMMUNOL, V70, P484; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; SYMONS JA, 1988, J IMMUNOL, V141, P2612; TIMONEN T, 1985, CLIN EXP IMMUNOL, V59, P85	30	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					590	593		10.1016/0140-6736(91)90605-O	http://dx.doi.org/10.1016/0140-6736(91)90605-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679152				2022-12-28	WOS:A1991GD80900002
J	DART, AM; LACOMBE, F; YEOH, JK; CAMERON, JD; JENNINGS, GL; LAUFER, E; ESMORE, DS				DART, AM; LACOMBE, F; YEOH, JK; CAMERON, JD; JENNINGS, GL; LAUFER, E; ESMORE, DS			AORTIC DISTENSIBILITY IN PATIENTS WITH ISOLATED HYPERCHOLESTEROLEMIA, CORONARY-ARTERY DISEASE, OR CARDIAC TRANSPLANT	LANCET			English	Article							HYPERTENSION; STIFFNESS; AGE	The stiffness of the thoracic aorta can be assessed non-invasively. If aortic stiffness can be shown to be related to coronary heart disease, perhaps it can be used to identify which patients with hypercholesterolaemia are most likely to have atheromatous changes and thus to be selected for intensive cholesterol-lowering treatment. Hence the distensibility of the transverse aortic arch was measured by echocardiography of the aortic arch in four groups of patients-symptom-free patients with normal serum cholesterol; symptom-free patients with raised serum cholesterol; patients with coronary heart disease (all with raised serum cholesterol), and post-heart-transplant patients. In all groups distensibility fell with age. The regression slope was steeper (p < 0.05) for patients with known coronary disease than for either of the disease-free groups, and among cardiac transplant recipients there was also a segregation of distensibility values between those with and without atheroma in their native hearts. The results indicate that aortic distensibility might be an indicator of coronary heart disease and that it might be useful in identifying which symptom-free subjects with modest hypercholesterolaemia should be treated aggressively.	ALFRED HOSP, ALFRED & BAKER MED UNIT, MELBOURNE, AUSTRALIA; ALFRED HOSP, HEART REPLACEMENT SERV, MELBOURNE, AUSTRALIA; ALFRED HOSP, LUNG REPLACEMENT SERV, MELBOURNE, AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health			Cameron, james/GQP-4595-2022; Jennings, Garry/B-3914-2009; Dart, Anthony M/E-7461-2010	Cameron, james/0000-0003-0589-0367; Dart, Anthony M/0000-0003-1360-3778; Jennings, Garry/0000-0002-7865-5483				BARNDT R, 1982, AM J CARDIOL, V49, P997, DOI 10.1016/0002-9149(82)92394-3; CORCOS T, 1988, J AM COLL CARDIOL, V11, P264, DOI 10.1016/0735-1097(88)90090-3; DENKE MA, 1990, ANN INTERN MED, V112, P780, DOI 10.7326/0003-4819-112-10-780; HAYASHI K, 1974, EXP MECH, V14, P440, DOI 10.1007/BF02324024; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; ISNARD RN, 1989, J AM COLL CARDIOL, V13, P399, DOI 10.1016/0735-1097(89)90518-4; KAWASAKI T, 1987, CARDIOVASC RES, V21, P678, DOI 10.1093/cvr/21.9.678; LACOMBE F, 1990, European Heart Journal, V11, P124; LEAF A, 1989, NEW ENGL J MED, V321, P680, DOI 10.1056/NEJM198909073211010; LEAROYD BM, 1966, CIRC RES, V18, P278, DOI 10.1161/01.RES.18.3.278; MOHIADDIN RH, 1989, BRIT HEART J, V62, P90; NEJJAR I, 1990, ATHEROSCLEROSIS, V80, P199, DOI 10.1016/0021-9150(90)90027-G; NORUSIS MJ, 1986, BASE MANUAL ADV STAT; OLIVARI MT, 1989, J HEART TRANSPLANT, V8, P34; ROACH MR, 1959, CAN J BIOCHEM PHYS, V37, P557, DOI 10.1139/y59-059; STAMLER JS, 1988, AM J CARDIOL, V62, P1268, DOI 10.1016/0002-9149(88)90272-X; STARLING RC, 1990, AM J CARDIOL, V65, P106, DOI 10.1016/0002-9149(90)90035-Y; STEFANADIS C, 1990, EUR HEART J, V11, P990, DOI 10.1093/oxfordjournals.eurheartj.a059639; STEFANADIS C, 1987, AM J CARDIOL, V59, P1300, DOI 10.1016/0002-9149(87)90908-8	19	246	246	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 3	1991	338	8762					270	273		10.1016/0140-6736(91)90415-L	http://dx.doi.org/10.1016/0140-6736(91)90415-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677109				2022-12-28	WOS:A1991FZ56500002
J	CHEESBROUGH, JS; MWEMA, FI; GREEN, SDR; TILLOTSON, GS				CHEESBROUGH, JS; MWEMA, FI; GREEN, SDR; TILLOTSON, GS			QUINOLONES IN CHILDREN WITH INVASIVE SALMONELLOSIS	LANCET			English	Letter									INST MED EVANGEL, DEPT PAEDIAT, KIMPESE, DEM REP CONGO; BAYER UK, NEWBURY, BERKS, ENGLAND	Bayer AG	CHEESBROUGH, JS (corresponding author), UNIV LIVERPOOL, CTR TROP MICROBIOL, LIVERPOOL L69 3BX, ENGLAND.							BLACK A, 1990, J ANTIMICROB CHEMOTH, V26, P25, DOI 10.1093/jac/26.suppl_F.25; DONIDAR SM, 1989, REV INFECT DIS, V11, P878; LEPAGE P, 1987, LANCET, V1, P1458; MANDAL BK, 1991, J INFECTION, V22, P1, DOI 10.1016/0163-4453(91)90758-K; NESBITT A, 1989, J TROP PEDIATRICS, V35, P35, DOI 10.1093/tropej/35.1.35; ROWE B, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93116-Q	6	28	28	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	1991	338	8759					127	127		10.1016/0140-6736(91)90127-B	http://dx.doi.org/10.1016/0140-6736(91)90127-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676461				2022-12-28	WOS:A1991FW16100057
J	COLLINGE, J; PALMER, MS; DRYDEN, AJ				COLLINGE, J; PALMER, MS; DRYDEN, AJ			GENETIC PREDISPOSITION TO IATROGENIC CREUTZFELDT-JAKOB DISEASE	LANCET			English	Note							PRION	The spongiform encephalopathy Creutzfeldt-Jakob disease (CJD) has been transmitted to man via administration of growth hormone and gonadotropin extracted from large pooled batches of human cadaveric pituitary glands. In the UK, 1908 individuals were exposed to potentially contaminated growth hormone, of whom 6 have so far manifested CJD. Examination of the prion protein genes of all these cases and of a single case of gonadotropin-related CJD showed that 4 had the uncommon valine 129 homozygous genotype indicating genetic susceptibility to prion infection. Such genetic susceptibility may be important in the aetiology of sporadic CJD disease.			COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,NORFOLK PL,LONDON W2 1PG,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUCHANAN CR, 1991, BRIT MED J, V302, P824, DOI 10.1136/bmj.302.6780.824; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191	6	474	491	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1441	1442		10.1016/0140-6736(91)93128-V	http://dx.doi.org/10.1016/0140-6736(91)93128-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675319				2022-12-28	WOS:A1991FR06000005
J	LEE, HH; SWANSON, P; ROSENBLATT, JD; CHEN, ISY; SHERWOOD, WC; SMITH, DE; TEGTMEIER, GE; FERNANDO, LP; FANG, CT; OSAME, M; KLEINMAN, SH				LEE, HH; SWANSON, P; ROSENBLATT, JD; CHEN, ISY; SHERWOOD, WC; SMITH, DE; TEGTMEIER, GE; FERNANDO, LP; FANG, CT; OSAME, M; KLEINMAN, SH			RELATIVE PREVALENCE AND RISK-FACTORS OF HTLV-I AND HTLV-II INFECTION IN UNITED-STATES BLOOD-DONORS	LANCET			English	Article							CELL LEUKEMIA-VIRUS; INTRAVENOUS DRUG-ABUSERS; T-CELL; LYMPHOMA VIRUS; ANTIBODIES; REGION; GENOME; AIDS	The clinical significance of human T-cell lymphotropic virus type II (HTLV-II) infection, unlike that of HTLV-I, is unknown, and the major known association of HTLV-II seropositivity is with intravenous drug abuse. Screening of blood donors for HTLV-I, now routine in North America, does not distinguish this retrovirus from HTLV-II. To find out more about the seroepidemiology of and risk factors for HTLV I and II, blood from 480 000 volunteer donors in five geographically separate US urban centres was tested for antibodies to HTLV-I/II and HIV-1. Confirmed HTLV-I/II seropositive donors were then followed up by DNA amplification to distinguish type I from type II and by interviews focusing on possible risk factors. HTLV seroprevalence was 3.3 times greater than that for HIV-1 (0.043% vs 0.013%). DNA amplification on 65 of the 207 HTLV-I/II seropositive donors revealed that 34 (52%) had HTLV-II infection and 28 (43% had HTLV-I; 3 samples were uninformative. Interviews of 49 donors showed that whereas HTLV-I was principally associated with donor origin from endemic regions, the major risk factor for HTLV-II infection was intravenous drug use. The surprisingly high rate of HTLV-II infection in US blood donors raises important public health and donor counselling issues since HTLV-I infection is associated with adult T-cell leukaemia and a neurological disorder while the pathogenicity of HTLV-II is as yet unclear.	JONSSON COMPREHENS CANC CTR,DEPT MED,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024; AMER RED CROSS,PENN JERSEY REG BLOOD SERV,PHILADELPHIA,PA; SE LOUISIANA INC,CTR BLOOD,NEW ORLEANS,LA; COMMUNITY BLOOD CTR GREATER KANSAS CITY,KANSAS CITY,KS; SACRAMENTO MED FDN,CTR BLOOD,SACRAMENTO,CA; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD; KAGOSHIMA UNIV,SCH MED,DEPT INTERNAL MED 3,KAGOSHIMA 890,JAPAN; AMER RED CROSS,LOS ANGELES CTY REG BLOOD SERV,LOS ANGELES,CA; AMER RED CROSS,ORANGE CTY REG BLOOD SERV,LOS ANGELES,CA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; American Red Cross; American Red Cross; Kagoshima University; American Red Cross; American Red Cross	LEE, HH (corresponding author), ABBOTT LABS,DIV DIAGNOST,DEPT 93B,BLDG R1A-3,N CHICAGO,IL 60064, USA.							ANDERSON DW, 1989, BLOOD, V74, P2585; AOKI T, 1985, INT J CANCER, V25, P301; BARRETT JE, 1986, AM J CLIN PATHOL, V86, P180, DOI 10.1093/ajcp/86.2.180; BIGGAR R, 1985, INT J CANCER, V25, P763; BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; BLATTNER WA, 1983, J INFECT DIS, V147, P406, DOI 10.1093/infdis/147.3.406; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN YMA, 1990, LANCET, V336, P1153, DOI 10.1016/0140-6736(90)92769-E; EHRLICH GD, 1989, BLOOD, V74, P1658; FUKASAWA M, 1987, VIROLOGY, V161, P315, DOI 10.1016/0042-6822(87)90123-1; HJELLE B, 1990, BLOOD, V76, P450; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEE HH, 1990, J INFECT DIS, V162, P347, DOI 10.1093/infdis/162.2.347; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PEREZ G, 1989, AM J KIDNEY DIS, V14, P39, DOI 10.1016/S0272-6386(89)80091-5; RATNER L, 1985, J VIROL, V54, P781, DOI 10.1128/JVI.54.3.781-790.1985; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; ROSENBLATT JD, 1990, BLOOD, V76, P409; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; STRAMER SL, 1989, JAMA-J AM MED ASSOC, V262, P64, DOI 10.1001/jama.262.1.64; TEDDER RS, 1984, LANCET, V2, P125; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS AE, 1988, SCIENCE, V240, P643, DOI 10.1126/science.2896386; ZELLA D, 1990, LANCET, V336, P575, DOI 10.1016/0140-6736(90)92140-D; 1988, MMWR, V37, P736; 1988, MMWR, V37, P745	30	115	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1435	1439		10.1016/0140-6736(91)93126-T	http://dx.doi.org/10.1016/0140-6736(91)93126-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675317				2022-12-28	WOS:A1991FR06000003
J	REDFIELD, RR; BIRX, DL; KETTER, N; TRAMONT, E; POLONIS, V; DAVIS, C; BRUNDAGE, JF; SMITH, G; JOHNSON, S; FOWLER, A; WIERZBA, T; SHAFFERMAN, A; VOLVOVITZ, F; OSTER, C; BURKE, DS				REDFIELD, RR; BIRX, DL; KETTER, N; TRAMONT, E; POLONIS, V; DAVIS, C; BRUNDAGE, JF; SMITH, G; JOHNSON, S; FOWLER, A; WIERZBA, T; SHAFFERMAN, A; VOLVOVITZ, F; OSTER, C; BURKE, DS			A PHASE-I EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF VACCINATION WITH RECOMBINANT GP160 IN PATIENTS WITH EARLY HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEROPOSITIVE INDIVIDUALS; HIV INFECTION; VIRAL ENVELOPE; LYMPHOCYTES-T; HTLV-III; AIDS; ANTIBODIES; TYPE-1; NEUTRALIZATION; GP120	Background. Despite multiple antiviral humoral and cellular immune responses, infection with the human immunodeficiency virus (HIV) results in a progressively debilitating disease. We hypothesized that a more effective immune response could be generated by post-infection vaccination with HIV-specific antigens. Methods. We performed a phase I trial of the safety and immunogenicity of a vaccine prepared from molecularly cloned envelope protein, gp160, in 30 volunteer subjects with HIV infection in Walter Reed stage 1 or 2. The vaccine was administered either on days 0, 30, and 120 or on days 0, 30, 60, 120, 150, and 180. HIV-specific humoral and cellular immune responses were measured; local and systemic reactions to vaccination, including general measures of immune function, were monitored. Results. In 19 of the 30 subjects both humoral and cellular immunity to HIV envelope proteins increased in response to vaccination with gp160. Seroconversion to selected envelope epitopes was observed, as were new T-cell proliferative responses to gp160. Response was associated with the CD4 cell count determined before vaccination (13 of 16 subjects [81 percent] with > 600 cells per milliliter responded, as compared with 6 of 14 [43 percent] with less-than-or-equal-to 600 cells per milliliter; P = 0.07) and with the number of injections administered (87 percent of subjects randomly assigned to receive six injections responded, as compared with 40 percent of those assigned to three injections; P = 0.02). Local reactions at the site of injection were mild. There were no adverse systemic reactions, including diminution of general in vitro or in vivo cellular immune function. After 10 months of follow-up, the mean CD4 count had not decreased in the 19 subjects who responded, but it had decreased by 7.3 percent in the 11 who did not respond. Conclusions. This gp160 vaccine is safe and immunogenic in volunteer patients with early HIV infection. Although it is too early to know whether this approach will be clinically useful, further scientific and therapeutic evaluation of HIV-specific vaccine therapy is warranted. Similar vaccines may prove to be effective for other chronic infections.	ISRAEL INST BIOL RES,DEPT BIOCHEM,IL-70450 NESS ZIONA,ISRAEL; HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD; MICROGENESYS INC,MERIDEN,CT; WALTER REED ARMY MED CTR,DEPT MED,INFECT DIS SERV,WASHINGTON,DC 20307; SRA TECHNOL INC,ROCKVILLE,MD; WALTER REED ARMY MED CTR,DIV RETROVIROL,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DIV PREVENT MED,WASHINGTON,DC 20307	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	REDFIELD, RR (corresponding author), WALTER REED ARMY MED CTR,DEPT RETROVIRAL RES,13 TAFT CT,ROCKVILLE,MD 20850, USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804; ASJO B, 1986, LANCET, V2, P660; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BIRX DL, 1986, NEW ENGL J MED, V314, P874, DOI 10.1056/NEJM198604033141403; BIRX DL, 1991, J ACQ IMMUN DEF SYND, V4, P188; BIRX DL, 1990, BLOOD, V76, P2303; BURKE DS, 1990, J ACQ IMMUN DEF SYND, V3, P1159; CHANG TW, 1985, BIO-TECHNOL, V3, P905, DOI 10.1038/nbt1085-905; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; DALGLEISH AG, 1988, VIROLOGY, V165, P209, DOI 10.1016/0042-6822(88)90674-5; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEE TH, 1988, VACCINES, P373; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; LEVY JA, 1988, NATURE, V333, P519, DOI 10.1038/333519a0; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; LYERLY HK, 1987, AIDS RES HUM RETROV, V3, P409, DOI 10.1089/aid.1987.3.409; MELBYE M, 1986, ANN INTERN MED, V104, P496, DOI 10.7326/0003-4819-104-4-496; MICHAEL NL, 1991, J VIROL, V65, P1291, DOI 10.1128/JVI.65.3.1291-1303.1991; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; POLONIS V, 1989, J CELL BIOL S13B, V109, P258; REDFIELD R R, 1987, Viral Immunology, V1, P69, DOI 10.1089/vim.1987.1.69; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; REDFIELD RR, 1988, SCI AM, V259, P90, DOI 10.1038/scientificamerican1088-90; RHOADS JL, IN PRESS J ACQUIR IM; RICKMAN WJ, 1989, CLIN IMMUNOL IMMUNOP, V52, P85, DOI 10.1016/0090-1229(89)90195-5; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; RUSCHE JR, 1989, P NATL ACAD SCI USA, V86, P1667; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P8697, DOI 10.1073/pnas.85.22.8697; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1988, J IMMUNOL, V141, P4181; SHAFFERMAN A, 1989, AIDS RES HUM RETROV, V5, P33, DOI 10.1089/aid.1989.5.33; STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914; SYU WJ, 1990, P NATL ACAD SCI USA, V87, P3695, DOI 10.1073/pnas.87.10.3695; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGES JM, 1991, J MED VIROL, V33, P58, DOI 10.1002/jmv.1890330112; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEINHOLD KJ, 1988, LANCET, V1, P902; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; ZAGURY D, 1987, NATURE, V326, P249, DOI 10.1038/326249a0; ZOLLAPAZNER S, 1987, P NATL ACAD SCI USA, V84, P5404, DOI 10.1073/pnas.84.15.5404	54	256	264	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1677	1684		10.1056/NEJM199106133242401	http://dx.doi.org/10.1056/NEJM199106133242401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	1674589				2022-12-28	WOS:A1991FQ15500001
J	LEE, HP; GOURLEY, L; DUFFY, SW; ESTEVE, J; LEE, J; DAY, NE				LEE, HP; GOURLEY, L; DUFFY, SW; ESTEVE, J; LEE, J; DAY, NE			DIETARY-EFFECTS ON BREAST-CANCER RISK IN SINGAPORE	LANCET			English	Article							CHINESE; POPULATION; FAT	It is suspected that diet influences the risk of getting breast cancer. A study of diet and breast cancer was done among 200 Singapore Chinese women with histologically confirmed disease and 420 matched controls. A quantitative food-frequency questionnaire was used to assess intakes of selected nutrients and foods 1 year before interview. Daily intakes were computed and risk analysed after adjustment for concomitant risk factors. In premenopausal women, high intakes of animal proteins and red meat were associated with increased risk. Decreased risk was associated with high intakes of polyunsaturated fatty acids (PUFA), beta-carotene, soya proteins, total soya products, a high PUFA to saturated fatty acid ratio, and a high proportion of soya to total protein. In multiple analysis, the variables which were significant after adjustment for each other were red meat (p < 0.001) as a predisposing factor, and PUFA (p = 0.02), beta-carotene (p = 0.003), and soya protein (p = 0.02) as protective factors. The analysis of dietary variables in postmenopausal women gave uniformly non-significant results. Our finding that soya products may protect against breast cancer in younger women is of interest since these foods are rich in phyto-oestrogens.	GLENEAGLES HOSP, SINGAPORE, SINGAPORE; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND; INT AGCY RES CANC, F-69372 LYONS, FRANCE	MRC Biostatistics Unit; World Health Organization; International Agency for Research on Cancer (IARC)	LEE, HP (corresponding author), NATL UNIV SINGAPORE, DEPT COMMUNITY OCCUPAT & FAMILY MED, LOWER KENT RIDGE RD, SINGAPORE 0511, SINGAPORE.							ARMSTRONG BK, 1985, CANCER RISKS PREVENT, P68; BARNES S, 1990, PROG CLIN BIOL RES, V347, P239; Breslow N, 1980, STATISTICAL METHODS, V32; DEWAARD F, 1964, CANCER, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z; GOURLEY L, 1988, EUR J CLIN NUTR, V42, P333; HIROHATA T, 1987, JNCI-J NATL CANCER I, V78, P595; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; ISCOVICH JM, 1989, INT J CANCER, V44, P770, DOI 10.1002/ijc.2910440504; La Vecchia C, 1987, Nutr Cancer, V10, P205; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LEE HP, 1988, INT J CANCER, V42, P159, DOI 10.1002/ijc.2910420204; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; ROHAN TE, 1988, INT J CANCER, V41, P390, DOI 10.1002/ijc.2910410312; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; ROHAN TE, 1988, INT J CANCER, V41, P695, DOI 10.1002/ijc.2910410510; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; ZARIDZE DG, 1990, INT J CANCER, V45, P807, DOI 10.1002/ijc.2910450502; ZARIDZE DG, 1991, IN PRESS INT J CANCE	20	648	663	3	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1197	1200		10.1016/0140-6736(91)92867-2	http://dx.doi.org/10.1016/0140-6736(91)92867-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673746				2022-12-28	WOS:A1991FM26100011
J	LEVINE, B; CHAISSON, RE				LEVINE, B; CHAISSON, RE			MYCOBACTERIUM-KANSASII - A CAUSE OF TREATABLE PULMONARY-DISEASE ASSOCIATED WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; AVIUM COMPLEX INFECTION; SYNDROME AIDS; TUBERCULOSIS; INTRACELLULARE; THERAPY	Objective: To assess the clinical features and response to therapy of Mycobacterium kansasii infection in patients with human immunodeficiency virus (HIV) infection. Design: We reviewed the records of all patients with M. kansasii and HIV infection treated between January 1985 and June 1990. Setting: The Johns Hopkins Hospital, Baltimore, Maryland. Results: Nineteen patients with M. kansasii and HIV infection were identified; 14 patients had exclusive pulmonary infection, 3 patients had pulmonary and extrapulmonary infection, and 2 patients had exclusive extrapulmonary infection. At the time of diagnosis of M. kansasii infection, the median CD4+ lymphocyte count was 49 cells/mu-L (range, 0 to 198 cells/mu-L), and 16 of 19 patients had a previous diagnosis of the acquired immunodeficiency syndrome (AIDS). All 17 patients with pulmonary infection presented with fever and cough of at least 2 weeks duration. Chest radiographs showed either focal upper lobe infiltrates (n = 8) or diffuse interstitial infiltrates (n = 9); 9 patients also had thin-walled cavitary lesions. Nine patients with pulmonary M. kansasii infection were treated with antituberculosis chemotherapy, with resolution of fever and respiratory symptoms, improvement of radiographic infiltrates, and sputum conversion; 1 patient with M. kansasii osteomyelitis also responsed to antituberculosis therapy. Autopsies done on 3 treated patients did not reveal any evidence of M. kansasii infection. Nine patients did not receive any antituberculosis chemotherapy; 2 untreated patients developed progressive cavitary pulmonary disease and died from M. kansasii pneumonia. Conclusions: Mycobacterium kansasii causes serious and potentially life-threatening pulmonary disease in patients with advanced HIV-related immunosuppression. In contrast to previous reports, our findings indicate that disease produced by M. kansasii in patients with HIV infection is responsive to antituberculosis chemotherapy.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University								AHN CH, 1982, AM REV RESPIR DIS, V125, P388; AHN CH, 1987, AM REV RESPIR DIS, V135, P10; [Anonymous], 1987, ANN INTERN MED, V106, P254, DOI 10.7326/0003-4819-106-2-254; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CHAN J, 1984, ANN INTERN MED, V101, P400, DOI 10.7326/0003-4819-101-3-400_1; CHAPMAN JS, 1977, ATYPICAL MYCOBACTERI; FOURNIER AM, 1988, CHEST, V93, P772, DOI 10.1378/chest.93.4.772; GREENE JB, 1982, ANN INTERN MED, V97, P539, DOI 10.7326/0003-4819-97-4-539; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HIRASUNA JD, 1987, ANN INTERN MED, V107, P784, DOI 10.7326/0003-4819-107-5-784_1; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; JACOBSON MA, 1989, AM J CLIN PATHOL, V91, P236, DOI 10.1093/ajcp/91.2.236; PFUETZE KH, 1965, AM REV RESPIR DIS, V92, P470; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SANDERS WE, 1990, PRINCIPLES PRACTICE, P1914; SCHRAUFNAGEL DE, 1986, BRIT J DIS CHEST, V80, P131, DOI 10.1016/0007-0971(86)90033-1; SHERER R, 1986, ANN INTERN MED, V105, P710, DOI 10.7326/0003-4819-105-5-710; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; TECSONTUMANG FT, 1984, ANN INTERN MED, V100, P461, DOI 10.7326/0003-4819-100-3-461_2; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; TSUKAMURA M, 1981, REV INFECT DIS, V3, P841; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926; WOLINSKY E, 1981, REV INFECT DIS, V3, P1025; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YOUNG LS, 1986, REV INFECT DIS, V8, P1024; YOUNG LS, 1988, J INFECT DIS, V157, P863, DOI 10.1093/infdis/157.5.863; 1987, MMWR, V36, pS3; 1981, AM REV RESPIR DIS, V123, P343; 1985, CTR DISEASE CONTROL, P165	32	100	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					861	868		10.7326/0003-4819-114-10-861	http://dx.doi.org/10.7326/0003-4819-114-10-861			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	1673053				2022-12-28	WOS:A1991FL65000005
J	BIXLER, EO; KALES, A; MANFREDI, RL; VGONTZAS, AN; TYSON, KL; KALES, JD				BIXLER, EO; KALES, A; MANFREDI, RL; VGONTZAS, AN; TYSON, KL; KALES, JD			NEXT-DAY MEMORY IMPAIRMENT WITH TRIAZOLAM USE	LANCET			English	Article							BENZODIAZEPINE HYPNOTICS; SLEEP; FLURAZEPAM; PSYCHOSIS; INSOMNIA; AMNESIA	The prevalence, rate, and degree of memory impairment for next-day activities during a short, intermittent course of bedtime doses of triazolam, temazepam, and placebo were assessed in a double-blind parallel-group study. 5 of the 6 subjects in the triazolam group reported at least one episode of next-day memory impairment/amnesia, with a total of 12 episodes being reported for the 30 subject-drug nights (a rate of 40%). In the temazepam group there were no such episodes of memory impairment. Immediate and delayed recall were also tested and related to whether active drug or placebo had been taken the night before. Impairment of delayed recall was significantly and several times greater than that in the temazepam or placebo groups. Next-day memory impairment/amnesia after a bedtime dose of triazolam tended to increase with continued or intermittent drug use. Cognitive impairments associated with triazolam probably represent a spectrum of organic brain dysfunction, with memory impairment/amnesia and confusion being the commonest, and milder manifestations and hallucinations and delusions the more severe and less common, features.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PSYCHIAT,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	BIXLER, EO (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,CTR SLEEP RES & TREATMENT,HERSHEY,PA 17033, USA.							ANELLO C, 1989, SEP PHARM DRUGS ADV; BIXLER EO, 1979, LIFE SCI, V25, P1379, DOI 10.1016/0024-3205(79)90415-6; BIXLER EO, 1987, PHARMACOLOGY, V35, P286, DOI 10.1159/000138322; BOATWRIGHT DE, 1987, J FORENSIC SCI, V32, P1118; DENSON R, 1987, PSYCHIAT J U OTTAWA, V12, P242; EINARSON TR, 1982, DRUG INTEL CLIN PHAR, V16, P330, DOI 10.1177/106002808201600411; GOLD PE, 1983, BEHAV NEURAL BIOL, V38, P151, DOI 10.1016/S0163-1047(83)90170-X; GREENBLATT DJ, 1989, ARCH GEN PSYCHIAT, V46, P326; HERITCH AJ, 1987, J CLIN PSYCHIAT, V48, P168; HUFF J S, 1989, Journal of Emergency Medicine, V7, P153; KALES A, 1986, CLIN PHARMACOL THER, V40, P378, DOI 10.1038/clpt.1986.194; KALES A, 1991, CLIN PHARMACOL THER, V49, P468, DOI 10.1038/clpt.1991.55; KALES A, 1976, J CLIN PHARMACOL, V16, P399, DOI 10.1002/j.1552-4604.1976.tb02414.x; KALES A, 1990, PSYCHIATRY WORLD PER, V3, P379; MORRIS HH, 1987, JAMA-J AM MED ASSOC, V258, P945, DOI 10.1001/jama.258.7.945; ODONNELL VM, 1988, HUM PERFORM, V1, P145; OSWALD I, 1989, LANCET, V2, P451; PATTERSON JF, 1987, SOUTHERN MED J, V80, P1425, DOI 10.1097/00007611-198711000-00020; PENETAR DM, 1989, AVIAT SPACE ENVIR MD, V60, P594; POITRAS R, 1980, UNION MED CAN, V109, P427; ROEHRS T, 1983, J CLIN PSYCHOPHARM, V3, P310; ROTH T, 1980, PSYCHOPHARMACOLOGY, V70, P231, DOI 10.1007/BF00427879; SCHARF MB, 1988, J CLIN PSYCHIAT, V49, P134; SCHOGT B, 1985, CAN J PSYCHIAT, V30, P462, DOI 10.1177/070674378503000633; SEIDEL WF, 1986, CLIN PHARMACOL THER, V40, P314, DOI 10.1038/clpt.1986.182; SHADER RI, 1983, J CLIN PSYCHOPHARM, V3, P272; SOLDATOS CR, 1986, DRUG INTEL CLIN PHAR, V20, P294, DOI 10.1177/106002808602000418; SPINWEBER CL, 1982, PSYCHOPHARMACOLOGY, V76, P5, DOI 10.1007/BF00430746; TAN TL, 1985, J FAM PRACTICE, V20, P592; VANDERKROEF C, 1979, LANCET, V2, P526; 1987, SCRIP, V1189, P34; 1987, SCRIP, V1207, P27; 1988, OMS, V2, P32; 1988, SCRIP, V1296, P3	34	80	81	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					827	831		10.1016/0140-6736(91)92524-6	http://dx.doi.org/10.1016/0140-6736(91)92524-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF228	1672921				2022-12-28	WOS:A1991FF22800012
J	LABELLE, P; MANTEL, G				LABELLE, P; MANTEL, G			SIMVASTATIN AND PROTEINURIA	LANCET			English	Letter											LABELLE, P (corresponding author), MERCK SHARP & DOHME LTD,W POINT,PA 19486, USA.							DESLYPERE JP, 1990, LANCET, V336, P1453, DOI 10.1016/0140-6736(90)93164-K; RABELINK AJ, 1990, LANCET, V335, P1045, DOI 10.1016/0140-6736(90)91118-T	2	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					864	864		10.1016/0140-6736(91)92581-L	http://dx.doi.org/10.1016/0140-6736(91)92581-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672961				2022-12-28	WOS:A1991FF22800063
J	GLASSER, SP; CLARK, PI; LIPICKY, RJ; HUBBARD, JM; YUSUF, S				GLASSER, SP; CLARK, PI; LIPICKY, RJ; HUBBARD, JM; YUSUF, S			EXPOSING PATIENTS WITH CHRONIC, STABLE, EXERTIONAL ANGINA TO PLACEBO PERIODS IN DRUG TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS	Because the safety of withholding standard therapy and enrolling patients with stable angina in placebo-controlled trials is not known, we identified all events leading to dropout from trials of 12 antianginal drugs submitted in support of new drug applications to the US Food and Drug Administration. Persons who dropped out of the trials were classified as cause due to adverse cardiovascular events or other causes without knowledge of drug assignment. There were 3161 subjects who entered any randomized, double-blind phase of placebo-controlled protocols; 197 (6.2%) withdrew because of cardiovascular events. There was no difference in risk of adverse events between drug and placebo groups. A prospectively defined subgroup analysis showed that groups who received calcium antagonists were at an increased risk of dropout compared with placebo groups (P = .04), primarily because of a disproportionate number of adverse events in studies of one drug. In conclusion, there were few adverse experiences associated with short-term placebo use. Withholding active treatment does not increase the risk of serious cardiac events.	UNIV S FLORIDA,COLL MED,MDC BOX 19,TAMPA,FL 33612; JAMES A HALEY VET ADM MED CTR,TAMPA,FL 33612; US FDA,ROCKVILLE,MD 20857; NHLBI,BETHESDA,MD 20892	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Glasser, Stephen P/S-5996-2019	Glasser, Stephen P/0000-0001-9620-6406; Yusuf, Salim/0000-0003-4776-5601				FEINSTEIN AR, 1980, EUR J CLIN PHARMACOL, V17, P1, DOI 10.1007/BF00561669; JOYCE CRB, 1982, BRIT J CLIN PHARMACO, V13, P313, DOI 10.1111/j.1365-2125.1982.tb01380.x; LASAGNA L, 1979, EUR J CLIN PHARMACOL, V15, P373, DOI 10.1007/BF00561733; LEBER P, 1986, PSYCHOPHARMACOL BULL, V22, P30; LEVINE JF, 1986, ETHICS REGULATION CL, P205; LEVINE RJ, 1987, CLIN PHARMACOL THER, V42, P247, DOI 10.1038/clpt.1987.141; Levit K R, 1985, Health Care Financ Rev, V7, P1; Makuch Robert W, 1989, IRB, V11, P1, DOI 10.2307/3563823; MANTEL N, 1959, J NATL CANCER I, V22, P719; RICKELS K, 1986, PSYCHOPHARMACOL BULL, V22, P19; ROSNER F, 1987, AM J MED, V82, P283, DOI 10.1016/0002-9343(87)90069-6; TEMPLE R, 1989, MED CLIN N AM, V73, P495, DOI 10.1016/S0025-7125(16)30685-X; TEMPLE R, 1982, DRUG INFORM J, V1, P10; WAY WL, 1984, NEW ENGL J MED, V311, P413; WILHELMSEN L, 1979, EUR J CLIN PHARMACOL, V146, P295; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	16	46	46	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1550	1554		10.1001/jama.265.12.1550	http://dx.doi.org/10.1001/jama.265.12.1550			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1671885				2022-12-28	WOS:A1991FC60400030
J	JOYNER, AL; HERRUP, K; AUERBACH, BA; DAVIS, CA; ROSSANT, J				JOYNER, AL; HERRUP, K; AUERBACH, BA; DAVIS, CA; ROSSANT, J			SUBTLE CEREBELLAR PHENOTYPE IN MICE HOMOZYGOUS FOR A TARGETED DELETION OF THE EN-2 HOMEOBOX	SCIENCE			English	Article							DROSOPHILA ENGRAILED GENE; PROTO-ONCOGENE INT-1; BOX-CONTAINING GENES; DNA-BINDING; HOMOLOGOUS RECOMBINATION; SEQUENCE HOMOLOGY; MOUSE CEREBELLUM; GRANULE CELL; EXPRESSION; EMBRYOGENESIS	The two mouse genes, En-1 and En-2, that are homologs of the Drosophila segmentation gene engrailed, show overlapping spatially restricted patterns of expression in the neural tube during embryogenesis, suggestive of a role in regional specification. Mice homozygous for a targeted mutation that deletes the homeobox were viable and showed no obvious defects in embryonic development. This may be due to functional redundancy of En-2 and the related En-1 gene product during embryogenesis. Consistent with this hypothesis, the mutant mice showed abnormal foliation in the adult cerebellum, where En-2, and not En-1, is normally expressed.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, WALTHAM, MA 02254 USA	University of Toronto	JOYNER, AL (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Herrup, Karl/C-5313-2014	Herrup, Karl/0000-0001-7786-5844	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020591, R01NS018381] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25334] Funding Source: Medline; NINDS NIH HHS [NS18381, NS20591] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V146, P355, DOI 10.1002/cne.901460305; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DAVIS CA, IN PRESS DEVELOPMENT; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FJOSE A, 1988, FEBS LETT, V231, P355, DOI 10.1016/0014-5793(88)80849-4; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GARDNER CA, 1988, J NEUROSCI RES, V21, P426, DOI 10.1002/jnr.490210234; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOLDOWITZ D, 1982, J NEUROSCI, V2, P1474; HEMMATIBRIVANLO.A, IN PRESS DEVELOPMENT; HERRUP K, 1987, NEUROSCIENCE, V23, P871, DOI 10.1016/0306-4522(87)90164-3; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; INGHAM P, 1985, NATURE, V317, P634, DOI 10.1038/317634a0; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1984, EMBO J, V3, P2839, DOI 10.1002/j.1460-2075.1984.tb02217.x; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LITTLE JW, COMMUNICATION; LOGAN C, 1989, GENOMICS, V4, P206, DOI 10.1016/0888-7543(89)90301-7; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NEUMANN PE, 1990, BRAIN RES, V524, P85, DOI 10.1016/0006-8993(90)90495-W; NJOLSTAD PR, 1988, BIOCHEM BIOPH RES CO, V157, P426, DOI 10.1016/S0006-291X(88)80266-3; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; Sidman Richard L., 1971, ATLAS MOUSE BRAIN SP; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TREISMAN J, 1989, CELL, V59, P553; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	46	360	365	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1239	1243		10.1126/science.1672471	http://dx.doi.org/10.1126/science.1672471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1672471				2022-12-28	WOS:A1991FA69100044
J	ELLIOTT, SJ				ELLIOTT, SJ			NEONATAL EXTRACORPOREAL MEMBRANE-OXYGENATION - HOW NOT TO ASSESS NOVEL TECHNOLOGIES	LANCET			English	Editorial Material							RESPIRATORY-FAILURE; INFANTS; TRIALS				ELLIOTT, SJ (corresponding author), BAYLOR UNIV, DEPT PEDIAT, HOUSTON, TX 77030 USA.							BARTLETT RH, 1985, PEDIATRICS, V76, P479; BARTLETT RH, 1976, T AM SOC ART INT ORG, V22, P80; CHALMERS TC, 1990, PEDIATRICS, V85, P366; CHEVALIER JY, 1990, LANCET, V335, P1364, DOI 10.1016/0140-6736(90)91244-5; CILLEY RE, 1986, PEDIATRICS, V78, P699; DWORETZ AR, 1989, PEDIATRICS, V84, P1; FINK SM, 1989, J PEDIATR-US, V115, P621, DOI 10.1016/S0022-3476(89)80298-7; GODDARDFINEGOLD J, IN PRESS PEDIATRICS; GREENOUGH A, 1990, LANCET, V336, P760, DOI 10.1016/0140-6736(90)92264-I; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; KUNDU SK, 1989, J LAB CLIN MED, V114, P58; LANTOS JD, 1990, NEW ENGL J MED, V323, P409, DOI 10.1056/NEJM199008093230610; LEWIN JS, 1989, PEDIATR RADIOL, V173, P361; LOTT IT, 1990, J PEDIATR-US, V116, P343, DOI 10.1016/S0022-3476(05)82818-5; NADING JH, 1989, CRIT CARE MED, V17, P423, DOI 10.1097/00003246-198905000-00009; NOLTE SH, 1989, T AM SOC ART INT ORG, V35, P30; OROURKE PP, 1989, PEDIATRICS, V84, P957; RAJU TNK, 1989, PEDIATRICS, V83, P343; SCHUMACHER RE, 1989, PEDIATRICS, V84, P793; SHNEIDER B, 1989, NEW ENGL J MED, V320, P1563; STEINHORN RH, 1989, J PEDIATR-US, V115, P625, DOI 10.1016/S0022-3476(89)80299-9; ZACH TL, 1990, J PEDIATR-US, V116, P440, DOI 10.1016/S0022-3476(05)82840-9; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1969, J AM STAT ASSOC, V64, P131, DOI 10.2307/2283724; 1988, LANCET, V2, P1289; 1990, SUMMARY REPORT U MIC; [No title captured]	28	28	28	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 23	1991	337	8739					476	478		10.1016/0140-6736(91)93406-Y	http://dx.doi.org/10.1016/0140-6736(91)93406-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671482				2022-12-28	WOS:A1991EY88700016
J	AHMED, YF; GILMARTIN, GM; HANLY, SM; NEVINS, JR; GREENE, WC				AHMED, YF; GILMARTIN, GM; HANLY, SM; NEVINS, JR; GREENE, WC			THE HTLV-I REX RESPONSE ELEMENT MEDIATES A NOVEL FORM OF MESSENGER-RNA POLYADENYLATION	CELL			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; POLY(A) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MULTIPLE FACTORS; 3' END; CLEAVAGE	HTLV-I structural gene expression is posttranscriptionally regulated by the Rex protein and the Rex response element (RexRE), a 255 nucleotide RNA stem-loop structure located in the retroviral 3' LTR. Independent of Rex, the RexRE also plays a critical role in the polyadenylation of all HTLV-I transcripts. Folding of the RexRE serves to spatially juxtapose the widely separated AAUAAA hexamer and GU-rich elements that are essential for polyadenylation. In turn, this folding promotes the cooperative and stable binding of two nuclear factors at these elements that commits this poly(A) site to 3' processing. These findings highlight a novel mechanism of 3' end formation in the HTLV family of retroviruses and underscore the general requirement for protein-protein interactions in the polyadenylation reaction.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University	AHMED, YF (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710, USA.							AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; Ausubel FM, 1988, MOL REPROD DEV; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BURNY A, 1980, BOVINE LEUKEMIA VIRU, P231; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; GALLO RC, 1985, CANCER RES, V45, P4524; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KIM JH, 1991, J VIROL, V65, P405, DOI 10.1128/JVI.65.1.405-414.1991; LE SY, 1988, NUCLEIC ACIDS RES, V16, P5153, DOI 10.1093/nar/16.11.5153; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MCDEVITT MA, 1988, GENE DEV, V2, P588, DOI 10.1101/gad.2.5.588; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SAGATA N, 1983, GENE, V26, P1, DOI 10.1016/0378-1119(83)90030-6; SAGATA N, 1984, P NATL ACAD SCI-BIOL, V81, P4741, DOI 10.1073/pnas.81.15.4741; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P1079, DOI 10.1073/pnas.81.4.1079; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1985, CANCER RES, V45, P4539; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	51	97	97	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					727	737		10.1016/0092-8674(91)90502-P	http://dx.doi.org/10.1016/0092-8674(91)90502-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1671761				2022-12-28	WOS:A1991EZ47800008
J	BRIEGEL, J; FORST, H; HELLINGER, H; HALLER, M				BRIEGEL, J; FORST, H; HELLINGER, H; HALLER, M			CONTRIBUTION OF CORTISOL DEFICIENCY TO SEPTIC SHOCK	LANCET			English	Letter											BRIEGEL, J (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,INST ANAESTHESIOL,INTENS CARE UNIT,W-8000 MUNICH 70,GERMANY.		Josef, Briegel/ABF-3522-2021; Briegel, Josef/AAG-3774-2019	Briegel, Josef/0000-0003-2837-8008				CATALANO RD, 1984, ARCH SURG-CHICAGO, V119, P145; HERMUS ARMM, 1990, J STEROID BIOCHEM, V37, P867, DOI 10.1016/0960-0760(90)90434-M; ROTHWELL, 1991, LANCET, V337, P582; VADAS P, 1988, J LAB CLIN MED, V111, P584	4	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					507	508		10.1016/0140-6736(91)90575-A	http://dx.doi.org/10.1016/0140-6736(91)90575-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678460				2022-12-28	WOS:A1991GC15300033
J	FALANGA, V; KIRSNER, RS; EAGLSTEIN, WH; KATZ, MH; KERDEL, FA				FALANGA, V; KIRSNER, RS; EAGLSTEIN, WH; KATZ, MH; KERDEL, FA			STANOZOLOL IN TREATMENT OF LEG ULCERS DUE TO CRYOFIBRINOGENEMIA	LANCET			English	Note								Five consecutive patients with cryofibrinogenaemia in association with painful leg ulcers and intravascular dermal thrombi were treated with stanozolol, an androgenic steroid with fibrinolytic properties. In all patients treatment was followed by rapid and striking pain relief and healing of the ulcers. Cryofibrinogenaemia was not detected on subsequent laboratory evaluation, and dermal intravascular thrombi had resolved on repeat histological examination.			FALANGA, V (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016250,MIAMI,FL 33136, USA.			Falanga, Vincent/0000-0003-2292-2017				AYRES ML, 1981, BRIT J SURG, V68, P51, DOI 10.1002/bjs.1800680117; COPEMAN PWM, 1979, BRIT J DERMATOL, V101, P57; JARRETT PEM, 1975, BRIT J SURG, V62, P654; KLEIN AD, 1991, ARCH DERMATOL, V127, P133; KLUFT C, 1984, THROMB HAEMOSTASIS, V51, P157; KORST DR, 1955, BLOOD, V10, P945, DOI 10.1182/blood.V10.9.945.945; MIALE JB, 1977, LABORATORY MED HEMAT, P1047; RACHMILEWITZ EA, 1970, ISRAEL J MED SCI, V6, P32; SMITH SB, 1972, AM J CLIN PATHOL, V58, P524; STATHAKIS NE, 1978, BLOOD, V51, P1211; ZLOTNICK A, 1969, ACTA HAEMATOL-BASEL, V42, P8, DOI 10.1159/000208756	11	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					347	348		10.1016/0140-6736(91)90483-6	http://dx.doi.org/10.1016/0140-6736(91)90483-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677702	hybrid			2022-12-28	WOS:A1991GA60700008
J	LANG, CC; MOTWANI, J; COUTIE, WJ; STRUTHERS, AD				LANG, CC; MOTWANI, J; COUTIE, WJ; STRUTHERS, AD			INFLUENCE OF CANDOXATRIL ON PLASMA BRAIN NATRIURETIC PEPTIDE IN HEART-FAILURE	LANCET			English	Letter							PORCINE BRAIN				LANG, CC (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.			Struthers, Allan/0000-0002-2926-2528; Lang, Chim/0000-0002-4530-3078				KAMBAYASHI Y, 1990, FEBS LETT, V259, P341, DOI 10.1016/0014-5793(90)80043-I; MUKOYAMA M, 1990, LANCET, V335, P801, DOI 10.1016/0140-6736(90)90925-U; NORTHRIDGE DB, 1989, LANCET, V2, P591; O'CONNELL J E, 1989, Journal of Hypertension, V7, P923, DOI 10.1097/00004872-198911000-00019; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; TOGASHI K, 1989, FEBS LETT, V250, P235, DOI 10.1016/0014-5793(89)80728-8; VOGTSCHADEN M, 1989, BIOCHEM BIOPH RES CO, V161, P1177, DOI 10.1016/0006-291X(89)91366-1	8	38	39	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					255	255		10.1016/0140-6736(91)90397-8	http://dx.doi.org/10.1016/0140-6736(91)90397-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676808				2022-12-28	WOS:A1991FY50400042
J	ROSEBUSH, PI; MAZUREK, MF				ROSEBUSH, PI; MAZUREK, MF			SERUM IRON AND NEUROLEPTIC MALIGNANT SYNDROME	LANCET			English	Note							PROTEIN	Neuroleptic malignant syndrome (NMS) is a fulminant, life-threatening reaction to neuroleptic medications. The only consistently described biochemical abnormalities are increased creatine kinase and leucocytosis. Because of a possible association between NMS and dopaminergic function and between serum iron and dopaminergic function, we prospectively measured serum iron in 26 episodes of NMS in twenty-three patients. In 25 episodes (96%) serum iron concentration was 10 mu-mol/l or lower - more than 2 SD below the mean normal value. Serum iron in 11 episodes (36%) was 4-mu-mol/l or lower. In each episode for which data are available, serum iron returned to normal upon resolution of the NMS. Serum iron may be a helpful adjunct for the diagnosis of the disorder. The pronounced reduction in serum iron suggests that the acute phase reaction may have a role in NMS.	MCMASTER UNIV,MED CTR,DEPT BIOMED SCI,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University	ROSEBUSH, PI (corresponding author), MCMASTER UNIV,MED CTR,DEPT PSYCHIAT,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							BARACOS V, 1983, NEW ENGL J MED, V308, P553, DOI 10.1056/NEJM198303103081002; BENSHACHAR D, 1985, J NEUROCHEM, V45, P999, DOI 10.1111/j.1471-4159.1985.tb05514.x; BROWN KW, 1987, LANCET, V1, P1234; GOLDBLUM SE, 1987, AM J PHYSIOL, V252, pE27, DOI 10.1152/ajpendo.1987.252.1.E27; GRIFFITHS JD, 1985, AM J CLIN PATHOL, V84, P649, DOI 10.1093/ajcp/84.5.649; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; ROSEBUSH P, 1989, AM J PSYCHIAT, V146, P717; ROSEBUSH PI, IN PRESS BR J PSYCHI; TAYLOR C, 1987, J APPL PHYSIOL, V62, P464, DOI 10.1152/jappl.1987.62.2.464; 1986, LANCET, V2, P1131	10	81	83	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					149	151		10.1016/0140-6736(91)90138-F	http://dx.doi.org/10.1016/0140-6736(91)90138-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677067				2022-12-28	WOS:A1991FX42400006
J	LINDELOF, B; SIGURGEIRSSON, B; TEGNER, E; LARKO, O; JOHANNESSON, A; BERNE, B; CHRISTENSEN, OB; ANDERSSON, T; TORNGREN, M; MOLIN, L; NYLANDERLUNDQVIST, E; EMTESTAM, L				LINDELOF, B; SIGURGEIRSSON, B; TEGNER, E; LARKO, O; JOHANNESSON, A; BERNE, B; CHRISTENSEN, OB; ANDERSSON, T; TORNGREN, M; MOLIN, L; NYLANDERLUNDQVIST, E; EMTESTAM, L			PUVA AND CANCER - A LARGE-SCALE EPIDEMIOLOGIC-STUDY	LANCET			English	Article							8-YEAR FOLLOW-UP; GENITAL TUMORS; SKIN-CANCER; PSORIASIS; PHOTOCHEMOTHERAPY; MEN	There is concern about the long-term carcinogenic effects of psoralen and ultraviolet A radiation (PUVA) therapy for treatment of skin disorders. A study of 4799 Swedish patients (2343 males, 2056 females; mean age at first treatment 45.3 years, range 6-93; mean follow-up 6.9 years males, 7.2 years females) who received PUVA between 1974 and 1985 showed a dose-dependent increase in the risk of squamous cell cancer of the skin. Male patients who had received more than 200 treatments had over 30 times the incidence of squamous cell cancer found in the general population. Significant increases (p < 0.05) were also found in the incidences of respiratory cancer in males and females, pancreatic cancer in males, and kidney and colonic cancer in females. This study confirms previous reports of a dose-dependent increase in the incidence of squamous cell cancer in patients treated with PUVA.	UNIV LUND HOSP,S-22185 LUND,SWEDEN; SAHLGRENS UNIV HOSP,S-41345 GOTHENBURG,SWEDEN; SWEDISH PSORIASIS ASSOC,STOCKHOLM,SWEDEN; UNIV HOSP UPPSALA,UPPSALA,SWEDEN; MALMO GEN HOSP,S-21401 MALMO,SWEDEN; LINKOPING UNIV HOSP,S-58185 LINKOPING,SWEDEN; DANDERYD HOSP,STOCKHOLM,SWEDEN; OREBRO MED CTR HOSP,OREBRO,SWEDEN; UMEA UNIV HOSP,S-90185 UMEA,SWEDEN; HUDDINGE HOSP,S-14186 HUDDINGE,SWEDEN	Lund University; Skane University Hospital; Sahlgrenska University Hospital; Uppsala University; Uppsala University Hospital; Linkoping University; Danderyds Hospital; Umea University	LINDELOF, B (corresponding author), KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM 60,SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				FORMAN AB, 1989, ARCH DERMATOL, V125, P515, DOI 10.1001/archderm.125.4.515; HENSELER T, 1987, J AM ACAD DERMATOL, V16, P108, DOI 10.1016/S0190-9622(87)70010-3; LINDELOF B, IN PRESS ACTA DERM V; MATTSSON B, 1984, THESIS KAROLINSKA I, P1; MCGARRY GW, 1990, NEW ENGL J MED, V323, P684; PERKINS W, 1990, LANCET, V336, P1248, DOI 10.1016/0140-6736(90)92860-K; SIGURGEIRSSON B, IN PRESS COMPUT METH; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; STERN RS, 1988, J INVEST DERMATOL, V91, P197, DOI 10.1111/1523-1747.ep12464847; TANEW A, 1986, J AM ACAD DERMATOL, V15, P960, DOI 10.1016/S0190-9622(86)70257-0	12	191	192	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					91	93		10.1016/0140-6736(91)90083-2	http://dx.doi.org/10.1016/0140-6736(91)90083-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676477				2022-12-28	WOS:A1991FW16100012
J	BAMFORD, J; SANDERCOCK, P; DENNIS, M; BURN, J; WARLOW, C				BAMFORD, J; SANDERCOCK, P; DENNIS, M; BURN, J; WARLOW, C			CLASSIFICATION AND NATURAL-HISTORY OF CLINICALLY IDENTIFIABLE SUBTYPES OF CEREBRAL INFARCTION	LANCET			English	Article							COMMUNITY-STROKE-PROJECT; ACUTE CEREBROVASCULAR-DISEASE; DATA-BANK; LACUNAR HYPOTHESIS; HEMORRHAGE; DESIGN	We describe the incidence and natural history of four clinically identifiable subgroups of cerebral infarction in a community-based study of 675 patients with first-ever stroke. Of 543 patients with a cerebral infarct, 92 (17%) had large anterior circulation infarcts with both cortical and subcortical involvement (total anterior circulation infarcts, TACI); 185 (34%) had more restricted and predominantly cortical infarcts (partial anterior circulation infarcts, PACI); 129 (24%) had infarcts clearly associated with the vertebrobasilar arterial territory (posterior circulation infarcts, POCI); and 137 (25%) had infarcts confined to the territory of the deep perforating arteries (lacunar infarcts, LACI). There were striking differences in natural history between the groups. The TACI group had a negligible chance of good functional outcome and mortality was high. More than twice as many deaths were due to the complications of immobility than to direct neurological sequelae of the infarct. Patients in the PACI group were much more likely to have an early recurrent stroke than were patients in other groups. Those in the POCI group were at greater risk of a recurrent stroke later in the first year after the index event but had the best chance of a good functional outcome. Despite the small anatomical size of the infarcts in the LACI group, many patients remained substantially handicapped. The findings have important implications for the planning of stroke treatment trials and suggest that various therapies could be directed specifically at the subgroups.	RIVERMEAD REHABIL CTR,OXFORD,ENGLAND; WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	BAMFORD, J (corresponding author), ST JAMES UNIV HOSP,DEPT NEUROL,BECKETT ST,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P1251, DOI 10.1136/jnnp.47.11.1251; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P819, DOI 10.1136/jnnp.53.9.819; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BARER DH, 1988, BRIT MED J, V296, P737, DOI 10.1136/bmj.296.6624.737; BLADIN PF, 1984, NEUROLOGY, V34, P1423, DOI 10.1212/WNL.34.11.1423; BROTT T, 1989, STROKE, V20, P871, DOI 10.1161/01.STR.20.7.871; CAPLAN LR, 1980, NEUROLOGY, V30, P72, DOI 10.1212/WNL.30.1.72; CAPLAN LR, 1988, HDB CLIN NEUROLOGY, P353; CHODOSH EH, 1988, NEUROLOGY, V38, P1674, DOI 10.1212/WNL.38.11.1674; ESCOURELLE R, 1978, MANUAL BASIC NEUROPA; FISHER CM, 1979, ARCH NEUROL-CHICAGO, V36, P65, DOI 10.1001/archneur.1979.00500380035003; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; HART RG, 1987, HEART STROKE, P117; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; HOMMEL M, 1990, STROKE, V21, P546, DOI 10.1161/01.STR.21.4.546; HUMPHREY PRD, 1985, POSTGRAD MED J, V61, P1039, DOI 10.1136/pgmj.61.722.1039; KASE CS, 1988, HDB CLIN NEUROLOGY, P353; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; STERMAN AB, 1987, STROKE, V18, P524, DOI 10.1161/01.STR.18.2.524; TURNEY TM, 1984, STROKE, V15, P790, DOI 10.1161/01.STR.15.5.790; WHISNANT J P, 1990, Stroke, V21, P637; 1985, NEW ENGL J MED, V313, P1191	30	2542	2677	4	93	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1521	1526		10.1016/0140-6736(91)93206-O	http://dx.doi.org/10.1016/0140-6736(91)93206-O			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675378				2022-12-28	WOS:A1991FT11600013
J	KREMER, EJ; PRITCHARD, M; LYNCH, M; YU, S; HOLMAN, K; BAKER, E; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI				KREMER, EJ; PRITCHARD, M; LYNCH, M; YU, S; HOLMAN, K; BAKER, E; WARREN, ST; SCHLESSINGER, D; SUTHERLAND, GR; RICHARDS, RI			MAPPING OF DNA INSTABILITY AT THE FRAGILE-X TO A TRINUCLEOTIDE REPEAT SEQUENCE P(CCG)N	SCIENCE			English	Article							NUCLEOTIDES; EXPRESSION	The sequence of a Pst I restriction fragment was determined that demonstrates instability in fragile X syndrome pedigrees. The region of instability was localized to a trinucleotide repeat p(CCG)n. The sequences flanking this repeat were identical in normal and affected individuals. The breakpoints in two somatic cell hybrids constructed to break at the fragile site also mapped to this repeat sequence. The repeat exhibits instability both when cloned in a nonhomologous host and after amplification by the polymerase chain reaction. These results suggest variation in the trinucleotide repeat copy number as the molecular basis for the instability and possibly the fragile site. This would account for the observed properties of this region in vivo and in vitro.	WASHINGTON UNIV,SCH MED,CTR GENET MED,ST LOUIS,MO 63110; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Washington University (WUSTL); Emory University; Emory University			Kremer, Eric J/D-3734-2013; Warren, Stephen T/A-2498-2012; Richards, Robert/ABE-6423-2020; Sutherland, Grant Robert/D-2606-2012; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Richards, Robert Ian/0000-0002-5978-6453				BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; KREMER E, UNPUB; KREMER EJ, IN PRESS AM J HUM GE; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Sutherland G, 1985, FRAGILE SITES HUMAN; SUTHERLAND GR, 1986, AM J MED GENET, V23, P409, DOI 10.1002/ajmg.1320230133; SUTHERLAND GR, 1988, MUTAT RES, V200, P207, DOI 10.1016/0027-5107(88)90084-X; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WILLIAMSON R, 1990, CYTOGENET CELL GENET, V55, P457, DOI 10.1159/000133027; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	13	834	866	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1711	1714		10.1126/science.1675488	http://dx.doi.org/10.1126/science.1675488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1675488				2022-12-28	WOS:A1991FT11400048
J	EDWARDS, B; BALLARDIE, F; ANDREW, S; FREEMONT, A; ODRISCOLL, J; CHALMERS, R				EDWARDS, B; BALLARDIE, F; ANDREW, S; FREEMONT, A; ODRISCOLL, J; CHALMERS, R			EPIDERMAL ICAM-1 IN PSORIASIS AFTER LONG-TERM CYCLOSPORINE	LANCET			English	Letter									DEPT PATHOL SCI,MANCHESTER,ENGLAND; SKIN HOSP,SALFORD,ENGLAND		EDWARDS, B (corresponding author), MANCHESTER ROYAL INFIRM,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND.		Freemont, Tony J/A-9000-2015	Freemont, Tony J/0000-0002-9780-208X				BARKER, 1991, LANCET, V337, P211; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; GUPTA AK, 1990, J AM ACAD DERMATOL, V22, P242, DOI 10.1016/0190-9622(90)70032-D; HO VC, 1990, J AM ACAD DERMATOL, V22, P94, DOI 10.1016/0190-9622(90)70015-A; NORRIS DA, 1990, J INVEST DERMATOL, V95, pS111, DOI 10.1111/1523-1747.ep12874977; PETZELBAUER P, 1991, J INVEST DERMATOL, V96, P362, DOI 10.1111/1523-1747.ep12465404	6	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1420	1420		10.1016/0140-6736(91)93112-M	http://dx.doi.org/10.1016/0140-6736(91)93112-M			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674801				2022-12-28	WOS:A1991FP87000049
J	POUPON, RE; BALKAU, B; ESCHWEGE, E; POUPON, R				POUPON, RE; BALKAU, B; ESCHWEGE, E; POUPON, R			A MULTICENTER, CONTROLLED TRIAL OF URSODIOL FOR THE TREATMENT OF PRIMARY BILIARY-CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URSODEOXYCHOLIC ACID; D-PENICILLAMINE; DOUBLE-BLIND; CHENODEOXYCHOLIC ACID; BILE-ACIDS; INTERNATIONAL TRIAL; RANDOMIZED TRIAL; AZATHIOPRINE; COLCHICINE; CYCLOSPORINE	Background. In primary biliary cirrhosis the hepatic lesions may result, at least in part, from the intracellular accumulation of potentially toxic endogenous bile acids. Preliminary work suggests that the administration of ursodiol (also called ursodeoxycholic acid), a hydrophilic bile acid without hepatotoxicity, leads to improvement in the condition of patients with primary biliary cirrhosis. Methods. We conducted a two-year, multicenter, double-blind trial to compare the efficacy of ursodiol with that of placebo. Patients with biopsy-proved primary biliary cirrhosis were randomly assigned to receive either ursodiol (13 to 15 mg per kilogram of body weight per day) (n = 73) or placebo (n = 73). Treatment failure was defined as a doubling of bilirubin levels to more than 70-mu-mol per liter or the occurrence of a severe complication (ascites or variceal bleeding) or an adverse reaction. Results. Treatment failed in 6 patients in the ursodiol group, as compared with 13 in the placebo group (P < 0.01 by Cox regression model). A single patient in each group withdrew because of minor adverse effects. After two years of treatment, the proportion of patients with clinically overt disease decreased only in the ursodiol group (P < 0.02). The patients treated with ursodiol had significant improvements in serum levels of bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, cholesterol, and IgM (all P < 0.001); the antimitochondrial-antibody titer (P < 0.01); and the Mayo risk score (P < 0.001). Follow-up analysis of 95 liver-biopsy specimens showed a significant improvement in the mean histologic score (P < 0.002) and in all the characteristic histologic features except fibrosis only in the group given ursodiol. Conclusions. Ursodiol is a safe and effective treatment for primary biliary cirrhosis.	HOP ST ANTOINE,SERV HEPATOL,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	POUPON, RE (corresponding author), INSERM,U21,16 AVE PAUL VAILLANT COUTURIER,F-94807 VILLEJUIF,FRANCE.			Poynard, Thierry/0000-0002-2050-640X; Cales, Paul/0000-0003-4866-5274				BASSENDINE MF, 1982, GUT, V23, pA909; BATTA AK, 1988, HEPATOLOGY, V8, P1221; BODENHEIMER H, 1988, GASTROENTEROLOGY, V95, P124, DOI 10.1016/0016-5085(88)90300-9; BODENHEIMER HC, 1985, HEPATOLOGY, V5, P1139, DOI 10.1002/hep.1840050613; CALMUS Y, 1990, HEPATOLOGY, V11, P12, DOI 10.1002/hep.1840110104; CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; COX DR, 1972, J R STAT SOC B, V34, P187; CROWE J, 1980, GASTROENTEROLOGY, V78, P1005; DICKSON ER, 1985, NEW ENGL J MED, V312, P1011, DOI 10.1056/NEJM198504183121602; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; DIXON WJ, 1988, BMDP STATISTICAL SOF; EPSTEIN O, 1981, LANCET, V1, P1275; HADZIYANNIS S, 1988, HEPATOLOGY, V8, P1421; HEATHCOTE J, 1976, GASTROENTEROLOGY, V70, P656; HOFFMAN AF, 1990, STRATEGIES TREATMENT, P13; HOOFNAGLE JH, 1986, GASTROENTEROLOGY, V91, P1327, DOI 10.1016/0016-5085(86)90183-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KITANI K, 1990, STRATEGIES TREATMENT, P43; LEUSCHNER U, 1989, GASTROENTEROLOGY, V97, P1268, DOI 10.1016/0016-5085(89)91698-3; LEUSCHNER U, 1990, HEPATOLOGY, V12, P957; LUDWIG J, 1978, VIRCHOWS ARCH A, V379, P103, DOI 10.1007/BF00432479; MALAVOLTI M, 1987, J LIPID RES, V28, P1281; MARKUS BH, 1989, NEW ENGL J MED, V320, P1709, DOI 10.1056/NEJM198906293202602; MARTEAU P, 1991, HEPATOLOGY, V12, P1206; MATLOFF DS, 1982, NEW ENGL J MED, V306, P319, DOI 10.1056/NEJM198202113060602; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MINUK GY, 1988, GASTROENTEROLOGY, V95, P1356, DOI 10.1016/0016-5085(88)90373-3; MITCHISON HC, 1989, HEPATOLOGY, V10, P420, DOI 10.1002/hep.1840100405; MUNOZ SJ, 1990, NEW ENGL J MED, V323, P1352; NEUBERGER J, 1985, GUT, V26, P114, DOI 10.1136/gut.26.2.114; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PODDA M, 1988, HEPATOLOGY, V8, P1266; POUPON R, 1987, LANCET, V1, P834; POUPON R, IN PRESS BILE ACIDS; POUPON RE, 1990, J HEPATOL, V11, P16, DOI 10.1016/0168-8278(90)90265-S; STELLAARD F, 1984, J LIPID RES, V25, P1313; STIEHL A, 1990, GASTROENTEROLOGY, V98, P424, DOI 10.1016/0016-5085(90)90834-N; TAAL BG, 1983, LIVER, V3, P345; TINT GS, 1986, GASTROENTEROLOGY, V91, P1007, DOI 10.1016/0016-5085(86)90708-0; TRIGER DR, 1980, GUT, V21, pA919; WARNES TW, 1987, J HEPATOL, V5, P1, DOI 10.1016/S0168-8278(87)80053-3; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003	44	678	686	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1548	1554		10.1056/NEJM199105303242204	http://dx.doi.org/10.1056/NEJM199105303242204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	1674105	Bronze			2022-12-28	WOS:A1991FN05100004
J	EAGGER, SA; LEVY, R; SAHAKIAN, BJ				EAGGER, SA; LEVY, R; SAHAKIAN, BJ			TACRINE IN ALZHEIMERS-DISEASE	LANCET			English	Article							DEMENTIA; DIAGNOSIS; MEMORY; SCALE	The efficacy and safety of tacrine (tetrahydroaminoacridine) plus lecithin were studied in a randomised, double-blind, placebo-controlled, crossover study. Patients with probable Alzheimer's disease were selected from those attending the memory clinic at a psychiatric hospital. Of the 89 patients included, 24 were withdrawn, 19 because of side-effects, 4 with other illnesses, and 1 for noncompliance. The active treatment was the maximum tolerated dose of tacrine up to 150 mg daily plus 10.8 g lecithin daily. Patients were randomly assigned to active or placebo treatment and crossed over after 13 weeks' treatment and 4 weeks' washout to the other treatment. The main outcome measures were the mini mental state examination (MMSE), the abbreviated mental test score (AMTS), and the carer's rating of the activities of daily living scale. Analysis for the 65 patients who completed the trial showed a significant beneficial effect of tacrine over placebo in the MMSE score (p < 0.0001; 95% confidence interval for group change on tacrine over that on placebo 1.67-3.71); 29 (45%) patients showed an improvement of 3 or more points on tacrine compared with 7 (11%) during placebo. The findings with the AMTS were similar (p = 0.0001; 95% Cl 0.36-1.38) but the ADL score showed no significant treatment effect. There was substantial variation in response among the subjects. Dose-dependent rises in serum liver enzymes were common but reversible. Tacrine produced an improvement in key outcome measures roughly equivalent to the deterioration which might have occurred over 6-12 months. The clinical relevance of the findings is a matter for individual judgment.	INST PSYCHIAT, DE CRESPIGNY PK, DENMARK HILL, LONDON SE5 8AF, ENGLAND				Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMES DJ, 1990, AUST NZ J MED, V20, P193, DOI 10.1111/j.1445-5994.1990.tb01309.x; BECKER JT, 1988, ARCH NEUROL-CHICAGO, V45, P263, DOI 10.1001/archneur.1988.00520270037018; Benton A.L., 1974, REVISED VISUAL RETEN; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; EVERITT BS, 1977, ANAL CONTINGENCY TAB, P114; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; HAMMEL P, 1990, J CLIN GASTROENTEROL, V12, P329, DOI 10.1097/00004836-199006000-00021; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; ISRAEL M, 1982, J NEUROCHEM, V39, P248, DOI 10.1111/j.1471-4159.1982.tb04727.x; KENDRICK DC, 1985, KENDRICK COGNITIVE T; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nelson H.E., 1982, NATIONAL ADULT READI; OBRIEN JT, 1991, AGE AGEING, V20, P129, DOI 10.1093/ageing/20.2.129; PERRY EK, 1986, BRIT MED BULL, V42, P63, DOI 10.1093/oxfordjournals.bmb.a072100; PHILPOT MP, 1987, INT J GERIATR PSYCH, V2, P195, DOI 10.1002/gps.930020310; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; SAHAKIAN BJ, 1990, NEUROPSYCHOLOGIA, V28, P1197, DOI 10.1016/0028-3932(90)90055-S; SAHAKIAN BJ, 1988, BRAIN, V111, P695, DOI 10.1093/brain/111.3.695; SALMON DP, 1990, NEUROLOGY, V40, P1225, DOI 10.1212/WNL.40.8.1225; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wechsler D, 1973, WECHSLER MEMORY SCAL; 1990, BRIT MED J, V300, P939; 1990, NEW ENGL J MED, V323, P919; 1989, 1989 PER CENTR NERV, P227	31	314	322	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1991	337	8748					989	992		10.1016/0140-6736(91)92656-M	http://dx.doi.org/10.1016/0140-6736(91)92656-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673209				2022-12-28	WOS:A1991FJ13500001
J	STUART, AG; WREN, C; SHARPLES, PM; HUNTER, S; HEY, EN				STUART, AG; WREN, C; SHARPLES, PM; HUNTER, S; HEY, EN			HYPOPLASTIC LEFT HEART SYNDROME - MORE POTENTIAL TRANSPLANT RECIPIENTS THAN SUITABLE DONORS	LANCET			English	Article							ORTHOTOPIC CARDIAC TRANSPLANTATION; ANENCEPHALIC INFANTS; ORGAN DONORS; EXPERIENCE; DEATH	Neonatal cardiac transplantation offers the prospect of survival for babies with hypoplastic left heart syndrome-but only if suitable donors are available. In a retrospective survey in the Northern health region of England and Wales, the likely need for neonatal cardiac transplantation far outweighed the potential availability of donors. Over 8 years (1983-90) hypoplastic left heart syndrome was identified in 38 newborn babies and in 9 fetuses in utero. Of 41 live births (including 3 diagnosed prenatally) 31 would have been candidates for a cardiac transplant, but only 4 suitable donors could be identified (3 with anencephaly born alive during the same period and 1 who died between 1979 and 1986 after a head injury). Analysis of all infant deaths in 1987-89 revealed only 3 potential donors from 426 deaths in the 3 years. Although more widespread antenatal diagnosis may lead to fewer liveborn babies with hypoplastic left heart syndrome, these findings indicate that an alternative source of donors needs to be identified before neonatal cardiac transplantation can be widely used in the treatment of this disorder.	FREEMAN RD HOSP,DEPT PAEDIAT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital; Newcastle University - UK				Stuart, Alan Graham/0000-0003-2789-2216				BAILEY LL, 1988, ANN SURG, V208, P279, DOI 10.1097/00000658-198809000-00004; BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; Bailey LL., 1984, HEART TRANSPLANT, V3, P265; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; DAVID TJ, 1983, J MED GENET, V20, P338, DOI 10.1136/jmg.20.5.338; HARRISON MR, 1986, LANCET, V2, P1383; HOLZGREVE W, 1987, NEW ENGL J MED, V326, P1069; LLOYD TR, 1989, AM HEART J, V117, P1337, DOI 10.1016/0002-8703(89)90416-X; MAVROUDIS C, 1989, J THORAC CARDIOV SUR, V97, P389; MAVROUDIS C, 1988, J THORAC CARDIOV SUR, V96, P912; MEDEARIS DN, 1989, NEW ENGL J MED, V321, P391, DOI 10.1056/NEJM198908103210610; MORRIS CD, 1990, PEDIATRICS, V85, P977; NORWOOD WI, 1981, J THORAC CARDIOV SUR, V82, P511; PEABODY JL, 1989, NEW ENGL J MED, V321, P344, DOI 10.1056/NEJM198908103210602; PIGOTT JD, 1988, ANN THORAC SURG, V45, P122; SHEWMON DA, 1988, HASTINGS CENT REP, V18, P11, DOI 10.2307/3562217; STILLER CR, 1988, TRANSPL P, V20, P1; TRUOG RD, 1989, NEW ENGL J MED, V321, P388, DOI 10.1056/NEJM198908103210609; TUCKER WY, 1990, J THORAC CARDIOV SUR, V99, P885; 1988, C MED ROYAL COLLEGES	20	21	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					957	959		10.1016/0140-6736(91)91581-E	http://dx.doi.org/10.1016/0140-6736(91)91581-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678040				2022-12-28	WOS:A1991FH13100014
J	SIMELL, T; KAPRIO, EA; MAENPAA, J; TUOMINEN, J; SIMELL, O				SIMELL, T; KAPRIO, EA; MAENPAA, J; TUOMINEN, J; SIMELL, O			RANDOMIZED PROSPECTIVE-STUDY OF SHORT-TERM AND LONG-TERM INITIAL STAY IN HOSPITAL BY CHILDREN WITH DIABETES-MELLITUS	LANCET			English	Article							SMALL-AREA VARIATIONS; INSULIN THERAPY; COMPLICATIONS	To assess how an isolated change in the pattern of care influences outcome of care and hospital use, a randomised prospective 2-year study was done in which 31 of 61 consecutive children with newly diagnosed insulin-dependent diabetes mellitus (IDDM) were admitted to hospital at disease onset for about a week and compared with the other 30 children who were admitted for about 4 weeks. Insulin treatment and education about diabetes were similar in the two groups. Duration of initial stay in hospital had no effect on metabolic control during the 2 years but time since diagnosis was significant with respect to effect on haemoglobin A1 (p = 0.001), haemoglobin A1c (p = 0.004), and insulin dose (p < 0.001). At 2 years, 45% of the children in the short-term group and 29% in the long-term group were C-peptide positive (p = NS); C-peptide positivity correlated with age. A change in the pattern of care of children with IDDM, led to a pronounced decrease in hospital use by this patient group. Irrespective of the length of initial stay in hospital, equally good metabolic control was obtained in both groups for 2 years.	AURORA CITY HOSP,HELSINKI,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND; UNIV TURKU,DEPT BIOSTAT,SF-20500 TURKU 50,FINLAND; UNIV TURKU,CARDIORESP RES UNIT,SF-20500 TURKU 50,FINLAND	University of Helsinki; University of Turku; University of Turku	SIMELL, T (corresponding author), UNIV TURKU,CHILDRENS HOSP,KIINAMYLLYNKATU 4-8,SF-20520 TURKU 52,FINLAND.							CLARSON C, 1987, DIABETES CARE, V10, P33, DOI 10.2337/diacare.10.1.33; DELAMATER AM, 1990, DIABETES CARE, V13, P492, DOI 10.2337/diacare.13.5.492; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; DUNCAN JA, 1986, CONT PEDIAT, V3, P79; HAMMAN RF, 1985, DIABETES CARE, V8, P94, DOI 10.2337/diacare.8.1.S94; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; Laron Z, 1979, Diabetes Care, V2, P342, DOI 10.2337/diacare.2.4.342; MACLURE A, 1984, LANCET, V2, P682; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; MULLIS P, 1988, DIABETOLOGIA, V31, P351, DOI 10.1007/BF02341502; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; SCHNEIDER AJ, 1983, AM J DIS CHILD, V137, P782, DOI 10.1001/archpedi.1983.02140340062017; SHAH SC, 1989, NEW ENGL J MED, V320, P550, DOI 10.1056/NEJM198903023200902; SIMELL T, 1990, NEW ENGL J MED, V322, P206; SIMELL T, 1987, CLIN JUDGEMENT DECIS, P376; SPAULDING RH, 1976, CAN MED ASSOC J, V114, P780; STENMAN UH, 1984, J CHROMATOGR, V297, P327, DOI 10.1016/S0021-9673(01)89052-X; SZAPIRO N, 1990, NEW ENGL J MED, V322, P206; TUOMILEHTO J, 1990, Diabetologia, V33, pA197; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; 1989, LANCET, V1, P1235; [No title captured]	24	25	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					656	660		10.1016/0140-6736(91)92464-D	http://dx.doi.org/10.1016/0140-6736(91)92464-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1672001				2022-12-28	WOS:A1991FB73000014
J	SAUNDERS, N; PATERSON, C				SAUNDERS, N; PATERSON, C			CAN WE ABANDON NAEGELE RULE	LANCET			English	Editorial Material								A pregnant woman may become anxious if she has not delivered by the date given to her by her physician. Much anxiety would be alleviated if a range of dates (38-42 weeks) was substituted for a specific date of delivery. 1			SAUNDERS, N (corresponding author), ST MARYS HOSP,SCH MED,DEPT OBSTET & GYNAECOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.							DENMAN T, 1782, INTRO PRACTICE MIDWI; HENDERSON M, 1967, ARCH ENVIRON HEALTH, V14, P905; MONTGOMERY WF, 1837, EXPOSITION SIGNS SYM; NESBITT R E Jr, 1955, Obstet Gynecol Surv, V10, P311, DOI 10.1097/00006254-195506000-00001; PARK GL, 1968, LANCET, V2, P1388; SPEERT H, 1958, ESSAYS EPONYMY; STEWART HL, 1952, JAMA-J AM MED ASSOC, V148, P1079	7	20	20	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					600	601		10.1016/0140-6736(91)91653-C	http://dx.doi.org/10.1016/0140-6736(91)91653-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671954				2022-12-28	WOS:A1991FA70200015
J	DANNA, PL; URBAN, C; BELLIN, E; RAHAL, JJ				DANNA, PL; URBAN, C; BELLIN, E; RAHAL, JJ			ROLE OF CANDIDA IN PATHOGENESIS OF ANTIBIOTIC-ASSOCIATED DIARRHEA IN ELDERLY INPATIENTS	LANCET			English	Article							INFECTION	The part that candida plays in antibiotic-associated diarrhoea was investigated in 24 elderly inpatients (mean age 74 years) who tested negative for Clostridium difficile toxin and other intestinal pathogens. 7 had intestinal overgrowth of Candida species (greater-than-or-equal-to 10(5) cfu/ml). None of the 24 matched, antibiotic-treated controls without diarrhoea had candida overgrowth. All 5 patients with diarrhoea and candida overgrowth treated with oral nystatin responded with resolution of diarrhoea and lowering of faecal counts to < 10(4) cfu/ml within 7 days of start of antifungal therapy despite continuation of antibacterial therapy. In the other 2 patients with candida overgrowth, the diarrhoea subsided spontaneously and faecal candida counts returned to normal (< 10(4) cfu/ml) after antibacterial agents were withdrawn. In patients without candida overgrowth, diarrhoea persisted until antibiotics were withdrawn, at a mean of 16 days after study entry.	BOOTH MEM MED CTR,INFECT DIS SECT,56-45 MAIN ST,FLUSHING,NY 11355; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; NYU,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10003	Yeshiva University; Albert Einstein College of Medicine; New York University								Alam S A, 1977, Bangladesh Med Res Counc Bull, V3, P32; BARTLETT JG, 1984, DM-DIS MON, V30, P1; BOLIVAR R, 1985, CANDIDIASIS, P181; BRABANDER J O, 1957, Can Med Assoc J, V77, P478; Chang T. W., 1985, BOCKUS GASTROENTEROL, P2583; CHRETIEN JH, 1982, MED CLIN N AM, V66, P675, DOI 10.1016/S0025-7125(16)31415-8; COHEN R, 1969, NEW ENGL J MED, V280, P638, DOI 10.1056/NEJM196903202801204; ERAS P, 1972, MEDICINE, V51, P367, DOI 10.1097/00005792-197209000-00002; FITZPATRICK JJ, 1966, AM J MED SCI, V252, P310, DOI 10.1097/00000441-196609000-00010; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GIULIANO M, 1987, ANTIMICROB AGENTS CH, V31, P202, DOI 10.1128/AAC.31.2.202; GORBACH SL, 1987, LANCET, V2, P1378; GORBACH SL, 1967, GASTROENTEROLOGY, V53, P845; GUPTA TP, 1990, GASTROENTEROLOGY, V98, P780, DOI 10.1016/0016-5085(90)90303-I; HELSTROM PB, 1979, INFECT IMMUN, V23, P764, DOI 10.1128/IAI.23.3.764-774.1979; KANE JG, 1976, LANCET, V1, P335; KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379; KOZINN PJ, 1962, PEDIATRICS, V30, P71; LEVINE MM, 1986, REV INFECT DIS, V8, pS206; SHOBHA NJ, 1981, GASTROENTEROLOGY, V80, P829; SOBEL JD, 1988, CRIT CARE CLIN, V4, P335; Thorne G M, 1988, Infect Dis Clin North Am, V2, P747; TRIER JS, 1984, AM J MED, V30, P39; YANNELLI B, 1988, AM J INFECT CONTROL, V16, P246, DOI 10.1016/S0196-6553(88)80003-8	24	59	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					511	514		10.1016/0140-6736(91)91296-7	http://dx.doi.org/10.1016/0140-6736(91)91296-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671890				2022-12-28	WOS:A1991EZ87400003
J	BRAHAMS, D				BRAHAMS, D			LATE BENOXAPROFEN CLAIMS	LANCET			English	Editorial Material																		1991, TIMES           0213	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					483	484		10.1016/0140-6736(91)93412-3	http://dx.doi.org/10.1016/0140-6736(91)93412-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671484				2022-12-28	WOS:A1991EY88700019
J	NAVARATNAM, DS; PRIDDLE, JD; MCDONALD, B; ESIRI, MM; ROBINSON, JR; SMITH, AD				NAVARATNAM, DS; PRIDDLE, JD; MCDONALD, B; ESIRI, MM; ROBINSON, JR; SMITH, AD			ANOMALOUS MOLECULAR-FORM OF ACETYLCHOLINESTERASE IN CEREBROSPINAL-FLUID IN HISTOLOGICALLY DIAGNOSED ALZHEIMERS-DISEASE	LANCET			English	Article							CSF ACETYLCHOLINESTERASE; HUMAN NEOCORTEX; NEURONS; HIPPOCAMPUS	The possibility that the different molecular forms of acetylcholinesterase (AChE) in cerebrospinal fluid (CSF) which can be revealed by isoelectric focusing may reflect changes in AChE in pathologically affected neurons in Alzheimer's disease was tested in a retrospective study. CSF samples obtained at necropsy from 33 patients with clinically diagnosed dementia, 9 with possible dementia, and 19 without a diagnosis of dementia were examined by isoelectric focusing. An additional band indicating an anomalous molecular form of AChE was present in CSF from 19 of 23 patients with a histological diagnosis of Alzheimer's disease and no other central nervous system disorder but in none of the 19 non-demented patients (without a histological diagnosis of Alzheimer's disease). The band was also present in 2 of 8 patients with histologically defined Alzheimer's disease plus other neurological disorders and in 4 of 8 patients with possible dementia who did not meet histopathological criteria for Alzheimer's disease. The absence of the anomalous form of AChE from the CSF of non-demented patients and its presence in the CSF of the majority of patients with Alzheimer's disease has implications for our understanding of the biological basis of the disease and might form the basis of an antemortem diagnostic test.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND; LITTLEMORE HOSP,OXFORD,ENGLAND	University of Oxford; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEYARD ME, 1987, NEUROCHEM INT, V11, P397, DOI 10.1016/0197-0186(87)90029-5; APPLEYARD ME, 1983, LANCET, V2, P452; APPLEYARD ME, 1987, BRAIN, V110, P1309, DOI 10.1093/brain/110.5.1309; ARENDT T, 1984, LANCET, V1, P173; CHUBB IW, 1976, NEUROSCIENCE, V1, P57, DOI 10.1016/0306-4522(76)90048-8; CHUBB IW, 1975, PROC R SOC SER B-BIO, V191, P245, DOI 10.1098/rspb.1975.0126; CROSS RB, 1982, MED LAB SCI, V39, P67; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GEULA C, 1989, BRAIN RES, V498, P185, DOI 10.1016/0006-8993(89)90419-8; GIULIAN GG, 1984, ANAL BIOCHEM, V142, P421, DOI 10.1016/0003-2697(84)90486-X; GREENFIELD SA, 1979, BRAIN RES, V177, P445, DOI 10.1016/0006-8993(79)90463-3; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LAMY C, 1989, NEUROPATH APPL NEURO, V15, P563, DOI 10.1111/j.1365-2990.1989.tb01255.x; MESULAM MM, 1988, ANN NEUROL, V24, P765, DOI 10.1002/ana.410240611; NAKAMURA S, 1985, NEUROSCI LETT, V61, P183, DOI 10.1016/0304-3940(85)90422-7; PERRY EK, 1986, BRIT MED BULL, V42, P63, DOI 10.1093/oxfordjournals.bmb.a072100; PERRY EK, 1981, METABOLIC DISORDERS, P382; SMITH AD, 1984, LANCET, V1, P513	18	60	64	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					447	450		10.1016/0140-6736(91)93391-L	http://dx.doi.org/10.1016/0140-6736(91)93391-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671469				2022-12-28	WOS:A1991EY88700002
J	VALE, RD				VALE, RD			SEVERING OF STABLE MICROTUBULES BY A MITOTICALLY ACTIVATED PROTEIN IN XENOPUS EGG EXTRACTS	CELL			English	Article							ACTIN-DEPOLYMERIZING FACTOR; DYNAMIC INSTABILITY; INDIVIDUAL MICROTUBULES; DETYROSINATED TUBULIN; ALPHA-TUBULIN; LIVING CELLS; BINDING; BRAIN; GELSOLIN; POLYMERIZATION	Eukaryotic cells disassemble and reorganize their cytoskeleton during the cell cycle and in response to environmental cues. Disassembly of the actin cytoskeleton is aided by proteins that sever filamentous actin, but microtubule-severing proteins thus far have not been identified. Here, we describe an activity in extracts from Xenopus eggs that rapidly severs stable microtubules along their length. Severing is elicited by a protein(s) whose activity is greatly stimulated during mitosis through a posttranslational mechanism. The microtubule-severing factor may be involved in disassembling the interphase microtubule network prior to constructing the mitotic spindle.			VALE, RD (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038499, R01GM038499] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38499] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; COOPER JA, 1986, J BIOL CHEM, V261, P477; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GARD DL, 1985, J CELL BIOL, V100, P764, DOI 10.1083/jcb.100.3.764; GARD DL, 1991, IN PRESS DEV BIOL; GIFFARD RG, 1984, J CELL BIOL, V98, P1796, DOI 10.1083/jcb.98.5.1796; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; HAGAN I, 1988, J CELL SCI, V91, P587; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HYMAN A, 1991, IN PRESS METH ENZYMO; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KHAWAJA S, 1988, J CELL BIOL, V106, P141, DOI 10.1083/jcb.106.1.141; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KRISTOFFERSON D, 1986, J CELL BIOL, V102, P1007, DOI 10.1083/jcb.102.3.1007; KUMAR N, 1981, J BIOL CHEM, V256, P7678; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY A, 1989, NATURE, V246, P614; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SAWIN KE, 1991, IN PRESS J CELL BIOL; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SHEETZ MP, 1986, METHOD ENZYMOL, V134, P531; SOLTYS BJ, 1985, J CELL BIOL, V100, P1682, DOI 10.1083/jcb.100.5.1682; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SUGINO H, 1982, CELL MOTIL CYTOSKEL, V2, P457, DOI 10.1002/cm.970020505; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1989, CELL MOVEMENT, V2, P287; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1980, J BIOL CHEM, V255, P9494	63	174	179	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					827	839		10.1016/0092-8674(91)90511-V	http://dx.doi.org/10.1016/0092-8674(91)90511-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1671762				2022-12-28	WOS:A1991EZ47800017
J	TABIN, CJ				TABIN, CJ			RETINOIDS, HOMEOBOXES, AND GROWTH-FACTORS - TOWARD MOLECULAR-MODELS FOR LIMB DEVELOPMENT	CELL			English	Review							CHICK WING BUD; ACID-BINDING-PROTEIN; APICAL ECTODERMAL RIDGE; EMBRYONAL CARCINOMA-CELLS; HORMONE RECEPTOR SUPERFAMILY; TISSUE-SPECIFIC EXPRESSION; REGENERATING AXOLOTL LIMB; BOX-CONTAINING GENES; PATTERN-FORMATION; THYROID-HORMONE				TABIN, CJ (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.							AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ALLES AJ, 1989, TERATOLOGY, V40, P163, DOI 10.1002/tera.1420400210; AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELL KM, 1986, J EMBRYOL EXP MORPH, V93, P257; BELL KM, 1985, J EMBRYOL EXP MORPH, V86, P219; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOUTIN EL, 1984, DEV BIOL, V104, P111, DOI 10.1016/0012-1606(84)90041-1; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1991, IN PRESS NUCL ACIDS; BREITMAN TR, 1981, BLOOD, V57, P1000; BRENT G A, 1989, New Biologist, V1, P329; BROCKES J, 1991, NATURE, V350, P15, DOI 10.1038/350015a0; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BRYANT SV, 1986, TRENDS GENET, V2, P153, DOI 10.1016/0168-9525(86)90210-6; CAMERON JA, 1986, NATURE, V321, P607, DOI 10.1038/321607a0; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Chytil F., 1984, RETINOIDS, V2, P90; COLBERGPOLEY AM, 1987, DIFFERENTIATION, V35, P206, DOI 10.1111/j.1432-0436.1987.tb00170.x; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, IN PRESS DEVELOPMENT; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DENCKER L, 1990, DEVELOPMENT, V110, P343; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESPESETH AS, 1989, GENE DEV, V3, P1647, DOI 10.1101/gad.3.11.1647; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALLON JF, 1975, J EXP ZOOL, V193, P449, DOI 10.1002/jez.1401930324; FALLON JF, 1968, DEV BIOL, V18, P553, DOI 10.1016/0012-1606(68)90026-2; FALLON JF, 1976, VERTEBRATE LIMB SOMI, P56; FERRETTI P, 1988, J EXP ZOOL, V247, P77, DOI 10.1002/jez.1402470111; FINCH RA, 1971, J EXP ZOOL, V176, P397, DOI 10.1002/jez.1401760403; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; GOETINCK PF, 1964, DEV BIOL, V10, P71, DOI 10.1016/0012-1606(64)90005-3; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; HAMPE A, 1960, J EMBRYOL EXP MORPH, V8, P241; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HINCHLIFFE JR, 1981, J EMBRYOL EXP MORPH, V62, P63; HOLDER N, 1989, DEVELOPMENT, V105, P585; HONIG LS, 1981, J EMBRYOL EXP MORPH, V62, P203; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HURLE JM, 1986, J EMBRYOL EXP MORPH, V94, P231; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAVOIS LC, 1986, J EMBRYOL EXP MORPH, V91, P135; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KIENY M, 1979, J EMBRYOL EXP MORPH, V49, P153; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEROY P, 1991, IN PRESS EMBO J; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LIBBY PR, 1982, CARCINOGENESIS, V3, P481, DOI 10.1093/carcin/3.5.481; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MADEN M, 1985, ROUX ARCH DEV BIOL, V194, P228, DOI 10.1007/BF00848251; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MADEN M, 1990, DEVELOPMENT, V109, P75; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; MADEN M, 1989, DEVELOPMENT, V107, P109; MADEN M, 1983, DEV BIOL, V98, P409, DOI 10.1016/0012-1606(83)90370-6; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MUNEOKA K, 1982, NATURE, V298, P369, DOI 10.1038/298369a0; NARDI JB, 1983, DIFFERENTIATION, V25, P27; NEWMAN SA, 1988, J THEOR BIOL, V134, P183, DOI 10.1016/S0022-5193(88)80201-7; NIAZI I A, 1978, Folia Biologica (Cracow), V26, P3; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PAPALOPULU N, 1990, ADV NEURAL REGENERAT, V60, P291; PAUTOU MP, 1973, J EMBRYOL EXP MORPH, V29, P175; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POHL TM, 1990, DEVELOPMENT, V110, P1153; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROBERTSON M, 1987, NATURE, V330, P420, DOI 10.1038/330420a0; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Saunders J., 1966, MAJOR PROBLEMS DEV B, P289; Saunders J W, 1983, Prog Clin Biol Res, V110 Pt A, P67; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1972, ANN NY ACAD SCI, V193, P29, DOI 10.1111/j.1749-6632.1972.tb27821.x; SAUNDERS JW, 1977, VERTEBRATE LIMB SOMI, P1; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1989, Molecular Reproduction and Development, V1, P107, DOI 10.1002/mrd.1080010205; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH JC, 1979, J EMBRYOL EXP MORPH, V52, P105; SMITH SM, 1991, DEVELOPMENT, V111, P245; SOLURSH M, 1981, DEV BIOL, V86, P471, DOI 10.1016/0012-1606(81)90205-0; STOCUM DL, 1972, J EXP ZOOL, V181, P49, DOI 10.1002/jez.1401810106; STONER CM, 1989, CANCER RES, V49, P1497; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUMMERBELL D, 1983, LIMB DEV REGENERAT A, P109; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; TABIN CJ, 1989, DEVELOPMENT, V105, P813; TAKASE S, 1986, ARCH BIOCHEM BIOPHYS, V247, P328, DOI 10.1016/0003-9861(86)90591-6; TAMURA K, 1990, DEV BIOL, V140, P20, DOI 10.1016/0012-1606(90)90049-O; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THALLER C, 1988, DEVELOPMENT, V103, P473; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; Thornton C S, 1968, Adv Morphog, V7, P205; TICKLE C, 1989, DEVELOPMENT, V106, P691; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1988, ROUX ARCH DEV BIOL, V197, P27, DOI 10.1007/BF00376038; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1976, NATURE, V259, P396, DOI 10.1038/259396a0; TODT WL, 1987, DEVELOPMENT, V101, P501; TOMASEK JJ, 1982, DEV BIOL, V90, P118, DOI 10.1016/0012-1606(82)90217-2; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; UMANSKI E, 1938, B BIOL MED EXP, V6, P141; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WEI LN, 1987, MOL ENDOCRINOL, V1, P526, DOI 10.1210/mend-1-8-526; WILSON DJ, 1987, DEVELOPMENT, V99, P99; Wolpert L, 1975, Ciba Found Symp, V0, P95; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZELENT A, 1991, IN PRESS EMBO J; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481; ZWILLING E, 1956, J EXP ZOOL, V132, P173, DOI 10.1002/jez.1401320111; ZWILLING E, 1956, J EXP ZOOL, V132, P157, DOI 10.1002/jez.1401320110; [No title captured]	166	440	451	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1991	66	2					199	217		10.1016/0092-8674(91)90612-3	http://dx.doi.org/10.1016/0092-8674(91)90612-3			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1677315				2022-12-28	WOS:A1991FY71200003
J	PALMER, MS; DRYDEN, AJ; HUGHES, JT; COLLINGE, J				PALMER, MS; DRYDEN, AJ; HUGHES, JT; COLLINGE, J			HOMOZYGOUS PRION PROTEIN GENOTYPE PREDISPOSES TO SPORADIC CREUTZFELDT-JAKOB DISEASE	NATURE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; GENE; DEMENTIA; MICE	THE human prion diseases, Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler syndrome (GSS), are neurodegenerative diseases that are unique in being both infectious and genetic. Transmission of both diseases and the animal spongiform encephalopathies (for example, scrapie and bovine spongiform encephalopathy) to experimental animals by intracerebral inoculation with brain homogenates is well documented 1. Despite their experimental transmissibility, missense and insertional mutations in the prion protein gene are associated with both GSS and familial CJD, demonstrating that the human familial cases are autosomal dominant diseases 2-6. More that 80% of CJD cases occur sporadically, however, and are not known to be associated with mutations. Here we report that 21 of 22 sporadic CJD cases and a further 19 of 23 suspected sporadic CJD cases are homozygous at the polymorphic amino-acid residue 129; 51% of the normal population are heterozygous at this site. We argue that homozygosity predisposes towards sporadic CJD and that this directly supports the hypothesis that interaction between prion protein molecules underlies the disease process.	ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,NORFOLK PL,LONDON W2 1PG,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND	Imperial College London; Radcliffe Infirmary					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; GIBBS CJ, 1973, SCIENCE, V182, P67, DOI 10.1126/science.182.4107.67; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; GOLDFARB LG, 1991, LANCET, V337, P15; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; MASTERS C L, 1987, P511; OWEN F, 1989, LANCET, V1, P51; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLER RO, 1989, PSYCHOL MED, V19, P1, DOI 10.1017/S0033291700010965; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191	21	736	757	0	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					340	342		10.1038/352340a0	http://dx.doi.org/10.1038/352340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1677164				2022-12-28	WOS:A1991FY28900072
J	TREGASKIS, B; MAYBERRY, JF				TREGASKIS, B; MAYBERRY, JF			ELDERLY PEOPLE AT HOME WHO CANNOT COPE	LANCET			English	Editorial Material											TREGASKIS, B (corresponding author), LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND.		Mayberry, John/AAP-2392-2020					FORSTER DP, 1980, BRIT MED J, V280, P739, DOI 10.1136/bmj.280.6215.739; GRAY JAM, 1990, J PUBLIC HEALTH MED, V12, P28, DOI 10.1093/oxfordjournals.pubmed.a042502; GRAY JAM, 1980, PUBLIC HEALTH, V94, P296, DOI 10.1016/S0033-3506(80)80078-3; Hoggett B., 1984, MENTAL HLTH LAW; MAYBERRY JF, 1991, THESIS U WALES; TOWLER JN, 1988, PUBLIC HEALTH, V102, P485, DOI 10.1016/S0033-3506(88)80087-8	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					47	47		10.1016/0140-6736(91)90026-L	http://dx.doi.org/10.1016/0140-6736(91)90026-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676095				2022-12-28	WOS:A1991FV29600019
J	PEREZAYUSO, RM; PIQUE, JM; BOSCH, J; PANES, J; GONZALEZ, A; PEREZ, R; RIGAU, J; QUINTERO, E; VALDERRAMA, R; VIVER, J; ESTEBAN, R; RODRIGO, L; BORDAS, JM; RODES, J				PEREZAYUSO, RM; PIQUE, JM; BOSCH, J; PANES, J; GONZALEZ, A; PEREZ, R; RIGAU, J; QUINTERO, E; VALDERRAMA, R; VIVER, J; ESTEBAN, R; RODRIGO, L; BORDAS, JM; RODES, J			PROPRANOLOL IN PREVENTION OF RECURRENT BLEEDING FROM SEVERE PORTAL HYPERTENSIVE GASTROPATHY IN CIRRHOSIS	LANCET			English	Article							BLOOD-FLOW; CONGESTIVE GASTROPATHY; ESOPHAGEAL-VARICES; VASCULAR ECTASIAS; GASTRIC-MUCOSA; ACID-SECRETION; RATS; PRESSURE; HEMODYNAMICS; RESISTANCE	The two main causes of gastrointestinal bleeding in cirrhosis are oesophageal varices and portal hypertensive gastropathy (PHG). Rebleeding from varices can be prevented by beta-blockers, but it is not clear whether these drugs effectively reduce rebleeding from PHG. 54 cirrhotic patients with acute or chronic bleeding from severe PHG took part in a randomised, controlled trial to investigate the efficacy of propranolol in prevention of rebleeding from PHG. 26 patients were randomised to receive propranolol daily at a dose that reduced the resting heart rate by 25% or to 55 bpm (20-160 mg twice daily), throughout mean follow-up of 21 (SD 11) months. 28 untreated controls were followed-up, with the same examinations, for 18 (13) months. The actuarial percentages of patients free of rebleeding from PHG were significantly higher in the propranolol-treated patients than in the untreated controls at 12 months (65% vs 38%, p < 0-05) and at 30 months of follow-up (52% vs 7%; p < 0-05). Propranolol-treated patients had fewer episodes of acute bleeding than controls (0.010 [0.004] vs 0.120 [0.040] per patient per month). Multivariate analysis showed that absence of propranolol treatment was the only predictive variable for rebleeding. Actuarial survival was slightly higher in the propranolol group than in the controls, but the difference was not significant. Thus, long-term propranolol treatment significantly reduces the frequency of rebleeding from severe PHG, and may improve the prognosis of cirrhotic patients with this disorder.	HOSP GEN GRANOLLERS,DEPT MED,BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROVINCIAL,LIVER UNIT,E-08036 BARCELONA,SPAIN; HOSP MUTUA TERRASSA,DEPT MED,BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,HOSP GEN VALLE HEBRON,DEPT MED,BARCELONA,SPAIN; UNIV OVIEDO,CIUDAD SANITARIA NTRA SRA COVADONGA,DEPT GASTROENTEROL,OVIEDO,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitario Mutua Terrassa; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; University of Oviedo	PEREZAYUSO, RM (corresponding author), UNIV BARCELONA,HOSP CLIN & PROVINCIAL,DEPT GASTROENTEROL,GASTROENTEROL UNIT,VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Quintero, Enrique/C-3841-2017; Panes, Julian/H-5991-2015	Quintero, Enrique/0000-0002-7244-8125; Panes, Julian/0000-0002-4971-6902; esteban, rafael/0000-0001-5280-392X; Gonzalez, Antonio/0000-0001-7212-4254				BENOIT JN, 1986, AM J PHYSIOL, V250, pG535, DOI 10.1152/ajpgi.1986.250.4.G535; BENOIT JN, 1986, SEMIN LIVER DIS, V6, P287, DOI 10.1055/s-2008-1040611; BOSCH J, 1984, HEPATOLOGY, V4, P1200, DOI 10.1002/hep.1840040617; COLOMBO M, 1989, HEPATOLOGY, V9, P433, DOI 10.1002/hep.1840090315; COX DR, 1972, J R STAT SOC B, V34, P187; Friedman LM., 1981, FUNDAMENTALS CLIN TR; GARCIATSAO G, 1986, HEPATOLOGY, V6, P101, DOI 10.1002/hep.1840060119; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; GROSZMANN RJ, 1984, GASTROENTEROLOGY, V86, P1611; HOSKING SW, 1987, HEPATOLOGY, V7, P437, DOI 10.1002/hep.1840070304; KITANO S, 1982, EUR SURG RES, V14, P221, DOI 10.1159/000128292; KROEGER RJ, 1985, HEPATOLOGY, V5, P97, DOI 10.1002/hep.1840050120; LEBREC D, 1984, HEPATOLOGY, V4, P355, DOI 10.1002/hep.1840040301; LEBREC D, 1988, J HEPATOL, V7, P118, DOI 10.1016/S0168-8278(88)80515-4; MCCORMACK TT, 1985, GUT, V26, P1226, DOI 10.1136/gut.26.11.1226; PAPAZIAN A, 1986, GUT, V27, P1199, DOI 10.1136/gut.27.10.1199; PEREZAYUSO RM, 1989, SCAND J GASTROENTERO, V24, P1073, DOI 10.3109/00365528909089257; PIQUE JM, 1988, GASTROENTEROLOGY, V95, P727, DOI 10.1016/S0016-5085(88)80021-0; PIQUE JM, 1990, HEPATOLOGY, V12, P476, DOI 10.1002/hep.1840120305; PIZCUETA MP, 1989, HEPATOLOGY, V10, P953, DOI 10.1002/hep.1840100610; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; QUINTERO E, 1986, DIGEST DIS SCI, V31, P897, DOI 10.1007/BF01303208; QUINTERO E, 1987, GASTROENTEROLOGY, V93, P1054, DOI 10.1016/0016-5085(87)90569-5; QUINTERO E, 1985, J HEPATOL S2, V1, pS315; RECTOR WG, 1985, CLIN GASTROENTEROL, V14, P139; SAPERAS E, 1990, AM J GASTROENTEROL, V85, P138; SARFEH IJ, 1988, SURGERY, V104, P79; SARFEH IJ, 1983, GASTROENTEROLOGY, V84, P987; TERES J, 1976, GUT, V17, P37, DOI 10.1136/gut.17.1.37; VANVLIET ACM, 1978, ENDOSCOPY, V10, P89, DOI 10.1055/s-0028-1098271	30	182	186	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1431	1434		10.1016/0140-6736(91)93125-S	http://dx.doi.org/10.1016/0140-6736(91)93125-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675316				2022-12-28	WOS:A1991FR06000002
J	MOLYNEUX, ME; TAYLOR, TE; THOMAS, CG; MANSOR, S; WIRIMA, JJ				MOLYNEUX, ME; TAYLOR, TE; THOMAS, CG; MANSOR, S; WIRIMA, JJ			EFFICACY OF QUININE FOR FALCIPARUM-MALARIA ACCORDING TO PREVIOUS CHLOROQUINE EXPOSURE	LANCET			English	Note							MALAWIAN CHILDREN; KINETICS	Chloroquine has been reported to antagonise the anti-parasitic action of quinine against Plasmodium falciparum in vitro. We looked for evidence of any such antagonism in vivo. In 123 Malawian children with cerebral malaria treated with parenteral quinine, the likelihood of survival and the rate of recovery were much the same in patients who had taken chloroquine and those who had not. In these circumstances we found no evidence of chloroquine/quinine antagonism.	QUEEN ELIZABETH CENT HOSP, BLANTYRE, MALAWI; UNIV LIVERPOOL, DEPT PHARMACOL & THERAPEUT, LIVERPOOL L69 3BX, ENGLAND	University of Malawi; University of Liverpool	MOLYNEUX, ME (corresponding author), UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, PEMBROKE PL, LIVERPOOL L3 5QA, ENGLAND.							KHOROMANA CO, 1986, AM J TROP MED HYG, V35, P465, DOI 10.4269/ajtmh.1986.35.465; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOOAREESUWAN S, 1986, BRIT J CLIN PHARMACO, V22, P31, DOI 10.1111/j.1365-2125.1986.tb02876.x; MANSOR SM, 1990, T ROY SOC TROP MED H, V84, P482, DOI 10.1016/0035-9203(90)90007-2; STAHEL E, 1988, T ROY SOC TROP MED H, V82, P221, DOI 10.1016/0035-9203(88)90417-8; [No title captured]; 1990, WHO TECH REP SER, V805	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1991	337	8754					1379	1380		10.1016/0140-6736(91)93063-F	http://dx.doi.org/10.1016/0140-6736(91)93063-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674766				2022-12-28	WOS:A1991FP87000006
J	LOCK, M				LOCK, M			CONTESTED MEANINGS OF THE MENOPAUSE	LANCET			English	Editorial Material							REPLACEMENT THERAPY; WOMEN				LOCK, M (corresponding author), MCGILL UNIV,DEPT HUMANITIES & SOCIAL STUDIES MED,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ETTINGER B, 1987, AM J OBSTET GYNECOL, V156, P1298, DOI 10.1016/0002-9378(87)90168-2; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; GOSDEN RG, 1985, BIOL MENOPAUSE, P1; GREENBLATT RB, 1980, MENOPAUSE COMPREHENS, P151; KASE N, 1974, JAMA-J AM MED ASSOC, V227, P318, DOI 10.1001/jama.227.3.318; KAUFERT PA, 1984, SOC SCI MED, V18, P279, DOI 10.1016/0277-9536(84)90091-1; KAUFERT PA, 1986, CULT MED PSYCHIAT, V10, P7, DOI 10.1007/BF00053260; LOCK M, 1988, MATURITAS, V10, P317, DOI 10.1016/0378-5122(88)90067-9; LOCK M, 1988, BIOMEDICAL KNOWLEDGE; MCKINLAY SM, 1986, CLIMACTERIC PERSPECT, P59; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P8; THORNEYCROFT IH, 1989, AM J OBSTET GYNECOL, V160, P1306, DOI 10.1016/S0002-9378(89)80018-3; WEISS KM, 1981, OTHER WAYS GROWING O, P25; WRIGHT Peter, 1982, PROBLEM MED KNOWLEDG	14	100	106	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1270	1272		10.1016/0140-6736(91)92931-Q	http://dx.doi.org/10.1016/0140-6736(91)92931-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674073				2022-12-28	WOS:A1991FN04700014
J	HEDLEY, ML; MANIATIS, T				HEDLEY, ML; MANIATIS, T			SEX-SPECIFIC SPLICING AND POLYADENYLATION OF DSX PRE-MESSENGER-RNA REQUIRES A SEQUENCE THAT BINDS SPECIFICALLY TO TRA-2 PROTEIN INVITRO	CELL			English	Article							DROSOPHILA DOUBLESEX GENE; MELANOGASTER; SITE; DIFFERENTIATION; IDENTIFICATION; TRANSFORMER; EXPRESSION; INTRON; RECOGNITION; EFFICIENCY	Somatic sex determination in Drosophila involves a hierarchy of regulated alternative pre-mRNA processing. Female-specific splicing and/or polyadenylation of doublesex (dsx) pre-mRNA, the final gene in this pathway, requires transformer (tra) and transformer-2 (tra-2) proteins. The mechanism by which these proteins regulate RNA processing has not been characterized. In this paper we show that tra-2 produced in Escherichia coli binds specifically to a site within the female-specific exon of dsx pre-mRNA. This site, which contains six copies of a 13 nucleotide repeat, is required not only for female-specific splicing, but also for female-specific polyadenylation. These observations suggest that tra-2 is a positive regulator of dsx pre-mRNA processing.			HEDLEY, ML (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM 42231, GM 13344] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; McKeown M, 1990, Genet Eng (N Y), V12, P139; MCLAUCHLAN J, 1989, CELL, V59, P1093, DOI 10.1016/0092-8674(89)90765-4; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SLEE R, 1990, Q REV BIOL, V65, P175, DOI 10.1086/416718; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	41	213	217	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					579	586		10.1016/0092-8674(91)90090-L	http://dx.doi.org/10.1016/0092-8674(91)90090-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1674449				2022-12-28	WOS:A1991FM03700008
J	LEMAISTRE, CF; ROSENBLUM, MG; REUBEN, JM; PARKINSON, DR; MENEGHETTI, CM; PARKER, K; SHAW, JP; DEISSEROTH, AB; WOODWORTH, T				LEMAISTRE, CF; ROSENBLUM, MG; REUBEN, JM; PARKINSON, DR; MENEGHETTI, CM; PARKER, K; SHAW, JP; DEISSEROTH, AB; WOODWORTH, T			THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC-LEUKEMIA	LANCET			English	Note							EXPRESSION; RECEPTORS; CELL	In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77025; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,HOUSTON,TX 77025; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77025; NCI,BETHESDA,MD 20892; SERAGEN INC,HOPKINTON,MA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LEMAISTRE, CF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED HEMATOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.							HOLTER W, 1987, J IMMUNOL, V138, P2917; KIYOKAWA T, 1989, CANCER RES, V49, P4042; LEMAISTRE CF, 1990, P AM ASSOC CANC RES, V31, pA1145; ROSOLEN A, 1989, BLOOD, V73, P1968; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	9	34	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1124	1125		10.1016/0140-6736(91)92788-4	http://dx.doi.org/10.1016/0140-6736(91)92788-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674015				2022-12-28	WOS:A1991FL12400005
J	BYRNE, P; OGUEH, O; SANTCASSIA, LJ				BYRNE, P; OGUEH, O; SANTCASSIA, LJ			OUTPATIENT LOOP DIATHERMY CONIZATION	LANCET			English	Letter											BYRNE, P (corresponding author), WALSGRAVE GEN HOSP,DEPT OBSTET & GYNAECOL,COVENTRY CV2 2DX,ENGLAND.							LUESLEY D, 1988, CANCER SURV, V7, P529; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; PRENDEVILLE W, 1989, BR J OBSTET GYNAECOL, V96, P1345	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					917	918		10.1016/0140-6736(91)90248-N	http://dx.doi.org/10.1016/0140-6736(91)90248-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672994				2022-12-28	WOS:A1991FG04800047
J	CLEMENS, JD; VANLOON, F; SACK, DA; RAO, MR; AHMED, F; CHAKRABORTY, J; KAY, BA; KHAN, MR; YUNUS, M; HARRIS, JR; SVENNERHOLM, AM; HOLMGREN, J				CLEMENS, JD; VANLOON, F; SACK, DA; RAO, MR; AHMED, F; CHAKRABORTY, J; KAY, BA; KHAN, MR; YUNUS, M; HARRIS, JR; SVENNERHOLM, AM; HOLMGREN, J			BIOTYPE AS DETERMINANT OF NATURAL IMMUNIZING EFFECT OF CHOLERA	LANCET			English	Note							VACCINES; BANGLADESH	To test the hypothesis that clinical Vibrio cholerae O1 infections protect against recurrent cholera, treated cholera episodes in a rural Bangladesh population of 188 153 people who were followed between 1985 and 1988 were analysed. Of the 2214 people with initial episodes of cholera, 7 had a second episode. The incidence of cholera was 61% lower in subjects who had had an earlier episode than in those without such an episode. Whereas initial episodes of classical cholera were associated with complete protection against subsequent cholera, initial episodes of El Tor cholera were associated with negligible protection.	INT CTR DIARRHOEL DIS RES,DHAKA,BANGLADESH; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; CTR DIS CONTROL,ENTER INFECT BRANCH,ATLANTA,GA 30333; UNIV MARYLAND,CTR VACCINE DEV,BALTIMORE,MD 21201; GOTHENBURG UNIV,DEPT MED MICROBIOL,S-41124 GOTHENBURG,SWEDEN	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore; University of Gothenburg	CLEMENS, JD (corresponding author), NICHHD,PREVENT RES PROGRAM,EXECUT PLAZA N BLDG,ROOM 640,BETHESDA,MD 20892, USA.			Harris, Jeffrey/0000-0001-8728-7195				CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, LANCET, V1, P1375; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Le vine MM, 1981, ACUTE ENTERIC INFECT, P443; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; ROTHMAN KJ, 1986, MODERN EPIDEMIOL; Ruzicka LT, 1978, DEMOGRAPHIC SURVEILL, V2; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; WOODWARD WE, 1971, J INFECT DIS, V123, P61, DOI 10.1093/infdis/123.1.61	10	52	52	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					883	884		10.1016/0140-6736(91)90207-6	http://dx.doi.org/10.1016/0140-6736(91)90207-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672971				2022-12-28	WOS:A1991FG04800006
J	BLOLAND, PB; REDD, SC; KAZEMBE, P; TEMBENU, R; WIRIMA, JJ; CAMPBELL, CC				BLOLAND, PB; REDD, SC; KAZEMBE, P; TEMBENU, R; WIRIMA, JJ; CAMPBELL, CC			COTRIMOXAZOLE FOR CHILDHOOD FEBRILE ILLNESS IN MALARIA-ENDEMIC REGIONS	LANCET			English	Note								The efficacy of co-trimoxazole for the treatment of Plasmodium falciparum parasitaemia in children younger than 5 years of age was evaluated in Malawi. 46 children with P falciparum parasitaemia, 37% of whom also met clinical criteria for a diagnosis of acute lower respiratory tract infection, were treated with 20 mg/kg co-trimoxazole twice daily for five days. Parasitaemia (mean clearance time 2.7 days) and symptoms were rapidly abolished and improvement was maintained during follow-up for 14 days. Co-trimoxazole may be an effective single treatment for febrile illness in young children in areas where malaria is endemic, resources are few, and diagnosis must rely on clinical findings alone.	CTR DIS CONTROL,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; MINIST HLTH,LILONGWE,MALAWI	Centers for Disease Control & Prevention - USA	BLOLAND, PB (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,F-12,ATLANTA,GA 30333, USA.							CAMPBELL H, 1988, LANCET, V2, P1182; GOOSEN TJ, 1976, CHEMOTHERAPY PARASIT, V6, P67; MOUNT DL, 1989, B WORLD HEALTH ORGAN, V67, P295; 1990, SUPERVISORY SKILLS M; 1981, B WORLD HEALTH ORGAN, V59, P707; 1986, WHO TECH REP SER, V735; 1984, WHO TECH REP SER, V711	7	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					518	520		10.1016/0140-6736(91)91299-A	http://dx.doi.org/10.1016/0140-6736(91)91299-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671892				2022-12-28	WOS:A1991EZ87400006
J	RODE, H; DEWET, PM; MILLAR, AJW; CYWES, S				RODE, H; DEWET, PM; MILLAR, AJW; CYWES, S			EFFICACY OF MUPIROCIN IN CUTANEOUS CANDIDIASIS	LANCET			English	Letter											RODE, H (corresponding author), UNIV CAPE TOWN,RED CROSS CHILDRENS HOSP,INST CHILD HLTH,DEPT PAEDIAT SURG,RONDEBOSCH 7700,SOUTH AFRICA.							RODE H, 1988, J ANTIMICROB CHEMOTH, V21, P589, DOI 10.1093/jac/21.5.589; RODE H, 1989, S AFR J SCI, V85, P462; WHITE AR, 1985, BACTROBAN MUPIROCIN, P19	3	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					578	578		10.1016/0140-6736(91)91149-O	http://dx.doi.org/10.1016/0140-6736(91)91149-O			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678836				2022-12-28	WOS:A1991GD00200047
J	SUSSMAN, JL; HAREL, M; FROLOW, F; OEFNER, C; GOLDMAN, A; TOKER, L; SILMAN, I				SUSSMAN, JL; HAREL, M; FROLOW, F; OEFNER, C; GOLDMAN, A; TOKER, L; SILMAN, I			ATOMIC-STRUCTURE OF ACETYLCHOLINESTERASE FROM TORPEDO-CALIFORNICA - A PROTOTYPIC ACETYLCHOLINE-BINDING PROTEIN	SCIENCE			English	Article							ELECTRIC-EEL ACETYLCHOLINESTERASE; ZINC SUPEROXIDE-DISMUTASE; MACROMOLECULAR CRYSTALLOGRAPHY; DIENELACTONE HYDROLASE; MOLECULAR-FORMS; SITE; LIGANDS; RESOLUTION; RECEPTOR; SEQUENCE	The three-dimensional structure of acetylcholinesterase from Torpedo californica electric organ has been determined by x-ray analysis to 2.8 angstrom resolution. The form crystallized is the glycolipid-anchored homodimer that was purified subsequent to solubilization with a bacterial phosphatidylinositol-specific phospholipase C. The enzyme monomer is an alpha/beta-protein that contains 537 amino acids. It consists of a 12-stranded mixed beta-sheet surrounded by 14 alpha-helices and bears a striking resemblance to several hydrolase structures including dienelactone hydrolase, serine carboxypeptidase-II, three neutral lipases, and haloalkane dehalogenase. The active site is unusual because it contains Glu, not Asp, in the Ser-His-acid catalytic triad and because the relation of the triad to the rest of the protein approximates a mirror image of that seen in the serine proteases. Furthermore, the active site lies near the bottom of a deep and narrow gorge that reaches halfway into the protein. Modeling of acetylcholine binding to the enzyme suggests that the quaternary ammonium ion is bound not to a negatively charged "anionic" site, but rather to some of the 14 aromatic residues that line the	RUTGERS STATE UNIV,WAKSMAN INST MICROBIOL,NEW BRUNSWICK,NJ 08903; F HOFFMANN LA ROCHE & CO LTD,CENT RES UNIT,CH-4002 BASEL,SWITZERLAND; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Rutgers State University New Brunswick; Roche Holding; Weizmann Institute of Science	SUSSMAN, JL (corresponding author), WEIZMANN INST SCI,DEPT STRUCT CHEM,IL-76100 REHOVOT,ISRAEL.		Frolow, Felix/A-1760-2013	Sussman, Joel/0000-0003-0306-3878				Adam G., 1968, STRUCTURAL CHEM MOL, P198; Amitai G, 1991, CHOLINESTERASES STRU, V285; [Anonymous], ENZYMES 3E; Barnard E.A., 1974, PERIPHERAL NERVOUS S, P201; BAZELYANSKY M, 1986, BIOCHEMISTRY-US, V25, P125, DOI 10.1021/bi00349a019; BELLEAU B, 1970, MOL PHARMACOL, V6, P41; BERGMANN F, 1950, BIOCHIM BIOPHYS ACTA, V6, P217, DOI 10.1016/0006-3002(50)90094-1; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; BERMAN HA, 1989, J BIOL CHEM, V264, P3951; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUMBERG S, 1978, BIOCHEMISTRY-US, V17, P1125, DOI 10.1021/bi00599a029; BON S, 1979, P NATL ACAD SCI USA, V76, P2546, DOI 10.1073/pnas.76.6.2546; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; CHOTHIA C, 1975, J MOL BIOL, V97, P55, DOI 10.1016/S0022-2836(75)80021-0; CHOTHIA C, 1968, NATURE, V219, P1156, DOI 10.1038/2191156a0; COHEN SG, 1989, BIOCHIM BIOPHYS ACTA, V997, P167, DOI 10.1016/0167-4838(89)90182-9; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; DOCTOR BP, 1989, COMPUTER ASSISTED MO, V289, P305; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Eigen M., 1974, QUANTUM STAT MECH NA, pp 37; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FUCHS S, 1974, ARCH BIOCHEM BIOPHYS, V165, P90, DOI 10.1016/0003-9861(74)90145-3; FUTERMAN AH, 1983, NEUROSCI LETT, V40, P85, DOI 10.1016/0304-3940(83)90097-6; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GENTRY MK, 1991, CHOLINESTERASES STRU, P394; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; GOELDNER MP, 1980, P NATL ACAD SCI-BIOL, V77, P6439, DOI 10.1073/pnas.77.11.6439; GUBERNATOR K, 1991, LIPASES STRUCTURE ME, V16, P9; HALLAK M, 1989, NEUROPHARMACOLOGY, V28, P199, DOI 10.1016/0028-3908(89)90093-2; HAREL M, 1991, BIOCHEMISTRY-US, V30, P5217, DOI 10.1021/bi00235a015; HAREL M, IN PRESS J MOL BIOL; HASINOFF BB, 1982, BIOCHIM BIOPHYS ACTA, V704, P52, DOI 10.1016/0167-4838(82)90131-5; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABACHNI.MI, 1970, PHARMACOL REV, V22, P355; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Katz B., 1966, NERVE MUSCLE SYNAPSE; KIEFFER B, 1986, FEBS LETT, V202, P91, DOI 10.1016/0014-5793(86)80655-X; KOELLE GB, 1963, CHOLINESTERASES ANTI, V12; LEUZINGER W, 1967, P NATL ACAD SCI USA, V57, P446, DOI 10.1073/pnas.57.2.446; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; MANAVALAN P, 1985, BIOCHIM BIOPHYS ACTA, V829, P365, DOI 10.1016/0167-4838(85)90246-8; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; MEUNIER JC, 1969, FEBS LETT, V2, P224, DOI 10.1016/0014-5793(69)80025-6; MOOSER G, 1974, BIOCHEMISTRY-US, V13, P2299, DOI 10.1021/bi00708a010; NACHMANSOHN D, 1975, CHEM MOL BASIS NERVE; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; OBRIEN RD, 1969, BIOCHEM J, V113, P713, DOI 10.1042/bj1130713; OLLIS DF, UNPUB; PAGE JD, 1985, J BIOL CHEM, V260, P1475; PATHAK D, 1988, J MOL BIOL, V204, P435, DOI 10.1016/0022-2836(88)90587-6; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PURDIE JE, 1966, BIOCHIM BIOPHYS ACTA, V128, P590, DOI 10.1016/0926-6593(66)90025-7; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; Reiner E., 1991, CHOLINESTERASES STRU, P227; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; ROSKOSKI R, 1974, BIOCHEMISTRY-US, V13, P5141, DOI 10.1021/bi00722a014; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCHRAG JD, 1988, J BIOL CHEM, V263, P9795; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SHERIFF S, 1981, BIOMOLECULAR STRUCTU, V20, P55; SHINITZKY M, 1973, FEBS LETT, V30, P125, DOI 10.1016/0014-5793(73)80633-7; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; SLABAS AR, 1990, BIOCHEM J, V269, P279, DOI 10.1042/bj2690279; STEINBERG GM, 1975, J MED CHEM, V18, P1056, DOI 10.1021/jm00245a002; STEINBERG N, 1990, BIOCHEM INT, V21, P1043; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; STERNBERG MJE, 1976, J MOL BIOL, V105, P367, DOI 10.1016/0022-2836(76)90099-1; SUSSMAN JL, 1988, J MOL BIOL, V203, P821, DOI 10.1016/0022-2836(88)90213-6; SUSSMAN JL, 1991, CHOLINESTERASES STRU, P7; SUSSMAN JL, 1989, 7TH P ANN CHEM DEF B, P309; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; Taylor P., 1990, PHARM BASIS THERAPEU, P131; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; WILSON IB, 1958, ARCH BIOCHEM BIOPHYS, V73, P131, DOI 10.1016/0003-9861(58)90248-0; WILSON IB, 1950, J BIOL CHEM, V186, P683; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	99	2413	2485	12	295	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					872	879		10.1126/science.1678899	http://dx.doi.org/10.1126/science.1678899			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1678899				2022-12-28	WOS:A1991GC15200036
J	SUTHERLAND, GR; HAAN, EA; KREMER, E; LYNCH, M; PRITCHARD, M; YU, S; RICHARDS, RI				SUTHERLAND, GR; HAAN, EA; KREMER, E; LYNCH, M; PRITCHARD, M; YU, S; RICHARDS, RI			HEREDITARY UNSTABLE DNA - A NEW EXPLANATION FOR SOME OLD GENETIC QUESTIONS	LANCET			English	Note							MECHANISM; ONSET	Fragile X syndrome, associated with the fragile X chromosome, is the most common cause of familial mental retardation. The condition is characterised by a heritable DNA sequence that consists of an abnormal number of CCG repeats, and which is unstable in both mitosis and meiosis. We suggest that such heritable unstable DNA sequences could be present in other parts of the genome and that these might explain a number of genetic events that are not well understood in terms of classic genetic mechanisms. Such poorly explained observations include anticipation, incomplete penetrance, variable expression, and possibly imprinting, variegation, and multifactorial inheritance.	ADELAIDE CHILDRENS HOSP INC,DEPT MED GENET,ADELAIDE,SA 5006,AUSTRALIA		SUTHERLAND, GR (corresponding author), ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA.		Kremer, Eric J/D-3734-2013; Sutherland, Grant Robert/D-2606-2012; Kremer, EJ/P-9838-2019; Richards, Robert/ABE-6423-2020	Kremer, EJ/0000-0001-6114-7530; Richards, Robert Ian/0000-0002-5978-6453				BAKER E, 1991, J MED GENET, V28, P356, DOI 10.1136/jmg.28.5.356; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HALL JG, 1990, ARCH DIS CHILD-FETAL, V65, P1013, DOI 10.1136/adc.65.10_Spec_No.1013; HARPER PS, 1972, LANCET, V2, P53; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD CD, 1987, GENETICS, V117, P587; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; REIK W, 1988, J MED GENET, V25, P805, DOI 10.1136/jmg.25.12.805; RENWICK JH, 1956, ANN HUM GENET, V21, P159, DOI 10.1111/j.1469-1809.1971.tb00278.x; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SUTHERLAND GR, 1989, CYTOGENET CELL GENET, V51, P452, DOI 10.1159/000132804; VANDERMAY AGL, 1989, LANCET, V2, P1292; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOGEL F, 1986, HUMAN GENETICS; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	18	71	72	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					289	292		10.1016/0140-6736(91)90426-P	http://dx.doi.org/10.1016/0140-6736(91)90426-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677119				2022-12-28	WOS:A1991FZ56500012
J	VOIGT, LF; WEISS, NS; CHU, J; DALING, JR; MCKNIGHT, B; VANBELLE, G				VOIGT, LF; WEISS, NS; CHU, J; DALING, JR; MCKNIGHT, B; VANBELLE, G			PROGESTAGEN SUPPLEMENTATION OF EXOGENOUS ESTROGENS AND RISK OF ENDOMETRIAL CANCER	LANCET			English	Article							REPLACEMENT THERAPY; CLIMACTERIC WOMEN; ESTROGENS; PROGESTOGENS; BIOCHEMISTRY; PREVENTION; PATTERNS; DISEASE; RECALL	The favourable effects of exogenous progestagen on the endometrium are well known, but have not been adequately quantified with respect to endometrial cancer. The benefits of progestagen need to be weighted against its possible untoward effects on the risk of breast cancer and cardiovascular disease. A population-based case-control study of endometrial cancer was undertaken to evaluate the benefits of progestagen use. 158 incident cases were identified between 1985 and 1987 among women aged 40-64 years who were residents of King County, Washington. Detailed interviews were conducted and the responses were compared with those of 182 controls selected by random telephone digit dialling. The risk of endometrial cancer among women who had used unopposed oestrogen for more than 3 years was over five times that of women who had used no hormones (relative risk [RR] 5.7, 95% confidence interval [Cl] 2.5-12.8), whereas those who had also used a progestagen for at least six months of that time had an RR of only 1.6 (95% Cl 0.6-3.9). The RR differed according to days per month that progestagen was used: 2.4 (0.6-9.3) for progestagen use of less than 10 days per month versus 1.1 (0.4-3.6) for use of 10 or more days per month. These results provide additional evidence that the use of progestagen for 10 or more days per cycle can reduce the excess risk of endometrial cancer associated with long-term postmenopausal oestrogen use.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	VOIGT, LF (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195, USA.				NCI NIH HHS [5R35CA39779] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERESFORD SAA, 1989, AM J EPIDEMIOL, V130, P202, DOI 10.1093/oxfordjournals.aje.a115313; FIGUEROACASAS PR, 1988, MATURITAS, V9, P309, DOI 10.1016/0378-5122(88)90096-5; GAMBRELL RD, 1986, MATURITAS, V8, P159, DOI 10.1016/0378-5122(86)90022-8; GELFAND MM, 1989, OBSTET GYNECOL, V74, P398; GRUBER JS, 1986, ADV CANC CONTROL HLT, P325; HARLOW BL, 1983, AM J EPIDEMIOL, V117, P632, DOI 10.1093/oxfordjournals.aje.a113586; HARLOW BL, 1988, AM J EPIDEMIOL, V127, P857, DOI 10.1093/oxfordjournals.aje.a114869; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PAGANINIHILL A, 1989, BRIT J CANCER, V59, P445, DOI 10.1038/bjc.1989.91; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P33; STADEL BV, 1975, AM J EPIDEMIOL, V102, P209, DOI 10.1093/oxfordjournals.aje.a112149; THOM MH, 1979, LANCET, V2, P455; VOIGT LF, 1989, ENDOMETRIAL CANCER, P1; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WHITEHEAD MI, 1979, J ROY SOC MED, V72, P322	20	235	243	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					274	277		10.1016/0140-6736(91)90417-N	http://dx.doi.org/10.1016/0140-6736(91)90417-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677110				2022-12-28	WOS:A1991FZ56500003
J	SOBALA, GM; CRABTREE, JE; PENTITH, JA; RATHBONE, BJ; SHALLCROSS, TM; WYATT, JI; DIXON, MF; HEATLEY, RV; AXON, ATR				SOBALA, GM; CRABTREE, JE; PENTITH, JA; RATHBONE, BJ; SHALLCROSS, TM; WYATT, JI; DIXON, MF; HEATLEY, RV; AXON, ATR			SCREENING DYSPEPSIA BY SEROLOGY TO HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; SCORING SYSTEM; YOUNG-PATIENTS	Owing to limited endoscopy resources, various screening strategies for endoscopy have been proposed. Helicobacter pylori can be detected with high sensitivity and specificity by serology, and therefore we assessed the effects on diagnostic accuracy and endoscopic workload of a policy of screening clinic patients with dyspepsia before endoscopy by a strategy based on age, Helicobacter pylori serology, and use of non-steroidal anti-inflammatory drugs. 1153 patients were studied, of whom 842 were of known histological H pylori status (histology group) and 293 had serum assessed prospectively by in-house and commercial ELISAs for detection of IgG antibodies to H pylori. Overall, the screening strategy would have reduced endoscopy workload by 23.3% (95% confidence interval 20.9-25.8%) and would have had a sensitivity for detection of peptic ulcer of 97.4% (94.5-99.1%). No peptic ulcer or malignant disease was missed in the patients studied prospectively, but 6 of 192 peptic ulcers in the histology group would have been missed. A policy of screening young dyspeptic patients for H pylori by serology is more sensitive than symptom-based screening strategies, and may have an important role in reducing endoscopy workload.	UNIV LEEDS,DEPT PATHOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; ST JAMES UNIV HOSP,DEPT MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; ST JAMES UNIV HOSP,DEPT PATHOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	University of Leeds; Saint James's University Hospital; Saint James's University Hospital	SOBALA, GM (corresponding author), GEN INFIRM,GASTROENTEROL UNIT,GREAT GEORGE ST,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Crabtree, Jean E/A-3549-2010					BROWN C, 1990, BRIT MED J, V300, P829, DOI 10.1136/bmj.300.6728.829; COGHLAN JG, 1987, LANCET, V2, P1109; CRABTREE JE, IN PRESS DIG DIS SCI; DAVENPORT PM, 1985, BRIT MED J, V290, P217, DOI 10.1136/bmj.290.6463.217; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HEATLEY RV, 1987, LANCET, V2, P779; HOLDSTOCK G, 1986, GASTROENTEROLOGY, V90, P1164, DOI 10.1016/0016-5085(86)90381-1; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MANN J, 1983, BRIT MED J, V287, P937, DOI 10.1136/bmj.287.6397.937; MARSHALL BJ, 1988, LANCET, V2, P1439; NEWELL DG, 1989, SERODIAG IMMUN INF D, V3, P1, DOI 10.1016/0888-0786(89)90010-3; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SHALLCROSS TM, 1990, ALIMENT PHARM THERAP, V4, P515; SOBALA GM, 1989, GASTROENTEROLOGY, V97, P357, DOI 10.1016/0016-5085(89)90071-1; SOBALA GM, 1990, EUR J GASTROEN HEPAT, V2, P445; SOBALA GM, 1989, GUT, V30, pA1514; SOBALA GM, 1989, LANCET, V1, P50; TYTGAT GNJ, 1990, WORKING PARTY REPORT; WILLIAMS B, 1988, LANCET, V2, P1349	19	242	245	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					94	96		10.1016/0140-6736(91)90085-4	http://dx.doi.org/10.1016/0140-6736(91)90085-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676478				2022-12-28	WOS:A1991FW16100013
J	MOFENSON, LM				MOFENSON, LM			INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF BACTERIAL-INFECTIONS IN CHILDREN WITH SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LACTATE-DEHYDROGENASE LEVELS; B-CELL LYMPHOPROLIFERATION; DEFICIENCY SYNDROME AIDS; GAMMA-GLOBULIN; IMMUNOGLOBULIN THERAPY; POSSIBLE INDICATOR; DISEASE-ACTIVITY; ENZYME LEVELS; COMPLEX; EFFICACY	Background. Serious recurrent bacterial infections are a major cause of morbidity and mortality in children infected with the human immunodeficiency virus (HIV). Because intravenous immune globulin has been shown to prevent bacterial infection in patients with primary immunodeficiency and in uncontrolled studies of HIV-infected children, we undertook a multicenter study of its safety and efficacy in children with symptomatic HIV infection. Methods. In a double-blind trial, 372 HIV-infected children (mean age, 40 months) with clinical or immunologic evidence of HIV disease were randomly assigned to receive either intravenous immune globulin (400 mg per kilogram of body weight) or placebo (0.1 percent albumin) every 28 days. The children were stratified into two groups according to CD4+ lymphocyte count at entry into the study and the clinical classification of the Centers for Disease Control. The median length of follow-up was 17 months. Results. For children in either group with CD4+ counts greater-than-or-equal-to 0.2 x 10(9) per liter (greater-than-or-equal-to 200 per cubic millimeter) at entry, treatment with intravenous immune globulin significantly increased the time free from serious infection; estimated infection-free rates after 24 months were 67 percent for children receiving immune globulin as compared with 48 percent for those receiving placebo (P = 0.01). In addition, immune globulin was associated with an overall reduction in the number of both serious and minor bacterial infections (relative risk, 0.68; P = 0.01) and in the number of hospitalizations tor acute care (relative risk, 0.65; P = 0.03). No such benefits were seen for children with CD4+ counts below 0.2 x 10(9) per liter at entry. For group 1 overall, there was a trend toward a difference in serious bacterial infection between immune globulin and placebo (24-month infection-free survival, 31 percent for intravenous immune globulin vs. 25 percent for placebo; P = 0.10). For group 2, the estimates of survival without serious infection were 73 percent with intravenous immune globulin as compared with 53 percent with placebo (P = 0.04). There was no effect of treatment on mortality for any group or CD4+ count at entry. Adverse reactions, noted for less than 1 percent of infusions, were minor. Conclusions. In symptomatic HIV-infected children the prophylactic use of intravenous immune globulin is safe, and it significantly increases the time free from serious bacterial infections for those entering treatment with CD4+ lymphocyte counts greater-than-or-equal-to 0.2 x 10(9) per liter.			MOFENSON, LM (corresponding author), NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; Pahwa, Savita/0000-0002-4470-4216; Shearer, William/0000-0002-2483-2130				BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; BLANCHE S, 1986, J PEDIATR-US, V109, P965, DOI 10.1016/S0022-3476(86)80277-3; BORKOWSKY W, 1987, J PEDIATR-US, V110, P563, DOI 10.1016/S0022-3476(87)80549-8; CALVELLI TA, 1986, PEDIATR INFECT DIS J, V5, pS207; Friedman LM, 1985, FUNDAMENTALS CLIN TR; Gayle J A, 1990, MMWR CDC Surveill Summ, V39, P23; GUPTA A, 1986, AM J DIS CHILD, V140, P143, DOI 10.1001/archpedi.1986.02140160061033; HAGUE RA, 1989, ARCH DIS CHILD, V64, P1146, DOI 10.1136/adc.64.8.1146; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOBAYASHI RH, 1990, PEDIATRICS, V85, P705; KRASINSKI K, 1988, PEDIATR INFECT DIS J, V7, P323, DOI 10.1097/00006454-198805000-00006; MILLER RG, 1974, BIOMETRIKA, V61, P1; MOFENSON LM, 1990, 30TH INT C ANT AG CH, P168; MOFENSON LM, 1991, PEDIATRIC AIDS CHALL, P633; MORELL A, 1970, J CLIN INVEST, V49, P673, DOI 10.1172/JCI106279; NOVELLO AC, 1989, PEDIATRICS, V84, P547; OCHS HD, 1987, J INFECT DIS, V156, P652, DOI 10.1093/infdis/156.4.652; OCHS HD, 1984, AM J MED, V76, P78, DOI 10.1016/0002-9343(84)90324-3; PAHWA S, 1986, DIAGN CLIN IMMUNOL, V4, P24; PIROFSKY B, 1984, AM J MED, V76, P53, DOI 10.1016/0002-9343(84)90320-6; RYAN A, 1988, LANCET, V2, P793; SCHAAD UB, 1988, EUR J PEDIATR, V147, P300, DOI 10.1007/BF00442700; SCHWARTZ RS, 1987, AM J MED, V83, P46, DOI 10.1016/0002-9343(87)90550-X; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SIEGAL FP, 1986, CLIN USE INTRAVENOUS, P373; SILVERMAN BA, 1985, AM J MED, V78, P728, DOI 10.1016/0002-9343(85)90275-X; STIEHM ER, 1991, PEDIATRIC AIDS CHALL, P95; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; WILLIAMS PE, 1988, J HOSP INFECT, V12, P67, DOI 10.1016/0195-6701(88)90032-1; WOOD CC, 1987, PEDIATR INFECT DIS J, V6, P564, DOI 10.1097/00006454-198706000-00015; 1987, MMWR, V36, P225; 1991, PHYSICIANS DESK REFE, P1521; 1988, NEW ENGL J MED, V319, P902; 1987, MMWR, V36, P235	36	117	125	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1991	325	2					73	80		10.1056/NEJM199107113250201	http://dx.doi.org/10.1056/NEJM199107113250201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV522	1675763	Bronze			2022-12-28	WOS:A1991FV52200001
J	MOTT, DD; LEWIS, DV				MOTT, DD; LEWIS, DV			FACILITATION OF THE INDUCTION OF LONG-TERM POTENTIATION BY GABA-B RECEPTORS	SCIENCE			English	Article							RAT DENTATE GYRUS; HIPPOCAMPAL-NEURONS; BACLOFEN; INHIBITION; DEPRESSION; 2-HYDROXY-SACLOFEN; INVITRO; STIMULATION; ANTAGONISTS; RESPONSES	Long-term potentiation (LTP), an in vitro model of learning, was induced in hippocampal slices by 5-hertz stimulation. During induction, gamma-aminobutyric acid A (GABA(A)) inhibition decreased, causing the N-methyl-D-aspartate receptor-mediated excitation to increase. 2-OH Saclofen, a GABA(B) receptor antagonist, prevented the reduction of inhibition, the increase of excitation, and the induction of LTP. Therefore, disinhibition caused by GABA(B) receptors is required for induction of LTP by 5-hertz stimulation. GABA(B) receptor modulation of synaptic plasticity occurs at frequencies in the range of the endogenous hippocampal theta rhythm, which has been shown to modulate LTP in vivo.	DUKE UNIV,MED CTR,DEPT PEDIAT NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University; Duke University	MOTT, DD (corresponding author), DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710, USA.			Mott, David/0000-0003-0758-8006	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027488] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27488] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDAHAN MI, 1990, BRAIN RES, V526, P308, DOI 10.1016/0006-8993(90)91237-B; BONANNO G, 1989, EUR J PHARM-MOLEC PH, V172, P41, DOI 10.1016/0922-4106(89)90043-6; COLLINGRIDGE GL, 1989, NMDA RECEPTOR, pCH9; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HERRON CE, 1985, NEUROSCI LETT, V60, P19, DOI 10.1016/0304-3940(85)90375-1; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; LAMBERT NA, 1989, NEUROSCI LETT, V107, P125, DOI 10.1016/0304-3940(89)90803-3; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; MISGELD U, 1989, PFLUG ARCH EUR J PHY, V414, P139, DOI 10.1007/BF00580955; MORRISETT RA, 1991, J NEUROSCI, V11, P203; MOTT D D, 1990, Society for Neuroscience Abstracts, V16, P945; MOTT DD, 1989, J PHARMACOL EXP THER, V249, P721; MOTT DD, 1990, NEUROSCI LETT, V113, P222, DOI 10.1016/0304-3940(90)90307-U; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; PACELLI GJ, 1989, BRAIN RES, V486, P26, DOI 10.1016/0006-8993(89)91273-0; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P524, DOI 10.1152/jn.1989.61.3.524; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0	25	262	264	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1718	1720		10.1126/science.1675489	http://dx.doi.org/10.1126/science.1675489			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1675489				2022-12-28	WOS:A1991FT11400050
J	HERING, R; STEINER, TJ				HERING, R; STEINER, TJ			ABRUPT OUTPATIENT WITHDRAWAL OF MEDICATION IN ANALGESIC-ABUSING MIGRAINEURS	LANCET			English	Note							ERGOTAMINE WITHDRAWAL; INDUCED HEADACHES	46 migraineurs with secondary chronic daily headache were treated for medication abuse as outpatients by abrupt withdrawal of the offending drugs. The patients were supported with adequate explanation of the disorder, regular follow-up, amitriptyline (10 mg at night), and naproxen (500 mg) for relief of headache symptoms. By 6 months of follow-up 37 patients had relief from chronic headaches, and analgesic intake had become intermittent and appropriate to the original occasional migraine episodes. 6 had substantially reduced analgesic intake, but headache severity was unchanged; 2 had not managed to reduce intake and headache was unchanged; and 1 patient withdrew after the first visit.			HERING, R (corresponding author), CHARING CROSS HOSP,PRINCESS MARGARET MIGRAINE CLIN,LONDON W6 8RF,ENGLAND.							BAUMGARTNER C, 1989, HEADACHE, V29, P510, DOI 10.1111/j.1526-4610.1989.hed2908510.x; BERNSTEIN AL, 1987, HEADACHE, V27, P458; DIENER HC, 1988, DEUT MED WOCHENSCHR, V113, P472, DOI 10.1055/s-2008-1067666; EDMEADS J, 1990, HEADACHE, V30, P614, DOI 10.1111/j.1526-4610.1990.hed3009614.x; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HOLLAND JV, 1983, 1ST P INT HEAD C MUN, P134; MACGREGOR EA, 1990, HEADACHE, V30, P571, DOI 10.1111/j.1526-4610.1990.hed3009571.x; MATHEW NT, 1987, HEADACHE, V27, P130, DOI 10.1111/j.1526-4610.1987.hed2703130.x; RAPOPORT AM, 1985, CEPHALALGIA S3, V5, P448; TFELTHANSEN P, 1981, CEPHALALGIA, V1, P29, DOI 10.1111/j.1468-2982.1981.tb00005.x	10	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1442	1443		10.1016/0140-6736(91)93129-W	http://dx.doi.org/10.1016/0140-6736(91)93129-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675320				2022-12-28	WOS:A1991FR06000006
J	SQUIRE, SB; ELFORD, J; BOR, R; TILSED, G; SALT, H; BAGDADES, EK; JANOSSY, G; GRIFFITHS, PD; JOHNSON, MA				SQUIRE, SB; ELFORD, J; BOR, R; TILSED, G; SALT, H; BAGDADES, EK; JANOSSY, G; GRIFFITHS, PD; JOHNSON, MA			OPEN ACCESS CLINIC PROVIDING HIV-I ANTIBODY RESULTS ON DAY OF TESTING - THE 1ST 12 MONTHS	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; EARLY DIAGNOSIS; ZIDOVUDINE AZT; INFECTION; EFFICACY; SAFETY	Objectives - To determine the sociodemographic profile, risk category, and prevalence of HIV-1 infection among people attending a clinic providing counselling, medical advice, and results of HIV-1 antibody testing on the day of consultation; to determine the stage of infection and peripheral blood CD4 cell count among attenders with detectable HIV-1 antibodies. Design - Analysis of prospectively collected data for the 12 months from March 1989. Setting - Same day testing clinic run by the HIV/AIDS team at an urban teaching hospital. Patients - 561 consecutive people choosing to attend and proceeding to HIV-1 testing. Results - The demand for the service caused it to run to capacity within six months. The median age of those attending was 28 years and 65% (364 patients) were male. The overall prevalence of HIV-1 infection was 3.9% (22 patients). The greatest prevalence was in men reporting their primary risk as homosexual contact (11.9%, 13/109. The median CD4 cell count in the 22 patients who had detectable HIV-1 antibodies was 0.31 X 10(9) cells/l (normal range 0.5 X l0(9)/l to 1.2 X l0(9)/l). Twenty of these patients were asymptomatic (Centers for Disease Control stages 11 or 111), 14 had CD4 cell counts below 0.5 X l0(9)/l. Conclusions - There is a recognisable demand for a service providing rapid results of HIV-1 antibody testing in this setting. The overall seroprevalence of 3.9% is comparable with the 5.8% reported from freestanding clinics in the United States. Most patients with HIV-I antibodies detected in this way are asymptomatic but could benefit from early medical intervention because of low CD4 cell counts.			SQUIRE, SB (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.			Squire, Stephen/0000-0001-7173-9038				BECK EJ, 1987, BRIT MED J, V295, P191, DOI 10.1136/bmj.295.6591.191; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GREEN J, 1987, CURRENT TOPICS AIDS, V1, P287; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LO B, 1989, ANN INTERN MED, V110, P727; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MURPHY FA, 1989, MMWR S5, V38, pS1; PHILLIPS AN, 1991, LANCET, V337, P389; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SONNEX C, 1987, BRIT MED J, V295, P193, DOI 10.1136/bmj.295.6591.193; SQUIRE SB, 1990, BRIT J HOSP MED, V44, P9; VOLBERDING P, 1989, J ACQ IMMUN DEF SYND, V2, P421; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR, V39, P137; 1987, MMWR S1, V36, pS3	17	27	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1991	302	6789					1383	1386		10.1136/bmj.302.6789.1383	http://dx.doi.org/10.1136/bmj.302.6789.1383			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR057	1676319	Green Published, Bronze			2022-12-28	WOS:A1991FR05700026
J	WARLOW, C				WARLOW, C			MRC-EUROPEAN-CAROTID-SURGERY-TRIAL - INTERIM RESULTS FOR SYMPTOMATIC PATIENTS WITH SEVERE (70-99-PERCENT) OR WITH MILD (0-29-PERCENT) CAROTID STENOSIS	LANCET			English	Article							TRANSIENT ISCHEMIC ATTACKS; ENDARTERECTOMY; DISEASE; STROKE	The European Carotid Surgery Trial is a multicentre trial of carotid endarterectomy for patients who, after a carotid territory non-disabling ischaemic stroke, transient ischaemic attack, or retinal infarct, are found to have a stenotic lesion in the relevant (ipsilateral) carotid artery. Over the past 10 years 2518 patients have been randomised, and the mean follow-up is now almost 3 years among the 2200 thus far available for analysis of the incidence of strokes that lasted more than 7 days. For the patients with "moderate" (30-69%) stenosis on their pre-randomisation angiogram the balance of surgical risk and eventual benefit remains uncertain, and full recruitment continues. For 374 patients with only "mild" (0-29%) stenosis there was little 3-year risk of ipsilateral ischaemic stroke, even in the absence of surgery, so any 3-year benefits of surgery were small, and were outweighed by its early risks. For 778 patients with "severe" (70-99%) stenosis, however, the risks of surgery were significantly outweighed by the later benefits: although 7.5% had a stroke (or died) within 30 days of surgery, during the next 3 years the risks of ipsilateral ischaemic stroke were (by life-table analysis) an extra 2.8% for surgery-allocated and 16.8% for control patients (a sixfold reduction, p < 0.0001). There was also a small reduction in other strokes, and at 3 years the total risk of surgical death, surgical stroke, ipsilateral ischaemic stroke, or any other stroke was 12.3% for surgery and 21.9% for control (difference 9.6% SD 3.3, 2p < 0.01). The main concern was to avoid disabling or fatal events, and, among severe stenosis patients, 3.7% had a disabling stroke (or died) within 30 days of surgery, an extra 1.1% surgery versus 8.4% control (p < 0.0001) had a disabling or fatal ipsilateral ischaemic stroke by 3 years, and the total 3-year risk of any disabling or fatal stroke (or surgical death) was 6.0% surgery versus 11.0% control (overall difference 5.0% SD 2.3, 2p < 0.05); but, for disabling or fatal stroke the control risks seemed to diminish after the first year, so delay of surgery by just a few months after clinical presentation might make this overall difference non-significant.			WARLOW, C (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Jensen, Troels Staehelin/A-3418-2009	Jensen, Troels Staehelin/0000-0002-3487-6380				[Anonymous], 1988, BRIT MED J, V296, P320; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MM, 1990, J NEUROL NEUROSUR PS, V53, P238, DOI 10.1136/jnnp.53.3.238; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DYKEN ML, 1986, STROKE, V17, P355, DOI 10.1161/01.STR.17.3.355; EASTCOTT HHG, 1954, LANCET, V2, P994; HANKEY GJ, 1991, BMJ-BRIT MED J, V302, P499, DOI 10.1136/bmj.302.6775.499; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WARLOW C, 1984, STROKE, V15, P1068, DOI 10.1161/01.STR.15.6.1068; 1991, CLIN ALERT BENEFIT C	16	2390	2503	0	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1991	337	8752					1235	1243		10.1016/0140-6736(91)92916-P	http://dx.doi.org/10.1016/0140-6736(91)92916-P			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674060				2022-12-28	WOS:A1991FN04700001
J	JAYNE, DRW; DAVIES, MJ; FOX, CJV; BLACK, CM; LOCKWOOD, CM				JAYNE, DRW; DAVIES, MJ; FOX, CJV; BLACK, CM; LOCKWOOD, CM			TREATMENT OF SYSTEMIC VASCULITIS WITH POOLED INTRAVENOUS IMMUNOGLOBULIN	LANCET			English	Article							ANTINEUTROPHIL CYTOPLASM ANTIBODIES; GAMMA-GLOBULIN; KAWASAKI SYNDROME; AUTOANTIBODIES; NEUTROPHILS; DIAGNOSIS; DISEASE; INVIVO	The therapeutic effect of a course of high-dose, pooled, intravenous immunoglobulin (IVIg) on disease activity and circulating antineutrophil cytoplasm antibodies (ANCA) was investigated in 7 patients with systemic vasculitis. 5 had active disease despite conventional immunosuppression, and 2 had not received any treatment. All 7 had clinical improvement, which was sustained in 6 and transient in 1. The fall in ANCA concentrations to a mean of 51% of the pre-treatment values was maintained during follow-up. C-reactive protein concentration also dropped considerably. IVIg seemed to confer a useful therapeutic effect without adverse reaction.	IPSWICH HOSP,DEPT MED,IPSWICH,SUFFOLK,ENGLAND; NORTHAMPTON GEN HOSP,DEPT MED,NORTHAMPTON NN1 5BD,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	JAYNE, DRW (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.		Davies, Michael/GWV-2527-2022	Jayne, David/0000-0002-1712-0637	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTA M, 1989, BLOOD, V74, P326; CHALOPIN JM, 1984, EUR J IMMUNOL, V14, P470, DOI 10.1002/eji.1830140516; COHEN J, 1982, Q J MED, V51, P1; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; GROTZ W, 1990, APMIS S19, V98, P54; HAYS WM, 1981, STATISTICS, P630; JAYNE DRW, 1989, CLIN NEPHROL, V32, P101; JORDAN SC, 1989, CLIN IMMUNOL IMMUNOP, V53, pS164, DOI 10.1016/0090-1229(89)90082-2; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; LEUNG DYM, 1989, LANCET, V2, P1298; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; PALLA R, 1986, CLIN NEPHROL, V26, P314; ROSSI F, 1991, CLIN EXP IMMUNOL, V83, P298; ROSSI F, 1989, IMMUNOL REV, V110, P215; SAVAGE COS, 1989, ARCH DIS CHILD, V64, P360, DOI 10.1136/adc.64.3.360; SAVAGE COS, 1987, LANCET, V1, P1389; SCHIFFERLI J, 1991, LANCET, V335, P457; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SULTAN Y, 1984, LANCET, V2, P765; VANDERWOUDE FJ, 1985, LANCET, V1, P425	23	258	266	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1137	1139		10.1016/0140-6736(91)92797-6	http://dx.doi.org/10.1016/0140-6736(91)92797-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674023				2022-12-28	WOS:A1991FL12400014
J	SCHULMAN, KA; LYNN, LA; GLICK, HA; EISENBERG, JM				SCHULMAN, KA; LYNN, LA; GLICK, HA; EISENBERG, JM			COST-EFFECTIVENESS OF LOW-DOSE ZIDOVUDINE THERAPY FOR ASYMPTOMATIC PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE; AIDS	We did a cost-effectiveness analysis of zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. The incremental direct medical costs of zidovudine therapy were determined, and data on the effects of therapy were derived from the report of the Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group Protocol 019. Zidovudine therapy has an annual incremental cost of $2653 per person. The cost per year of life saved ranges between $6553 and $70 526, depending on which epidemiologic model of potential long-term zidovudine effect is used (in sensitivity analyses, the cost per year of life saved ranges between $2649 and $250 546). Although expensive, zidovudine therapy has the potential to yield a substantial survival benefit to patients. The cost effectiveness of zidovudine therapy compares favorably with that of other common medical therapies.	UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HILTS PJ, 1989, NY TIMES        0819, pA1; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; SCITOVSKY AA, 1990, PUBLIC HLTH REP, V102, P5; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1982, MANUAL LABORATORY WO; 1990, MMWR, V39, P20; 1988, PUBLIC HLTH REP S1, V103, P35; 1989, MONTHLY VITAL STATIS, V37, P1; 1989, NY TIMES        0820, pE22; 1990, HIV AIDS SURVEILLANC, P1; 1989, ACTG 019 QUESTIONS A; 1989, JAMA-J AM MED ASSOC, V261, P75	21	114	114	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					798	802		10.7326/0003-4819-114-9-798	http://dx.doi.org/10.7326/0003-4819-114-9-798			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	1672806				2022-12-28	WOS:A1991FJ11700012
J	BRAHAMS, D				BRAHAMS, D			HYPOGLYCEMIA AND INTENT	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1030	1030		10.1016/0140-6736(91)92679-V	http://dx.doi.org/10.1016/0140-6736(91)92679-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673179				2022-12-28	WOS:A1991FJ13500018
J	BUSHBY, KMD; THAMBYAYAH, M; GARDNERMEDWIN, D				BUSHBY, KMD; THAMBYAYAH, M; GARDNERMEDWIN, D			PREVALENCE AND INCIDENCE OF BECKER MUSCULAR-DYSTROPHY	LANCET			English	Article							DUCHENNE; DIAGNOSIS; DELETION; BENIGN	We measured the prevalence and incidence of Becker muscular dystrophy in the Northern Health Region of England, UK. Patients were identified from the records of the Regional Neurological Centre and Muscular Dystrophy Group laboratories, Newcastle upon Tyne, and by writing to local doctors. We used cDNA probes and/or dystrophin immunolabelling of muscle-biopsy samples to prove the diagnosis of all cases. Results were compared with the known prevalence and incidence of Duchenne muscular dystrophy. 73 patients alive and resident in the Northern Health Region were identified, giving a prevalence rate of 2.38/100 000. This compares with a prevalence of Duchenne muscular dystrophy of 2.48/100 000. The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.	UNIV NEWCASTLE UPON TYNE,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT NEUROBIOL & GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK								BECKER P E, 1955, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V193, P427, DOI 10.1007/BF00343141; BEGGS AH, 1990, J CLIN INVEST, V85, P613, DOI 10.1172/JCI114482; CLARKE A, 1989, LANCET, V1, P443; EMERY AEH, 1976, CLIN GENET, V10, P189; GARDNER-MEDWIN D, 1970, Journal of Medical Genetics, V7, P334, DOI 10.1136/jmg.7.4.334; GARDNERMEDWIN D, 1989, BRAIN DEV-JPN, V11, P91, DOI 10.1016/S0387-7604(89)80075-0; GARDNERMEDWIN D, 1980, BRIT MED BULL, V36, P109, DOI 10.1093/oxfordjournals.bmb.a071623; GOSPE SM, 1989, NEUROLOGY, V39, P1277, DOI 10.1212/WNL.39.10.1277; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; MONCKTON G, 1982, CLIN GENET, V21, P19; MOSTACCIUOLO ML, 1987, HUM GENET, V75, P217, DOI 10.1007/BF00281062; NICHOLSON LVB, 1990, ACTA NEUROPATHOL, V80, P239, DOI 10.1007/BF00294640; NORMAN A, 1989, LANCET, V1, P466; TANGSRUD SE, 1988, CLIN GENET, V34, P145	17	128	133	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1022	1024		10.1016/0140-6736(91)92671-N	http://dx.doi.org/10.1016/0140-6736(91)92671-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673177				2022-12-28	WOS:A1991FJ13500015
J	BRILLIANT, MH; GONDO, Y; EICHER, EM				BRILLIANT, MH; GONDO, Y; EICHER, EM			DIRECT MOLECULAR-IDENTIFICATION OF THE MOUSE PINK-EYED UNSTABLE MUTATION BY GENOME SCANNING	SCIENCE			English	Article							RECOMBINANT-INBRED STRAINS; COAT-COLOR MUTATION; HUMAN DNA; MICE; GENE; CHROMOSOME-7; PROVIRUS; LINKAGE; RATES; LOCUS	DNA sequences associated with the mouse pink-eyed unstable mutation were identified in the absence of closely linked molecular markers and without prior knowledge of the encoded gene product. This was accomplished by "genome scanning," a technique in which high-resolution Southern blots of genomic DNAs were hybridized to a dispersed and moderately repetitive DNA sequence. In this assay, pink-eyed unstable DNA was distinguished from the DNA of wild-type and revertant mice by enhanced hybridization to one of several hundred resolved fragments. The fragments showing enhanced hybridization in pink-eyed unstable DNA was cloned and found to lie within a DNA duplication that is located close to, or within, the pink-eyed dilution locus. The duplication associated with the mouse pink-eyed unstable mutation may mediate the high reversion frequency characteristic of this mutation.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory	BRILLIANT, MH (corresponding author), FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111, USA.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489	NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05529] Funding Source: Medline; NIGMS NIH HHS [GM43840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; BURT DW, 1984, NUCLEIC ACIDS RES, V12, P8579, DOI 10.1093/nar/12.22.8579; COPELAND NG, 1983, CELL, V33, P379, DOI 10.1016/0092-8674(83)90419-1; DEOL MS, 1983, J EMBRYOL EXP MORPH, V78, P291; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GONDO Y, UNPUB; Haldane JBS, 1915, J GENET, V5, P133, DOI 10.1007/BF02985370; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KNOBLER R L, 1984, Experimental and Clinical Immunogenetics, V1, P217; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MINTZ B, 1970, CONTROL MECHANISMS E, P15; ORKIN SH, 1986, CELL, V47, P854; PHILLIPS JS, 1977, MOUSE NEWS LETT, V56, P38; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHLAGER G, 1967, GENETICS, V57, P319; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; SILVER J, 1986, P NATL ACAD SCI USA, V83, P1423, DOI 10.1073/pnas.83.5.1423; SILVERS WK, 1979, COAT COLORS MICE, P90; SOUTHERN EM, 1975, J MOL BIOL, V98, P5503; Sturtevant AH, 1925, GENETICS, V10, P117; TARTOF KD, 1988, GENETICS, V120, P1; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; WHITNEY JB, 1982, J HERED, V73, P12, DOI 10.1093/oxfordjournals.jhered.a109567; WOLFE HG, 1963, 11TH P INT C GEN, P251	31	114	115	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					566	569		10.1126/science.1673574	http://dx.doi.org/10.1126/science.1673574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1673574				2022-12-28	WOS:A1991FJ12700047
J	IZPISUABELMONTE, JC; TICKLE, C; DOLLE, P; WOLPERT, L; DUBOULE, D				IZPISUABELMONTE, JC; TICKLE, C; DOLLE, P; WOLPERT, L; DUBOULE, D			EXPRESSION OF THE HOMEOBOX HOX-4 GENES AND THE SPECIFICATION OF POSITION IN CHICK WING DEVELOPMENT	NATURE			English	Article							RETINOIC ACID; LIMB-BUD; QUANTITATIVE-ANALYSIS; PATTERN-FORMATION; MURINE; MORPHOGENESIS; ORGANIZATION	The chicken Hox-4 homeogenes, like those of the mouse, are coordinately expressed in partially overlapping domains during wing development. Local application of retinoic acid, a putative endogenous morphogen, induces de novo transcription of Hox-4 genes. The mirror-image patterns of Hox-4 gene expression, which are obtained in this way, correlate with the subsequent development of mirror-image patterns of digits. Hox-4 genes probably encode positional information.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,POSTFACH 102209,W-6900 HEIDELBERG 1,GERMANY; UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DP,ENGLAND	European Molecular Biology Laboratory (EMBL); University of London; University College London			Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090; duboule, denis/0000-0001-9961-2960				DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUMMERBELL D, 1979, J EMBRYOL EXP MORPH, V50, P217; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0	26	368	378	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					585	589		10.1038/350585a0	http://dx.doi.org/10.1038/350585a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1673231				2022-12-28	WOS:A1991FH11200050
J	CHISAKA, O; CAPECCHI, MR				CHISAKA, O; CAPECCHI, MR			REGIONALLY RESTRICTED DEVELOPMENTAL DEFECTS RESULTING FROM TARGETED DISRUPTION OF THE MOUSE HOMEOBOX GENE HOX-1.5	NATURE			English	Article							DROSOPHILA HOMEOTIC GENES; NEURAL CREST CELLS; MOLECULAR-GENETICS; DNA-SEQUENCE; STEM-CELLS; EXPRESSION; COMPLEX; ANTENNAPEDIA; EMBRYO; MURINE	Gene targeting in mouse embryo-derived stem cells has been used to disrupt the homeobox gene hox-1.5. Mice heterozygous at the hox-1.5 locus appear normal, whereas hox-1.5-/hox-1.5- mice die at or shortly after birth. These homozygotes are athymic, aparathyroid, have reduced thyroid and submaxillary tissue and exhibit a wide range of throat abnormalities. In addition, they often feature defects of the heart and arteries as well as craniofacial abnormalities. These deficiencies are remarkably similar to the pathology of the human congenital disorder DiGeorge's syndrome.			CHISAKA, O (corresponding author), UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BOCKMAN DE, 1989, ANAT RECORD, V225, P209, DOI 10.1002/ar.1092250306; BOCKMAN DE, 1984, SCIENCE, V223, P498, DOI 10.1126/science.6606851; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; COULY G, 1988, DEVELOPMENT, V103, P101; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FAINSOD A, 1987, DEV BIOL, V124, P125, DOI 10.1016/0012-1606(87)90465-9; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREENBERG F, 1988, AM J HUM GENET, V43, P605; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAUFMAN TC, 1980, GENETICS, V94, P115; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; LEDOUARIN NM, 1980, NEURAL CREST; LELEIVRE CS, 1975, J EMBRYOL EXP MORPH, V34, P125; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1987, NATURE, V325, P21, DOI 10.1038/325021b0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V38, P675, DOI 10.1016/0092-8674(84)90262-9; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P916; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PULTZ MA, 1988, GENE DEV, V2, P901, DOI 10.1101/gad.2.7.901; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1984, P NATL ACAD SCI USA, V81, P3115; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	48	742	755	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					473	479		10.1038/350473a0	http://dx.doi.org/10.1038/350473a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1673020				2022-12-28	WOS:A1991FG14300041
J	YEUNG, ST; YOONG, C; SPINK, J; GALBRAITH, A; SMITH, PJ				YEUNG, ST; YOONG, C; SPINK, J; GALBRAITH, A; SMITH, PJ			FUNCTIONAL MYOCARDIAL IMPAIRMENT IN CHILDREN TREATED WITH ANTHRACYCLINES FOR CANCER	LANCET			English	Article							DOXORUBICIN CARDIOTOXICITY; ADRIAMYCIN; CARDIOMYOPATHY	A non-invasive exercise method was used to look for myocardial damage in apparently normal children who had received moderate doses of anthracyclines for treatment of cancer. 19 children (mean [SD] age 10.6 [4.3] years) who had received anthracyclines (mean total dose 230 [119] mg/m2) and 10 who had received other cytotoxic drugs (mean age 13.3 [4.9] years) were selected from 263 children attending routine follow-up examinations. They underwent measurement of heart rate, blood pressure, and left ventricular dimensions by echocardiography before and after exercise on a bicycle for a maximum of 10 min. All 29 were in remission. All the subjects showed normal fractional shortening (FS = left ventricular end-diastolic minus end-systolic diameter as a percentage of the end-diastolic diameter) at rest, but the increase in FS on exercise was significantly lower in the children who had received anthracyclines than in those who had not (3 [16]% vs 23 [17]%; p < 0.05). This difference remained significant after adjustment for age and drug exposure. However, there were no significant differences between the groups in the adjusted mean percentage changes on exercise in heart rate or systolic or diastolic blood pressure. Disease type had no effect on the cardiological indices. Thus, many children who have received anthracyclines may have suffered subclinical myocardial damage. Post-exercise echocardiography seems a useful noninvasive method for detecting such damage. Long-term cardiological follow-up of these patients is needed.	UNIV QUEENSLAND,SCH MED,DEPT PATHOL,HERSTON RD,HERSTON,QLD 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD,AUSTRALIA; PRINCE CHARLES HOSP,CHERMSIDE,QLD,AUSTRALIA	University of Queensland; Royal Children's Hospital Brisbane; Prince Charles Hospital								BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BLUM RH, 1975, CANCER CHEMOTH REP 3, V6, P247; BRISTOW MR, 1981, AM HEART J, V102, P709, DOI 10.1016/0002-8703(81)90096-X; CARTER SK, 1975, J NATL CANCER I, V55, P1265, DOI 10.1093/jnci/55.6.1265; DEARTH J, 1984, MED PEDIATR ONCOL, V12, P54, DOI 10.1002/mpo.2950120113; HAUSDORF G, 1988, BRIT HEART J, V60, P309; MARCHANDISE B, 1989, AM HEART J, V118, P92, DOI 10.1016/0002-8703(89)90077-X; PRAGA C, 1979, CANCER TREAT REP, V63, P827; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1982, SEMIN ONCOL, V9, P23	10	82	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					816	818		10.1016/0140-6736(91)92516-5	http://dx.doi.org/10.1016/0140-6736(91)92516-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672914				2022-12-28	WOS:A1991FF22800004
J	JACOBSON, HR				JACOBSON, HR			CHRONIC-RENAL-FAILURE - PATHOPHYSIOLOGY	LANCET			English	Article							EXPERIMENTAL GLOMERULONEPHRITIS; PROGRESSION; DISEASE; HYPERTROPHY; EXPRESSION; SCLEROSIS				JACOBSON, HR (corresponding author), VANDERBILT UNIV,MED CTR,DIV NEPHROL,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097, P50DK039261] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39261, DK37097] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON DR, 1987, AM J PHYSIOL, V253, pF783, DOI 10.1152/ajprenal.1987.253.5.F783; BALDWIN DS, 1987, AM J KIDNEY DIS, V10, P186, DOI 10.1016/S0272-6386(87)80173-7; BOHLE A, 1977, VIRCHOWS ARCH A, V375, P87, DOI 10.1007/BF00428097; BOHLE A, 1977, VIRCHOWS ARCH A, V373, P14; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BROWN SA, 1991, J AM SOC NEPHROL, V1, P1169; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DIAMOND JR, 1990, AM J PHYSIOL, V258, pF1, DOI 10.1152/ajprenal.1990.258.1.F1; DWORKIN LD, 1990, J AM SOC NEPHROL, V1, pS21; ELFENBEIN IB, 1974, ARCH PATHOL, V97, P143; FAGIN JA, 1987, ENDOCRINOLOGY, V120, P718, DOI 10.1210/endo-120-2-718; FOGO A, 1989, SEMIN NEPHROL, V9, P329; FOGO A, 1990, KIDNEY INT, V38, P115, DOI 10.1038/ki.1990.175; HIRSCHBERG R, 1991, J AM SOC NEPHROL, V1, P1034; KEANE WF, 1991, KIDNEY INT, V39, pS41; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KLAHR S, 1989, KIDNEY INT, V36, pS27; LAU K, 1989, KIDNEY INT, V36, P918, DOI 10.1038/ki.1989.281; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; REMUZZI G, 1990, KIDNEY INT, V38, P384, DOI 10.1038/ki.1990.217; RUBIN K, 1988, LANCET, V1, P1353; SEGAL R, 1989, KIDNEY INT, V36, pS2; STRIKER LJ, 1991, LAB INVEST, V564, P446; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WOLF G, 1991, KIDNEY INT, V39, P401, DOI 10.1038/ki.1991.52; YEE J, 1991, SEMIN NEPHROL, V11, P361	27	113	114	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					419	423		10.1016/0140-6736(91)91042-S	http://dx.doi.org/10.1016/0140-6736(91)91042-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678092				2022-12-28	WOS:A1991GB44600013
J	BROWNER, WS; SEELEY, DG; VOGT, TM; CUMMINGS, SR				BROWNER, WS; SEELEY, DG; VOGT, TM; CUMMINGS, SR			NONTRAUMA MORTALITY IN ELDERLY WOMEN WITH LOW BONE-MINERAL DENSITY	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; STROKE-ASSOCIATED MORTALITY; HIP FRACTURE; LONG-TERM; RISK; THIAZIDE; HYPERTENSION; OSTEOPOROSIS; POPULATION; MENOPAUSE	9704 ambulatory women aged 65 years or older were prospectively studied to determine whether low bone mineral density (osteopenia) was associated with mortality. Bone mineral density was measured at entry to the study by single-photon absorptiometry. 299 women died during a mean of 2.8 years' follow-up. Osteopenia was associated with increased non-trauma mortality, probably because it is a marker for several other adverse factors. Each standard deviation decrease in proximal radius bone mineral density (0.104 g/cm2) was associated with a 1.19-fold increase in mortality (95% confidence interval 1.04-1.36), adjusted for age and duration of follow-up. Diminished bone mineral density at the proximal radius was strongly associated with deaths from stroke (relative risk = 1.74; 95% Cl 1.12-2.70), an association that was not confounded by history of previous stroke, hypertension, postmenopausal use of oestrogen, thiazide diuretic treatment, diabetes mellitus, and smoking. Most deaths in women with low bone mineral density are unrelated to the occurrence of fractures-an observation that should be taken into account when estimating the need for and cost-effectiveness of bone-density screening and fracture prevention programmes.	VET AFFAIRS MED CTR,DEPT MED,GEN INTERNAL MED SECT,SAN FRANCISCO,CA; KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); Kaiser Permanente; University of California System; University of California San Francisco	BROWNER, WS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,PREVENT SCI GRP,74 NEW MONTGOMERY,SUITE 600,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN JM, 1987, OSTEOPOROSIS 1987, P45; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BOHANNON RW, 1986, ARCH PHYS MED REHAB, V67, P390; BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515; BUKOSKI RD, 1990, HYPERTENSION, V16, P523, DOI 10.1161/01.HYP.16.5.523; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Callaway CW., 1988, ANTHROPOMETRIC STAND, P39; CAULEY JA, 1990, AM J EPIDEMIOL, V132, P884, DOI 10.1093/oxfordjournals.aje.a115731; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DYKEN ML, 1985, 71022A AM HEART ASS; ETTINGER B, 1988, MATURITAS, V10, P271, DOI 10.1016/0378-5122(88)90063-1; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FRANKS AL, 1987, AM J OBSTET GYNECOL, V156, P20, DOI 10.1016/0002-9378(87)90196-7; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; JACOBSEN SJ, 1990, AM J EPIDEMIOL, V132, P755; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LINDSAY R, 1976, LANCET, V1, P1038; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; 1980, INT CLASSIFICATION D, V1	31	337	348	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					355	358		10.1016/0140-6736(91)90489-C	http://dx.doi.org/10.1016/0140-6736(91)90489-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677708				2022-12-28	WOS:A1991GA60700014
J	ROSENSTOCK, L; KEIFER, M; DANIELL, WE; MCCONNELL, R; CLAYPOOLE, K				ROSENSTOCK, L; KEIFER, M; DANIELL, WE; MCCONNELL, R; CLAYPOOLE, K			CHRONIC CENTRAL-NERVOUS-SYSTEM EFFECTS OF ACUTE ORGANOPHOSPHATE PESTICIDE INTOXICATION	LANCET			English	Article							HEALTH	Acute organophosphate pesticide poisonings cause substantial morbidity and mortality world wide; however, whether organophosphates cause chronic neurological sequelae has not been established. To see whether single episodes of acute unintentional organophosphate intoxication lead to chronic neuropsychological dysfunction, we carried out a retrospective study of agricultural workers in Nicaragua who had been admitted to hospital between July 1, 1986, and July 31, 1988, for occupationally related organophosphate intoxication. This "poisoned" group (36 men) was tested on average about two years after the episode of pesticide poisoning and compared with a matched control group. The poisoned group did much worse than the control group on all neuropsychological subtests, with significantly worse performance on five of six subtests of a World Health Organisation neuropsychological test battery and on 3 of 6 additional tests that assessed verbal and visual attention, visual memory, visuomotor speed, sequencing and problem solving, and motor steadiness and dexterity. Differences in neuropsychological performance could not be explained by other factors. The findings of a persistent decrease in neuropsychological performance among individuals with previous intoxication emphasise the importance of prevention of even single episodes of organophosphate poisoning.	UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,MT SINAI SCH MED,DIV OCCUPAT & ENVIRONM HLTH,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle	ROSENSTOCK, L (corresponding author), UNIV WASHINGTON,OCCUPAT MED PROGRAM,ZA-66,SEATTLE,WA 98195, USA.							[Anonymous], 1990, PUBLIC HLTH IMPACT P; BURCHFIEL JL, 1976, TOXICOL APPL PHARM, V35, P365, DOI 10.1016/0041-008X(76)90296-9; COSTA LG, 1988, RECENT ADV NERVOUS S; Coye M J, 1985, J Public Health Policy, V6, P349, DOI 10.2307/3342402; Derogatis L.R., 1982, BRIEF SYMPTOM INDEX; DILLE JR, 1964, AEROSPACE MED, V35, P475; DUFFY FH, 1979, TOXICOL APPL PHARM, V47, P161, DOI 10.1016/0041-008X(79)90083-8; DURHAM WF, 1965, ARCH ENVIRON HEALTH, V10, P55, DOI 10.1080/00039896.1965.10663953; ESKANAZI B, 1988, MED NEUROPSYCHOLOGY, P223; GERCHON S, 1961, LANCET, V1, P1371; Hogstedt C, 1984, BIOL MONITORING SURV; HOLMES JH, 1957, T AM CLIN CLIMAT ASS, V68, P86; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; JEYARATNAM J, 1985, SCAND J WORK ENV HEA, V11, P229, DOI 10.5271/sjweh.2230; JEYARATNAM J, 1985, BRIT J IND MED, V42, P505; KARCZMAR AG, 1984, FUND APPL TOXICOL, V4, pS1, DOI 10.1016/0272-0590(84)90133-7; LEWIS R, 1977, ANN M SE PSYCHOL ASS; MARONI M, 1986, TOXICOL LETT, V33, P115, DOI 10.1016/0378-4274(86)90076-7; MCCONNELL R, 1990, AM J PUBLIC HEALTH, V80, P1236, DOI 10.2105/AJPH.80.10.1236; Metcalf D R, 1969, Ann N Y Acad Sci, V160, P357, DOI 10.1111/j.1749-6632.1969.tb15857.x; MIDTLING JE, 1985, WESTERN J MED, V142, P514; Murphy DS, 1986, CASARETT DOULLS TOXI, P519; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1985, HALSTEAD REITAN NEUR; Rey A, 1964, LEXAMEN CLINIQUE PSY; Rosenstock L., 1987, Toxicology of pesticides: experimental, clinical and regulatory perspectives., P197; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; SENANAYAKE N, 1987, NEW ENGL J MED, V316, P761, DOI 10.1056/NEJM198703263161301; TABERSHAW IR, 1966, JOM-J OCCUP MED, V8, P5; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; 1986, OPERATIONAL GUIDE WH; 1986, WHOVBC86926	32	364	381	0	29	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					223	227		10.1016/0140-6736(91)90356-T	http://dx.doi.org/10.1016/0140-6736(91)90356-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676786				2022-12-28	WOS:A1991FY50400011
J	HENDERSON, C				HENDERSON, C			COMMUNITY CONTROL OF SCABIES	LANCET			English	Letter											HENDERSON, C (corresponding author), YORK DIST GEN HOSP,YORK YO3 7HE,N YORKSHIRE,ENGLAND.							TAPLIN, 1991, LANCET, V337, P1016	1	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1548	1548		10.1016/0140-6736(91)93240-A	http://dx.doi.org/10.1016/0140-6736(91)93240-A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT116	1675397				2022-12-28	WOS:A1991FT11600037
J	SVEDMAN, P; LUNDIN, S; SVEDMAN, C				SVEDMAN, P; LUNDIN, S; SVEDMAN, C			ADMINISTRATION OF ANTIDIURETIC PEPTIDE (DDAVP) BY WAY OF SUCTION DEEPITHELIALIZED SKIN	LANCET			English	Article							PLASMA-CONCENTRATIONS; DIABETES-INSIPIDUS; VASOPRESSIN; INTRANASAL; HUMANS; IONTOPHORESIS; DESMOPRESSIN; ABSORPTION; INFUSION; ANALOG	Transdermal drug delivery seems a promising way of achieving complete, predictable absorption, but the epidermis is a barrier for most drugs. A new technique for transdermal drug delivery, in which a small patch of epidermis was removed, was tested in seven healthy volunteers by means of the antidiuretic peptide 1-deamino-8-D-arginine vasopressin (DDAVP). The epithelium of a small area of forearm skin (diameter 5 mm) was removed painlessly, and in a standard way, by a simple device operating at a preset vacuum. DDAVP was given by way of improvised occlusive reservoirs. Plasma DDAVP concentration/time curves conformed closely with zero-order kinetics, which suggests that the bioavailability approached 100%, corresponding to that for direct intravenous infusion. Four volunteers were given DDAVP daily for 4 days by way of the de-epithelialised site; there were no signs that re-epithelialisation hindered permeation. All plasma DDAVP values substantially exceeded the lowest effective therapeutic concentration for patients with diabetes insipidus. The vacuum removal of the epithelium caused pronounced hyperaemia in the de-epithelialised dermis (assessed by laser doppler flow measurement); the hyperaemia persisted, unaffected by DDAVP, and may have contributed to the efficient permeation. The skin spot appeared normal at 6 weeks.	UNIV LUND, DEPT PLAST & RECONSTRUCT SURG, S-22101 LUND, SWEDEN; UNIV LUND, DEPT CLIN PHARMACOL, S-22101 LUND, SWEDEN	Lund University; Lund University								ANDERSSO.KE, 1972, ACTA MED SCAND, V192, P21; BANERJEE PS, 1989, INT J PHARM, V49, P199, DOI 10.1016/0378-5173(89)90342-6; CHAMBERS GR, 1984, UPSALA J MED SCI, V89, P91, DOI 10.3109/03009738409178468; CHIEN YW, 1989, J PHARM SCI-US, V78, P376, DOI 10.1002/jps.2600780507; COWLEY AW, 1987, VASOPRESSIN, P389; HAMMER M, 1985, J PHARMACOL EXP THER, V234, P754; HARRIS AS, 1986, J PHARM SCI, V75, P1085, DOI 10.1002/jps.2600751113; KIISTALA U, 1976, THESIS HELSINKI; KUTLU N, 1990, INT J MICROCIRC CLIN, V9, P102; LASHMAR UT, 1989, J PHARM PHARMACOL, V41, P118, DOI 10.1111/j.2042-7158.1989.tb06405.x; LOUTER LR, 1983, AM J OBSTET GYNECOL, V146, P533; LUNDIN S, 1985, EXPERIENTIA, V41, P933, DOI 10.1007/BF01970020; MILLER LL, 1990, J PHARM SCI, V79, P490, DOI 10.1002/jps.2600790607; NILSSON GE, 1980, IEEE T BIO-MED ENG, V27, P12, DOI 10.1109/TBME.1980.326686; SAKSELA O, 1981, J INVEST DERMATOL, V77, P283, DOI 10.1111/1523-1747.ep12482457; SHAW JE, 1984, AM HEART J, V108, P217, DOI 10.1016/0002-8703(84)90578-7; SRINIVASAN V, 1990, J PHARM SCI, V79, P588, DOI 10.1002/jps.2600790708; Svedman P, 1991, J Invest Surg, V4, P175, DOI 10.3109/08941939109140778; SVEDMAN P, 1983, LANCET, V2, P532; SVEDMAN P, 1990, INT J MICROCIRC CLIN, V9, P160; TRYDING N, 1987, NEPHRON, V45, P27, DOI 10.1159/000184066; VILHARDT H, 1986, ACTA PHARMACOL TOX, V58, P379; VILHARDT H, 1984, ACTA ENDOCRINOL-COP, V105, P474, DOI 10.1530/acta.0.1050474; VILHARDT H, 1986, GEN PHARMACOL-VASC S, V17, P481, DOI 10.1016/0306-3623(86)90198-9; WIECHERS JW, 1987, PHARMACEUT RES, V4, P519, DOI 10.1023/A:1016439908270	25	18	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	1991	337	8756					1506	1509		10.1016/0140-6736(91)93197-H	http://dx.doi.org/10.1016/0140-6736(91)93197-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675370				2022-12-28	WOS:A1991FT11600004
J	DREWS, GN; BOWMAN, JL; MEYEROWITZ, EM				DREWS, GN; BOWMAN, JL; MEYEROWITZ, EM			NEGATIVE REGULATION OF THE ARABIDOPSIS HOMEOTIC GENE AGAMOUS BY THE APETALA2 PRODUCT	CELL			English	Article							FLOWER DEVELOPMENT; FLORAL DEVELOPMENT; ULTRABITHORAX TRANSCRIPTS; DROSOPHILA EMBRYOS; SPATIAL EXPRESSION; BITHORAX COMPLEX; ANTENNAPEDIA; THALIANA; PATTERN; PROTEIN	We characterized the distribution of AGAMOUS (AG) RNA during early flower development in Arabidopsis. Mutations in this homeotic gene cause the transformation of stamens to petals in floral whorl 3 and of carpels to another ag flower in floral whorl 4. We found that AG RNA is present in the stamen and carpel primordia but is undetectable in sepal and petal primordia throughout early wild-type flower development, consistent with the mutant phenotype. We also analyzed the distribution of AG RNA in apetela2 (ap2) mutant flowers. AP2 is a floral homeotic gene that is necessary for the normal development of sepals and petals in floral whorls 1 and 2. In ap2 mutant flowers, AG RNA is present in the organ primordia of all floral whorls. These observations show that the expression patterns of the Arabidopsis floral homeotic genes are in part established by regulatory interactions between these genes.			DREWS, GN (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009	Bowman, John/0000-0001-7347-3691	NIGMS NIH HHS [GM13100-03, 5T32-GM07616] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013100, T32GM007616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM ME, 1983, EMBO J, V2, P2075, DOI 10.1002/j.1460-2075.1983.tb01703.x; AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BLASER HW, 1950, AM J BOT, V37, P297, DOI 10.2307/2437850; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1991, IN PRESS S SOC EXPT, V44; BOWMAN JL, 1991, IN PRESS DEVELOPMENT; BOWMAN JL, 1988, OXFORD SURV PLANT MO, V5, P57; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DERMEN H, 1947, AM J BOT, V34, P32, DOI 10.2307/2437192; DERMEN H, 1973, AM J BOT, V60, P283, DOI 10.2307/2441220; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JACK T, 1990, EMBO J, V9, P1187, DOI 10.1002/j.1460-2075.1990.tb08226.x; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; LEVINE M, 1983, EMBO J, V2, P2037, DOI 10.1002/j.1460-2075.1983.tb01697.x; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MEYEROWITZ EM, 1989, DEVELOPMENT, V106, P209; MEYEROWITZ EM, 1991, IN PRESS DEVELOPME S; Pruitt RE, 1987, GENETIC REGULATION D, P327; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; Satina S, 1941, AM J BOT, V28, P862, DOI 10.2307/2436864; Satina S, 1944, AM J BOT, V31, P493, DOI 10.2307/2437412; Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558; Satina S, 1943, AM J BOT, V30, P453, DOI 10.2307/2437281; SATINA S, 1945, AM J BOT, V32, P72, DOI 10.2307/2437113; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	522	576	6	85	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					991	1002		10.1016/0092-8674(91)90551-9	http://dx.doi.org/10.1016/0092-8674(91)90551-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675158				2022-12-28	WOS:A1991FR04700010
J	WRIGHT, DH; JONES, DB; CLARK, H; MEAD, GM; HODGES, E; HOWELL, WM				WRIGHT, DH; JONES, DB; CLARK, H; MEAD, GM; HODGES, E; HOWELL, WM			IS ADULT-ONSET CELIAC-DISEASE DUE TO A LOW-GRADE LYMPHOMA OF INTRAEPITHELIAL LYMPHOCYTES-T	LANCET			English	Article							MALIGNANT HISTIOCYTOSIS; INTESTINAL LYMPHOMA; CELIAC-DISEASE; CELL LYMPHOMA; MALABSORPTION; ENTEROPATHY	Enteropathy-associated T-cell lymphoma commonly presents with malabsorption, and debate continues as to whether adult-onset coeliac disease (CD) is itself a form of low-grade lymphoma. A 59-year-old man with adult-onset CD required resection of a segment of oedematous jejunum. Histological examination of this tissue revealed an intense intraepithelial lymphocytosis. Immunophenotypic (CD3 -, CD4 -, CD8 -, CD34 -, and CD45 RO-) and cytogenetic (deletion of the Y chromosome and chromosome 9) abnormalities were found, together with monoclonal T-cell-receptor gene rearrangements. Some patients with adult-onset CD may have low-grade lymphoma from the outset of their illness.	SOUTHAMPTON GEN HOSP,DEPT MED ONCOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; SOUTHAMPTON GEN HOSP,REG IMMUNOL SERV,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton; University of Southampton	WRIGHT, DH (corresponding author), SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ALFSEN GC, 1989, HUM PATHOL, V20, P909; GOUGH KR, 1962, GUT, V3, P232, DOI 10.1136/gut.3.3.232; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; ISAACSON P, 1978, HUM PATHOL, V9, P661, DOI 10.1016/S0046-8177(78)80049-5; ISAACSON P, 1978, LANCET, V1, P67; ISAACSON PG, 1985, LANCET, V2, P688; MARSH MN, 1983, J CLIN PATHOL, V36, P149, DOI 10.1136/jcp.36.2.149; OFARRELLY C, 1986, BRIT MED J, V293, P908, DOI 10.1136/bmj.293.6552.908; SWINSON CM, 1983, LANCET, V1, P111; WHITEHEAD R, 1968, GUT, V9, P569, DOI 10.1136/gut.9.5.569	10	74	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1373	1374		10.1016/0140-6736(91)93059-I	http://dx.doi.org/10.1016/0140-6736(91)93059-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674763				2022-12-28	WOS:A1991FP87000003
J	BRAVERMAN, AS				BRAVERMAN, AS			MEDICAL ONCOLOGY IN THE 1990S	LANCET			English	Editorial Material											BRAVERMAN, AS (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV HEMATOL ONCOL,BOX 55,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; CHABNER BA, 1986, J CLIN ONCOL, V4, P625	2	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					901	902		10.1016/0140-6736(91)90218-E	http://dx.doi.org/10.1016/0140-6736(91)90218-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672980				2022-12-28	WOS:A1991FG04800015
J	[Anonymous]				[Anonymous]			THE HIV CATCH-22	LANCET			English	Editorial Material																		ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; RILEY VC, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90853-H; 1990, LANCET, V336, P1501; 1990, LANCET, V335, P821	5	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					843	843						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672926				2022-12-28	WOS:A1991FF22800018
J	FIRTH, HV; BOYD, PA; CHAMBERLAIN, P; MACKENZIE, IZ; LINDENBAUM, RH; HUSON, SM				FIRTH, HV; BOYD, PA; CHAMBERLAIN, P; MACKENZIE, IZ; LINDENBAUM, RH; HUSON, SM			SEVERE LIMB ABNORMALITIES AFTER CHORION VILLUS SAMPLING AT 56-66 DAYS GESTATION	LANCET			English	Note								Among 289 pregnancies in which chorion villus sampling (CVS) was carried out at 56-66 days' gestation, 5 babies with severe limb abnormalities were subsequently identified. 4 had oromandibular-limb hypogenesis syndromes, and the other had a terminal transverse limb reduction defect. This high incidence raises the possibility that CVS was an aetiological factor for these developmental anomalies.	JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND		FIRTH, HV (corresponding author), CHURCHILL HOSP,DEPT MED GENET,OXFORD OX3 7LJ,ENGLAND.							BOUWESBAVINCK JN, 1986, AM J MED GENET, V23, P903, DOI 10.1002/ajmg.1320230405; BOYD PA, 1990, PRENATAL DIAG, V10, P437, DOI 10.1002/pd.1970100705; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GORLIN RJ, 1990, OXFORD MONOGRAPHS ME, V19, P666; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; JONES KL, 1988, SMITHS RECOGNISABLE, P588; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; WEBSTER WS, 1988, TERATOLOGY, V38, pA199; 1990, MB34 OFF POP CENS SU; 1991, MB35 OFF POP CENS SU	11	270	280	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					762	763		10.1016/0140-6736(91)91374-4	http://dx.doi.org/10.1016/0140-6736(91)91374-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672394				2022-12-28	WOS:A1991FD88400006
J	MILES, KA; HAYBALL, M; DIXON, AK				MILES, KA; HAYBALL, M; DIXON, AK			COLOR PERFUSION IMAGING - A NEW APPLICATION OF COMPUTED-TOMOGRAPHY	LANCET			English	Note							BLOOD-FLOW	We describe a new application for imaging with computed tomography (CT) in which a quantifiable map of tissue perfusion is created and displayed by means of a colour scale. A rapid sequence of images is acquired without table movement immediately after a bolus intravenous injection of radiographic contrast medium. The rate of enhancement in each pixel within the chosen slice can then be used to determine perfusion. The technique provides a quantifiable display of regional perfusion combined with the high spatial resolution afforded by CT.	ADDENBROOKES HOSP,DEPT NUCL MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED PHYS,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	MILES, KA (corresponding author), ADDENBROOKES HOSP,DEPT RADIOL,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.			Miles, Kenneth/0000-0002-5920-381X				AXEL L, 1979, INVEST RADIOL, V14, P389; Hindmarsh T, 1975, Acta Radiol Suppl, V346, P45; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; MILES KA, 1990, BRIT J RADIOL, V63, P991; MILES KA, IN PRESS BR J RADIOL; PETERS AM, 1987, CARDIOVASC RES, V21, P830, DOI 10.1093/cvr/21.11.830; PETERS AM, 1987, NUCL MED COMMUN, V8, P823, DOI 10.1097/00006231-198710000-00009; RUSSELL SB, 1974, BRIT J RADIOL, V47, P268, DOI 10.1259/0007-1285-47-557-268	8	136	215	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					643	645		10.1016/0140-6736(91)92455-B	http://dx.doi.org/10.1016/0140-6736(91)92455-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671994				2022-12-28	WOS:A1991FB73000006
J	HENTSCHEL, E; NEMEC, H; SCHUTZE, K; HIRSCHL, A; DRAGOSICS, B; BRANDSTATTER, G; TAUFER, M				HENTSCHEL, E; NEMEC, H; SCHUTZE, K; HIRSCHL, A; DRAGOSICS, B; BRANDSTATTER, G; TAUFER, M			DUODENAL-ULCER RECURRENCE AND HELICOBACTER-PYLORI	LANCET			English	Letter									UNIV VIENNA,INST HYG,A-1010 VIENNA,AUSTRIA; AMBULATORIUM SUD,VIENNA,AUSTRIA; LANDESKRANKENHAUS GRAZ,A-8020 GRAZ,AUSTRIA	University of Vienna	HENTSCHEL, E (corresponding author), HANUSCH HOSP,A-1140 VIENNA,AUSTRIA.							FIOCCA, 1991, LANCET, V337, P1614	1	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					569	569		10.1016/0140-6736(91)91130-M	http://dx.doi.org/10.1016/0140-6736(91)91130-M			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678818				2022-12-28	WOS:A1991GD00200027
J	MATSUBARA, Y; NARISAWA, K; TADA, K; IKEDA, H; YAO, YQ; DANKS, DM; GREEN, A; MCCABE, ERB				MATSUBARA, Y; NARISAWA, K; TADA, K; IKEDA, H; YAO, YQ; DANKS, DM; GREEN, A; MCCABE, ERB			PREVALENCE OF K329E MUTATION IN MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE DETERMINED FROM GUTHRIE CARDS	LANCET			English	Article							DEFICIENCY; DIAGNOSIS	Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an autosomal recessive disorder that has been associated with sudden infant death syndrome and a condition resembling Reye's syndrome. The point mutation K329E is thought to be the commonest mutation causing MCAD deficiency in caucasian patients. The prevalence of this mutation was determined by use of dried blood spots on Guthrie cards obtained during neonatal screening programmes. 12 carriers were identified among 479 newborn babies in Britain, 5 among 353 in Australia, and 5 among 536 in North America but none among 500 in Japan. Since presymptomatic diagnosis and appropriate dietary management can prevent life-threatening episodes in MCAD deficiency, population-based DNA screening for this potentially fatal disorder might be justified in countries with a high frequency of this mutation.	TOHOKU UNIV,SCH MED,DEPT PEDIAT,SENDAI,MIYAGI 980,JAPAN; ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; HOLLYMOOR HOSP,W MIDLANDS REG NEONATAL SCREENING LAB,BIRMINGHAM,ENGLAND; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Tohoku University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Baylor College of Medicine; Baylor College of Medicine	MATSUBARA, Y (corresponding author), TOHOKU UNIV,SCH MED,DEPT BIOCHEM GENET,1-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN.							BLAKEMORE AIF, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90907-7; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; MATSUBARA Y, 1990, LANCET, V335, P1589, DOI 10.1016/0140-6736(90)91413-5; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; RINALDO P, 1988, NEW ENGL J MED, V319, P1308, DOI 10.1056/NEJM198811173192003; Roe C, 1989, METABOLIC BASIS INHE, P889; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; [No title captured]; 1986, LANCET, V2, P1073	11	105	106	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					552	553		10.1016/0140-6736(91)91110-G	http://dx.doi.org/10.1016/0140-6736(91)91110-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678810				2022-12-28	WOS:A1991GD00200014
J	RIMM, EB; GIOVANNUCCI, EL; WILLETT, WC; COLDITZ, GA; ASCHERIO, A; ROSNER, B; STAMPFER, MJ				RIMM, EB; GIOVANNUCCI, EL; WILLETT, WC; COLDITZ, GA; ASCHERIO, A; ROSNER, B; STAMPFER, MJ			PROSPECTIVE-STUDY OF ALCOHOL-CONSUMPTION AND RISK OF CORONARY-DISEASE IN MEN	LANCET			English	Article							DENSITY-LIPOPROTEIN SUBFRACTIONS; HEART-DISEASE; NUTRIENT INTAKE; MODERATE; CESSATION	Although an inverse association between alcohol consumption and risk of coronary artery disease has been consistently found in several types of studies, some have argued that the association is due at least partly to the inclusion in the non-drinking reference group of men who abstain because of pre-existing disease. The association between self-reported alcohol intake and coronary disease was studied prospectively among 51 529 male health professionals. In 1986 the participants completed questionnaires about food and alcohol intake and medical history, heart disease risk factors, and dietary changes in the previous 10 years. Follow-up questionnaires in 1988 sought information about newly diagnosed coronary disease. 350 confirmed cases of coronary disease occurred. After adjustment for coronary risk factors, including dietary intake of cholesterol, fat, and dietary fibre, increasing alcohol intake was inversely related to coronary disease incidence (p for trend < 0.001). Exclusion of 10 302 current non-drinkers or 16 342 men with disorders potentially related to coronary disease (eg, hypertension, diabetes, and gout) which might have led men to reduce their alcohol intake, did not substantially affect the relative risks. These findings support the hypothesis that the inverse relation between alcohol consumption and risk of coronary disease is causal.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	RIMM, EB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35464] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; COLDITZ GA, IN PRESS AM J CLIN N; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HASKELL WL, 1985, JAMA-J AM MED ASSOC, V253, P2854; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HUNTER DJ, IN PRESS AM J EPIDEM; JONES BR, 1982, AM J CLIN NUTR, V35, P135, DOI 10.1093/ajcn/35.1.135; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MILLER GJ, 1975, LANCET, V1, P16; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; RIMM EB, IN PRESS AM J EPIDEM; Rose GA, 1982, MONOGRAPH SERIES WHO, V58; ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THOMSON M, 1988, AM J CLIN NUTR, V47, P139, DOI 10.1093/ajcn/47.1.139; THORNTON J, 1983, LANCET, V2, P819; VALIMAKI M, 1986, ATHEROSCLEROSIS, V59, P147, DOI 10.1016/0021-9150(86)90043-2; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1987, DHHS ADM871519 NAT I; 1988, DHSS8850210 PUBL; 1976, COMPOSITION FOODS HD	30	1001	1008	0	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					464	468		10.1016/0140-6736(91)90542-W	http://dx.doi.org/10.1016/0140-6736(91)90542-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678444				2022-12-28	WOS:A1991GC15300002
J	NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB				NELSON, SR; HAWKINS, PN; RICHARDSON, S; LAVENDER, JP; SETHI, D; GOWER, PE; PUGH, CW; WINEARLS, CG; OLIVER, DO; PEPYS, MB			IMAGING OF HEMODIALYSIS-ASSOCIATED AMYLOIDOSIS WITH I-123 SERUM AMYLOID-P COMPONENT	LANCET			English	Article							LONG-TERM HEMODIALYSIS; SYSTEMIC AMYLOIDOSIS; BETA-2-MICROGLOBULIN AMYLOIDOSIS; RENAL-TRANSPLANTATION; DEPOSITS; PROTEIN	Long-term haemodialysis is frequently complicated by amyloid deposition in which the fibrils consist of beta-2-microglobulin. Dialysis-related amyloid disease causes extensive morbidity and has been associated with deaths in some cases. All amyloid deposits contain amyloid P component that is derived from the normal circulating protein, serum amyloid P component (SAP). We have used scintigraphic imaging after injection of I-123-labelled SAP to assess the distribution of amyloidosis in 38 patients receiving long-term haemodialysis for end-stage renal failure. There was focal localisation of tracer at all sites where histological examination confirmed amyloid deposition. Splenic uptake was seen in 12 patients, indicating splenic amyloidosis, but there was no evidence of other visceral involvement. 6 control subjects who had been dialysed for under 1.5 years showed no localisation of tracer, nor was there any uptake of I-123-labelled human serum albumin in 3 long-term dialysis patients with histologically confirmed amyloidosis and positive I-123-SAP images. Negative scans were also obtained in 5 patients who had been transplanted 0.8-2.4 years previously, despite past evidence of dialysis arthropathy (5) and histologically proven amyloidosis (4). I-123-SAP scintigraphy may be helpful as a non-invasive method for both the diagnosis and monitoring of dialysis-associated amyloidosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,IMMUNOL MED UNIT,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RADIOL,LONDON W12 0NN,ENGLAND; CHARING CROSS HOSP,DEPT MED,RENAL UNIT,LONDON W6 8RP,ENGLAND; CHURCHILL HOSP,RENAL UNIT,OXFORD OX3 7LJ,ENGLAND	Imperial College London; Imperial College London; Imperial College London; University of Oxford			Hawkins, Philip N/C-5573-2008	Pugh, Chris/0000-0002-5170-1662				BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; CHOI HSH, 1989, GASTROENTEROLOGY, V96, P230, DOI 10.1016/0016-5085(89)90785-3; DESTRIHOU CV, 1990, INT YB NEPHROLOGY, P217; FLOEGE J, 1989, NEPHRON, V51, P444, DOI 10.1159/000185351; FLOEGE J, 1990, KIDNEY INT, V38, P1169, DOI 10.1038/ki.1990.329; FUCHS A, 1987, AM J CLIN PATHOL, V88, P302, DOI 10.1093/ajcp/88.3.302; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1990, J CLIN INVEST, V86, P1862, DOI 10.1172/JCI114917; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; JADOUL M, 1989, CLIN NEPHROL, V32, P194; MAHER ER, 1988, BRIT MED J, V297, P265, DOI 10.1136/bmj.297.6643.265; MANTZOURANIS EC, 1985, J BIOL CHEM, V280, P7752; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; ORFILA C, 1987, NEPHROL DIAL TRANSPL, V2, P448; Pepys M. B, 1988, IMMUNOLOGICAL DISEAS, V1, P631; PEPYS MB, CLIN EXP; PRELLI F, 1985, J BIOL CHEM, V260, P12865; SETHI D, 1989, AM J NEPHROL, V9, P173, DOI 10.1159/000167959; SHINODA T, 1989, CLIN NEPHROL, V32, P284; STONE WJ, 1989, AM J NEPHROL, V9, P177, DOI 10.1159/000167962; THEAKER JM, 1987, J CLIN PATHOL, V40, P1247, DOI 10.1136/jcp.40.10.1247	24	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					335	339		10.1016/0140-6736(91)90478-8	http://dx.doi.org/10.1016/0140-6736(91)90478-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677697				2022-12-28	WOS:A1991GA60700003
J	SEHGAL, A; SINGH, V; BHAMBHANI, S; LUTHRA, UK				SEHGAL, A; SINGH, V; BHAMBHANI, S; LUTHRA, UK			SCREENING FOR CERVICAL-CANCER BY DIRECT INSPECTION	LANCET			English	Note								Since cytology-based screening Programmes for cervical cancer cannot be provided on a large scale in developing countries, an alternative approach is needed. To find out whether visual inspection of the cervix is an adequate alternative, women with cytological evidence of dysplasia were followed up cytologically and colposcopically until cancer was detected, and the gross appearance of the cervix was recorded at each stage. Although only 40-50% of cancers were accompanied by abnormal-looking cervices, whereas 71% were detectable on cytology and 87% on colposcopy, visual inspection may be useful in areas where cytological screening programmes are not available.			SEHGAL, A (corresponding author), MAULANA AZAD MED COLL,INST CYTOL & PREVENT ONCOL,BAHADUR SHAH ZAFAR MARG,NEW DELHI 110002,INDIA.							LUTHRA UK, 1987, ACTA CYTOL, V31, P226; STJERNSWARD J, 1987, World Health Forum, V8, P42	2	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					282	282		10.1016/0140-6736(91)90420-T	http://dx.doi.org/10.1016/0140-6736(91)90420-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677113				2022-12-28	WOS:A1991FZ56500006
J	TEELUCKSINGH, S; PADFIELD, PL; TIBI, L; GOUGH, KJ; HOLT, PR				TEELUCKSINGH, S; PADFIELD, PL; TIBI, L; GOUGH, KJ; HOLT, PR			INHALED CORTICOSTEROIDS, BONE-FORMATION, AND OSTEOCALCIN	LANCET			English	Letter							BECLOMETHASONE DIPROPIONATE; AEROSOL; ASTHMA		ROYAL INFIRM,DEPT CLIN CHEM,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; FISONS PHARMACEUT,LOUGHBOROUGH,ENGLAND	Royal Infirmary of Edinburgh	TEELUCKSINGH, S (corresponding author), WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CLARK TJH, 1972, LANCET, V1, P1361; LITTLEWOOD JM, 1988, LANCET, V1, P115; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; REID IR, 1986, J CLIN ENDOCR METAB, V62, P379, DOI 10.1210/jcem-62-2-379; STEAD RJ, 1989, BRIT MED J, V298, P403, DOI 10.1136/bmj.298.6671.403	6	86	86	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					60	61		10.1016/0140-6736(91)90058-W	http://dx.doi.org/10.1016/0140-6736(91)90058-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676119				2022-12-28	WOS:A1991FV29600053
J	THALER, MM; PARK, CK; LANDERS, DV; WARA, DW; HOUGHTON, M; VEEREMANWAUTERS, G; SWEET, RL; HAN, JH				THALER, MM; PARK, CK; LANDERS, DV; WARA, DW; HOUGHTON, M; VEEREMANWAUTERS, G; SWEET, RL; HAN, JH			VERTICAL TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							INFANT TRANSMISSION	There is evidence that hepatitis C virus (HCV) may be vertically transmitted from infected mothers to their children. To test this hypothesis, we prospectively studied 10 pregnant women at high risk from parenterally or sexually transmitted diseases with the polymerase chain reaction. HCV RNA was found in 8 newborn babies delivered by women who were anti-HCV seropositive, and persisted for 2-19 months of follow-up. Anti-HCV detected in 7 infants cleared by 9 months and remained undetectable thereafter. Serum alanine aminotransferase was raised in 3 infants. The findings provide evidence of vertical transmission of HCV and suggest that perinatal infection may initiate a silent disease process or chronic carrier state.	CHIRON CORP,EMERYVILLE,CA; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; HALLYM UNIV,COLL MED,DEPT INTERNAL MED,CHUNCHON,SOUTH KOREA	Novartis; University of California System; University of California San Francisco; Hallym University	THALER, MM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,M680,BOX 0136,SAN FRANCISCO,CA 94143, USA.			Houghton, Michael/0000-0003-3762-6771	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01271] Funding Source: Medline; NICHD NIH HHS [NICHD 24640] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; CHOO QL, 1990, BRIT MED BULL, V46, P423, DOI 10.1093/oxfordjournals.bmb.a072408; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; WEINTRAUB S, 1990, J CLIN EXP NEUROPSYC, V12, P49	7	244	246	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					17	18		10.1016/0140-6736(91)90006-B	http://dx.doi.org/10.1016/0140-6736(91)90006-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676085				2022-12-28	WOS:A1991FV29600005
J	WEETMAN, AP				WEETMAN, AP			THYROID-ASSOCIATED EYE DISEASE - PATHOPHYSIOLOGY	LANCET			English	Article							LINKED IMMUNOSORBENT-ASSAY; GRAVES OPHTHALMOPATHY; ENDOCRINE OPHTHALMOPATHY; MUSCLE ANTIBODIES; SERA; IMMUNOGLOBULINS; FIBROBLASTS; ANTIGENS; PROTEIN; CELL				WEETMAN, AP (corresponding author), UNIV SHEFFIELD,NO GEN HOSP,CTR CLIN SCI,DEPT MED,SHEFFIELD S5 7A,ENGLAND.							AHMANN A, 1987, J CLIN ENDOCR METAB, V64, P454, DOI 10.1210/jcem-64-3-454; ATKINSON S, 1984, LANCET, V2, P374; BAHN RS, 1989, J CLIN ENDOCR METAB, V69, P622, DOI 10.1210/jcem-69-3-622; BARTALENA L, 1989, NEW ENGL J MED, V321, P1350; BECH K, 1989, ACTA ENDOCRINOL-COP, V121, P117; CAMPBELL RJ, 1989, ACTA ENDOCRINOL-COP, V121, P9; DONG Q, IN PRESS J CLIN ENDO; JACOBSON DH, 1984, ENDOCR REV, V5, P200, DOI 10.1210/edrv-5-2-200; KADLUBOWSKI M, 1987, J CLIN LAB IMMUNOL, V24, P105; KENDALLTAYLOR P, 1988, CLIN ENDOCRINOL, V28, P601, DOI 10.1111/j.1365-2265.1988.tb00234.x; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LUDGATE M, 1989, AUTOIMMUNITY, V3, P167, DOI 10.3109/08916938909099014; MUNRO RE, 1973, J CLIN ENDOCR METAB, V37, P286, DOI 10.1210/jcem-37-2-286; PRUMMEL MF, 1990, ARCH INTERN MED, V150, P1098, DOI 10.1001/archinte.150.5.1098; ROTELLA CM, 1986, J CLIN ENDOCR METAB, V62, P357, DOI 10.1210/jcem-62-2-357; SALVI M, 1990, J CLIN ENDOCR METAB, V70, P89, DOI 10.1210/jcem-70-1-89; SCHIFFERDECKER E, 1989, ACTA ENDOCRINOL-COP, V121, P643, DOI 10.1530/acta.0.1210643; SHINE B, 1990, LANCET, V335, P1261, DOI 10.1016/0140-6736(90)91315-2; SRIDAMA V, 1987, ARCH INTERN MED, V147, P229, DOI 10.1001/archinte.147.2.229; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAO TW, 1989, J CLIN ENDOCR METAB, V69, P90, DOI 10.1210/jcem-69-1-90; WEETMAN AP, 1989, CLIN EXP IMMUNOL, V75, P222; WEETMAN AP, 1989, BRIT J OPHTHALMOL, V73, P323, DOI 10.1136/bjo.73.5.323; WEETMAN AP, 1988, CLIN ENDOCRINOL, V28, P619, DOI 10.1111/j.1365-2265.1988.tb00236.x; WEIGHTMAN D, 1989, J ENDOCRINOL, V122, P201, DOI 10.1677/joe.0.1220201; WESTERMARK K, 1989, ACTA ENDOCRINOL-COP, V121, P85; ZHANG ZG, 1989, ACTA ENDOCRINOL-COP, V121, P23	27	177	182	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					25	28		10.1016/0140-6736(91)90013-F	http://dx.doi.org/10.1016/0140-6736(91)90013-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676091				2022-12-28	WOS:A1991FV29600012
J	FRANKEL, S				FRANKEL, S			HEALTH NEEDS, HEALTH-CARE REQUIREMENTS, AND THE MYTH OF INFINITE DEMAND	LANCET			English	Editorial Material											FRANKEL, S (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,HLTH CARE EVALUAT UNIT,BRISTOL BS8 2PR,ENGLAND.							ABRAMSON JH, 1978, J EPIDEMIOL COMMUN H, V32, P59, DOI 10.1136/jech.32.1.59; BROOK RH, 1986, ISSUES SCI TECHNOL, V3, P68; BUNKER JP, 1970, NEW ENGL J MED, V282, P135, DOI 10.1056/NEJM197001152820306; CARSTAIRS V, 1989, COMMUNITY MED, V11, P363; DAVIDGE M, 1987, LANCET, V1, P794; Duthie RB., 1981, ORTHOPAEDIC SERVICES; FIELD MG, 1989, SUCCESS CRISIS NATIO; FRANKEL S, 1990, EPIDEMIOLOGICALLY BA; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; POWELL JE, 1976, MED POLITICS; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WILCOCK GK, 1979, INT J EPIDEMIOL, V8, P247, DOI 10.1093/ije/8.3.247; 1988, REV RESOURCES ALLOCA	13	37	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1588	1590		10.1016/0140-6736(91)93276-F	http://dx.doi.org/10.1016/0140-6736(91)93276-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU551	1675721				2022-12-28	WOS:A1991FU55100017
J	KLEIN, PD; GRAHAM, DY; GAILLOUR, A; OPEKUN, AR; SMITH, EO				KLEIN, PD; GRAHAM, DY; GAILLOUR, A; OPEKUN, AR; SMITH, EO			WATER SOURCE AS RISK FACTOR FOR HELICOBACTER-PYLORI INFECTION IN PERUVIAN CHILDREN	LANCET			English	Article							CAMPYLOBACTER-PYLORI; GASTRITIS; DISEASE	Helicobacter pylori infection is widespread among Peruvian adults by the age of 30, but the age at which children become infected, the prevalence of disease, and the role of socioeconomic status in the epidemiology of infection are not known. We used the C-13-urea breath test to study the prevalence of infection in 407 Peruvian children from Lima, aged 2 months to 12 years, from families of low and high socioeconomic status. Peruvian children acquire H pylori early in life and the number of infected individuals increases rapidly with age; overall prevalence was 48%. H pylori infection was independent of sex, but was highly correlated with socioeconomic status; prevalence of infection was higher among children from low-income families than among those from high-income families (56% vs 32%, p = 0.001). Children whose homes had external water sources were three times more likely to be infected than were those whose homes had internal water sources. Among families with internal water sources, there was no difference in H pylori infection associated with income. Children from high-income families whose homes were supplied with municipal water were 12 times more likely to be infected than were those from high-income families whose water supply came from community wells. The findings show that the prevalence of H pylori infection is high among young Peruvian children and that the municipal water supply seems to be an important source of infection among Lima children from families of both low and high socioeconomic status.	AB PRISMA,LIMA,PERU; UNIV PERUANA CAYETANO,HEREDIA,COSTA RICA; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218; BAYLOR UNIV,DEPT MED,HOUSTON,TX 77030; VET ADM MED CTR,HOUSTON,TX 77211	Johns Hopkins University; Baylor University; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	KLEIN, PD (corresponding author), BAYLOR UNIV,DEPT PEDIAT,USDA ARS,CHILDRENS NUTR RES CTR,1100 BATES ST,HOUSTON,TX 77030, USA.		Graham, David/AAL-2165-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035369, R01DK039048, R22DK035369, R01DK028129] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35369, DK 39048, DK 28129] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURSTEIN M, 1990, Gastroenterology, V98, pA27; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; GRAHAM DY, 1989, GASTROEN CLIN BIOL, V13, pB84; GRAHAM DY, 1987, LANCET, V1, P1174; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; KLEIN PD, 1989, CAMPYLOBACTER PYLORI, P94; LANGENBERG W, 1990, J INFECT DIS, V161, P507, DOI 10.1093/infdis/161.3.507; LLOYD BJ, 1989, WATER SCI TECHNOL, V21, P579, DOI 10.2166/wst.1989.0260; MARQUIS GS, 1990, AM J PUBLIC HEALTH, V80, P146, DOI 10.2105/AJPH.80.2.146; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; Mead GH., 1936, SOCIAL PSYCHOL SELEC; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; SHAHAMAT M, 1989, KLIN WOCHENSCHR S18, V67, P62; SHAHAMAT M, 1989, KLIN WOCHENSCHR S18, V67, P63; WEST AP, 1990, J CLIN PATHOL, V43, P609, DOI 10.1136/jcp.43.7.609-b; 1990, AM J GASTROENTEROL, V85, P819	16	454	483	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1503	1506		10.1016/0140-6736(91)93196-G	http://dx.doi.org/10.1016/0140-6736(91)93196-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675369				2022-12-28	WOS:A1991FT11600003
J	JESSOP, EG				JESSOP, EG			DOCTORS AND PRIORITIES	LANCET			English	Editorial Material											JESSOP, EG (corresponding author), NE ESSEX HLTH AUTHOR,TURNER RD,COLCHESTER CO5 4JR,ENGLAND.							BEECHAM L, 1991, BRIT MED J, V302, P1026; DEAN M, 1991, LANCET, V337, P351, DOI 10.1016/0140-6736(91)90961-N; ROBERTS CJ, 1985, LANCET, V1, P89	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1464	1464		10.1016/0140-6736(91)93142-V	http://dx.doi.org/10.1016/0140-6736(91)93142-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675331				2022-12-28	WOS:A1991FR06000018
J	AGID, Y				AGID, Y			PARKINSONS-DISEASE - PATHOPHYSIOLOGY	LANCET			English	Article							COMPLEX-I DEFICIENCY; SUPEROXIDE-DISMUTASE; SUBSTANTIA NIGRA; BRAIN; DEGENERATION; ETIOLOGY; CHAIN		HOP LA PITIE SALPETRIERE, INSERM, U289, F-75634 PARIS 13, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	AGID, Y (corresponding author), HOP LA PITIE SALPETRIERE, NEUROL & NEUROPSYCHOL SERV, 47 BLVD HOP, F-75634 PARIS 13, FRANCE.							Agid Y, 1987, MOVEMENT DISORD, V1, P166; ALONSO MA, 1986, CAN J NEUROL SCI, V13, P248, DOI 10.1017/S0317167100036362; Ben-Shachar D, 1990, J Neural Transm Suppl, V29, P251; BLIN J, IN PRESS J NEUROL NE; BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CEBALLOS I, 1990, LANCET, V335, P1035, DOI 10.1016/0140-6736(90)91099-V; DEGUEURCE AM, 1986, ACTA PHYSIOL SCAND, V126, P313, DOI 10.1111/j.1748-1716.1986.tb07821.x; DEXTER DT, 1990, J NEUROCHEM, V55, P16, DOI 10.1111/j.1471-4159.1990.tb08814.x; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; DUBOIS B, 1990, NEUROLOGY, V40, P38, DOI 10.1212/WNL.40.1.38; DUVOISIN RC, 1986, ANN NEUROL, V19, P409, DOI 10.1002/ana.410190422; ELIZAN TS, 1987, VIRUSES IMMUNITY MEN, P47; GIBB WRG, 1990, ADV NEUROL, V53, P31; GIBB WRG, 1988, NEUROLOGY, V38, P1402, DOI 10.1212/WNL.38.9.1402; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HIRSCH EC, 1991, J NEUROCHEM, V56, P446, DOI 10.1111/j.1471-4159.1991.tb08170.x; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JAVOYAGID F, 1990, NEUROSCIENCE, V38, P245, DOI 10.1016/0306-4522(90)90389-L; JELLINGER K, 1990, ADV NEUROL, V53, P1; JOHNSON WG, 1990, MOVEMENT DISORD, V5, P187, DOI 10.1002/mds.870050302; Koller W.C., 1986, ADV NEUROL, V45, P317; KONRADI C, 1989, NEUROSCIENCE, V33, P383, DOI 10.1016/0306-4522(89)90218-2; LANGSTON JW, 1989, MOVEMENT DISORD, V4, pS15, DOI 10.1002/mds.870040504; MANN DMA, 1983, MECH AGEING DEV, V21, P193, DOI 10.1016/0047-6374(83)90074-X; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MARTTILA RJ, 1988, J NEUROL SCI, V86, P321, DOI 10.1016/0022-510X(88)90108-6; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; RIEDERER P, 1976, J NEURAL TRANSM, V38, P277, DOI 10.1007/BF01249445; ROBBINS JH, 1985, J NEUROL NEUROSUR PS, V48, P916, DOI 10.1136/jnnp.48.9.916; SAGGU H, 1989, J NEUROCHEM, V53, P692, DOI 10.1111/j.1471-4159.1989.tb11759.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHAPIRA AHV, 1990, MOVEMENT DISORD, V5, P294, DOI 10.1002/mds.870050406; SCHERMAN D, 1989, ANN NEUROL, V26, P551, DOI 10.1002/ana.410260409; TANNER CM, 1989, TRENDS NEUROSCI, V12, P49, DOI 10.1016/0166-2236(89)90135-5; WARING RH, 1989, LANCET, V2, P356	44	396	411	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1991	337	8753					1321	1324		10.1016/0140-6736(91)92989-F	http://dx.doi.org/10.1016/0140-6736(91)92989-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674304				2022-12-28	WOS:A1991FP08400012
J	FOSTER, A				FOSTER, A			WHO WILL OPERATE ON AFRICA 3-MILLION CURABLY BLIND PEOPLE	LANCET			English	Article								About half the 6 million blind people in sub-Saharan Africa have surgically curable cataract. The available manpower and resources can only provide services for less than 10% of the new blind cataract patients each year, and little is being done for the estimated 3 million "cataract backlog". A serious limiting factor to the development of prevention of blindness programmes is lack of trained manpower. Despite an increase in the number of ophthalmologists trained in cataract surgery (which varies greatly from country to country), this number is not keeping pace with increased demand for eye-care services, especially in large rural populations. Initiatives that will help to overcome this dilemma are specific post-graduate courses in community ophthalmology in Africa, plans to develop a one-year diploma in ophthalmology course for English-speaking West African countries, and a proposal to upgrade a similar course in Zimbabwe. Additionally there is a need for the training of more ophthalmic assistants, cataract surgeons, and nurses in the diagnosis and management of common ophthalmic disorders. Experienced expatriate ophthalmologists also have an important role in the teaching of doctors and ophthalmic assistants how to select patients and carry out successful inexpensive cataract surgery with appropriate technology and limited facilities.			FOSTER, A (corresponding author), INT CTR EYE HLTH,27-29 CAYTON ST,LONDON EC1V 9EJ,ENGLAND.			Foster, Allen/0000-0003-2368-4436				FOSTER A, 1991, CLIN OPHTHALMOLOGY, V5; 1990, OPHTHALMIC MANPOWER; 1988, OPHTHALMIC MANPOWER	3	52	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1267	1269		10.1016/0140-6736(91)92929-V	http://dx.doi.org/10.1016/0140-6736(91)92929-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674072				2022-12-28	WOS:A1991FN04700013
J	LAWSON, HW; BRAUN, MM; GLASS, RIM; STINE, SE; MONROE, SS; ATRASH, HK; LEE, LE; ENGLENDER, SJ				LAWSON, HW; BRAUN, MM; GLASS, RIM; STINE, SE; MONROE, SS; ATRASH, HK; LEE, LE; ENGLENDER, SJ			WATERBORNE OUTBREAK OF NORWALK VIRUS GASTROENTERITIS AT A SOUTHWEST UNITED-STATES RESORT - ROLE OF GEOLOGICAL FORMATIONS IN CONTAMINATION OF WELL WATER	LANCET			English	Article							NONBACTERIAL GASTROENTERITIS	From April 17 to May 1, 1989, gastroenteritis developed in about 900 people during a visit to a new resort in Arizona, USA. Of 240 guests surveyed, 110 had a gastrointestinal illness that was significantly associated with the drinking of tap water from the resort's well (relative risk = 16.1, 95% confidence interval 14.5 to 17.8) and this risk increased significantly with the number of glasses of water consumed (p < 0.005). Three of seven paired sera tested for antibodies to the Norwalk agent had a four-fold or greater rise in titre. Water contaminated with faecal coliforms was traced back to the deep water well, which remained contaminated even after prolonged pumping. Effluent from the resort's sewage treatment facility seeped through fractures in the subsurface rock (with little filtration) directly into the resort's deep well. Although the latest technology was used to design the resort's water and sewage treatment plants, the region's unique geological conditions posed unexpected problems that may trouble developers faced with similar subsurface geological formations and arid climatic conditions in many parts of the world. In these areas, novel solutions are needed to provide adequate facilities for the treatment of sewage and supply of pure drinking water.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA 30333; ARIZONA DEPT HLTH SERV,PHOENIX,AZ 85007; CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Arizona Department of Health Services; Centers for Disease Control & Prevention - USA				Monroe, Stephan/0000-0002-5424-716X				CRAUN GF, 1988, J AM WATER WORKS ASS, V80, P40; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; Gerba C., 1984, GROUNDWATER POLLUTIO, P65; GERBA CP, 1979, AM J PUBLIC HEALTH, V69, P1116, DOI 10.2105/AJPH.69.11.1116; GLASS RI, 1988, VIRUSES GUT, P87; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; 1990, MMWR, V39, P1	13	79	81	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1200	1204						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673747				2022-12-28	WOS:A1991FM26100012
J	AKHRAS, F; JACKSON, G				AKHRAS, F; JACKSON, G			RAISED EXERCISE DIASTOLIC BLOOD-PRESSURE AS INDICATOR OF ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; 2-DIMENSIONAL ECHOCARDIOGRAPHY	91 (16.8%) of 541 consecutive patients investigated for chest pain or after recent uncomplicated myocardial infarction had a rise in diastolic blood pressure (DBP) of more than 15 mm Hg during a symptom-limited treadmill test. 63 also had electrocardiographic evidence of ischaemia, but 28 did not have 1 mm ST segment depression, of whom 24 had angiographic evidence of more than 70% stenosis of two or more major coronary arteries. 55 of these 91 patients underwent coronary artery bypass surgery; repeat angiography in 22 at 12 months showed an improved left ventricular ejection fraction in 18 who had a normal postoperative DBP response, but no change in ejection fraction in the 4 who still had an abnormal rise in DBP on exercise. Exercise-induced ischaemia may cause a reversible fall in cardiac output that sometimes leads to reflex vasoconstriction and a rise in DBP before a fall in systolic blood pressure or ECG evidence of ST segment depression. An abnormal DBP response to exercise may identify some patients at high risk of myocardial infarction who might otherwise have false-negative exercise tests.	GUYS HOSP,DEPT CARDIOL,LONDON SE1 9RT,ENGLAND; LEWISHAM HOSP,DEPT CARDIOL,LONDON SE13 6LH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust								AKHRAS F, 1985, BRIT HEART J, V53, P598; AKHRAS F, 1988, J AM COLL CARDIOL, V11, P102; BOUCHARD RJ, 1971, CIRCULATION, V44, P1072, DOI 10.1161/01.CIR.44.6.1072; BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9; ELLESTAD MH, 1986, STRESS TESTING PRINC, P86; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SHEPS DS, 1979, AM J CARDIOL, V43, P708, DOI 10.1016/0002-9149(79)90067-5; WEINER DA, 1982, AM J CARDIOL, V49, P1627, DOI 10.1016/0002-9149(82)90238-7; WOLTHUIS RA, 1977, CIRCULATION, V55, P153, DOI 10.1161/01.CIR.55.1.153	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					899	900		10.1016/0140-6736(91)90216-C	http://dx.doi.org/10.1016/0140-6736(91)90216-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672979				2022-12-28	WOS:A1991FG04800014
J	PAIN, B; WOODS, CM; SAEZ, J; FLICKINGER, T; RAINES, M; PEYROL, S; MOSCOVICI, C; MOSCOVICI, MG; KUNG, HJ; JURDIC, P; LAZARIDES, E; SAMARUT, J				PAIN, B; WOODS, CM; SAEZ, J; FLICKINGER, T; RAINES, M; PEYROL, S; MOSCOVICI, C; MOSCOVICI, MG; KUNG, HJ; JURDIC, P; LAZARIDES, E; SAMARUT, J			EGF-R AS A HEMATOPOIETIC GROWTH-FACTOR RECEPTOR - THE C-ERBB PRODUCT IS PRESENT IN CHICKEN ERYTHROCYTIC PROGENITORS AND CONTROLS THEIR SELF-RENEWAL	CELL			English	Article							THYROID-HORMONE RECEPTOR; AVIAN-LEUKOSIS VIRUS; TARGET-CELLS; ERYTHROBLASTOSIS; EXPRESSION; ACTIVATION; ONCOGENE; PROTEIN; INVITRO; DIFFERENTIATION	c-erbB, encoding the EGF receptor (EGF-R), was originally identified as the cellular homolog of a chicken leukemia oncogene. In humans, EGF-R is distributed widely except in hemopoietic tissues, and its amplification is associated with epidermal and glial malignancies. Here we show that c-erbB is present in normal chicken erythrocytic progenitors and transmits the mitogenic signal induced by TGF-alpha. Cells that contain high affinity EGF-R are at approximately the BFU-E stage, and their long-term renewal can be induced by TGF-alpha. Upon addition of insulin and erythropoietin, they can be induced to terminally differentiate into red cells. We previously demonstrated that v-erbA blocks differentiation of chicken erythrocytic progenitors but does not abrogate their growth factor dependence for proliferation. These data indicate that proliferation and differentiation are not necessarily coupled in these cells. They also demonstrate a direct role of c-erbB in the control of self-renewal of normal chicken erythrocytic progenitors and could account for the predominant leukemogenic potential of the chicken erbB gene.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; HOP DEBROUSSE, INSERM, F-69005 Lyon, FRANCE; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA; PASTEUR INST, Lyon, FRANCE; VET ADM MED CTR, TUMOR VIROL LAB, GAINESVILLE, FL 32601 USA	California Institute of Technology; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PAIN, B (corresponding author), ECOLE NORMALE SUPER LYON, INRA, CNRS, BIOL MOLEC & CELLULAIRE LAB, 46 ALLEE ITALIE, F-69364 Lyon 07, FRANCE.		Kung, Hsing-Jien/C-7651-2013; Samarut, Jacques/AAD-2587-2019; Pain, Bertrand/A-7686-2015	Pain, Bertrand/0000-0002-1210-8444	NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NCI NIH HHS [CA39207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN TD, 1990, COLONY STIMULATING F, P1; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BERNIER M, 1986, ENDOCRINOLOGY, V118, P2254, DOI 10.1210/endo-118-6-2254; BEUG H, 1982, J CELL PHYSIOL, P195; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GLINEUR C, 1989, ONCOGENE, V4, P1247; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; ISCOVE N, 1990, NATURE, V347, P126, DOI 10.1038/347126a0; KAZIMIERCZAK J, 1986, CELL TISSUE RES, V245, P487; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MAIHLE NJ, 1991, IN PRESS P NATL ACAD; MILLER M, 1990, ONCOGENE, V5, P1125; MURA CV, 1981, J BIOL CHEM, V256, P9767; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NILSEN TW, 1985, JCELL, V41, P7149; PAIN B, 1990, New Biologist, V2, P284; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SAMARUT J, 1908, J CELL PHYSL, V105, P553; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	40	93	96	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					37	46		10.1016/0092-8674(91)90405-N	http://dx.doi.org/10.1016/0092-8674(91)90405-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1672832	Bronze			2022-12-28	WOS:A1991FF77300006
J	WILKINSON, SM; CARTWRIGHT, PH; ENGLISH, JSC				WILKINSON, SM; CARTWRIGHT, PH; ENGLISH, JSC			HYDROCORTISONE - AN IMPORTANT CUTANEOUS ALLERGEN	LANCET			English	Note							CONTACT-DERMATITIS	We have found a high incidence (4.8%) of allergy to hydrocortisone in patients with suspected allergic contact dermatitis. In view of this finding we would suggest that, in any condition that does not improve or that deteriorates after administration of hydrocortisone, allergy to this compound should be considered.			WILKINSON, SM (corresponding author), N STAFFORDSHIRE HOSP,CENT OUTPATIENTS DEPT,DEPT DERMATOL,STOKE ON TRENT ST4 7PA,ENGLAND.			Wilkinson, Stephen Mark/0000-0001-7253-3461				ALANI MD, 1972, ANN ALLERGY, V30, P181; CHURCH R, 1960, BRIT J DERMATOL, V72, P341, DOI 10.1111/j.1365-2133.1960.tb13814.x; COMAISH S, 1969, BRIT J DERMATOL, V81, P919, DOI 10.1111/j.1365-2133.1969.tb15974.x; DOOMSGOOSSENS A, 1986, CONTACT DERMATITIS, V14, P94, DOI 10.1111/j.1600-0536.1986.tb01168.x; ENGLISH JSC, 1990, CONTACT DERMATITIS, V23, P196, DOI 10.1111/j.1600-0536.1990.tb04789.x; KING RA, 1960, LANCET, V2, P1093; LAUERMA AI, 1990, BRIT J DERMATOL, V123, P699, DOI 10.1111/j.1365-2133.1990.tb04186.x; PARAMSOTHY Y, 1988, CONTACT DERMATITIS, V18, P30, DOI 10.1111/j.1600-0536.1988.tb05486.x; WILKINSON M, 1990, CONTACT DERMATITIS, V23, P120, DOI 10.1111/j.1600-0536.1990.tb03240.x; 1989, CONTACT DERMATITIS, V20, P158	10	70	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					761	762		10.1016/0140-6736(91)91373-3	http://dx.doi.org/10.1016/0140-6736(91)91373-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672393				2022-12-28	WOS:A1991FD88400005
J	BOSANQUET, AG				BOSANQUET, AG			CORRELATIONS BETWEEN THERAPEUTIC RESPONSE OF LEUKEMIAS AND INVITRO DRUG-SENSITIVITY ASSAY	LANCET			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMATOLOGICAL MALIGNANCIES; TUMOR CHEMOSENSITIVITY; CYTO-TOXICITY	To develop the differential staining cytotoxicity (DiSC) assay, an in-vitro drug sensitivity test designed specifically for use with fresh human haematological tumour cells, into a predictive test for response to therapy as well as a tool for identifying new treatment strategies, test results have been correlated with response in patients with haematological malignancies. 22 of 119 tests indicated extreme drug resistance (tumour cell survival > 55%) in vitro. None of these patients responded to chemotherapy. The proportion of patients responding to therapy and 50% patient survival rose with in-vitro drug sensitivity. 11 specimens showing extreme drug resistance to the agents prescribed for the patient were subjected to drug sensitivity tests of drugs not prescribed; patients showing some sensitivity to these drugs had better survival than did those with extreme drug resistance to all drugs tested. The DiSC assay can also be used to identify new agents worth testing in clinical trials, and cross resistance profiles of new agents may indicate what combinations might be useful.			BOSANQUET, AG (corresponding author), ROYAL UNITED HOSP,WOLFSON CTR,BATH CANC RES UNIT,BATH BA1 3NG,ENGLAND.							BIRD MC, 1986, BRIT J CANCER, V53, P539, DOI 10.1038/bjc.1986.84; BIRD MC, 1985, HEMATOL ONCOL, V3, P1, DOI 10.1002/hon.2900030102; BIRD MC, 1986, LEUKEMIA RES, V10, P445, DOI 10.1016/0145-2126(86)90075-5; BIRD MC, 1988, CANCER, V61, P1104, DOI 10.1002/1097-0142(19880315)61:6<1104::AID-CNCR2820610609>3.0.CO;2-6; BOSANQUET AG, 1983, BRIT J CANCER, V47, P781, DOI 10.1038/bjc.1983.131; CALVERT AH, 1988, LANCET, V2, P577; CHESON BD, 1989, AM J HEMATOL, V32, P72, DOI 10.1002/ajh.2830320115; EFFERTH T, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1771; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; KEATING MJ, 1988, NOUV REV FR HEMATOL, V30, P461; KERN DH, 1990, J NATL CANCER I, V82, P582, DOI 10.1093/jnci/82.7.582; SALMON SE, 1978, NEW ENGL J MED, V298, P1321, DOI 10.1056/NEJM197806152982401; SANFILIPPO O, 1989, EUR UROL, V16, P450; SHOEMAKER RH, 1986, CANCER TREAT REP, V70, P9; TIDEFELT U, 1989, EUR J HAEMATOL, V43, P374; VEERMAN AJP, 1990, BRIT J HAEMATOL, V74, P381, DOI 10.1111/j.1365-2141.1990.tb06323.x; VONHOFF DD, 1990, J NATL CANCER I, V82, P110, DOI 10.1093/jnci/82.2.110; WEISENTHAL LM, 1983, CANCER RES, V43, P258; WEISENTHAL LM, 1983, CANCER RES, V43, P749; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615; WEISENTHAL LM, 1989, ADV CLIN ONCOL, V1, P91	21	70	72	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					711	714		10.1016/0140-6736(91)90287-Y	http://dx.doi.org/10.1016/0140-6736(91)90287-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672185				2022-12-28	WOS:A1991FD36700017
J	NEWTON, CRJC; KIRKHAM, FJ; WINSTANLEY, PA; PASVOL, G; PESHU, N; WARRELL, DA; MARSH, K				NEWTON, CRJC; KIRKHAM, FJ; WINSTANLEY, PA; PASVOL, G; PESHU, N; WARRELL, DA; MARSH, K			INTRACRANIAL-PRESSURE IN AFRICAN CHILDREN WITH CEREBRAL MALARIA	LANCET			English	Article							EDEMA	Opening lumbar cerebrospinal fluid (CSF) pressure was measured with a paediatric spinal fluid manometer in 26 of 61 Kenyan children (mean age 39 months) with cerebral malaria. In all cases pressure was above normal (mean [SD] 22.6 [7.4] cm CSF, range 10.5-36). Clinical features of our patients suggest that intracranial hypertension is important in the pathogenesis of cerebral malaria in children, especially as a cause of death. We suggest that raised intracranial pressure is secondary to increased cerebral blood volume. Lowering intracranial pressure may significantly reduce the mortality and morbidity of cerebral malaria. The potential risks and benefits of lumbar puncture should be considered carefully in patients with suspected cerebral malaria.	INST CHILD HLTH, DEPT NEUROL, 30 GUILFORD ST, LONDON WC1N 2AP, ENGLAND; KENYA GOVT MED RES CTR, KILIFI COASTAL UNIT, KILIFI, KENYA; JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND	University of London; University College London; Kenya Medical Research Institute; University of Oxford			Kirkham, Fenella/C-2442-2009; Newton, Charles RJC/B-7578-2014; Newton, Charles/C-6222-2009; Pasvol, Geoffrey/B-7113-2009	Kirkham, Fenella/0000-0002-2443-7958; Newton, Charles RJC/0000-0002-6999-5507; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Commey J. O. O., 1980, Ghana Medical Journal, V19, P68; GOITEIN KJ, 1983, ARCH DIS CHILD, V58, P184, DOI 10.1136/adc.58.3.184; HASSLER W, 1988, J NEUROSURG, V68, P745; JENSEN MD, 1983, J PARASITOL, V69, P1060, DOI 10.2307/3280864; KINGSTON ME, 1971, J TROP MED HYG, V74, P249; KIRKHAM FJ, 1987, J NEUROL NEUROSUR PS, V50, P1504, DOI 10.1136/jnnp.50.11.1504; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LOOAREESUWAN S, 1983, LANCET, V1, P434; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; Miller J D, 1972, Prog Brain Res, V35, P411; MINNS RA, 1989, ARCH DIS CHILD, V64, P814, DOI 10.1136/adc.64.6.814; MOLYNEUX ME, 1989, Q J MED, V71, P441; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SCHMUTZHARD E, 1984, T ROY SOC TROP MED H, V78, P351, DOI 10.1016/0035-9203(84)90118-4; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; THAPA B R, 1988, Indian Pediatrics, V25, P61; THOMAS JD, 1971, TROP GEOGR MED, V23, P232; WARRELL DA, 1988, LANCET, V2, P534; WARRELL DA, 1986, AM J TROP MED HYG, V35, P882, DOI 10.4269/ajtmh.1986.35.882; [No title captured]	23	169	171	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1991	337	8741					573	576		10.1016/0140-6736(91)91638-B	http://dx.doi.org/10.1016/0140-6736(91)91638-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671941				2022-12-28	WOS:A1991FA70200002
J	ECCLES, M; BRADSHAW, C				ECCLES, M; BRADSHAW, C			USE OF SECONDARY PROPHYLAXIS AGAINST MYOCARDIAL-INFARCTION IN THE NORTH OF ENGLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To record the use of secondary prophylactic drugs in patients discharged from hospital having had a myocardial infarction. Design - Prospective postal questionnaire survey of a random one in two sample of general practitioners in the region. Setting - The nine family practitioner committee areas within the Northern Regional Health Authority. Patients - Patients who had had a myocardial infarction and were discharged to their general practitioner. Main outcome measure - Whether beta-blockers or aspirin, or both, were given on discharge. Results - Of 267 patients, 158 (59%) were treated suboptimally in that they did not receive a secondary prophylactic drug to which they had no contraindication. For most patients this entailed underuse of one drug, but 17 (6%) of patients received no treatment. beta-blockers were 2.5 times less likely to be used than aspirin. Treatment was not associated with the age or sex of the patient, risk of further infarction, or hospital of discharge. Conclusions - Secondary prophylaxis after myocardial infarction is practised haphazardly. It should be offered to all patients who can tolerate it, after a trial period to assess any side effects of the drugs if necessary.	UNIV NEWCASTLE UPON TYNE, CTR HLTH SERV RES, NEWCASTLE UPON TYNE NE2 4AA, ENGLAND; MARSDEN RD HLTH CTR, S SHIELDS NE34 6RE, TYNE & WEAR, ENGLAND	Newcastle University - UK; Royal Marsden NHS Foundation Trust			Eccles, Martin P/AAD-4029-2020					[Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; BLOOMFIELD P, 1987, BMJ-BRIT MED J, V3295, P1431; FRY J, 1979, COMMN DISEASES THEIR; HAMPTON JR, 1982, BRIT MED J, V285, P33, DOI 10.1136/bmj.285.6334.33; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; JULIAN DG, 1988, BMJ-BRIT MED J, V297, P497, DOI 10.1136/bmj.297.6647.497; KAPLAN NM, 1987, ARCH INTERN MED, V147, P1160, DOI 10.1001/archinte.147.6.1160; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; ORME M, 1988, BRIT MED J, V296, P307, DOI 10.1136/bmj.296.6618.307; 1986, MORBIDITY STATISTICS; 1987, DRUG THER B, V25, P17; 1990, BRIT NATIONAL FORMUL; 1990, DRUG THER B, V28, P47	14	53	53	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					91	92		10.1136/bmj.302.6768.91	http://dx.doi.org/10.1136/bmj.302.6768.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671652	Green Published, Bronze			2022-12-28	WOS:A1991ER95100022
J	ROBINSON, BA; JOHANSSON, L; SHAW, J				ROBINSON, BA; JOHANSSON, L; SHAW, J			ORAL NALOXONE IN OPIOID-ASSOCIATED CONSTIPATION	LANCET			English	Letter									UNIV OTAGO,SCH PHARM,DUNEDIN,NEW ZEALAND	University of Otago	ROBINSON, BA (corresponding author), CHRISTCHURCH HOSP,ONCOL SERV,CHRISTCHURCH,NEW ZEALAND.		robinson, bridget/K-7619-2019	Robinson, Bridget/0000-0001-9483-9146				Culpepper-Morgan J A, 1989, NIDA Res Monogr, V95, P399; SYKES, 1991, LANCET, V337, P1475	2	15	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					581	582		10.1016/0140-6736(91)91156-O	http://dx.doi.org/10.1016/0140-6736(91)91156-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678844				2022-12-28	WOS:A1991GD00200055
J	BRAHAMS, D				BRAHAMS, D			MEDICINE AND THE LAW - DRUG-COMPANY DATA AND THE PUBLIC-INTEREST	LANCET			English	Editorial Material																			0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					502	503		10.1016/0140-6736(91)90565-7	http://dx.doi.org/10.1016/0140-6736(91)90565-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678456				2022-12-28	WOS:A1991GC15300020
J	SANJOSE, S; ROMAN, E; BERAL, V				SANJOSE, S; ROMAN, E; BERAL, V			LOW-BIRTH-WEIGHT AND PRETERM DELIVERY, SCOTLAND, 1981-84 - EFFECT OF PARENTS OCCUPATION	LANCET			English	Article							GESTATIONAL-AGE; PREGNANCY; REPRODUCTION; PREMATURITY; WORK	The relation between prematurity and parenteral occupation was examined in a national study of 252 147 liveborn babies delivered in Scotland between 1981 and 1984. Information about mothers' and fathers' work was routinely collected at the first antenatal visit, and birthweight and gestational age were recorded at delivery. Preterm delivery (< 37 weeks' gestation) and low birthweight (< 2500 g) were more frequent in the children of mothers and of fathers employed in manual rather than in non-manual jobs. The risk of preterm delivery and/or low birthweight was more than 50% higher in the children of women who worked with electrical, metal, or leather goods than in the children of other female manual workers. These findings were not explained by maternal age, gravidity, marital status, previous perinatal death, baby's sex, or father's social class. For male manual workers, only the children of ceramic workers had an increased risk of prematurity. The risk of a baby being small-for-gestational age (less-than-or-equal-to 5th gestation-specific birthweight percentile) varied little with mother's or father's occupation. Overall, the results suggest that parental occupational exposures do not have a pronounced effect on the risk of prematurity, and when there are adverse effects they are associated with maternal rather than paternal exposures.	RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND; INT AGCY RES CANC,F-69372 LYONS,FRANCE	Radcliffe Infirmary; University of Oxford; World Health Organization; International Agency for Research on Cancer (IARC)				Roman, Eve/0000-0001-7603-3704				[Anonymous], 1980, CLASSIFICATION OCCUP; ARMSTRONG BG, 1989, BRIT J IND MED, V46, P196; AXELSON O, 1989, BRIT J IND MED, V46, P505; CLARKE M, 1985, BRIT MED J, V290, P1235, DOI 10.1136/bmj.290.6477.1235; COLE SK, 1980, PERINATAL AUDIT SURV, P39; FLETCHER AC, 1985, REPRODUCTIVE HAZARDS; LIPSCOMB JA, 1991, J OCCUP ENVIRON MED, V33, P597; MAMELLE N, 1984, AM J EPIDEMIOL, V119, P309, DOI 10.1093/oxfordjournals.aje.a113750; MCDONALD AD, 1988, BRIT J IND MED, V45, P56; McDowall M. E., 1985, STUDIES MED POPULATI; ROSENBERG MJ, 1987, J OCCUP ENVIRON MED, V29, P584; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SANJOSE S, 1989, THESIS LONDON U; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1201, DOI 10.1093/oxfordjournals.aje.a115241; 1987, BIRTHWEIGHT STATISTI; 1990, LANCET, V336, P1289	16	57	57	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					428	431		10.1016/0140-6736(91)91045-V	http://dx.doi.org/10.1016/0140-6736(91)91045-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB446	1678094				2022-12-28	WOS:A1991GB44600015
J	MORTENSEN, N; HUMPHREYS, MS				MORTENSEN, N; HUMPHREYS, MS			THE ANAL CONTINENCE PLUG - A DISPOSABLE DEVICE FOR PATIENTS WITH ANORECTAL INCONTINENCE	LANCET			English	Article							FECAL INCONTINENCE; REPAIR	Anorectal incontinence is most commonly found in the elderly, but colorectal surgeons now see an increasing number of younger patients with this condition. Although medical and surgical treatments are available, a proportion of patients remain refractory to therapy. We investigated the efficacy of three designs of anal continence plug. 8 women and 2 men (mean age, 52 years) who were incontinent to both liquid and solid stool tested each plug for three consecutive weeks. 1 patient withdrew from the study. The median weartime for the optimum plug design was 12 h, and there were no episodes of incontinence in 82% of the periods during which the plug was in place. Patients required a median of eleven plugs per week, and in 82% of cases insertion was as easy as with a suppository. Plugs may have a place in the management of patients with anorectal incontinence.			MORTENSEN, N (corresponding author), JOHN RADCLIFFE HOSP,DEPT SURG & GASTROENTEROL,OXFORD OX3 9DU,ENGLAND.							BROCKLEHURST JC, 1975, CLIN GASTROENTEROL, V4, P479; BROWNING GGP, 1983, BRIT J SURG, V70, P101, DOI 10.1002/bjs.1800700216; BURCHARTH F, 1986, LANCET, V2, P1062; MILLER R, 1988, BRIT J SURG, V75, P101, DOI 10.1002/bjs.1800750204; YOSHIOKA K, 1989, BRIT J SURG, V76, P1054, DOI 10.1002/bjs.1800761023	5	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					295	297		10.1016/0140-6736(91)90428-R	http://dx.doi.org/10.1016/0140-6736(91)90428-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677121				2022-12-28	WOS:A1991FZ56500014
J	BOLLAG, U; BOLLAGALBRECHT, E				BOLLAG, U; BOLLAGALBRECHT, E			RECOMMENDATIONS DERIVED FROM PRACTICE AUDIT FOR THE TREATMENT OF ACUTE OTITIS-MEDIA	LANCET			English	Article							DOUBLE-BLIND; CHILDREN; MANAGEMENT	There is much disagreement about diagnostic criteria and optimum treatment for acute otitis media (OM). From a practice audit of the management of OM, we went on to develop and test a protocol in which we defined criteria for the diagnosis and treatment of this disorder. In a two-year study of 168 children aged 0-16 years with acute OM (and confirmed in a second study of another 62 children during the following year), we found that the main feature of otitis media is intense pain in the ear and is accompanied in 90% of cases by upper respiratory tract infection (URTI) at presentation. Hearing loss is common and otorrhoea develops in about 10% of children. Antibiotics, which are prescribed by most physicians, are not needed in the first instance, but we recommend vigorous treatment with analgesics. Supportive measures are similar to those used for the management of URTI. Follow-up evaluation is essential to detect the few refractory cases that must be referred to the specialist.										ARMSTRONG D, 1990, RES METHODS GENERAL; BLUESTONE CD, 1983, PEDIATRIC OTOLARYNGO; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; BOLLAG U, 1990, CLIN PEDIATR, V29, P244, DOI 10.1177/000992289002900410; BOLLAG U, 1984, HELV PAEDIATR ACTA, V39, P341; BOLLAG U, 1986, SPECTRUM, V27, P52; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; Chalmers D, 1989, CLIN DEV MED, V108, P1; FLEMING DM, 1989, INFLUENZA INFLUENZA, P213; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; FROOM J, 1982, J FAM PRACTICE, V15, P743; FRY J, 1961, CATARRHAL CHILD; HAYDEN GF, 1981, CLIN PEDIATR, V20, P99, DOI 10.1177/000992288102000203; KETTLETY A, 1907, BR J AUDIO, V21, P73; LOWE JF, 1963, LANCET, V2, P1129; PUKANDER J, 1983, ACTA OTO-LARYNGOL, V95, P117, DOI 10.3109/00016488309130924; SCHWARTZ DM, 1980, ANN OTOL RHINOL S68, V68, P211; SCHWARTZ RH, 1981, CLIN PEDIATR, V20, P549, DOI 10.1177/000992288102000901; SKINNER WM, 1978, OTOLARYNGOL CLIN N A, V11, P631; STOOL S, 1989, POSTGRAD MED, V85, P40; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	22	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					96	99		10.1016/0140-6736(91)90086-5	http://dx.doi.org/10.1016/0140-6736(91)90086-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676479				2022-12-28	WOS:A1991FW16100014
J	CASTRILLO, JL; THEILL, LE; KARIN, M				CASTRILLO, JL; THEILL, LE; KARIN, M			FUNCTION OF THE HOMEODOMAIN PROTEIN GHF1 IN PITUITARY CELL-PROLIFERATION	SCIENCE			English	Article							HORMONE-RELEASING FACTOR; GENE; MICE; OLIGODEOXYNUCLEOTIDE; SOMATOTROPHS; REPLICATION; EXPRESSION; INHIBITION; ELEMENTS; INVITRO	Mutations that cause pituitary dwarfism in the mouse reside in the gene encoding the transcription factor growth hormone factor 1 (GHF1 or pit1). These dwarf mice (dw and dw(J)) are deficient in growth hormone (GH) and prolactin (PRL) synthesis and exhibit pituitary hypoplasia, suggesting a stem cell defect. With antisense oligonucleotide technology, a cell culture model of this genetic defect was developed. Specific inhibition of GHF1 synthesis by complementary oligonucleotides led to a marked decrease in GH and PRL expression and to a marked decrease in proliferation of somatotrophic cell lines. These results provide direct evidence that the homeodomain protein GHF1 is required not only for the establishment and maintenance of the differentiated phenotype but for cell proliferation as well.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTKE A, 1964, ANAT RECORD, V149, P225, DOI 10.1002/ar.1091490206; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CASTRILLO JL, UNPUB; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; Francis Torben, 1944, ACTA PATH ET MICROBIOL SCAND, V21, P928; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIKAWA K, 1986, NEUROENDOCRINOLOGY, V43, P537, DOI 10.1159/000124579; Karin M, 1990, CURR OPIN CELL BIOL, V2, P996, DOI 10.1016/0955-0674(90)90148-8; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROUX M, 1982, CELL TISSUE RES, V223, P415, DOI 10.1007/BF01258498; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Snell GD, 1929, P NATL ACAD SCI USA, V15, P274, DOI 10.1073/pnas.15.3.274; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; WILSON DB, 1981, J ANAT, V133, P407; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	32	236	239	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					197	199		10.1126/science.1677216	http://dx.doi.org/10.1126/science.1677216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1677216				2022-12-28	WOS:A1991FW16000037
J	DOUGLAS, AS; ALSAYER, H; RAWLES, JM; ALLAN, TM				DOUGLAS, AS; ALSAYER, H; RAWLES, JM; ALLAN, TM			SEASONALITY OF DISEASE IN KUWAIT	LANCET			English	Article							MORTALITY	To compare the seasonal variation in total mortality and deaths from cardiovascular, respiratory, and malignant disease, data were collected from North-East Scotland (Grampian region) and Kuwait. Seasonal differences were similar, in both timing and degree, for total mortality and deaths from circulatory disease, but were greater in Kuwait for respiratory disease. Peak mortality was during winter in both areas: in Grampian, when the climate is most uncomfortable, and in Kuwait, when the climate is at its most comfortable. Socioeconomic changes in Kuwait have been accompanied by a rapid fall in the degree of seasonality (deseasonality) for both total and infant mortality. These findings suggest that mortality peaks in winter, not because of a seasonally low temperature, but because of a seasonal fall in mean temperature irrespective of the annual mean temperature.	KUWAIT UNIV,FAC MED,KUWAIT,KUWAIT; UNIV ABERDEEN,SCH MED,WELLCOME LIB,ABERDEEN AB9 1FX,SCOTLAND	Kuwait University; University of Aberdeen	DOUGLAS, AS (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,POLWARTH BLDG,ABERDEEN AB9 2ZB,SCOTLAND.							ALKULAIB AA, WEATHER CLIMATE KUWA, P68; ALLAN TM, 1966, BRIT MED J, V1, P673, DOI 10.1136/bmj.1.5488.673-b; ANDERSON TW, 1970, LANCET, V1, P291; ARORA RC, 1984, BIOL PSYCHIAT, V19, P795; Aschoff J., 1981, HDB BEHAVIORAL NEURO, V4, P475; CHOI K, 1981, AM J EPIDEMIOL, V113, P215, DOI 10.1093/oxfordjournals.aje.a113090; DOUGLAS AS, 1990, AUST NZ J MED, V20, P669, DOI 10.1111/j.1445-5994.1990.tb00397.x; DOUGLAS AS, IN PRESS SCOT MED J; IZZO JL, 1990, AM J HYPERTENS, V3, P405, DOI 10.1093/ajh/3.5.405; JENKINSGM, 1968, SPECTRAL ANAL ITS AP; MCLAREN M, 1990, FIBRINOLYSIS, V4, P116, DOI 10.1016/0268-9499(90)90382-T; PASAMANICK B, 1960, MILBANK FUND Q, V38, P248, DOI 10.2307/3348689; QUETELET MA, 1842, TREATISE MAN DEV HIS, P34; Riggs H. E., 1944, GASTROENTEROL, V3, P480; ROGOT E, 1976, AM J EPIDEMIOL, V103, P565, DOI 10.1093/oxfordjournals.aje.a112261; SAKAMOTOMOMIYAM.M, 1977, SEASONALITY HUMAN MO; Sothern R., 1972, PHYSIOL TEACH, V1, P1; WIRZJUSTICE A, 1977, CHRONOBIOLOGIA, V4, P165; 1979, UN DEMOGRAPHIC YB 19; 1987, UN DEMOGRAPHIC YB 19; 1958, MO617C 3, P109; 1982, TABLES TEMPERATURE 3, P165; 1990, NAUTICAL ALMANAC YEA; 1975, UN DEMOGRAPHIC YB 19	24	81	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1393	1397		10.1016/0140-6736(91)93069-L	http://dx.doi.org/10.1016/0140-6736(91)93069-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674772				2022-12-28	WOS:A1991FP87000012
J	WAKEFIELD, AE; GUIVER, L; MILLER, RF; HOPKIN, JM				WAKEFIELD, AE; GUIVER, L; MILLER, RF; HOPKIN, JM			DNA AMPLIFICATION ON INDUCED SPUTUM SAMPLES FOR DIAGNOSIS OF PNEUMOCYSTIS-CARINII PNEUMONIA	LANCET			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; TRANS-BRONCHIAL BIOPSY; BRONCHOALVEOLAR LAVAGE	DNA amplification and silver staining were used to identify Pneumocystis carinii in bronchoscopic lavage and induced sputum samples during 51 episodes of respiratory illness in 47 subjects with HIV infection. In 20 episodes, in which the clinical diagnosis was pneumocystis pneumonia (PCP), silver stain was positive in 14 lavage samples (70%) and 7 sputum samples (35%), whereas DNA amplification was positive in 19 lavage samples (95%) and 18 sputum samples (90%). DNA amplification was positive in only 1 of 31 patients without PCP (PCP developed in this patient within 1 0 weeks). DNA amplification on induced sputum offers a powerful technique for diagnosis of PCP.	MIDDLESEX HOSP,UNIV COLL & MIDDLESEX SCH MED,DEPT MED,LONDON W1,ENGLAND; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of London; University College London; University of Oxford	WAKEFIELD, AE (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,DEPT PAEDIAT,MOLEC INFECT DIS GRP,OXFORD OX3 9DU,ENGLAND.			Miller, Robert/0000-0003-2067-4291	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; BROADDUS C, 1985, ANN INTERN MED, V102, P747, DOI 10.7326/0003-4819-102-6-747; GRIFFITHS MH, 1989, THORAX, V44, P554, DOI 10.1136/thx.44.7.554; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; MILLER RF, 1989, THORAX, V44, P559, DOI 10.1136/thx.44.7.559; PITCHENIK AE, 1986, AM REV RESPIR DIS, V133, P226; WAKEFIELD AE, 1990, MOL BIOCHEM PARASIT, V43, P69, DOI 10.1016/0166-6851(90)90131-5; WAKEFIELD AE, 1990, LANCET, V336, P451, DOI 10.1016/0140-6736(90)92008-6	8	152	159	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1378	1379		10.1016/0140-6736(91)93062-E	http://dx.doi.org/10.1016/0140-6736(91)93062-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674765				2022-12-28	WOS:A1991FP87000005
J	BRAHAMS, D				BRAHAMS, D			ABORTION FOR 12-YEAR-OLD AGAINST MOTHERS WISHES	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1337	1338		10.1016/0140-6736(91)92999-I	http://dx.doi.org/10.1016/0140-6736(91)92999-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP084	1674308				2022-12-28	WOS:A1991FP08400017
J	DAHLITZ, M; ALVAREZ, B; VIGNAU, J; ENGLISH, J; ARENDT, J; PARKES, JD				DAHLITZ, M; ALVAREZ, B; VIGNAU, J; ENGLISH, J; ARENDT, J; PARKES, JD			DELAYED SLEEP PHASE SYNDROME RESPONSE TO MELATONIN	LANCET			English	Article							WAKE CYCLE; BLIND MAN; DISORDER; RHYTHM	The actions of melatonin on the sleep-wake cycle were investigated by means of a randomised, double-blind, placebo-controlled trial in 8 subjects with a delayed sleep phase syndrome attending a sleep disorders clinic. In randomised order the subjects received placebo or melatonin 5 mg daily for 4 weeks with a 1 week washout period between the treatments. Drug or placebo was given at 2200 h, 5 h before the mean time of sleep onset determined by pretrial sleep logs. In all 8 subjects sleep onset time (mean advance 82[range 19-124] min; p < 0.01) and wake time (117 [10-187] min; p < 0.01) were significantly earlier during melatonin treatment than during placebo. Mean total sleep time was slightly less on melatonin (8 h 12 min) than on placebo (8 h 46 min). Alertness acrophase calculated from the subjects' ratings of alertness made every 2 h while awake wasunaltered. Melatonin may act as a phase-setter for sleep-wake cycles in subjects with a delayed sleep phase syndrome.	UNIV LONDON,INST PSYCHIAT,DEPT NEUROL,DE CRESPIGNY PK,DENMARK HILL,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT NEUROL,LONDON WC2R 2LS,ENGLAND; UNIV SURREY,SCH BIOL SCI,GUILDFORD GU2 5XH,SURREY,ENGLAND; UNIV LILLE,DEPT PSYCHIAT,LILLE,FRANCE	University of London; University of London; King's College London; University of Surrey; Universite de Lille - ISITE; Universite de Lille								ALDHOUS ME, 1990, SEP P EUR PIN STUDY, P107; ANTONTAY F, 1971, LIFE SCI, V10, P841, DOI 10.1016/0024-3205(71)90155-X; ARENDT J, 1986, BRIT MED J, V292, P1170, DOI 10.1136/bmj.292.6529.1170; ARENDT J, 1984, NEUROSCI LETT, V45, P317, DOI 10.1016/0304-3940(84)90245-3; ARENDT J, 1988, LANCET, V1, P772; ARMSTRONG SM, 1986, J NEURAL TRANSM-SUPP, V21, P375; BOJKOWSKI CJ, 1990, CLIN ENDOCRINOL, V33, P435, DOI 10.1111/j.1365-2265.1990.tb03882.x; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; FOLKARD S, 1990, NEUROSCI LETT, V113, P193, DOI 10.1016/0304-3940(90)90302-P; FOLKARD S, 1985, NATURE, V313, P678, DOI 10.1038/313678a0; KRAUSE DN, 1990, TRENDS NEUROSCI, V13, P464, DOI 10.1016/0166-2236(90)90100-O; LERNER AB, 1978, J NEURAL TRANSM-SUPP, V13, P339; NICHOLSON AN, 1979, SLEEP RES, P109; OKAWA M, 1987, SLEEP, V10, P101, DOI 10.1093/sleep/10.2.101; RECHSCHAFFEN A, 1968, NINDB NIH204 PUBL; SACK RL, 1988, SLEEP RES, V17, P396; THORPY MJ, 1988, J ADOLESCENT HEALTH, V9, P22, DOI 10.1016/0197-0070(88)90014-9; Volirath L., 1981, ADV BIOSCI, V29, P327; WALDHAUSER F, 1990, PSYCHOPHARMACOLOGY, V200, P333; WEITZMAN ED, 1981, ARCH GEN PSYCHIAT, V38, P737	20	327	331	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1121	1124		10.1016/0140-6736(91)92787-3	http://dx.doi.org/10.1016/0140-6736(91)92787-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674014				2022-12-28	WOS:A1991FL12400004
J	EVERALL, IP; LUTHERT, PJ; LANTOS, PL				EVERALL, IP; LUTHERT, PJ; LANTOS, PL			NEURONAL LOSS IN THE FRONTAL-CORTEX IN HIV-INFECTION	LANCET			English	Article							IMMUNE-DEFICIENCY SYNDROME; ARBITRARY PARTICLES; AIDS; VIRUS; NUMBER; NEUROPATHOLOGY; ENCEPHALOPATHY; PATHOLOGY; PROTEIN; BRAINS	In an attempt to elucidate the cause and mechanism of the dementia and other neurological disorders that can occur in HIV-1 infection, we have quantitatively assessed neuronal populations, by means of a stereological technique (the disector), in the frontal cortex of patients with HIV infection. Eleven of sixty-five brains in the Medical Research Council Central AIDS Brain Bank were selected for study. The selected patients died without opportunistic infection or neoplasm affecting the brain; they had HIV encephalitis or minimal changes. We compared their neuronal counts with those of eight control subjects (seven died of systemic illness, one of pontine haemorrhage which did not affect the cerebral hemispheres). The neuronal numerical density was significantly lower in the HIV group than in the control group (mean [SD] 307 [46] vs 499 [113] x 10(2) per mm3; p < 0.001). This difference represents a loss of about 38%. There was no significant difference between the HIV subgroups, which suggests that neuronal loss occurs in cases of minor pathology as well as in HIV encephalitis. This finding contributes to the understanding of dementia in AIDS patients and has important implications for their future treatment.			EVERALL, IP (corresponding author), INST PSYCHIAT,DEPT NEUROPATHOL,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.			Luthert, Philip/0000-0001-7276-6898				BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BUDKA H, 1989, ACTA NEUROPATHOL, V77, P225, DOI 10.1007/BF00687573; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CIARDI A, 1990, ACTA NEUROPATHOL, V81, P51, DOI 10.1007/BF00662637; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN LG, 1985, AIDS RES, V1, P447; EVERALL IP, 1991, IN PRESS NEUROPATHOL; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GUNDERSEN HJG, 1981, J MICROSC-OXFORD, V121, P65, DOI 10.1111/j.1365-2818.1981.tb01199.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LANG W, 1989, ACTA NEUROPATHOL, V77, P379, DOI 10.1007/BF00687372; MARIO M, 1990, AIDS, V4, P831; Michaels J, 1988, Immunodefic Rev, V1, P71; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; WILEY CA, IN PRESS ANN NEUROL	21	465	467	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1119	1121		10.1016/0140-6736(91)92786-2	http://dx.doi.org/10.1016/0140-6736(91)92786-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674013				2022-12-28	WOS:A1991FL12400003
J	BRESSAC, B; KEW, M; WANDS, J; OZTURK, M				BRESSAC, B; KEW, M; WANDS, J; OZTURK, M			SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA	NATURE			English	Article							HEPATITIS-B VIRUS; CELL-LINE; LIVER; DNA; ESTABLISHMENT	HEPATOCELLULAR carcinoma (HCC) is a prevalent cancer in sub-Saharan Africa and eastern Asia 1. Hepatitis B virus and aflatoxins are risk factors for HCC 2, but the molecular mechanism of human hepatocellular carcinogenesis is largely unknown 3. Abnormalities in the structure and expression of the tumour-suppressor gene p53 are frequent in HCC cell lines 4, and allelic losses from chromosome 17p have been found in HCCs from China 5 and Japan 6. Here we report on allelic deletions from chromosome 17p and mutations of the p53 gene found in 50% of primary HCCs from southern Africa. Four of five mutations detected were G --> T substitutions, with clustering at codon 249. This mutation specificity could reflect exposure to a specific carcinogen, one candidate being aflatoxin B1 (ref. 7), a food contaminant in Africa 8, which is both a mutagen that induces G to T substitution 9 and a liver-specific carcinogen 10.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,MGH E,149 13TH ST,BOSTON,MA 02129; UNIV WITWATERSRAND,PARKTOWN 2193,SOUTH AFRICA	Harvard University; Massachusetts General Hospital; University of Witwatersrand			OZTURK, MEHMET/AAS-7241-2021; Paillerets, Brigitte Bressac-de/D-8954-2018; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; 				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOSCH FX, 1989, LIVER CELL CARCINOMA, P3; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHIBA I, 1990, ONCOGENE, V5, P1603; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; FUJIMORI M, 1991, CANCER RES, V51, P89; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; MAKLIN D, 1990, SCIENCE, V250, P1233; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHARANI U, 1988, NUCLEIC ACIDS RES, V16, P7757, DOI 10.1093/nar/16.15.7757; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NEWBERNE PM, 1969, CANCER RES, V29, P236; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SLAGLE BL, 1991, CANCER RES, V51, P49; VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YANG SS, 1990, CANCER RES, V50, pS5658; YEH FS, 1989, CANCER RES, V49, P2506	29	1265	1304	0	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					429	431		10.1038/350429a0	http://dx.doi.org/10.1038/350429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1672732				2022-12-28	WOS:A1991FF04200052
J	BLOOM, BS				BLOOM, BS			CROSS-NATIONAL CHANGES IN THE EFFECTS OF PEPTIC-ULCER DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							ANTI-INFLAMMATORY DRUGS; HOSPITAL ADMISSIONS; RISING FREQUENCY; CONTROLLED TRIAL; ELDERLY PEOPLE; UNITED-KINGDOM; MORTALITY; PERFORATION; PREVENTION	Objective: To describe and to analyze the changing effects of peptic ulcer disease over time. Design: Variables relating to peptic ulcer disease from 1970-1986 were compared. The variables included rates of mortality, hospitalizations, operations, physician visits, and endoscopies, and the amount of disability-related loss of work and early retirement in six countries (Belgium, England and Wales, the Federal Republic of Germany, The Netherlands, Sweden, and the United States). Measurements: Nonparametric epidemiologic time-trend analysis. Main Results: The historic, slow, declining trend in mortality and hospitalization rates continued. The rate of operations for peptic ulcer disease exhibited a large, one-time reduction, then returned to a parallel declining trend, but at a lower level. The rate of physician visits declined by 50%. The greatest changes were found in the rate of endoscopy use and in disability-related loss of work and early retirement, where increasing trends were quickly followed by decreasing trends. The elderly, especially women, generally did not share many of these benefits. Conclusions: The effects of new interventions can be understood more fully by examining several variables in many countries over a long time. Contrary to expectations, the effects of the widespread use of histamine H-2 antagonists have been more indirect (affecting work loss and disability retirement more) than direct (affecting high-cost medical service use and mortality less).			BLOOM, BS (corresponding author), UNIV PENN, 2L, NURSE EDUC BLDG, PHILADELPHIA, PA 19104 USA.							Bloom B S, 1989, Int J Technol Assess Health Care, V5, P215; BLOOM BS, 1989, ARCH INTERN MED, V149, P1019, DOI 10.1001/archinte.149.5.1019; BLOOM BS, 1989, J CLIN GASTROENTEROL, V11, P615, DOI 10.1097/00004836-198912000-00003; BLOOM BS, 1990, J CLIN GASTROENTEROL, V12, P100, DOI 10.1097/00004836-199002000-00026; BROWN RC, 1976, BRIT MED J, V1, P35, DOI 10.1136/bmj.1.6000.35; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; COGGON D, 1981, LANCET, V1, P1302; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FINEBERG HV, 1981, LANCET, V1, P1305; GRAHAM DY, 1988, LANCET, V2, P1277; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; Illingworth CFW, 1944, BRIT MED J, V1944, P655; Illingworth CFW, 1944, BRIT MED J, V1944, P617; Jenning D, 1940, LANCET, V1, P395; Jennings D, 1940, LANCET, V1, P444; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; KURATA JH, 1986, AM J PUBLIC HEALTH, V76, P700, DOI 10.2105/AJPH.76.6.700; SUSSER M, 1967, J CHRON DIS, V20, P435, DOI 10.1016/0021-9681(67)90015-X; SUSSER M, 1982, J CHRON DIS, V35, P29, DOI 10.1016/0021-9681(82)90027-3; WALT R, 1986, LANCET, V1, P489	20	41	41	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					558	562		10.7326/0003-4819-114-7-558	http://dx.doi.org/10.7326/0003-4819-114-7-558			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1672061				2022-12-28	WOS:A1991FD66100006
J	NOHNO, T; NOJI, S; KOYAMA, E; OHYAMA, K; MYOKAI, F; KUROIWA, A; SAITO, T; TANIGUCHI, S				NOHNO, T; NOJI, S; KOYAMA, E; OHYAMA, K; MYOKAI, F; KUROIWA, A; SAITO, T; TANIGUCHI, S			INVOLVEMENT OF THE CHOX-4 CHICKEN HOMEOBOX GENES IN DETERMINATION OF ANTEROPOSTERIOR AXIAL POLARITY DURING LIMB DEVELOPMENT	CELL			English	Article							RETINOIC ACID RECEPTOR; EXPRESSION PATTERN; LOCAL APPLICATION; GROWTH-FACTORS; MOUSE; MURINE; TRANSCRIPTS; PROTEIN; FAMILY; IDENTIFICATION	We have isolated and identified four chicken homeobox genes in the upstream region of the Chox-4 complex. The Chox-4g and -4f genes, at the 5' extremity of the complex, were expressed locally in the vicinity of the zone of polarizing activity (ZPA) at early stages of limb development, substantiating the involvement of the genes in anteroposterior axis determination. To confirm their function, we implanted a bead containing retinoic acid, or the ZPA itself, in the anterior margin of the limb bud, leading to formation of mirror-image duplicated digits, and observed the resultant change in gene expression. Expression of the Chox-4g and -4f genes was induced in the new digit-forming region. Those results suggest that positional information assigned by a ZPA morphogen is imprinted on cellular memory by expression of the Chox-4 genes to maintain positional signaling along the anteroposterior axis in the limb field.	OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH DENT,DEPT BIOCHEM, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH DENT,DEPT PERIODONTOL & ENDODONTOL, OKAYAMA 700, JAPAN; TOHOKU UNIV, DEPT CELL BIOL,TB & CANC RES INST,AOBA KU, SENDAI, MIYAGI 980, JAPAN	Okayama University; Okayama University; Okayama University; Tohoku University	NOHNO, T (corresponding author), KAWASAKI MED SCH, DEPT PHARMACOL, 577 MATSUSHIMA, KURASHIKI, OKAYAMA 70101, JAPAN.		Nohno, Tsutomu/B-6923-2008	Nohno, Tsutomu/0000-0002-0351-5603; Kuroiwa, Atsushi/0000-0001-7710-4041				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; ALTABA AR, 1989, NATURE, V341, P33; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; DESCHAMPS J, 1987, DIFFERENTIATION, V35, P21, DOI 10.1111/j.1432-0436.1987.tb00147.x; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; EICHELE G, 1984, ANAL BIOCHEM, V142, P542, DOI 10.1016/0003-2697(84)90504-9; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NOJI S, 1989, FEBS LETT, V257, P93, DOI 10.1016/0014-5793(89)81794-6; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; NOJI S, 1990, CYTOCHEM, V23, P353; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RUBERTE E, 1990, DEVELOPMENT, V108, P213; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1990, NUCLEIC ACIDS RES, V18, P1739, DOI 10.1093/nar/18.7.1739; SAUNDERS JW, 1988, EPITHELIAL MESENCHYM, P78; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	46	225	235	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1197	1205		10.1016/0092-8674(91)90274-3	http://dx.doi.org/10.1016/0092-8674(91)90274-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1672266				2022-12-28	WOS:A1991FD55800017
J	VOLLBRECHT, E; VEIT, B; SINHA, N; HAKE, S				VOLLBRECHT, E; VEIT, B; SINHA, N; HAKE, S			THE DEVELOPMENTAL GENE KNOTTED-1 IS A MEMBER OF A MAIZE HOMEOBOX GENE FAMILY	NATURE			English	Article							DROSOPHILA; ANTENNAPEDIA; EXPRESSION; PROTEINS; HOMEODOMAIN; TRANSCRIPTS; SEQUENCES; REGION; LOCUS	THE Knotted-1 (Kn1) locus is defined by several dominant gain-of-function mutations that alter leaf development. Foci of cells along the lateral veins do not differentiate properly, but continue to divide, forming outpocketings or knots. The ligule, a fringe normally found at the junction of leaf blade and sheath, is often displaced and perpendicular to its normal position 1-3. The phenotype is manifested in all cell layers of the leaf blade, but is controlled by a subgroup of cells of the inner layer 4. Mutations result from the insertion of transposable elements 5 or a tandem duplication 6. We show that the Kn1 gene encodes a homeodomain-containing protein, the first identified in the plant kingdom. Sequence comparisons strongly suggest that Kn1 acts as a transcription factor. Here we use the Kn1 homeobox to isolate other expressed homeobox genes in maize. The Kn1 homeobox may permit the isolation of genes that, like animal and fungal counterparts 7, regulate cell fate determination.	USDA ARS,CTR PLANT GENE EXPRESS,800 BUCHANAN ST,ALBANY,CA 94710; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	United States Department of Agriculture (USDA); University of California System; University of California Berkeley				Sinha, Neelima/0000-0002-1494-7065; Vollbrecht, Erik/0000-0003-4919-1365				Bryan AA, 1941, J HERED, V32, P343, DOI 10.1093/oxfordjournals.jhered.a104959; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FREELING M, 1985, GENETICS, V111, P617; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GELINAS D, 1969, AM J BOT, V56, P671, DOI 10.2307/2440442; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; HAKE S, 1985, PLANT GENETICS, P61; HANLEY BA, 1988, NUCLEIC ACIDS RES, V16, P7159, DOI 10.1093/nar/16.14.7159; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LANGDALE JA, 1989, DEV BIOL, V133, P128, DOI 10.1016/0012-1606(89)90304-7; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SINHA N, 1990, DEV BIOL, V141, P203, DOI 10.1016/0012-1606(90)90115-Y; VEIT B, 1990, GENETICS, V125, P623; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	34	573	633	2	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					241	243		10.1038/350241a0	http://dx.doi.org/10.1038/350241a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1672445				2022-12-28	WOS:A1991FC77900061
J	EPSTEIN, WV; HENKE, CJ; YELIN, EH; KATZ, PP				EPSTEIN, WV; HENKE, CJ; YELIN, EH; KATZ, PP			EFFECT OF PARENTERALLY ADMINISTERED GOLD THERAPY ON THE COURSE OF ADULT RHEUMATOID-ARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; SODIUM THIOMALATE; HEALTH-STATUS; DISABILITY; MORTALITY; OUTCOMES; PLACEBO; DISEASE	Objective: To describe the course of rheumatoid arthritis over 5 years in adults and to evaluate the effect of parenterally administered gold salts on that course. Design: A prospective observational study of adults with rheumatoid arthritis. Data derived from annual interviews with patients from 1983 to 1988 and from physician surveys in 1983 and 1987. Setting: Rheumatology practices in the community. Patients: The study began in 1982 with 822 adults who had rheumatoid arthritis and were under the care of rheumatologists. Interventions: Those selected by rheumatologists in the management of their patients. Measurements: Information describing sociodemographic and clinical characteristics, course, and therapy was collected from patients and verified by physician reports. Functional status, measured by the Health Assessment Questionnaire, and the number of painful joints were used as outcome variables. Outcome variables were adjusted for age, sex, disease duration, baseline values of the outcome variable, and the use of four disease-remittive agents other than gold. Main Results: Multivariate repeated-measures analysis of variance showed no change in the course of rheumatoid arthritis over 5 years. The use of parenteral gold for at least 2 consecutive years at the start of the observation period produced, on average, no change in the course over 5 years in the two outcome variables. Conclusion: In our study of a community-based population of adults with rheumatoid arthritis who were under the care of community rheumatologists, we found that there was, on average, no statistically significant change in function or number of painful joints between 1983 and 1988. Patients receiving parenteral gold therapy for at least 2 consecutive years did not show a statistically significant difference in outcome when compared with those not receiving such therapy.	UNIV CALIF SAN FRANCISCO, ROSALIND RUSSELL ARTHRITIS CTR, SAN FRANCISCO, CA 94143 USA; KAISER PERMANENTE MED CTR, OAKLAND, CA USA	University of California System; University of California San Francisco; Kaiser Permanente					NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIA NIH HHS [K04AG00273] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000273] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P1093, DOI 10.1002/anr.1780320907; ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P844; [Anonymous], 1960, ANN RHEUM DIS, V19, P95; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BOMBARDIER C, 1985, J RHEUMATOL, V12, P403; BOMBARDIER C, 1982, J RHEUMATOL, V9, P798; BRADLEY LA, 1989, ARTHRITIS RHEUM, V32, P1611, DOI 10.1002/anr.1780321220; BYE B, 1982, SSA1311745 PUBL, P1; EPSTEIN WV, 1989, J RHEUMATOL, V16, P1291; GABRIEL SE, 1988, MEDICINE, V67, P58, DOI 10.1097/00005792-198801000-00004; GOLDMAN AE, 1983, AM J MED, V75, P79, DOI 10.1016/0002-9343(83)90479-5; GORDON DA, 1989, TXB RHEUMATOLOGY, P804; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; KUSHNER I, 1989, J RHEUMATOL, V16, P1; LOUIS TA, 1988, STAT MED, V7, P29, DOI 10.1002/sim.4780070108; MEENAN RF, 1988, AM J PUBLIC HEALTH, V78, P1484, DOI 10.2105/AJPH.78.11.1484; NEVITT MC, 1986, ANN INTERN MED, V105, P421, DOI 10.7326/0003-4819-105-3-421; OREGLIA A, 1986, ABRIDGED LIFE TABLES; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1986, J RHEUMATOL, V13, P841; RAGAN C, 1951, B NEW YORK ACAD MED, V27, P63; SHARP JT, 1982, ARTHRITIS RHEUM, V25, P540, DOI 10.1002/art.1780250508; SHERRER YS, 1987, J RHEUMATOL, V14, P705; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; WOLFE F, 1988, J RHEUMATOL, V15, P1480; WOLFE F, 1990, J RHEUMATOL, V17, P24; YELIN E, 1987, ARTHRITIS RHEUM, V30, P507, DOI 10.1002/art.1780300504; YELIN E, 1987, J RHEUMATOL, V14, P710; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1961, ANN RHEUM DIS, V20, P315	34	54	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					437	444		10.7326/0003-4819-114-6-437	http://dx.doi.org/10.7326/0003-4819-114-6-437			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1671630				2022-12-28	WOS:A1991FB64000001
J	DEAN, JD; JONES, CJH; HUTCHISON, SJ; PETERS, JR; HENDERSON, AH				DEAN, JD; JONES, CJH; HUTCHISON, SJ; PETERS, JR; HENDERSON, AH			HYPERINSULINEMIA AND MICROVASCULAR ANGINA (SYNDROME-X)	LANCET			English	Note								Glucose and insulin responses to a glucose load in 11 patients with angina attributed to microvascular coronary dysfunction were compared with those in 11 healthy subjects matched for age, sex, and body mass. Stimulated hyperinsulinaemia was demonstrated in the microvascular angina group. The findings suggest a role for increased concentrations of insulin in coronary microvascular dysfunction.	UNIV COLL CARDIFF,DEPT CARDIOL,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES; UNIV COLL CARDIFF,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; FACTOR SM, 1985, PROG CARDIOVASC DIS, V27, P395, DOI 10.1016/0033-0620(85)90002-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GELTMAN EM, 1990, J AM COLL CARDIOL, V16, P586, DOI 10.1016/0735-1097(90)90347-R; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; STALDER M, 1981, DIABETOLOGIA, V21, P544; 1987, LANCET, V2, P1247	10	120	123	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					456	457						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671472				2022-12-28	WOS:A1991EY88700005
J	TREASURE, T; RAPHAEL, MJ				TREASURE, T; RAPHAEL, MJ			INVESTIGATION OF SUSPECTED DISSECTION OF THE THORACIC AORTA	LANCET			English	Review							TRANSOESOPHAGEAL ECHOCARDIOGRAPHY; DIAGNOSIS; REPAIR		ROYAL BROMPTON & NATL HEART HOSP,DEPT IMAGING,LONDON SW3 6HP,ENGLAND	Imperial College London	TREASURE, T (corresponding author), ST GEORGE HOSP,DEPT CARDIOTHORAC SURG,BLACKSHAW RD,LONDON SW17 0QT,ENGLAND.							ARCINIEGAS JG, 1981, AM J CARDIOL, V47, P890, DOI 10.1016/0002-9149(81)90190-9; Daily P O, 1970, Ann Thorac Surg, V10, P237; DEBAKEY ME, 1965, J THORAC CARDIOV SUR, V49, P130, DOI 10.1016/S0022-5223(19)33323-9; DEMOS TC, 1989, SEMIN ROENTGENOL, V24, P22, DOI 10.1016/0037-198X(89)90051-5; EAGLE KA, 1986, AM J CARDIOL, V57, P322, DOI 10.1016/0002-9149(86)90912-4; EARNEST F, 1979, MAYO CLIN PROC, V54, P43; ERBEL R, 1989, LANCET, V1, P457; ERBEL R, 1987, BRIT HEART J, V58, P45; JAGANNATH AS, 1986, AM J ROENTGENOL, V147, P1123, DOI 10.2214/ajr.147.6.1123; KERN MJ, 1990, AM HEART J, V119, P143, DOI 10.1016/S0002-8703(05)80094-8; KERSTINGSOMMERHOFF BA, 1988, RADIOLOGY, V166, P651, DOI 10.1148/radiology.166.3.3340758; LYONS J, 1988, BRIT HEART J, V59, P239; MATSUDA H, 1989, CIRCULATION, V80, P243; MILLER DC, 1979, J THORAC CARDIOV SUR, V78, P365; MORGAN JM, 1990, BRIT HEART J, V64, P261; MURDAY AJ, 1987, BRIT HEART J, V57, P548; SHUFORD WH, 1969, NEW ENGL J MED, V280, P225, DOI 10.1056/NEJM196901302800501; SINGH H, 1986, BRIT HEART J, V56, P171; STUMPER O, 1990, BRIT HEART J, V64, P282; TAAMS MA, 1988, EUR HEART J, V9, P1308, DOI 10.1093/oxfordjournals.eurheartj.a062448; THORSEN MK, 1985, CRC CRIT REV DIAGN I, V26, P291; VASSILE N, 1986, J COMPUT ASSIST TOMO, V10, P211; WHEAT M W JR, 1973, Progress in Cardiovascular Diseases, V16, P87, DOI 10.1016/0033-0620(73)90006-6	23	31	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					490	495		10.1016/0140-6736(91)90556-5	http://dx.doi.org/10.1016/0140-6736(91)90556-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678454				2022-12-28	WOS:A1991GC15300016
J	LENZI, M; JOHNSON, PJ; MCFARLANE, IG; BALLARDINI, G; SMITH, HM; MCFARLANE, BM; BRIDGER, C; VERGANI, D; BIANCHI, FB; WILLIAMS, R				LENZI, M; JOHNSON, PJ; MCFARLANE, IG; BALLARDINI, G; SMITH, HM; MCFARLANE, BM; BRIDGER, C; VERGANI, D; BIANCHI, FB; WILLIAMS, R			ANTIBODIES TO HEPATITIS-C VIRUS IN AUTOIMMUNE LIVER-DISEASE - EVIDENCE FOR GEOGRAPHICAL HETEROGENEITY	LANCET			English	Article							ASIALOGLYCOPROTEIN RECEPTOR PROTEIN; RECOMBINANT INTERFERON-ALFA; CHRONIC ACTIVE HEPATITIS; NON-B-HEPATITIS; CHRONIC NON-A; CONTROLLED TRIAL; AUTOANTIBODIES; INFECTION; THERAPY	To resolve conflicting reports about the occurrence of antibodies against hepatitis C virus (HCV) in patients with autoimmune chronic active hepatitis (Al-CAH), sera from UK and Italian patients were tested with the original anti-HCV assay (Ortho) and a novel anti-HCV assay (UBI), based entirely on synthetic HCV peptides. 28 (60%) of 47 Italian patients with type-1 Al-CAH were anti-HCV-positive by Ortho ELISA, 25 of whom were also strongly positive by the UBI assay. 15 (60%) of 25 UK patients with type-1 Al-CAH were HCV-positive by Ortho ELISA but only 2 were positive by the UBI assay. Similarly, 29 (88%) of 33 Italian patients with type-2 Al-CAH, but 0 of 10 UK patients, were very strongly anti-HCV-positive with the UBI assay. Italian patients with Al-CAH appear to have a high frequency of genuine exposure to HCV, whereas seropositivity by the Ortho HCV ELISA in UK patients is likely to represent a false-positive result. These findings indicate important geographical and/or genetic influences in autoimmune liver disease among different populations.	UNIV BOLOGNA,CATTEDRA SEMEIOT MED,IST CLIN MED GEN & TERAPIA MED,I-40126 BOLOGNA,ITALY; UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT IMMUNOL,LONDON SE5 8RX,ENGLAND; KINGS COLL,SCH MED & DENT,LONDON SE5 8RX,ENGLAND	University of Bologna; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London			Vergani, Diego/H-7610-2019	opoku, anita/0000-0001-7243-8157				CASSANI F, 1988, ITAL J GASTROENTEROL, V20, P171; CRIVELLI O, 1983, CLIN EXP IMMUNOL, V54, P232; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DUSSAIX E, 1990, LANCET, V335, P1160, DOI 10.1016/0140-6736(90)91163-5; ESTEBAN JI, 1989, LANCET, V2, P294; GALBRAITH RM, 1976, LANCET, V1, P930; HAUKENES G, 1990, J HEPATOL, V11, P389, DOI 10.1016/0168-8278(90)90228-J; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; HOSEIN B, 1991, P NATL ACAD SCI USA, V88, P3647, DOI 10.1073/pnas.88.9.3647; IDEO G, 1990, LANCET, V335, P353, DOI 10.1016/0140-6736(90)90636-J; IDEO G, 1990, Journal of Hepatology, V11, pS31, DOI 10.1016/0168-8278(90)91458-9; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LENZI M, 1990, 2ND INT S HCV, P122; LUNEL F, 1990, 2ND INT S HCV LOS AN, P53; MACKAY IR, 1985, CLIN EXP IMMUNOL, V61, P39; MARCELLIN P, 1990, Journal of Hepatology, V11, pS43, DOI 10.1016/0168-8278(90)91508-T; MCFARLANE BM, 1985, J IMMUNOL METHODS, V77, P219, DOI 10.1016/0022-1759(85)90034-1; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MISHIRO S, 1990, LANCET, V336, P1400, DOI 10.1016/0140-6736(90)93101-T; SHERLOCK S, 1989, LANCET, V2, P1168; TREICHEL U, 1990, HEPATOLOGY, V11, P606, DOI 10.1002/hep.1840110413; TREMOLADA F, 1990, Journal of Hepatology, V11, pS117, DOI 10.1016/0168-8278(90)91800-C; VENTO S, 1988, J CLIN LAB IMMUNOL, V25, P1; VENTO S, 1989, LANCET, V2, P926; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M	27	214	215	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					277	280		10.1016/0140-6736(91)90418-O	http://dx.doi.org/10.1016/0140-6736(91)90418-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ565	1677111				2022-12-28	WOS:A1991FZ56500004
J	PIALOUX, G; YOULE, M; DUPONT, B; GAZZARD, B; CAUWENBERGH, GFMJ; STOFFELS, PAM; DAVIES, S; DESAINTMARTIN, J; JANSSEN, PAJ				PIALOUX, G; YOULE, M; DUPONT, B; GAZZARD, B; CAUWENBERGH, GFMJ; STOFFELS, PAM; DAVIES, S; DESAINTMARTIN, J; JANSSEN, PAJ			PHARMACOKINETICS OF R-82913 IN PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX	LANCET			English	Article							REPLICATION	R 82913, a tetrahydroimidazobenzodiazepinthione (TIBO) derivative with potent activity against human immunodeficiency virus 1 (HIV-1) in vitro, was given to 22 patients with AIDS or AIDS-related complex in a dose-escalating pilot study. Doses of 10 to 300 mg administered daily by intravenous infusion were well tolerated for up to 50 weeks, with no haematological or biochemical evidence of toxicity. Mean OKT4 cell count rose slightly during the second month of treatment when higher steady-state plasma concentrations of the drug were achieved. Median p24 antigen concentration fell by 41% during the first month of therapy. When the rise in p24 antigen before therapy was compared to the fall during treatment, end-point analysis showed a significant difference (p < 0.03). The combination of potent antiretroviral activity in vitro and the observed effect on H IV p24 antigen and absence of toxicity in vivo indicate that R 82913 and related TIBO derivatives merit further study in the treatment of retroviral infections.	WESTMINSTER MED SCH & HOSP,DEAN RYLE ST,LONDON SW1P 2AP,ENGLAND; HOP INST PASTEUR,PARIS,FRANCE; CHU NECKER ENFANTS MALAD,F-75730 PARIS 15,FRANCE; ST STEPHENS HOSP,LONDON SW10 9TH,ENGLAND; JANSSEN RES FDN,BEERSE,BELGIUM; INST PASTEUR,IMMUNOHAEMATOL UNIT,F-75724 PARIS 15,FRANCE	Imperial College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Johnson & Johnson; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; NAKASHIMA H, 1986, ANTIMICROB AGENTS CH, V30, P9033; PAUUWELS R, 1990, DESIGN ANTIAIDS DRUG, P103; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; YARCHOAN R, 1986, LANCET, V1, P575	5	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					140	143		10.1016/0140-6736(91)90135-C	http://dx.doi.org/10.1016/0140-6736(91)90135-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677064				2022-12-28	WOS:A1991FX42400003
J	EMMERSON, BT				EMMERSON, BT			IDENTIFICATION OF THE CAUSES OF PERSISTENT HYPERURICEMIA	LANCET			English	Article								Accurate identification of the factors that contribute to hyperuricaemia in an individual may enable some of these factors to be modified, and lead to permanent correction of the hyperuricaemia. A protocol is described which can supplement clinical assessment. Measurement of the effects on serum urate and urinary urate excretion of a low-purine diet for 7 days facilitates the identification of the contributions made by urate production (either endogenous or from purine consumption) and renal underexcretion of urate (either as a low urate clearance in the absence of renal disease or due to renal glomerular insufficiency).			EMMERSON, BT (corresponding author), UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,DEPT MED,BRISBANE,QLD 4102,AUSTRALIA.							BATCH JA, 1984, AUST NZ J MED, V14, P852, DOI 10.1111/j.1445-5994.1984.tb03788.x; BROCHNERMORTENS.K, 1937, ACTA MED SCAND, V84, P127; EMMERSON BT, 1983, HYPERURICAEMIA GOUT; FOX IH, 1981, METABOLISM, V30, P616, DOI 10.1016/0026-0495(81)90142-6; KELLEY WN, 1967, P NATL ACAD SCI USA, V57, P1735, DOI 10.1073/pnas.57.6.1735; NUGENT CA, 1959, J CLIN INVEST, V38, P1890, DOI 10.1172/JCI103966; SEEGMILLER J, 1961, J CLIN INVEST, V40, P1304, DOI 10.1172/JCI104360; STAFFORD W, 1983, ADV EXP MED BIOL, V165, P309	8	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1461	1463		10.1016/0140-6736(91)93141-U	http://dx.doi.org/10.1016/0140-6736(91)93141-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675330				2022-12-28	WOS:A1991FR06000017
J	BOWDEN, FJ; MCPHEE, DA; DEACON, NJ; CUMMING, SA; DOHERTY, RR; SONZA, S; LUCAS, CR; CROWE, SM				BOWDEN, FJ; MCPHEE, DA; DEACON, NJ; CUMMING, SA; DOHERTY, RR; SONZA, S; LUCAS, CR; CROWE, SM			ANTIBODIES TO GP41 AND NEF IN OTHERWISE HIV-NEGATIVE HOMOSEXUAL MAN WITH KAPOSIS-SARCOMA	LANCET			English	Note							LESIONS	A homosexual man with histologically confirmed Kaposi's sarcoma remained seronegative for HIV-1, HIV-2, and HTLV-I on conventional tests over a 4-year period. HIV cultures were also negative on thirteen separate occasions. However, serum antibodies to synthetic peptide analogues of the gp41 and nef regions of HIV-1 were consistently detected on an enzyme immunoassay. Tests with the polymerase chain reaction with primers directed to the gag and env regions were negative. The antigens to which the antibodies were produced might have come from a defective HIV mutant, another retrovirus, or a hitherto unknown "agent of Kaposi's sarcoma" with similar antigenic epitopes.	MACFARLANE BURNET CTR MED RES,NATL CTR AIDS VIROL,FAIRFIELD,VIC 3078,AUSTRALIA; FAIRFIELD HOSP,FAIRFIELD,VIC,AUSTRALIA		BOWDEN, FJ (corresponding author), MACFARLANE BURNET CTR MED RES,AIDS PATHOGENESIS RES UNIT,YARRA BEND RD,FAIRFIELD,VIC 3078,AUSTRALIA.		McPhee, Dale A/D-1825-2011; Doherty, Richard/GVT-7356-2022	Doherty, Richard/0000-0002-3141-0083				AFRASIABI R, 1986, AM J MED, V81, P969, DOI 10.1016/0002-9343(86)90389-X; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CUMMING SA, 1990, AIDS, V4, P83, DOI 10.1097/00002030-199001000-00012; CUMMINGS A, IN PRESS AIDS RES HU; DICTOR M, 1988, J AM ACAD DERMATOL, V18, P398, DOI 10.1016/S0190-9622(88)70056-0; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; LOWDELL CP, 1989, J ROY SOC MED, V82, P226, DOI 10.1177/014107688908200416; MARQUART KH, 1986, ARCH PATHOL LAB MED, V110, P346; MURET MPG, 1990, LANCET, V335, P969; RAPPERSBERGER K, 1990, J INVEST DERMATOL, V95, P371, DOI 10.1111/1523-1747.ep12555450; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	11	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1313	1314		10.1016/0140-6736(91)92982-8	http://dx.doi.org/10.1016/0140-6736(91)92982-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP084	1674298				2022-12-28	WOS:A1991FP08400005
J	KEATING, JN; TRIMBLE, KC; MULCAHY, F; SCOTT, JM; WEIR, DG				KEATING, JN; TRIMBLE, KC; MULCAHY, F; SCOTT, JM; WEIR, DG			EVIDENCE OF BRAIN METHYLTRANSFERASE INHIBITION AND EARLY BRAIN INVOLVEMENT IN HIV-POSITIVE PATIENTS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; COMBINED DEGENERATION; S-ADENOSYLMETHIONINE; L-HOMOCYSTEINE; L-METHIONINE; DEFICIENCY; ADENOSINE; AIDS	The myelopathy associated with human immunodeficiency virus (HIV) infection closely resembles that in subacute combined degeneration, a disorder of vitamin B-12 metabolism. To investigate whether the disorders share a pathogenetic mechanism, S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the cerebrospinal fluid (CSF) of 20 HIV-seropositive patients and 30 HIV-negative patients who were undergoing lumbar puncture for other medical reasons. The HIV-seropositive patients had significantly lower CSF concentrations of SAM (mean 77 [SD 25] vs 131 [35] nmol/l; p < 0.001) and significantly higher concentrations of SAH (30.5 [6.8] vs 19.0 [7.1] nmol/l; p < 0.001) than the controls. There was therefore a significant difference between the groups in the SAM/SAH (methylation) ratio (HIV 2.7 [1.0] vs control 7.6 [3.4]; p < 0.001). There were no correlations between SAM or SAH concentrations or methylation ratio and age or sex in both groups, or serum B-12 and folate concentrations, CSF folate, serum or CSF methylmalonic acid, risk factors, body mass index, specific drug treatment received, or disease stage in the HIV group. This finding suggests that HIV affects the brain from a very early stage of the infection. We suggest that, as in the pig, the CSF methylation ratio closely reflects that in the brain. In HIV-infected patients a reduced brain methylation ratio would inhibit methyltransferase enzymes, which would lead to hypomethylation in the central nervous system and ultimately to neurological lesions. In a pig model of subacute combined degeneration and in vitamin-B-12-deficient human beings, the primary cause of the low methylation ratio is impaired recycling of SAH back to SAM, a process which requires vitamin-B-12-dependent methionine synthase. The HIV patients in this study were vitamin B-12 and folate replete, which suggests a different cause for the low methylation ratio.	ST JAMES HOSP, MED SCH BLDG, DUBLIN 8, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT CLIN MED, DUBLIN 2, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin								BARNES DM, 1987, SCIENCE, V235, P1574, DOI 10.1126/science.3103218; BEACH RS, 1988, JAMA-J AM MED ASSOC, V259, P519, DOI 10.1001/jama.1988.03720040017014; BOUDES P, 1990, LANCET, V335, P1401, DOI 10.1016/0140-6736(90)91279-J; DEFERRA F, 1984, CANCER RES, V44, P2297; DELAHABA G, 1959, J BIOL CHEM, V234, P603; EPSTEIN L G, 1984, AIDS Research, V1, P447; GHARIB A, 1982, J NEUROCHEM, V38, P810, DOI 10.1111/j.1471-4159.1982.tb08702.x; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; HERBERT V, 1990, AM J HEMATOL, V34, P132, DOI 10.1002/ajh.2830340210; Herbert V, 1961, FED PROC, V20, P453; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; HYLAND K, 1988, NEUROLOGY, V38, P459, DOI 10.1212/WNL.38.3.459; KELLEHER BP, 1990, MED LAB SCI, V47, P90; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; LAYZER RB, 1978, NEUROLOGY, V28, P504, DOI 10.1212/WNL.28.5.504; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MCMURRAY CH, 1986, J CHROMATOGR, V378, P201, DOI 10.1016/S0378-4347(00)80713-6; MOLLOY A M, 1986, P505; MOLLOY AM, 1990, BIOMED CHROMATOGR, V4, P257, DOI 10.1002/bmc.1130040611; MOLLOY AM, 1989, CHEM BIOL PTERIDINES, P881; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; SCOTT JM, 1974, AM J MED TECHNOL, V40, P125; SCOTT JM, 1981, LANCET, V2, P334; SURTEES R, 1990, LANCET, V335, P619, DOI 10.1016/0140-6736(90)90409-X; SURTEES R, 1990, J NEUROL NEUROSUR PS, V53, P569, DOI 10.1136/jnnp.53.7.569; WAGNER J, 1986, ANAL BIOCHEM, V154, P604, DOI 10.1016/0003-2697(86)90036-9; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x; WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987	31	65	65	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1991	337	8747					935	939		10.1016/0140-6736(91)91570-K	http://dx.doi.org/10.1016/0140-6736(91)91570-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678030				2022-12-28	WOS:A1991FH13100003
J	JENKINS, MM; HILTON, CJ; DEKOCK, JC; PALMER, JBD				JENKINS, MM; HILTON, CJ; DEKOCK, JC; PALMER, JBD			EXACERBATIONS OF ASTHMA IN PATIENTS ON SALMETEROL	LANCET			English	Letter											JENKINS, MM (corresponding author), GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND.							SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A	1	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					913	914		10.1016/0140-6736(91)90242-H	http://dx.doi.org/10.1016/0140-6736(91)90242-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672988				2022-12-28	WOS:A1991FG04800035
J	GESSA, GI; CANU, A; DELZOMPO, M; BURRAI, C; SERRA, G				GESSA, GI; CANU, A; DELZOMPO, M; BURRAI, C; SERRA, G			LACK OF ACUTE ANTIPSYCHOTIC EFFECT OF SCH-23390, A SELECTIVE DOPAMINE D1 RECEPTOR ANTAGONIST	LANCET			English	Letter											GESSA, GI (corresponding author), UNIV CAGLIARI,BERNARD B BRODIE DEPT NEUROSCI,I-09124 CAGLIARI,ITALY.							BARONE P, 1987, NEUROLOGY, V37, P1592, DOI 10.1212/WNL.37.10.1592; ONALI P, 1985, BRAIN RES, V340, P1, DOI 10.1016/0006-8993(85)90769-3; SERRA G, IN PRESS BRAIN RES; Waddington J L, 1989, J Psychopharmacol, V3, P54, DOI 10.1177/026988118900300202; WADDINGTON JL, 1989, PHARMACOL THERAPEUT, V43, P1, DOI 10.1016/0163-7258(89)90046-6	5	26	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					854	855		10.1016/0140-6736(91)92565-J	http://dx.doi.org/10.1016/0140-6736(91)92565-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672945				2022-12-28	WOS:A1991FF22800042
J	GOSLING, P; ANDREWS, DJ; CHESNER, IM				GOSLING, P; ANDREWS, DJ; CHESNER, IM			EFFECT OF ANTIINFLAMMATORY DRUGS ON URINARY MICROALBUMIN EXCRETION	LANCET			English	Letter									UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	GOSLING, P (corresponding author), SELLY OAK HOSP,DEPT BIOCHEM,BIRMINGHAM B29 6JD,ENGLAND.							BRODOWS RG, 1986, DIABETES CARE, V9, P189, DOI 10.2337/diacare.9.2.189; HOULT JRS, 1986, DRUGS, V32, P18, DOI 10.2165/00003495-198600321-00005; LOTE CJ, 1989, PROSTAG LEUKOTR ESS, V36, P203, DOI 10.1016/0952-3278(89)90134-8; RAMPART M, 1986, BIOCHEM PHARMACOL, V35, P581, DOI 10.1016/0006-2952(86)90351-5; RAMPTON DS, 1984, GUT, V25, P1399, DOI 10.1136/gut.25.12.1399; SHEARMAN CP, 1988, LANCET, V2, P906; VRIESENDORP R, 1986, CLIN NEPHROL, V25, P105	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					855	855		10.1016/0140-6736(91)92566-K	http://dx.doi.org/10.1016/0140-6736(91)92566-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672946				2022-12-28	WOS:A1991FF22800043
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			POSTMENOPAUSAL ESTROGEN AND CARDIOPROTECTION	LANCET			English	Editorial Material							ESTROGEN USE; MORTALITY; DISEASE; THERAPY; WOMEN				VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; DAVIS ME, 1964, CLIN OBSTET GYNECOL, V7, P558; GAMBRELL RD, 1982, ACTA OBSTET GYNECO S, V106, P37; KNOPP RH, 1988, OBSTET GYNECOL, V72, pS23; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NORDIN BEC, 1990, LANCET, V336, P1327, DOI 10.1016/0140-6736(90)93018-K; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENSON JC, 1990, LANCET, V336, P1121, DOI 10.1016/0140-6736(90)92590-E; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WILSON RA, 1963, J AM GERIATR SOC, V11, P347, DOI 10.1111/j.1532-5415.1963.tb00068.x; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1977, BRIT MED J, V1, P862	19	32	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					833	834		10.1016/0140-6736(91)92526-8	http://dx.doi.org/10.1016/0140-6736(91)92526-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672923				2022-12-28	WOS:A1991FF22800014
J	CHO, KWY; MORITA, EA; WRIGHT, CVE; DEROBERTIS, EM				CHO, KWY; MORITA, EA; WRIGHT, CVE; DEROBERTIS, EM			OVEREXPRESSION OF A HOMEODOMAIN PROTEIN CONFERS AXIS-FORMING ACTIVITY TO UNCOMMITTED XENOPUS EMBRYONIC-CELLS	CELL			English	Article							RETINOIC ACID; GROWTH-FACTORS; HOMEOBOX GENE; MESODERM; INDUCTION; LAEVIS; IDENTIFICATION; SPECIFICITY; DROSOPHILA; ORGANIZER	The anteroposterior character of mesoderm induced by a peptide growth factor (XTC-MIF) was tested by transplantation into host Xenopus gastrulae. Both retinoic acid and a homeodomain protein were able to override the anteriorizing effect of the growth factor. Microinjection of a posteriorly expressed homeobox mRNA can respecify anteroposterior identity, transforming head mesoderm into tail-inducing mesoderm. Unexpectedly, overexpression of XIHbox 6 protein in the transplanted cells, without addition of growth factors, caused the formation of tail-like structures. The cells overexpressing XIHbox 6 were able to recruit cells from the host into the secondary axis. The results suggest that vertebrate homeodomain proteins are part of the biochemical pathway leading to the generation of the body axis.			CHO, KWY (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.			De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21502-06] Funding Source: Medline; NIGMS NIH HHS [GM-07104, GM08243] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA AR, 1989, NATURE, V341, P33; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COOKE J, 1989, DEVELOPMENT, V107, P229; DALE L, 1987, DEVELOPMENT, V100, P279; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOLTFRETER J, 1955, ANAL DEV; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JONES EA, 1987, DEVELOPMENT, V101, P557; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nieuwkoop P. D., 1969, ROUX ARCH ENTW MECH, V162, P34; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROSA F, 1988, SCIENCE, V239, P782; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; SPEMANN H, 1918, ROUX ARCH ENTW MECH, V43, P448; Spemann H., 1938, EMBRYONIC DEV INDUCT; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1989, DEVELOPMENT, V106, P691; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	47	93	95	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					55	64		10.1016/0092-8674(91)90407-P	http://dx.doi.org/10.1016/0092-8674(91)90407-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1672833	Bronze			2022-12-28	WOS:A1991FF77300008
J	MCGUIRE, P; FAHY, T				MCGUIRE, P; FAHY, T			CHRONIC PARANOID PSYCHOSIS AFTER MISUSE OF MDMA (ECSTASY)	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,LONDON SE5,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	MCGUIRE, P (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,PSYCHIAT,LONDON SE5 8SJ,ENGLAND.			McGuire, Philip/0000-0003-4381-0532; Fahy, Thomas/0000-0003-3019-3547				Connell PH, 1958, MAUDSLEY MONOGRAPH, V5; GREER G, 1985, AM J PSYCHIAT, V142, P1391; MCKENNA DJ, 1990, J NEUROCHEM, V54, P14, DOI 10.1111/j.1471-4159.1990.tb13277.x; PRICE LH, 1989, ARCH GEN PSYCHIAT, V46, P20; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1	5	102	103	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					697	697		10.1136/bmj.302.6778.697	http://dx.doi.org/10.1136/bmj.302.6778.697			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	1673631	Green Published, Bronze			2022-12-28	WOS:A1991FE33300024
J	GULLO, L; BARBARA, L				GULLO, L; BARBARA, L			TREATMENT OF PANCREATIC PSEUDOCYSTS WITH OCTREOTIDE	LANCET			English	Note							MANAGEMENT; CYSTS	Pancreatic pseudocysts are a common and painful complication of chronic pancreatitis. Seven patients (six male, one female; mean age 49.9 years) with chronic pancreatitis complicated by pseudocysts and persistent pain were treated with the pancreatic anti-secretory drug octreotide for 2 weeks. Octreotide caused no notable changes in the size of the pseudocysts of three patients. In the remaining four patients, the pseudocysts decreased in size by a mean of 42% (range 29-52%), and pain disappeared completely. These findings suggest a role for octreotide in the treatment of pancreatic pseudocysts.			GULLO, L (corresponding author), UNIV BOLOGNA,POLICLIN S ORSOLA,MED CLIN 1,STUDY PANCREAT DIS UNIT,I-40138 BOLOGNA,ITALY.							BRADLEY EL, 1979, AM J SURG, V137, P135, DOI 10.1016/0002-9610(79)90024-2; CREMER M, 1989, GASTROINTEST ENDOSC, V35, P1, DOI 10.1016/S0016-5107(89)72677-8; CREUTZFELDT W, 1987, AM J MED, V82, P49, DOI 10.1016/0002-9343(87)90426-8; GULLO L, 1977, REND GASTROENTEROL, V9, P97; GULLO L, IN PRESS AM J GASTRO; SAHEL J, 1987, PANCREAS, V2, P447, DOI 10.1097/00006676-198707000-00012; VANSONNENBERG E, 1982, RADIOLOGY, V142, P1	7	51	51	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					540	541		10.1016/0140-6736(91)91102-Z	http://dx.doi.org/10.1016/0140-6736(91)91102-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678802				2022-12-28	WOS:A1991GD00200006
J	KENYON, K; CONTENTE, S; TRACKMAN, PC; TANG, J; KAGAN, HM; FRIEDMAN, RM				KENYON, K; CONTENTE, S; TRACKMAN, PC; TANG, J; KAGAN, HM; FRIEDMAN, RM			LYSYL OXIDASE AND RRG MESSENGER-RNA	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; SEQUENCE; CELLS		BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University	KENYON, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Contente, Sara/0000-0002-8099-2817	NCI NIH HHS [R01 CA37351-04A1] Funding Source: Medline; NHLBI NIH HHS [P01 HL13262] Funding Source: Medline; NIAMS NIH HHS [R37 AR18880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037351] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P4863; BENSON D, 1990, GENOMICS, V6, P389, DOI 10.1016/0888-7543(90)90583-G; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; KAGAN HM, 1984, J BIOL CHEM, V259, P1203; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KESHMIRIAN J, 1989, J NEUROCYTOL, V18, P491, DOI 10.1007/BF01474545; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; KUIVANIEMI H, 1986, BIOCHIM BIOPHYS ACTA, V883, P326, DOI 10.1016/0304-4165(86)90325-9; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, IN PRESS BIOCHEMISTR	14	201	213	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					802	802		10.1126/science.1678898	http://dx.doi.org/10.1126/science.1678898			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1678898				2022-12-28	WOS:A1991GB29500045
J	GRANTHAMMCGREGOR, SM; POWELL, CA; WALKER, SP; HIMES, JH				GRANTHAMMCGREGOR, SM; POWELL, CA; WALKER, SP; HIMES, JH			NUTRITIONAL SUPPLEMENTATION, PSYCHOSOCIAL STIMULATION, AND MENTAL-DEVELOPMENT OF STUNTED CHILDREN - THE JAMAICAN STUDY	LANCET			English	Article							COGNITIVE-DEVELOPMENT; MALNUTRITION; KINGSTON; GROWTH; YOUNG	There is little unequivocal evidence that nutritional supplementation of undernourished children has a beneficial effect on their mental development. The effects of nutritional supplementation, with or without psychosocial stimulation, of growth-retarded (stunted) children aged 9-24 months were assessed in a study in Kingston, Jamaica. 129 children from poor neighbourhoods were randomly assigned to four groups - control, supplemented only, stimulated only, and supplemented plus stimulated. A group of matched non-stunted children (n = 32) was also included. The supplement comprised 1 kg milk-based formula per week for 2 years, and the stimulation weekly play sessions at home with a community health aide. The children's development (DQ) was assessed on the Griffiths mental development scales. Initially the stunted groups' DQs were lower than those of the nonstunted group, and those of the control group declined during the study, increasing their deficit. Stimulation and supplementation had significant independent beneficial effects on the children's development. Estimates of the supplementation effect ranged from 2.2 (95% confidence limits - 1.4, 5.7) for the hand and eye subscale to 12.4 (5.4, 19.5) for the locomotor subscale and those for the stimulation effect from 6.4 (2.8, 10.0) for hand and eye to 10.3 (3.3, 17.3) for locomotor. The treatment effects were additive, and combined interventions were significantly more effective than either alone. These findings suggest that poor mental development in stunted children is at least partly attributable to undernutrition.	UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	GRANTHAMMCGREGOR, SM (corresponding author), UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA.							[Anonymous], 1965, PEABODY PICTURE VOCA; BARRY RG, 1984, ANN GLACIOL, V5, P9, DOI 10.3189/1984AoG5-1-9-15; BEATON GH, 1982, AM J CLIN NUTR S, V35; CALDWELL BM, 1967, PEDIATRICS, V40, P46; CHAMBERS CM, 1986, J CHILD PSYCHOL PSYC, V27, P117, DOI 10.1111/j.1469-7610.1986.tb00627.x; CHAVEZ A, 1982, GROWING UP DEV COMMU; CLARKE NW, IN PRESS ECOL FOOD N; FREEMAN HE, 1980, AM J PUBLIC HEALTH, V70, P1277, DOI 10.2105/AJPH.70.12.1277; Grantham-McGregor S., 1987, Early nutrition and later achievement, P128; GRANTHAMMCGREGOR S, 1987, PEDIATRICS, V79, P247; GRIFFITHS R, 1967, ABILITIES BABIES; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; JAMISON DT, 1977, J DEV ECON, V20, P299; JOOS SK, 1983, CHILD DEV, V54, P669; KELLER W, 1988, NESTLE NUTRITION WOR, V14, P17; KLEIN RE, 1979, MALNUTRITION ENV BEH, P219; LASKY RE, 1981, CHILD DEV, V52, P220; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; MARTORELL R, 1988, NESTLE NUTRITION WOR, V14, P57; MCKAY H, 1978, SCIENCE, V200, P270, DOI 10.1126/science.635585; MOOCK PR, 1986, J DEV ECON, V20, P33, DOI 10.1016/0304-3878(86)90004-0; MORA JO, 1979, BEHAVIORAL EFFECTS E, P255; POWELL C, 1989, Pediatrics, V84, P157; POWELL CA, 1985, AM J CLIN NUTR, V41, P1322, DOI 10.1093/ajcn/41.6.1322; Richardson S A, 1974, Adv Pediatr, V21, P167; WABER DP, 1981, AM J CLIN NUTR, V34, P807, DOI 10.1093/ajcn/34.4.807; WALKER S, IN PRESS AM J CLIN N; WALKER SP, 1990, W INDIAN MED J, V39, P12; WALKER SP, 1990, EUR J CLIN NUTR, V44, P527; Waterlow J.C., 1985, NUTR ADAPTATION MAN, P1	30	311	320	1	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					1	5		10.1016/0140-6736(91)90001-6	http://dx.doi.org/10.1016/0140-6736(91)90001-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FV296	1676083				2022-12-28	WOS:A1991FV29600001
J	WEATHERALL, DJ				WEATHERALL, DJ			EXAMINING UNDERGRADUATE EXAMINATIONS	LANCET			English	Article											WEATHERALL, DJ (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.							GRANT J, 1988, MED EDUC, V22, P173, DOI 10.1111/j.1365-2923.1988.tb00002.x; Harden R M, 1979, Med Educ, V13, P305; HARDEN RM, 1975, BRIT MED J, V1, P447, DOI 10.1136/bmj.1.5955.447; Harden RM, 1979, MED EDUC, V13, P39, DOI DOI 10.1111/J.1365-2923.1979.TB00918.X; LENNOX B, 1974, HINTS SETTING EVALUA; STOKES J, 1974, CLIN EXAMINATION ASS; Weinstein MC, 1980, CLIN DECISION ANAL; 1980, RECOMMENDATIONS BASI	8	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					37	39		10.1016/0140-6736(91)90017-J	http://dx.doi.org/10.1016/0140-6736(91)90017-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676093				2022-12-28	WOS:A1991FV29600015
J	KRISTIANSEN, BE; ASK, E; JENKINS, A; FERMER, C; RADSTROM, P; SKOLD, O				KRISTIANSEN, BE; ASK, E; JENKINS, A; FERMER, C; RADSTROM, P; SKOLD, O			RAPID DIAGNOSIS OF MENINGOCOCCAL MENINGITIS BY POLYMERASE CHAIN-REACTION	LANCET			English	Note								Rapid diagnosis of meningococcal disease followed by early treatment is essential. However, culture of blood or cerebrospinal fluid (CSF) may be unsuccessful because antibiotic treatment is often started before adequate specimens are collected, and because bacteria may die during transportation to the laboratory. We have used the polymerase chain reaction (PCR) to detect meningococcal DNA in a culture-negative CSF of a 15-year-old girl with meningococcal disease. Two oligonucleotides flanking the dihydropteroate synthase gene (dhps) of Neisseria meningitidis were used as primers. The PCR reaction is a rapid technique for the early detection of meningococcal meningitis, and also when culture is negative.	UNIV UPPSALA,CTR BIOMED,DEPT PHARMACEUT MICROBIOL,S-75123 UPPSALA,SWEDEN	Uppsala University	KRISTIANSEN, BE (corresponding author), AS TELELAB,TELEMARK BIOMED CTR,POB 1868 GULSET,N-3701 SKIEN,NORWAY.			Kristiansen, Bjorn - Erik/0000-0001-8299-4624; Jenkins, Andrew/0000-0003-2588-8483				AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; COOVADIA YM, 1989, LANCET, V2, P677; GEDDEDAHL TW, 1983, NAT I PUBLIC HLTH AN, V2, P155; KRISTIANSEN BE, 1990, ANTIMICROB AGENTS CH, V34, P2227; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335	6	77	80	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1568	1569		10.1016/0140-6736(91)93262-8	http://dx.doi.org/10.1016/0140-6736(91)93262-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675709				2022-12-28	WOS:A1991FU55100005
J	ALONSO, PL; LINDSAY, SW; ARMSTRONG, JRM; CONTEH, M; HILL, AG; DAVID, PH; FEGAN, G; DEFRANCISCO, A; HALL, AJ; SHENTON, FC; CHAM, K; GREENWOOD, BM				ALONSO, PL; LINDSAY, SW; ARMSTRONG, JRM; CONTEH, M; HILL, AG; DAVID, PH; FEGAN, G; DEFRANCISCO, A; HALL, AJ; SHENTON, FC; CHAM, K; GREENWOOD, BM			THE EFFECT OF INSECTICIDE-TREATED BED NETS ON MORTALITY OF GAMBIAN CHILDREN	LANCET			English	Article							MALARIA; PROGRAM	Insecticide treatment of bed nets ("mosquito nets") may be a cheap and acceptable method of reducing the morbidity and mortality caused by malaria. In a rural area of The Gambia, bed nets in villages participating in a primary health-care (PHC) scheme were treated with permethrin at the beginning of the malaria transmission season. Additionally, children aged 6 months to 5 years were randomised to receive weekly either chemoprophylaxis with maloprim or a placebo throughout the malaria transmission season. We measured mortality in children in PHC villages before and after the interventions described, and compared this with mortality in villages where no interventions occurred (non-PHC villages). About 92% of children in PHC villages slept under insecticide-treated bed nets. In the year before intervention, mortality in children aged 1-4 years was lower in non-PHC villages. After intervention, the overall mortality and mortality attributable to malaria of children aged 1-4 in the intervention villages was 37% and 30%, respectively, of that in the non-PHC villages. Among children who slept under treated nets, we found no evidence of an additional benefit of chemoprophylaxis in preventing deaths. Insecticide-treated bed nets are simple to introduce and can reduce mortality from malaria.	MRC LABS,BANJUL,SENEGAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED,CTR POPULAT STUDIES,LONDON WC1E 7HT,ENGLAND; INT AGCY RES CANC,GAMBIA HEPATITIS INTERVENT STUDY,F-69372 LYONS,FRANCE	University of London; London School of Hygiene & Tropical Medicine; World Health Organization; International Agency for Research on Cancer (IARC)			Shenton, Fiona/A-4397-2012; Alonso, Pedro L/AAZ-3645-2020; Fegan, Greg W/O-8079-2018	Alonso, Pedro L/0000-0003-3292-3443; Fegan, Greg W/0000-0002-2663-2765				ALONSO PL, 1987, ANN TROP PAEDIATR, V7, P187, DOI 10.1080/02724936.1987.11748504; Curtis C. F., 1990, Appropriate technology in vector control., P5; GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P534, DOI 10.1016/0035-9203(87)90396-8; GREENWOOD BM, 1986, B WORLD HEALTH ORGAN, V64, P909; GREENWOOD BM, 1988, LANCET, V1, P1121; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91, DOI 10.1080/02724936.1987.11748482; Rozendaal J. A., 1989, Tropical Diseases Bulletin, V86, pR1; SHENTON FC, 1988, T ROY SOC TROP MED H, V82, P216, DOI 10.1016/0035-9203(88)90415-4; SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; 1987, WHOVBC89981	13	340	341	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1499	1502		10.1016/0140-6736(91)93194-E	http://dx.doi.org/10.1016/0140-6736(91)93194-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675368				2022-12-28	WOS:A1991FT11600002
J	MARMOT, MG; SMITH, GD; STANSFELD, S; PATEL, C; NORTH, F; HEAD, J; WHITE, I; BRUNNER, E; FEENEY, A				MARMOT, MG; SMITH, GD; STANSFELD, S; PATEL, C; NORTH, F; HEAD, J; WHITE, I; BRUNNER, E; FEENEY, A			HEALTH INEQUALITIES AMONG BRITISH CIVIL-SERVANTS - THE WHITEHALL-II STUDY	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; SOCIAL INEQUALITIES; RISK-FACTORS; MORTALITY; DEATH; HOSTILITY	The Whitehall study of British civil servants begun in 1967, showed a steep inverse association between social class, as assessed by grade of employment, and mortality from a wide range of diseases. Between 1985 and 1988 we investigated the degree and causes of the social gradient in morbidity in a new cohort of 10 314 civil servants (6900 men, 3414 women) aged 35-55 (the Whitehall 11 study). Participants were asked to answer a self-administered questionnaire and attend a screening examination. In the 20 years separating the two studies there has been no diminution in social class difference in morbidity: we found an inverse association between employment grade and prevalence of angina, electrocardiogram evidence of ischaemia, and symptoms of chronic bronchitis. Self-perceived health status and symptoms were worse in subjects in lower status jobs. There were clear employment-grade differences in health-risk behaviours including smoking, diet, and exercise, in economic circumstances, in possible effects of early-life environment as reflected by height, in social circumstances at work (eg, monotonous work characterised by low control and low satisfaction), and in social supports. Healthy behaviours should be encouraged across the whole of society; more attention should be paid to the social environments, job design, and the consequences of income inequality.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	MARMOT, MG (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT EPIDEMIOL & PUBL HLTH,66-72 GOWER ST,LONDON WC1E 6EA,ENGLAND.		Marmot, M G/Y-3920-2019; Davey Smith, George/A-7407-2013; Head, Jenny/GYA-2625-2022; Brunner, Eric/H-2114-2011	Marmot, M G/0000-0002-2431-6419; Davey Smith, George/0000-0002-1407-8314; Brunner, Eric/0000-0002-0595-4474; White, Ian/0000-0002-6718-7661; Head, Jennifer/0000-0002-6054-0872	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust)		AIACH P, 1990, SOC SCI MED, V31, P267, DOI 10.1016/0277-9536(90)90273-U; ALFREDSSON L, 1985, INT J EPIDEMIOL, V14, P378, DOI 10.1093/ije/14.3.378; [Anonymous], 1980, INEQUALITIES HLTH RE; BAREFOOT JC, 1983, PSYCHOSOM MED, V45, P59, DOI 10.1097/00006842-198303000-00008; BARKER DJP, 1989, LANCET, V2, P577; BENSHLOMO Y, 1991, LANCET, P530; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; FOX J, 1982, LONGITUDINAL STUDY S; Goldberg DP., 1972, DETECTION PSYCHIATRI; Goldblatt PO, 1988, POPUL TRENDS, V51, P9; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HUNT ME, 1985, J ARCHIT PLAN RES, V2, P151; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; REID DD, 1974, LANCET, V1, P469; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; Rose G, 1982, CARDIOVASCULAR SURVE; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SHEKELLE RB, 1983, PSYCHOSOM MED, V45, P109, DOI 10.1097/00006842-198305000-00003; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; WHITEHEAD M, 1988, INEQUALITIES HLTH, P215; 1989, GENERAL HOUSEHOLD SU; 1978, OCCUPATIONAL MORTALI	30	2254	2280	4	438	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1387	1393		10.1016/0140-6736(91)93068-K	http://dx.doi.org/10.1016/0140-6736(91)93068-K			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP870	1674771				2022-12-28	WOS:A1991FP87000011
J	VANDERBLIEK, AM; MEYEROWITZ, EM				VANDERBLIEK, AM; MEYEROWITZ, EM			DYNAMIN-LIKE PROTEIN ENCODED BY THE DROSOPHILA-SHIBIRE GENE ASSOCIATED WITH VESICULAR TRAFFIC	NATURE			English	Article							TEMPERATURE-SENSITIVE MUTANT; MECHANOCHEMICAL ENZYME; INFLUENZA-VIRUS; MELANOGASTER; MICROTUBULES; ENDOCYTOSIS; MUTATIONS; CLONING; MOTOR	TEMPERATURE-sensitive paralysis is the most striking defect of adult Drosophila carrying the shibire mutation 1. This is believed to be due to a reversible block of endocytosis, which prevents membrane cycling and thus depletes synaptic vesicles 2, 3. The shibire mutation also affects many tissues outside the nervous system 4-7. We have now mapped and characterized the shibire gene. A 275-kilobase yeast artificial chromosome was subcloned into cosmids, among which the gene was then located by analysing with restriction-fragment length polymorphisms. A 15-kilobase fragment of wild-type DNA rescues the mutant phenotype and the sequence of two mutant alleles show differences with wild type, demonstrating that we have isolated the shibire gene. The gene encodes a protein that is highly similar to rat dynamin 8, 9, 69% of the amino-acid sequence is identical. Dynamin is a GTP-driven mechanochemical enzyme related to mammalian mx-proteins 10 and to the yeast vps 1 gene product 11. Because the shibire gene product and dynamin have extensive similarity, we propose that they are cognate homologues. Dynamin causes microtubules to slide along each other in vitro 12 and in extracts it is associated with a distinct, but so far uncharacterized, membrane fraction 13. In light of the shibire phenotype, we suggest that these proteins provide the motor for vesicular transport during endocytosis.			VANDERBLIEK, AM (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009					ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P458, DOI 10.1093/nar/17.1.458; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HUMMON MR, 1988, ROUX ARCH DEV BIOL, V197, P383, DOI 10.1007/BF00398989; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KIM YT, 1990, J NEUROGENET, V7, P1, DOI 10.3109/01677069009084149; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; NARITA K, 1989, J CELL PHYSIOL, V141, P383, DOI 10.1002/jcp.1041410220; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POODRY CA, 1990, DEV BIOL, V138, P464, DOI 10.1016/0012-1606(90)90212-2; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	26	632	637	1	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					411	414		10.1038/351411a0	http://dx.doi.org/10.1038/351411a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1674590				2022-12-28	WOS:A1991FN85600060
J	BREWIN, TB				BREWIN, TB			3 WAYS OF GIVING BAD-NEWS	LANCET			English	Editorial Material																			0	51	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1207	1209		10.1016/0140-6736(91)92870-8	http://dx.doi.org/10.1016/0140-6736(91)92870-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673749				2022-12-28	WOS:A1991FM26100014
J	KESSLER, M; NETTER, P; MAHEUT, H; WOLF, C; PRENAT, E; HUU, TC; GAUCHER, A				KESSLER, M; NETTER, P; MAHEUT, H; WOLF, C; PRENAT, E; HUU, TC; GAUCHER, A			HIGHLY PERMEABLE AND BIOCOMPATIBLE MEMBRANES AND PREVALENCE OF DIALYSIS-ASSOCIATED ARTHROPATHY	LANCET			English	Letter							BETA-2-MICROGLOBULIN AMYLOIDOSIS; OSTEOARTHROPATHY		CTR HOSP REG UNIV NANCY,DEPT RHEUMATOL,CNRS,URA 1288,F-54500 VANDOEUVRE NANCY,FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU de Nancy	KESSLER, M (corresponding author), CTR HOSP REG UNIV NANCY,DEPT NEPHROL,CNRS,URA 1288,F-54500 VANDOEUVRE NANCY,FRANCE.							CHANARD J, 1989, BRIT MED J, V298, P867, DOI 10.1136/bmj.298.6677.867; CORNELIS F, 1989, ARTHRITIS RHEUM, V32, P785, DOI 10.1002/anr.1780320619; DESTRIHOU CV, 1988, NEPHROL DIAL TRANSPL, V3, P552; KESSLER M, IN PRESS BR J RHEUMA; KUNTZ D, 1984, ARTHRITIS RHEUM-US, V27, P369, DOI 10.1002/art.1780270402; RENAUD H, 1988, NEPHROL DIAL TRANSPL, V3, P820; VANDENBROUCKE JM, 1986, LANCET, V1, P1210; ZINGRAFF JJ, 1990, NEW ENGL J MED, V323, P1070	8	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1092	1093		10.1016/0140-6736(91)91736-E	http://dx.doi.org/10.1016/0140-6736(91)91736-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673510				2022-12-28	WOS:A1991FK20400030
J	KEATING, M; ATKINSON, D; DUNN, C; TIMOTHY, K; VINCENT, GM; LEPPERT, M				KEATING, M; ATKINSON, D; DUNN, C; TIMOTHY, K; VINCENT, GM; LEPPERT, M			LINKAGE OF A CARDIAC-ARRHYTHMIA, THE LONG QT SYNDROME, AND THE HARVEY RAS-1 GENE	SCIENCE			English	Article							ANIRIDIA-WILMS TUMOR; CANCER-PATIENTS; LOCALIZATION; C-HA-RAS1; ONCOGENE; PROTEINS; PRODUCT; LOCUS; CELLS	Genetic factors contribute to heart disease. In this study, linkage analyses have been performed in a family that is predisposed to sudden death from cardiac arrhythmias, the long QT syndrome (LQT). A DNA marker at the Harvey ras-1 locus (H-ras-1) was linked to LQT with a logarithm of the likelihood ratio for linkage (lod score) of 16.44 at theta = 0, which confirms the genetic basis of this trait and localizes this gene to the short arm of chromosome 11. As no recombination was observed between LQT and H-ras-1, and there is a physiological rationale for its involvement in this disease, ras becomes a candidate for the disease locus.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84132; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84143; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	KEATING, M (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,DIV CARDIOL,SALT LAKE CITY,UT 84132, USA.							Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; DAUSSET J, 1986, PRESSE MED, V15, P1801; DEMARTINVILLE B, 1983, NATURE, V305, P641, DOI 10.1038/305641a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GIUFFRE RM, 1990, AM J HUM GENET, V47; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HUERRE C, 1983, NATURE, V305, P638, DOI 10.1038/305638a0; ITOH S, 1962, CLIN PEDIATR PHILADE, V21, P20; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JHANWAR SC, 1983, P NATL ACAD SCI-BIOL, V80, P4794, DOI 10.1073/pnas.80.15.4794; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KEATING MT, UNPUB; KLINGER HP, 1989, CYTOGENET CELL GENET, V51, P740; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; MCKUSICK VA, 1908, MENDELIAN INHERITANC; MELKI J, 1987, CYTOGENET CELL GENET, V40, P775; ROMANO C, 1965, LANCET, V1, P658; SCHATZKIN A, 1984, AM HEART J, V107, P1300, DOI 10.1016/0002-8703(84)90302-8; SCHWARTZ P J, 1989, Journal of the American College of Cardiology, V13, p20A; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; VINCENT GM, 1989, CIRCULATION S2, V80, P654; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEITKAMP LR, 1989, CYTOGENET CELL GENET, V51, P1106; WEITKAMP LR, 1985, CYTOGENET CELL GENET, V40, P775; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	34	443	458	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					704	706		10.1126/science.1673802	http://dx.doi.org/10.1126/science.1673802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1673802				2022-12-28	WOS:A1991FK18500048
J	ALLAN, LD; COOK, A; SULLIVAN, I; SHARLAND, GK				ALLAN, LD; COOK, A; SULLIVAN, I; SHARLAND, GK			HYPOPLASTIC LEFT HEART SYNDROME - EFFECTS OF FETAL ECHOCARDIOGRAPHY ON BIRTH PREVALENCE	LANCET			English	Article							DISEASE	Hypoplastic left heart syndrome was diagnosed prenatally and confirmed in 105 fetuses since 1983 at a regional referral centre. An increased detection rate since 1988 is probably related to increased experience in the use of a four-chamber view of the fetal heart during routine obstetric ultrasound scanning. When the diagnosis was made sufficiently early, most parents chose to terminate the pregnancy after the prognosis and surgical options were explained. By contrast, after an increase in the mid 1980s, since 1988 there has been a striking fall in the number of newborn babies with hypoplastic left heart syndrome treated at a supraregional referral centre. More widespread use of four-chamber cardiac screening during routine fetal ultrasonography may reduce the number of newborn babies with hypoplastic left heart syndrome-a factor which should be taken into account when the likely requirements for neonatal cardiac transplantation facilities are calculated.	GUYS HOSP,DEPT PATHOL,LONDON SE1 9RT,ENGLAND; HOSP SICK CHILDREN,DEPT PAEDIAT CARDIOL,LONDON WC1N 3JH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	ALLAN, LD (corresponding author), GUYS HOSP,DEPT PERINATAL CARDIOL,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.			Cook, Andrew/0000-0001-5079-7546				ALLAN LD, 1989, INT J CARDIOL, V25, P341, DOI 10.1016/0167-5273(89)90226-X; ALLAN LD, 1984, BRIT HEART J, V52, P542; ALLAN LD, 1986, BRIT MED J, V292, P1717, DOI 10.1136/bmj.292.6537.1717; BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; CULLEN S, 1990, BRIT HEART J, V64, P90; FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520; JONAS R, 1990, AUG CARD SOC AUSTR N; MELIONES JN, 1990, CIRCULATION, V82, P151; MURDISON KA, 1990, CIRCULATION, V82, P199; PAHL E, 1990, J PEDIATR, V116, P117	11	62	63	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					959	961		10.1016/0140-6736(91)91582-F	http://dx.doi.org/10.1016/0140-6736(91)91582-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678041				2022-12-28	WOS:A1991FH13100015
J	HALL, JC; TARALA, R; HARRIS, J; TAPPER, J; CHRISTIANSEN, K				HALL, JC; TARALA, R; HARRIS, J; TAPPER, J; CHRISTIANSEN, K			INCENTIVE SPIROMETRY VERSUS ROUTINE CHEST PHYSIOTHERAPY FOR PREVENTION OF PULMONARY COMPLICATIONS AFTER ABDOMINAL-SURGERY	LANCET			English	Article							DIAPHRAGMATIC FUNCTION; ATELECTASIS; CARE	We entered 876 patients into a clinical trial aimed at preventing pulmonary complications after abdominal surgery. Patients either received conventional chest physiotherapy or were encouraged to perform maximal inspiratory manoeuvres for 5 min during each hour while awake, using an incentive spirometer. The incidence of pulmonary complications did not differ significantly between the groups: incentive spirometry 68 of 431 (15.8%, 95% Cl 14.0-17.6%), and chest physiotherapy 68 of 445 (15.3%, Cl 13.6-17.0%). Nor was there a difference between the groups in the incidence of positive clinical signs, pyrexia, abnormal chest radiographs, pathogens in sputum, respiratory failure (PO2 < 60 mm Hg), or length of stay in hospital. We conclude that prophylactic incentive spirometry and chest physiotherapy are of equivalent clinical efficacy in the general management of patients undergoing abdominal surgery.	UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT MICROBIOL, PERTH, WA 6000, AUSTRALIA; UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT PHYSIOTHERAPY, PERTH, WA 6000, AUSTRALIA; UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT RES MED, PERTH, WA 6000, AUSTRALIA	Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia	HALL, JC (corresponding author), UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, DEPT SURG, WELLINGTON ST, PERTH, WA 6000, AUSTRALIA.							[Anonymous], 1965, LANCET, V1, P775; BARTLETT RH, 1973, JAMA-J AM MED ASSOC, V224, P1017, DOI 10.1001/jama.224.7.1017; BARTLETT RH, 1973, SURG GYNECOL OBSTET, V137, P925; CELLI BR, 1984, AM REV RESPIR DIS, V130, P12; CHUTER TAM, 1989, SURGERY, V105, P488; COLEMAN DL, 1987, CHEST, V92, P520, DOI 10.1378/chest.92.3.520; CRAVEN JL, 1974, BRIT J SURG, V61, P793, DOI 10.1002/bjs.1800611012; DEMERS RR, 1976, RESP CARE, V21, P234; DUREUIL B, 1987, BRIT J ANAESTH, V59, P1230, DOI 10.1093/bja/59.10.1230; FRISANCHO AR, 1981, AM J CLIN NUTR, V34, P2540, DOI 10.1093/ajcn/34.11.2540; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GRACEY DR, 1979, CHEST, V76, P123, DOI 10.1378/chest.76.2.123; JACKSON CV, 1988, ARCH INTERN MED, V148, P2120, DOI 10.1001/archinte.148.10.2120; JONES JG, 1987, BRIT J ANAESTH, V59, P949, DOI 10.1093/bja/59.8.949; JUNG R, 1980, CHEST, V78, P31, DOI 10.1378/chest.78.1.31; KIRILOFF LH, 1985, CHEST, V88, P436, DOI 10.1378/chest.88.3.436; LATIMER RG, 1971, AM J SURG, V122, P622, DOI 10.1016/0002-9610(71)90290-X; LYAGER S, 1979, ACTA ANAESTH SCAND, V23, P312, DOI 10.1111/j.1399-6576.1979.tb01456.x; MACHIN D, 1987, STATISTICAL TABLES D, P20; MITCHELL C, 1982, AUST NZ J SURG, V52, P203, DOI 10.1111/j.1445-2197.1982.tb06103.x; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; ODONOHUE WJ, 1985, CHEST, V87, P76, DOI 10.1378/chest.87.1.76; ROUKEMA JA, 1988, ARCH SURG-CHICAGO, V123, P30; SCHWIEGER I, 1986, CHEST, V89, P652, DOI 10.1378/chest.89.5.652; SELSBY DS, 1989, BMJ-BRIT MED J, V298, P541, DOI 10.1136/bmj.298.6673.541; THOREN L, 1954, ACTA CHIR SCAND, V107, P193; TORRINGTON KG, 1988, CHEST, V93, P946, DOI 10.1378/chest.93.5.946; VACANTI CJ, 1970, ANESTH ANAL CURR RES, V49, P564; WIGHTMAN JAU, 1954, ACTA CHIR SCAND, V107, P193; 1989, PRINCIPLES ANALGESIC, P10	30	76	78	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1991	337	8747					953	956		10.1016/0140-6736(91)91580-N	http://dx.doi.org/10.1016/0140-6736(91)91580-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678039				2022-12-28	WOS:A1991FH13100013
J	HENON, PR; BUTTURINI, A; GALE, RP				HENON, PR; BUTTURINI, A; GALE, RP			BLOOD-DERIVED HEMATOPOIETIC-CELL TRANSPLANTS - BLOOD TO BLOOD	LANCET			English	Editorial Material							HEMATOPOIETIC STEM-CELLS; BONE-MARROW TRANSPLANTATION; NON-LYMPHOBLASTIC LEUKEMIA; TOTAL-BODY IRRADIATION; UMBILICAL-CORD BLOOD; AUTOLOGOUS TRANSPLANTATION; MULTIPLE-MYELOMA; EARLY REMISSION; RECIPIENTS; PATIENT		UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,10833 LE CONTE AVE,LOS ANGELES,CA 90024; HOP HASENRAIN,INST HAEMATOL & TRANSFUS RES,F-68100 MULHOUSE,FRANCE; HOP HASENRAIN,HAEMATOL SERV,F-68100 MULHOUSE,FRANCE; UNIV PARMA,DEPT PAEDIAT,DIV HAEMATOL & ONCOL,I-43100 PARMA,ITALY	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Parma					NCI NIH HHS [CA 38569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAPRO M, 1988, PATHOL BIOL, V36, P56; BELL AJ, 1989, BRIT J HAEMATOL, V71, P162, DOI 10.1111/j.1365-2141.1989.tb06294.x; BELL AJ, 1986, BONE MARROW TRANSPL, V1, P103; BERENSON J, 1987, BLOOD, V70, P1550; BRANCH DR, 1982, TRANSPLANTATION, V34, P226, DOI 10.1097/00007890-198210000-00018; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; DURNAM DM, 1989, BLOOD, V74, P2220; EPSTEIN J, 1990, NEW ENGL J MED, V322, P664, DOI 10.1056/NEJM199003083221005; FERMAND JP, 1989, BLOOD, V73, P20; GALE RP, 1978, TRANSPLANT P, V10, P223; GALE RP, 1989, LANCET, V2, P315; GIANNI AM, 1989, LANCET, V2, P580; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; HENON P, 1988, BONE MARROW TRANSPL, V3, P171; HENON P, 1988, BRIT J HAEMATOL, V70, P254, DOI 10.1111/j.1365-2141.1988.tb02474.x; HENON PR, 1990, HAEMATOLOGICA, V75, P53; JUTTNER CA, 1990, BONE MARROW TRANSPL, V5, P22; KESSINGER A, 1988, BLOOD, V71, P723; KESSINGER A, 1990, J CELL BIOCH S14A, V310, P310; KORBLING M, 1990, BONE MARROW TRANSPL, V5, P39; KORBLING M, 1986, BLOOD, V67, P529; MCCARTHY DM, 1984, CRC CR REV CL LAB SC, V20, P1; MICKLEM HS, 1975, NATURE, V256, P41, DOI 10.1038/256041a0; PETERS WP, 1989, BLOOD S, V74, P50; REIFFERS J, 1986, EXP HEMATOL, V14, P312; REIFFERS J, 1989, BONE MARROW TRANSPL, P331; RICHMAN CM, 1976, BLOOD, V47, P1031; SCHMITZ N, 1985, BRIT J HAEMATOL, V60, P239, DOI 10.1111/j.1365-2141.1985.tb07409.x; SHIOBARA S, 1982, TRANSPLANT P, V14, P429; TO LB, 1986, LANCET, V2, P404; TO LB, 1984, BRIT J HAEMATOL, V58, P399, DOI 10.1111/j.1365-2141.1984.tb03987.x; TO LB, 1987, LEUKEMIA RES, V11, P327, DOI 10.1016/0145-2126(87)90176-7; WALKER H, 1986, BRIT J HAEMATOL, V62, P385, DOI 10.1111/j.1365-2141.1986.tb02942.x; ZEHNBAUER BA, 1986, BLOOD, V67, P835; ZITTOUN R, 1990, BLOOD S1, V76, pA340	35	43	48	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					961	963		10.1016/0140-6736(91)91583-G	http://dx.doi.org/10.1016/0140-6736(91)91583-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678042				2022-12-28	WOS:A1991FH13100016
J	BARBACCI, M; REPKE, JT; CHAISSON, RE				BARBACCI, M; REPKE, JT; CHAISSON, RE			ROUTINE PRENATAL SCREENING FOR HIV-INFECTION	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; SEROPREVALENCE; NEWBORNS; WOMEN	Guidelines in most developed countries for testing pregnant women for HIV infection recommend that screening should be directed to groups with acknowledged risk factors for infection. Our prospective study of HIV seroprevalence among 2724 pregnant women in an inner-city area of Baltimore, USA, showed that if these guidelines had been applied only 57% of HIV-seropositive women would have been detected. By offering counselling and HIV testing to all pregnant women, the detection rate was raised to 87%. We conclude that screening directed at women who admit risk factors is not effective in identifying HIV-infected women and that routine HIV screening should be offered to all pregnant women.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University								ASCHER MS, 1987, SEROLOGIC TESTS HIV; BARBACCI MB, 1990, SEX TRANSM DIS, V17, P122, DOI 10.1097/00007435-199007000-00002; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; IPPOLITO G, 1989, IMPLICATIONS SIDA ME, P141; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; MINKOFF HL, 1988, AM J OBSTET GYNECOL, V159, P793, DOI 10.1016/S0002-9378(88)80136-4; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; PECKHAM CS, 1990, LANCET, V335, P516, DOI 10.1016/0140-6736(90)90746-R; 1989, MMWR, V38, pS1; 1985, MMWR, V34, P721; 1987, PREVENTION HUMAN IMM, P1; 1990, MARYLAND AIDS UPDATE	13	117	118	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					709	711		10.1016/0140-6736(91)90286-X	http://dx.doi.org/10.1016/0140-6736(91)90286-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672184	hybrid			2022-12-28	WOS:A1991FD36700016
J	MALCOLM, S; CLAYTONSMITH, J; NICHOLS, M; ROBB, S; WEBB, T; ARMOUR, JAL; JEFFREYS, AJ; PEMBREY, ME				MALCOLM, S; CLAYTONSMITH, J; NICHOLS, M; ROBB, S; WEBB, T; ARMOUR, JAL; JEFFREYS, AJ; PEMBREY, ME			UNIPARENTAL PATERNAL DISOMY IN ANGELMANS SYNDROME	LANCET			English	Article							PRADER-WILLI SYNDROME; PARENTAL ORIGIN; CHROMOSOME-15 DELETION	Angelman's syndrome and Prader-Willi syndrome are both causes of mental retardation with recognisable, but quite different, clinical phenotypes. Both are associated with deletions of chromosome 15q11-13, of maternal origin in Angelman's and paternal in Prader-Willi. Prader-Willi can arise by inheritance of two chromosomes 15 from the mother and none from the father (uniparental maternal disomy). In 2 patients with Angelman's syndrome we found evidence of uniparental paternal disomy. The phenotypic effects of maternal and paternal disomy of chromosome 15 are very different and inheritance of two normal 15s from one parent does not lead to normal development-strong evidence in man for genomic imprinting, in which the same gene has different effects dependent upon its parental origin.	UNIV BIRMINGHAM,DEPT CLIN GENET,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; HOSP SICK CHILDREN,DEPT NEUROL,LONDON WC1N 3JH,ENGLAND	University of Birmingham; University of Leicester; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	MALCOLM, S (corresponding author), INST CHILD HLTH,MOTHERCARE DEPT PAEDIAT GENET,GUILFORD ST,LONDON WC1N 1EH,ENGLAND.			Armour, John/0000-0002-8558-8506				ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; ARMOUR JAL, 1990, GENOMICS, V8, P501, DOI 10.1016/0888-7543(90)90037-U; BOYD SG, 1988, EUR J PEDIATR, V147, P508, DOI 10.1007/BF00441976; BUTLER MG, 1983, LANCET, V1, P1285; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CREASY MR, 1982, CHROMOSOME ABERRATIO, P122; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; IMAIZUMI K, 1990, AM J MED GENET, V35, P314, DOI 10.1002/ajmg.1320350305; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KNOLL JHM, 1989, HUM GENET, V83, P205, DOI 10.1007/BF00286723; LEDBETTER DH, 1988, PRADERWILLI SYNDROME, P13; MAGENIS RE, 1987, AM J MED GENET, V28, P829, DOI 10.1002/ajmg.1320280407; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1990, AM J HUM GENET S, V47, pA227; NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; PEMBREY M, 1989, J MED GENET, V26, P73, DOI 10.1136/jmg.26.2.73; RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313	24	267	267	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					694	697		10.1016/0140-6736(91)90278-W	http://dx.doi.org/10.1016/0140-6736(91)90278-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672177				2022-12-28	WOS:A1991FD36700008
J	BAIRD, PA; SADOVNICK, AD; YEE, IML				BAIRD, PA; SADOVNICK, AD; YEE, IML			MATERNAL AGE AND BIRTH-DEFECTS - A POPULATION STUDY	LANCET			English	Article							CONGENITAL-MALFORMATIONS; GENETIC-DISORDERS; MORTALITY; CHILDREN	Since more and more women in developed countries are delaying childbearing to an older age, it is important to find out whether birth defects, other than those resulting from chromosomal anomalies, are related to maternal age. We have studied all 26 859 children with birth defects of unknown aetiology identified among 576 815 consecutive livebirths in British Columbia. All these cases' records were linked with provincial birth records to allow determination of maternal age at birth. We excluded children with chromosomal anomalies and those with other birth defects of known aetiology. Only 3 of the 43 birth defect categories studied showed significant maternal-age-specific trends: there were decreasing linear trends with maternal age for patent ductus arteriosus (chi-2 = 36.65, 1 df, p < 0.01) and hypertrophic pyloric stenosis (chi-2 = 4.90, 1 df, p < 0.05) and a bell-shaped curve (risk increasing to maternal age 30 then falling) for congenital dislocatable hip/hip click. The findings from this population-based analysis of no association between the incidence of birth defects of unknown aetiology and advancing maternal age should be reassuring to healthy women who opt to delay childbearing.	MINIST HLTH BRITISH COLUMBIA, DIV VITAL STAT, HLTH SURVEILLANCE REGISTRY, VANCOUVER, BC, CANADA		BAIRD, PA (corresponding author), UNIV BRITISH COLUMBIA, DEPT MED GENET, 226-6174 UNIV BLVD, VANCOUVER V6T 1W5, BC, CANADA.							BAIRD PA, 1988, AM J HUM GENET, V42, P677; BECKER RA, 1984, INTERACTIVE ENV DATA, P426; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; BISHOP YMM, 1975, DISCRETE MULTIVARIAT, P357; BUGNON P, 1980, J GYNECOL OBST BIO R, V9, P405; Chung C S, 1975, Birth Defects Orig Artic Ser, V11, P1; CZEIZEL A, 1984, MUTAT RES, V128, P73, DOI 10.1016/0027-5107(84)90049-6; CZEIZEL A, 1988, MATURITAS, P73; ELWOOD JM, 1980, EPIDEMIOLOGY ANENCEP, P181; FLEISS JL, 1981, STATISTICAL METHODS, P138; FRIEDE A, 1988, OBSTET GYNECOL, V72, P152; GILLBERG C, 1982, DEV MED CHILD NEUROL, V24, P437; GILLBERG C, 1980, J AUTISM DEV DISORD, V10, P293, DOI 10.1007/BF02408288; HASSOLD T, 1980, ANN HUM GENET, V44, P29, DOI 10.1111/j.1469-1809.1980.tb00943.x; HAY S, 1972, TERATOLOGY, V6, P271, DOI 10.1002/tera.1420060304; Hook E B, 1979, Birth Defects Orig Artic Ser, V15, P81; JAYASEKARA R, 1978, J BIOSOC SCI, V10, P255, DOI 10.1017/S002193200001172X; KHOURY MJ, 1988, PEDIATRICS, V82, P83; KIELY JL, 1986, AM J EPIDEMIOL, V123, P444, DOI 10.1093/oxfordjournals.aje.a114259; MATSUNAGA E, 1980, TERATOLOGY, V21, P323, DOI 10.1002/tera.1420210308; Penrose LS, 1933, J GENET, V27, P219, DOI 10.1007/BF02984413; ROUX C, 1982, J GYNECOL OBST BIO R, V11, P215; TRIMBLE BK, 1978, AM J MED GENET, V2, P1, DOI 10.1002/ajmg.1320020102; Ventura S J, 1989, Vital Health Stat 21, P1; WARBURTON D, 1983, AM J HUM GENET, V35, P1059; YASIN SY, 1988, J REPROD MED, V33, P209	26	84	89	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 2	1991	337	8740					527	530		10.1016/0140-6736(91)91306-F	http://dx.doi.org/10.1016/0140-6736(91)91306-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671898				2022-12-28	WOS:A1991EZ87400013
J	FONSECA, V; THOMAS, M; KATRAK, A; SWENY, P; MOORHEAD, JF				FONSECA, V; THOMAS, M; KATRAK, A; SWENY, P; MOORHEAD, JF			CAN URINARY THYROID-HORMONE LOSS CAUSE HYPOTHYROIDISM	LANCET			English	Note								Four patients presented with nephrotic syndrome associated with hypothyroidism; none had thyroid antibodies. Hypothyroidism resolved on remission of nephrotic syndrome in two patients; thyroxine (T4) replacement was ineffective during periods of gross proteinuria in another; and the fourth had had normal thyroid function a year before presentation. Urinary T4 excretion was measured in ten further patients with proteinuria. It was detectable in the urine in five, who had significantly lower serum free T4 (8.5 [95% confidence interval 5.8-11.2] vs 13.9 [11.1-16.7] pmol/l; p < 0.01) and free triiodothyronine (3.1 [2.2-4.0] vs 4.9 [3.8-6.0] pmol/l; p < 0.01) concentrations than the five patients without detectable urinary T4.			FONSECA, V (corresponding author), ROYAL FREE HOSP,POND ST,LONDON NW3 2QG,ENGLAND.		Moorhead, John/M-7404-2014					AFRASIABI MA, 1979, ANN INTERN MED, V90, P335, DOI 10.7326/0003-4819-90-3-335; CHAN V, 1972, LANCET, V1, P4; GAVIN LA, 1978, J CLIN ENDOCR METAB, V46, P125, DOI 10.1210/jcem-46-1-125; HUNTER WM, 1983, IMMUNASSAYS CLIN CHE, P69; MOORHEAD JF, 1982, LANCET, V2, P1309; OREILLY DS, 1988, J ENDOCRINOL, V118, P349, DOI 10.1677/joe.0.1180349	6	35	37	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					475	476		10.1016/0140-6736(91)90546-2	http://dx.doi.org/10.1016/0140-6736(91)90546-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678446				2022-12-28	WOS:A1991GC15300006
J	JONES, AL; HILL, AS; SOUKOP, M; HUTCHEON, AW; CASSIDY, J; KAYE, SB; SIKORA, K; CARNEY, DN; CUNNINGHAM, D				JONES, AL; HILL, AS; SOUKOP, M; HUTCHEON, AW; CASSIDY, J; KAYE, SB; SIKORA, K; CARNEY, DN; CUNNINGHAM, D			COMPARISON OF DEXAMETHASONE AND ONDANSETRON IN THE PROPHYLAXIS OF EMESIS INDUCED BY MODERATELY EMETOGENIC CHEMOTHERAPY	LANCET			English	Article							CISPLATIN-INDUCED EMESIS; HIGH-DOSE METOCLOPRAMIDE; CANCER-CHEMOTHERAPY; RECEPTOR ANTAGONIST; ANTIEMETIC EFFICACY; INDUCED NAUSEA; GR-38032F; SEROTONIN; PREVENTION; GR-C507/75	A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist - ondansetron - and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens. Patients were treated as outpatients and received intravenous ondansetron 4 mg or dexamethasone 8 mg before chemotherapy and oral maintenance (ondansetron 4 mg every 6 h and dexamethasone reducing from 4 mg to 1 mg 6-hourly between days 1 and 5) for 5 days. 112 patients were treated (38 men, 73 women, 1 with no gender recorded; age range 30-73 years) and 100 were evaluable for cross-over analysis. Patients taking ondansetron or dexamethasone reported no significant difference in complete and major control of acute (83% vs 79%, p = 0.46) or delayed (82% vs 88%, p = 0.214) emesis (vomiting plus retches). Significantly more patients on dexamethasone (87%) than on ondansetron (72%) reported control of delayed nausea (days 2-5) (p = 0.003). Both drugs were well tolerated with no significant difference in the number of adverse events, and this is reflected by similar patient preference for ondansetron (40%) and dexamethasone (30%) (p = 0.244). Both drugs offer adequate out-patient control of chemotherapy-induced emesis; however, dexamethasone has an advantage in the control of delayed nausea, and also in terms of cost and resource allocation.	INST CANC RES,MED SECT,SUTTON SM2 5PT,SURREY,ENGLAND; BEATSON ONCOL CTR,GLASGOW,SCOTLAND; MATER HOSP,DEPT MED ONCOL,DUBLIN,IRELAND; HAMMERSMITH HOSP,DEPT CLIN ONCOL,LONDON W12 0HS,ENGLAND; ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT MED ONCOL,GLASGOW G4 0SF,SCOTLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; Beatson Oncology Centre; Mater Misericordiae University Hospital; University College Dublin; Imperial College London; University of Aberdeen; University of Glasgow; Royal Marsden NHS Foundation Trust				Cunningham, David/0000-0001-5158-1069				AAPRO M, 1983, J CLIN ONCOL, V2, P466; COATES A, 1983, EUR J CANCER CLIN ON, V19, P203, DOI 10.1016/0277-5379(83)90418-2; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, BRIT MED J, V295, P250, DOI 10.1136/bmj.295.6592.250; CUNNINGHAM D, 1987, LANCET, V1, P1461, DOI 10.1016/S0140-6736(87)92208-2; CUNNINGHAM D, 1989, LANCET, V1, P1323; DRAPKIN RL, 1982, P AN M AM SOC CLIN, V1, pC236; EISMAN JA, 1986, CONCURRENT THERAPY, V27, P42; HAWTHORN J, 1990, BRIT J CANCER, V61, P56, DOI 10.1038/bjc.1990.12; HESKETH PJ, 1989, J CLIN ONCOL, V7, P700, DOI 10.1200/JCO.1989.7.6.700; HUMPHREY PPA, 1984, NEUROPHARMACOLOGY, V23, P1503, DOI 10.1016/0028-3908(84)90094-7; IBRAHIM EM, 1986, EUR J CANCER CLIN ON, V22, P283, DOI 10.1016/0277-5379(86)90392-5; KENWARD MG, 1987, APPL STAT-J ROY ST C, V36, P192, DOI 10.2307/2347551; KILPATRICK GJ, 1987, NATURE, V330, P746, DOI 10.1038/330746a0; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; KRIS MG, 1988, J CLIN ONCOL, V6, P659, DOI 10.1200/JCO.1988.6.4.659; LINDLEY CM, 1989, J CLIN ONCOL, V7, P1142, DOI 10.1200/JCO.1989.7.8.1142; MARKMAN M, 1984, NEW ENGL J MED, V311, P549, DOI 10.1056/NEJM198408303110901; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MORRAN C, 1979, BMJ-BRIT MED J, V1, P1323, DOI 10.1136/bmj.1.6174.1323-a; OLVER IN, 1986, CANCER TREAT REP, V70, P555; RICH WM, 1980, GYNECOL ONCOL, V9, P193, DOI 10.1016/0090-8258(80)90027-X; SCHMOLL HJ, 1989, EUR J CANCER CLIN ON, V25, P535	24	186	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					483	487		10.1016/0140-6736(91)90554-3	http://dx.doi.org/10.1016/0140-6736(91)90554-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678453				2022-12-28	WOS:A1991GC15300014
J	EHRNST, A; LINDGREN, S; DICTOR, M; JOHANSSON, B; SONNERBORG, A; CZAJKOWSKI, J; SUNDIN, G; BOHLIN, AB				EHRNST, A; LINDGREN, S; DICTOR, M; JOHANSSON, B; SONNERBORG, A; CZAJKOWSKI, J; SUNDIN, G; BOHLIN, AB			HIV IN PREGNANT-WOMEN AND THEIR OFFSPRING - EVIDENCE FOR LATE TRANSMISSION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VERTICAL TRANSMISSION; MATERNAL ANTIBODIES; CHILDREN BORN; INFECTION; TYPE-1; BLOOD; PLACENTA; INFANTS; MOTHERS	To assess the role of maternal viraemia in vertical transmission of HIV and the extent to which viraemia occurs during the various stages of pregnancy, we have attempted to detect human immunodeficiency virus (HIV) in 44 pregnant HIV-1 infected women during 47 pregnancies (30 continued, 17 aborted) and in 30 children and 12 fetuses. Infectious HIV was detected at some time during pregnancy in 59% of women from plasma and in 83% from either peripheral blood mononuclear cells or plasma. HIV was not isolated from any of the newborn babies (0/27) at birth. The mothers had a significantly higher frequency of viraemia during pregnancy than their children had by 6 months of age (p = 0.002); by this time HIV was recovered from 5 (26%) of 19 infants. HIV was not detected by virus isolation, in-situ hybridisation, or polymerase chain reaction (PCR) in 10 fetuses; the other 2 fetuses were positive either by in-situ hybridisation or by PCR but neither result could be confirmed in a second organ or by the other methods of detection. The findings show that there is no consistent spread of HIV across the placenta during maternal viraemia, and indicate that in most cases transmission occurs close to or at delivery.	HUDDINGE UNIV HOSP,DEPT OBSTET & GYNAECOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN; UNIV LUND HOSP,DEPT PATHOL,S-22185 LUND,SWEDEN	Karolinska Institutet; Karolinska Institutet; Lund University; Skane University Hospital	EHRNST, A (corresponding author), STOCKHOLM CTY COUNCIL,CENT MICROBIOL LAB,DEPT VIROL,BOX 70470,S-10726 STOCKHOLM,SWEDEN.		Sönnerborg, Anders/W-2011-2019	Sönnerborg, Anders/0000-0001-8928-3374				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; GENDELMAN HE, 1986, IN SITU HYBRIDIZATIO, P203; GOEDERT JJ, 1989, LANCET, V2, P1351; GREENSPOON JS, 1989, AM J OBSTET GYNECOL, V161, P501, DOI 10.1016/0002-9378(89)90556-5; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOUSSET C, 1990, HUM PATHOL, V21, P404, DOI 10.1016/0046-8177(90)90202-G; JOVAISAS E, 1985, LANCET, V2, P1129; LYNMAN WD, 1990, AIDS, V4, P917; MARION RW, 1987, AM J DIS CHILD, V141, P429, DOI 10.1001/archpedi.1987.04460040087022; MARION RW, 1986, AM J DIS CHILD, V140, P429; MYERS G, 1990, HUMAN RETROVIRUSES A; PEUCHMAUR M, 1989, AM J OBSTET GYNECOL, V160, P765, DOI 10.1016/S0002-9378(89)80083-3; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUBINSTEIN A, 1986, CLIN IMMUNOL IMMUNOP, V40, P115, DOI 10.1016/0090-1229(86)90074-7; Rubinstein A, 1986, Curr Probl Pediatr, V16, P361; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; Siegel S., 1988, NONPARAMETRIC STAT B; SONNERBORG A, IN PRESS AIDS RES HU; SONNERBORG A, IN PRESS IMMUNOL INF; SPRECHER S, 1986, LANCET, V2, P288; 1991, LANCET, P253; [No title captured]	29	192	193	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					203	207		10.1016/0140-6736(91)90347-R	http://dx.doi.org/10.1016/0140-6736(91)90347-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676777				2022-12-28	WOS:A1991FY50400002
J	SETH, R; RAYMOND, FD; MAKGOBA, MW				SETH, R; RAYMOND, FD; MAKGOBA, MW			CIRCULATING ICAM-1 ISOFORMS - DIAGNOSTIC PROSPECTS FOR INFLAMMATORY AND IMMUNE DISORDERS	LANCET			English	Note							INTERCELLULAR-ADHESION MOLECULE-1; EXPRESSION; LIGAND; CELLS	Intercellular adhesion molecule-1 (ICAM-1, CD54) is an important early marker of immune activation and response. Evidence on its role has come from immunohistological staining of tissues, since no free circulating ICAM-1 has been detected. By means of monoclonal antibodies against ICAM-1 and a sensitive chemiluminescence technique, free circulating ICAM-1 was detected in serum from sixteen healthy young volunteers. The concentrations varied among the subjects. Non-denaturing gel separation methods showed that ICAM-1 circulates in at least three isoforms, the proportions of which also varied. These findings have important implications for the investigation, diagnosis, and therapeutic monitoring of various inflammatory, neoplastic, and immune disorders.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,DIV MOLEC ENDOCRINOL,DU CANE RD,LONDON W12 0NN,ENGLAND	Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS DH, 1989, LANCET, V2, P1122; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P831; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; VOGETSEDER W, 1989, INT J CANCER, V43, P768, DOI 10.1002/ijc.2910430504; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WEETMAN AP, 1989, J ENDOCRINOL, V122, P185, DOI 10.1677/joe.0.1220185	10	392	402	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					83	84		10.1016/0140-6736(91)90077-3	http://dx.doi.org/10.1016/0140-6736(91)90077-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676471				2022-12-28	WOS:A1991FW16100006
J	ABRAHAMSON, S				ABRAHAMSON, S			THE DOMINANCE OF RESEARCH IN STAFFING OF MEDICAL-SCHOOLS - TIME FOR A CHANGE	LANCET			English	Article											ABRAHAMSON, S (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED EDUC,1975 ZONAL AVE,KAM 200,LOS ANGELES,CA 90033, USA.							ABRAHAMSON S, 1988, TEACHING LEARNING ME, V1; ABRAHAMSON S, 1990, 29TH ANN RIME C SAN; ABRAHAMSON S, 1990, TEACH LEARN MED, V2, P120; MULLER S, 1984, J MED ED 2, V59	4	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1586	1588		10.1016/0140-6736(91)93275-E	http://dx.doi.org/10.1016/0140-6736(91)93275-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675720				2022-12-28	WOS:A1991FU55100016
J	SWIFT, RI; DANPURE, HJ; OSMAN, S; GAER, J; TSIKOS, C; PETERS, AM; LAVENDER, JP; TEBBUT, S; HABIB, NA; WOOD, CB				SWIFT, RI; DANPURE, HJ; OSMAN, S; GAER, J; TSIKOS, C; PETERS, AM; LAVENDER, JP; TEBBUT, S; HABIB, NA; WOOD, CB			IMAGING OF METASTATIC COLORECTAL-CANCER WITH TUMOR-ACTIVATED KILLER LYMPHOCYTES	LANCET			English	Note							INFILTRATING LYMPHOCYTES; MELANOMA; INTERLEUKIN-2	Adoptive immunotherapy may be useful for treating or visualising metastatic cancer. Lymphocytes were taken from 6 patients with metastatic colorectal cancer and cultured with cells from the patients primary tumour to produce tumour-activated killer (TAK) lymphocytes. We re-injected each patient with In-111-labelled TAK cells in order to visualise metastases. Images were taken with a gamma-camera for up to 48 h after injection. Metastases were revealed as early as 4 h in the lung and as late as 48 h in the abdomen. Liver images produced "cold" spots corresponding to metastatic lesions. Lymph nodes were not visualised. Re-injection of TAK cells raised against autologous colorectal tumours reveals the sites of metastases.	HAMMERSMITH HOSP,DEPT SURG,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,MRC,CYCLOTRON UNIT,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,DEPT DIAGNOST RADIOL,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London; Imperial College London								BALCH CM, 1990, ARCH SURG-CHICAGO, V125, P200; FISHER B, 1989, J CLIN ONCOL, V7, P250, DOI 10.1200/JCO.1989.7.2.250; GRIFFITH KD, 1989, J NATL CANCER I, V81, P1709, DOI 10.1093/jnci/81.22.1709; LAVENDER JP, 1977, BRIT MED J, V2, P797, DOI 10.1136/bmj.2.6090.797; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SWIFT RI, IN PRESS EUR J SURG	7	10	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1511	1512		10.1016/0140-6736(91)93199-J	http://dx.doi.org/10.1016/0140-6736(91)93199-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675372				2022-12-28	WOS:A1991FT11600006
J	BRAHAMS, D				BRAHAMS, D			DISCIPLINARY PROCEEDINGS BEFORE THE GMC - ALL MATTERS TO BE CONSIDERED TOGETHER	LANCET			English	Editorial Material																		1988, GENERAL MED COUNCIL	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					907	907		10.1016/0140-6736(91)90226-F	http://dx.doi.org/10.1016/0140-6736(91)90226-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672981				2022-12-28	WOS:A1991FG04800017
J	COWLEY, AJ; FULLWOOD, LJ; MULLER, AF; STAINER, K; SKENE, AM; HAMPTON, JR				COWLEY, AJ; FULLWOOD, LJ; MULLER, AF; STAINER, K; SKENE, AM; HAMPTON, JR			EXERCISE CAPABILITY IN HEART-FAILURE - IS CARDIAC-OUTPUT IMPORTANT AFTER ALL	LANCET			English	Article							CAPACITY; PERFORMANCE	The exercise capability of 39 patients with severe chronic heart failure was assessed in several ways and compared with measurements of cardiac output. The relation between cardiac index and exercise tolerance measured on a treadmill was poor (r = 0.191, p = 0.245). However, exercise tolerance measured with a series of self-paced corridor walk tests showed moderate correlations with cardiac index (r = -0.404, p = 0.015 to r = -0.516, p = 0.001) and customary activity assessed by step counting correlated better with cardiac index (r = 0.537, p < 0.001). Cardiac output therefore seems to be a factor determining patients' exercise capability when they choose their own walking speed but not when they undergo formal treadmill tests in the laboratory.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,BRITISH HEART FDN STAT GRP,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	COWLEY, AJ (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.							BASSEY EJ, 1987, EUR J APPL PHYSIOL O, V56, P323, DOI 10.1007/BF00690900; COWLEY AJ, 1986, BRIT HEART J, V55, P75; COWLEY AJ, 1986, LANCET, V2, P1422; FRANCIOSA JA, 1979, AM J MED, V67, P460, DOI 10.1016/0002-9343(79)90794-0; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; FRANCIOSA JA, 1980, AM J MED, V69, P559, DOI 10.1016/0002-9343(80)90468-4; LIPKIN DP, 1986, BRIT MED J, V292, P635; MASSIE BM, 1984, CIRCULATION, V69, P1135, DOI 10.1161/01.CIR.69.6.1135; PACKER M, 1985, CIRCULATION, V71, P761, DOI 10.1161/01.CIR.71.4.761; WILSON JR, 1985, CIRCULATION, V71, P57, DOI 10.1161/01.CIR.71.1.57	10	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					771	773		10.1016/0140-6736(91)91381-4	http://dx.doi.org/10.1016/0140-6736(91)91381-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672400				2022-12-28	WOS:A1991FD88400013
J	SONG, G; HANG, CS; HUANG, YC; HOU, FY				SONG, G; HANG, CS; HUANG, YC; HOU, FY			PRELIMINARY TRIALS OF INACTIVATED VACCINE AGAINST HEMORRHAGIC-FEVER WITH RENAL SYNDROME	LANCET			English	Letter									MINIST PUBL HLTH,CHANGCHUN INST BIOL PROD,CHANGCHUN,PEOPLES R CHINA		SONG, G (corresponding author), CHINESE ACAD PREVENT MED,INST VIROL,BEIJING 100052,PEOPLES R CHINA.							HAN HZ, 1990, CHIN J PUBL HLTH, V9, P73; Liu PQ, 1984, B JIANGXI MED COLL, V3, P1; SONG G, 1984, LANCET, V1, P677	3	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					801	801		10.1016/0140-6736(91)91431-S	http://dx.doi.org/10.1016/0140-6736(91)91431-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672432				2022-12-28	WOS:A1991FD88400056
J	SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G				SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G			CONTRACEPTIVE EFFECTS OF EXTENDED LACTATIONAL AMENORRHEA - BEYOND THE BELLAGIO CONSENSUS	LANCET			English	Article								We have recorded the duration of lactational anovulation and amenorrhoea in a well-nourished group of Australian women who breastfed their babies throughout the study. The data enabled us to compare the theoretical cumulative probability of conception among breastfeeding women who had unprotected intercourse irrespective of their menstrual status with that of those who had unprotected intercourse only during lactational amenorrhoea. Breastfeeding alone is not an effective form of contraception, since all the women in our study resumed normal ovulation while still breastfeeding. However, among women who have unprotected intercourse only during lactational amenorrhoea but adopt other contraceptive measures when they resume menstruation, only 1.7% would have become pregnant during the first 6 months of amenorrhoea, only 7% after 12 months, and only 13% after 24 months. Thus for our women it would be possible to extend the Bellagio Consensus Conference guidelines which stated that lactational amenorrhoea can only be relied on as a contraceptive for the first 6 months post-partum in women who are fully or almost fully breastfeeding. The lactational amenorrhoea method can be relied on for excellent contraceptive protection in the first 6 months of breastfeeding, irrespective of when supplements are introduced into the baby's diet; for women who continue to breastfeed the method can also give good protection for up to 12 months post partum. Once menstruation has returned, other forms of contraception are essential to prevent pregnancy.	NURSING MOTHERS ASSOC AUSTRALIAL,NUNAWADING,AUSTRALIA; MONASH UNIV,DEPT ANAT,MELBOURNE,VIC 3004,AUSTRALIA	Monash University	SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,MELBOURNE 3168,AUSTRALIA.		Shaw, Geoff/A-6916-2012	Shaw, Geoff/0000-0002-7421-7136; Renfree, Marilyn/0000-0002-4589-0436				GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LEWIS PR, IN PRESS FERTIL STER; RODRIGUEZ G, 1988, BREASTFEEDING LENGTH; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; THAPA S, 1988, NATURE, V335, P679, DOI 10.1038/335679a0; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; 1988, LANCET, V2, P1204	8	75	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					715	717		10.1016/0140-6736(91)90288-Z	http://dx.doi.org/10.1016/0140-6736(91)90288-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672186				2022-12-28	WOS:A1991FD36700018
J	MACKIE, RM; BUFALINO, R; MORABITO, A; SUTHERLAND, C; CASCINELLI, N				MACKIE, RM; BUFALINO, R; MORABITO, A; SUTHERLAND, C; CASCINELLI, N			LACK OF EFFECT OF PREGNANCY ON OUTCOME OF MELANOMA	LANCET			English	Article							MALIGNANT-MELANOMA; REPRODUCTIVE FACTORS; RISK	To determine the effect of pregnancy on prognosis in melanoma we investigated 388 women treated for stage 1 primary cutaneous disease during their childbearing years. 85 women had been treated before any pregnancy, 92 during pregnancy, 143 after they had completed all pregnancies, and 68 between pregnancies. Women who had received treatment while pregnant had primary tumours of significantly greater thickness than did those in the other three groups (p = 0.002). Other possible confounding factors (site, age, parity) did not differ between the groups. Once tumour thickness was controlled for, survival rate of women in whom melanoma was diagnosed and treated while they were pregnant did not differ from that in the other three groups. Cox regression analysis showed no differences between the three groups of women who were not pregnant at diagnosis. Women with melanoma should be advised about pregnancy on the basis of thickness and site of tumour and evidence of vascular spread, and not hormonal status.	IST NAZL STUDIO & CURA TUMORI,I-20133 MILAN,ITALY; TULANE UNIV,DEPT SURG,NEW ORLEANS,LA 70118	Fondazione IRCCS Istituto Nazionale Tumori Milan; Tulane University	MACKIE, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							BALCH CM, 1985, CUTANEOUS MELANOMA, P328; GALLAGHER RP, 1985, BRIT J CANCER, V52, P901, DOI 10.1038/bjc.1985.275; HOUGHTON AN, 1981, CANCER-AM CANCER SOC, V48, P407, DOI 10.1002/1097-0142(19810715)48:2<407::AID-CNCR2820480231>3.0.CO;2-L; LANDTHALER M, 1985, DEUT MED WOCHENSCHR, V110, P1319, DOI 10.1055/s-2008-1069002; MACKIE RM, 1989, LANCET, V2, P487; MACKIE RM, 1985, LANCET, V2, P859; MORABITO A, 1980, ANAL DONNEES 1980; OSTERLIND A, 1988, INT J CANCER, V42, P821, DOI 10.1002/ijc.2910420603; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SHIU MH, 1976, CANCER, V37, P181, DOI 10.1002/1097-0142(197601)37:1<181::AID-CNCR2820370126>3.0.CO;2-F; SLINGLUFF CL, 1990, ANN SURG, V211, P552, DOI 10.1097/00000658-199005000-00005; SUTHERLAND CM, 1983, J SURG ONCOL, V22, P191, DOI 10.1002/jso.2930220312; SUTHERLAND CM, 1983, SURG GYNECOL OBSTET, V157, P443; WONG JH, 1989, ARCH SURG-CHICAGO, V124, P1227	14	117	119	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					653	655		10.1016/0140-6736(91)92462-B	http://dx.doi.org/10.1016/0140-6736(91)92462-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1672000				2022-12-28	WOS:A1991FB73000013
J	SOMA, M; FUMAGALLI, R; PAOLETTI, R; MESCHIA, M; MAINI, MC; CROSIGNANI, P; GHANEM, K; GAUBATZ, J; MORRISETT, JD				SOMA, M; FUMAGALLI, R; PAOLETTI, R; MESCHIA, M; MAINI, MC; CROSIGNANI, P; GHANEM, K; GAUBATZ, J; MORRISETT, JD			PLASMA LP(A) CONCENTRATION AFTER ESTROGEN AND PROGESTAGEN IN POSTMENOPAUSAL WOMEN	LANCET			English	Letter							LIPOPROTEIN LP(A)		UNIV MILAN,DEPT OBSTET & GYNAECOL,I-20122 MILAN,ITALY; BAYLOR UNIV,METHODIST HOSP,HOUSTON,TX 77030	University of Milan; Baylor University; The Methodist Hospital System; The Methodist Hospital - Houston	SOMA, M (corresponding author), UNIV MILAN,INST PHARMACOL SCI,I-20133 MILAN,ITALY.							DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; MESCHIA M, 1989, 45TH ANN M AM FERT S, P1068; Sandkamp M, 1990, LIPOPROTEIN A, P205	6	127	129	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					612	612		10.1016/0140-6736(91)91674-J	http://dx.doi.org/10.1016/0140-6736(91)91674-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671962				2022-12-28	WOS:A1991FA70200029
J	VINCENT, A; HEITZ, D; PETIT, C; KRETZ, C; OBERLE, I; MANDEL, JL				VINCENT, A; HEITZ, D; PETIT, C; KRETZ, C; OBERLE, I; MANDEL, JL			ABNORMAL PATTERN DETECTED IN FRAGILE-X PATIENTS BY PULSED-FIELD GEL-ELECTROPHORESIS	NATURE			English	Article							MENTAL-RETARDATION; MUTATION; INHERITANCE; EXPRESSION; MARKERS; MALES	THE fragile-X syndrome is the most frequent inherited form of mental retardation, with an incidence of 1 in 1,500 males. It is characterized by the presence of a fragile site at Xq27.3 induced in vitro by folate deprivation or by inhibitors of deoxynucleotide synthesis 1. Its mode of inheritance is unusual for an X-linked trait, with incomplete penetrance in both males and females. Some phenotypically normal males transmit the mutation to all their daughters who rarely express any symptoms, but penetrance is high in sons and daughters of these carrier women 2. Genetic and physical mapping of the Xq27-q28 region has confirmed that the disease locus is located at or very near the fragile site 3-6. Hypotheses proposed to account for the abnormalities in the inheritance of the disease include sequence rearrangements by meiotic recombination 1,7,8 or a mutation that affects reactivation of an inactive X chromosome during differentiation of female germ cells 9,10. To detect such rearrangements, or methylation changes that may reflect a locally inactive X chromosome, we used pulsed-field gel analysis of DNA from fragile-X patients with probes close to the fragile-X locus. The probe Do33 (DXS465) detected abnormal patterns in fragile-X patients, but not in normal controls or in non-expressing male transmitters.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Petit, Christine/0000-0002-9069-002X				BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LEDBETTER DH, 1986, NATURE, V324, P161, DOI 10.1038/324161a0; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1986, P NATL ACAD SCI USA, V83, P1016, DOI 10.1073/pnas.83.4.1016; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SUTHERS GK, 1990, AM J HUM GENET, V47, P187; SUTHERS GK, 1989, SCIENCE, V246, P1298, DOI 10.1126/science.2573953; SUTHERS GK, IN PRESS AM J HUM GE; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856	14	195	198	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					624	626		10.1038/349624a0	http://dx.doi.org/10.1038/349624a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1672039				2022-12-28	WOS:A1991EX57000064
J	BRAHAMS, D				BRAHAMS, D			PERTUSSIS-VACCINE AND ENCEPHALOPATHY, AN IRISH CASE	LANCET			English	Editorial Material																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					305	305		10.1016/0140-6736(91)90437-T	http://dx.doi.org/10.1016/0140-6736(91)90437-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677124				2022-12-28	WOS:A1991FZ56500018
J	KUCK, KH; SCHLUTER, M; GEIGER, M; SIEBELS, J; DUCKECK, W				KUCK, KH; SCHLUTER, M; GEIGER, M; SIEBELS, J; DUCKECK, W			RADIOFREQUENCY CURRENT CATHETER ABLATION OF ACCESSORY ATRIOVENTRICULAR PATHWAYS	LANCET			English	Article							PARKINSON-WHITE SYNDROME; ELECTRODE CONFIGURATION; CONDUCTION; TACHYCARDIA; BLOCK	Tachyarrhythmias mediated by an accessory atrioventricular pathway and which are refractory to drug therapy have been treated surgically with variable success. Early results of direct-current catheter ablation were encouraging but were associated with complications such as barotrauma and the need for a general anaesthetic. We have investigated the endocardial application of radiofrequency current which is a potentially safer technique. Of 105 patients with an accessory atrioventricular pathway, 79 were located on the left side of the heart and 32 on the right side. Accessory pathway conduction was permanently abolished in 93 (89%) patients. Complications developed in 3 patients: thrombotic occlusion of a femoral artery, arteriovenous fistula formation at the site of groin puncture, and left ventricular rupture with cardiac tamponade after direct-current shocks. There were no deaths from the procedure. We conclude that radiofrequency current catheter ablation is both effective and safe for patients with symptomatic tachyarrhythmias mediated by accessory atrioventricular pathways.			KUCK, KH (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,DEPT CARDIOL,W-2000 HAMBURG 20,GERMANY.		Poposka, Lidija/N-6851-2019	Poposka, Lidija/0000-0002-2539-6828				BECKER AE, 1978, CIRCULATION, V57, P870, DOI 10.1161/01.CIR.57.5.870; BORGGREFE M, 1987, J AM COLL CARDIOL, V10, P576, DOI 10.1016/S0735-1097(87)80200-0; COX JL, 1985, J THORAC CARDIOV SUR, V90, P490; EVANS GT, 1988, PACE, V11, P1621, DOI 10.1111/j.1540-8159.1988.tb06284.x; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; JACKMAN W, 1990, CIRCULATION, V82, P689; JACKMAN WM, 1983, CIRCULATION, V68, P906, DOI 10.1161/01.CIR.68.5.906; JACKMAN WM, 1988, CIRCULATION, V78, P1288, DOI 10.1161/01.CIR.78.5.1288; JACKMAN WM, IN PRESS CIRCULATION; KUCK KH, 1990, CIRCULATION, V82, P407, DOI 10.1161/01.CIR.82.2.407; KUCK KH, 1989, PACE, V12, P1681, DOI 10.1111/j.1540-8159.1989.tb01847.x; KUCK KH, 1988, EUR HEART J, V9, P927, DOI 10.1093/oxfordjournals.eurheartj.a062589; KUCK KH, IN PRESS PACE; KUNZE KP, 1985, J AM COLL CARDIOL, V6, P1428, DOI 10.1016/S0735-1097(85)80236-9; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; MORADY F, 1990, CIRCULATION, V82, P689; MORADY F, 1989, CIRCULATION, V79, P1160, DOI 10.1161/01.CIR.79.6.1160; NATHAN AW, 1984, LANCET, V1, P1280; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; WARD DE, 1985, BRIT HEART J, V53, P64	20	333	343	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1557	1561		10.1016/0140-6736(91)93258-B	http://dx.doi.org/10.1016/0140-6736(91)93258-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675706				2022-12-28	WOS:A1991FU55100002
J	HELEWA, A; GOLDSMITH, CH; LEE, P; BOMBARDIER, C; HANES, B; SMYTHE, HA; TUGWELL, P				HELEWA, A; GOLDSMITH, CH; LEE, P; BOMBARDIER, C; HANES, B; SMYTHE, HA; TUGWELL, P			EFFECTS OF OCCUPATIONAL-THERAPY HOME SERVICE ON PATIENTS WITH RHEUMATOID-ARTHRITIS	LANCET			English	Article								Because there is little information about the efficacy of home occupational therapy, we decided to assess the effects of a home service on patients with rheumatoid arthritis. 105 patients aged 18-70 years, on stable medical therapy, were randomised to receive a 6-week comprehensive programme of occupational therapy (experimental group, 53 patients) or to receive no such treatment (control group, 52). At 6 weeks, control patients received the experimental regimen, and experimental patients were continued on treatment as needed up to 12 weeks. Outcomes were measured at baseline, 6, and 12 weeks with a global functional capacity score (functional score). At 6 weeks the functional score for the experimental group was significantly higher than that for the control group (mean difference = 8.1, 95% Cl 1-7 to 15.8, p = 0.012). Control patients at 12 weeks showed a similar improvement to experimental patients at 6 weeks, and between 6 and 12 weeks the experimental patients were stable. Occupational therapy leads to a statistically significant and clinically important improvement in function in patients with rheumatoid arthritis.	MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA; ARTHRITIS SOC OCCUPAT THERAPY SERV, ONTARIO DIV, TORONTO, ONTARIO, CANADA; WELLESLEY COLL HOSP, DEPT RHEUMATOL, TORONTO M4Y 1J3, ONTARIO, CANADA	McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	HELEWA, A (corresponding author), UNIV WESTERN ONTARIO, ELBORN COLL, DEPT PHYS THERAPY, LONDON N6G 1H1, ONTARIO, CANADA.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				ALTMAN DG, 1985, STATISTICIAN, V34, P125; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; COHEN S, 1966, J CHRON DIS, V19, P631; DEBBECQ AL, GUIDE NOMINAL GROUP; EBERL DR, 1976, ARTHRITIS RHEUM, V19, P1278, DOI 10.1002/art.1780190608; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GOLDSMITH C H, 1987, Arthritis and Rheumatism, V30, pS101; HELEWA A, 1987, J RHEUMATOL, V14, P87; HUSKISSON EC, 1982, J RHEUMATOL, V9, P768; MEENAN RF, 1980, ARTHRITIS RHEUM, V23, P146, DOI 10.1002/art.1780230203; MOWAT AG, 1980, ANN RHEUM DIS, V39, P12, DOI 10.1136/ard.39.1.12; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SMYTHE HA, 1977, J RHEUMATOL, V4, P144; 1955, ANN RHEUM DIS, V14, P353	14	48	48	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 15	1991	337	8755					1453	1456		10.1016/0140-6736(91)93138-Y	http://dx.doi.org/10.1016/0140-6736(91)93138-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675329				2022-12-28	WOS:A1991FR06000015
J	BRIDGES, BA; COLE, J; ARLETT, CF; GREEN, MHL; WAUGH, APW; BEARE, D; HENSHAW, DL; LAST, RD				BRIDGES, BA; COLE, J; ARLETT, CF; GREEN, MHL; WAUGH, APW; BEARE, D; HENSHAW, DL; LAST, RD			POSSIBLE ASSOCIATION BETWEEN MUTANT FREQUENCY IN PERIPHERAL LYMPHOCYTES AND DOMESTIC RADON CONCENTRATIONS	LANCET			English	Article							LEUKEMIA; CELLS; LUNG	To investigate whether previously found geographical correlations between leukaemia incidence and exposure to radon are reflected in a detectable mutagenic effect on individuals, the frequency of mutations in the hypoxanthine guanine phosphoribosyl transferase gene (hprt) in peripheral blood T lymphocytes was measured in subjects with known domestic radon concentrations. These concentrations were measured in December, 1989, in house in Street, Somerset, UK, by passive alpha-track radon detectors. 20 non-smoking subjects aged 36-55 years were selected from the patient list at the local health centre on the basis of the radon concentrations in their homes - the range selected varied by a factor of ten. Blood samples for preparation of T lymphocytes were taken in July, 1990. There was a significant association between the log mutant frequency and radon concentration (t = 3.47, p < 0.01). A second analysis of a further set of radon measurements (October, 1990, to January, 1991), in both living rooms and bedrooms, and repeated mutant frequency determinations also showed a significant relation, which remained significant even after exclusion of the highest frequency and adjustment for subject's age and cloning efficiency. These data must be regarded as preliminary and further more extensive studies should be done to determine whether the observed association is causal.	UNIV BRISTOL, HH WILLS PHYS LAB, BRISTOL BS8 1TL, AVON, ENGLAND; HLTH CTR, SOMERSET, ENGLAND	University of Bristol	BRIDGES, BA (corresponding author), UNIV SUSSEX, MRC, CELL MUTAT UNIT, BRIGHTON BN1 9RR, ENGLAND.							ALEXANDER FE, 1990, LANCET, V335, P1336; BAVERSTOCK KF, 1990, LANCET, V335, P1337; BRIDGES BA, 1989, LEUKEMIA, V3, P846; CLARKE RH, 1989, NATURE, V338, P197, DOI 10.1038/338197a0; COLE J, 1990, PROG CLIN BIOL RES, V340, P25; COLE J, 1988, MUTAT RES, V204, P493, DOI 10.1016/0165-1218(88)90044-4; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; HOLT PG, 1988, IMMUNOLOGY, V64, P649; HOLT PG, 1986, CLIN EXP IMMUNOL, V66, P188; LUCIE NP, 1989, LANCET, V2, P99; Pabst R, 1988, Adv Exp Med Biol, V237, P553; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; Pohl-Ruling J., 1988, BERZELIUS S, P103; RICHARDSON RB, IN PRESS BR J RADIOL; SANKARANARAYANAN K, 1988, AM J HUM GENET, V42, P651; THACKER J, IN PRESS ADV RAD BIO; WRIXON AD, 1988, R190 NAT RAD PROT BO; 1988, BIER4 REP	18	69	71	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1187	1189		10.1016/0140-6736(91)92859-Z	http://dx.doi.org/10.1016/0140-6736(91)92859-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673739				2022-12-28	WOS:A1991FM26100004
J	HURWITZ, B; ASSERSON, T				HURWITZ, B; ASSERSON, T			TAX-EXEMPTION FOR SEVERE MENTAL IMPAIRMENT	LANCET			English	Editorial Material											HURWITZ, B (corresponding author), THE SURGERY,1 ASHBY GROVE,LONDON N1 3PR,ENGLAND.							1991, MENTAL IMPAIRMENT SE, P7; 1989, PLCO8912 DEP HLTH ME; 1990, PLCO907 DEP HLTH MEM	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1147	1148		10.1016/0140-6736(91)92803-A	http://dx.doi.org/10.1016/0140-6736(91)92803-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL124	1674026				2022-12-28	WOS:A1991FL12400017
J	BRENNER, TJ; DAHL, KE; OLSON, B; MILLER, G; ANDIMAN, WA				BRENNER, TJ; DAHL, KE; OLSON, B; MILLER, G; ANDIMAN, WA			RELATION BETWEEN HIV-1 SYNCYTIUM INHIBITION ANTIBODIES AND CLINICAL OUTCOME IN CHILDREN	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENVELOPE GLYCOPROTEIN; AIDS RETROVIRUS; HTLV-III; INVOLVEMENT; ASSOCIATION; RECEPTOR; ANTIGEN; FUSION; TYPE-1	Syncytium formation, a feature of HIV-1-induced cytopathology, allows the virus to propagate through cell-to-cell spread. An assay has been developed to measure antibodies (syncytium inhibition, SI) that inhibit this process. Two cell lines were used: the indicator cells, which are not HIV-1 infected, bear CD4 receptors on their surface; the fusogenic HIV-1 infected cells, which do not release virus but are responsible for initiating syncytium formation, are free of CD4 receptors. Co-cultivation of about 10(5) of each of these cells induces the emergence of 70-100 multinucleated giant cells within 48 h. Sera from 34 children born to HIV-1-infected mothers were tested by western blot (WB) and SI assay. SI antibodies were detected in the blood of 15 (65%) of 23 WB-positive children and in none of 11 WB-negative children. There were striking differences in prevalence and titre of SI antibodies in children with lymphocytic interstitial pneumonitis (LIP) compared with those with opportunistic infections (OI). All 8 children with LIP had SI antibodies ranging in titre from 40 to > 320. By contrast, only 2 of 7 with OI had SI antibodies, in both of whom the SI titre was 20 (p < 0.05). No sera from children who had seroreverted contained SI antibodies. The findings point to the need to identify the specific HIV-I peptides or epitopes responsible for syncytium formation since SI antibodies correlate with clinical outcome in children.	YALE UNIV,SCH MED,DEPT PEDIAT,333 CEDAR ST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT LAB MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Yale University					NIAID NIH HHS [AI21186] Funding Source: Medline; NIDA NIH HHS [R01-DA05899] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI021186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005899] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDIMAN WA, 1985, LANCET, V2, P1390; ANDIMAN WA, 1990, AM J DIS CHILD, V144, P758, DOI 10.1001/archpedi.1990.02150310026020; DAHL KE, 1990, J VIROL, V64, P1771, DOI 10.1128/JVI.64.4.1771-1783.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; GOEDERT JJ, 1989, LANCET, V2, P1351; HILDRETH JEK, 1989, SCIENCE, V244, P1075, DOI 10.1126/science.2543075; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HO DD, 1990, IN PRESS J VIROL; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LJUNGGREN K, 1990, J INFECT DIS, V161, P198, DOI 10.1093/infdis/161.2.198; MARTIN K, 1987, J INFECT DIS, V155, P54, DOI 10.1093/infdis/155.1.54; ROBERTGUROFF M, 1987, PEDIATR RES, V21, P547, DOI 10.1203/00006450-198706000-00008; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; SHARER LR, 1985, HUM PATHOL, V16, P760, DOI 10.1016/S0046-8177(85)80245-8; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; VALENTIN A, 1990, J IMMUNOL, V144, P934; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7; WILSON G, 1979, VIROLOGY, V95, P351, DOI 10.1016/0042-6822(79)90490-2; YOFFE B, 1987, P NATL ACAD SCI USA, V84, P1429, DOI 10.1073/pnas.84.5.1429	23	14	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1001	1005		10.1016/0140-6736(91)92660-T	http://dx.doi.org/10.1016/0140-6736(91)92660-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673167	hybrid			2022-12-28	WOS:A1991FJ13500004
J	SACHDEV, HPS; KRISHNA, J; PURI, RK; SATYANARAYANA, L; KUMAR, S				SACHDEV, HPS; KRISHNA, J; PURI, RK; SATYANARAYANA, L; KUMAR, S			WATER SUPPLEMENTATION IN EXCLUSIVELY BREAST-FED INFANTS DURING SUMMER IN THE TROPICS	LANCET			English	Article							HOT CLIMATE	This study was designed to determine the need for water supplementation to maintain water homoeostasis in exclusively breastfed infants during summer in a tropical country. A prestudy questionnaire revealed that 97% of 34 nurses and 63% of 70 doctors advocated such supplementation. 45 healthy, male, exclusively breastfed babies, aged 1-4 months, were recruited from a well-baby clinic. 9 who had never received supplemental water plus a random selection of 14 others were allocated to group I (breastmilk only); the remaining 22 infants were allocated to group II (breastmilk plus supplemental fluid according to the mother's usual practice). The babies were studied at the hospital for 8 h; breastmilk intake was measured by weighing the infant before and after each feed, water intake by calibrated bottles, and urine output by accurate collection and measurement. The maximum room temperatures were 34-41-degrees-C and relative humidities 9-60% (below 50% in all but 3 infants). In group II the mean water intake was 11% (95% confidence interval 7-16%) of the total fluid intake. Both breastmilk intake (274 vs 210 ml) and total fluid intake (274 vs 233 ml) were higher in group I than in group II (p = 0.003, p = 0.073, respectively), after adjustment for age, weight, length, room temperature, and humidity. However, there were no significant differences between the groups in urine output, urine or serum osmolality, weight change, or rectal temperature whether or not the factors adjusted for included total fluid intake. Thus, exclusively breastfed infants do not need supplemental water to maintain water homoeostasis; a reduced breastmilk intake is a potential disadvantage of this practice.	INDIAN COUNCIL MED RES, NEW DELHI, INDIA; MAULANA AZAD MED COLL, DEPT PEDIAT, NEW DELHI, INDIA; MAULANA AZAD MED COLL, INST CYTOL & PREVENT ONCOL, NEW DELHI, INDIA	Indian Council of Medical Research (ICMR); Maulana Azad Medical College; Indian Council of Medical Research (ICMR); ICMR - National Institute of Cancer Prevention & Research (NICPR); Maulana Azad Medical College			Krishna, Jyoti/K-7288-2019	Sachdev, Harshpal Singh/0000-0002-4956-9391				ALMROTH SG, 1978, AM J CLIN NUTR, V31, P1154, DOI 10.1093/ajcn/31.7.1154; ARMELINI PA, 1979, CLIN PEDIATR, V18, P424, DOI 10.1177/000992287901800709; ARNEIL GC, 1984, TXB PEDIATRICS, P261; BAUER JD, 1982, CLIN LABORATORY METH, P31; BEHAR M, 1987, Indian Pediatrics, V24, P837; BLACK RE, 1982, T ROY SOC TROP MED H, V76, P259, DOI 10.1016/0035-9203(82)90292-9; BROWN KH, 1986, J PEDIATR-US, V108, P677, DOI 10.1016/S0022-3476(86)81040-X; GOLDBERG NM, 1983, ARCH DIS CHILD, V58, P73, DOI 10.1136/adc.58.1.73; GUIGNARD JP, 1987, PEDIATR NEPHROL, P921; HUGHES JG, 1984, SYNOPSIS PEDIATRICS, P167; HYDE TA, 1983, LYNCHS MED LABORATOR, P83; MARTINES JC, 1989, B WORLD HEALTH ORGAN, V67, P151; SPOCK B, 1976, BABY CHILDCARE, P158; WHITEHEAD RG, 1982, ACTA PAEDIATR SCAND, P43; ZIAI M, 1975, PEDIATRICS, P162; ZIEGLER EE, 1971, J PEDIATR-US, V78, P561, DOI 10.1016/S0022-3476(71)80456-0; 1974, BETTER HOMES GARDENS, P162	17	59	64	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1991	337	8747					929	933		10.1016/0140-6736(91)91568-F	http://dx.doi.org/10.1016/0140-6736(91)91568-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678028				2022-12-28	WOS:A1991FH13100001
J	EASTERBROOK, PJ; BERLIN, JA; GOPALAN, R; MATTHEWS, DR				EASTERBROOK, PJ; BERLIN, JA; GOPALAN, R; MATTHEWS, DR			PUBLICATION BIAS IN CLINICAL RESEARCH	LANCET			English	Article							META-ANALYSIS; TRIALS; HYPOTHESIS; DESIGN	In a retrospective survey, 487 research projects approved by the Central Oxford Research Ethics Committee between 1984 and 1987, were studied for evidence of publication bias. As of May, 1990, 285 of the studies had been analysed by the investigators, and 52% of these had been published. Studies with statistically significant results were more likely to be published than those finding no difference between the study groups (adjusted odds ratio [OR] 2.32; 95% confidence interval [Cl] 1.25-4.28). Studies with significant results were also more likely to lead to a greater number of publications and presentations and to be published in journals with a high citation impact factor. An increased likelihood of publication was also associated with a high rating by the investigator of the importance of the study results, and with increasing sample size. The tendency towards publication bias was greater with observational and laboratory-based experimental studies (OR = 3.79; 95% Cl = 1.47-9.76) than with randomised clinical trials (OR = 0.84; 95% Cl = 0.34-2.09). We have confirmed the presence of publication bias in a cohort of clinical research studies. These findings suggest that conclusions based only on a review of published data should be interpreted cautiously, especially for observational studies. Improved strategies are needed to identify the results of unpublished as well as published studies.	UNIV PENN,SCH MED,GEN INTERNAL MED SECT,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; JOHN RADCLIFFE HOSP,CENT OXFORD RES ETH COMM,OXFORD OX3 9DU,ENGLAND	University of Pennsylvania; University of Oxford	EASTERBROOK, PJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INTERNAL MED,BALTIMORE,MD 21205, USA.		Easterbrook, Philippa J/A-3937-2009	Easterbrook, Philippa/0000-0002-2603-5418				ANGELL M, 1989, NEW ENGL J MED, V321, P464, DOI 10.1056/NEJM198908173210708; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BEGG CB, 1985, STAT MED, V4, P1, DOI 10.1002/sim.4780040103; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; COURSOL A, 1986, PROF PSYCHOL-RES PR, V17, P136, DOI 10.1037/0735-7028.17.2.136; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1988, CONTROL CLIN TRIALS, V9, P76; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Dickersin K, 1990, CONTROLLED CLIN TRIA, V11, P255; EASTERBROOK P, 1987, BRIT MED J, V295, P1347, DOI 10.1136/bmj.295.6609.1347-a; EASTERBROOK PJ, IN PRESS STAT MED; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GARFIELD E, 1977, SCI INFORMATION A, V10, P1; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; Iyengar S., 1988, STAT SCI, V3, P109, DOI DOI 10.1214/SS/1177013012; KLEIN S, 1986, CANCER, V58, P1378, DOI 10.1002/1097-0142(19860915)58:6<1378::AID-CNCR2820580635>3.0.CO;2-S; KOCHAR MS, 1986, J CHRON DIS, V39, P147, DOI 10.1016/0021-9681(86)90071-8; KOREN G, 1989, LANCET, V2, P1440; LAURITSEN K, 1987, LANCET, V1, P1091; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P240; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SACKS HS, 1983, ARCH INTERN MED, V143, P753, DOI 10.1001/archinte.143.4.753; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; Smith ML, 1980, EVALUATION ED INT RE, V4, P22, DOI DOI 10.1016/0191-765X(80)90004-X; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137	28	2193	2215	4	153	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					867	872		10.1016/0140-6736(91)90201-Y	http://dx.doi.org/10.1016/0140-6736(91)90201-Y			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672966				2022-12-28	WOS:A1991FG04800001
J	TULPPALA, M; VIINIKKA, L; YLIKORKALA, O				TULPPALA, M; VIINIKKA, L; YLIKORKALA, O			THROMBOXANE DOMINANCE AND PROSTACYCLIN DEFICIENCY IN HABITUAL ABORTION	LANCET			English	Article							RECURRENT ABORTION; PREGNANCY; WOMEN	To evaluate the significance of vasoactive prostanoids in habitual abortion, we measured urinary excretion of prostacyclin metabolites (6-keto-PGF1-alpha and 2,3-dinor-6-keto-PGF1-alpha) and of thromboxane A2 metabolites (TxB2 and 2,3-dinor-TxB2) during 25 pregnancies in 22 women with recurrent spontaneous abortion (RSA). The control group were 16 pregnant women with no history of abortion. Ultrasound examination at first follow-up appointment showed a living fetus in 23 pregnancies of women with RSA. 9 of these pregnancies ended in abortion; 14 continued to term as did all the pregnancies in the control group. Compared with controls, women with RSA had a lower (p < 0.05) ratio of prostacyclin to thromboxane between weeks 4 and 7 of gestation and a lower (p < 0.01) output of 2,3-dinor-6-keto-PGF1-alpha between weeks 8 and 11. Women whose pregnancies ended in abortion had higher (p < 0.05) output of 2,3-dinor-TxB2 between weeks 4 and 7 of gestation and lower (p < 0.01) excretion of 2,3-dinor-6-keto-PGF1-alpha between weeks 8 and 11 compared with women whose pregnancies proceeded to term. We conclude that deficiency of vasodilatory prostacyclin may be a factor in habitual abortion.	UNIV CENT HOSP HELSINKI,DEP OBSTET & GYNAECOL 1,SF-00290 HELSINKI,FINLAND; UNIV CENT HOSP HELSINKI,CHILDRENS HOSP,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	TULPPALA, M (corresponding author), UNIV CENT HOSP HELSINKI,DEPT OBSTET & GYNAECOL 2,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							CASEY ML, 1986, SEMIN PERINATOL, V10, P270; DECASTELLARNAU C, 1988, EUR J OBSTET GYN R B, V29, P173, DOI 10.1016/0028-2243(88)90145-1; FRIEDMAN SA, 1988, OBSTET GYNECOL, V71, P122; GOLAN A, 1989, FERTIL STERIL, V51, P747; HILL JA, 1990, AM J REPROD IMMUNOL, V22, P33, DOI 10.1111/j.1600-0897.1990.tb01029.x; JOGEE M, 1983, BRIT J OBSTET GYNAEC, V90, P247, DOI 10.1111/j.1471-0528.1983.tb08618.x; MCNEELY MJ, 1988, FERTIL STERIL, V50, P1; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; NOORT WA, 1990, EUR J OBSTET GYN R B, V35, P15, DOI 10.1016/0028-2243(90)90137-P; PARISI VM, 1986, SEMIN PERINATOL, V10, P288; PORTNOI MF, 1988, OBSTET GYNECOL, V72, P31; REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A; Rushton DI, 1988, EARLY PREGNANCY LOSS, P149; SCOTT JR, 1987, OBSTET GYNECOL, V70, P645; STIRRAT GM, 1990, LANCET, V336, P728, DOI 10.1016/0140-6736(90)92215-4; WALLENBURG HCS, 1986, LANCET, V1, P1; WALSH SW, 1990, SEMIN PERINATOL, V14, P152; YLIKORKALA O, 1986, J CLIN ENDOCR METAB, V63, P1307, DOI 10.1210/jcem-63-6-1307; YLIKORKALA O, 1985, AM J OBSTET GYNECOL, V152, P318, DOI 10.1016/S0002-9378(85)80221-0	19	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					879	881		10.1016/0140-6736(91)90205-4	http://dx.doi.org/10.1016/0140-6736(91)90205-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672969				2022-12-28	WOS:A1991FG04800004
J	HOEH, WR; BLAKLEY, KH; BROWN, WM				HOEH, WR; BLAKLEY, KH; BROWN, WM			HETEROPLASMY SUGGESTS LIMITED BIPARENTAL INHERITANCE OF MYTILUS MITOCHONDRIAL-DNA	SCIENCE			English	Article							EVOLUTIONARY GENETICS; D-LOOP; GALLOPROVINCIALIS; NUCLEAR; EDULIS	Strict maternal inheritance of mitochondrial DNA is commonly observed in animals. There is usually only one mitochondrial DNA population (homoplasmy) within an individual. Mussels of the Mytilus edulis species group appear to be exceptions in both respects. Of 150 Mytilus individuals examined, 85 were heteroplasmic. Mitochondrial DNA types within heteroplasmic individuals differed greatly; in one comparison, the inferred sequence difference was 20 +/- 5 percent. Homoplasmic individuals with mitochondrial DNA similar to the heteroplasmic mitochondrial DNA types were found. These observations are best explained by the hypothesis that biparental inheritance of mitochondrial DNA can occur in Mytilus.	UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MUSEUM ZOOL,MOLEC SYSTEMAT LAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								Avise J.C., 1983, P147; AVISE JC, 1986, PHILOS T ROY SOC B, V312, P325, DOI 10.1098/rstb.1986.0011; BAYNE B. L., 1965, OPHELIA, V2, P1; BIRKY CW, 1989, GENETICS, V121, P613; Brown W.M., 1985, MOL EVOLUTIONARY GEN, P399; DENSMORE LD, 1985, GENETICS, V110, P689; Field IA, 1922, B BUR FISH WASH, V38, P127; GOSLING EM, 1984, MALACOLOGIA, V25, P551; HARRISON RG, 1985, SCIENCE, V228, P1446, DOI 10.1126/science.228.4706.1446; HOEH WR, UNPUB; KONDO R, 1990, GENETICS, V126, P657; LANSMAN RA, 1983, EVOLUTION, V37, P1, DOI 10.1111/j.1558-5646.1983.tb05509.x; LONGO FJ, 1969, J EXP ZOOL, V172, P97, DOI 10.1002/jez.1401720108; MCDONALD JH, 1988, MAR BIOL, V99, P111, DOI 10.1007/BF00644984; Meves F., 1915, Arch Mikr Anat Bonn Abt ii, V87; MORITZ C, 1986, SCIENCE, V233, P1425, DOI 10.1126/science.3018925; NEI M, 1983, GENETICS, V105, P207; OLIVO PD, 1983, NATURE, V306, P400, DOI 10.1038/306400a0; SATTA Y, 1988, GENET RES, V52, P1, DOI 10.1017/S0016672300027245; SNYDER M, 1987, P NATL ACAD SCI USA, V84, P7595, DOI 10.1073/pnas.84.21.7595; VARVIO SL, 1988, MAR BIOL, V98, P51, DOI 10.1007/BF00392658; VAWTER L, 1986, SCIENCE, V234, P194, DOI 10.1126/science.3018931	22	168	178	5	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1488	1490		10.1126/science.1672472	http://dx.doi.org/10.1126/science.1672472			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1672472				2022-12-28	WOS:A1991FC85300049
J	DRISCOLL, M; CHALFIE, M				DRISCOLL, M; CHALFIE, M			THE MEC-4 GENE IS A MEMBER OF A FAMILY OF CAENORHABDITIS-ELEGANS GENES THAT CAN MUTATE TO INDUCE NEURONAL DEGENERATION	NATURE			English	Article							TRANSPOSABLE ELEMENT; CDNA SEQUENCE; RAT-BRAIN; PROTEIN; CHANNEL; RECEPTOR; MOUSE; TRANSFORMATION; ACTIVATION; MEMBRANE	Three dominant mutations of mec-4, a gene needed for mechanosensation, cause the touch-receptor neurons of Caenorhabditis elegans to degenerate. With deg-1, another C. elegans gene that can mutate to induce neuronal degeneration and that is similar in sequence, mec-4 defines a new gene family. Cross-hybridizing sequences are detectable in other species, raising the possibility that degenerative conditions in other organisms may be caused by mutations in similar genes. All three dominant mec-4 mutations affect the same amino acid. Effects of amino-acid substitutions at this position suggest that steric hindrance may induce the degenerative state.			DRISCOLL, M (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,1012 SHERMAN FAIRCHILD CTR,NEW YORK,NY 10027, USA.							ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P859; BRENNER S, 1974, GENETICS, V77, P71; CADDY KWT, 1975, BRAIN RES, V91, P276, DOI 10.1016/0006-8993(75)90548-X; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COOMBE PE, 1986, J NEUROGENET, V3, P135, DOI 10.3109/01677068609106845; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN MC, 1972, SCIENCE, V176, P800, DOI 10.1126/science.176.4036.800; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN RK, 1987, GENETICS, V116, P377; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIRANO A, 1974, J NEUROPATH EXP NEUR, V34, P1; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDIS SC, 1978, J COMP NEUROL, V177, P125, DOI 10.1002/cne.901770109; MESSER A, 1987, J NEUROGENET, V4, P201, DOI 10.3109/01677068709102341; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAI T, 1988, J BIOCHEM-TOKYO, V103, P281, DOI 10.1093/oxfordjournals.jbchem.a122261; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	44	462	480	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					588	593		10.1038/349588a0	http://dx.doi.org/10.1038/349588a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1672038				2022-12-28	WOS:A1991EX57000051
J	STANFORD, JL; GRANGE, JM; POZNIAK, A				STANFORD, JL; GRANGE, JM; POZNIAK, A			IS AFRICA LOST	LANCET			English	Editorial Material							PULMONARY TUBERCULOSIS; MYCOBACTERIUM-VACCAE; IMMUNOTHERAPY		ROYAL BROMPTON & NATL HEART HOSP,LONDON,ENGLAND; UNIV ZIMBABWE,DEPT MED,HARARE,ZIMBABWE	Imperial College London; University of Zimbabwe	STANFORD, JL (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,RIDING HOUSE ST,LONDON W1P 7LD,ENGLAND.							BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; BALASUBRAMANIAN R, 1990, TUBERCLE, V71, P253, DOI 10.1016/0041-3879(90)90037-9; Ferebee SH, 1969, ADV TUBERC RES, V17, P29; FESTENSTEIN F, 1991, J APPL BACTERIOL, V17, P19; MICHIHIKO S, 1989, LANCET, V1, P1206; Pozniak A, 1987, B INT UNION TUBERC L, V62, P39; ROOK GAW, 1981, TUBERCLE, V62, P63, DOI 10.1016/0041-3879(81)90038-6; ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O; SAIDI KG, 1989, INT J LEPROSY, V57, P45; STANFORD JL, 1991, APMIS, V99, P103, DOI 10.1111/j.1699-0463.1991.tb05127.x; STANFORD JL, 1990, TUBERCLE, V71, P87, DOI 10.1016/0041-3879(90)90002-P; 1988, AM REV RESPIR DIS, V137, P1147	12	54	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					557	558		10.1016/0140-6736(91)91113-9	http://dx.doi.org/10.1016/0140-6736(91)91113-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678812				2022-12-28	WOS:A1991GD00200016
J	CONNOLLY, MJ; ASTRIDGE, PS; WHITE, EG; MORLEY, CA; COWAN, JC				CONNOLLY, MJ; ASTRIDGE, PS; WHITE, EG; MORLEY, CA; COWAN, JC			TORSADES-DE-POINTES VENTRICULAR-TACHYCARDIA AND TERODILINE	LANCET			English	Note							URINARY-INCONTINENCE	We report five patients (four women, one man; mean age 74 years, range 55-87) taking terodiline who had torsades de pointes ventricular tachycardia associated with prolongation of the QT interval. The QT interval was normal before the introduction of terodiline in three patients and returned to normal after terodiline withdrawal in four. Atrioventricular conduction disturbance or bradycardia were evident in all patients. Terodiline should be prescribed with caution to elderly patients.	GEN INFIRM,DEPT CARDIOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; ST LUKES HOSP,DEPT GERIATR MED,BRADFORD,ENGLAND; ST LUKES HOSP,DEPT CARDIOL,BRADFORD,ENGLAND	Leeds General Infirmary								COWAN JC, 1991, OXFORD TXB ADVERSE D; DAVIES SW, 1991, BRIT MED J, V302, P1276, DOI 10.1136/bmj.302.6787.1276; HALLEN B, 1989, EUR J CLIN PHARMACOL, V36, P487, DOI 10.1007/BF00558074; HUSTED S, 1980, ACTA PHARMACOL TOX, V46, P20; LANGTRY HD, 1990, DRUGS, V40, P748, DOI 10.2165/00003495-199040050-00008; LECLERCQ JF, 1983, ARCH MAL COEUR VAISS, V76, P341; MCLEOD AA, 1991, BRIT MED J, V302, P1469, DOI 10.1136/bmj.302.6790.1469-c; PURITZ R, 1977, BRIT MED J, V2, P608, DOI 10.1136/bmj.2.6087.608; SMITH WM, 1980, ANN INTERN MED, V93, P578, DOI 10.7326/0003-4819-93-4-578	9	65	67	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					344	345		10.1016/0140-6736(91)90481-4	http://dx.doi.org/10.1016/0140-6736(91)90481-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677700				2022-12-28	WOS:A1991GA60700006
J	GRAHAM, NMH; ZEGER, SL; PARK, LP; PHAIR, JP; DETELS, R; VERMUND, SH; HO, MT; SAAH, AJ				GRAHAM, NMH; ZEGER, SL; PARK, LP; PHAIR, JP; DETELS, R; VERMUND, SH; HO, MT; SAAH, AJ			EFFECT OF ZIDOVUDINE AND PNEUMOCYSTIS-CARINII PNEUMONIA PROPHYLAXIS ON PROGRESSION OF HIV-1 INFECTION TO AIDS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; EFFICACY; SULFAMETHOXAZOLE; PENTAMIDINE; SAFETY; AZT	Although used widely, the effectiveness of zidovudine therapy and primary prophylaxis for Pneumocystis carinii pneumonia (PCP) in HIV-1-infected individuals, has not been assessed in a large cohort. We have done an observational study between October, 1986, and October, 1990, of a cohort of 2145 HIV-1-seropositive men and 371 who seroconverted during the study. A Markov chain transitional analysis was used to examine the effect of zidovudine and PCP prophylaxis on the probability of progression of HIV-1 infection to AIDS (after 6,12,18, and 24 months) after follow-up visits categorised into one of six disease states. The six starting states were based on CD4+ lymphocyte counts and the presence of HIV-related symptoms. Use of pre-AIDS zidovudine and PCP prophylaxis was associated with significant reductions in rates of progression to AIDS at 6,12,18, and 24 months for participants starting with less than 350 CD4+ lymphocytes/mu-l. For those starting with 350 or more CD4+ lymphocytes/mu-l, non-significant protective trends were seen during 12, 18, and 24 month intervals. In multivariate log-linear models virtually all the treatment effect was due to zidovudine. However, after adjusting for the effects of zidovudine, PCP prophylaxis reduced significantly the probability of progression to a first episode of PCP during 6,12,18, and 24 month intervals. This study suggests that early primary PCP prophylaxis is effective in preventing first episodes of PCP, and that the efficacy of zidovudine demonstrated in clinical trials can be translated to the population level.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NORTHWESTERN UNIV,HOWARD BROWN MEM CLIN,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV PITTSBURGH,SCH PUBL HLTH,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15260	Johns Hopkins University; Johns Hopkins University; Northwestern University; Northwestern University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	GRAHAM, NMH (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.		Vermund, Sten/AAD-3592-2020	Vermund, Sten/0000-0001-7289-8698; Zeger, Scott/0000-0001-8907-1603	PHS HHS [N01-A1-72676, N01-A1-72634, N0-A1-32535] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRESTI A, 1990, CATEGORICAL DATA ANA, P406; BYAR DP, 1976, NEW ENGL J MED, V295, P74, DOI 10.1056/NEJM197607082950204; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GIRARD PM, 1989, LANCET, V1, P1348; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GREEN SB, 1984, STAT MED, V3, P361, DOI 10.1002/sim.4780030413; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; PHAIR J, 1990, NEW ENGL J MED, V332, P161; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR S1S, V36	18	164	164	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					265	269		10.1016/0140-6736(91)90414-K	http://dx.doi.org/10.1016/0140-6736(91)90414-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677108	hybrid			2022-12-28	WOS:A1991FZ56500001
J	DESMARCHAIS, JE				DESMARCHAIS, JE			FROM TRADITIONAL TO PROBLEM-BASED CURRICULUM - HOW THE SWITCH WAS MADE AT SHERBROOKE, CANADA	LANCET			English	Article											DESMARCHAIS, JE (corresponding author), UNIV SHERBROOKE,FAC MED,3001,12E AVE NORD,SHERBROOKE J1H 5N4,QUEBEC,CANADA.							ABRAHAMSON S, 1977, J MED EDUC, V53, P951; Barbeau D, 1990, ANN COMMUNITY ORIENT, V3, P25; Barrows H., 1980, PROBLEM BASED LEARNI; Barrows H., 1985, DESIGN PROBLEM BASED; DESMARCHAIS JE, 1990, CAN MED ASSOC J, V142, P734; DESMARCHAIS JE, 1990, ANN COMMUNITY ORIENT, V3, P35; DESMARCHAIS JE, 1990, ANN COMMUNITY ORIENT, V3, P9; GRANDMAISON P, 1991, CAN MED ASSOC J, V144, P557; GUILBERT JJ, 1985, REV ED MED, V4, P13; SPAULDING WB, 1969, CAN MED ASSOC J, V100, P659; 1984, PHYSICIANS 21ST CENT	11	32	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					234	237		10.1016/0140-6736(91)90359-W	http://dx.doi.org/10.1016/0140-6736(91)90359-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FY504	1676789				2022-12-28	WOS:A1991FY50400014
J	MENTER, A; BARKER, JNWN				MENTER, A; BARKER, JNWN			PSORIASIS IN PRACTICE	LANCET			English	Article							CYCLOSPORINE THERAPY; METHOTREXATE; PUVA		GUYS HOSP,DEPT DERMATOL,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	MENTER, A (corresponding author), BAYLOR UNIV,MED CTR,DEPT DERMATOL,3409 WORTH ST,DALLAS,TX 75246, USA.		menter md, alan/A-8250-2009	Barker, Jonathan/0000-0002-9030-183X				CAMP R, 1988, J INVEST DERMATOL, V90, P550; DAVID M, 1989, J AM ACAD DERMATOL, V21, P511, DOI 10.1016/S0190-9622(89)70217-6; ELLIS CN, 1986, JAMA-J AM MED ASSOC, V256, P3110, DOI 10.1001/jama.256.22.3110; ELLIS CN, 1987, J AM ACAD DERMATOL, V16, P267, DOI 10.1016/S0190-9622(87)70037-1; FRADIN MS, 1990, J AM ACAD DERMATOL, V23, P1265, DOI 10.1016/0190-9622(90)70353-J; GILBERT SC, 1989, J AM ACAD DERMATOL, V21, P470, DOI 10.1016/S0190-9622(89)70209-7; GILBERT SC, 1990, ARCH INTERN MED, V150, P889, DOI 10.1001/archinte.150.4.889; Goeckerman W., 1925, NW MED, V24, P229; GUPTA AK, 1989, J AM ACAD DERMATOL, V20, P797, DOI 10.1016/S0190-9622(89)70092-X; INGRAM JT, 1953, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.4836.591; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; LECZINSKY C G, 1948, Acta Derm Venereol, V28, P483; MARKS JM, 1986, BRIT J DERMATOL, V115, P745, DOI 10.1111/j.1365-2133.1986.tb06663.x; MOLL JMH, 1979, CLIN ORTHOP RELAT R, V143, P66; MUELLER W, 1979, NEW ENGL J MED, V301, P555; PERTOZZI JW, 1978, BRIT J DERMATOL, V98, P437; ROEGNIK K, 1988, J AM ACAD DEMRATOL, V19, P145; ROENIGK HH, 1983, CLEVELAND CLIN Q, V50, P107, DOI 10.3949/ccjm.50.2.107; SCHAEFER H, 1980, BRIT J DERMATOL, V102, P571, DOI 10.1111/j.1365-2133.1980.tb07657.x; SILVERMAN AK, 1987, J AM ACAD DERMATOL, V16, P1027, DOI 10.1016/S0190-9622(87)70133-9; Squire B, 1876, BRIT MED J, V2, P819; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; WRIGHT V, 1985, TXB RHEUMATOLOGY, P1021; ZAIAS N, 1969, ARCH DERMATOL, V99, P567, DOI 10.1001/archderm.99.5.567; 1986, TXB DERMATOLOGY 4TH, P1480	26	29	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					231	234		10.1016/0140-6736(91)90358-V	http://dx.doi.org/10.1016/0140-6736(91)90358-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676788				2022-12-28	WOS:A1991FY50400013
J	DIAMOND, MS; STAUNTON, DE; MARLIN, SD; SPRINGER, TA				DIAMOND, MS; STAUNTON, DE; MARLIN, SD; SPRINGER, TA			BINDING OF THE INTEGRIN MAC-1 (CD11B/CD18) TO THE 3RD IMMUNOGLOBULIN-LIKE DOMAIN OF ICAM-1 (CD54) AND ITS REGULATION BY GLYCOSYLATION	CELL			English	Article								Both the integrins LFA-1 and Mac-1 bind to ICAM-1, an immunoglobulin superfamily member. Previously, we localized the binding sites of LFA-1 and the major group of human rhinoviruses to the first NH2-terminal immunoglobulin-like domain of ICAM-1. Here, we show that the binding site on ICAM-1 for Mac-1 is unexpectedly distinct from that for LFA-1 and maps to the third NH2-terminal immunoglobulin-like domain. These findings provide a function for the tandem duplication of immunoglobulin-like domains in ICAM-1 and have implications for other immunoglobulin superfamily members. Mutations at two sites in the third domain that destroy consensus sequences for N-linked glycosylation enhance binding to purified Mac-1. Agents that interfere with carbohydrate processing provide evidence that the size of the N-linked oligosaccharide side chains on ICAM-1 affects binding to Mac-1 but not to LFA- 1. Thus, we suggest that the extent of glycosylation on ICAM-1 may regulate adhesion to LFA-1 or Mac-1 in vivo.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CTR BLOOD RES, BOSTON, MA 02115 USA; BOEHRINGER INGELHEIM PHARMACEUT, RIDGEFIELD, CT 06877 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Boehringer Ingelheim	DIAMOND, MS (corresponding author), HARVARD UNIV, SCH MED, COMM CELL & DEV BIOL, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Diamond, Michael/AAH-1733-2019	Diamond, Michael/0000-0002-8791-3165	NATIONAL CANCER INSTITUTE [R01CA031799, R37CA031799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NCI NIH HHS [CA31799] Funding Source: Medline; NIGMS NIH HHS [T32GM07753-11, T32 GM007753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BARTON RW, 1989, J IMMUNOL, V143, P1278; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BERNSTEIN ID, 1986, HUMAN MYELOID HEMATO, P1; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DEFOUGEROLLES AR, 1991, IN PRESS J EXP MED; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1989, COLD SPRING HARB SYM, V54, P753; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDELMAN GM, 1970, BIOCHEMISTRY-US, V9, P3197, DOI 10.1021/bi00818a012; FLAVIN T, 1991, TRANSPLANT P, V23, P533; FLEIT HB, 1989, LEUKOCYTE TYPING, V4, P579; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; HARLAN JM, 1985, BLOOD, V66, P167; HASKARD D, 1986, J IMMUNOL, V137, P2901; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HSIEH P, 1984, J BIOL CHEM, V259, P2375; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; JOHNSTON SC, 1990, J IMMUNOL, V145, P1181; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KRENSKY AM, 1983, J IMMUNOL, V131, P611; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1; LO SK, 1989, J IMMUNOL, V143, P3325; MAIO M, 1989, J IMMUNOL, V143, P181; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MILLER LJ, 1986, J IMMUNOL, V137, P2891; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; SPRINGER TA, 1987, CURRENT PROTOCOLS MO; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUMMER MD, 1988, MANUAL METHODS BACUL; TAKEI F, 1985, J IMMUNOL, V134, P1403; TOMASSINI JE, 1989, J BIOL CHEM, V264, P1656; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	73	734	768	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					961	971		10.1016/0092-8674(91)90548-D	http://dx.doi.org/10.1016/0092-8674(91)90548-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675157				2022-12-28	WOS:A1991FR04700007
J	ORMEROD, WE				ORMEROD, WE			UNJUSTIFIED DIAGNOSIS OF MENTAL DISORDER	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1331	1332		10.1016/0140-6736(91)92992-B	http://dx.doi.org/10.1016/0140-6736(91)92992-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP084	1674307				2022-12-28	WOS:A1991FP08400015
J	AYA, T; KINOSHITA, T; IMAI, S; KOIZUMI, S; MIZUNO, F; OSATO, T; SATOH, C; OIKAWA, T; KUZUMAKI, N; OHIGASHI, H; KOSHIMIZU, K				AYA, T; KINOSHITA, T; IMAI, S; KOIZUMI, S; MIZUNO, F; OSATO, T; SATOH, C; OIKAWA, T; KUZUMAKI, N; OHIGASHI, H; KOSHIMIZU, K			CHROMOSOME-TRANSLOCATION AND C-MYC ACTIVATION BY EPSTEIN-BARR-VIRUS AND EUPHORBIA-TIRUCALLI IN LYMPHOCYTES-B	LANCET			English	Note								Dual exposure to Epstein-Barr virus and purified 4-deoxyphorbol ester derived from the plant Euphorbia tirucalli induced a high frequency of chromosomal rearrangements in human B lymphocytes in vitro. Rearrangements most commonly affected chromosome 8, the chromosome most often showing structural changes in Burkitt's lymphoma (BL) cells. E tirucalli is indigenous in parts of Africa where BL is endemic and may be an important risk factor for the disease.	HOKKAIDO UNIV, SCH MED, INST CANC, DEPT VIROL, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO UNIV, FAC AGR, DEPT FOOD SCI & TECHNOL, KYOTO 606, JAPAN; HOKKAIDO UNIV, SCH MED, INST CANC, MOLEC GENET LAB, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Kyoto University; Hokkaido University								EPSTEIN MA, 1979, EPSTEINBARR VIRUS, P1; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; OSATO T, 1987, LANCET, V1, P1257	3	30	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1991	337	8751					1190	1190		10.1016/0140-6736(91)92861-U	http://dx.doi.org/10.1016/0140-6736(91)92861-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673740				2022-12-28	WOS:A1991FM26100005
J	YANG, ZH; STULZ, P; VONSEGESSER, L; BAUER, E; TURINA, M; LUSCHER, TF				YANG, ZH; STULZ, P; VONSEGESSER, L; BAUER, E; TURINA, M; LUSCHER, TF			DIFFERENT INTERACTIONS OF PLATELETS WITH ARTERIAL AND VENOUS CORONARY-BYPASS VESSELS	LANCET			English	Article							INTERNAL-MAMMARY-ARTERY; ENDOTHELIUM-DEPENDENT RELAXATION; NITRIC-OXIDE; RELAXING FACTOR; SAPHENOUS-VEIN; GRAFT; SEROTONIN; INHIBITOR; DISEASE	We studied the interaction of platelets with the wall of human internal mammary arteries and saphenous veins, suspended in organ chambers for measurement of isometric tension. Vessels were obtained during coronary bypass surgery and cut into 5 mm rings; in some the endothelium was chemically removed. Rings from several patients were randomly chosen for each experiment, and in each ring six concentrations of platelets (from healthy blood donors; 1-75 x 10(3)/mu-l) were tested consecutively and concentration-response curves constructed; the areas under these curves were used for statistical comparisons. In rings of internal mammary artery contracted in response to noradrenaline, aggregating platelets induced endothelium-dependent relaxation which was prevented by apyrase (0.67 U/ml ADPase activity) and L-N(G)-monomethylarginine (1 mmol/l). By contrast, in saphenous vein rings contracted in response to noradrenaline, aggregating platelets induced only a further increase in tension. In quiescent vessels, the platelet-induced contraction did not occur in arteries with endothelium but that in veins was greater and facilitated by endothelium. Preincubation of platelets with aspirin (10-mu-mol/l) reduced the contraction in both vessels, but contraction was abolished only in the presence of both the thromboxane receptor antagonist SQ-30741 and the serotoninergic (5HT2) receptor antagonist ketanserin. These findings show that platelet-derived ADP causes release of nitric oxide by the endothelium of internal mammary artery but not of saphenous vein; thromboxane A2 and serotonin mediate contraction in vein but not artery with endothelium. These differences may contribute to differences in graft function and the clinical efficacy of antiplatelet drugs.	UNIV HOSP BASEL,DEPT MED,DIV CARDIOL,CH-4031 BASEL,SWITZERLAND; UNIV HOSP ZURICH,DEPT CARDIOVASC SURG,CH-8091 ZURICH,SWITZERLAND; UNIV HOSP BASEL,DEPT RES,VASC RES LAB,CH-4031 BASEL,SWITZERLAND; UNIV HOSP BASEL,DEPT THORAC & CARDIAC SURG,CH-4031 BASEL,SWITZERLAND	University of Basel; University of Zurich; University Zurich Hospital; University of Basel; University of Basel								BAUMGARTNER HR, 1985, ANN NY ACAD SCI, V454, P162, DOI 10.1111/j.1749-6632.1985.tb11855.x; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; COHEN RA, 1983, SCIENCE, V221, P273, DOI 10.1126/science.6574604; COLIER BS, 1990, NEW ENGL J MED, V322, P33; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FUSTER V, 1986, CIRCULATION, V73, P227, DOI 10.1161/01.CIR.73.2.227; GAVAGHAN TP, 1990, J AM COLL CARDIOL, V15, P1250, DOI 10.1016/S0735-1097(10)80009-9; GRONDIN CM, 1984, CIRCULATION, V70, P208; HOUSTON DS, 1985, AM J PHYSIOL, V248, pH389, DOI 10.1152/ajpheart.1985.248.3.H389; LEHMACHER W, 1987, MED INFORMATIK STATI, P156; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Luscher T.F., 1990, ENDOTHELIUM MODULATO, V001-228; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PATSCHEKE H, 1990, BLUT, V60, P261, DOI 10.1007/BF01736225; PEPINE CJ, 1990, J AM COLL CARDIOL, V15, P1259, DOI 10.1016/S0735-1097(10)80010-5; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; SCHUMACHER WA, 1989, PROSTAGLANDINS, V38, P335, DOI 10.1016/0090-6980(89)90137-8; SINGH RN, 1983, CARDIOVASC INTER RAD, V6, P72, DOI 10.1007/BF02552775; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; Thom S, 1988, RELAXING CONTRACTING, P511; WILLERSON JT, 1989, CIRCULATION, V80, P206; YANG Z, 1991, CIRC RES, V68, P52, DOI 10.1161/01.RES.68.1.52; YANG ZH, 1989, CIRCULATION, V80, P1041, DOI 10.1161/01.CIR.80.4.1041	26	104	103	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					939	943		10.1016/0140-6736(91)91571-B	http://dx.doi.org/10.1016/0140-6736(91)91571-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678031				2022-12-28	WOS:A1991FH13100004
J	FAUCI, AS; SCHNITTMAN, SM; POLI, G; KOENIG, S; PANTALEO, G				FAUCI, AS; SCHNITTMAN, SM; POLI, G; KOENIG, S; PANTALEO, G			IMMUNOPATHOGENIC MECHANISMS IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CYTO-TOXIC LYMPHOCYTES; IMMUNE-DEFICIENCY SYNDROME; PERIPHERAL-BLOOD LYMPHOCYTES; TUMOR NECROSIS FACTOR; NF-KAPPA-B; T-CELL; SEROPOSITIVE INDIVIDUALS; NATURAL-KILLER; HTLV-III/LAV; MONONUCLEAR PHAGOCYTES	An understanding of the immunopathogenic mechanisms of infection with human immunodeficiency virus (HIV) is fundamental in developing successful approaches to designing effective therapeutic and vaccine strategies. In this regard, we have investigated the mechanisms by which HIV inserts itself into the human immune system and uses the elaborate cytokine network to its own replicative advantage. We have also shown that the burden of HIV in CD4+ T cells is directly associated with a decline in this cell population in vivo and a progression to disease. Mononuclear phagocytes may play a role in the pathogenesis of HIV infection by serving as reservoirs of the virus. Of note is the fact that monocytes in the peripheral blood of HIV-infected individuals are rarely infected in vivo, whereas infected-tissue macrophages may play a role in organ-specific HIV-related pathogenesis. The role of HIV-specific humoral and cell-mediated immunity in HIV infection is not well understood. However, fine specificity of responses against HIV have been delineated in some in-vitro systems. It is unclear why these responses, particularly HIV-specific cytolytic T-cell responses, diminish over the course of infection and are unable to contain progression of infection.			FAUCI, AS (corresponding author), NIAID, BLDG 31, ROOM 7A03, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Pantaleo, Giuseppe/K-6163-2016					AOKI S, 1989, INTERSCIENCE C ANTIM; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BONAVIDA B, 1986, J IMMUNOL, V137, P1157; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BREEN EC, 1990, J IMMUNOL, V144, P480; CARNEY WP, 1983, J IMMUNOL, V130, P390; CERAMI A, 1988, IMMUNOL TODAY, V9, P28, DOI 10.1016/0167-5699(88)91353-9; CHAYT KJ, 1986, JAMA-J AM MED ASSOC, V256, P2356, DOI 10.1001/jama.256.17.2356; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DEVASH Y, 1990, J IMMUNOL, V87, P3445; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ERICKSONMILLER CL, 1988, EXP HEMATOL, V16, P184; FAUCI AS, 1989, ANN INTERN MED, V110, P373, DOI 10.7326/0003-4819-110-5-373; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS T, 1986, J IMMUNOL, V136, P4049; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GOEDERT JJ, 1989, LANCET, V2, P1351; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1990, 6TH P INT C AIDS, V1, P152; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1990, J IMMUNOL, V145, P127; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOUP RA, 1989, BLOOD, V73, P1909; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LANE HC, 1985, ANNU REV IMMUNOL, V3, P477, DOI 10.1146/annurev.iy.03.040185.002401; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LANE HC, 1988, LANCET, V2, P1218; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINKERISRAELI M, 1988, CLIN EXP IMMUNOL, V73, P236; LUM LG, 1987, BLOOD, V69, P369; LYERLY HK, 1987, AIDS RES HUM RETROV, V3, P409, DOI 10.1089/aid.1987.3.409; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; MASSARI FE, 1990, J IMMUNOL, V144, P4628; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MITCHELL LC, 1989, J IMMUNOL, V142, P1548; MORETTA A, 1990, J EXP MED, V171, P695, DOI 10.1084/jem.171.3.695; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NARA PL, 1989, VACCINES 89 MODERN A, P137; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PERNO CF, 1990, J EXP MED, V171, P1043, DOI 10.1084/jem.171.4.1043; PITZALIS C, 1987, J RHEUMATOL, V14, P662; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI G, 1985, CLIN EXP IMMUNOL, V62, P136; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POPOVIC M, 1984, LANCET, V2, P1472; POTTS BJ, 1990, VIROLOGY, V175, P465, DOI 10.1016/0042-6822(90)90431-P; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; REDFIELD R, 1990, 6TH P INT C AIDS, V3, P209; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; RIVIERE Y, 1989, J VIROL, V63, P2270, DOI 10.1128/JVI.63.5.2270-2277.1989; ROBERTGUROFF M, 1988, AIDS RES HUM RETROV, V4, P343, DOI 10.1089/aid.1988.4.343; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROOK AH, 1985, J INFECT DIS, V152, P627, DOI 10.1093/infdis/152.3.627; ROOK AH, 1985, J IMMUNOL, V134, P1503; ROOK AH, 1983, J CLIN INVEST, V72, P398, DOI 10.1172/JCI110981; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; ROSENBERG ZF, 1990, J NIH RES, V2, P41; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SALAZARGONZALEZ JF, 1985, J IMMUNOL, V135, P1778; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SARIN PS, 1986, SCIENCE, V232, P1135, DOI 10.1126/science.3010464; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SETHI KK, 1988, NATURE, V335, P178, DOI 10.1038/335178a0; SHEARER GM, 1985, J CLIN INVEST, V76, P1699, DOI 10.1172/JCI112158; SMITH PD, 1984, J CLIN INVEST, V74, P2121, DOI 10.1172/JCI111637; SNYDERMAN R, 1984, IMMUNOL TODAY, V5, P240, DOI 10.1016/0167-5699(84)90097-5; TAS M, 1988, CLIN EXP IMMUNOL, V71, P13; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; TYLER DS, 1989, AIDS RES HUM RETROV, V5, P557, DOI 10.1089/aid.1989.5.557; WAHL SM, 1989, J IMMUNOL, V142, P3553; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WALKER CM, 1989, CELL IMMUNOL, V119, P470, DOI 10.1016/0008-8749(89)90259-1; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WARREN RQ, 1990, J VIROL, V64, P486, DOI 10.1128/JVI.64.2.486-492.1990; WEINHOLD KJ, 1988, LANCET, V1, P902; WEISS SH, 1988, SCIENCE, V239, P68, DOI 10.1126/science.3336776; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	112	277	282	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					678	693		10.7326/0003-4819-114-8-678	http://dx.doi.org/10.7326/0003-4819-114-8-678			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	1672248				2022-12-28	WOS:A1991FG03100011
J	HASTY, P; RAMIREZSOLIS, R; KRUMLAUF, R; BRADLEY, A				HASTY, P; RAMIREZSOLIS, R; KRUMLAUF, R; BRADLEY, A			INTRODUCTION OF A SUBTLE MUTATION INTO THE HOX-2.6 LOCUS IN EMBRYONIC STEM-CELLS	NATURE			English	Article							GERM-LINE TRANSMISSION; HOMOLOGOUS RECOMBINATION; ES CELLS; GENE; EXPRESSION; MURINE; ORGANIZATION; DISRUPTION; REGIONS	GENE targeting in embryonic stem (ES) cells is a powerful tool for generating mice with null alleles 1. Current methods of gene inactivation in ES cells introduce a neomycin gene (neo) cassette both as a mutagen and a selection marker for transfected cells 2-11. Although null alleles are valuable, changes at the nucleotide level of a gene are very important for functional analysis. One gene family in which subtle mutations would be particularly valuable are the clusters of Hox homeobox genes 12-16. Inactivation of genes in a cluster with a neo cassette that includes promoter/enhancer elements may deregulate transcription of neighbouring genes and generate a phenotype which is difficult to interpret. We describe here a highly efficient gene targeting method, termed the 'hit and run' procedure. This generates ES cells with subtle site-specific mutations with no selectable marker and may be useful for most genes. We have developed this procedure at the hypoxanthine phosphoribosyltransferase (hprt) locus and subsequently isolated ES cells with a premature stop codon in the homeobox of Hox-2.6 (ref. 14).	BAYLOR UNIV, INST MOLEC GENET, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Baylor College of Medicine; Baylor University; MRC National Institute for Medical Research			Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Bradley, Allan/0000-0002-2349-8839; Ramirez-Solis, Ramiro/0000-0003-4182-173X; Hasty, Paul/0000-0003-3046-0131				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAKER MD, 1988, P NATL ACAD SCI USA, V85, P6432, DOI 10.1073/pnas.85.17.6432; BAKER MD, 1989, MOL CELL BIOL, V9, P5500, DOI 10.1128/MCB.9.12.5500; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	27	265	301	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1991	350	6315					243	246		10.1038/350243a0	http://dx.doi.org/10.1038/350243a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1672446				2022-12-28	WOS:A1991FC77900062
J	KALK, WJ; VERIAVA, Y				KALK, WJ; VERIAVA, Y			HOSPITAL MANAGEMENT OF VOLUNTARY TOTAL FASTING AMONG POLITICAL PRISONERS	LANCET			English	Editorial Material								In 1989 20 political detainees, held without trial for up to 32 months, were admitted, on hunger strike, to the Johannesburg Hospital, South Africa. Most were held under the regulations of the State of Emergency (since revoked) and 5 were held incommunicado under section 29 of the Internal Security Act (still in force). Guidelines for ethical management were based on the Declaration of Tokyo, which included the understanding that such detentions constituted mental torture. Conditions of detention in hospital were complicated by police interference in medical and nursing care, and by the chaining of some prisoners to their beds. Doctors are in a unique position to protest against inhuman treatment of prisoners, and should use this authority.	CORONAT HOSP,DEPT MED,JOHANNESBURG,SOUTH AFRICA; NATL & MED DENT ASSOC DETAINEES SERV,PARKTOWN 2193,SOUTH AFRICA; UNIV WITWATERSRAND,SCH MED,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand; University of Witwatersrand	KALK, WJ (corresponding author), UNIV WITWATERSRAND,SCH MED,DEPT MED,PARKTOWN 2193,SOUTH AFRICA.							FROMMEL D, 1984, LANCET, V1, P1451, DOI 10.1016/S0140-6736(84)91941-X; HARDING TW, 1989, LANCET, V1, P1191; LEVIN J, 1988, S AFR MED J, V74, P460; VERIAVA Y, 1989, CRITICAL HLTH, V26, P39; 1975, WORLD MED J, V22, P87; 1989, S89278 U WITW FM DOC; 1989, WEEKLY MAIL     0303; 1988, LANCET, V2, P1402; 1989, NATAL MERCURY   1028; 1981, HDB MED ETHICS	10	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					660	662		10.1016/0140-6736(91)92465-E	http://dx.doi.org/10.1016/0140-6736(91)92465-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB730	1672002				2022-12-28	WOS:A1991FB73000015
J	COONEY, EL; COLLIER, AC; GREENBERG, PD; COOMBS, RW; ZARLING, J; ARDITTI, DE; HOFFMAN, MC; HU, SL; COREY, L				COONEY, EL; COLLIER, AC; GREENBERG, PD; COOMBS, RW; ZARLING, J; ARDITTI, DE; HOFFMAN, MC; HU, SL; COREY, L			SAFETY OF AND IMMUNOLOGICAL RESPONSE TO A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING HIV ENVELOPE GLYCOPROTEIN	LANCET			English	Article							AIDS VIRUS; NEUTRALIZING ANTIBODIES; GENE; IMMUNIZATION; PROTECTION	In a randomised phase I trial of a recombinant vaccinia virus vaccine expressing the gp160 envelope gene of the human immunodeficiency virus (HIVAC-1e) 35 healthy, HIV-seronegative males, 31 of whom had a history of smallpox immunisation and 4 of whom were vaccinia naive, were vaccinated and then boosted 8 weeks later with HIVAC-1e or standard NY strain vaccinia virus. The frequency, duration, and titre of virus isolation from the vaccination site and occurrence of local side-effects were similar between the two groups of vaccinees. Vaccinia-naive (vac-n) subjects shed virus from the vaccination site for longer and at a higher titre than did vaccinia-primed (vac-p) individuals (19 vs 7 days and 10(7) vs 10(5) pfu/ml, respectively). In-vitro T-cell proliferative responses to one or more HIV antigen preparations developed in 13 of 16 vaccinia-primed subjects inoculated with HIVAC-1e. T-cell responses were, however, transient and in no subject did antibodies to HIV become detectable. The 2 vaccinia-naive subjects vaccinated with HIVAC-1e showed strong T-cell responses to homologous and heterologous strains of whole virus and to recombinant gp160 protein that remained detectable for over a year; antibodies to HIV envelope also developed in both. Recombinant vaccinia virus vaccines induce T-cell priming to the foreign gene products in most individuals. If used as the sole immunising agent they will be most efficacious in vaccinia-naive individuals.	UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE CTR,SEATTLE,WA 98195; ONCOGEN CORP,SEATTLE,WA; BRISTOL MYERS SQUIBB CO,WALLINGFORD,CT	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Bristol-Myers Squibb			Corey, Lawrence/AAE-1796-2020; Hu, Shiu-Lok/A-3196-2008	Corey, Lawrence/0000-0002-2179-2436; Hu, Shiu-Lok/0000-0003-4336-7964				BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; DEWAR RL, 1989, J VIROL, V63, P129, DOI 10.1128/JVI.63.1.129-136.1989; DOLIN R, 1989, 5 INT C AIDS MONTR; EARL PL, 1986, SCIENCE, V234, P728, DOI 10.1126/science.3490689; EVANS DJ, 1989, NATURE, V339, P385, DOI 10.1038/339385a0; FLEXNER C, 1988, NATURE, V335, P259, DOI 10.1038/335259a0; GUROFF RM, 1985, NATURE, V316, P72; HU SL, 1986, NATURE, V320, P537, DOI 10.1038/320537a0; HUNG PP, 1988, NAT IMMUN CELL GROW, V7, P135; JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LANE HC, 1989, 5 INT C AIDS MONTR C; MATTHEWS TJ, 1988, SCI AM           OCT, P120; MYERS G, 1989, HUMAN RETROVIRUSES A; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; ROONEY JF, 1988, J VIROL, V62, P1530, DOI 10.1128/JVI.62.5.1530-1534.1988; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; ZAGURY D, 1988, NATURE, V332, P728, DOI 10.1038/332728a0; ZAGURY D, 1987, NATURE, V326, P249, DOI 10.1038/326249a0; ZARLING JM, 1986, NATURE, V323, P344, DOI 10.1038/323344a0; ZARLING JM, 1987, J IMMUNOL, V139, P988; 1972, WHO TECH REP, V493, P36	24	293	315	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					567	572		10.1016/0140-6736(91)91636-9	http://dx.doi.org/10.1016/0140-6736(91)91636-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671940				2022-12-28	WOS:A1991FA70200001
J	KINSELLA, J; CARTER, R; REID, WH; CAMPBELL, D; CLARK, CJ				KINSELLA, J; CARTER, R; REID, WH; CAMPBELL, D; CLARK, CJ			INCREASED AIRWAYS REACTIVITY AFTER SMOKE-INHALATION	LANCET			English	Article							BRONCHIAL HYPERREACTIVITY; ASTHMA; INJURY; SENSITIVITY; EXPOSURE; BURNS	13 fire victims who required treatment after smoke inhalation underwent lung function assessment within 3 days of injury and 3 months later. Initial airways hyperreactivity improved over this period, but FEV1 and airways specific conductance did not change significantly. There was a strong correlation between exposure carboxyhaemoglobin concentration (an indicator of smoke exposure) and initial airways specific conductance (r + 0.79; p = 0.006). Airways obstruction after smoke inhalation in house fires may be more common and more persistent than is generally recognised. Early lung function tests would allow the incidence of pulmonary complications after smoke inhalation and the potential benefits of early use of inhaled anti-inflammatory drugs to be assessed.	HAIRMYRES HOSP,DEPT RESP MED,GLASGOW G7S 8RG,SCOTLAND; UNIV GLASGOW,DEPT ANAESTHESIA,GLASGOW G12 8QQ,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT RESP MED,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,REG BURNS UNIT,GLASGOW G4 0SF,SCOTLAND	University Hospital Hairmyres; University of Glasgow; University of Glasgow; University of Glasgow			Kinsella, John/B-8252-2011					BARNES PJ, 1989, BRIT MED J, V299, P695, DOI 10.1136/bmj.299.6701.695; BOSCHETTO P, 1989, European Respiratory Journal, V2, p456S; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CLARK CJ, 1981, LANCET, V1, P1332; CLARK CJ, 1986, BRIT MED J, V292, P1303, DOI 10.1136/bmj.292.6531.1303; CLARK CJ, 1988, LANCET, V2, P872, DOI 10.1016/S0140-6736(88)92471-3; CLARK CJ, 1988, THORAX, V43, P828; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DJUKANOVIC R, 1989, HOSP UPDATE, V16, P266; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; OLIVIERI D, 1989, European Respiratory Journal, V2, p540S; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; STENTON SC, 1988, BRIT J DIS CHEST, V82, P436, DOI 10.1016/0007-0971(88)90102-7; Sumi K., 1973, J FIRE FLAMMABILITY, V4, P15; TRUNKEY D, 1978, SURG CLIN N AM, V135, P250; VINCENT NJ, 1970, J APPL PHYSIOL, V29, P336; VIVORI E, 1977, BRIT MED J, V2, P1462, DOI 10.1136/bmj.2.6100.1462; 1970, BR PLASTICS, V44, P59; 1987, AM REV RESPIR DIS, V136, P225; 1986, UK FIRE STATISTICS 1	24	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					595	597		10.1016/0140-6736(91)91650-J	http://dx.doi.org/10.1016/0140-6736(91)91650-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671952				2022-12-28	WOS:A1991FA70200013
J	FISHER, B; ANDERSON, S; FISHER, ER; REDMOND, C; WICKERHAM, DL; WOLMARK, N; MAMOUNAS, EP; DEUTSCH, M; MARGOLESE, R				FISHER, B; ANDERSON, S; FISHER, ER; REDMOND, C; WICKERHAM, DL; WOLMARK, N; MAMOUNAS, EP; DEUTSCH, M; MARGOLESE, R			SIGNIFICANCE OF IPSILATERAL BREAST-TUMOR RECURRENCE AFTER LUMPECTOMY	LANCET			English	Article							RANDOMIZED CLINICAL-TRIAL; COMPARING TOTAL MASTECTOMY; SURGICAL ADJUVANT BREAST; PATHOLOGIC FINDINGS; TREATMENT FAILURE; CANCER; DISCRIMINANTS; RADIATION; SURVIVAL; PROJECT	Breast cancer treatment trials from the US National Surgical Adjuvant Breast and Bowel Project have established breast-conserving operations as a replacement for radical mastectomy (NSABP B-04), and have shown that in terms of survival free from distant disease there was no significant difference between lumpectomy, lumpectomy plus breast irradiation, and total mastectomy (NSABP B-06). 9-year follow-up data from B-06 are used here to address the issue of ipsilateral breast tumour recurrence (IBTR) and the development of distant disease, a question with important clinical and biological implications. A Cox regression model on fixed co-variates (ie, features such as tumour type or size present at surgery and not subsequently alterable) and on IBTR, which is time dependent and not fixed, revealed that the risk of distant disease was 3.41 times greater after adjustment for co-variates in patients in whom an IBTR developed. IBTR proved to be a powerful independent predictor of distant disease. However, it is a marker of risk for, not a cause of, distant metastasis. While mastectomy or breast irradiation following lumpectomy prevent expression of the marker they do not lower the risk of distant disease. These findings further justify the use of lumpectomy.			FISHER, B (corresponding author), NATL SURG ADJUVANT BREAST & BOWEL PROJECT HEADQUAR, HEADQUARTERS, ROOM 914, SCAIFE HALL, PITTSBURGH, PA 15261 USA.			Anderson, Stewart/0000-0001-8948-0650	NCI NIH HHS [NCI-U10-CA-12027, NCI-U10-CA-37377, NCI-U10-CA-39086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA012027, U10CA037377, U10CA039086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1977, CANCER-AM CANCER SOC, V39, P2827, DOI 10.1002/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO;2-I; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1985, WORLD J SURG, V9, P692, DOI 10.1007/BF01655182; FISHER B, 1980, CANCER RES, V40, P3863; FISHER B, IN PRESS J NATL CANC; Fisher E R, 1980, Pathol Annu, V15, P239; FISHER ER, 1984, CANCER-AM CANCER SOC, V53, P712; FISHER ER, 1990, CANCER, V65, P2121, DOI 10.1002/1097-0142(19900501)65:9+<2121::AID-CNCR2820651408>3.0.CO;2-M; FISHER ER, 1980, CANCER, V46, P908, DOI 10.1002/1097-0142(19800815)46:4+<908::AID-CNCR2820461310>3.0.CO;2-5; GAIL MH, 1981, BIOMETRICS, V37, P67, DOI 10.2307/2530523; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; STOTTER A, 1990, ANN SURG, V212, P166, DOI 10.1097/00000658-199008000-00009	18	471	479	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1991	338	8763					327	331		10.1016/0140-6736(91)90475-5	http://dx.doi.org/10.1016/0140-6736(91)90475-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677695				2022-12-28	WOS:A1991GA60700001
J	NICOLAS, JF; CHAMCHICK, N; THIVOLET, J; WIJDENES, J; MOREL, P; REVILLARD, JP				NICOLAS, JF; CHAMCHICK, N; THIVOLET, J; WIJDENES, J; MOREL, P; REVILLARD, JP			CD4 ANTIBODY TREATMENT OF SEVERE PSORIASIS	LANCET			English	Letter									HOP EDOUARD HERRIOT,INSERM,U209,F-69437 LYONS,FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	NICOLAS, JF (corresponding author), HOP EDOUARD HERRIOT,INSERM,U80,DERMATOL CLIN,F-69437 LYONS,FRANCE.		Nicolas, Jean-François/AAW-9289-2020	NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X				BOS JD, 1988, BRIT J DERMATOL, V118, P141, DOI 10.1111/j.1365-2133.1988.tb01768.x; POIZOTMARTIN, 1991, LANCET, V337, P1477; VALDIMARSSON H, 1986, IMMUNOL TODAY, V7, P256, DOI 10.1016/0167-5699(86)90005-8	3	118	125	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					321	321		10.1016/0140-6736(91)90465-2	http://dx.doi.org/10.1016/0140-6736(91)90465-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677144				2022-12-28	WOS:A1991FZ56500051
J	DOVER, SB; GRAHAM, A; FITZSIMONS, E; MOORE, MR; MCCOLL, KEL				DOVER, SB; GRAHAM, A; FITZSIMONS, E; MOORE, MR; MCCOLL, KEL			HEME-ARGINATE PLUS TIN-PROTOPORPHYRIN FOR ACUTE HEPATIC PORPHYRIA	LANCET			English	Letter							SN-PROTOPORPHYRIN; HEME; INHIBITOR				DOVER, SB (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,PORPHYRIA RES UNIT,GLASGOW G11 6NT,SCOTLAND.		Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534				BERGLUND L, 1988, HEPATOLOGY, V8, P625, DOI 10.1002/hep.1840080331; BERGLUND L, 1990, GUT, V31, P899, DOI 10.1136/gut.31.8.899; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; HERRICK AL, 1989, LANCET, V1, P1295	4	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					263	263		10.1016/0140-6736(91)90411-H	http://dx.doi.org/10.1016/0140-6736(91)90411-H			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676821				2022-12-28	WOS:A1991FY50400061
J	SALASPURO, M; KESO, L				SALASPURO, M; KESO, L			ALCOHOLISM-TREATMENT ACCORDING TO THE MINNESOTA MODEL	LANCET			English	Letter											SALASPURO, M (corresponding author), UNIV HELSINKI,ALCOHOL DIS RES UNIT,SF-00290 HELSINKI 29,FINLAND.		Salaspuro, Mikko/AAW-5575-2021	Salaspuro, Mikko/0000-0002-7562-5414				KESO L, 1990, ALCOHOL CLIN EXP RES, V14, P584, DOI 10.1111/j.1530-0277.1990.tb01206.x; 1991, LANCET, V337, P422	2	2	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1550	1550		10.1016/0140-6736(91)93246-6	http://dx.doi.org/10.1016/0140-6736(91)93246-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT116	1675400				2022-12-28	WOS:A1991FT11600044
J	LOCATELLI, F; ALBERTI, D; GRAZIANI, G; BUCCIANTI, G; REDAELLI, B; GIANGRANDE, A				LOCATELLI, F; ALBERTI, D; GRAZIANI, G; BUCCIANTI, G; REDAELLI, B; GIANGRANDE, A			PROSPECTIVE, RANDOMIZED, MULTICENTER TRIAL OF EFFECT OF PROTEIN RESTRICTION ON PROGRESSION OF CHRONIC RENAL-INSUFFICIENCY	LANCET			English	Article							DIETARY-PROTEIN; FAILURE; DISEASE; CREATININE; QUESTIONS; THERAPY	A multicentre, prospective trial was organised to clarify the role of protein restriction in the progression of chronic renal insufficiency (CRI). 456 adult patients were assigned either a low-protein diet (0.6 g/kg body weight daily; n = 226) or a "normal" controlled-protein diet (1.0 g/kg daily; n = 230) and were stratified into three groups (A-C) with increasing baseline plasma creatinine concentrations. Each patient was followed up for 2 years or until an endpoint (a doubling of the baseline plasma creatinine or a need for dialysis) was reached. The difference between the diet groups in cumulative renal survival defined by these endpoints (27 low-protein, 42 controlled-protein) was of borderline significance (p < 0.06). The difference in renal survival between the low-protein and controlled-protein diet groups was of borderline significance in group A (0 vs 4 endpoints), significant in group B (10 vs 21 endpoints; p < 0.025), and not significant in group C. There were no differences among the diet groups or subgroups in mean plasma creatinine concentrations, creatinine clearance, the slope of the plasma creatinine reciprocal, or mean blood pressures. Compliance was good in the controlled-protein group but poor for the low-protein diet: the difference in protein intake between the groups was substantially less than that required by the protocol. However, there was no correlation between the progression of renal failure and protein catabolic rate. These findings offer little, if any, support to the hypothesis that protein restriction retards CRI progression: careful medical care and a "normal" controlled protein intake also allow very slow progression of CRI.	OSPED MAGGIORE GRANELLI,IST RICOVERO & CURA CARATTERE SCI,SERV NEPHROL,MILAN,ITALY; OSPED S GERARDO DE TINTORI,DIV NEPHROL,MONZA,ITALY; OSPED PROV,DIV NEPHROL,BUSTO ARIZIO,ITALY; CIBA GEIGY CORP,DEPT MED,ORIGGIO,ITALY; OSPED MAGGIORE CROFF,IST RICOVERO & CURA CARATTERE SCI,DIV NEPHROL,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico	LOCATELLI, F (corresponding author), OSPED LECCO,DIV NEFROL & DIALISI,I-22053 LECCO,ITALY.			safarikia, samira/0000-0002-7254-0634				ALVESTRAND A, 1988, NEPHROL DIAL TRANSPL, V3, P624, DOI 10.1093/oxfordjournals.ndt.a091717; BARSOTTI G, 1983, KIDNEY INT S16, V24, P278; BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; ELNAHAS AM, 1986, LANCET, V1, P597; ELNAHAS AM, 1984, BRIT MED J, V289, P1337, DOI 10.1136/bmj.289.6455.1337; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GIORDANO C, 1985, KIDNEY NIT, V17, P66; GIOVANNETTI S, 1986, LANCET, V2, P1140; Gretz N, 1986, Contrib Nephrol, V53, P82; GRETZ N, 1989, NUTRITIONAL TREATMEN, P211; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; HUNSICKER LG, 1989, SEMIN NEPHROL, V9, P380; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; KAMPER AL, 1989, 26TH C EUR DIAL TRAN, P63; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; LOCATELLI F, 1989, CONTRIB NEPHROL, V75, P141; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MASCHIO G, 1982, KIDNEY INT, V22, P371, DOI 10.1038/ki.1982.184; MASCHIO G, 1989, CONTRIB NEPHROL, V75, P147; OLDRIZZI L, 1985, KIDNEY INT, V27, P553, DOI 10.1038/ki.1985.46; OLDRIZZI L, 1989, AM J NEPHROL, V9, P184, DOI 10.1159/000167963; ROSEMBERG ME, 1986, KIDNEY INT, V29, pA325; ROSMAN JB, 1984, LANCET, V2, P1291; ROSMAN JB, 1989, KIDNEY INT, V36, pS96; WALKER JD, 1989, LANCET, V2, P1411; WALSER M, 1988, KIDNEY INT, V34, P412, DOI 10.1038/ki.1988.196; WALSER M, 1979, CLIN NEPHROL, V11, P66; WILLIAMS PS, 1988, Q J MED, V67, P343	30	226	228	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1299	1304		10.1016/0140-6736(91)92977-A	http://dx.doi.org/10.1016/0140-6736(91)92977-A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674294				2022-12-28	WOS:A1991FP08400001
J	GARDOSI, JO; SCHRAM, CM; SYMONDS, EM				GARDOSI, JO; SCHRAM, CM; SYMONDS, EM			ADAPTATION OF PULSE OXIMETRY FOR FETAL MONITORING DURING LABOR	LANCET			English	Article							OXYGEN	Application of pulse oximetry to intrapartum monitoring was investigated in 105 women. No adequate reading could be obtained in 44 cases. Two major sources of artifact, related to probe apposition and signal processing, were identified and excluded. The average arterial oxygen saturation from the fetal scalp was 82% (SD 6%), which is higher than has been inferred from pO2 levels. Readings below 60% or the development of an unstable baseline suggest the presence of substantial hypoxia and acidosis.			GARDOSI, JO (corresponding author), QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND.		Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				ANDREWS BF, 1965, AM J OBSTET GYNECOL, V91, P85, DOI 10.1016/0002-9378(65)90590-9; DAMIANOU D, 1991, IEE ABSTR, V89, P3; GARDOSI J, 1989, LANCET, V2, P692; HARRIS AP, 1988, J CLIN MONITOR, V4, P175, DOI 10.1007/BF01621812; JOHNSON N, 1991, BRIT J OBSTET GYNAEC, V98, P36, DOI 10.1111/j.1471-0528.1991.tb10308.x; JOHNSON SB, 1990, HEALTH PSYCHOL, V9, P493, DOI 10.1037/0278-6133.9.4.493; PEAT S, 1988, LANCET, V2, P213; ROSEN M, 1990, 1ST INT S INTR SURV; SCHRAM CMH, 1991, BRIT J OBSTET GYNAEC, V98, P113, DOI 10.1111/j.1471-0528.1991.tb10327.x; SOUTHALL DP, 1987, ARCH DIS CHILD, V62, P882, DOI 10.1136/adc.62.9.882; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; 1990, LANCET, V335, P1130	12	68	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1265	1267		10.1016/0140-6736(91)92928-U	http://dx.doi.org/10.1016/0140-6736(91)92928-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674071				2022-12-28	WOS:A1991FN04700012
J	TONNESEN, F; LAURSEN, LC; IBSEN, T; EVALD, T; STAHL, E				TONNESEN, F; LAURSEN, LC; IBSEN, T; EVALD, T; STAHL, E			TERBUTALINE POWDER IN ACUTE BRONCHIAL OBSTRUCTION	LANCET			English	Letter									AB DRACO,S-22101 LUND,SWEDEN		TONNESEN, F (corresponding author), GLOSTRUP CTY HOSP,DEPT MED C,DK-2600 GLOSTRUP,DENMARK.							DOLOVICH M, 1988, American Review of Respiratory Disease, V137, P433; NEWHOUSE MT, 1990, EUR RESPIR J, V3, P1232	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1099	1100						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673522				2022-12-28	WOS:A1991FK20400047
J	BROWN, P; GOLDFARB, LG; GAJDUSEK, DC				BROWN, P; GOLDFARB, LG; GAJDUSEK, DC			THE NEW BIOLOGY OF SPONGIFORM ENCEPHALOPATHY - INFECTIOUS AMYLOIDOSES WITH A GENETIC TWIST	LANCET			English	Review							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; PRION PROTEIN; SCRAPIE PRION; HUMAN-BRAIN; LINKAGE; PRP; PRECURSOR				BROWN, P (corresponding author), NINCDS,CENT NERVOUS SYST STUDIES LAB,BLDG 36,ROOM 5B21,BETHESDA,MD 20892, USA.							BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BENDHEIM P, IN PRESS NEUROLOGY; BRAIG HR, 1985, EMBO J, V4, P2309, DOI 10.1002/j.1460-2075.1985.tb03931.x; BROWN P, 1990, P NATL ACAD SCI USA, V87, P7240, DOI 10.1073/pnas.87.18.7240; BROWN P, 1990, J INFECT DIS, V161, P467, DOI 10.1093/infdis/161.3.467; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; Brown P, 1990, ANTIVIR CHEM CHEMOTH, V1, P75, DOI 10.1177/095632029000100201; BROWN P, 1991, NEUROLOGY, V41, P375, DOI 10.1212/WNL.41.3.375; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BROWN P, 1990, AUST NZ J MED, V20, P633, DOI 10.1111/j.1445-5994.1990.tb00390.x; BROWN P, IN PRESS NEUROLOGY; BROWN P, 1991, IN PRESS J NEUROL SC; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CHO HJ, 1980, INTERVIROLOGY, V14, P213, DOI 10.1159/000149185; DICKINSON AG, 1968, J COMP PATHOL, V78, P313, DOI 10.1016/0021-9975(68)90007-8; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; DOHURA K, 1990, ANN NEUROL, V27, P121, DOI 10.1002/ana.410270205; FARLOW MR, 1989, NEUROLOGY, V39, P1446, DOI 10.1212/WNL.39.11.1446; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; GAJDUSEK DC, 1990, 1990 P EUR COMM SEM; GIBBONS RA, 1967, NATURE, V215, P1041, DOI 10.1038/2151041a0; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GOLDFARB LG, 1990, EXP NEUROL, V108, P247, DOI 10.1016/0014-4886(90)90130-K; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P174, DOI 10.1016/0140-6736(90)91693-5; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GORDON WS, 1966, ARS9153 USDA REP SCR, P53; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HARRIS D A, 1989, Society for Neuroscience Abstracts, V15, P164; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; HUNTER N, 1989, VET REC, V124, P364, DOI 10.1136/vr.124.14.364; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEWIN P, 1972, CAN MED ASSOC J, V127, P471; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; NIETO A, 1991, LANCET, V337, P622, DOI 10.1016/0140-6736(91)91696-R; OWEN F, 1989, LANCET, V1, P51; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; ROBAKIS NK, 1986, BIOCHEM BIOPH RES CO, V140, P758, DOI 10.1016/0006-291X(86)90796-5; SAFAR J, 1990, P NATL ACAD SCI USA, V87, P6373, DOI 10.1073/pnas.87.16.6373; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; WAKASUGI S, 1988, AMYLOID AMYLOIDOSES, P393; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WILLS PR, 1989, MICROB PATHOGENESIS, V6, P235, DOI 10.1016/0882-4010(89)90098-3; YI S, 1990, 6TH INT S AM OSL, P58	52	128	128	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1019	1022		10.1016/0140-6736(91)92670-W	http://dx.doi.org/10.1016/0140-6736(91)92670-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673176				2022-12-28	WOS:A1991FJ13500014
J	ROTHWELL, PM; UDWADIA, ZF; LAWLER, PG				ROTHWELL, PM; UDWADIA, ZF; LAWLER, PG			CORTISOL RESPONSE TO CORTICOTROPIN AND SURVIVAL IN SEPTIC SHOCK	LANCET			English	Note								Corticotropin stimulation tests were used to assess adrenocortical function in 32 patients with septic shock. 13 patients had a poor cortisol response (rise < 250 nmol/l) to corticotropin, all of whom died. However, there were only 6 deaths among the 19 patients with adequate responses (p < 0.001). These results suggest that some patients with septic shock may have relative adrenocortical insufficiency.	S CLEVELAND HOSP,INTENS THERAPY UNIT,MIDDLESBROUGH,ENGLAND				Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				FINLAY WEI, 1982, LANCET, V1, P1414; HERMAN AH, 1971, SURG GYNECOL OBSTETR, V132, P795; HINSHAW LB, 1985, CIRC SHOCK, V16, P265; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; NICHOLSON DP, 1989, CRIT CARE CLIN, V5, P151; SCHEIN RMH, 1990, CRIT CARE MED, V18, P259, DOI 10.1097/00003246-199003000-00002; SIBBALD WJ, 1977, ANN SURG, V186, P29, DOI 10.1097/00000658-197707000-00005	7	314	329	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					582	583		10.1016/0140-6736(91)91641-7	http://dx.doi.org/10.1016/0140-6736(91)91641-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671944				2022-12-28	WOS:A1991FA70200005
J	TOMLINSON, DR; FRENCH, PD; HARRIS, JRW; MERCEY, DE				TOMLINSON, DR; FRENCH, PD; HARRIS, JRW; MERCEY, DE			DOES RECTAL GONORRHEA REFLECT UNSAFE SEX	LANCET			English	Letter									MIDDLESEX HOSP,DEPT GENITOURINARY MED,LONDON W1,ENGLAND	University of London; University College London	TOMLINSON, DR (corresponding author), ST MARYS HOSP,DEPT GENITOURINARY MED,JEFFERISS WING,LONDON W2 1NY,ENGLAND.							RILEY, 1991, LANCET, V337, P183	1	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					501	502		10.1016/0140-6736(91)93447-H	http://dx.doi.org/10.1016/0140-6736(91)93447-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671511				2022-12-28	WOS:A1991EY88700063
J	CHERNEVSKAYA, NI; OBUKHOV, AG; KRISHTAL, OA				CHERNEVSKAYA, NI; OBUKHOV, AG; KRISHTAL, OA			NMDA RECEPTOR AGONISTS SELECTIVELY BLOCK N-TYPE CALCIUM CHANNELS IN HIPPOCAMPAL-NEURONS	NATURE			English	Article							EXCITATORY AMINO-ACIDS; CHICK SENSORY NEURONS; GUINEA-PIG INVITRO; SYNAPTIC TRANSMISSION; OMEGA-CONOTOXIN; RAT HIPPOCAMPUS; CA1 NEURONS; CURRENTS; MODULATION; ACTIVATION	THE modulation of voltage-dependent calcium channels by various neurotransmitters had been demonstrated in many neurons 1-4,. Because of the critical role of Ca2+ in transmitter release and, more generally, in transmembrane signalling, this modulation has important functional implications. Hippocampal neurons posses low-threshold (T-type) Ca2+ channels and both L- and N-type high voltage-activated Ca2+ channels. 5-7 N-type Ca2+ channels are blocked selectively by omega-conotoxin 8, 9 and adenosine 10, 11. These substances both block excitatory synaptic transmission in the hippocampus 12-13, whereas dihydropyridines, which selectively block L-type channels 14, are ineffective 12. Excitatory synaptic transmission in the hippocampus displays a number of plasticity phenomena that are initiated by Ca2+ entry through ionic channels operated by N-methyl-D-aspartate (NMDA) receptors 15, 16. Here we report that NMDA receptor agonists selectively and effectively depress N-type Ca2+ channels which are involved in neurotransmitter release from presynaptic sites. The inhibitory effect is eliminated by the competitive NMDA antagonist D-2-amino-5-phosphonovalerate, does not require Ca2+ entry into the cell, and is probably receptor-mediated. This phenomenon may provide a negative feedback between the liberation of excitatory transmitter and entry of Ca2+ into the cell, and could be important in presynaptic inhibition and in the regulation of synaptic plasticity.	AA BOGOMOLETZ PHYSIOL INST,BOGOMOLETZ STR 4,KIEV 252024,UKRAINE,USSR	National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology			Obukhov, Alexander G/C-7246-2008; Krishtal, Oleg A/C-7739-2016	Obukhov, Alexander G/0000-0002-3862-6004; Krishtal, Oleg A/0000-0003-3342-9930				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERTOLINO M, 1989, NEUROPHARMACOLOGY, V28, P453, DOI 10.1016/0028-3908(89)90078-6; CHIZHMAKOV IV, 1989, NEUROSCI LETT, V99, P131, DOI 10.1016/0304-3940(89)90277-2; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DEISZ RA, 1985, NEUROSCI LETT, V56, P205, DOI 10.1016/0304-3940(85)90130-2; DOCHERTY RJ, 1986, NEUROSCI LETT, V70, P110, DOI 10.1016/0304-3940(86)90447-7; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GAHWILER BH, 1987, NEUROSCIENCE, V20, P731, DOI 10.1016/0306-4522(87)90236-3; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HONORE T, 1982, J NEUROCHEM, V38, P173, DOI 10.1111/j.1471-4159.1982.tb10868.x; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KRISHTAL OA, 1988, NEUROSCI LETT, V85, P82, DOI 10.1016/0304-3940(88)90433-8; KRISHTAL OA, 1989, NEUROSCI LETT, V102, P197, DOI 10.1016/0304-3940(89)90078-5; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; OKADA Y, 1980, EUR J PHARMACOL, V68, P483; OZAWA S, 1989, BRAIN RES, V495, P329, DOI 10.1016/0006-8993(89)90225-4; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; TAKAHASHI K, 1989, NEUROSCI LETT, V104, P229, DOI 10.1016/0304-3940(89)90359-5; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V415, P255, DOI 10.1007/BF00370874; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; ZORUMSKI CF, 1988, J NEUROSCI, V8, P4277	26	63	66	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					418	420		10.1038/349418a0	http://dx.doi.org/10.1038/349418a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1671527				2022-12-28	WOS:A1991EV51400052
J	ENNIS, M; CLARK, A; GRUDZINSKAS, JG				ENNIS, M; CLARK, A; GRUDZINSKAS, JG			CHANGE IN OBSTETRIC PRACTICE IN RESPONSE TO FEAR OF LITIGATION IN THE BRITISH-ISLES	LANCET			English	Article							MEDICAL MALPRACTICE; PERSPECTIVE	The increased number of medical negligence claims against obstetricians and gynaecologists has led to concerns about a trend towards defensive medical practice in the UK. The attitudes of obstetricians in the British Isles to tests of fetal and maternal wellbeing, which may influence decisions about patient care, were investigated in 3194 Fellows and Members of the Royal College of Obstetricians and Gynaecologists. Perceived accuracy of tests ranged from 86.3% for fetal blood sampling to 25.9% for biochemical tests. Despite some tests being perceived as having poor accuracy, all were widely used even by those who deemed them inaccurate. The most frequent explanations given for this paradoxical finding were that such tests were an aid to clinical judgement and were necessary for medicolegal reasons. Our data indicate that tests deemed to be inaccurate are used in clinical practice because some obstetricians fear litigation. Our findings were not influenced by age, gender, grade of doctor, or site of practice.	UNIV LONDON UNIV COLL,DEPT PSYCHOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London								ACHESON ED, 1991, HOSPITAL DOCTOR 0110, P12; CAPSTICK JB, 1990, LANCET, V336, P931, DOI 10.1016/0140-6736(90)92291-O; CLEMENTS RV, 1991, BRIT J OBSTET GYNAEC, V98, P423, DOI 10.1111/j.1471-0528.1991.tb10334.x; FENN P, 1990, BRIT MED J, V301, P949; FRANCOME C, 1987, CHANGING CHILDBIRTH; LISTON SL, 1985, JAMA-J AM MED ASSOC, V253, P3095, DOI 10.1001/jama.1985.03350450067023; Moser C.A., 1989, SURVEY METHODS SOCIA; MURRAY WDG, 1988, MED PROTECTION SOC A; QUAM L, 1987, BRIT MED J, V294, P1597, DOI 10.1136/bmj.294.6587.1597; QUAM L, 1987, BRIT MED J, V294, P1529, DOI 10.1136/bmj.294.6586.1529; SMITH R, 1986, BRIT MED J, V293, P461, DOI 10.1136/bmj.293.6545.461; STABILE I, 1990, CLIN RADIOL, V42, P395, DOI 10.1016/S0009-9260(05)80891-8; SYMONDS EM, 1985, BRIT J OBSTET GYNAEC, V92, P1072; TANCREDI LR, 1978, SCIENCE, V200, P879, DOI 10.1126/science.644329; Teff Harvey, 1985, Law Q Rev, V101, P432; VINCENT CA, 1991, BRIT J OBSTET GYNAEC, V98, P390, DOI 10.1111/j.1471-0528.1991.tb13430.x; 1990, PATIENTS DOCTORS LAW	17	22	22	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					616	618		10.1016/0140-6736(91)90616-W	http://dx.doi.org/10.1016/0140-6736(91)90616-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679160				2022-12-28	WOS:A1991GD80900012
J	BAGGIO, B; GAMBARO, G; MARCHINI, F; MARZARO, G; WILLIAMS, HE; BORSATTI, A				BAGGIO, B; GAMBARO, G; MARCHINI, F; MARZARO, G; WILLIAMS, HE; BORSATTI, A			CORRECTION OF ERYTHROCYTE ABNORMALITIES IN IDIOPATHIC CALCIUM-OXALATE NEPHROLITHIASIS AND REDUCTION OF URINARY OXALATE BY ORAL GLYCOSAMINOGLYCANS	LANCET			English	Article							PROTEIN-PHOSPHORYLATION; INHIBITION; TRANSPORT; EXCHANGE; CLONING; KINASE; FLUX; CDNA	Calcium-oxalate nephrolithiasis is associated with a defect in erythrocyte oxalate self-exchange and an abnormal rate of erythrocyte membrane protein phosphorylation. There is evidence that glycosaminoglycans (GAGs) have a regulatory effect on both of these processes. This study tested the hypothesis that modifications of erythrocyte oxalate self-exchange induced by oral GAGs are paralleled by similar changes in overall oxalate metabolism. 40 patients with idiopathic calcium-oxalate nephrolithiasis were treated for 15 days with 60 mg/day of a mixture of GAGs. By day 15 of treatment there were significant reductions from baseline in erythrocyte oxalate self-exchange (mean [SD] 1.67 [1.18] vs 2.59 [1.63] x 10(2) per min; p < 0.005) and erythrocyte membrane protein phosphorylation (55.8 [7.3] vs 72.9 [6.8] x 10(-3) cpm/mg protein; p < 0.005), but also in urinary oxalate excretion (0.24 [0.09] vs 0.31 [0.15) mmol/24 h; p < 0.005). This finding suggests similar changes in both erythrocytes and other cells more important in oxalate handling. The changes had reversed by 15 days after withdrawal of treatment. Acute intravenous administration of GAGs (60 mg) induced a fall in carbon-14-labelled oxalate renal clearance (143 [13] vs 169 [28] ml/min; p < 0.005), which strongly suggests the participation of the kidney. However, reduced oxalate absorption from the intestine, and even decreased synthesis of oxalate, cannot be ruled out.	UNIV PADUA,INST INTERNAL MED,DIV NEPHROL,I-35100 PADUA,ITALY; UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of Padua; University of California System; University of California Davis				Gambaro, Giovanni/0000-0001-5733-2370				ALPER SL, 1987, KIDNEY INT       S23, V32, P117; BAGGIO B, 1984, LANCET, V2, P12, DOI 10.1016/S0140-6736(84)91998-6; BAGGIO B, 1986, IRCS MED SCI-BIOCHEM, V14, P368; BAGGIO B, 1984, LANCET, V2, P223; BAGGIO B, 1990, CLIN SCI, V79, P113, DOI 10.1042/cs0790113; BAGGIO B, 1986, NEW ENGL J MED, V314, P599, DOI 10.1056/NEJM198603063141002; BAGGIO B, 1988, INHIBITORS CRYSTALLI, P211; BIOVIN P, 1985, FEBS LETT, V186, P89; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CHOI HR, 1988, MOL CELL BIOL, V8, P4416; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; SUGIMOTO T, 1989, UROLITHIASIS, P431; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILLIAMS HE, 1989, J UROLOGY, V141, P742, DOI 10.1016/S0022-5347(17)40999-2; WILLIAMS HE, 1971, CLIN SCI, V41, P213, DOI 10.1042/cs0410213; WISE BC, 1982, J BIOL CHEM, V257, P8489; WORCESTER EM, 1986, J CLIN INVEST, V77, P1888, DOI 10.1172/JCI112516	20	26	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					403	405		10.1016/0140-6736(91)91030-X	http://dx.doi.org/10.1016/0140-6736(91)91030-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678082				2022-12-28	WOS:A1991GB44600003
J	GODFREY, R				GODFREY, R			ALL CHANGE	LANCET			English	Editorial Material											GODFREY, R (corresponding author), SOUTHAMPTON UNIV HOSP,SOUTHAMPTON SO9 4XY,ENGLAND.							ABRAHAMSON S, 1978, J MED EDUC, V53, P952; CROMBIE AL, 1991, BRIT J HOSP MED, V45, P127; ENGEL CE, 1989, ANN COMMUNITY ORIENT, V2, P85; FABING H, 1956, FISCHERISMS BEING SH; MCMANUS IC, 1989, BRIT MED J, V298, P1051, DOI 10.1136/bmj.298.6680.1051; NEWBLE DI, 1986, MED EDUC, V20, P162, DOI 10.1111/j.1365-2923.1986.tb01163.x; OKELL CC, 1938, LANCET, V1, P107; SCHMIDT HG, 1987, J MED EDUC, V62, P305; 1991, LANCET, V337, P1087; 1984, PHYSICIANS 21ST CENT; 1988, REPORT SURVEY MED ED; 1988, LANCET, V2, P462; 1988, LANCET, V1, P1373	13	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					297	299		10.1016/0140-6736(91)90429-S	http://dx.doi.org/10.1016/0140-6736(91)90429-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677122				2022-12-28	WOS:A1991FZ56500015
J	SEAL, D; FICKER, L; WRIGHT, P; ANDREWS, V				SEAL, D; FICKER, L; WRIGHT, P; ANDREWS, V			THE CASE AGAINST THIOMERSAL	LANCET			English	Letter							VACCINATION REACTIONS; THIMEROSAL		MOORFIELDS EYE HOSP,LONDON EC1,ENGLAND									COX NH, 1988, CONTACT DERMATITIS, V18, P229, DOI 10.1111/j.1600-0536.1988.tb02809.x; COX NH, 1987, BRIT MED J, V294, P250, DOI 10.1136/bmj.294.6566.250; FICKER L, 1991, AM J OPHTHALMOL, V111, P473, DOI 10.1016/S0002-9394(14)72383-9; HANSSON H, 1970, BRIT J DERMATOL, V83, P349, DOI 10.1111/j.1365-2133.1970.tb15714.x; Maibach H, 1975, Contact Dermatitis, V1, P221, DOI 10.1111/j.1600-0536.1975.tb05387.x; RIETSCHEL RL, 1990, DERMATOL CLIN, V8, P161, DOI 10.1016/S0733-8635(18)30543-6; WILSON LA, 1981, OPHTHALMOLOGY, V88, P804	7	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1991	338	8762					315	316		10.1016/0140-6736(91)90455-X	http://dx.doi.org/10.1016/0140-6736(91)90455-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ565	1677134				2022-12-28	WOS:A1991FZ56500038
J	GOTTLIEB, MS; ZACKIN, RA; FIALA, M; HENRY, DH; MARCEL, AJ; COMBS, KL; VIEIRA, J; LIEBMAN, HA; CONE, LA; HILLMAN, KS; GOTTLIEB, AA				GOTTLIEB, MS; ZACKIN, RA; FIALA, M; HENRY, DH; MARCEL, AJ; COMBS, KL; VIEIRA, J; LIEBMAN, HA; CONE, LA; HILLMAN, KS; GOTTLIEB, AA			RESPONSE TO TREATMENT WITH THE LEUKOCYTE-DERIVED IMMUNOMODULATOR IMREG-1 IN IMMUNOCOMPROMISED PATIENTS WITH AIDS-RELATED COMPLEX - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; HYPERSENSITIVITY; COHORT	Objective: To determine if a 6-month course of therapy with IMREG-1, a leukocyte-derived immunomodulator, slows disease progression in patients with AIDS-related complex. Design: Randomized, double-blind trial. Setting: Five academic-and three community-based clinics. Patients: Immunocompromised patients (143) with HIV. Interventions: IMREG-1 or placebo every 2 weeks (13 doses). Main Results: Twelve of forty-eight patients on placebo and 5 of 95 patients on IMREG-1 experienced adverse events (AIDS-defining opportunistic infection or neoplasm, wasting syndrome, HIV-associated encephalopathy, or peripheral sensory neuropathy). Based on an intention-to-treat analysis, Kaplan-Meier event probabilities were 26% for the placebo group and 6% for the IMREG-1 group (P < 0.001); based on the Cox proportional hazards model, the relative risk for patients on placebo compared with patients on IMREG-1 was 5.1 (95% Cl, 1.8 to 14.8). The frequency of symptoms significantly increased from baseline in patients receiving placebo. The mean decrease in CD4+ cells from baseline was 80 x 10(6) cells/L in the placebo group and 29 x 10(6) cells/L in patients on IMREG-1, with 20% (8) and 38% (32) of patients, respectively, showing a trend toward an increase (P = 0.04). In patients receiving IMREG-1, the size and rate of delayed hypersensitivity responses were larger than in the placebo group. Conclusions: Patients with AIDS-related complex experienced fewer adverse events and constitutional symptoms after IMREG-1 treatment. The slower loss of CD4+ cells and increased size and rate of delayed hypersensitivity responses most likely reflect the effect of IMREG-1 on the immune system. No toxicity related to IMREG-1 administration was observed.	IMREG INC, NEW ORLEANS, LA USA; BAPTIST HOSP, MED CTR, NEW ORLEANS, LA USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; BOSTON UNIV, BOSTON, MA 02215 USA; BROOKLYN CALEDONIAN HOSP, BROOKLYN, NY 11201 USA; SUNY HLTH SCI CTR, BROOKLYN, NY USA; EISENHOWER MED CTR, RANCHO MIRAGE, CA USA; GRAD HOSP PHILADELPHIA, PHILADELPHIA, PA 19146 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY USA; COLUMBIA UNIV, NEW YORK, NY 10027 USA; CASE WESTERN RESERVE UNIV HOSP, CLEVELAND, OH 44106 USA	Boston Medical Center; Boston University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Case Western Reserve University; Case Western Reserve University Hospital	GOTTLIEB, MS (corresponding author), IMREG INC, 1 KENDALL SQ, BLDG 400, CAMBRIDGE, MA 02139 USA.		Henry, David/AAU-4650-2020	Henry, David/0000-0001-7169-7704				FIALA M, 1989, 5 INT C AIDS MONTR, P398; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOTTLIEB AA, 1984, J IMMUNOL, V132, P256; GOTTLIEB AA, 1982, CLIN EXP IMMUNOL, V50, P434; GOTTLIEB AA, 1980, J IMMUNOL, V124, P885; GOTTLIEB AA, 1987, CLIN RES, V35, pA607; GOTTLIEB AA, 1987, CLIN IMMUNOLOGY, P357; GOTTLIEB AA, 1987, 3 INT C AIDS WASH, P203; GOTTLIEB AA, 1979, IMMUNE REGULATORS TR, P339; GOTTLIEB MS, 1989, 5 INT C AIDS MONTR; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; LANDESMAN SH, 1987, 3 INT C AIDS WASH, P100; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SINHA SK, 1988, BIO-TECHNOL, V6, P810, DOI 10.1038/nbt0788-810; SIZEMORE RC, 1988, FASEB J, V2, pA830; 1987, MMWR, V36, pS1; [No title captured]	18	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1991	115	2					84	91		10.7326/0003-4819-115-2-84	http://dx.doi.org/10.7326/0003-4819-115-2-84			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW091	1676251				2022-12-28	WOS:A1991FW09100002
J	BANG, AT; BANG, RA				BANG, AT; BANG, RA			BREATH COUNTER FOR DIAGNOSIS OF CHILDHOOD PNEUMONIA	LANCET			English	Letter											BANG, AT (corresponding author), SEARCH,GADCHIROLI 442605,INDIA.							BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; CHERIAN T, 1988, LANCET, V2, P125; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; WHOARI905	4	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					116	116		10.1016/0140-6736(91)90108-2	http://dx.doi.org/10.1016/0140-6736(91)90108-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676442				2022-12-28	WOS:A1991FW16100030
J	HAMILTON, JD; OGUNBODE, O				HAMILTON, JD; OGUNBODE, O			MEDICAL-EDUCATION IN THE COMMUNITY - A NIGERIAN EXPERIENCE	LANCET			English	Article									UNIV ILORIN,WHO,COLLABORATING CTR COMMUNITY BASED EDUC,ILORIN,NIGERIA	University of Ilorin; World Health Organization	HAMILTON, JD (corresponding author), UNIV NEWCASTLE,FAC MED,NEWCASTLE,NSW 2308,AUSTRALIA.								0	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					99	102		10.1016/0140-6736(91)90087-6	http://dx.doi.org/10.1016/0140-6736(91)90087-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FW161	1676480				2022-12-28	WOS:A1991FW16100015
J	GHOSH, P; HOLBERT, C; READ, R; ARMSTRONG, S; WILSON, D				GHOSH, P; HOLBERT, C; READ, R; ARMSTRONG, S; WILSON, D			CHONDROPROTECTION AND NSAIDS	LANCET			English	Letter							ARTICULAR-CARTILAGE; OSTEOARTHRITIS; MENISCECTOMY		MURDOCH UNIV,SCH VET STUDIES,MURDOCH,WA 6150,AUSTRALIA	Murdoch University	GHOSH, P (corresponding author), UNIV SYDNEY,ROYAL N SHORE HOSP,RAYMOND PURVES RES LABS,ST LEONARDS,NSW 2065,AUSTRALIA.							BUCKLANDWRIGHT JC, 1990, ARTHRITIS RHEUM, V33, P57, DOI 10.1002/art.1780330107; GHOSH P, 1990, ANN RHEUM DIS, V49, P338, DOI 10.1136/ard.49.5.338-c; GHOSH P, 1983, J SURG RES, V35, P461, DOI 10.1016/0022-4804(83)90035-5; GHOSH P, 1991, J RHEUMATOL, V18, P143; GHOSH P, 1991, J RHEUMATOL, V18, P161; HANNAN N, 1987, J ORTHOPAED RES, V5, P47, DOI 10.1002/jor.1100050108; KARVONEN RL, 1990, ANN RHEUM DIS, V49, P672, DOI 10.1136/ard.49.9.672; KONGTAWELERT P, 1990, CLIN CHIM ACTA, V195, P17, DOI 10.1016/0009-8981(90)90190-4; SHINMEI M, 1991, T ORTHOP RES SOC, V16, P230; 1991, LANCET, V337, P769	10	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1612	1613		10.1016/0140-6736(91)93313-X	http://dx.doi.org/10.1016/0140-6736(91)93313-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675743				2022-12-28	WOS:A1991FU55100060
J	Cantu, TG; Korek, JS				Cantu, TG; Korek, JS			Central-Nervous-System Reactions to Hist Amine-2 Receptor Blockers	ANNALS OF INTERNAL MEDICINE			English	Review						Hist Amine-H2 Receptor Blockers; Central Nervous System Diseases; Cimetidine; Ranitidine; Drug Reactions	INDUCED MENTAL CONFUSION; ZOLLINGER-ELLISON SYNDROME; OUTPATIENT SURVEILLANCE PROGRAM; GASTRIC HYPERSECRETORY STATES; CIMETIDINE-INDUCED DELIRIUM; ADVERSE REACTIONS; PHYSOSTIGMINE REVERSAL; CSF CONCENTRATIONS; TOXIC PSYCHOSIS; ILL PATIENTS	Purpose: To review the incidence, risk factors, pharmacology, and management of central nervous system reactions to histamine-2 receptor (H-2) blockers. Data Identification: English-language articles were identified through a search of the MEDLINE and Current Contents databases. Bibliographies of retrieved articles were examined for relevant articles. Case reports submitted to the Food and Drug Administration through 19 September 1989 were obtained. Study Selection: Studies on the association between central nervous system toxicity (psychosis, agitation, hallucinations, delirium, mental status changes, disorientation, confusion, irritability, obtundation, or hostility) and H-2 blockers were analyzed. Data Extraction: All data on the incidence of and potential predisposing factors for central nervous system reactions to H-2 blockers were analyzed. Limitations of the data are discussed. Results of Data Synthesis: Central nervous system toxicities have been associated with all H-2 blockers. These reactions generally occur during the first 2 weeks of therapy and resolve within 3 days of drug withdrawal. The estimated incidence of central nervous system reactions is 0.2% or less in outpatients and 1.6% to 80% in hospitalized patients. Cimetidine is most frequently associated with these reactions; however, no clear evidence exists that one H-2 blocker is more likely than another to cause a reaction. Risk factors for central nervous system reactions have been proposed, but only advanced age has some, albeit limited, data to support it as a risk factor. Studies have only infrequently established causality and there have been difficulties in establishing risk factors for and relative incidences of a phenomenon that occurs infrequently in outpatients and that can be multifactorial in origin. Conclusions: All H-2 blockers are associated with central nervous system reactions. There is no clear evidence of a higher rate of reactions with one H-2 blocker compared with another.	Johns Hopkins Univ, Dept Pharm, Drug Informat Serv, Carnegie 180, 600 N Wolfe St, Baltimore, MD 21205 USA; Univ Maryland, Baltimore, MD 21201 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Cantu, TG (corresponding author), Johns Hopkins Univ, Dept Pharm, Drug Informat Serv, Carnegie 180, 600 N Wolfe St, Baltimore, MD 21205 USA.							ADLER LE, 1980, AM J PSYCHIAT, V137, P1112; AGARWAL SK, 1978, JAMA-J AM MED ASSOC, V240, P214, DOI 10.1001/jama.1978.03290030032013; ARNESON GA, 1979, AM J PSYCHIAT, V136, P1348; BACIGALUPO A, 1978, LANCET, V2, P45; BARNHART CC, 1979, AM J PSYCHIAT, V136, P725; BASAVARAJU NG, 1980, NEW YORK STATE J MED, V80, P1287; BATEMAN DN, 1988, BMJ-BRIT MED J, V296, P761, DOI 10.1136/bmj.296.6624.761; BONFILS S, 1988, SCAND J GASTROENTERO, V23, P111, DOI 10.3109/00365528809099137; BORIES P, 1980, LANCET, V2, P755; BRIER KL, 1980, CRIT CARE MED, V8, P760, DOI 10.1097/00003246-198012000-00016; CARSON JL, 1986, MED TOXICOL ADV DRUG, V1, P237, DOI 10.1007/BF03259840; CASPI A, 1980, HOSP FORMUL, V15, P204; CAVANAGH RL, 1983, J PHARMACOL EXP THER, V224, P171; CERRA FB, 1982, ANN SURG, V196, P565, DOI 10.1097/00000658-198211000-00009; COHEN N, 1989, J CLIN GASTROENTEROL, V11, P68, DOI 10.1097/00004836-198902000-00017; DALTON MJ, 1986, EPILEPSIA, V27, P553, DOI 10.1111/j.1528-1157.1986.tb03583.x; DAS AF, 1990, INTERNAL MED, V11, P3; DAVIES WA, 1983, MED J AUSTRALIA, V2, P478, DOI 10.5694/j.1326-5377.1983.tb122597.x; DAVIS TG, 1980, JAMA-J AM MED ASSOC, V243, P1912, DOI 10.1001/jama.243.19.1912; DELANEY JC, 1977, LANCET, V2, P512; DELMILLER D, 1983, AM J PSYCHIAT, V140, P351; EDMONDS ME, 1979, J ROY SOC MED, V72, P172, DOI 10.1177/014107687907200304; EPSTEIN CM, 1984, LANCET, V1, P1071; FENNELLY ME, 1987, CRIT CARE MED, V15, P1165; FRESTON JW, 1982, ANN INTERN MED, V97, P728, DOI 10.7326/0003-4819-97-5-728; GIFFORD LM, 1980, JAMA-J AM MED ASSOC, V243, P1532, DOI 10.1001/jama.243.15.1532; GOFF DC, 1985, J CLIN PSYCHIAT, V46, P400; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; GORDON C, 1981, PSYCHOSOMATICS, V22, P251; GRAHAM JR, 1979, MED J AUSTRALIA, V2, P491; GRIFFIN JP, 1985, ADVERSE DRUG REACT T, V4, P213; GRIMSON TA, 1977, LANCET, V1, P858; HALES RE, 1986, MIL MED, V151, P587, DOI 10.1093/milmed/151.11.587; HENANN NE, 1988, DRUG INTEL CLIN PHAR, V22, P976, DOI 10.1177/106002808802201209; HUGHES JD, 1983, MED J AUSTRALIA, V2, P12, DOI 10.5694/j.1326-5377.1983.tb142072.x; HUMPHRIES TJ, 1984, AM J GASTROENTEROL, V79, P593; ILLINGWORTH RN, 1979, BRIT MED J, V1, P453, DOI 10.1136/bmj.1.6161.453-a; INMAN WH, 1983, PEM NEWS, V1, P1; JENIKE MA, 1983, J CLIN PSYCHOPHARM, V3, P43; JENSEN RT, 1984, AM J MED, V77, P90; JENSEN RT, 1983, ANN INTERN MED, V98, P59, DOI 10.7326/0003-4819-98-1-59; JONES DGC, 1985, Q J MED, V54, P253; JONSSON KA, 1984, BRIT J CLIN PHARMACO, V17, P781, DOI 10.1111/j.1365-2125.1984.tb02420.x; KAGEVI I, 1987, BRIT J CLIN PHARMACO, V24, P849, DOI 10.1111/j.1365-2125.1987.tb03261.x; KAGEVI I, 1985, LANCET, V1, P164; KIMELBLATT BJ, 1980, GASTROENTEROLOGY, V78, P791; KINNELL HG, 1979, BRIT MED J, V2, P1438, DOI 10.1136/bmj.2.6202.1438; KLOTZ SA, 1978, ANN INTERN MED, V88, P579, DOI 10.7326/0003-4819-88-4-579_2; Kowalsky S F, 1989, Hosp Pharm, V24, P105; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; KRENZELOK EP, 1987, ANN EMERG MED, V16, P1217, DOI 10.1016/S0196-0644(87)80226-3; LAKOSKI JM, 1983, EUR J PHARMACOL, V88, P241, DOI 10.1016/0014-2999(83)90011-0; LEVINE ML, 1978, JAMA-J AM MED ASSOC, V240, P1238, DOI 10.1001/jama.1978.03290120032011; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; LOFGREN RP, 1982, ANN INTERN MED, V96, P378, DOI 10.7326/0003-4819-96-3-378_2; MACDERMOTT AJ, 1987, BRIT MED J, V294, P1616, DOI 10.1136/bmj.294.6587.1616-b; MANDAL SK, 1986, BRIT J CLIN PRACT, V40, P260; MANI RB, 1984, LANCET, V2, P98; MARTINEZABAD M, 1988, DRUG INTEL CLIN PHAR, V22, P914, DOI 10.1177/106002808802201124; MCCARTHY DM, 1978, GASTROENTEROLOGY, V74, P453; MCGUIGAN JE, 1981, GASTROENTEROLOGY, V80, P181; MCMILLEN MA, 1978, NEW ENGL J MED, V298, P284; MENZIESGOW N, 1977, LANCET, V2, P928; MEREDITH TJ, 1979, LANCET, V2, P1367; MOGELNICKI SR, 1979, JAMA-J AM MED ASSOC, V241, P826; NATH C, 1988, LIFE SCI, V42, P2413, DOI 10.1016/0024-3205(88)90339-6; NATH C, 1982, PSYCHOPHARMACOLOGY, V76, P228, DOI 10.1007/BF00432550; NELSON PG, 1977, LANCET, V2, P928; NG JYK, 1981, MED J AUSTRALIA, V1, P656, DOI 10.5694/j.1326-5377.1981.tb135932.x; NIV Y, 1986, ANN INTERN MED, V105, P977, DOI 10.7326/0003-4819-105-6-977_1; NOUEL O, 1980, GASTROENTEROLOGY, V79, P780; OBRIEN JG, 1989, PRIMARY CARE, V16, P349; PEDRAZZOLI S, 1983, ARCH SURG-CHICAGO, V118, P256; PORTER JB, 1984, PHARMACOTHERAPY, V4, P381; PORTER JB, 1986, ARCH INTERN MED, V146, P2237, DOI 10.1001/archinte.146.11.2237; POTTER HP, 1986, J CLIN GASTROENTEROL, V8, P275, DOI 10.1097/00004836-198606000-00015; PRICE W, 1985, EUR J CLIN PHARMACOL, V29, P375, DOI 10.1007/BF00544097; PUCINO F, 1985, PHARMACOTHERAPY, V5, P314; QUAP CW, 1978, DRUG INTEL CLIN PHAR, V12, P121, DOI 10.1177/106002807801200210; RE L, 1983, PHARMACOL RES COMMUN, V15, P485, DOI 10.1016/S0031-6989(83)80068-X; RICHTER JM, 1989, AM J MED, V87, P278; ROBINSON TJ, 1977, LANCET, V2, P719; ROSSE RB, 1986, J CLIN PSYCHIAT, V47, P99; RUSSELL WL, 1980, AM J HOSP PHARM, V37, P1667, DOI 10.1093/ajhp/37.12.1667; SAIGENJI K, 1987, SCAND J GASTROENTERO, V22, P34, DOI 10.3109/00365528709090138; SASTRY BSR, 1976, EUR J PHARMACOL, V38, P269, DOI 10.1016/0014-2999(76)90329-0; SCHENTAG JJ, 1981, CLIN PHARMACOL THER, V29, P737, DOI 10.1038/clpt.1981.104; SCHENTAG JJ, 1979, LANCET, V1, P177, DOI 10.1016/S0140-6736(79)90578-6; SCHWARTZ JC, 1975, LIFE SCI, V17, P503, DOI 10.1016/0024-3205(75)90083-1; SCHWARTZ JC, 1986, J EXP BIOL, V124, P203; SHAMBUREK RD, 1990, NEW ENGL J MED, V322, P438, DOI 10.1056/NEJM199002153220705; SILVERSTONE PH, 1984, LANCET, V1, P1071; SONNENBLICK M, 1986, AM J PSYCHIAT, V143, P257; SONNENBLICK M, 1982, POSTGRAD MED J, V58, P415, DOI 10.1136/pgmj.58.681.415; SPEARS JB, 1978, AM J HOSP PHARM, V35, P1035; STROM BL, 1988, J RHEUMATOL, V15, P9; TAKAYANAGI I, 1978, J PHARM PHARMACOL, V30, P519, DOI 10.1111/j.2042-7158.1978.tb13310.x; THOMPSON J, 1979, LANCET, V1, P725; TRZECIAKOWSKI JP, 1986, LIFE SCI, V38, P173, DOI 10.1016/0024-3205(86)90009-3; VANSWEDEN B, 1984, EUR NEUROL, V23, P300, DOI 10.1159/000115746; VICKERY TR, 1978, DRUG INTEL CLIN PHAR, V12, P242, DOI 10.1177/106002807801200408; VINAYEK R, 1986, AM J MED, V81, P49, DOI 10.1016/0002-9343(86)90600-5; WALT RP, 1981, SCAND J GASTROENTERO, V16, P19; WEDDINGTON WW, 1981, JAMA-J AM MED ASSOC, V245, P1058; WELAGE LS, 1988, GASTROENTEROLOGY, V94, pA491; WOOD CA, 1978, JAMA-J AM MED ASSOC, V239, P2550; YUDOFSKY SC, 1980, GEN HOSP PSYCHIAT, V2, P233, DOI 10.1016/0163-8343(80)90068-7	107	96	105	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1027	1034		10.7326/0003-4819-114-12-1027	http://dx.doi.org/10.7326/0003-4819-114-12-1027			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	1674198				2022-12-28	WOS:A1991FQ55500007
J	FELDMAN, Z; CONTANT, CF; ROBERTSON, CS; NARAYAN, RK; GROSSMAN, RG				FELDMAN, Z; CONTANT, CF; ROBERTSON, CS; NARAYAN, RK; GROSSMAN, RG			EVALUATION OF THE LEEDS PROGNOSTIC SCORE FOR SEVERE HEAD-INJURY	LANCET			English	Article								According to the Leeds scale for identifying severely head injured patients, death can be predicted with certainty within 12 hours of admission if a patient has a score higher than 13. The withdrawal of treatment from such patients has considerable moral and legal implications. Therefore, to test the reliability of the Leeds scale, it was applied to two patient populations with severe head injuries (479 retrospectively, 131 prospectively). In both groups the scale failed to predict mortality with 100% accuracy: in the first group, 16 of 23 (69.6%) of the patients with a score of more than 13 (and therefore predicted to die) died, and 380 (83.3%) of 456 patients with scores of 13 or less survived; the data for the second group are 6/10 (60%) and 98/121 (81%), respectively. The findings suggest that the Leeds prediction model is not infallible and should be applied cautiously when making decisions about the early termination of care in severely head injured patients.			FELDMAN, Z (corresponding author), BAYLOR UNIV,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			Feldman, Zeev/0000-0002-9719-3894	NINDS NIH HHS [N01-NS-9-23148, P01-NS-27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027616] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; GIBSON RM, 1989, LANCET, V2, P369; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NARAYAN RK, 1989, TXB HEAD INJURY, P420; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; TEASDALE G, 1974, LANCET, V2, P81; TITTERINGTON DM, 1981, J ROY STAT SOC A STA, V144, P145, DOI 10.2307/2981918	11	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1451	1453		10.1016/0140-6736(91)93137-X	http://dx.doi.org/10.1016/0140-6736(91)93137-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675328				2022-12-28	WOS:A1991FR06000014
J	CHAKRABORTY, A				CHAKRABORTY, A			CULTURE, COLONIALISM, AND PSYCHIATRY	LANCET			English	Article																		Bhattacharya DP., 1986, PAGALAMI ETHNOPSYCHI; BURTONBRADLEY BG, 1990, TRANSCULT PSYCHIATRY, V28, P75; CHAKRABORTY A, 1990, SOCIAL STRESS MENTAL; CHAKRABORTY A, 1973, PSYCHIATRY, P804; Chakraborty A., 1974, TRANSCULT PSYCHIATRY, V11, P102; DEBREVIL G, 1976, PSYCHIATRY, V39, P130; FOVCAVIT M, 1967, MADNESS CIVILISATION; Geertz Clifford, 1973, INTERPRETATION CULTU; Kakar Sudhir., 1982, SHAMANS MYSTICS DOCT; KLEINMAN A, 1978, SOC SCI MED-MED ANTH, V12, P85, DOI 10.1016/0160-7987(78)90014-5; LEFF J, 1987, British Journal of Psychiatry, V151, P166, DOI 10.1192/bjp.151.2.166; LITTLEWOOD, 1990, BRIT J PSYCHIAT, V156, P308; LITTLEWOOD R, 1988, SOC SCI MED, V27, P129, DOI 10.1016/0277-9536(88)90322-X; LITTLEWOOD R, 1987, CULT MED PSYCHIAT, V11, P289, DOI 10.1007/BF00048517; LITTLEWOOD R, 1985, RECENT ADV CLIN PSYC; LITTLEWOOD R, 1989, ALIENS ALIENISTS; McDaniel June, 1989, MADNESS SAINTS ECSTA; MURPHY HBM, 1977, PSYCHOL MED, V7, P369, DOI 10.1017/S0033291700004335; SARTORIUS N, 1988, BRIT J PSYCHIAT, V152, P9, DOI 10.1192/S000712500029555X; SARTORIUS N, 1987, SEARCH COURSE SCHIZO; SKULTANS V, 1987, MAN, V22, P661, DOI 10.2307/2803357; WILLIAMS R, 1961, CULTURE SOC 1780-195	22	20	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1204	1207		10.1016/0140-6736(91)92869-4	http://dx.doi.org/10.1016/0140-6736(91)92869-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM261	1673748				2022-12-28	WOS:A1991FM26100013
J	SORSCHER, EJ; HUANG, Z				SORSCHER, EJ; HUANG, Z			DIAGNOSIS OF GENETIC-DISEASE BY PRIMER-SPECIFIED RESTRICTION MAP MODIFICATION, WITH APPLICATION TO CYSTIC-FIBROSIS AND RETINITIS-PIGMENTOSA	LANCET			English	Article							ENZYMATICALLY AMPLIFIED DNA; OLIGONUCLEOTIDE PROBES; RHODOPSIN; MUTATION	Detection of small alterations or abnormalities in genomic DNA (eg, point mutations or small deletions) has become increasingly important in the diagnosis of genetic disease and polymorphism. When a mutation or polymorphism creates a new restriction endonuclease site, it can easily be identified by polymerase chain reaction (PCR) amplification of the DNA region of interest, followed by digestion with the restriction endonuclease. However, useful restriction sites are the exception, and a variety of specialised techniques have been developed to identify subtle DNA abnormalities. We have shown that where a DNA mutation does not create a useful novel restriction site, such a site can be introduced by PCR and specially chosen primers. The approach is simple and inexpensive and should be broadly applicable in the diagnosis of genetic polymorphism and mutation. The technique is illustrated here by the three base-pair deletion responsible for most cases of cystic fibrosis and by detection of the point mutation in the rhodopsin gene that has been associated with some cases of autosomal dominant retinitis pigmentosa.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	SORSCHER, EJ (corresponding author), UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.			Sorscher, Eric J./0000-0001-9341-3354				[Anonymous], 1989, METABOLIC BASIS INHE, V34, P253; BALLABIO A, 1990, NATURE, V343, P220, DOI 10.1038/343220a0; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Erlich HA, 1989, PCR TECHNOLOGY, P36; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, NEW ENGL J MED, V319, P537, DOI 10.1056/NEJM198809013190903; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, ANAL BIOCHEM, V186, P64, DOI 10.1016/0003-2697(90)90573-R	12	39	44	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1115	1118		10.1016/0140-6736(91)92785-Z	http://dx.doi.org/10.1016/0140-6736(91)92785-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674012				2022-12-28	WOS:A1991FL12400002
J	BRANCH, DW; DUDLEY, DJ; MITCHELL, MD				BRANCH, DW; DUDLEY, DJ; MITCHELL, MD			PRELIMINARY EVIDENCE FOR HOMEOSTATIC MECHANISM REGULATING ENDOTHELIN PRODUCTION IN PREECLAMPSIA	LANCET			English	Note								To find out whether a serum factor in pre-eclamptic women is the cause of the raised serum endothelin concentrations associated with the disorder, the effect of serum from pre-eclamptic women on endothelin production by endothelial cells was compared with that of serum from pregnant and non-pregnant controls. The finding that pre-eclamptic serum suppresses endothelin production suggests that it contains a factor that might be part of a homoeostatic response to raised serum endothelin concentrations in pre-eclampsia.			BRANCH, DW (corresponding author), UNIV UTAH,SCH MED,DEPT OBSTET & GYNECOL,ROOM 2B200 MED CTR,50 N MED DR,SALT LAKE CITY,UT 84132, USA.		Mitchell, Murray/A-8639-2010	Mitchell, Murray/0000-0002-6167-7176				CUNNINGHAM FG, 1989, HYPERTENSIVE DISORDE; DUDLEY DJ, 1990, AM J OBSTET GYNECOL, V162, P953, DOI 10.1016/0002-9378(90)91296-O; FIRTH JD, 1988, LANCET, V2, P1179; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL MD, 1991, SEMIN PERINATOL, V15, P79; MORTENSEN LH, 1990, HYPERTENSION, V15, P729, DOI 10.1161/01.HYP.15.6.729; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; VAJAYARAGHAVEN J, 1990, J BIOL CHEM, V265, P14150; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; 1990, HOSP PRACT, V14, P25	11	38	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					943	945		10.1016/0140-6736(91)91572-C	http://dx.doi.org/10.1016/0140-6736(91)91572-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678032				2022-12-28	WOS:A1991FH13100005
J	KOLLER, KJ; LOWE, DG; BENNETT, GL; MINAMINO, N; KANGAWA, K; MATSUO, H; GOEDDEL, DV				KOLLER, KJ; LOWE, DG; BENNETT, GL; MINAMINO, N; KANGAWA, K; MATSUO, H; GOEDDEL, DV			SELECTIVE ACTIVATION OF THE B-NATRIURETIC PEPTIDE RECEPTOR BY C-TYPE NATRIURETIC PEPTIDE (CNP)	SCIENCE			English	Article							GUANYLATE-CYCLASE; SEQUENCE-ANALYSIS; ATRIAL; BRAIN; PRECURSOR; CLONING; BINDING; PLASMA	The natriuretic peptides are hormones that can stimulate natriuretic, diuretic, and vasorelaxant activity in vivo, presumably through the activation of two known cell surface receptor guanylyl cyclases (ANPR-A and ANPR-B). Although atrial natriuretic peptide (ANP) and, to a lesser extent, brain natriuretic peptide (BNP) are efficient activators of the ANPR-A guanylyl cyclase, neither hormone can significantly stimulate ANPR-B. A member of this hormone family, C-type natriuretic peptide (CNP), potently and selectively activated the human ANPR-B guanylyl cyclase. CNP does not increase guanosine 3',5'-monophosphate accumulation in cells expressing human ANPR-A. The affinity of CNP for ANPR-B is 50- or 500-fold higher than ANP or BNP, respectively. This ligand-receptor pair may be involved in the regulation of fluid homeostasis by the central nervous system.	GENENTECH INC,DEPT IMMUNOL RES & ASSAY TECHNOL,S SAN FRANCISCO,CA 94080; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN; MIYAZAKI MED COLL,DEPT BIOCHEM,MIYAZAKI 88916,JAPAN	Roche Holding; Genentech; National Cerebral & Cardiovascular Center - Japan; University of Miyazaki	KOLLER, KJ (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080, USA.							ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; CHABOT JG, 1990, CURRENT ASPECTS NEUR, V1, pCH2; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1990, BIOCHEM BIOPH RES CO, V170, P201, DOI 10.1016/0006-291X(90)91260-Y; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; KAMBAYASHI Y, 1990, FEBS LETT, V259, P341, DOI 10.1016/0014-5793(90)80043-I; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOLLER KP, UNPUB; LOWE DA, UNPUB; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MCGREGOR A, 1990, J CLIN ENDOCR METAB, V70, P1103, DOI 10.1210/jcem-70-4-1103; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; MINAMINO N, UNPUB; MIYATA A, 1985, BIOCHEM BIOPH RES CO, V129, P248, DOI 10.1016/0006-291X(85)91429-9; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SONG DL, 1988, FEBS LETT, V232, P125, DOI 10.1016/0014-5793(88)80400-9; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; WILCOX JD, UNPUB	31	729	754	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					120	123		10.1126/science.1672777	http://dx.doi.org/10.1126/science.1672777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1672777				2022-12-28	WOS:A1991FE95200048
J	MAKI, M; AINE, L; LIPSANEN, V; KOSKIMIES, S				MAKI, M; AINE, L; LIPSANEN, V; KOSKIMIES, S			DENTAL ENAMEL DEFECTS IN 1ST-DEGREE RELATIVES OF CELIAC-DISEASE PATIENTS	LANCET			English	Note								To find out whether dental changes can be used to screen for coeliac disease among apparently healthy relatives of patients with the disorder, 56 healthy first-degree relatives of such patients were subjected to dental examination and small bowel biopsy. 25 had coeliac-type general permanent-tooth enamel lesions. All 7 who had histological evidence of coeliac disease also had enamel lesions. The finding that enamel defects may occur without small bowel changes must be borne in mind in screening. The coeliac-type enamel changes were strongly associated with HLA-DR3, and most of the DR3 alleles belonged to the extended haplotype A1; B8; DR3 group.	UNIV HOSP TAMPERE,DEPT ORAL & MAXILLOFACIAL SURG,TAMPERE,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	Tampere University; Tampere University Hospital	MAKI, M (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,SF-33520 TAMPERE,FINLAND.							AINE L, 1986, Proceedings of the Finnish Dental Society, V82, P1; AINE L, 1990, J ORAL PATHOL MED, V19, P241, DOI 10.1111/j.1600-0714.1990.tb00834.x; AMOS DB, 1969, TRANSPLANTATION, V7, P220, DOI 10.1097/00007890-196903000-00023; DUPONT B, 1989, IMMUNOBIOLOGY HLA IM, V2; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, IN PRESS GUT; Massier M, 1941, AM J DIS CHILD, V62, P33; NIKIFORUK G, 1981, J PEDIATR-US, V98, P888, DOI 10.1016/S0022-3476(81)80580-X	8	47	48	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					763	764		10.1016/0140-6736(91)91375-5	http://dx.doi.org/10.1016/0140-6736(91)91375-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672395				2022-12-28	WOS:A1991FD88400007
J	PARK, KGM; HAYES, PD; GARLICK, PJ; SEWELL, H; EREMIN, O				PARK, KGM; HAYES, PD; GARLICK, PJ; SEWELL, H; EREMIN, O			STIMULATION OF LYMPHOCYTE NATURAL CYTOTOXICITY BY L-ARGININE	LANCET			English	Note							CELL	In vitro L-arginine enhanced natural-killer (NK) and lymphokine-activated-killer (LAK) cell activity; this cytotoxicity was mediated by CD56+ cells. In vivo arginine supplements (30 g/day for 3 days) increased the number of circulating CD56+ cells by a median of 32% in eight volunteers (p < 0.01); this increase was associated with a mean rise of 91% in NK cell activity (p = 0.003) and of 58% in LAK cell activity (p = 0.001) in thirteen volunteers. These findings have potentially important implications for the modulation of natural cytotoxicity in a wide range of disease states.	UNIV ABERDEEN, DEPT PATHOL, ABERDEEN AB9 2ZD, SCOTLAND; ROWETT RES INST, BUCKSBURN AB2 9SB, ABERDEEN, SCOTLAND	University of Aberdeen; University of Aberdeen	PARK, KGM (corresponding author), UNIV ABERDEEN, DEPT SURG, POLWORTH BLDG, ABERDEEN AB9 2ZD, SCOTLAND.							BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BARBUL A, 1981, SURGERY, V90, P244; DIANZANI U, 1989, EUR J IMMUNOL, V19, P1037, DOI 10.1002/eji.1830190613; EREMIN O, 1981, BRIT J CANCER, V44, P166, DOI 10.1038/bjc.1981.167; KNUDSEN PJ, 1986, J IMMUNOL, V137, P3189; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; PROSS HF, 1984, J IMMUNOL METHODS, V68, P235; REYNOLDS JV, 1990, ANN SURG, V211, P202, DOI 10.1097/00000658-199002000-00013; RODER JC, 1979, J IMMUNOL, V123, P2785; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	10	85	93	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	1991	337	8742					645	646		10.1016/0140-6736(91)92456-C	http://dx.doi.org/10.1016/0140-6736(91)92456-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671995				2022-12-28	WOS:A1991FB73000007
J	LASSEN, MR; BORRIS, LC				LASSEN, MR; BORRIS, LC			MOBILIZATION AFTER HIP-SURGERY AND EFFICACY OF THROMBOPROPHYLAXIS	LANCET			English	Letter											LASSEN, MR (corresponding author), AALBORG HOSP,DEPT ORTHOPAED,VENOUS THROMBOSIS GRP,DK-9000 AALBORG,DENMARK.			Borris, Lars/0000-0002-0527-1518				LASSEN MR, 1991, ACTA ORTHOP SCAND, V62, P33, DOI 10.3109/17453679108993088	1	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					618	618		10.1016/0140-6736(91)91686-O	http://dx.doi.org/10.1016/0140-6736(91)91686-O			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671973				2022-12-28	WOS:A1991FA70200043
J	CHOO, KE; ARIFFIN, WA; ONG, KH; SIVAKUMARAN, S				CHOO, KE; ARIFFIN, WA; ONG, KH; SIVAKUMARAN, S			AZTREONAM FAILURE IN TYPHOID-FEVER	LANCET			English	Letter									UNIV SAINS MALAYSIA,DEPT MICROBIOL,KELANTAN,MALAYSIA	Universiti Sains Malaysia	CHOO, KE (corresponding author), UNIV SAINS MALAYSIA,SCH MED,DEPT PAEDIAT,KUBANG KERIAN,KELANTAN,MALAYSIA.							FARID Z, 1990, SCAND J INFECT DIS, V22, P505, DOI 10.3109/00365549009027085; SOE GB, 1987, REV INFECT DIS, V9, P719; TANAKAKIDO J, 1990, PEDIATR INFECT DIS J, V9, P44, DOI 10.1097/00006454-199001000-00010	3	1	1	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					498	498		10.1016/0140-6736(91)93439-G	http://dx.doi.org/10.1016/0140-6736(91)93439-G			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671505				2022-12-28	WOS:A1991EY88700055
J	TRAPE, JF; DUPLANTIER, JM; BOUGANALI, H; GODELUCK, B; LEGROS, F; CORNET, JP; CAMICAS, JL				TRAPE, JF; DUPLANTIER, JM; BOUGANALI, H; GODELUCK, B; LEGROS, F; CORNET, JP; CAMICAS, JL			TICK-BORNE BORRELIOSIS IN WEST AFRICA	LANCET			English	Article								Reported cases of tick-borne relapsing fever due to the spirochaete Borrelia crocidurae are rare in West Africa, and few epidemiological data are available. To see how common relapsing fever is in Senegal thick blood smears from cases of fever of unknown origin and from randomly selected clinic outpatients from a rural dispensary were examined for Borrelia. The prevalence of Borrelia infections in small mammals was also assessed. Borrelia was seen in smears of 12 (0.9%) of 1340 children. All children who tested positive had complained of acute fever. Prevalence was 0% (0/496), 0.5% (2/417), 1.6% (5/308), and 4.2% (5/119) at ages 0-1, 2-4, 5-9, and 10-14, respectively. 26 other instances of borreliosis were seen in patients from different regions of Senegal. Blood samples from 7 of these patients were inoculated intraperitoneally into white mice; serious infection developed in all mice. Borrelia was seen in thick smears from 65 of 461 wild rodents or insectivores. Six rodents species were infected. From a sample of 93 rodents, 33.3% were infected, as judged by intraperitoneal inoculation of white mice, compared with 14.1% by direct smear examination. The findings suggest that borreliosis has a wide distribution and a high incidence in Senegal. This disease may be a major cause of morbidity in rural areas throughout much of West Africa.			TRAPE, JF (corresponding author), ORSTOM,BP 1386,DAKAR,SENEGAMBIA.							BALTAZARD M., 1954, BULL SOC PATHOL EXOT, V47, P878; BALTAZARD M., 1948, Bulletin de la Societe de Pathologie Exotique, V41, P399; BOIRON H., 1949, BULL SOC PATH EXOT, V42, P62; COLLIGNON R., 1989, SANTE POPULATION SEN; LEGER Andre, 1917, Bulletin de la Societe de Pathologie Exotique, V10, P280; Mathis C., 1934, Ann Inst Pasteur Paris T, V52, P166; MATHIS C., 1928, BULL SOC PATH EXOT, V21, P472; 1989, WHOVBC89967	8	52	52	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					473	475		10.1016/0140-6736(91)93404-W	http://dx.doi.org/10.1016/0140-6736(91)93404-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671481				2022-12-28	WOS:A1991EY88700015
J	MCKHANN, GM; CORNBLATH, DR; HO, T; LI, CY; BAI, AY; WU, HS; YEI, QF; ZHANG, WC; ZHAORI, Z; JIANG, Z; GRIFFIN, JW; ASBURY, AK				MCKHANN, GM; CORNBLATH, DR; HO, T; LI, CY; BAI, AY; WU, HS; YEI, QF; ZHANG, WC; ZHAORI, Z; JIANG, Z; GRIFFIN, JW; ASBURY, AK			CLINICAL AND ELECTROPHYSIOLOGICAL ASPECTS OF ACUTE PARALYTIC DISEASE OF CHILDREN AND YOUNG-ADULTS IN NORTHERN CHINA	LANCET			English	Article								Acute peripheral nervous system diseases leading to paralysis in children are rare in Europe and the USA, whereas epidemics of a Guillain-Barre-like syndrome occur annually among children in rural parts of northern China. To clarify the features of this disorder 36 patients, aged 15 months to 37 years (median 7) with this syndrome were investigated; 91% were from rural areas. In 47%, a prodromal illness was reported in the preceding 4 weeks. Leg weakness and resistance to neck flexion were the earliest symptoms. The weakness ascended rapidly and symmetrically to affect the arms and respiratory muscles, with maximum weakness occurring a mean of 6 days after onset of weakness. Bulbar weakness occurred in 61% of patients, but only 1 had extraocular paresis. Respiratory assistance was needed by 31% of patients. Tendon reflexes were lost as weakness developed. 42% of patients had raised concentrations of protein in the cerebrospinal fluid, and the mean cell count was 3 cells/mu-l (range 0-12/mu-l). Electrodiagnostic studies in 22 patients showed severe reductions in motor evoked amplitudes from distal stimulation. Sensory action potentials were normal. Electromyography revealed denervation potentials in limb muscles. The distinctive epidemiological, clinical, and neurophysiological characteristics of this illness suggest that the disorder is different from both Guillain-Barre syndrome and poliomyelitis. The neurophysiological findings support the hypothesis that the disorder is a reversible distal motor nerve terminal or anterior horn cell lesion.	HEBEI MED COLL,SECOND TEACHING HOSP,DEPT NEUROL,SHIJIAZHUANG,PEOPLES R CHINA; BEIJING CHILDRENS HOSP,DEPT NEUROL,BEIJING,PEOPLES R CHINA; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104	Capital Medical University; Johns Hopkins University; University of Pennsylvania			Ho, Tony W/F-1019-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023936, P01NS022849] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22849, NS23936] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ALTER M, 1990, ANN NEUROL, V27, pS7, DOI 10.1002/ana.410270704; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BROWN WF, 1984, BRAIN, V107, P219, DOI 10.1093/brain/107.1.219; CHIAE CK, 1986, CHINESE J PSYCHIATRY, V19, P149; CORNBLATH D R, 1990, Neurology, V40, P458; CORNBLATH DR, 1990, ANN NEUROL, V27, pS17, DOI 10.1002/ana.410270706; HUSHENG W, 1988, BRAIN DEV, V10, P147; PAULSON GW, 1970, DEV MED CHILD NEUROL, V12, P604; RAMOSALV.M, 1969, J AMER MED ASSOC, V207, P1481; SUN JY, 1991, CHINESE J NEUROL PSY, V15, P75; WADIA NH, 1983, J NEUROL NEUROSUR PS, V46, P599, DOI 10.1136/jnnp.46.7.599; WITTE JJ, 1966, AM J EPIDEMIOL, V83, P189, DOI 10.1093/oxfordjournals.aje.a120574; XUE G, 1980, ZHOGHUA YUFANGYIXUE, V14, P123; YOHANNAN MD, 1991, J INFECTION, V22, P129, DOI 10.1016/0163-4453(91)91503-P; ZHANG ZL, 1979, CHIN J NEUROL PSYCHI, V12, P17; ZHAO BX, 1981, ANN NEUROL, V9, P146, DOI 10.1002/ana.410090720	17	180	188	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					593	597		10.1016/0140-6736(91)90606-P	http://dx.doi.org/10.1016/0140-6736(91)90606-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679153	hybrid			2022-12-28	WOS:A1991GD80900003
J	MCMANUS, IC				MCMANUS, IC			HOW WILL MEDICAL-EDUCATION CHANGE	LANCET			English	Article							CURRICULUM				MCMANUS, IC (corresponding author), ST MARYS HOSP,SCH MED,DEPT PSYCHIAT,NORFOLK PL,LONDON W2 1PG,ENGLAND.			McManus, Ian/0000-0003-3510-4814				BLOOM SW, 1989, MED EDUC, V23, P228, DOI 10.1111/j.1365-2923.1989.tb01538.x; CHURCHLAND PM, 1990, THINKING INVITATION, V3, P199; CLAYDEN GS, 1988, MED EDUC, V22, P456; COLES CR, 1990, INNOVATION MED ED EV, P76; Flexner A., 1910, FLEXNER REPORT; GILBERT W, 1991, NATURE, V349, P99, DOI 10.1038/349099a0; GRANT J, 1989, MED EDUC, V23, P252, DOI 10.1111/j.1365-2923.1989.tb01540.x; HELSEL SK, 1990, VIRTUAL REALITY THEO; HSU FH, 1990, SCI AM, V263, P18; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MCGUIRE C, 1989, MED EDUC, V23, P221, DOI 10.1111/j.1365-2923.1989.tb01537.x; MCMANUS IC, 1989, BRIT MED J, V298, P1051, DOI 10.1136/bmj.298.6680.1051; Mennin S., 1987, INNOVATIVE TRACKS ES; NIELSEN J, 1990, HYPERTEXT HYPERMEDIA; PARRY KM, 1989, MED EDUC, V23, P301, DOI 10.1111/j.1365-2923.1989.tb01549.x; RYLE JA, 1948, NATURAL HIST DISEASE, P1; SCHWART S, 1986, MED THINKING PSYCH M, P198; STIX G, 1991, SCI AM, V264, P116; VANDERVLEUTEN CPM, 1990, INNOVATION MED ED EV, P404; WALTON HJ, 1989, MED EDUC, V23, P542, DOI 10.1111/j.1365-2923.1989.tb01581.x; 1987, LANCET, V2, P1128	21	28	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1519	1521		10.1016/0140-6736(91)93205-N	http://dx.doi.org/10.1016/0140-6736(91)93205-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT116	1675377				2022-12-28	WOS:A1991FT11600012
J	TODD, JA; AITMAN, TJ; CORNALL, RJ; GHOSH, S; HALL, JRS; HEARNE, CM; KNIGHT, AM; LOVE, JM; MCALEER, MA; PRINS, JB; RODRIGUES, N; LATHROP, M; PRESSEY, A; DELARATO, NH; PETERSON, LB; WICKER, LS				TODD, JA; AITMAN, TJ; CORNALL, RJ; GHOSH, S; HALL, JRS; HEARNE, CM; KNIGHT, AM; LOVE, JM; MCALEER, MA; PRINS, JB; RODRIGUES, N; LATHROP, M; PRESSEY, A; DELARATO, NH; PETERSON, LB; WICKER, LS			GENETIC-ANALYSIS OF AUTOIMMUNE TYPE-1 DIABETES-MELLITUS IN MICE	NATURE			English	Article							DNA POLYMORPHISMS; NOD MOUSE; NONOBESE; INSULITIS; EXPRESSION; PREVENTION; LINKAGE; HETEROGENEITY; RECOMBINATION; CONSTRUCTION	Two genes, Idd-3 and Idd-4, that influence the onset of autoimmune type 1 diabetes in the nonobese diabetic mouse have been located on chromosomes 3 and 11, outside the chromosome 17 major histocompatibility complex. A genetic map of the mouse genome, analysed using the polymerase chain reaction, has been assembled specifically for the study. On the basis of comparative maps of the mouse and human genomes, the homologue of Idd-3 may reside on human chromosomes 1 or 4 and Idd-4 on chromosome 17.	CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; CTR ETUD POLYMORPHISME HUMAINE,F-75010 PARIS,FRANCE; MERCK SHARP & DOHME LTD,DEPT CELLULAR & MOLEC PHARMACOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,AUTOIMMUNE DIS RES,RAHWAY,NJ 07065	Merck & Company; Merck & Company	TODD, JA (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.		Todd, John A/A-3542-2010; Wicker, Linda S/F-7384-2010	Todd, John A/0000-0003-2740-8148; Prins, Jan-Bas/0000-0002-1831-8522; Aitman, Timothy/0000-0002-7875-4502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; AITMAN TJ, IN PRESS MAMMALIAN G; BOTTAZZO GF, 1989, BRIT MED BULL, V45, P37, DOI 10.1093/oxfordjournals.bmb.a072319; CARTER TC, 1951, J GENET, V50, P307, DOI 10.1007/BF02996226; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CORNALL RJ, IN PRESS GENOMICS; FAUSTMAN D, 1989, DIABETES, V38, P1462, DOI 10.2337/diabetes.38.11.1462; HATAMORI N, 1990, DIABETES, V39, P1070, DOI 10.2337/diabetes.39.9.1070; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, IN PRESS MAMMALIAN G; HEROLD KC, 1990, DIABETES, V39, P815, DOI 10.2337/diabetes.39.7.815; HILLYARD AL, 1990, LOCUS MAP MOUSE COMP; JANSSEN LAJ, 1990, GENOMICS, V8, P237, DOI 10.1016/0888-7543(90)90277-2; KNIGHT AM, 1990, MOL CELL PROBE, V4, P497, DOI 10.1016/0890-8508(90)90008-N; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; LIVINGSTONE A, 1991, J IMMUNOL, V146, P529; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NEUMANN PE, IN PRESS P NATN ACAD; OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; OTT J, 1985, ANAL HUMAN GENETIC L; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PATERSON AH, 1991, GENETICS, V127, P181; PHILBRICK WM, 1990, EMBO J, V9, P2485, DOI 10.1002/j.1460-2075.1990.tb07427.x; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RICE J, 1989, GENET EPIDEMIOL, V6, P161, DOI 10.1002/gepi.1370060130; RISCH N, 1987, AM J HUM GENET, V40, P1; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SIBLEY RK, 1985, LAB INVEST, V53, P132; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; Suzuki T, 1987, IMMUNE DEFICIENT ANI, P112, DOI DOI 10.1159/000413303; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; THOMSON G, 1988, AM J HUM GENET, V43, P799; TODD JA, 1990, IMMUNOL TODAY, V11, P122, DOI 10.1016/0167-5699(90)90049-F; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE R, 1985, NATURE, V313, P101, DOI 10.1038/313101a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1989, J IMMUNOL, V142, P781; WICKER LS, IN PRESS P P S BIOME; WICKER LS, IN PRESS FRONTIERS D, V2; WILBERZ S, 1991, DIABETOLOGIA, V34, P2, DOI 10.1007/BF00404016	50	506	508	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					542	547		10.1038/351542a0	http://dx.doi.org/10.1038/351542a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1675432				2022-12-28	WOS:A1991FR03400049
J	HAMMANS, SR; SWEENEY, MG; BROCKINGTON, M; MORGANHUGHES, JA; HARDING, AE				HAMMANS, SR; SWEENEY, MG; BROCKINGTON, M; MORGANHUGHES, JA; HARDING, AE			MITOCHONDRIAL ENCEPHALOPATHIES - MOLECULAR GENETIC DIAGNOSIS FROM BLOOD-SAMPLES	LANCET			English	Article							DNA; MUTATION; DELETIONS; EPILEPSY; MERRF	Point mutations of mitochondrial DNA have been described in the muscle of patients with syndromes of myoclonic epilepsy and ragged red fibres (MERRF) and of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS). We have found the MERRF mutation in members of 6 British kindreds; 2 of these had unusual phenotypes but all index patients had myoclonus. The MELAS mutation was detected in 17 patients from 16 families, who had a wide range of clinical features that particularly affected the central nervous system; stroke-like episodes were observed in 10.3 patients with mitochondrial DNA mutations did not have ragged red fibres on muscle biopsy, generally considered to be the morphological hallmark of mitochondrial diseases. In all 6 patients with the MERRF mutation, and 10 of 11 with the MELAS mutation, the genetic defect was easily detected in blood cells as well as muscle (blood samples were not available in 6 patients with MELAS mutations in muscle). Molecular genetic analysis of blood samples represents an inexpensive and reliable screening test for mitochondrial encephalopathies, and use of such techniques could influence diagnosis and genetic counselling in patients with seizure disorders and young-onset stroke.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND	University of London; University College London								AICARDI J, 1990, ANN NEUROL, V28, P113; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; POULTON J, 1989, LANCET, V1, P236; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; ZEVIANI M, 1991, AM J HUM GENET, V48, P203	11	173	175	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1311	1313		10.1016/0140-6736(91)92981-7	http://dx.doi.org/10.1016/0140-6736(91)92981-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674297				2022-12-28	WOS:A1991FP08400004
J	COURSAGET, P; YVONNET, B; GILKS, WR; WANG, CC; DAY, NE; CHIRON, JP; DIOPMAR, I				COURSAGET, P; YVONNET, B; GILKS, WR; WANG, CC; DAY, NE; CHIRON, JP; DIOPMAR, I			SCHEDULING OF REVACCINATION AGAINST HEPATITIS-B VIRUS	LANCET			English	Article							ENDEMIC AREA; ANTI-HBS; VACCINE; DIALYSIS; EFFICACY; INFANTS	Studies have shown that to maintain protection against infection after a primary course of hepatitis B immunisation, revaccination can be scheduled on the basis of an anti-hepatitis B virus surface antigen (anti-HBs) titre obtained 1 month after the booster dose. However, schemes which require post-booster testing may present practical difficulties. We applied a random-effects regression model to data from 118 Senegalese infants given three injections of hepatitis B vaccine about 6 weeks apart and a booster injection at 13 months, and show that revaccination can be scheduled on the basis of an anti-HBs titre recorded at the time of the booster dose. We also show that titre-at-booster is no less accurate in predicting future titre than 1-month post-booster titre. In several other studies the post-booster decline in anti-HBs conforms to the same mathematical description, indicating the generality of our findings.	FAC PHARM TOURS, INST VIROL TOURS, TOURS, FRANCE; FAC MED & PHARM DAKAR, DAKAR, SENEGAMBIA; ACAD SINICA, INST STAT, TAIPEI 115, TAIWAN; FAC PHARM TOURS, MICROBIOL LAB, TOURS, FRANCE	Academia Sinica - Taiwan								BENHAMOU E, 1986, NEW ENGL J MED, V314, P1710; COUROUCE AM, 1984, NEW ENGL J MED, V311, P1515; COURSAGET P, 1986, LANCET, V2, P1143; CROSNIER J, 1981, LANCET, V1, P455; DENTICO P, 1990, COLLOQ INSE, V194, P325; GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; GESEMANN M, 1989, LANCET, V2, P1274; GILKS WR, 1990, COLLOQ INSE, V194, P409; GILKS WR, 1989, LANCET, V2, P1273; GOUDEAU A, 1990, COLLOQ INSE, V194, P123; GROB PJ, 1990, COLLOQ INSE, V194, P437; GROB PJ, 1985, SCHWEIZ MED WSCHR, V115, P394; JILG W, 1990, LANCET, V335, P173, DOI 10.1016/0140-6736(90)90050-F; LAPLANCHE A, 1987, LANCET, V1, P1206; NOMMENSEN FE, 1990, LANCET, V335, P479, DOI 10.1016/0140-6736(90)90716-I; NOMMENSEN FE, 1989, LANCET, V2, P847; OON CJ, 1990, COLLOQ INSE, V194, P475; RAWAL BK, 1989, LANCET, V2, P1274; SIEGEL S, 1956, NONPARAMETRIC STAT, P47; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; YVONNET B, 1987, J MED VIROL, V22, P315, DOI 10.1002/jmv.1890220404; ZACHOVAL R, 1984, J INFECT DIS, V150, P112, DOI 10.1093/infdis/150.1.112; ZANETTI AR, 1990, COLLOQ INSE, V194, P79; 1988, LANCET, V1, P875	25	64	64	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1180	1183		10.1016/0140-6736(91)92857-X	http://dx.doi.org/10.1016/0140-6736(91)92857-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673737				2022-12-28	WOS:A1991FM26100002
J	MCKINNEY, RE; MAHA, MA; CONNOR, EM; FEINBERG, J; SCOTT, GB; WULFSOHN, M; MCINTOSH, K; BORKOWSKY, W; MODLIN, JF; WEINTRUB, P; ODONNELL, K; GELBER, RD; ROGERS, GK; LEHRMAN, SN; WILFERT, CM				MCKINNEY, RE; MAHA, MA; CONNOR, EM; FEINBERG, J; SCOTT, GB; WULFSOHN, M; MCINTOSH, K; BORKOWSKY, W; MODLIN, JF; WEINTRUB, P; ODONNELL, K; GELBER, RD; ROGERS, GK; LEHRMAN, SN; WILFERT, CM			A MULTICENTER TRIAL OF ORAL ZIDOVUDINE IN CHILDREN WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; INFECTION; AZT; SURVIVAL; TYPE-1	Background and Methods. Zidovudine has been shown to be an effective antiretroviral treatment in adults with human immunodeficiency virus (HIV) infection. We examined the safety of zidovudine and the tolerance of and therapeutic response to the drug in 88 children with advanced HIV disease. During a 24-week outpatient trial, zidovudine (180 mg per square meter of body-surface area per dose) was given by mouth every six hours and serial measurements were made of clinical, immunologic, and virologic indexes. Children who completed 24 weeks of treatment were permitted to continue receiving zidovudine. Results. Of the 88 children (mean age, 3.9 years; range, 4 months to 11 years), 61 completed the initial 24-week trial, and 49 continued to receive zidovudine for up to 90 weeks (median follow-up, 56 weeks). The patients generally tolerated zidovudine well. One or more episodes of hematologic toxicity occurred in 54 children (61 percent) - anemia (hemoglobin level, < 75 g per liter) in 23 children (26 percent) and neutropenia (neutrophil count, < 0.75 X 10(9) per liter) in 42 (48 percent). Many of these abnormalities resolved spontaneously, but 30 children required transfusions or a modification of the dose of zidovudine. Only three children had to stop receiving the drug because of hematologic toxicity. Kaplan-Meier analysis demonstrated that the probability of survival was 0.89 after 24 weeks and 0.79 after 52 weeks. There was marked improvement in weight gain, cognitive function (mainly in children < 3 years old), serum and cerebrospinal fluid concentrations of p24 antigen, and the proportion of cerebrospinal fluid cultures negative for HIV. CD4+ lymphocyte counts (mean at base line, 0.263 X 10(9) per liter) improved during the first 12 weeks, although the improvement was not sustained through the 24th week. Conclusions. Zidovudine in a dose of 180 mg per square meter every six hours can be safely administered to children with advanced HIV disease. The resultant clinical, immunologic, and virologic improvements in children are similar to those reported with zidovudine in adults.	BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709; NEW JERSEY CHILDRENS HOSP,NEWARK,NJ; NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL 33152; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; NYU,SCH MED,DEPT PEDIAT,NEW YORK,NY 10003; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Burroughs Wellcome Fund; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Miami; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; New York University; Johns Hopkins University	MCKINNEY, RE (corresponding author), DUKE UNIV,MED CTR,SCH MED,DEPT PEDIAT,BOX 3461,DURHAM,NC 27710, USA.			feinberg, judith/0000-0003-4206-7214				BALIS FM, 1989, J PEDIATR-US, V114, P880, DOI 10.1016/S0022-3476(89)80158-1; BALIS FM, 1989, ANN INTERN MED, V110, P279, DOI 10.7326/0003-4819-110-4-279; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1; MICHALSKI FJ, 1989, YALE J BIOL MED, V62, P93; PARKS WP, 1988, J ACQ IMMUN DEF SYND, V1, P125; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; ROWE PC, 1987, H LANE HDB MANUAL PE, P325; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1987, MMWR S, V36, pS1; 1969, BAYLEY SCALES INFANT; 1989, MMWR, V38, P1; 1972, MCCARTHY SCALES CHIL	23	199	202	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1018	1025		10.1056/NEJM199104113241503	http://dx.doi.org/10.1056/NEJM199104113241503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	1672443				2022-12-28	WOS:A1991FF77100003
J	CONNOR, E; BAGARAZZI, M; MCSHERRY, G; HOLLAND, B; BOLAND, M; DENNY, T; OLESKE, J				CONNOR, E; BAGARAZZI, M; MCSHERRY, G; HOLLAND, B; BOLAND, M; DENNY, T; OLESKE, J			CLINICAL AND LABORATORY CORRELATES OF PNEUMOCYSTIS-CARINII PNEUMONIA IN CHILDREN INFECTED WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; PROGNOSTIC FACTORS; LIFE EXPECTANCY; SURVIVAL; DISEASE; AIDS	The case histories of 27 children with Pneumocystis carinii pneumonia (PCP) who were followed up in the AIDS Program at the Children's Hospital of New Jersey, Newark, are reviewed. The mean and median age at PCP diagnosis were 10.8 and 7.7 months, respectively. All of the children had other clinical evidence of infection with the human immunodeficiency virus that was documented prior to the diagnosis of PCP or found at the time of PCP diagnosis. Most patients who presented to the hospital were acutely ill, and complications of treatment occurred in 70%. Overall, 89% of the patients died and 70% survived for less than 6 months after diagnosis of PCP. Median survival after the diagnosis of PCP was only 2.0 months and the median life span of children with PCP was only 14.4 months. Only 40% of children with PCP had CD4 lymphocyte counts at or below the threshold for institution of PCP prophylaxis in adults of 200 X 10(6) cells/L (200 cells/mm3).	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	CONNOR, E (corresponding author), CHILDRENS HOSP NEW JERSEY,DEPT PEDIAT,AIDS PROGRAM,15 S 9TH ST,NEWARK,NJ 07107, USA.		Bagarazzi, Mark L/AAU-1383-2021; Oleske, James/C-1951-2016	Oleske, James/0000-0003-2305-5605; Denny, Thomas/0000-0002-7364-8276	NIAID NIH HHS [1 U01 AI25883-01] Funding Source: Medline; PHS HHS [U64/CCU202219-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025883] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; DENNY TN, 1990, PEDIATR RES, V27, P155; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MCCULLOUGH PC, 1986, RESPIRATION, V50, P286, DOI 10.1159/000194940; MCSHERRY G, 1988, 28TH INT C ANT AG CH; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUBINSTEIN A, 1986, J PEDIATR-US, V108, P498, DOI 10.1016/S0022-3476(86)80822-8; SANDERSLAUFER D, 1990, PEDIATR RES, V27, P183; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1989, MMWR S5, V38, P1; 1987, MMWR, V36, P225	25	53	53	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1693	1697		10.1001/jama.265.13.1693	http://dx.doi.org/10.1001/jama.265.13.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1672168				2022-12-28	WOS:A1991FD65900024
J	MASUDA, T; SHIMURA, S; SASAKI, H; TAKISHIMA, T				MASUDA, T; SHIMURA, S; SASAKI, H; TAKISHIMA, T			SURFACTANT APOPROTEIN-A CONCENTRATION IN SPUTUM FOR DIAGNOSIS OF PULMONARY ALVEOLAR PROTEINOSIS	LANCET			English	Article							HUMAN AMNIOTIC-FLUID; MONOCLONAL-ANTIBODIES; IMMUNOASSAY; LAVAGE; MANAGEMENT	Pulmonary alveolar proteinosis (PAP), a disease characterised by accumulation of surfactant in alveoli, is diagnosed on the basis of invasive biopsy procedures. We have measured apoprotein A (SP-A) concentrations in sputum to see if this is useful for the diagnosis of PAP. Sputum samples from three patients with PAP and twenty patients with other pulmonary disease were assayed using monoclonal antibodies to SP-A. SP-A concentrations were 400 times higher in patients with PAP than in the controls, suggestions that this measurement is useful for the diagnosis of PAP, especially where lung biopsy is contraindicated.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN	Tohoku University								AKINO T, 1989, CLIN CHEM, V34, P1513; CLAYPOOL WD, 1984, CHEST, V85, P605; CORRIN B, 1970, THORAX, V25, P230, DOI 10.1136/thx.25.2.230; COSTELLO JF, 1975, THORAX, V30, P121, DOI 10.1136/thx.30.2.121; GONZALEZROTHI RJ, 1986, CHEST, V90, P656, DOI 10.1378/chest.90.5.656; HONDA Y, 1989, CLIN CHIM ACTA, V181, P11, DOI 10.1016/0009-8981(89)90312-4; KING RJ, 1972, AM J PHYSIOL, V223, P715, DOI 10.1152/ajplegacy.1972.223.3.715; KUROKI Y, 1985, BIOCHIM BIOPHYS ACTA, V836, P201; KUROKI Y, 1985, PEDIATR RES, V19, P1017, DOI 10.1203/00006450-198510000-00013; LARSON RK, 1965, ANN INTERN MED, V62, P292, DOI 10.7326/0003-4819-62-2-292; MARTIN RJ, 1980, AM REV RESPIR DIS, V121, P819; ROGERS RM, 1978, AM REV RESPIR DIS, V118, P255; SATO S, 1978, TOHOKU J EXP MED, V126, P257; SHIMIZU H, 1989, TOHOKU J EXP MED, V157, P269, DOI 10.1620/tjem.157.269; SINGH G, 1983, CHEST, V83, P82, DOI 10.1378/chest.83.1.82; SMITH LJ, 1980, CHEST, V78, P765, DOI 10.1378/chest.78.5.765; SNYDER JM, 1988, PEDIATR RES, V24, P728, DOI 10.1203/00006450-198812000-00016; VIDONE RA, 1966, DIS CHEST, V49, P326, DOI 10.1378/chest.49.3.326	18	33	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					580	582		10.1016/0140-6736(91)91640-G	http://dx.doi.org/10.1016/0140-6736(91)91640-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671943				2022-12-28	WOS:A1991FA70200004
J	INFANTE, PF				INFANTE, PF			PREVENTION VERSUS CHEMOPHOBIA - A DEFENSE OF RODENT CARCINOGENICITY TESTS	LANCET			English	Editorial Material							BENZENE; MORTALITY				INFANTE, PF (corresponding author), US OCCUPAT SAFETY & HLTH ADM,HLTH STAND PROGRAM,ROOM N3718,200 CONSTITUT AVE NW,WASHINGTON,DC 20210, USA.							ABELSON PH, 1990, SCIENCE, V249, P1357, DOI 10.1126/science.2402628; ALLEN BC, 1988, RISK ANAL, V8, P531, DOI 10.1111/j.1539-6924.1988.tb01193.x; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BAILAR JC, 1988, RISK ANAL, V8, P485, DOI 10.1111/j.1539-6924.1988.tb01189.x; BINGHAM E, 1976, ANN NY ACAD SCI, V271, P14, DOI 10.1111/j.1749-6632.1976.tb23087.x; BOND GG, 1986, BRIT J IND MED, V43, P685; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; GHANAYEM BI, IN PRESS PROG CLIN B; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HOEL DG, 1988, CARCINOGENESIS, V9, P2045, DOI 10.1093/carcin/9.11.2045; MALTONI C, 1983, AM J IND MED, V4, P589, DOI 10.1002/ajim.4700040503; OTT MG, 1978, ARCH ENVIRON HEALTH, V33, P3, DOI 10.1080/00039896.1978.10667299; SAFFIOTTI U, 1977, COLD SPRING HARBOR C, V4, P1311; SOLT DB, 1983, CANCER RES, V43, P188; SONTAG JM, 1976, DHHS NIH76801 NCI; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; TOMATIS L, 1977, COLD SPRING HARBOR C, V4, P1339; 1984, FED REGISTER, V49, P25734; 1987, FED REGISTER, V52, P34460; 1987, FED REGISTER, V52, P46168; 1990, FED REGISTER, V55, P4052	23	12	12	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					538	540		10.1016/0140-6736(91)91310-Q	http://dx.doi.org/10.1016/0140-6736(91)91310-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671901				2022-12-28	WOS:A1991EZ87400016
J	RUSKIN, J; LARIVIERE, M				RUSKIN, J; LARIVIERE, M			LOW-DOSE COTRIMOXAZOLE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	LANCET			English	Article							SULFAMETHOXAZOLE; CHEMOPROPHYLAXIS; PENTAMIDINE; AIDS	The efficacy and tolerability of low, intermittent doses of co-trimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole given Monday, Wednesday, Friday) for prophylaxis against Pneumocystis carinii pneumonia (PCP) was assessed retrospectively in 116 patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex at high risk of PCP. 92% were receiving concomitant zidovudine. 71 with previous episode(s) of PCP were followed a mean of 18.5 months (range 3-42). 45 without past PCP but with depletion of CD4 cells to < 200/mu-l were observed for a mean of 24.2 months (range 9-40). PCP did not develop in any patient on co-trimoxazole. 33 (28%) had side-effects, mainly rash, pruritus, and nausea. 15 discontinued co-trimoxazole, but only 11 (9%), who withdrew in the first month, were clearly drug-intolerant. Thus, low-dose, thrice weekly cotrimoxazole completely prevents AIDS-associated PCP, is cost-effective, and well tolerated by more than 85% of patients. Controlled comparisons of this regimen with other prophylactic agents are warranted.			RUSKIN, J (corresponding author), KAISER PERMANENTE MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,1505 N EDGEMONT ST,LOS ANGELES,CA 90027, USA.							BERNARD EM, 1989, 5 INT C AIDS MONTR; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GIRARD PM, 1989, LANCET, V1, P1348; GLUCKSTEIN D, 1988, 4 INT C AIDS STOCKH; GOLDEN JA, 1989, LANCET, V1, P654; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1979, ANTIMICROB AGENTS CH, V16, P333, DOI 10.1128/AAC.16.3.333; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; NICHOLAS P, 1990, 6 INT C AIDS SAN FRA; PESANTI EL, 1980, J INFECT DIS, V141, P775, DOI 10.1093/infdis/141.6.775; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; TELZAK EE, 1990, REV INFECT DIS, V12, P380; [No title captured]; 1989, AIDS WKLY SURV  0130, P1; 1989, MMWR, V38, P1	20	126	126	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					468	471		10.1016/0140-6736(91)93402-U	http://dx.doi.org/10.1016/0140-6736(91)93402-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671479				2022-12-28	WOS:A1991EY88700013
J	LAPORTE, JP; FOUILLARD, L; DOUAY, L; EUGENEJOLCHINE, I; ISNARD, F; STACHOWIAK, J; NAJMAN, A; GORIN, NC				LAPORTE, JP; FOUILLARD, L; DOUAY, L; EUGENEJOLCHINE, I; ISNARD, F; STACHOWIAK, J; NAJMAN, A; GORIN, NC			GM-CSF INSTEAD OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION AFTER THE BEAM REGIMEN	LANCET			English	Note							COLONY-STIMULATING FACTOR; RECOMBINANT; CHEMOTHERAPY; FAILURE	Five patients with resistant non-Hodgkin lymphoma (NHL) were given granulocyte-macrophage colony-stimulating factor (GM-CSF, 250-mu-g/m2 daily) after the BEAM pretransplant chemotherapy regimen (carmustine 300 mg/m2, etoposide 1.2 g/m2, cytarabine 800 mg/m2, melphalan 140 mg/m2) because persistent lymphoma cell infiltration of the bone marrow precluded autologous bone-marrow transplantation (BMT). In three patients full haemopoietic reconstitution occurred, with similar kinetics to that seen after autologous BMT. The other two patients died without sustained haemopoietic recovery. GM-CSF may replace autologous BMT in highly selected cases of NHL with progressive disease and bone-marrow involvement.	HOP ST ANTOINE,SERV MALAD SANG,BONE MARROW TRANSPLANT UNIT,F-75571 PARIS 12,FRANCE; FORMAT ASSOCIEE CLAUDE BERNARD,UNITE RECH GREFFES CELLULES SOUCHES HEMATOPOIET,PARIS,FRANCE; FDN CTR NATL TRANSFUS SANGUINE,PARIS,FRANCE; LAB HOECHST PARIS,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								[Anonymous], 1982, CANCER, V49, P2112; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BROXMEYER HE, 1987, P NATL ACAD SCI USA, V84, P3871, DOI 10.1073/pnas.84.11.3871; FOUILLARD L, 1989, LANCET, V1, P1460; GORIN NC, 1986, BLOOD, V67, P1367; NEMUNAITIS J, 1990, BLOOD, V76, P245; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; SHUENING FG, 1989, BLOOD, V74, P1308; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501	9	43	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					601	602		10.1016/0140-6736(91)90609-S	http://dx.doi.org/10.1016/0140-6736(91)90609-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679155				2022-12-28	WOS:A1991GD80900005
J	PECKHAM, M				PECKHAM, M			RESEARCH-AND-DEVELOPMENT FOR THE NATIONAL-HEALTH-SERVICE	LANCET			English	Article											PECKHAM, M (corresponding author), DEPT HLTH, RICHMOND HOUSE, 79 WHITEHALL, LONDON SW1A 2NS, ENGLAND.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; Baum M, 1989, Int J Technol Assess Health Care, V5, P305; Chalmers I, 1989, EFFECTIVE CARE PREGN; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1991, LANCET, P1472; 1988, PRIORITIES MED RES; 1991, LANCET, V337, P1448; 1991, HLTH NATION; 1986, MED EQUIPMENT REPORT; 1991, LANCET, P1491; 1990, REPORT WORKING PARTY	13	80	81	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1991	338	8763					367	371		10.1016/0140-6736(91)90494-A	http://dx.doi.org/10.1016/0140-6736(91)90494-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677710				2022-12-28	WOS:A1991GA60700017
J	MITCHELL, SW; MBOUP, S; MINGLE, J; SAMBE, D; TUKEI, P; MILENGE, K; NYAMONGO, J; MUBARAK, OK; SANKALE, JL; HANSON, DS; QUINN, TC				MITCHELL, SW; MBOUP, S; MINGLE, J; SAMBE, D; TUKEI, P; MILENGE, K; NYAMONGO, J; MUBARAK, OK; SANKALE, JL; HANSON, DS; QUINN, TC			FIELD-EVALUATION OF ALTERNATIVE HIV TESTING STRATEGY WITH A RAPID IMMUNOBINDING ASSAY AND AN AGGLUTINATION ASSAY	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LATEX AGGLUTINATION; SCREENING ASSAYS; ANTIBODY	A rapid immunobinding assay ('HIVCHEK', Ortho) and an agglutination assay ('Serodia-HIV', Fujirebio) were evaluated as an alternative to enzyme-linked immunosorbent assay (ELISA) and western blot under field conditions in Africa for detection of antibody to human immunodeficiency virus (HIV). 7106 specimens were tested at 25 laboratories in Kenya, Ghana, Senegal, and Zaire. HIVCHEK was used as a screening test, and serodia-HIV as a supplemental test to evaluate these assays in an alternative testing strategy to the standard ELISA/western blot testing procedure. In each country, HIVCHEK was more sensitive and specific than ELISA when compared with western blot. The sensitivity of HIVCHEK ranged from 87.0 to 96.3% and the specificity from 99.0 to 100%. The sensitivity and specificity of serodia-HIV ranged from 85 to 98% and from 88 to 98%, respectively. The sensitivity and specificity were affected by the presence of HIV-2 in Ghana and Senegal. Overall, with an HIV-1 prevalence of 14.8% in Kenya and 22.5% in Zaire, the sensitivities of the alternative strategy were 96.4% and 91.4%, the specificities 99.6% and 100%, the positive predictive values 97.6% and 100%, and the negative predictive values 99.3% and 97.9% for Kenya and Zaire, respectively. With this testing format there was an estimated average cost saving of up to 82% over the conventional strategy with ELISA/western blot. This procedure constitutes a reasonable alternative to the standard ELISA/western blot combination.	UNIV DAKAR, DAKAR, SENEGAMBIA; UNIV GHANA, SCH MED, ACCRA, GHANA; SOINS SANTE PRIMAIRES MILIEU RURALE, KINSHASA, DEM REP CONGO; KENYA GOVT MED RES CTR, VIRUS RES CTR, NAIROBI, KENYA; NATL PUBL, HLTH LAB SERV, NAIROBI, KENYA; NOGUCHI MEM INST MED RES, ACCRA, GHANA; HOP LE DANTEC, DAKAR, SENEGAMBIA; NIAID, BETHESDA, MD 20892 USA	University of Ghana; Kenya Medical Research Institute; University of Ghana; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	MITCHELL, SW (corresponding author), FAMILY HLTH INT, POB 13950, RES TRIANGLE PK BRANCH, DURHAM, NC 27709 USA.							CONSTANTINE NT, 1989, AIDS, V3, P313, DOI 10.1097/00002030-198905000-00012; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; QUINN TC, 1988, JAMA-J AM MED ASSOC, V260, P510, DOI 10.1001/jama.260.4.510; RIGGIN CH, 1987, J CLIN MICROBIOL, V25, P1772, DOI 10.1128/JCM.25.9.1772-1773.1987; SPIELBERG F, 1989, LANCET, V1, P580; SPIELBERG FA, 1990, J CLIN MICROBIOL, V28, P303, DOI 10.1128/JCM.28.2.303-306.1990; VANDEPERRE P, 1988, J CLIN MICROBIOL, V26, P552, DOI 10.1128/JCM.26.3.552-556.1988; YOSHIDA T, 1987, J CLIN MICROBIOL, V25, P1433, DOI 10.1128/JCM.25.8.1433-1437.1987; 1989, MMWR, V38, P57	9	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1991	337	8753					1328	1331		10.1016/0140-6736(91)92991-A	http://dx.doi.org/10.1016/0140-6736(91)92991-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674306				2022-12-28	WOS:A1991FP08400014
J	NICOLETTI, F; MERONI, PL; LUNETTA, M; VIGO, R; PALERMO, T; PAPALIA, D; BARCELLINI, W; DIMAURO, M; CARUSONICOLETTI, M; MUGHINI, L; ZANUSSI, C				NICOLETTI, F; MERONI, PL; LUNETTA, M; VIGO, R; PALERMO, T; PAPALIA, D; BARCELLINI, W; DIMAURO, M; CARUSONICOLETTI, M; MUGHINI, L; ZANUSSI, C			SODIUM FUSIDATE AND INCREASED REMISSION RATE OF INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Letter									UNIV CATANIA, DEPT PAEDIAT, I-95124 CATANIA, ITALY; UNIV MILAN, INST INTERNAL MED INFECT DIS & IMMUNOPATHOL, I-20122 MILAN, ITALY	University of Catania; University of Milan	NICOLETTI, F (corresponding author), UNIV CATANIA, DEPT MED PATHOL & METAB DIS 2, I-95124 CATANIA, ITALY.		meroni, pier luigi/K-8473-2016; Nicoletti, Ferdinando/M-4428-2016	meroni, pier luigi/0000-0002-3394-1451; Nicoletti, Ferdinando/0000-0002-4570-8462; Barcellini, Wilma/0000-0003-1428-9944				BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BENDTZEN K, 1990, Cytokine, V2, P423; BENDTZEN K, 1991, LANCET, V337, P552, DOI 10.1016/0140-6736(91)91337-T; NICOLETTI F, 1990, LANCET, V336, P319, DOI 10.1016/0140-6736(90)91860-D; NICOLETTI F, 1990, IMMUNOL LETT, V23, P211, DOI 10.1016/0165-2478(90)90194-U; 1979, DIABETES, V26, P1039	6	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1991	337	8752					1292	1292		10.1016/0140-6736(91)92964-4	http://dx.doi.org/10.1016/0140-6736(91)92964-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674091				2022-12-28	WOS:A1991FN04700047
J	SCHEPERHUGHES, N				SCHEPERHUGHES, N			SOCIAL INDIFFERENCE TO CHILD-DEATH	LANCET			English	Editorial Material							INFANT-MORTALITY				SCHEPERHUGHES, N (corresponding author), UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720, USA.							Aries P., 1962, CENTURIES CHILDHOOD; ARMSTRONG D, 1986, SOCIOL HEALTH ILL, V8, P211, DOI 10.1111/1467-9566.ep11340331; BHATTACHARYYA AK, 1983, INT PERSPECTIVES FAM, P107; Cassidy Claire, 1980, SOCIAL BIOL PREDICTO, P109; Choudhury A., 1976, POP STUD-J DEMOG, V30, P249, DOI [10.1080/00324728.1976.10412733, DOI 10.1080/00324728.1976.10412733]; DEVRIES MW, 1987, CHILD SURVIVAL, P95; ENGELS F, 1958, CONDITION WORKING CL, P160; GRANT JP, 1990, STATE WORLDS CHILDRE; HARTMANN H, 1958, EGO PSYCHOL PROBLEM, P51; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; MULL JD, 1984, J FAM PRACTICE, V18, P485; PELTO G, 1989, HUM ORGAN, P40; RUDDICK S, 1989, MATERNAL THINKING PO, P17; Scheper-Hughes Nancy, 1987, CHILD SURVIVAL ANTHR, P1, DOI [DOI 10.1007/978-94-009-3393-4_1, 10.1007/978-94-009-3393-4_1]; SCHEPERHUGHES N, 1990, SOCIETY, V27, P57, DOI 10.1007/BF02699099; SCHEPERHUGHES N, 1984, SOC SCI MED, V19, P535, DOI 10.1016/0277-9536(84)90049-2; SCHEPERHUGHES NM, 1991, IN PRESS DEATH WEEPI; SCRIMSHAW SCM, 1978, POPUL DEV REV, V4, P383, DOI 10.2307/1972856; WILLIAMS Cicely D., 1935, Lancet, P1151; Wright Peter W. G., 1988, BIOMEDICINE EXAMINED, P299	21	23	23	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1144	1147		10.1016/0140-6736(91)92800-H	http://dx.doi.org/10.1016/0140-6736(91)92800-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL124	1674025				2022-12-28	WOS:A1991FL12400016
J	SIDDIQUE, AK; BAQUI, AH; EUSOF, A; HAIDER, K; HOSSAIN, MA; BASHIR, I; ZAMAN, K				SIDDIQUE, AK; BAQUI, AH; EUSOF, A; HAIDER, K; HOSSAIN, MA; BASHIR, I; ZAMAN, K			SURVIVAL OF CLASSIC CHOLERA IN BANGLADESH	LANCET			English	Note							VIBRIO-CHOLERAE	During the present cholera pandemic the El Tor biotype of Vibrio cholerae has completely displaced the classic biotype, except in Bangladesh. We studied the distribution of these two biotypes in twenty-four rural districts during epidemics in 1988-89; there was clustering of the classic biotype in the southern region and of the El Tor biotype in all other regions. These findings suggest that the southern coastal region is now (and may always have been) the habitat of classic cholera. The selective distribution of V cholerae O1 biotypes in Bangladesh may have been affected by ecological changes occurring in the country.	INT CTR DIARRHOEL DIS RES,DIV LAB SCI,DHAKA 1000,BANGLADESH; INT CTR DIARRHOEL DIS RES,EPIDEM CONTROL PREPAREDNESS PROGRAM,DHAKA 1000,BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	SIDDIQUE, AK (corresponding author), INT CTR DIARRHOEL DIS RES,COMMUNITY HLTH DIV,GPO BOX 128,DHAKA 1000,BANGLADESH.							BART KJ, 1970, J INFECT DIS, V121, pS17, DOI 10.1093/infdis/121.Supplement.S17; COLWELL RR, 1981, APPL ENVIRON MICROB, V41, P555, DOI 10.1128/AEM.41.2.555-558.1981; FELSENFELD O, 1963, B WORLD HEALTH ORGAN, V28, P289; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; KAPER J, 1979, APPL ENVIRON MICROB, V37, P91, DOI 10.1128/AEM.37.1.91-103.1979; SAMADI AR, 1983, LANCET, V1, P805; SIDDIQUE AK, 1989, LANCET, V1, P396; SINGLETON FL, 1982, APPL ENVIRON MICROB, V44, P1047, DOI 10.1128/AEM.44.5.1047-1058.1982; 1974, GUIDELINES LABORATOR	9	53	60	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1125	1127		10.1016/0140-6736(91)92789-5	http://dx.doi.org/10.1016/0140-6736(91)92789-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674016				2022-12-28	WOS:A1991FL12400006
J	TAYLOR, IK; OSHAUGHNESSY, KM; FULLER, RW; DOLLERY, CT				TAYLOR, IK; OSHAUGHNESSY, KM; FULLER, RW; DOLLERY, CT			EFFECT OF CYSTEINYL-LEUKOTRIENE RECEPTOR ANTAGONIST ICI 204.219 ON ALLERGEN-INDUCED BRONCHOCONSTRICTION AND AIRWAY HYPERREACTIVITY IN ATOPIC SUBJECTS	LANCET			English	Article							IMMEDIATE BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; SODIUM CROMOGLYCATE; ASTHMATIC REACTIONS; ANTIGEN CHALLENGE; HISTAMINE; MEDIATORS	The effects of a highly selective leukotriene D4 receptor antagonist, ICI 204.219, on allergen-induced bronchoconstriction and changes in airway reactivity were evaluated in a double-blind, placebo-controlled, crossover trial. Ten atopic subjects were selected for the study on the basis of an immediate fall in forced expiratory volume in 1 s (FEV1) of at least 15% and a least a doubling dose fall in their PC20-histamine (the concentration of histamine needed to reduce FEV1 by 20%) after antigen challenge. Baseline PC20-histamine was determined before the ingestion of a single oral 40 mg dose of ICI 204.219 or matched placebo. 2 h later subjects were challenged with aerosolised allergen; FEV1 was measured for the next 6 h then PC20-histamine was remeasured. Two subjects did not complete the study for reasons not related to the trial medication. ICI 204.219 significantly attenuated the early and late phase bronchoconstriction to inhaled allergen (mean treatment differences in area under the FEV1-time curves 2529 [95% CI 1085-3972] DELTA-%FEV1.min; p < 0.005: and 3537 [528-6545] DELTA-%FEV1.min; p < 0.03) and suppressed the allergen-induced increase in non-specific bronchial reactivity (mean treatment difference 1.03 [0.34-1.71] doubling dilutions of histamine; p < 0.01). These findings suggest that ICI 204.219 may be a disease-modifying agent in asthma. Further studies are under way to evaluate its clinical efficacy.	ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND	Imperial College London	TAYLOR, IK (corresponding author), ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DUCANE RD,LONDON W12 0NN,ENGLAND.							ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BARNES N, 1987, J ALLERGY CLIN IMMUN, V79, P816, DOI 10.1016/0091-6749(87)90215-6; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P185; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; DAHL R, 1986, EUR J RESPIR DIS, V69, P263; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; FORDHUTCHINSON A, 1986, HYPERTENSION, V8, P44; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HUI K P, 1990, American Review of Respiratory Disease, V141, pA32; KAY MG, 1990, AM REV RESPIR DIS, V141, P993; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; LAI CKW, 1990, J APPL PHYSIOL, V68, P919, DOI 10.1152/jappl.1990.68.3.919; LEE TH, 1989, CLIN EXP ALLERGY, V19, P15; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; OHICKEY SP, IN PRESS THORAX; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; PHILLIPS GD, 1989, J APPL PHYSIOL, V66, P304, DOI 10.1152/jappl.1989.66.1.304; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988; TAYLOR GW, 1989, LANCET, V1, P584; VATHENEN AS, 1989, THORAX, V44, pP350; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814	32	386	387	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					690	694		10.1016/0140-6736(91)90277-V	http://dx.doi.org/10.1016/0140-6736(91)90277-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672176				2022-12-28	WOS:A1991FD36700007
J	FRYDMAN, R; BATON, C; LELAIDIER, C; VIAL, M; BOURGET, P; FERNANDEZ, H				FRYDMAN, R; BATON, C; LELAIDIER, C; VIAL, M; BOURGET, P; FERNANDEZ, H			MIFEPRISTONE FOR INDUCTION OF LABOR	LANCET			English	Letter							RU-486		HOP ANTOINE BECLERE,DIV PHARMACEUT,F-92141 CLAMART,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	FRYDMAN, R (corresponding author), HOP ANTOINE BECLERE,DEPT GYNAECOL,F-92141 CLAMART,FRANCE.							DURLOT F, 1988, HUM REPROD, V3, P583, DOI 10.1093/oxfordjournals.humrep.a136749; FRYDMAN R, 1985, LANCET, V2, P1252; FRYDMAN R, 1988, HUM REPROD, V3, P803, DOI 10.1093/oxfordjournals.humrep.a136786; URQUHART DR, 1987, LANCET, V2, P1405; WOLF JP, 1989, AM J OBSTET GYNECOL, V160, P45, DOI 10.1016/0002-9378(89)90084-7	5	22	25	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					488	489		10.1016/0140-6736(91)93421-5	http://dx.doi.org/10.1016/0140-6736(91)93421-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671487				2022-12-28	WOS:A1991EY88700033
J	HARRISON, PJ; MCLAUGHLIN, D; KERWIN, RW				HARRISON, PJ; MCLAUGHLIN, D; KERWIN, RW			DECREASED HIPPOCAMPAL EXPRESSION OF A GLUTAMATE RECEPTOR GENE IN SCHIZOPHRENIA	LANCET			English	Article							HYPOTHESIS	A striking and specific loss of the messenger RNA that encodes a non-N-methyl D-aspartate (non-NMDA) glutamate receptor was found in hippocampal tissue obtained at necropsy from 6 patients with schizophrenia, when compared to specimens from 8 controls without neurological or psychiatric signs or symptoms. These findings support suggestions of aberrant glutamatergic function in schizophrenia. Evidence that gene expression may be abnormal in schizophrenia, with decreased production of an excitatory neurotransmitter receptor, may have therapeutic as well as pathogenetic implications.	INST PSYCHIAT,DEPT NEUROSCI,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND; ST MARYS HOSP,SCH MED,DEPT ANAT,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT PSYCHIAT,LONDON W2 1PG,ENGLAND	University of London; King's College London; University of London; King's College London; Imperial College London; Imperial College London			McLaughlin, Danny/J-6818-2013	McLaughlin, Daniel/0000-0002-7060-7321; Harrison, Paul/0000-0002-6719-1126	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSHULER LL, 1987, ARCH GEN PSYCHIAT, V44, P1094; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; DEUTSCH SI, 1989, CLIN NEUROPHARMACOL, V12, P1, DOI 10.1097/00002826-198902000-00001; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; Harrison P J, 1990, Neuroreport, V1, P149, DOI 10.1097/00001756-199010000-00017; HARRISON PJ, 1990, PROG NEUROBIOL, V34, P271, DOI 10.1016/0301-0082(90)90007-4; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KERWIN R, 1990, NEUROSCIENCE, V39, P25, DOI 10.1016/0306-4522(90)90219-T; KERWIN RW, 1988, LANCET, V1, P583; KERWIN RW, 1990, NEUROSCI LETT, V118, P164, DOI 10.1016/0304-3940(90)90617-I; KIM JS, 1980, NEUROSCI LETT, V20, P379, DOI 10.1016/0304-3940(80)90178-0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MELDRUM B S, 1987, Journal of Psychopharmacology, V1, P217, DOI 10.1177/026988118700100401; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; OKADA F, IN PRESS J NEURAL TR; ROBERTS GW, 1990, TRENDS NEUROSCI, V13, P207, DOI 10.1016/0166-2236(90)90161-3; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Spitzer RL, 1975, RES DIAGNOSTIC CRITE; STORMANN T, 1990, Society for Neuroscience Abstracts, V16, P959; VANTOL HHM, 1990, NEUROSCI LETT, V111, P303, DOI 10.1016/0304-3940(90)90279-I; WACHTEL H, 1990, TRENDS PHARMACOL SCI, V11, P219, DOI 10.1016/0165-6147(90)90243-2	25	217	219	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					450	452		10.1016/0140-6736(91)93392-M	http://dx.doi.org/10.1016/0140-6736(91)93392-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY887	1671470				2022-12-28	WOS:A1991EY88700003
J	POTTS, M; ANDERSON, R; BOILY, MC				POTTS, M; ANDERSON, R; BOILY, MC			SLOWING THE SPREAD OF HUMAN-IMMUNODEFICIENCY-VIRUS IN DEVELOPING-COUNTRIES	LANCET			English	Review							HIV-INFECTION; AIDS		UNIV LONDON,IMPERIAL COLL,PARASITE EPIDEMIOL RES GRP,LONDON,ENGLAND	Imperial College London; University of London	POTTS, M (corresponding author), INT FAMILY HLTH,1ST FLOOR,MARGARET PYKE CTR,15 BATEMANS BLDG,LONDON W1V 5TW,ENGLAND.			Boily, Marie-Claude/0000-0003-3919-006X; Anderson, Roy/0000-0002-9528-3175				ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; AUVERT B, 1990, INT J EPIDEMIOL, V19, P417, DOI 10.1093/ije/19.2.417; BOILY MC, IN PRESS IMA J MATH; Ewing T, 1990, Nature, V346, P595; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; KERKE NJN, 1990, AIDS, V4, P743; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MHALU F, 1991, J ACQ IMMUN DEF SYND, V4, P290; PADIAN NS, 1988, AIDS, V2, P413, DOI 10.1097/00002030-198812000-00001; POTTS DM, 1989, AIDS S1, V1, pS259; PRAZUCK T, 1990, 6TH INT C AIDS SAN F; RONALD A, 1991, AIDS SOC         JAN, P1; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; SOKAL D, 1990, OCT INT C ASS AIDS P; THANGCHARVEN P, 1989, HIV INFECTION THAILA; WILLIAMSON N, 1991, AIDSED NEWSLETTER, V2, P28; 1991, RECENT HIV SEROPREVA; 1991, LANCET, V337, P253	18	73	73	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					608	613		10.1016/0140-6736(91)90614-U	http://dx.doi.org/10.1016/0140-6736(91)90614-U			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD809	1679159				2022-12-28	WOS:A1991GD80900010
J	DEPREZ, PH; GHOSH, P; GOODLAD, RA; LACEY, SL; MILLERSHIP, S; PLAYFORD, RJ; LEE, CY; CALAM, J				DEPREZ, PH; GHOSH, P; GOODLAD, RA; LACEY, SL; MILLERSHIP, S; PLAYFORD, RJ; LEE, CY; CALAM, J			HYPERGASTRINEMIA - A NEW MECHANISM	LANCET			English	Note							ACID	The mechanism by which lack of gastric acid causes hypergastrinaemia was investigated in seven patients with pernicious anaemia. Perfusion of gastric juice from the fasting patients (adjusted to pH 7.0) into the stomachs of conscious rats caused a significant rise in plasma gastrin (median 14 [range 2-20] pmol/l to 27 [12-65] pmol/l; p < 0.01), whereas perfusion of bicarbonate buffer (18 [13-23] pmol/l to 20 [9-25] pmol/l) or gastric juice from a duodenal ulcer patient (also pH 7.0; 13 [3-30] pmol/l to 17 [9-27] pmol/l) had no significant effect. During gastric lavage at pH 7.0 the median plasma gastrin concentration of the pernicious anaemia patients fell from 320 (63-1760) pmol/l to 125 (46-760) pmol/l (p < 0.03).	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DU CANE RD,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,LONDON W12 0NN,ENGLAND; IMPERIAL CANC RES FUND,DEPT HISTOPATHOL,LONDON WC2A 3PX,ENGLAND	Imperial College London; Imperial College London; Cancer Research UK			Deprez, Pierre/AAC-5546-2019	Deprez, Pierre/0000-0001-8926-8967; Playford, Raymond/0000-0003-1235-8504; Goodlad, Robert/0000-0002-7660-4287				BORDI C, 1991, CANCER-AM CANCER SOC, V67, P663, DOI 10.1002/1097-0142(19910201)67:3<663::AID-CNCR2820670323>3.0.CO;2-L; BURLINSON B, 1990, LANCET, V335, P419, DOI 10.1016/0140-6736(90)90260-C; CALAM J, 1991, CLIN SCI, V80, P281, DOI 10.1042/cs0800281; FUKUOKA SI, 1990, PANCREAS, V5, P1, DOI 10.1097/00006676-199001000-00001; GOODLAD RA, 1987, GUT, V28, P177; HEATHCOTE JG, 1965, NATURE, V207, P941, DOI 10.1038/207941a0; YALOW RS, 1970, GASTROENTEROLOGY, V58, P1	7	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					410	411		10.1016/0140-6736(91)91034-R	http://dx.doi.org/10.1016/0140-6736(91)91034-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678084				2022-12-28	WOS:A1991GB44600005
J	LALLOZ, MRA; MCVEY, JH; PATTINSON, JK; TUDDENHAM, EGD				LALLOZ, MRA; MCVEY, JH; PATTINSON, JK; TUDDENHAM, EGD			HEMOPHILIA-A DIAGNOSIS BY ANALYSIS OF A HYPERVARIABLE DINUCLEOTIDE REPEAT WITHIN THE FACTOR-VIII GENE	LANCET			English	Article							HEMOPHILIA-A; INVITRO AMPLIFICATION; PRENATAL-DIAGNOSIS; DNA ANALYSIS; POLYMORPHISM; MICROSATELLITE; POLYMERASE; SEQUENCES; PROBE	The diagnosis of haemophilia A and the identification of carriers has greatly improved with knowledge of the structure of the gene for factor VIII. This has permitted the defect to be tracked in families by the study of restriction fragment length polymorphisms (RFLPs), irrespective of the nature of the molecular defect. However, this approach is time-consuming and the information yielded falls away as more polymorphisms are added. Within the factor VIII gene lies another source of polymorphism, a dinucleotide repeat sequence of varying length known as (CA)n. Conventional mapping localised this (CA)n repeat to intron 13. The polymerase chain reaction, used to examine (CA)n variability in genomic DNA from 25 males and 67 females, revealed eight allelic bands between n = 16 and n = 24. 91% of females were heterozygous for this repeat, and family studies showed X-linked mendelian inheritance with allelic frequencies ranging from 1% to 45%. The intron 13 (CA)n repeat is tightly linked with established RFLPs and tracks with haemophilia A in family studies. The analysis requires DNA from other family members, and relatives of sporadic cases of haemophilia A are only amenable to exclusion. Nonetheless, this intron 13 (CA)n repeat provides the most highly informative marker so far available for factor VIII gene tracking studies in haemophilia A kindreds and a result can be available within a day.			LALLOZ, MRA (corresponding author), CLIN RES CTR,HAEMOSTASIS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909; McVey, John/0000-0002-7416-533X				AHRENS P, 1987, HUM GENET, V76, P127, DOI 10.1007/BF00284907; ANTONARAKIS SE, 1985, NEW ENGL J MED, V313, P842, DOI 10.1056/NEJM198510033131402; GITSCHIER J, 1985, NATURE, V314, P738, DOI 10.1038/314738a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GRAHAM JB, 1990, BRIT J HAEMATOL, V76, P75, DOI 10.1111/j.1365-2141.1990.tb07839.x; HARPER K, 1984, LANCET, V2, P6; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LITT M, 1989, AM J HUM GENET, V44, P397; Maniatis T., 1982, MOL CLONING; MILLAR DS, 1990, HUM GENET, V86, P219; OBERLE I, 1985, NEW ENGL J MED, V312, P682, DOI 10.1056/NEJM198503143121103; PATTINSON JK, 1990, BLOOD, V76, P2242; ROTBLAT F, 1981, THROMB RES, V21, P931; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SURIN VL, 1990, NUCLEIC ACIDS RES, V18, P3432, DOI 10.1093/nar/18.11.3432; TANTRAVAHI U, 1986, CYTOGENET CELL GENET, V42, P75, DOI 10.1159/000132255; TAYLOR GR, 1989, LANCET, V2, P454; Tuddenham E G, 1989, Baillieres Clin Haematol, V2, P849, DOI 10.1016/S0950-3536(89)80049-6; WEBER JL, 1989, AM J HUM GENET, V44, P388; WION KL, 1986, NUCLEIC ACIDS RES, V14, P4535, DOI 10.1093/nar/14.11.4535; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; YOUSSOUFIAN H, 1987, NUCLEIC ACIDS RES, V15, P6312, DOI 10.1093/nar/15.15.6312	27	145	148	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					207	211		10.1016/0140-6736(91)90348-S	http://dx.doi.org/10.1016/0140-6736(91)90348-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676778				2022-12-28	WOS:A1991FY50400003
J	BENARON, DA; BOWEN, FW				BENARON, DA; BOWEN, FW			VARIATION OF INITIAL SERUM BILIRUBIN RISE IN NEWBORN-INFANTS WITH TYPE OF ILLNESS	LANCET			English	Article							NEONATAL HYPERBILIRUBINEMIA; PHOTOTHERAPY; JAUNDICE	Hyperbilirubinaemia in newborn infants is generally regarded as a problem, and bilirubin itself as toxic metabolic waste, but the high frequency in newborn infants suggests that the excess of neonatal bilirubin may have a positive function. To investigate the hypothesis that bilirubin has a role as a free-radical scavenger, the rate of rise in serum bilirubin in the first few days of life was measured in 44 infants with five illnesses thought to enhance free-radical production and in 58 control infants. The infants were selected from 2700 consecutive births by exclusion of those with factors known to affect bilirubin metabolism, including enteral feeding. The control infants were those who seemed to be ill and received treatment, including restriction of enteral feeds, but in whom no illness, or disorders not related to free-radical production, were found. The mean serum bilirubin rise was significantly lower in the combined illness group than in the control group (36.1 [95% Cl 26.9-45.3] vs 66.7 [55.9-77.5] mu-mol.l-1.day-1; p < 0.0001). In subgroup analyses the mean rises in infants with circulatory failure, neonatal depression/asphyxia, aspiration syndromes, and proven sepsis were significantly lower than in controls matched for gestational age and birthweight, but rises in infants with respiratory distress and their matched controls did not differ. These findings are consistent with the hypothesis that bilirubin is consumed in vivo as an antioxidant. Such consumption may operate in vivo in addition to the standard pathways for bilirubin metabolism (production, isomerisation, and excretion).	HOSP UNIV PENN,SCH MED,NEWBORN PEDIAT SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	BENARON, DA (corresponding author), STANFORD UNIV HOSP,SCH MED,DIV NEONATOL,750 WELCH RD,SUITE 315,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027346] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00088] Funding Source: Medline; NHLBI NIH HHS [HL-07027] Funding Source: Medline; NINDS NIH HHS [NS-27346] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEER H., 1959, CHIMIA, V13, P291; BERK PD, 1977, CHEM PHYSL PIGMENTS; BERNHARD K, 1954, HELV CHIM ACTA, V37, P306, DOI 10.1002/hlca.19540370139; BROWN AK, 1985, PEDIATRICS, V75, P393; CHOWDHURY JR, 1989, METABOLIC BASIS INHE, P1367; CREMER RJ, 1958, LANCET, V1, P1094; DANCIS J, 1959, PEDIATRICS, V24, P980; DREW JH, 1976, J PEDIATR-US, V89, P657, DOI 10.1016/S0022-3476(76)80413-1; GALLIANI G, 1985, EXPERIENTIA, V41, P1559, DOI 10.1007/BF01964806; GARTNER LM, 1977, J PEDIATR-US, V90, P513, DOI 10.1016/S0022-3476(77)80360-0; GARTNER LM, 1987, NEONATAL PERINATAL M, P946; Hardy JB, 1979, 1 YEAR LIFE COLLABOR, P104; HEYMAN E, 1989, NEW ENGL J MED, V320, P256; JAFFE ER, 1970, BLOOD-J HEMATOL, V35, P116, DOI 10.1182/blood.V35.1.116.116; KAWADE N, 1981, BIOCHEM J, V196, P257, DOI 10.1042/bj1960257; KUHR M, 1982, J PEDIATR GASTR NUTR, V1, P485, DOI 10.1097/00005176-198212000-00007; LIGHTNER DA, 1984, ACCOUNTS CHEM RES, V17, P417, DOI 10.1021/ar00108a002; LINN S, 1985, PEDIATRICS, V75, P770; MAISELS MJ, 1988, PEDIATRICS, V81, P505; Maisels MJ, 1987, NEONATOLOGY PATHOPHY, P534; MOWATT P, 1987, UNCONJUGATED HYPERBI, P24; PEEVY KJ, 1980, PEDIATRICS, V66, P417; REED GA, 1985, PROSTAGLANDINS, V30, P153, DOI 10.1016/S0090-6980(85)80019-8; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL; THALER MM, 1989, GASTROINTESTINAL DIS, P1640; USHER R, 1987, NEONATOLOGY PATHOPHY, P264; WOOLLEY MM, 1974, J PEDIATR SURG, V9, P359, DOI 10.1016/S0022-3468(74)80293-9; [No title captured]	29	60	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					78	81		10.1016/0140-6736(91)90074-Y	http://dx.doi.org/10.1016/0140-6736(91)90074-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676469	hybrid			2022-12-28	WOS:A1991FW16100004
J	STOUT, RW; CRAWFORD, V				STOUT, RW; CRAWFORD, V			SEASONAL-VARIATIONS IN FIBRINOGEN CONCENTRATIONS AMONG ELDERLY PEOPLE	LANCET			English	Article							PLASMA; MORTALITY; PRESSURE; CORONARY; WINTER	Mortality and morbidity in elderly people are higher in winter than in summer months, with seasonal variations in rates of both fatal and non-fatal myocardial infarction and stroke. To identify factors that might contribute to the excess winter frequency of cardiovascular disease in the elderly, we studied 100 subjects aged 75 and over who lived in either their own homes or in sheltered or residential accommodation. Each person was visited each month for one year, body and environmental temperatures were noted, and cardiovascular risk factors were measured. 32 subjects withdrew from the study. Significant seasonal effects were found for fibrinogen, plasma viscosity, and HDL cholesterol (p < 0.003, Bonferroni adjustment). Plasma fibrinogen concentrations showed the greatest seasonal change and were 23% higher in the coldest six months compared with summer months. Fibrinogen was significantly (p < 0.05) and negatively related to core body temperature and all measures of environmental temperature. Those living in institutions had greater changes in plasma fibrinogen than those living in the community. The seasonal variation in plasma fibrinogen concentration is large enough to increase the risk of both myocardial infarction and stroke in winter.			STOUT, RW (corresponding author), QUEENS UNIV BELFAST, DEPT GERIATR MED, BELFAST BT7 9BL, NORTH IRELAND.							Alderson M. R., 1985, Health Trends, V4, P87; BASTOW MD, 1983, LANCET, V1, P143; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; BROOKE OG, 1973, J PHYSIOL-LONDON, V231, pP91; BULL G M, 1975, Age and Ageing, V4, P232, DOI 10.1093/ageing/4.4.232; BULL G M, 1975, Age and Ageing, V4, P19, DOI 10.1093/ageing/4.1.19; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; BULL GM, 1979, J CLIN PATHOL, V32, P16, DOI 10.1136/jcp.32.1.16; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLINS KJ, 1986, AGE AGEING, V15, P212, DOI 10.1093/ageing/15.4.212; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; JARRETT RJ, 1984, DIABETOLOGIA, V27, P574, DOI 10.1007/BF00276970; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; KEATINGE WR, 1986, BRIT MED J, V293, P732, DOI 10.1136/bmj.293.6549.732-a; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; MACMILLAN AL, 1967, LANCET, V2, P165; MARSHALL RJ, 1988, INT J EPIDEMIOL, V17, P325, DOI 10.1093/ije/17.2.325; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCKEE CM, 1989, EUR J EPIDEMIOL, V5, P178, DOI 10.1007/BF00156826; MEADE TW, 1980, LANCET, V1, P1050; WASSERTHEILSMOL.S, 1990, BIOSTATISTICS EPIDEM, P49	24	231	236	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1991	338	8758					9	13		10.1016/0140-6736(91)90004-9	http://dx.doi.org/10.1016/0140-6736(91)90004-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676131				2022-12-28	WOS:A1991FV29600003
J	HENRY, I; BONAITIPELLIE, C; CHEHENSSE, V; BELDJORD, C; SCHWARTZ, C; UTERMANN, G; JUNIEN, C				HENRY, I; BONAITIPELLIE, C; CHEHENSSE, V; BELDJORD, C; SCHWARTZ, C; UTERMANN, G; JUNIEN, C			UNIPARENTAL PATERNAL DISOMY IN A GENETIC CANCER-PREDISPOSING SYNDROME	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; WILMS TUMOR; ADRENOCORTICAL CARCINOMA; CHROMOSOME-11; 11P15.5; ALLELES; TRISOMY; MARKERS; LOCUS	THE 11p15.5 region of human chromosome 11 seems to contain a locus or loci involved in congenital overgrowth anomalies as well as in the genesis of many tumours associated with the Beckwith-Wiedemann syndrome (BWS) 1-6. Given the unusual differential parental allele involvement in the different aetiological forms of BWS 5, 7 and the loss of maternal alleles in associated tumours 8-10, we have now used 11p15.5 markers to determine the parental origin of chromosome 11 in eight sporadic cases of BWS. Probands in three informative families had uniparental paternal disomy for region 11p15.5. Further, an overall greatly increased frequency of homozygosity for several 11p15.5 markers in 21 sporadic BWS patients suggest that isodisomy probably accounts for an even higher proportion of BWS sporadic cases. This demonstrates that uniparental paternal disomy can be associated with a genetic cancer-predisposing syndrome.	INSERM,U155,F-75016 PARIS,FRANCE; INSERM,U129,F-75014 PARIS,FRANCE; GREENWOOD GENET CTR,GREENWOOD,SC 29646; UNIV INNSBRUCK,A-6020 INNSBRUCK,AUSTRIA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Greenwood Genetic Center; University of Innsbruck	HENRY, I (corresponding author), INSERM,U73,CHATEAU LONGCHAMP,F-75016 PARIS,FRANCE.							ALECK K, 1985, ANN GENET-PARIS, V28, P102; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1985, ANN HUM GENET, V49, P173, DOI 10.1111/j.1469-1809.1985.tb01691.x; JUNIEN C, 1989, CYTOGENET CELL GENET, V51, P226, DOI 10.1159/000132793; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LUBINSKY M, 1974, LANCET, V1, P932; MANNENS M, 1988, AM J HUM GENET, V31, P41; MANNENS M, 1988, CYTOGENET CELL GENET, V46, P655; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NIIKAWA N, 1986, AM J MED GENET, V24, P41, DOI 10.1002/ajmg.1320240107; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PING AJ, 1989, AM J HUM GENET, V44, P720; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; TAKAHIKO Y, 1989, J NATL CANCER I, V81, P518; TURLEAU C, 1985, ANN GENET-PARIS, V28, P93; VOSS R, 1989, AM J HUM GENET, V45, P373; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	23	369	375	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					665	667		10.1038/351665a0	http://dx.doi.org/10.1038/351665a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1675767				2022-12-28	WOS:A1991FT11200071
J	PATRIARCA, G; NUCERA, E; SCHINCO, G; SCHIAVINO, D; PAPA, G; FAIS, G				PATRIARCA, G; NUCERA, E; SCHINCO, G; SCHIAVINO, D; PAPA, G; FAIS, G			PREVENTION OF RELAPSE IN NASAL POLYPOSIS	LANCET			English	Letter											PATRIARCA, G (corresponding author), POLICLIN A GEMELLI,DEPT ALLERGY,I-00168 ROME,ITALY.							PATRIARCA G, 1986, ARCH OTO-RHINO-LARYN, V243, P16, DOI 10.1007/BF00457900; PATRIARCA G, IN PRESS ANN ALLERGY	2	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1488	1488		10.1016/0140-6736(91)93185-C	http://dx.doi.org/10.1016/0140-6736(91)93185-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675359				2022-12-28	WOS:A1991FR06000063
J	DESAI, KM; SESSA, WC; VANE, JR				DESAI, KM; SESSA, WC; VANE, JR			INVOLVEMENT OF NITRIC-OXIDE IN THE REFLEX RELAXATION OF THE STOMACH TO ACCOMMODATE FOOD OR FLUID	NATURE			English	Article							L-ARGININE; GLYCERYL TRINITRATE; GUANYLATE-CYCLASE; METHYLENE-BLUE; STIMULATION; NITROPRUSSIDE; INHIBITOR; MUSCLE	THE fundus of the guinea-pig stomach actively dilates in response to low increases in intragastric pressure 1. This physiological response, now called adaptive relaxation 2,3, accommodates the intake of liquid or food. It is independent of external innervation, resistant to ganglion blockade, but reflex in origin. The nerves involved are neither adrenergic nor cholinergic in nature. Non-adrenergic, non-cholinergic (NANC) nerves have now been recognized in many parts of the gastrointestinal tract 4 and have recently been linked with release of nitric oxide (NO) on electrical stimulation 5-7. Here we show that adaptive relaxation in isolated stomach of the guinea pig is mediated by a NANC neurotransmitter substance indistinguishable from NO derived from L-arginine 8. This is substantiated by inhibition of adaptive relaxation by N(G)-monomethyl-L-arginine or N-omega-nitro-L-arginine methyl ester, both inhibitors of NO synthesis 9,10, and by methylene blue, an inhibitor of soluble guanylate cyclase 11. There are two distinct neuronal pathways signalling NO-dependent adaptive relaxation, as evidenced by tetrodotoxin sensitivity. The first is a local reflex arc, the afferent fibres of which sense changes in intragastric pressure. The second is stimulated by an agonist for ganglionic nicotinic receptors. Thus, the functional significance of NO release from NANC nerves in the stomach is to bring about adaptive relaxation through a reflex response to increases in intragastric pressure.	ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London			Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Desai, Kaushik/0000-0001-9355-4528				ABRAHAMSSON H, 1973, ACTA PHYSL SCAND S, V390, P5; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V102, P434, DOI 10.1111/j.1476-5381.1991.tb12191.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; GILLESPIE JS, 1982, MOTILIYT DIGESTIVE T; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LI CG, 1990, EUR J PHARMACOL, V191, P303; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEYER JH, 1987, PHYSL GASTROINTESTIN; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; MURPHY S, 1990, J NEUROCHEM, V55, P349, DOI 10.1111/j.1471-4159.1990.tb08860.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PATON WDM, 1963, J PHYSIOL-LONDON, V165, P10, DOI 10.1113/jphysiol.1963.sp007040; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x	18	507	519	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					477	479		10.1038/351477a0	http://dx.doi.org/10.1038/351477a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1675430				2022-12-28	WOS:A1991FP75800054
J	CLOUGH, CG				CLOUGH, CG			PARKINSONS-DISEASE - MANAGEMENT	LANCET			English	Article							SUBCUTANEOUS APOMORPHINE; FOLLOW-UP; LEVODOPA; TRANSPLANTATION; STRIATUM; RELEASE; GRAFTS				CLOUGH, CG (corresponding author), BROOK REG MOVEMENT DISORDER CLIN,SHOOTERS HILL RD,LONDON SE18 4LW,ENGLAND.							BARKER R, 1989, LANCET, V1, P675, DOI 10.1016/S0140-6736(89)92183-1; BONN MC, 1987, SCIENCE, V237, P913; BOWEN FP, 1975, NEUROLOGY, V25, P701, DOI 10.1212/WNL.25.8.701; BROWN RG, 1990, J NEUROL NEUROSUR PS, V53, P480, DOI 10.1136/jnnp.53.6.480; BRUNDIN P, 1988, EXP BRAIN RES, V70, P192; CLOUGH CG, 1985, ADV NEUROL; CLOUGH CG, 1984, BRIT MED J, V287, P124; COHEN G, 1989, ANN NEUROL, V26, P689, DOI 10.1002/ana.410260518; COHEN G, 1985, EUR J PHARMACOL, V106, P209; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; DURIFF F, 1990, J NEUROL NEUROSUR PS, V53, P1104; EBMEIER KP, 1991, PSYCHOL MED, V26, P69; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; FRANKEL JP, 1990, J NEUROL NEUROSUR PS, V53, P96, DOI 10.1136/jnnp.53.2.96; FREED CR, 1990, ARCH NEUROL-CHICAGO, V47, P505, DOI 10.1001/archneur.1990.00530050021007; GIBB WRG, 1990, ADV NEUROL, V53, P55; GIBB WRG, 1987, BRAIN, V110, P1131, DOI 10.1093/brain/110.5.1131; GOETZ CG, 1989, NEW ENGL J MED, V320, P337, DOI 10.1056/NEJM198902093200601; GOETZ CG, 1990, NEUROLOGY S3, V46, P50; HENDERSON BTH, IN PRESS ARCH NEUROL; HITCHCOCK ER, 1988, LANCET, V1, P1274; HORSTINK MWIM, 1990, J NEUROL NEUROSUR PS, V53, P224, DOI 10.1136/jnnp.53.3.224; KOLLER WC, 1987, HDB PARKINSONS DISEA; LANGSTON JW, 1990, NEUROLOGY, V40, P70; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1989, ARCH NEUROL-CHICAGO, V46, P615, DOI 10.1001/archneur.1989.00520420033021; MACMAHON DG, 1990, J NEUROL NEUROSUR PS, V53, P220, DOI 10.1136/jnnp.53.3.220; MUTCH WJ, 1986, BRIT MED J, V293, P675, DOI 10.1136/bmj.293.6548.675; Pinder R., 1990, MANAGEMENT CHRONIC I; REDMOND DE, 1986, LANCET, V1, P1125; REDMOND DG, 1990, LANCET, P820; RINNE UK, 1987, NEUROLOGY, V37, P826, DOI 10.1212/WNL.37.5.826; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SCHWAB RS, 1951, T AM NEUROL ASSOC, V76, P251; STERN Y, 1990, NEUROLOGY, V40, P261, DOI 10.1212/WNL.40.2.261; STEVENTON GB, 1989, NEUROLOGY, V39, P883, DOI 10.1212/WNL.39.7.883; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; TODES CJ, 1985, J NEUROL NEUROSUR PS, V48, P97, DOI 10.1136/jnnp.48.2.97; VIDAILHET MJ, 1990, LANCET, V336, P316, DOI 10.1016/0140-6736(90)91855-5; YAHR MD, 1969, ARCH NEUROL-CHICAGO, V21, P343, DOI 10.1001/archneur.1969.00480160015001; 1989, NEW ENGL J MED, V321, P1364	41	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1324	1327		10.1016/0140-6736(91)92990-J	http://dx.doi.org/10.1016/0140-6736(91)92990-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674305				2022-12-28	WOS:A1991FP08400013
J	REICHARD, O; ANDERSSON, J; SCHVARCZ, R; WEILAND, O				REICHARD, O; ANDERSSON, J; SCHVARCZ, R; WEILAND, O			RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS-C	LANCET			English	Article							RECOMBINANT INTERFERON-ALFA; NON-B-HEPATITIS; NON-A; CONTROLLED TRIAL; ANTIBODIES; THERAPY; VIRUS	We evaluated oral ribavirin as therapy for chronic hepatitis C infection in a pilot study including 10 patients. Patients (7 men, 3 women; mean age 40 years, range 23-54) all had biopsy-proven chronic non-A, non-B hepatitis and were repeatedly positive for antibodies to hepatitis C virus. Treatment was with oral ribavirin 1000-1200 mg per day in two divided doses for 12 weeks. The median serum alanine aminotransferase concentration for all patients at enrolment was 3.15-mu-kat/I (range 1.22-7.79) and decreased significantly (p < 0.005) to 1.25-mu-kat/I (0.78-2.04) after 12 weeks of treatment. Within 6 weeks of the end of treatment the median serum alanine aminotransferase concentration was not significantly different from that before treatment. Side-effects were mild and fully reversible after cessation of therapy. We conclude that ribavirin is the first drug to offer a potentially effective oral treatment for chronic hepatitis C. It should be further evaluated in controlled trials, possibly in combination with interferon alpha.	KAROLINSKA INST,ROSLAGSTULLS HOSP,DEPT INFECT DIS,BOX 5651,S-11489 STOCKHOLM,SWEDEN; KAROLINSKA INST,DANDERYDS HOSP,DEPT INFECT DIS,STOCKHOLM,SWEDEN	Karolinska Institutet; Danderyds Hospital; Karolinska Institutet								CANONICO PG, 1984, CLIN APPLICATION RIB, P79; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; JOHNSON EM, 1990, J AM COLL TOXICOL, V9, P114; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MATTSSON L, 1988, LIVER, V8, P184; MATTSSON L, 1988, SCAND J INFECT DIS, V20, P371, DOI 10.3109/00365548809032470; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; PATKI SA, 1982, CHEMOTHERAPY, V28, P298, DOI 10.1159/000238094; PATTERSON JL, 1990, REV INFECT DIS, V12, P1132; ROBERTS RB, 1990, J INFECT DIS, V162, P638, DOI 10.1093/infdis/162.3.638; SIDWELL R, 1972, SCIENCE, V117, P705; VANDERPOEL CL, 1989, LANCET, V2, P297	14	264	268	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1058	1061		10.1016/0140-6736(91)91707-2	http://dx.doi.org/10.1016/0140-6736(91)91707-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673493				2022-12-28	WOS:A1991FK20400004
J	PETROS, AJ; HEWLETT, AM; BOGLE, RG; PEARSON, JD				PETROS, AJ; HEWLETT, AM; BOGLE, RG; PEARSON, JD			L-ARGININE-INDUCED HYPOTENSION	LANCET			English	Letter							NITRIC-OXIDE		CLIN RES CTR,VASC BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND		PETROS, AJ (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,DEPT ANAESTHESIA,HARROW HA1 3UJ,MIDDX,ENGLAND.							ANTONUCCI F, 1990, LANCET, V336, P1449, DOI 10.1016/0140-6736(90)93156-J; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; HISHIKAWA, 1991, LANCET, V337, P683; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; VALLANCE P, 1989, LANCET, V2, P997; 1990, LANCET, V336, P696	6	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1044	1045		10.1016/0140-6736(91)92708-A	http://dx.doi.org/10.1016/0140-6736(91)92708-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673199				2022-12-28	WOS:A1991FJ13500049
J	RICKMAN, LS; GORDON, DM; WISTAR, R; KRZYCH, U; GROSS, M; HOLLINGDALE, MR; EGAN, JE; CHULAY, JD; HOFFMAN, SL				RICKMAN, LS; GORDON, DM; WISTAR, R; KRZYCH, U; GROSS, M; HOLLINGDALE, MR; EGAN, JE; CHULAY, JD; HOFFMAN, SL			USE OF ADJUVANT CONTAINING MYCOBACTERIAL CELL-WALL SKELETON, MONOPHOSPHORYL LIPID-A, AND SQUALANE IN MALARIA CIRCUMSPOROZOITE PROTEIN VACCINE	LANCET			English	Article							PLASMODIUM-FALCIPARUM; PHASE-I; MURABUTIDE	Human immune responses to modern synthetic and recombinant peptide vaccines administered with the standard adjuvant, aluminum hydroxide, tend to be poor, hence the search for better adjuvants. Antibody responses to a Plasmodium falciparum circumsporozoite (CS) protein vaccine, R32NS1(81), administered with an adjuvant containing cell-wall skeleton of mycobacteria and monophosphoryl lipid A in squalane (MPL/CWS) have been compared to responses to the same immunogen administered with aluminum hydroxide. 2 weeks after the third dose the following indices were greater in the 5 patients who received MPL/CWS than in controls (p < 0.05): the geometric mean concentration (2.0 vs 25.4-mu-g/ml) and avidity index of antibodies to the P falciparum CS protein by ELISA, the geometric mean titre to P falciparum sporozoites by IFAT (1/115 vs 1/1600), and the geometric mean inhibition of sporozoite invasion of hepatoma cells in vitro (37.6 vs 90.3%). For R32NS1(81) MPL/CWS is superior to aluminum hydroxide as an adjuvant, and the data support the evaluation of this complex as an adjuvant for other vaccines.	USN, MED RES INST,DEPT INFECT DIS,MALARIA PROGRAM, 12300 WASHINGTON AVE, ROCKVILLE, MD 20852 USA; BIOMED RES INST, ROCKVILLE, MD USA; SMITHKLINE BEECHAM, DEPT MOLEC GENET, KING OF PRUSSIA, PA USA; WALTER REED ARMY MED CTR, DEPT IMMUNOL, WASHINGTON, DC 20307 USA; NATL NAVAL MED CTR, DIV INFECT DIS, BETHESDA, MD 20814 USA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; GlaxoSmithKline; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Walter Reed National Military Medical Center								BAEZ M, 1980, NUCLEIC ACIDS RES, V8, P5845, DOI 10.1093/nar/8.23.5845; BALLOU WR, 1987, LANCET, V1, P1277; Chulay J.D, 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P61, DOI 10.1016/0035-9203(89)90606-8; EDELMAN R, 1980, REV INFECT DIS, V2, P370; HERRINGTON DA, IN PRESS B WHO; HOLLINGDALE MR, 1984, J IMMUNOL, V132, P909; JONES WR, 1988, LANCET, V1, P1295; MALCOLM MS, 1988, CANCER RES, V48, P5883; OBERLING F, 1985, INT J IMMUNOPHARMACO, V7, P398, DOI 10.1016/0192-0561(85)90443-6; Plotkin SA, 1988, VACCINES-BASEL; PROFETA ML, 1987, LANCET, V1, P973; PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1; RIBI E, 1984, J BIOL RESP MODIF, V3, P1; RIBI E, 1978, IMMUNOTHERAPY HUMAN, P131; RUDBACH JA, 1988, TECHNOLOGICAL ADV VA, P443; TELZAK E, 1986, J INFECT DIS, V153, P628, DOI 10.1093/infdis/153.3.628; VOSIKA GJ, 1984, CANCER IMMUNOL IMMUN, V18, P107; YAMAMURA Y, 1981, PROGR CANCER RES THE, V16, P71	18	67	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					998	1001		10.1016/0140-6736(91)92659-P	http://dx.doi.org/10.1016/0140-6736(91)92659-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673211				2022-12-28	WOS:A1991FJ13500003
J	TAPLIN, D; PORCELAIN, SL; MEINKING, TL; ATHEY, RL; CHEN, JA; CASTILLERO, PM; SANCHEZ, R				TAPLIN, D; PORCELAIN, SL; MEINKING, TL; ATHEY, RL; CHEN, JA; CASTILLERO, PM; SANCHEZ, R			COMMUNITY CONTROL OF SCABIES - A MODEL BASED ON USE OF PERMETHRIN CREAM	LANCET			English	Article							ERADICATION	For 18 years treatment with lindane or crotamiton products has failed to stem the epidemic of scabies among the Kuna Indians in the San Blas islands of the Republic of Panama. Permethrin 5% cream was introduced as the only treatment in a programme to control scabies on an island of 756 inhabitants and involving workers recruited locally. Prevalence fell from 33% to less than 1% after every person was treated. As long as continued surveillance and treatment of newly introduced cases was maintained, prevalence of scabies remained below 1.5% for over 3 years. When supply of medication was interrupted for 3 weeks, prevalence rose to 3.6%. When control was lost after the US invasion of Panama, prevalence rose to 12% within 3 months. Bacterial skin infections decreased dramatically when scabies was controlled. Permethrin is safe and effective even in areas where this disease has become resistant to lindane.	UNIV MIAMI, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33101 USA; MINIST HLTH, SISTEMA INTEGRADO, SALUD, PANAMA	University of Miami; Ministerio de Salud de la Republica de Panama	TAPLIN, D (corresponding author), UNIV MIAMI, SCH MED, DEPT DERMATOL & CUTANEOUS SURG, POB 016960, R-117, MIAMI, FL 33101 USA.							ALLEN AM, 1974, AM J TROP MED HYG, V23, P950, DOI 10.4269/ajtmh.1974.23.950; BLUMENTHAL DS, 1976, AM J EPIDEMIOL, V104, P667, DOI 10.1093/oxfordjournals.aje.a112345; DAVIES JE, 1983, ARCH DERMATOL, V119, P142, DOI 10.1001/archderm.119.2.142; MEINKING TL, 1990, ADV DERMATOLOGY, P131; SCHULTZ MW, 1990, ARCH DERMATOL, V126, P167, DOI 10.1001/archderm.126.2.167; SVARTMAN M, 1972, LANCET, V1, P249; TAPLIN D, 1983, J AM ACAD DERMATOL, V9, P546, DOI 10.1016/S0190-9622(83)70167-2; TAPLIN D, 1989, PRIMARY CARE, V16, P551; TAPLIN D, 1983, J AM ACAD DERMATOL, V9, P550, DOI 10.1016/S0190-9622(83)70168-4; TAPLIN D, 1973, LANCET, V1, P501; TAPLIN D, 1986, J AM ACAD DERMATOL, V15, P995; TAPLIN D, 1974, CLIN PHARMACOL THER, V16, P905, DOI 10.1002/cpt1974165part2905; TAPLIN D, 1981, SKIN MICROBIOLOGY RE, P113	13	121	123	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1991	337	8748					1016	1018		10.1016/0140-6736(91)92669-S	http://dx.doi.org/10.1016/0140-6736(91)92669-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673175	hybrid			2022-12-28	WOS:A1991FJ13500013
J	LITTLER, E; BAYLIS, SA; ZENG, Y; CONWAY, MJ; MACKETT, M; ARRAND, JR				LITTLER, E; BAYLIS, SA; ZENG, Y; CONWAY, MJ; MACKETT, M; ARRAND, JR			DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA BY MEANS OF RECOMBINANT EPSTEIN-BARR-VIRUS PROTEINS	LANCET			English	Article							ANTIBODY; DNASE; TRANSCRIPTION; EXPRESSION	The immune response of patients with nasopharyngeal carcinoma to Epstein-Barr virus (EBV) antigens is diagnostic of the tumour. Existing tests use EBV antigens produced in EBV-infected lymphoblastoid cells, but the virus replicates poorly in these cells. Serum samples from 18 patients diagnosed as having nasopharyngeal carcinoma were screened by western blot analysis, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence tests for antibodies to the EBV-coded alkaline deoxyribonuclease (DNase), thymidine kinase, and membrane antigen (gp340/220) produced in recombinant baculovirus or bovine papillomavirus systems. Each protein was a useful diagnostic marker for nasopharyngeal carcinoma, although in the gp340/220 ELISAs there was substantial overlap for both IgG and IgA antibodies between serum samples from nasopharyngeal carcinoma patients and those from healthy donors seropositive for EBV. The EBV thymidine kinase was the most sensitive predictor of nasopharyngeal carcinoma; all such samples showed both IgG and IgA antibody responses to this protein and all gave clearly distinct titres from those of the EBV-seropositive donors in the IgA test. Each of the recombinant systems described is suitable for use in large-scale screening programmes for the early diagnosis of nasopharyngeal carcinoma.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,CANC RES CAMPAIGN LABS,MANCHESTER M20 9BX,LANCS,ENGLAND; CHINESE ACAD SCI,INST VIROL,BEIJING,PEOPLES R CHINA	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Chinese Academy of Sciences	LITTLER, E (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.							BAYLIS SA, 1989, NUCLEIC ACIDS RES, V17, P7609, DOI 10.1093/nar/17.19.7609; BAYLIS SA, 1991, VIROLOGY, V181, P390, DOI 10.1016/0042-6822(91)90511-9; CHEN JY, 1989, J MED VIROL, V27, P269, DOI 10.1002/jmv.1890270403; CHENG YC, 1980, P NATL ACAD SCI-BIOL, V77, P6162, DOI 10.1073/pnas.77.10.6162; CONWAY M, 1989, J GEN VIROL, V70, P729, DOI 10.1099/0022-1317-70-3-729; HENLE W, 1970, J NATL CANCER I, V44, P225; HENLE W, 1973, JNCI-J NATL CANCER I, V51, P361; LI SL, 1982, TUMOURS HEAD NECK, P251; LITTLER E, 1990, INT J CANCER, V45, P1028, DOI 10.1002/ijc.2910450608; LIU MY, 1989, J MED VIROL, V28, P101, DOI 10.1002/jmv.1890280209; NEILSEN NH, 1977, ACTA PATHOL MICROB A, V5, P850; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; SHANMUGARATNAM K, 1979, CANCER, V44, P1029, DOI 10.1002/1097-0142(197909)44:3<1029::AID-CNCR2820440335>3.0.CO;2-5; SHANMUGARATNAM K, 1972, IARC SCI PUBL, V2, P239; SIMMONS MJ, 1982, UICC71 TECHN REP; TAN RS, 1982, INT J CANCER, V30, P561, DOI 10.1002/ijc.2910300505; TUGWOOD JD, 1987, J GEN VIROL, V68, P1081, DOI 10.1099/0022-1317-68-4-1081; TURENNETESSIER M, 1989, INT J CANCER, V43, P45; Waterhouse JA, 1982, IARC SCI PUBLICATION, VIV; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZENG J, 1983, INT J CANCER, V31, P599, DOI 10.1002/ijc.2910310511; ZENG Y, 1983, INTERVIROLOGY, V20, P190, DOI 10.1159/000149391; ZENG Y, 1987, Chinese Journal of Virology, V3, P396; ZURHAUSEN H, 1970, NATURE, V228, P1956; 1950, NCI MONOGRAPH, V59	25	38	41	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					685	689		10.1016/0140-6736(91)90275-T	http://dx.doi.org/10.1016/0140-6736(91)90275-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672175				2022-12-28	WOS:A1991FD36700006
J	VANDIJK, JG; DORRESTEIJN, M; HAAN, J; FERRARI, MD				VANDIJK, JG; DORRESTEIJN, M; HAAN, J; FERRARI, MD			NO CONFIRMATION OF VISUAL EVOKED-POTENTIAL DIAGNOSTIC-TEST FOR MIGRAINE	LANCET			English	Note								We have attempted to replicate the results of studies on a diagnostic test reported to have 90% sensitivity and 89-96% specificity for migraine. The technique is based on peak-to-peak measurements of fast background electroencephalographic activity during a visual evoked potential (VEP) study. VEP latencies and amplitudes did not differ significantly, and showed substantial overlap, between a group of eight migraine patients and ten age-matched healthy controls. We could not recognise previously described fast activity or measure it objectively by peak-to-peak measurements. We cannot confirm that measurement of fast wave activity in the VEP background is useful in diagnosis of migraine.			VANDIJK, JG (corresponding author), LEIDEN UNIV HOSP,DEPT NEUROL CLIN NEUROPHYSIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.							MARSTERS JB, 1988, HEADACHE, V28, P526, DOI 10.1111/j.1526-4610.1988.hed2808526.x; MORTIMER MJ, 1990, LANCET, V335, P789, DOI 10.1016/0140-6736(90)90903-I; MORTIMER MJ, 1990, HEADACHE, V30, P285, DOI 10.1111/j.1526-4610.1990.hed3005285.x; MORTIMER MJ, 1990, LANCET, V335, P75, DOI 10.1016/0140-6736(90)90541-C; Regan D., 1989, HUMAN BRAIN ELECTROP; VANDIJK JG, 1990, LANCET, V335, P480; VANDIJK JG, 1989, NEW TRENDS CLIN NEUR, P107; WINTER AL, 1987, MIGRAINE CLIN THERAP, P485; 1988, CEPHALALGIA S, V7, P1	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					517	518		10.1016/0140-6736(91)91298-9	http://dx.doi.org/10.1016/0140-6736(91)91298-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671891				2022-12-28	WOS:A1991EZ87400005
J	EINHAUPL, KM; VILLRINGER, A; MEISTER, W; MEHRAEIN, S; GARNER, C; PELLKOFER, M; HABERL, RL; PFISTER, HW; SCHMIEDEK, P				EINHAUPL, KM; VILLRINGER, A; MEISTER, W; MEHRAEIN, S; GARNER, C; PELLKOFER, M; HABERL, RL; PFISTER, HW; SCHMIEDEK, P			HEPARIN TREATMENT IN SINUS VENOUS THROMBOSIS	LANCET			English	Article							HEMORRHAGE; INFARCTION; INFUSION; CANCER	Treatment of sinus venous thrombosis (SVT) is controversial. Although heparin has been used for this condition, many investigators have opposed its use because of the frequent occurrence of intracranial haemorrhage (ICH) in SVT. Therefore we have evaluated anticoagulation with adjusted-dose intravenous heparin for treatment of aseptic SVT in a randomised, blinded (patient and observer), placebo-controlled study in 20 patients (10 heparin, 10 placebo). The clinical course of the two groups, as judged by a newly designed SVT-severity scale, started to differ in favour of the heparin group after 3 days of treatment (p < 0.05, Mann-Whitney U-test) and the difference remained significant (p < 0.01) after 8 days of treatment. After 3 months, 8 of the heparin-treated patients had a complete clinical recovery and 2 had slight residual neurological deficits. In the placebo group, only 1 patient had a complete recovery, 6 patients had neurological deficits, and 3 patients died (p < 0.01, modified Fisher's exact test). An additional retrospective study on the relation between heparin treatment and ICH in SVT patients was based on 102 patients, 43 of whom had an ICH. 27 of these patients were treated with dose-adjusted, intravenous heparin after the ICH. Of these 27 patients, 4 died (mortality 15%), and 14 patients completely recovered. Of the 13 patients that did not receive heparin after ICH, 9 died (mortality 69%) and only 3 patients completely recovered. We conclude that anticoagulation with dose-adjusted intravenous heparin is an effective treatment in patients with SVT and that ICH is not a contraindication to heparin treatment in these patients.	UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT NEUROSURG,W-8000 MUNICH 70,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT INTERNAL MED,W-8000 MUNICH 70,GERMANY	University of Munich; University of Munich	EINHAUPL, KM (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,NEUROL POLIKLIN,DEPT NEUROL,MARCHIONINISTR 15,W-8000 MUNICH 70,GERMANY.			Villringer, Arno/0000-0003-2604-2404				BOGDAHN U, 1980, PATHOLOGISCHE ERREGB, P675; BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; BOUSSER MG, 1987, LANCET, V1, P923; BUONANNO FS, 1978, J COMPUT ASSIST TOMO, V2, P281, DOI 10.1097/00004728-197807000-00008; CASTLEMAN B, 1962, NEW ENGL J MED, V267, P1084; DIROCCO C, 1981, ARCH NEUROL-CHICAGO, V38, P431, DOI 10.1001/archneur.1981.00510070065011; DOERSTELMANN D, 1981, NERVENARZT, V52, P243; DRAKE ME, 1983, ARCH NEUROL-CHICAGO, V40, P44, DOI 10.1001/archneur.1983.04050010064018; ESTANOL B, 1979, STROKE, V10, P680, DOI 10.1161/01.STR.10.6.680; GETTELFINGER DM, 1977, ARCH NEUROL-CHICAGO, V34, P1; GROCH SN, 1959, NEUROLOGY, V9, P786, DOI 10.1212/WNL.9.11.786; Hacker H, 1969, Nervenarzt, V40, P440; HANLEY DF, 1988, STROKE, V19, P903, DOI 10.1161/01.STR.19.7.903; HARVEY JE, 1974, BRIT MED J, V5, P84; HICKEY WF, 1982, AM J MED, V73, P740; JACEWICZ M, 1991, CEREBRAL SINUS THROM, P157; LIEBERMAN A, 1978, STROKE, V9, P18, DOI 10.1161/01.STR.9.1.18; NISHIMURA RN, 1982, ARCH NEUROL-CHICAGO, V33, P439; PERSSON L, 1990, NEUROSURGERY, V26, P117, DOI 10.1227/00006123-199001000-00016; Rinaldi I, 1973, Va Med Mon (1918), V100, P632; Scharrer I, 1971, Radiologe, V11, P426; SCOTT JA, 1988, J NEUROSURG, V68, P284, DOI 10.3171/jns.1988.68.2.0284; SHIELDS RW, 1984, STROKE, V15, P426, DOI 10.1161/01.STR.15.3.426; SIGSBEE B, 1979, NEUROLOGY, V29, P139, DOI 10.1212/WNL.29.2.139; SINDOU M, 1980, SURG NEUROL, V13, P215; STANDFIELD FR, 1942, BRIT MED J, V4, P436; YERBY MS, 1980, STROKE, V11, P294, DOI 10.1161/01.STR.11.3.294	27	644	680	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					597	600		10.1016/0140-6736(91)90607-Q	http://dx.doi.org/10.1016/0140-6736(91)90607-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679154				2022-12-28	WOS:A1991GD80900004
J	SOKOL, RJ; JOHNSON, KE; KARRER, FM; NARKEWICZ, MR; SMITH, D; KAM, I				SOKOL, RJ; JOHNSON, KE; KARRER, FM; NARKEWICZ, MR; SMITH, D; KAM, I			IMPROVEMENT OF CYCLOSPORINE ABSORPTION IN CHILDREN AFTER LIVER-TRANSPLANTATION BY MEANS OF WATER-SOLUBLE VITAMIN-E	LANCET			English	Article							POLYETHYLENE GLYCOL-1000 SUCCINATE; CHRONIC CHILDHOOD CHOLESTASIS; E-DEFICIENCY; PHARMACOKINETICS; TOCOPHEROL; RATS	Many childhood recipients of liver transplantation require massive doses of cyclosporin to achieve therapeutic blood concentrations of the drug. The impaired absorption of this strongly lipophilic drug may be due to reduced intestinal absorptive area, suboptimal mixing of the drug with hepatobiliary secretions, or residual cholestasis. Improvement of cyclosporin absorption was sought by means of oral coadministration of d-alpha-tocopheryl-polyethylene-glycol-1000 succinate (TPGS), a water-soluble form of vitamin E which can form micelles. 25 mg/kg daily of TPGS was given to six paediatric liver transplant recipients and one young adult with severe hepatobiliary graft-vs-host disease after bone-marrow transplantation, who required 29-136 mg/kg cyclosporin daily to achieve therapeutic cyclosporin blood concentrations. Five responded; the oral cyclosporin dose could be reduced by 40-72% within 2 months. In addition, intravenous cyclosporin was stopped in two of the responders. In the two non-responders the cyclosporin doses at entry were similar to those in the responders after TPGS treatment. Oral cyclosporin absorption tests correctly predicted the outcome of treatment in three responders and one non-responder tested. Treatment with TPGS to enhance cyclosporin absorption might be a useful way of reducing the high cost of immunosuppression in paediatric liver transplant recipients.	UNIV COLORADO, SCH MED, DEPT PEDIAT, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, CTR PEDIAT LIVER, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT SURG, DENVER, CO 80202 USA; UNIV COLORADO, SCH PHARM, DIV PHARM PRACTICE, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver	SOKOL, RJ (corresponding author), CHILDRENS HOSP, CTR PEDIAT LIVER, 1056 E 14TH AVE, B290, DENVER, CO 80218 USA.				NCRR NIH HHS [RR-00069] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARGAO EA, 1990, HEPATOLOGY, V12, P886; BIERI JG, 1979, AM J CLIN NUTR, V32, P2143, DOI 10.1093/ajcn/32.10.2143; BURCKART G, 1985, TRANSPLANT P, V17, P1172; ERICZON BG, 1987, TRANSPLANT P, V19, P1248; EVANS RW, 1988, TRANSPL P, V20, P49; FIRST MR, 1989, LANCET, V2, P1198, DOI 10.1016/S0140-6736(89)91802-3; GIBALDI M, 1982, PHARMACOKINETICS, P410; HORWITT MK, 1972, ANN NY ACAD SCI, V203, P223, DOI 10.1111/j.1749-6632.1972.tb27878.x; PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002; SHAW BW, 1988, J PEDIATR GASTR NUTR, V7, P797, DOI 10.1097/00005176-198811000-00003; SHAW BW, 1988, J PEDIATR GASTR NUTR, V7, P157, DOI 10.1097/00005176-198803000-00001; SOKOL RJ, 1989, ANN NY ACAD SCI, V570, P156; SOKOL RJ, 1987, J PEDIATR-US, V111, P830, DOI 10.1016/S0022-3476(87)80196-8; SOKOL RJ, 1987, GASTROENTEROLOGY, V93, P975, DOI 10.1016/0016-5085(87)90559-2; TRABER MG, 1986, AM J CLIN NUTR, V44, P914, DOI 10.1093/ajcn/44.6.914; WADHWA NK, 1987, TRANSPLANTATION, V43, P211, DOI 10.1097/00007890-198702000-00009; WHITINGTON PF, 1990, NEW ENGL J MED, V322, P733, DOI 10.1056/NEJM199003153221105; WHITINGTON PF, 1989, HEPATOLOGY, V9, P393, DOI 10.1002/hep.1840090308; WONG PY, 1990, TRANSPLANT P, V22, P1166; ZITELLI BJ, 1983, TRANSPLANT P, V15, P1284; ZITELLI BJ, 1990, PEDIATRIC HEPATOLOGY, P363; ZOELLNER N, 1962, Z GES EXP MED, V135, P545	22	73	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 27	1991	338	8761					212	215		10.1016/0140-6736(91)90349-T	http://dx.doi.org/10.1016/0140-6736(91)90349-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676779				2022-12-28	WOS:A1991FY50400004
J	UHARI, M; NUUTINEN, M; TURTINEN, J; POKKA, T				UHARI, M; NUUTINEN, M; TURTINEN, J; POKKA, T			PULSE SOUNDS AND MEASUREMENT OF DIASTOLIC BLOOD-PRESSURE IN CHILDREN	LANCET			English	Article								Controversy exists over the value of measuring diastolic blood pressure (BP) in children, and over whether this should be measured at Korotkoff's fourth phase (K4) or fifth phase (K5) of pulse sounds. We measured diastolic BP in 3012 randomly selected Finnish children aged 6-18 years in 1980, and in 2885 of the same individuals in 1983 and 2500 in 1986. BP was measured with a standard mercury sphygmomanometer in 1980 and 1983, and with a random-zero sphygmomanometer in 1986. K4 was consistently absent in 187 individuals (3.2%) in 1980 and 1983, and in 155 individuals (6.2%) in 1986. K5 was absent in only 34 individuals (0.6%) in 1980/83 and 5 (0.2%) in 1986. The difference between mean K4 and K5 diastolic BP varied from 6.5 to 9.2 mm Hg depending upon age. K4 and K5 BPs showed good correlation in all age groups. Reliable and repeatable BP measurements in all age groups of children are best achieved with K5 as the indicator of diastolic BP.			UHARI, M (corresponding author), UNIV OULU, DEPT PAEDIAT, SF-90220 OULU, FINLAND.							AKERBLOM HK, 1985, ACTA PAEDIATR SCAND, P49; [Anonymous], 1987, PEDIATRICS, V79, P1; BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; DILLON MJ, 1988, ARCH DIS CHILD, V63, P347, DOI 10.1136/adc.63.4.347; HOLLAND WW, 1964, BRIT MED J, V2, P1241, DOI 10.1136/bmj.2.5419.1241; Kirkendall W.M., 1981, STROKE, V12, P555; LONDE S, 1984, 1983 NHLBI WORKSH JU, P107; UHARI M, 1979, ACTA PAEDIATR SCAND, V68, P193, DOI 10.1111/j.1651-2227.1979.tb04988.x; WEISMANN DN, 1988, PEDIATRICS, V82, P112; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; 1982, JAMA-J AM MED ASSOC, V213, P1143	11	36	37	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	1991	338	8760					159	161		10.1016/0140-6736(91)90145-F	http://dx.doi.org/10.1016/0140-6736(91)90145-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677074				2022-12-28	WOS:A1991FX42400013
J	MARTIN, J; LANGER, T; BOTEVA, R; SCHRAMEL, A; HORWICH, AL; HARTL, FU				MARTIN, J; LANGER, T; BOTEVA, R; SCHRAMEL, A; HORWICH, AL; HARTL, FU			CHAPERONIN-MEDIATED PROTEIN FOLDING AT THE SURFACE OF GROEL THROUGH A MOLTEN GLOBULE-LIKE INTERMEDIATE	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; LIVER DIHYDROFOLATE-REDUCTASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PRECURSOR PROTEINS; RIBULOSEBISPHOSPHATE-CARBOXYLASE; ATP HYDROLYSIS; RHODANESE; HSP60; MITOCHONDRIA	Folding of two monomeric enzymes mediated by groE has been reconstituted in vitro. The groEL protein stabilizes the polypeptides in a conformation resembling the 'molten globule' state. Mg-ATP and groES then promote the acquisition of ordered tertiary structure at the surface of groEL. Folding requires the hydrolysis of about 100 ATP molecules per protein monomer. This active process of surface-mediated chain folding might represent a general mechanism for the formation of protein structure in vivo.	UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; UNIV MUNICH,INST ZOOL,W-8000 MUNICH 2,GERMANY	University of Munich; Howard Hughes Medical Institute; Yale University; Yale University; University of Munich			Hartl, F. Ulrich/Y-8206-2019	Langer, Thomas/0000-0003-1250-1462				BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FAYET O, 1986, MOL GEN GENET, V202, P35; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2206; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARVEY EP, 1989, PROTEINS, V6, P259, DOI 10.1002/prot.340060308; GATENBY AA, 1990, ANNU REV CELL BIOL, V6, P125; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, IN PRESS SEMIN IMMUN; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KUMAR AA, 1980, BIOCHEMISTRY-US, V19, P667, DOI 10.1021/bi00545a010; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTOASALOMA P, 1990, BIOCHIM BIOPHYS ACTA, V1041, P140; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1990, J BIOL CHEM, V265, P5967; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257	54	810	817	0	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					36	42		10.1038/352036a0	http://dx.doi.org/10.1038/352036a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1676490				2022-12-28	WOS:A1991FV17800061
J	PAYEN, JF; BOURDON, L; MEZIN, P; JACQUOT, C; LEBAS, JF; STIEGLITZ, P; BENABID, AL				PAYEN, JF; BOURDON, L; MEZIN, P; JACQUOT, C; LEBAS, JF; STIEGLITZ, P; BENABID, AL			SUSCEPTIBILITY TO MALIGNANT HYPERTHERMIA DETECTED NONINVASIVELY	LANCET			English	Letter									HOP A MICHALLON,DEPT ANAESTHESIA,LA TRONCHE,FRANCE; HOP A MICHALLON,CELLULAR PATHOL LAB,LA TRONCHE,FRANCE; CRSSA BEE,LA TRONCHE,FRANCE	CHU Grenoble Alpes; CHU Grenoble Alpes	PAYEN, JF (corresponding author), CHU GRENOBLE,HOP A MICHALLON,INSERM,U318,F-38043 GRENOBLE,FRANCE.		Payen, Jean-Francois/L-6667-2014; Benabid, Alim L/Q-3506-2017					KOZAK-REISS G, 1988, Anesthesiology (Hagerstown), V69, pA415, DOI 10.1097/00000542-198809010-00414; OLGIN J, 1988, ANESTHESIOLOGY, V68, P507; OLGIN J, 1991, ANESTH ANALG, V72, P36; YOUNKIN DP, 1987, NEUROLOGY, V37, P165, DOI 10.1212/WNL.37.1.165; 1984, BRIT J ANAESTH, V56, P1267	5	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1550	1551		10.1016/0140-6736(91)93247-7	http://dx.doi.org/10.1016/0140-6736(91)93247-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675403				2022-12-28	WOS:A1991FT11600045
J	NAVOT, D; BERGH, PA; WILLIAMS, MA; GARRISI, GJ; GUZMAN, I; SANDLER, B; GRUNFELD, L				NAVOT, D; BERGH, PA; WILLIAMS, MA; GARRISI, GJ; GUZMAN, I; SANDLER, B; GRUNFELD, L			POOR OOCYTE QUALITY RATHER THAN IMPLANTATION FAILURE AS A CAUSE OF AGE-RELATED DECLINE IN FEMALE FERTILITY	LANCET			English	Article							PREGNANCY; DONATION; CYCLES; WOMEN	Female fertility declines with advancing age. To establish whether this age-related reproductive failure results from diminished oocyte quality or uterine/endometrial inadequacy we investigated ovum donation in 35 infertile women, aged 40 years or older (mean 42.7 [SE 0.3]) who had failed at attempts at conception with their own (self) oocytes. Oocytes were donated by 29 young individuals (mean age 33.4 [0.7]) undergoing in-vitro fertilisation (IVF). 8 (5.3%) pregnancies were achieved in 150 cycles of ovulation induction with self-oocytes and 2 (3.3%) in 60 such cycles by in-vitro fertilisation (IVF), but none attained viability. By contrast in 50 cycles with donated oocytes 28 (56%) pregnancies and 15 (30%) deliveries were realised (p < 0.005). The rate of implantation per embryo transferred was higher (14.7%) with donated oocytes than that with self-oocytes (3.3%) (p < 0.01 ). To further elucidate the contribution of age to reproductive outcome, pregnancy results were compared between the young donors and older recipients. Both donors and recipients shared oocytes from the same induced cohort. Rates for clinical pregnancy and delivery did not differ between donors (33% and 23%) and recipients (40% and 30%). Our data suggest that the age-related decline in female fertility is attributable to oocyte quality and is correctable by ovum donation. The uterus can adequately sustain pregnancies even when reproductive potential is artificially prolonged into the late 40s.			NAVOT, D (corresponding author), MT SINAI MED CTR,DEPT OBSTET GYNECOL & REPROD SCI,DIV REPROD ENDOCRINOL,NEW YORK,NY 10029, USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014				Burger HG, 1981, TESTIS, P381; FELDBERG D, 1990, J IN VITRO FERTIL EM, V7, P257, DOI 10.1007/BF01129530; FORMAN R, 1988, FERTIL STERIL, V49, P118; GIDLEYBAIRD A, 1985, FERTIL STERIL, V45, P59; GOSDEN RG, 1985, ANN NY ACAD SCI, V442, P45, DOI 10.1111/j.1749-6632.1985.tb37504.x; GOSTWAMY RK, 1988, HUM REPROD, V3, P955; Hansen J P, 1986, Obstet Gynecol Surv, V41, P726, DOI 10.1097/00006254-198611000-00024; LAUFER N, 1983, FERTIL STERIL S40, V1, P73; NAVOT D, 1987, FERTIL STERIL, V47, P234; NAVOT D, 1991, J CLIN ENDOCR METAB, V72, P408, DOI 10.1210/jcem-72-2-408; NAVOT D, 1989, J CLIN ENDOCR METAB, V68, P801, DOI 10.1210/jcem-68-4-801; NAVOT D, 1986, NEW ENGL J MED, V314, P806, DOI 10.1056/NEJM198603273141302; Rogers PAW, 1989, BLASTOCYST IMPLANTAT, P231; SANDLER B, 1989, LOW DOSE LUPRON ENHA; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; SERHAL PF, 1989, LANCET, V1, P1185; SHWARTZ D, 1982, NEW ENGL J MED, V305, P404; SOULES MR, 1982, J AM GERIATR SOC, V30, P547, DOI 10.1111/j.1532-5415.1982.tb05661.x; SSPENCER G, 1983, US DEP COMMERCE P25, V952; 1986, FERTIL STERIL S46, V1, P1; 1990, FERTIL STERIL, V53, P13	21	415	436	1	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1375	1377		10.1016/0140-6736(91)93060-M	http://dx.doi.org/10.1016/0140-6736(91)93060-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674764				2022-12-28	WOS:A1991FP87000004
J	DWYER, T; PONSONBY, ALB; NEWMAN, NM; GIBBONS, LE				DWYER, T; PONSONBY, ALB; NEWMAN, NM; GIBBONS, LE			PROSPECTIVE COHORT STUDY OF PRONE SLEEPING POSITION AND SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article							COT DEATH	Studies of the link between prone sleeping position and sudden infant death syndrome have been criticised on grounds of recall bias and for not taking into account possible confounding effects. To avoid recall bias and to allow measurement of important biological factors a prospective cohort study of the cause of sudden infant death syndrome (SIDS) is being conducted. The infants included are those at high risk of the syndrome as assessed by a perinatal score. Of the 3110 members of the cohort born between January, 1988, and end of March, 1990, 23 infants later died of SIDS. Sleep position information was available for 15 of these. Matched analysis to control for the confounding effects of infant birthweight and maternal age indicated that prone sleeping position was associated with an increased risk of SIDS (OR 4.47 95% Cl [1.30-15.43]). The findings are strengthened by the results of a concurrent retrospective case-control study of 42 SIDS cases in which the prone position was also associated with an increased risk of SIDS (unadjusted OR 3.45 [1.59-7.49]).			DWYER, T (corresponding author), UNIV TASMANIA,MENZIES CTR POPULAT HLTH RES,43 COLLINS ST,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657				BEAL S, 1988, MED J AUSTRALIA, V149, P562, DOI 10.5694/j.1326-5377.1988.tb120774.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; Breslow N, 1980, STATISTICAL METHODS, V32; Breslow N. E., 1987, STATISTICAL METHODS, VII; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DEJONGE GA, 1989, LANCET, V2, P1149; DESPAIGNET ET, 1990, TASMANIA PAED PERIN, V4, P422; EMERY JL, 1988, LANCET, V2, P738; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; ENGELBERTS AC, 1990, BRIT MED J, V301, P493; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FROGGATT P, 1970, SUDDEN INFANT DEATH, P40; GILLES FH, 1979, AM J DIS CHILD, V133, P30, DOI 10.1001/archpedi.1979.02130010036005; GUNTHEROTH WG, 1990, BRIT MED J, V301, P492; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEE M, 1988, LANCET, V1, P1332; MANTEL N, 1959, NAT CANCER I, V22, P819; MCGLASHAN ND, 1986, LANCET, V1, P106; MORRIS JA, 1989, BRIT MED J, V298, P958; NELSON EAS, 1989, LANCET, V1, P199; NEWMAN NM, 1986, AUST PAEDIATR J, V22, P111; NICHOLL JP, 1988, LANCET, V2, P106; SATERNUS KS, 1985, FESTSCHRIFT LEITHOFF, P67; SCOTT S, 1990, BRIT MED J, V301, P493, DOI 10.1136/bmj.301.6750.493-b; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; SOUTHALL D, 1990, BRIT MED J, V301, P492; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1986, NEW ZEAL MED J, V99, P324; TONKIN SL, 1979, PEDIATRICS, V63, P261; WAILOO MP, 1990, BRIT MED J, V301, P492, DOI 10.1136/bmj.301.6750.492-b; 1990, SUDDEN INFANT DEATH	33	279	283	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1244	1247		10.1016/0140-6736(91)92917-Q	http://dx.doi.org/10.1016/0140-6736(91)92917-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674061				2022-12-28	WOS:A1991FN04700002
J	OCARROLL, RE; HAYES, PC; EBMEIER, KP; DOUGALL, N; MURRAY, C; BEST, JJK; BOUCHIER, IAD; GOODWIN, GM				OCARROLL, RE; HAYES, PC; EBMEIER, KP; DOUGALL, N; MURRAY, C; BEST, JJK; BOUCHIER, IAD; GOODWIN, GM			REGIONAL CEREBRAL BLOOD-FLOW AND COGNITIVE FUNCTION IN PATIENTS WITH CHRONIC LIVER-DISEASE	LANCET			English	Article							HEPATOCELLULAR DISEASE; SCAN ABNORMALITIES; ENCEPHALOPATHY; SYSTEM; BRAIN	Subtle impairments of cognitive function may be an important cause of occupational and psychosocial morbidity in patients with chronic liver disease. Correlation of structural brain abnormalities with cognitive deficits has yielded inconsistent results. 10 patients with cirrhotic liver disease were compared with 10 age, education, and intelligence matched control subjects. Neuropsychological assessment revealed significant overall cognitive impairments in cirrhotic patients compared with controls (p = 0.02). Regional cerebral blood flow was measured by single photon emission computed tomography (SPET or SPECT) and showed increased uptake of radiotracer in the right and left posterior parts of the basal ganglia and right occipital lobe, together with reduced uptake in the right anterior cingulate region. The degree of cognitive impairment was directly correlated with functional abnormalities in the basal ganglia and limbic cortex (p < 0.05). Our results suggest that impaired cognitive status may be associated with abnormalities of regional brain function in patients with chronic liver disease. Since these deficits are clinically inapparent, our findings have important implications for identification and management of patients with chronic liver disease.	ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT MED RADIOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh	OCARROLL, RE (corresponding author), ROYAL EDINBURGH & ASSOC HOSP,MRC,BRAIN METAB UNIT,EDINBURGH EH10 5HF,SCOTLAND.		O'Carroll, Ronan E/A-5040-2009; Dougall, Nadine J/O-8145-2015; Ebmeier, Klaus Peter/B-4789-2008	O'Carroll, Ronan E/0000-0002-5130-291X; Dougall, Nadine J/0000-0003-3462-6960; Ebmeier, Klaus Peter/0000-0002-5190-7038	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNTHAL P, 1987, HEPATOLOGY, V7, P107, DOI 10.1002/hep.1840070122; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; DELONG MR, 1990, FUNCTION DYSFUNCTION; DUNK AA, 1989, DEV CLIN EXPT NEUROP, P39; GAMMAL SH, 1989, MED CLIN N AM, V73, P793, DOI 10.1016/S0025-7125(16)30639-3; HUNTER R, 1989, PSYCHOL MED, V19, P847, DOI 10.1017/S0033291700005560; LOCKWOOD AH, 1991, J CEREBR BLOOD F MET, V11, P331, DOI 10.1038/jcbfm.1991.66; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MOORE JW, 1989, J HEPATOL, V9, P319, DOI 10.1016/0168-8278(89)90140-2; NEIRINCKX RD, 1988, J CEREBR BLOOD F MET, V8, pS4, DOI 10.1038/jcbfm.1988.27; Nelson H.E., 1982, NATIONAL ADULT READI; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; SCHOMERUS H, 1981, DIGEST DIS SCI, V26, P622, DOI 10.1007/BF01367675; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; TARTER RE, 1987, INT J NEUROSCI, V32, P901, DOI 10.3109/00207458709043346; TARTER RE, 1988, MED NEUROPSYCHOLOGY, P75	18	128	129	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1250	1253		10.1016/0140-6736(91)92920-W	http://dx.doi.org/10.1016/0140-6736(91)92920-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN047	1674063				2022-12-28	WOS:A1991FN04700004
J	PAYNEROBINSON, HM; GOLDEN, MHN; GOLDEN, BE; SIMEON, DT				PAYNEROBINSON, HM; GOLDEN, MHN; GOLDEN, BE; SIMEON, DT			THE ZINC SANDWICH AND GROWTH	LANCET			English	Letter							BINDING				PAYNEROBINSON, HM (corresponding author), UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA.		Golden, Michael/AAB-8989-2020	Golden, Michael/0000-0002-4039-7538; SIMEON, DONALD/0000-0002-6197-9369				ARQUILLA ER, 1978, ENDOCRINOLOGY, V103, P1440, DOI 10.1210/endo-103-4-1440; GOLDEN BE, 1979, AM J CLIN NUTR, V32, P2940; HERINGTON AC, 1985, BIOCHEM INT, V11, P853; MAES M, 1983, J ENDOCRINOL, V97, P243, DOI 10.1677/joe.0.0970243; ROBINSON H, 1977, PEDIATR RES, V11, P637, DOI 10.1203/00006450-197705000-00003; 1991, LANCET, V337, P273; 1991, LANCET, V337, P146	7	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					925	926		10.1016/0140-6736(91)90267-S	http://dx.doi.org/10.1016/0140-6736(91)90267-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1673011				2022-12-28	WOS:A1991FG04800069
J	SHARPE, N; SMITH, H; MURPHY, J; GREAVES, S; HART, H; GAMBLE, G				SHARPE, N; SMITH, H; MURPHY, J; GREAVES, S; HART, H; GAMBLE, G			EARLY PREVENTION OF LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION WITH ANGIOTENSIN-CONVERTING-ENZYME INHIBITION	LANCET			English	Article							CAPTOPRIL; DILATATION; ECHOCARDIOGRAPHY; EXPANSION; VOLUME; SIZE; RAT	Left ventricular dysfunction can be improved with angiotensin-converting-enzyme inhibition started 1 week after myocardial infarction or later. To see whether earlier intervention may confer greater benefit, a double-blind study was carried out in which 100 patients with Q wave myocardial infarction, but without clinical heart failure, were randomly allocated treatment with captopril 50 mg twice daily or placebo starting 24-48 h after onset of symptoms. Left ventricular volumes were measured regularly during 3 months of treatment and after a 48 h withdrawal period by means of two-dimensional echocardiography. The placebo group showed significant increases in left ventricular end-diastolic (LVEDVI) and end-systolic (LVESVI) volume indices, with the ejection fraction unchanged. By contrast, the captopril group showed a slight but not significant rise in LVEDVI and a significant reduction in LVESVI with ejection fraction increased significantly. At 3 months there was a 4.6% difference in the change in ejection fraction from baseline between the groups (p < 0.0001). Most of the treatment benefit was evident at 1 month and there were no changes in left ventricular volumes after 48 h withdrawal of treatment at 3 months. Heart failure requiring treatment with frusemide developed in 7 patients in each group during the study period; 3 of these (1 captopril-treated, 2 placebo-treated) had to be withdrawn from the trial with severe heart failure requiring open treatment. Thus early treatment with captopril is effective in preventing the ventricular dilatation that can occur after Q wave myocardial infarction.			SHARPE, N (corresponding author), UNIV AUCKLAND, AUCKLAND HOSP, SCH MED, DEPT MED, PK RD, AUCKLAND, NEW ZEALAND.			Gamble, Greg/0000-0003-0412-3203				COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; DALY P, 1985, CIRCULATION, V71, P317, DOI 10.1161/01.CIR.71.2.317; DZAU VJ, 1987, CIRCULATION, V75, P134; EATON LW, 1979, NEW ENGL J MED, V300, P57, DOI 10.1056/NEJM197901113000202; ERLEBACHER JA, 1982, AM J CARDIOL, V49, P1120, DOI 10.1016/0002-9149(82)90035-2; GAYRG, 1990, J AM COLL CARDIOL, V16, P967; HOCHMAN JS, 1982, CIRCULATION, V65, P1446, DOI 10.1161/01.CIR.65.7.1446; JEREMY RW, 1987, J AM COLL CARDIOL, V9, P989, DOI 10.1016/S0735-1097(87)80298-X; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; LINDPAINTNER K, 1988, CIRCULATION, V77, P18; MAGRINI F, 1987, MCIRCULATION, V75, pS1168; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; PFEFFER JM, 1985, CIRC RES, V57, P84, DOI 10.1161/01.RES.57.1.84; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; RAYA TE, 1989, CIRC RES, V64, P330, DOI 10.1161/01.RES.64.2.330; SHARPE DN, 1984, CIRCULATION, V70, P271, DOI 10.1161/01.CIR.70.2.271; SHARPE DN, IN PRESS J CARDIOVAS; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1990, EUR HEART J, V11, P147, DOI 10.1093/eurheartj/11.suppl_B.147; STARLING MR, 1981, CIRCULATION, V63, P1075, DOI 10.1161/01.CIR.63.5.1075; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WEISMAN HF, 1985, J AM COLL CARDIOL, V5, P1355, DOI 10.1016/S0735-1097(85)80348-X; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; 1987, SAS STAT GUIDE PERSO	27	299	304	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	1991	337	8746					872	876		10.1016/0140-6736(91)90202-Z	http://dx.doi.org/10.1016/0140-6736(91)90202-Z			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672967				2022-12-28	WOS:A1991FG04800002
J	SAMUEL, D; BISMUTH, A; MATHIEU, D; ARULNADEN, JL; REYNES, M; BENHAMOU, JP; BRECHOT, C; BISMUTH, H				SAMUEL, D; BISMUTH, A; MATHIEU, D; ARULNADEN, JL; REYNES, M; BENHAMOU, JP; BRECHOT, C; BISMUTH, H			PASSIVE IMMUNOPROPHYLAXIS AFTER LIVER-TRANSPLANTATION IN HBSAG-POSITIVE PATIENTS	LANCET			English	Article							HEPATITIS-B-VIRUS; RECIPIENTS; INFECTION; REACTIVATION; REINFECTION; ALLOGRAFTS	110 HBsAg-positive patients underwent orthotopic liver transplantation and received long-term anti-hepatitis B virus (HBV) passive immunoprophylaxis with anti-HBs immunoglobulin. During a mean follow-up period of 20 months, all patients became HBsAg negative after transplantation but circulating HBsAg reappeared in 25 (22.7%). Overall 1-year survival was 83.6% and overall 2-year actuarial recurrence of HBsAg was 29% (59% after posthepatitis B cirrhosis, 13% after posthepatitis B-delta cirrhosis, and 0% after fulminant hepatitis B). Patients with HBV cirrhosis who were HBV-DNA positive had a much greater risk of HBsAg recurrence than patients who were HBV-DNA negative (96% vs 29% at 2 years). Reappearance of HBsAg was associated with evidence of HBV replication and abnormal histological findings in the graft. Long-term passive anti-HBV immunoprophylaxis significantly reduced HBV reinfection and improved survival in patients without evidence of active HBV replication before orthotopic liver transplantation.	HOP PAUL BROUSSE,HAEMATOL LAB,F-94800 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,MICROBIOL LAB,F-94800 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,PATHOL LAB,F-94800 VILLEJUIF,FRANCE; UNIV PARIS 11,HEPATOBILIARY SURG & LIVER TRANSPLANTAT RES UNIT,F-91405 ORSAY,FRANCE; HOP BEAUJON,HEPATOL UNIT,CLICHY,FRANCE; INST PASTEUR,HYBRIDOTEST LAB,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	SAMUEL, D (corresponding author), PARIS S UNIV,HOP PAUL BROUSSE,HEPATOBILIARY SURG & LIVER TRANSPLANTAT RES UNIT,F-94800 VILLEJUIF,FRANCE.							BISMUTH H, 1990, AM J SURG, V160, P105, DOI 10.1016/S0002-9610(05)80878-5; BISMUTH H, 1988, TRANSPLANT P, V20, P486; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; DEGOS F, 1988, GASTROENTEROLOGY, V94, P151, DOI 10.1016/0016-5085(88)90623-3; DEMETRIS AJ, 1986, AM J PATHOL, V125, P161; FERAY C, 1990, TRANSPLANTATION, V49, P1155, DOI 10.1097/00007890-199006000-00025; GUGENHEIM J, 1987, TRANSPLANT P, V19, P3805; HOOFNAGLE JH, 1982, ANN INTERN MED, V96, P447, DOI 10.7326/0003-4819-96-4-447; KROGSGAARD K, 1987, HEPATOLOGY, V7, P42, DOI 10.1002/hep.1840070110; LAM KC, 1981, NEW ENGL J MED, V304, P380, DOI 10.1056/NEJM198102123040702; LAUCHART W, 1987, TRANSPLANT P, V19, P2387; LAUCHART W, 1987, TRANSPL P, V19, P4051; NAGINGTON J, 1977, LANCET, V1, P558, DOI 10.1016/s0140-6736(77)91995-x; PARFREY PS, 1985, TRANSPLANTATION, V39, P610, DOI 10.1097/00007890-198506000-00007; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; SCOTTO J, 1983, HEPATOLOGY, V3, P279; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; ZIGNEGO AL, 1988, VIRAL HEPATITIS LIVE, P808	18	362	364	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					813	815		10.1016/0140-6736(91)92515-4	http://dx.doi.org/10.1016/0140-6736(91)92515-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672913				2022-12-28	WOS:A1991FF22800003
J	BOWER, M; COLSTON, KW; STEIN, RC; HEDLEY, A; GAZET, JC; FORD, HT; COOMBES, RC				BOWER, M; COLSTON, KW; STEIN, RC; HEDLEY, A; GAZET, JC; FORD, HT; COOMBES, RC			TOPICAL CALCIPOTRIOL TREATMENT IN ADVANCED BREAST-CANCER	LANCET			English	Note							IMMUNOCYTOCHEMICAL DETECTION; 1,25-DIHYDROXYVITAMIN-D3; RECEPTOR; DIFFERENTIATION; PROLIFERATION; GROWTH	19 patients with locally advanced or cutaneous metastatic breast cancer were treated with the topical vitamin D analogue calcipotriol 100-mu-g daily. 14 patients completed 6 weeks' treatment; 3 showed a 50% reduction in the bidimensional diameter of treated lesions and 1 other patient showed a minimal response. 2 patients became hypercalcaemic during treatment. In all patients who responded the tumours contained receptors for 1,25-dihydroxyvitamin D3, shown by immunocytochemistry.	ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC BIOL,CLIN ONCOL UNIT,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND; ST GEORGE HOSP,COMBINED BREAST CLIN,LONDON,ENGLAND	St Georges University London; St Georges University London; St Georges University London			Stein, Robert C/N-6679-2015	Stein, Robert C/0000-0003-2969-0415; Bower, Mark/0000-0002-4077-6351; Coombes, Raoul Charles/0000-0002-4811-1100				BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BERGER U, 1987, CANCER RES, V47, P6793; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; COLSTON K, 1986, ENDOCRINOLOGY, V119, P397, DOI 10.1210/endo-119-1-397; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; KOGA M, 1988, CANCER RES, V48, P2734; MATSUI T, 1986, CANCER RES, V46, P5827; MCGUIRE WL, 1973, J CLIN ENDOCR METAB, V37, P986, DOI 10.1210/jcem-37-6-986; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506	10	113	115	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					701	702		10.1016/0140-6736(91)90280-3	http://dx.doi.org/10.1016/0140-6736(91)90280-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672178				2022-12-28	WOS:A1991FD36700010
J	RIJK, MCM; VANHOGEZAND, RA; VANLIER, HJJ; VANTONGEREN, JHM				RIJK, MCM; VANHOGEZAND, RA; VANLIER, HJJ; VANTONGEREN, JHM			SULFASALAZINE AND PREDNISONE COMPARED WITH SULFASALAZINE FOR TREATING ACTIVE CROHN DISEASE - A DOUBLE-BLIND, RANDOMIZED, MULTICENTER TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG-TREATMENT; INDEX	Objective: To determine whether sulphasalazine plus prednisone is more effect Design: Randomized, double-blind, placebo-controlled trial. Setting: Multicenter trial in one university hospital and nine general hospitals. Patients: Patients with active Crohn disease and a Van Hees Activity Index of 140 or more. Of 71 patients who were randomly assigned, 60 completed treatment and were analyzed. Interventions: For 16 weeks, 30 patients received sulphasalazine, 6 g/d (or 4 g/d if adverse effects occurred) and prednisone, 30 mg/d initially. Prednisone therapy was tapered in increments of 5 mg/2 wk to 10 mg/d after 8 weeks. Thirty other patients received sulphasalazine and a placebo. Measurements and Main Results: In the first 6 weeks of treatment, the Van Hees Activity Index decreased to a median of 70% (interquartile range, 57% to 81%) of the initial value in patients treated with sulphasalazine and prednisone and to a median of 87% (interquartile range, 70% to 94%) in patients treated with sulphasalazine alone (P = 0.001). In the last 4 weeks of treatment, the corresponding figures were 63% (interquartile range, 40% to 75%) and 70% (interquartile range, 54% to 90%) (P = 0.10). The Crohn's Disease Activity Index decreased in the first 6 weeks to a median of 65% (interquartile range, 57% to 86%) in patients receiving sulphasalazine and prednisone and to a median of 75% (interquartile range, 58% to 101%) in patients receiving sulphasalazine alone (P = 0.13). In the last 4 weeks of treatment, the corresponding figures were 65% (interquartile range, 42% to 90%) and 76% (interquartile range, 49% to 110%) (P = 0.19). Conclusion: The use of prednisone in addition to sulphasalazine in patients with active Crohn disease results in a significantly faster initial improvement, but not in a significantly better result after 16 weeks of treatment, when disease activity is measured by the Van Hees Activity Index.	UNIV HOSP NIJMEGEN, NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen								BEGG CB, 1980, BIOMETRICS, V36, P81, DOI 10.2307/2530497; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; MARSHAK RH, 1972, CLIN GASTROENTEROL, V1, P265; RIJK MCM, 1989, SCAND J GASTROENTERO, V24, P1179, DOI 10.3109/00365528909090784; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; VANHEES PAM, 1980, GUT, V21, P279, DOI 10.1136/gut.21.4.279; VANHEES PAM, 1981, GUT, V22, P404, DOI 10.1136/gut.22.5.404; VANHEES PAM, 1979, GUT, V20, P300, DOI 10.1136/gut.20.4.300	9	41	41	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					445	450		10.7326/0003-4819-114-6-445	http://dx.doi.org/10.7326/0003-4819-114-6-445			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1671631				2022-12-28	WOS:A1991FB64000002
J	BATES, I; BEDUADDO, G; BEVAN, DH; RUTHERFORD, TR				BATES, I; BEDUADDO, G; BEVAN, DH; RUTHERFORD, TR			USE OF IMMUNOGLOBULIN GENE REARRANGEMENTS TO SHOW CLONAL LYMPHOPROLIFERATION IN HYPER-REACTIVE MALARIAL SPLENOMEGALY	LANCET			English	Article							LEUKEMIA	In Africa, hyper-reactive malarial splenomegaly (HMS), which is also known as tropical splenomegaly syndrome, can be associated with a prominent lymphocytosis in blood and bone marrow that is difficult to distinguish clinically from chronic lymphocytic leukaemia (CLL). The observation that some patients with HMS become resistant to treatment with anti-malarial drugs has led to the suggestion that HMS may evolve into a malignant lymphoproliferative disorder. To test this hypothesis, 22 Ghanaian patients with HMS and/or lymphocytosis were categorised by degree of response to proguanil according to standard clinical criteria, and DNA was extracted from peripheral blood cells and screened for rearrangements of the Jh region of the immunoglobulin gene with a DNA probe. Clonal rearrangements of the Jh region were found in all 3 patients with no response, in none of 13 patients with sustained response, and in 2 of 6 patients with moderate response or relapse on proguanil therapy. The detection of such rearrangements, and hence clonal lymphoproliferation in individuals with clinical features intermediate between HMS and CLL, supports the hypothesis that HMS may evolve into a malignant lymphoproliferative disorder.	KOMFO ANOKYE TEACHING HOSP,KUMASI,GHANA	Kwame Nkrumah University Science & Technology	BATES, I (corresponding author), ST GEORGE HOSP,SCH MED,DIV HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1989, ANN INTERN MED, V110, P236; BATES I, IN PRESS J CLIN PATH; BOUCHE JP, 1981, ANAL BIOCHEM, V115, P42, DOI 10.1016/0003-2697(81)90519-4; ESSIEN EM, 1976, E AFR MED J, V53, P96; FAKUNLE YM, 1981, CLIN HAEMATOL, V10, P963; FAKUNLE YM, 1979, TROP GEOGR MED, V31, P353; FAKUNLE YM, 1978, CLIN EXP IMMUNOL, V33, P239; GRIESSER H, 1989, BLOOD, V73, P1402; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; PIESSENS WF, 1985, J CLIN INVEST, V75, P1821, DOI 10.1172/JCI111895; PISZKIEWICZ D, 1989, THROMB RES, V55, P627, DOI 10.1016/0049-3848(89)90395-2; SUGDEN B, 1989, NATURE, V339, P179, DOI 10.1038/339179a0; UKAEJIOFO E O, 1987, African Journal of Medicine and Medical Sciences, V16, P113; WATSONWILLIAMS EJ, 1968, BMJ-BRIT MED J, V4, P793, DOI 10.1136/bmj.4.5634.793	14	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					505	507		10.1016/0140-6736(91)91293-4	http://dx.doi.org/10.1016/0140-6736(91)91293-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671888				2022-12-28	WOS:A1991EZ87400001
J	BENSHLOMO, Y; SMITH, GD				BENSHLOMO, Y; SMITH, GD			DEPRIVATION IN INFANCY OR IN ADULT LIFE - WHICH IS MORE IMPORTANT FOR MORTALITY RISK	LANCET			English	Article							ISCHEMIC HEART-DISEASE; SOCIAL-CLASS; CHILDHOOD; ENGLAND; WALES; DEATH; WEIGHT; GROWTH	Previous ecological studies have suggested that early life factors are important causes of adult cardiovascular and respiratory disease, by showing geographic correlations between past infant mortality rates and present adult mortality rates. However, these studies inadequately take account of the fact that areas which were severely deprived earlier this century remain the most deprived today. Thus the ecological relation between infant and adult mortality rates could simply reflect persistence in the geographic distribution of poor socioeconomic circumstances. To explore this hypothesis further infant mortality rates for 1895-1908 for 43 counties in England and Wales were correlated with cause-specific adult mortality for 1969-73 in people aged 65-74 years, with and without adjustment for present-day social deprivation and social class. The strong simple correlations found between infant mortality in 1895-1908 and adult mortality from various causes in 1969-73 were generally much attenuated or abolished by controlling for indices of present-day socioeconomic circumstances. Our results suggest that previous studies give no strong support for any direct influence of factors acting in early life on adult coronary heart disease mortality risk. Studies which gather data about infancy, childhood, and the full course of adult life are required to clarify this issue.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London			Davey Smith, George/A-7407-2013; Ben-Shlomo, Yoav/ABD-2004-2021	Davey Smith, George/0000-0002-1407-8314; Ben-Shlomo, Yoav/0000-0001-6648-3007	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BLANE D, 1987, RADICAL COMMUNITY ME, P31; BUCK C, 1982, J EPIDEMIOL COMMUN H, V36, P27, DOI 10.1136/jech.36.1.27; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; COLLEY JRT, 1973, BRIT MED J, V2, P195; ELFORD J, 1989, LANCET, V1, P343; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; ELFORD J, 1989, LANCET, V2, P984; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; Kermack WO, 1934, LANCET, V1, P698; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P144; KNIGHT I, 1984, OPCS SS1138; LEON DA, 1989, INT J CANCER, V43, P986, DOI 10.1002/ijc.2910430606; MANN SL, IN PRESS J EPIDEMIOL; MARMOT MG, 1984, LANCET, V1, P1003; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; OSMOND C, 1990, J EPIDEMIOL COMMUN H, V44, P139, DOI 10.1136/jech.44.2.139; PECK AMN, 1989, J EPIDEMIOL COMMUN H, V43, P380, DOI 10.1136/jech.43.4.380; POCOCK SJ, 1987, LANCET, V2, P197; RONA RJ, 1981, BRIT MED BULL, V37, P265, DOI 10.1093/oxfordjournals.bmb.a071713; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; Rothman K, 1986, MODERN EPIDEMIOLOGY; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; SMITH GD, 1991, BRIT MED J, V302, P113; SMTH GD, 1990, J EPIDEMIOL COMMUNIT, V44, P265; STRACHAN DP, 1988, BMJ-BRIT MED J, V296, P890, DOI 10.1136/bmj.296.6626.890; WAALER HT, 1984, ACTA MED SCAND S, V679, P1; WALD N, 1988, SMOKING HABITS SOCIA, P57; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUN H, V33, P199, DOI 10.1136/jech.33.3.199; 1978, OCCUPATIONAL MORTALI	38	180	185	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					530	534		10.1016/0140-6736(91)91307-G	http://dx.doi.org/10.1016/0140-6736(91)91307-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671899				2022-12-28	WOS:A1991EZ87400014
J	DIZHOOR, AM; RAY, S; KUMAR, S; NIEMI, G; SPENCER, M; BROLLEY, D; WALSH, KA; PHILIPOV, PP; HURLEY, JB; STRYER, L				DIZHOOR, AM; RAY, S; KUMAR, S; NIEMI, G; SPENCER, M; BROLLEY, D; WALSH, KA; PHILIPOV, PP; HURLEY, JB; STRYER, L			RECOVERIN - A CALCIUM SENSITIVE ACTIVATOR OF RETINAL ROD GUANYLATE-CYCLASE	SCIENCE			English	Article							AMINO-ACID SEQUENCE; CONE PHOTORECEPTORS; ALPHA-TRANSDUCIN; OUTER SEGMENT; PROTEINS; RED; RHODOPSIN; GTPASE; GENE	Vertebrate retinal photoreceptors recover from photoexcitation-induced hydrolysis of guanosine 3', 5'-monophosphate (cyclic GMP) by resynthesizing cyclic GMP, which reopens cation channels that have been closed by light. Activation of guanylate cyclase by light-induced depletion of cytosolic calcium is a key event in this recovery process. This cyclase has now been shown to be regulated by a 23-kilodalton calcium binding protein. The protein is present in both rod and cone photoreceptors and was named recoverin because it promotes recovery of the dark state. The amino acid sequence of recoverin exhibits three potential calcium binding sites (EF hands). That recoverin binds calcium was confirmed with calcium-45 and by observing calcium-induced changes in its tryptophan fluorescence. Recoverin activated guanylate cyclase when free calcium was lowered from 450 to 40 nM, an effect that was blocked by an antibody to recoverin. Thus, guanylate cyclase in retinal rods is stimulated during recovery by the calcium-free form of recoverin. A comparison of recoverin with other calcium binding proteins reveals that it may represent, along with the protein visinin, a family of proteins that are regulated by submicromolar calcium concentrations.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; MV LOMONOSOV STATE UNIV, BELOZERSKY LAB MOLEC BIOL & BIOORGAN CHEM, MOSCOW 119899, USSR; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA	University of Washington; University of Washington Seattle; Lomonosov Moscow State University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University			Philippov, Pavel P/A-8939-2012		NEI NIH HHS [EY06641, EY02005] Funding Source: Medline; NIGMS NIH HHS [GM15731] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002005, R01EY002005] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DIZHOOR AM, 1989, BIOCHEM BIOPH RES CO, V162, P544, DOI 10.1016/0006-291X(89)92031-7; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAMBRECHT HG, IN PRESS EMBO J; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; POLANS AS, IN PRESS J CELL BIOL; ROHLICH P, 1989, J COMP NEUROL, V289, P395, DOI 10.1002/cne.902890305; SATHER WA, 1988, BIOPHYS J, V53, pA390; SZEL A, 1988, J COMP NEUROL, V273, P593, DOI 10.1002/cne.902730413; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YAU KW, 1984, NATURE, V309, P352, DOI 10.1038/309352a0; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0	22	499	509	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 22	1991	251	4996					915	918		10.1126/science.1672047	http://dx.doi.org/10.1126/science.1672047			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1672047				2022-12-28	WOS:A1991EY62900037
J	IRELAND, A; HARTLEY, L; RYLEY, N; MCGEE, JOD; TROWELL, JM; CHAPMAN, RW				IRELAND, A; HARTLEY, L; RYLEY, N; MCGEE, JOD; TROWELL, JM; CHAPMAN, RW			RAISED GAMMA-GLUTAMYL-TRANSFERASE ACTIVITY AND THE NEED FOR LIVER-BIOPSY	BRITISH MEDICAL JOURNAL			English	Article									JOHN RADCLIFFE HOSP,DEPT GASTROENTEROL & HISTOPATHOL,OXFORD OX3 9DU,ENGLAND	University of Oxford								ATTERBURY CE, 1988, J CLIN GASTROENTEROL, V10, P605, DOI 10.1097/00004836-198812000-00003; LATCHAM RW, 1986, BRIT J PSYCHIAT, V149, P353, DOI 10.1192/bjp.149.3.353; NAKANO M, 1982, GASTROENTEROLOGY, V83, P777; TALLEY NJ, 1988, J CLIN GASTROENTEROL, V10, P647, DOI 10.1097/00004836-198812000-00015; WHITEHEAD TP, 1978, LANCET, V1, P978	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					388	389		10.1136/bmj.302.6773.388	http://dx.doi.org/10.1136/bmj.302.6773.388			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1672259	Bronze, Green Published			2022-12-28	WOS:A1991EX85800028
J	JACOBSON, MA; BACCHETTI, P; KOLOKATHIS, A; CHAISSON, RE; SZABO, S; POLSKY, B; VALAINIS, GT; MILDVAN, D; ABRAMS, D; WILBER, J; WINGER, E; SACKS, HS; HENDRICKSEN, C; MOSS, A				JACOBSON, MA; BACCHETTI, P; KOLOKATHIS, A; CHAISSON, RE; SZABO, S; POLSKY, B; VALAINIS, GT; MILDVAN, D; ABRAMS, D; WILBER, J; WINGER, E; SACKS, HS; HENDRICKSEN, C; MOSS, A			SURROGATE MARKERS FOR SURVIVAL IN PATIENTS WITH AIDS AND AIDS RELATED COMPLEX TREATED WITH ZIDOVUDINE	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS TYPE-1; PLACEBO-CONTROLLED TRIAL; RECEIVING ZIDOVUDINE; SAN-FRANCISCO; INFECTION; SERUM; HIV; AZIDOTHYMIDINE; EXPERIENCE; EXPRESSION	Objective - To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta-2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex. Design - Retrospective study of changes in laboratory markers and survival. Setting - Multicentre trial at university hospital clinics. Subjects - '90 Patients with AIDS or AIDS related complex. Intervention - Patients started zidovudine 200 mg orally every four hours. Fifty six of the patients died a median 17 months after starting zidovudine; the remaining 34 patients were followed up for a median 25.5 months. Main outcome measures - Changes in CD4+ lymphocyte count and serum concentrations of p24 antigen and antibody, beta-2 microglobulin, and neopterin; survival of the patient. Results - The pretreatment characteristics that independently predicted poor survival were determined using a multivariate proportional hazards models: a diagnosis of AIDS (upsilon-AIDS related complex), age over 45 years, and the logarithm of serum neopterin concentration. When these baseline characteristics were controlled for the logarithm of CD4+ lymphocyte count at weeks 8-12 of treatment (p = 0.007) and an increase in serum beta-2 microglobulin concentration at weeks 8-12 (p = 0.05) also independently correlated with survival. In the 38 patients with a better pretreatment prognosis, 24 month survival estimated by the product-limit method was 88% for those with a good response on both surrogate markers during early treatment compared with only 50% for those with a poor response on either marker. In the 38 with a worse pretreatment prognosis, 24 month survival was estimated to be 49% for those with a good response on both surrogate markers compared with only 18% for those with a poor response on either. Conclusion - These data suggest that CD4+ lymphocyte count at 8-12 weeks and, perhaps, change in serum beta-2 microglobulin concentration could be surrogate end points for clinical outcome in trials of antiretroviral drugs for patients with HIV disease.	SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; BETH ISRAEL MED CTR,DEPT MED,NEW YORK,NY 10003; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021; TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70118; BETH ISRAEL MED CTR,DIV INFECT DIS,NEW YORK,NY 10003; CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA 94704; IMMUNODIAGNOST LABS INC,SAN LEANDRO,CA; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOMATH,NEW YORK,NY 10029	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Cornell University; Tulane University; Harvard University; Beth Israel Deaconess Medical Center; California Department of Health Care Services; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	JACOBSON, MA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94110, USA.				NIAID NIH HHS [AI27663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOWICZ M, 1986, MED LETT DRUGS THER, V28, P107; ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; COX DR, 1984, ANAL SURVIVAL DATA, P91; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOUDSMIT J, 1986, LANCET, V2, P177; HARRELL FE, 1986, 11TH P ANN SAS US GR; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; JACOBSON MA, 1989, J INFECT DIS, V159, P1029, DOI 10.1093/infdis/159.6.1029; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; KRUPPENBACHER JP, 1988, LANCET, V1, P298; Kubo R T, 1976, Contemp Top Immunobiol, V5, P267; Lehman EL, 1975, NONPARAMETRICS STATI, P120; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; STEINBERG JP, 1989, J ACQ IMMUN DEF SYND, V2, P229; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; Weiss R., 1990, SURROGATE ENDPOINTS; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; 1985, SUGI SUPPLEMENTAL LI	28	128	130	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					73	78		10.1136/bmj.302.6768.73	http://dx.doi.org/10.1136/bmj.302.6768.73			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671651	Green Published, Bronze			2022-12-28	WOS:A1991ER95100015
J	SHULMAN, AG				SHULMAN, AG			SETTING THE RECORD STRAIGHT ON LOW-DOSE HEPARIN	LANCET			English	Editorial Material							ATHEROSCLEROSIS; ENDOTHELIUM; PREVENTION		CEDARS SINAI MED CTR,DEPT SURG,LOS ANGELES,CA 90048	Cedars Sinai Medical Center								[Anonymous], 1990, GOODMAN GILMANS PHAR; BICK RL, 1985, SEMIN THROMB HEMOST, V11, P213, DOI 10.1055/s-2007-1004377; ENGELBERG H, 1990, HEPARIN PREVENTION A; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; Guyton AC, 1986, TXB MED PHYSL; HEIM CR, 1986, ADV INTERNAL MED, V31, P181; HELLGREN M, 1981, THROMB RES, V21, P493, DOI 10.1016/0049-3848(81)90150-X; HIEBERT LM, 1976, THROMB RES, V8, P195, DOI 10.1016/0049-3848(76)90262-0; HIEBERT LM, 1976, ARTERY, V2, P26; JAQUES LB, 1991, J LAB CLIN MED, V117, P122; Jaques LB, 1980, PHARMACOL REV, V31, P99; KAKKAR W, 1974, HEPARIN STRUCTURE FU, P323; KANABROCKI EL, 1990, ANN R CHRON, V7, P169; LEVINE MN, 1986, SEMIN THROMB HEMOST, V12, P39, DOI 10.1055/s-2007-1003533; MAJERUS PW, ANTICOAGULANT THROMB; SAMUELS PB, 1952, ANN SURG, V136, P422, DOI 10.1097/00000658-195210000-00010; SAYEN JJ, 1982, T AM CLIN CLIMAT ASS, V94, P141; SERNERI GGN, 1987, LANCET, V1, P937; SHULMAN AG, 1988, NEW ENGL J MED, V319, P1154; SHULMAN AG, 1990, BIOMED PHARMACOTHER, V44, P303, DOI 10.1016/0753-3322(90)90133-T; WEST J, 1985, BEST TAYLOR PHYSL BA; Williams WJ., 1990, HEMATOLOGY HEMATOLOGY, V4th; Wilson J. D., 1991, HARRISONS PRINCIPLES; WYNGAARDEN JB, 1988, CECIL TXB MED; ZUGIBE FT, 1963, J HISTOCHEM CYTOCHEM, V11, P35, DOI 10.1177/11.1.35; 1986, JAMA-J AM MED ASSOC, V256, P744; 1989, MANUFACTURERS PRODUC	27	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1991	338	8767					619	620		10.1016/0140-6736(91)90617-X	http://dx.doi.org/10.1016/0140-6736(91)90617-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD809	1679161				2022-12-28	WOS:A1991GD80900013
J	SUTRISNA, B; FRERICHS, RR; REINGOLD, AL				SUTRISNA, B; FRERICHS, RR; REINGOLD, AL			RANDOMIZED, CONTROLLED TRIAL OF EFFECTIVENESS OF AMPICILLIN IN MILD ACUTE RESPIRATORY-INFECTIONS IN INDONESIAN CHILDREN	LANCET			English	Article							DEATH	The recommended treatment for mild acute respiratory infections (ARI) in children is supportive care only, but many physicians, especially in developing countries, continue to prescribe antibiotic treatment because they believe it prevents progression to more severe ARI. To find out whether ampicillin treatment conferred any benefit over supportive care alone, a randomised, controlled trial was carried out among 889 children (under 5 years) with mild ARI in Indonesia. 447 were randomly allocated ampicillin (25-30 mg/kg body weight three times daily for 5 days) plus supportive care (continued breastfeeding, clearing of the nose, and paracetamol to control fever); 442 were allocated supportive care only. The treatment groups were almost identical after randomisation in terms of age, sex, level of parental education, history of measles immunisation, and fever. After 1 week the percentages cured were nearly identical (204 [46%] ampicillin; 209 [47%] control), as were the percentages of cases progressing to moderate ARI (56 [13%] vs 53 [12%]). The effect of treatment was not modified by age, sex, measles immunisation status, or the educational level of the parents. At the 2-week follow-up, the percentages cured were 62% (277) in the ampicillin group and 58% (256) in the control group; 14% of both groups had progressed to moderate ARI; and 24% (107) and 28% (123), respectively, still had mild ARI. None of the differences in outcome between the ampicillin and control groups was statistically significant. Thus, ampicillin plus supportive care offers no benefit over supportive care alone for treatment of mild ARI in young Indonesian children.	UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024; UNIV INDONESIA,FAC PUBL HLTH,DEPOK,INDONESIA; UNIV CALIF BERKELEY,DEPT BIOMED & ENVIRONM HLTH SCI,BERKELEY,CA 94720	University of California System; University of California Los Angeles; University of Indonesia; University of California System; University of California Berkeley				Sutrisna, Bambang/0000-0002-5277-3879				CAMPBELL H, 1988, LANCET, V2, P1182; DEAN AG, 1990, EP INFO VERSION 5 WO; DENNY FW, 1986, AM J TROP MED HYG, V35, P1; GORDON M, 1974, MED J AUSTRALIA, V9, P304; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; KUNIN CM, 1990, REV INFECT DIS, V12, P12; LEXOMBOON U, 1971, J PEDIATR-US, V78, P772, DOI 10.1016/S0022-3476(71)80347-5; SHANN F, 1984, LANCET, V2, P537; SPIKA JS, 1989, ANN TROP PAEDIATR, V9, P33, DOI 10.1080/02724936.1989.11748592; STANSFIELD SK, 1987, PEDIATR INFECT DIS J, V6, P622, DOI 10.1097/00006454-198707000-00002; WEINBERG GA, 1990, B WORLD HEALTH ORGAN, V68, P79; 1981, B WORLD HEALTH ORGAN, V59, P707; 1984, B WORLD HEALTH ORGAN, V62, P47; 1988, HLTH WORKER MANUAL A; 1982, B WORLD HEALTH ORGAN, V60, P521; 1988, EPI LOG PLUS STATIST	16	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					471	474		10.1016/0140-6736(91)90544-Y	http://dx.doi.org/10.1016/0140-6736(91)90544-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678445	Green Submitted, Green Published			2022-12-28	WOS:A1991GC15300004
J	PIETERS, R; HUISMANS, DR; LOONEN, AH; HAHLEN, K; VANDERDOESVANDENBERG, A; VANWERING, ER; VEERMAN, AJP				PIETERS, R; HUISMANS, DR; LOONEN, AH; HAHLEN, K; VANDERDOESVANDENBERG, A; VANWERING, ER; VEERMAN, AJP			RELATION OF CELLULAR-DRUG RESISTANCE TO LONG-TERM CLINICAL OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							DYE EXCLUSION ASSAY; MTT-ASSAY; LEUKEMIA-CELLS; CANCER-CHEMOTHERAPY; CHEMOSENSITIVITY; INVITRO; CHILDREN; INVIVO; SENSITIVITY	The clinical relevance of cellular drug resistance in children with acute lymphoblastic leukaemia (ALL) is unknown. The relation between in-vitro sensitivity to chemotherapeutic drugs at initial diagnosis and long-term clinical outcome was investigated in 44 children with ALL. The short-term MTT assay was used to assess sensitivity to prednisolone, vincristine, colaspase (asparaginase), daunorubicin, and thioguanine (instead of mercaptopurine which is unstable in vitro). For vincristine and colaspase there was no difference in outcome (probability of continuous complete remission) between sensitive and resistant patients. However, the probability of continuous complete remission was significantly lower in patients with resistant cells than in those with sensitive cells for thioguanine (p < 0.01), daunorubicin (p < 0.02), and prednisolone (p < 0.05). For prednisolone there was a significant worsening of the prognosis (p < 0.05) from the extremely sensitive patients through an intermediate group to the most resistant group. The prognostic significance of cellular drug resistance was independent of white-blood-cell count, age, sex, and hepatosplenomegaly. Leukaemic cells from boys were more resistant to thioguanine than those from girls. Thus, the short-term highly efficient MTT assay can help to predict long-term response to chemotherapy in childhood ALL.	ERASMUS UNIV,SOPHIA CHILDRENS HOSP,SUBDIV HAEMATO ONCOL,3000 DR ROTTERDAM,NETHERLANDS; DUTCH CHILDHOOD LEUKEMIA STUDY GRP,THE HAGUE,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	PIETERS, R (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.		Veerman, Anjo/AAT-2443-2020	Veerman, Anjo JP/0000-0002-9309-301X				ASSELIN BL, 1989, CANCER RES, V49, P4363; BIRD MC, 1985, HEMATOL ONCOL, V3, P1, DOI 10.1002/hon.2900030102; CAMPLING BG, 1988, LEUKEMIA RES, V12, P823, DOI 10.1016/0145-2126(88)90036-7; EVANS WE, 1989, PEDIATR CLIN N AM, V36, P1199; HONGO T, 1990, CANCER-AM CANCER SOC, V65, P1263, DOI 10.1002/1097-0142(19900315)65:6<1263::AID-CNCR2820650602>3.0.CO;2-S; HONGO T, 1987, JPN J CANC CHEMOTHER, V14, P472; KERN DH, 1990, J NATL CANCER I, V82, P582, DOI 10.1093/jnci/82.7.582; KIRKPATRICK DL, 1990, LEUKEMIA RES, V14, P459, DOI 10.1016/0145-2126(90)90033-6; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816; LILLEYMAN JS, 1984, BRIT J CANCER, V49, P703, DOI 10.1038/bjc.1984.111; MATTERN J, 1982, CANCER TREAT REV, V9, P267, DOI 10.1016/S0305-7372(82)80041-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIETERS R, 1988, CANCER LETT, V41, P323, DOI 10.1016/0304-3835(88)90294-7; PIETERS R, 1989, BRIT J CANCER, V59, P217, DOI 10.1038/bjc.1989.44; PIETERS R, 1990, BLOOD, V76, P2327; PIETERS R, 1991, THESIS FREE U AMSTER; RIEHM H, 1987, ACUTE LEUKEMIAS PROG, P139; ROTHENBERG ML, 1989, BLOOD, V74, P1388; SANTINI V, 1989, HEMATOL ONCOL, V7, P287, DOI 10.1002/hon.2900070405; SARGENT JM, 1989, BRIT J CANCER, V60, P206, DOI 10.1038/bjc.1989.252; TAWA A, 1990, JPN J PEDIATR HEMATO, V4, P38; Thompson E B, 1986, Adv Exp Med Biol, V196, P111; TIDEFELT U, 1989, EUR J HAEMATOL, V43, P374; TWENTYMAN PR, 1989, BRIT J HAEMATOL, V71, P19, DOI 10.1111/j.1365-2141.1989.tb06268.x; TWENTYMAN PR, 1985, BRIT J CANCER, V51, P295, DOI 10.1038/bjc.1985.42; VANDENDOEL LJ, 1988, EUR J HAEMATOL, V41, P170; VEERMAN AJP, 1990, BRIT J HAEMATOL, V74, P381, DOI 10.1111/j.1365-2141.1990.tb06323.x; WEISENTHAL LM, 1986, CANCER TREAT REP, V70, P1283; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615	30	217	220	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					399	403		10.1016/0140-6736(91)91029-T	http://dx.doi.org/10.1016/0140-6736(91)91029-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678081				2022-12-28	WOS:A1991GB44600002
J	KENYON, C; WANG, B				KENYON, C; WANG, B			A CLUSTER OF ANTENNAPEDIA-CLASS HOMEOBOX GENES IN A NONSEGMENTED ANIMAL	SCIENCE			English	Editorial Material							NEMATODE CAENORHABDITIS-ELEGANS; PATTERN-FORMATION; C-ELEGANS				KENYON, C (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; Clark R. B., 1964, DYNAMICS METAZOAN EV; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; Hyman LH, 1951, INVERTEBRATES PLATYH, VII; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; WANG B, C ELEGANS DATA BASE	14	89	92	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					516	517		10.1126/science.1677487	http://dx.doi.org/10.1126/science.1677487			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1677487				2022-12-28	WOS:A1991FZ34700026
J	BOROK, Z; BUHL, R; GRIMES, GJ; BOKSER, AD; HUBBARD, RC; HOLROYD, KJ; ROUM, JH; CZERSKI, DB; CANTIN, AM; CRYSTAL, RG				BOROK, Z; BUHL, R; GRIMES, GJ; BOKSER, AD; HUBBARD, RC; HOLROYD, KJ; ROUM, JH; CZERSKI, DB; CANTIN, AM; CRYSTAL, RG			EFFECT OF GLUTATHIONE AEROSOL ON OXIDANT-ANTIOXIDANT IMBALANCE IN IDIOPATHIC PULMONARY FIBROSIS	LANCET			English	Note							LOWER RESPIRATORY-TRACT; INTERSTITIAL LUNG-DISEASES; CHRONIC INFLAMMATION; UNKNOWN CAUSE; DEFICIENCY; FLUID	Idiopathic pulmonary fibrosis (IPF) is characterised by alveolar inflammation, exaggerated release of oxidants, and subnormal concentrations of the antioxidant glutathione in respiratory epithelial lining fluid (ELF). Glutathione (600 mg twice daily for 3 days) was given by aerosol to 10 patients with IPF. Total ELF glutathione rose transiently, ELF oxidised glutathione concentrations increased, and there was a decrease in spontaneous superoxide anion release by alveolar macrophages. Thus, glutathione by aerosol could be a means of reversing the oxidant-antioxidant imbalance in IPF.	NHLBI,PULM BRANCH,BLDG 10 ROOM 6D03,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT PHARM,BETHESDA,MD 20892; CHU SHERBROOKE,SERV PNEUMOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of Sherbrooke				Borok, Zea/0000-0001-8673-8177; Holroyd, Kenneth/0000-0001-6050-3935				BUHL R, 1990, P NATL ACAD SCI USA, V87, P4063, DOI 10.1073/pnas.87.11.4063; BUHL R, 1989, LANCET, V2, P1294; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; FORMAN HJ, 1990, AM J PHYSIOL, V259, pL102, DOI 10.1152/ajplung.1990.259.2.L102; MEISTER A, 1988, J BIOL CHEM, V263, P17205; SIES H, 1984, METHOD ENZYMOL, V105, P445; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171	10	169	176	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					215	216		10.1016/0140-6736(91)90350-X	http://dx.doi.org/10.1016/0140-6736(91)90350-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676780				2022-12-28	WOS:A1991FY50400005
J	LUPSKI, JR; DEOCALUNA, RM; SLAUGENHAUPT, S; PENTAO, L; GUZZETTA, V; TRASK, BJ; SAUCEDOCARDENAS, O; BARKER, DF; KILLIAN, JM; GARCIA, CA; CHAKRAVARTI, A; PATEL, PI				LUPSKI, JR; DEOCALUNA, RM; SLAUGENHAUPT, S; PENTAO, L; GUZZETTA, V; TRASK, BJ; SAUCEDOCARDENAS, O; BARKER, DF; KILLIAN, JM; GARCIA, CA; CHAKRAVARTI, A; PATEL, PI			DNA DUPLICATION ASSOCIATED WITH CHARCOT-MARIE-TOOTH DISEASE TYPE-1A	CELL			English	Article							NEUROPATHY TYPE-I; MULTILOCUS LINKAGE ANALYSIS; PERICENTROMERIC REGION; INTERSTITIAL DELETION; GEL-ELECTROPHORESIS; HEREDITARY MOTOR; GENETIC-LINKAGE; CHROMOSOME-17; RECEPTOR; LOCUS	Charcot-Marie-Tooth disease type 1A (CMT1A) was localized by genetic mapping to a 3 cM interval on human chromosome 17p. DNA markers within this interval revealed a duplication that is completely linked and associated with CMT1A. The duplication was demonstrated in affected individuals by the presence of three alleles at a highly polymorphic locus, by dosage differences at RFLP alleles, and by two-color fluorescence in situ hybridization. Pulsed-field gel electrophoresis of genomic DNA from patients of different ethnic origins showed a novel SacII fragment of 500 kb associated with CMT1A. A severely affected CMT1A offspring from a mating between two affected individuals was demonstrated to have this duplication present on each chromosome 17. We have demonstrated that failure to recognize the molecular duplication can lead to misinterpretation of marker genotypes for affected individuals, identification of false recombinants, and incorrect localization of the disease locus.	BAYLOR UNIV,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR UNIV,DEPT NEUROL,HOUSTON,TX 77030; LOUISIANA STATE UNIV,MED CTR,DEPT PATHOL,NEW ORLEANS,LA 70112; BAYLOR UNIV,CTR HUMAN GENOME,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,LIVERMORE,CA 94550; UNIV UTAH,SCH MED,DEPT MED INFORMAT,SALT LAKE CITY,UT 84130; LOUISIANA STATE UNIV,MED CTR,DEPT NEUROL,NEW ORLEANS,LA 70112	Baylor University; Baylor University; Louisiana State University System; Baylor University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Utah System of Higher Education; University of Utah; Louisiana State University System	LUPSKI, JR (corresponding author), BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Barker, David/HHZ-0471-2022; Patel, Pragna/H-9129-2017	Barker, David/0000-0002-1438-4100; Patel, Pragna/0000-0003-3584-1072	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000774] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000344, R01HG000256] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG-00256-01, HG 00344] Funding Source: Medline; NICHD NIH HHS [HD00774] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BEDFORD MT, 1990, BIOTECHNIQUES, V9, P744; BEESON D, 1990, ANN HUM GENET, V54, P199, DOI 10.1111/j.1469-1809.1990.tb00378.x; BIRD TD, 1978, CLIN GENET, V14, P43; BIRD TD, 1982, AM J HUM GENET, V34, P388; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Bridges CB, 1936, SCIENCE, V83, P210, DOI 10.1126/science.83.2148.210; CHANCE PF, 1990, AM J HUM GENET, V47, P915; Charcot JM, 1886, REV MED-PARIS, V6, P97; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; DAUSSET J, 1986, PRESSE MED, V15, P1801; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888-7543(87)90034-6; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FRANCO B, 1990, NUCLEIC ACIDS RES, V18, P7196, DOI 10.1093/nar/18.23.7196-a; GREEN MC, 1989, GENETIC VARIANTS STR; GRUNDY HO, 1989, IMMUNOGENETICS, V29, P331, DOI 10.1007/BF00352843; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; KILLIAN JM, 1979, ANN NEUROL, V5, P515, DOI 10.1002/ana.410050604; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; LATHROP GM, 1988, AM J HUM GENET, V42, P498; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LINDSLEY DL, 1985, DROS INF SERV, V62; LITT M, 1989, AM J HUM GENET, V44, P397; LUPSKI JR, 1991, CURRENT NEUROLOGY, P1; MAGENIS RE, 1986, AM J MED GENET, V24, P415, DOI 10.1002/ajmg.1320240304; MCALPINE PJ, 1990, GENOMICS, V7, P408, DOI 10.1016/0888-7543(90)90175-T; McKusick VA, 1990, MENDELIAN INHERITANC; MIDDLETONPRICE HR, 1990, AM J HUM GENET, V46, P92; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORTON NE, 1956, AM J HUM GENET, V8, P80; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P10073, DOI 10.1093/nar/15.23.10073; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; OTT J, 1978, ANN HUM GENET, V42, P255, DOI 10.1111/j.1469-1809.1978.tb00657.x; OTT J, 1985, ANAL HUMAN GENETIC L; PATEL PI, 1990, AM J HUM GENET, V47, P926; PATEL PI, 1990, AM J HUM GENET, V46, P801; RAEYMAEKERS P, 1989, AM J HUM GENET, V45, P953; RAY R, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ CE, 1986, CYTOGENET CELL GENET, V43, P117, DOI 10.1159/000132307; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHYAMALA V, 1990, EMBO J, V9, P939, DOI 10.1002/j.1460-2075.1990.tb08192.x; SKRE H, 1974, CLIN GENET, V6, P98; SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATTON RF, 1986, AM J MED GENET, V24, P421, DOI 10.1002/ajmg.1320240305; SULLIVAN DE, 1987, BIOTECHNIQUES, V5, P672; TIMMERMAN V, 1990, AM J HUM GENET, V47, P680; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TSUBOTA SI, 1989, GENETICS, V122, P881; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; VANCE JM, 1991, GENOMICS, V9, P623, DOI 10.1016/0888-7543(91)90355-I; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, GENOME ANAL, V1, P157; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; WRIGHT EC, 1990, GENOMICS, V7, P103, DOI 10.1016/0888-7543(90)90524-X; ZOGHBI HY, 1989, AM J HUM GENET, V44, P255	62	1133	1152	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					219	232		10.1016/0092-8674(91)90613-4	http://dx.doi.org/10.1016/0092-8674(91)90613-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1677316				2022-12-28	WOS:A1991FY71200004
J	BLUMBERG, B; WRIGHT, CVE; DEROBERTIS, EM; CHO, KWY				BLUMBERG, B; WRIGHT, CVE; DEROBERTIS, EM; CHO, KWY			ORGANIZER-SPECIFIC HOMEOBOX GENES IN XENOPUS-LAEVIS EMBRYOS	SCIENCE			English	Article							DNA-BINDING SPECIFICITY; EARLY DROSOPHILA EMBRYO; BICOID PROTEIN; HOMEODOMAIN PROTEINS; ANTERIOR STRUCTURES; EXPRESSION VECTOR; GROWTH-FACTORS; MESODERM; AXIS; TRANSCRIPTION	The dorsal blastopore lip of the early Xenopus laevis gastrula can organize a complete secondary body axis when transplanted to another embryo. A search for potential gene regulatory components specifically expressed in the organizer was undertaken that resulted in the identification of four types of complementary DNAs from homeobox-containing genes that fulfill this criterion. The most abundant of these encodes a DNA-binding specificity similar to that of the Drosophila melanogaster anterior morphogen bicoid. The other three are also homologous to developmentally significant Drosophila genes. These four genes may participate in the regulation of the developmental potential of the organizer.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD-21502, HD-07273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, F32HD007273, R01HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; Cho K., UNPUB; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; Dawid I.B., 1990, Current Topics in Developmental Biology, V24, P261, DOI 10.1016/S0070-2153(08)60090-3; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HAN JH, 1988, NUCLEIC ACIDS RES, V16, P11837, DOI 10.1093/nar/16.24.11837; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HOLTFRETER HB, 1965, THESIS U ROCHESTER; JAYNES JB, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P47; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; NAKAMURA O, 1978, ORG MILESTONE HALF C; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H, 1931, Wilhelm Roux Arch Entwickl Mech Org, V123, P389, DOI 10.1007/BF01380646; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1990, DEVELOPMENT, V109, P363; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TREISMAN J, 1989, CELL, V59, P553; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	45	342	349	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					194	196		10.1126/science.1677215	http://dx.doi.org/10.1126/science.1677215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1677215				2022-12-28	WOS:A1991FW16000036
J	FELLS, P				FELLS, P			THYROID-ASSOCIATED EYE DISEASE - CLINICAL MANAGEMENT	LANCET			English	Article							GRAVES OPHTHALMOPATHY; ORBITAL DECOMPRESSION; RADIOTHERAPY				FELLS, P (corresponding author), MOORFIELDS EYE HOSP,CITY RD,LONDON EC1V 2PD,ENGLAND.							ANDERSON RL, 1981, ARCH OPHTHALMOL-CHIC, V99, P120; DAY RM, 1968, ARCH OPHTHALMOL-CHIC, V79, P279, DOI 10.1001/archopht.1968.03850040281009; DONALDSON SS, 1973, J CLIN ENDOCR METAB, V37, P276, DOI 10.1210/jcem-37-2-276; ELSTON JS, 1985, BRIT J OPHTHALMOL, V69, P718, DOI 10.1136/bjo.69.10.718; FELLS P, 1986, T OPHTHAL SOC UK, V105, P413; FELLS P, 1987, BRIT J OPHTHALMOL, V71, P107, DOI 10.1136/bjo.71.2.107; FELLS P, 1982, DOC OPHTHALMOL P SER, V32, P197; FELLS P, 1973, 2ND P INT S ORB DIS, P409; HALES IB, 1960, Q J MED, V29, P113; KENDALLTAYLOR P, 1988, BRIT MED J, V297, P1574, DOI 10.1136/bmj.297.6663.1574; LYONS CJ, 1990, EYE, V4, P538, DOI 10.1038/eye.1990.74; MOURITS MP, 1989, BRIT J OPHTHALMOL, V73, P639, DOI 10.1136/bjo.73.8.639; MOURITS MP, 1990, OPHTHALMOLOGY, V97, P636; PETERSEN IA, 1990, INT J RADIAT ONCOL, V19, P259, DOI 10.1016/0360-3016(90)90532-O; POTTS M, 1990, INVEST OPHTHALMOL VI, V31; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; SCOTT WE, 1981, OPHTHALMOLOGY, V88, P493; SHORR N, 1986, OPHTHALMOLOGY, V93, P476; SIMONSZ HJ, 1989, NEURO-OPHTHALMOLOGY, V9, P243, DOI 10.3109/01658108908997361; TROBE JD, 1978, ARCH OPHTHALMOL-CHIC, V96, P1199, DOI 10.1001/archopht.1978.03910060033007; TROKEL SL, 1981, OPHTHALMOLOGY, V88, P553; Waller R R, 1982, Trans Am Ophthalmol Soc, V80, P855	22	35	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					29	32		10.1016/0140-6736(91)90014-G	http://dx.doi.org/10.1016/0140-6736(91)90014-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676092				2022-12-28	WOS:A1991FV29600013
J	SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL				SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL			LONG-TERM EFFECTS OF VACUUM AND FORCEPS DELIVERIES	LANCET			English	Article							EXTRACTION; MIDFORCEPS; INFANT; LABOR; AGE	The long-term effects of vacuum and forceps deliveries are largely unknown. We determined the long-term outcome of instrumental deliveries in 52 282 infants born in Jerusalem between 1964 and 1972. For each individual, events at birth were related to results of an intelligence test and medical examination done at 17 years of age by the Israeli Defence Forces draft board. 1747 individuals were delivered by vacuum, 937 by forceps, 47 500 by spontaneous delivery, and 2098 by caesarean section. Crude data showed that mean intelligence scores at 17 were significantly higher (p < 0.0001) in the vacuum and forceps deliveries groups than in the spontaneous-delivery group; however, after adjustment for confounding factors by stepwise multiple regression, these differences were no longer seen. Although the forceps-delivery group had functional impairment of feet, vision, and retina compared with the spontaneous-delivery group, and the vacuum-extraction group had impairment of the legs, differences were small. Our findings suggest that infants delivered by vacuum or forceps are not at risk of physical and cognitive impairment at 17 years of age.	ISRAELI DEF FORCES MED CORPS, MED STAT BRANCH, JERUSALEM, ISRAEL; BIKUR CHOLIM HOSP, DEPT NEONATOL, JERUSALEM, ISRAEL; STANFORD UNIV, MED CTR, SCH MED, DEPT PEDIAT, STANFORD, CA 94305 USA; TEL AVIV UNIV, SACKLER SCH MED, DIV PEDIAT IMMUNOL, TEL AVIV, ISRAEL	Stanford University; Tel Aviv University; Sackler Faculty of Medicine	SEIDMAN, DS (corresponding author), CHAIM SHEBA MED CTR, DEPT OBSTET & GYNAECOL, IL-52621 TEL HASHOMER, ISRAEL.							BJERRE I, 1974, DEV MED CHILD NEUROL, V16, P378; BLENNOW G, 1977, ACTA OBSTET GYN SCAN, V56, P189, DOI 10.3109/00016347709162119; Broman S. H., 1975, PRESCHOOL IQ PRENATA; CARMODY F, 1986, ACTA OBSTET GYN SCAN, V65, P763, DOI 10.3109/00016348609161497; CYR RM, 1984, AM J OBSTET GYNECOL, V148, P490, DOI 10.1016/0002-9378(84)90733-6; DAVIES AM, 1969, ISRAEL J MED SCI, V5, P1095; DIERKER LJ, 1986, AM J OBSTET GYNECOL, V154, P764, DOI 10.1016/0002-9378(86)90452-7; DIERKER LJ, 1985, AM J OBSTET GYNECOL, V152, P176, DOI 10.1016/S0002-9378(85)80019-3; EGGE K, 1981, ACTA OBSTET GYN SCAN, V60, P153; EHLERS N, 1974, ACTA OPHTHALMOL, V52, P73; FALL O, 1986, ACTA OBSTET GYN SCAN, V65, P75, DOI 10.3109/00016348609158234; FRIEDMAN EA, 1987, CLIN OBSTET GYNECOL, V30, P93, DOI 10.1097/00003081-198703000-00014; FRIEDMAN EA, 1977, AM J OBSTET GYNECOL, V127, P779, DOI 10.1016/0002-9378(77)90257-5; FRIEDMAN EA, 1984, AM J OBSTET GYNECOL, V150, P941, DOI 10.1016/0002-9378(84)90386-7; HARLAP S, 1971, ISRAEL J MED SCI, V7, P1115; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; KARK JD, 1986, ISRAEL J MED SCI, V22, P318; MATARAZZO JD, 1972, WESCHLERS MEASUREMEN; MCBRIDE WG, 1979, MED J AUSTRALIA, V1, P301, DOI 10.5694/j.1326-5377.1979.tb112116.x; MUNSAT TL, 1963, AM J OBSTET GYNECOL, V85, P1083, DOI 10.1016/S0002-9378(16)35643-5; NELSON KB, 1989, CLIN PERINATOL, V16, P995, DOI 10.1016/S0095-5108(18)30617-1; NGAN HYS, 1990, AUST NZ J OBSTET GYN, V30, P111, DOI 10.1111/j.1479-828X.1990.tb03237.x; NILSEN ST, 1984, ACTA OBSTET GYN SCAN, V63, P549, DOI 10.3109/00016348409156718; ROSNER M, 1987, ARCH OPHTHALMOL-CHIC, V105, P1508; SCHENKER JG, 1966, OBSTET GYNECOL, V27, P521, DOI 10.1097/00006250-196604000-00014; SEIDMAN DS, IN PRESS OBSTET GYNE; Vacca A, 1989, EFFECTIVE CARE PREGN, P1216	27	35	35	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	1991	337	8757					1583	1585		10.1016/0140-6736(91)93273-C	http://dx.doi.org/10.1016/0140-6736(91)93273-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675719				2022-12-28	WOS:A1991FU55100015
J	KAUFFMAN, L; EVANS, DIK; STEVENS, RF; WEINKOVE, C				KAUFFMAN, L; EVANS, DIK; STEVENS, RF; WEINKOVE, C			BONE-MARROW TRANSPLANTATION FOR CONGENITAL ERYTHROPOIETIC PORPHYRIA	LANCET			English	Note								Congenital erythropoietic porphyria, a disorder of haem synthesis, is caused by uroporphyrinogen III synthase deficiency in bone-marrow normoblasts. Uroporphyrins and coproporphyrins accumulate and cause oxidative damage to cells exposed to sunlight. Uroporphyrin overproduction was greatly reduced and skin changes reversed in a girl who received a bone-marrow graft from an HLA-identical sibling at 10 years of age. The patient died 11 months after transplantation because of severe progressive pneumonitis and encephalopathy associated with cytomegalovirus infection, but the encouraging response up to 8 months after engraftment indicates a possible benefit of bone-marrow transplantation in the treatment of this rare but usually fatal inherited disease.	ROYAL MANCHESTER CHILDRENS HOSP,DEPT HAEMATOL,MANCHESTER M27 1HA,LANCS,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,BONE MARROW TRANSPLANT UNIT,MANCHESTER M27 1HA,LANCS,ENGLAND; HOPE HOSP,DEPT MED CLIN BIOCHEM,SALFORD M6 8HD,LANCS,ENGLAND	Royal Manchester Children's Hospital; Royal Manchester Children's Hospital								BARRANGER JA, 1984, NEW ENGL J MED, V331, P1629; DEYBACH JC, 1990, BLOOD, V75, P1763; LIM CK, 1984, CLIN CHIM ACTA, V139, P35; RANK JM, 1990, BRIT J HAEMATOL, V75, P617, DOI 10.1111/j.1365-2141.1990.tb07809.x; ROMEO G, 1969, P NATL ACAD SCI USA, V63, P856, DOI 10.1073/pnas.63.3.856; 1986, LANCET, V2, P788	6	72	72	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1991	337	8756					1510	1511		10.1016/0140-6736(91)93198-I	http://dx.doi.org/10.1016/0140-6736(91)93198-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT116	1675371				2022-12-28	WOS:A1991FT11600005
J	GLASIER, A; THONG, KJ; DEWAR, M; MACKIE, M; BAIRD, DT				GLASIER, A; THONG, KJ; DEWAR, M; MACKIE, M; BAIRD, DT			POSTCOITAL CONTRACEPTION WITH MIFEPRISTONE	LANCET			English	Letter									DEAN TERRACE FAMILY PLANNING CTR,EDINBURGH EH4 1NL,SCOTLAND		GLASIER, A (corresponding author), UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							Baird D T, 1988, J Reprod Fertil Suppl, V36, P173; DIXON GW, 1980, JAMA-J AM MED ASSOC, V244, P1336, DOI 10.1001/jama.244.12.1336; DUNCAN S, 1990, T I BRIT GEOGR, V15, P112, DOI 10.2307/623097; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111	4	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1414	1415		10.1016/0140-6736(91)93097-S	http://dx.doi.org/10.1016/0140-6736(91)93097-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674786				2022-12-28	WOS:A1991FP87000033
J	SOMERS, VK; CONWAY, J; JOHNSTON, J; SLEIGHT, P				SOMERS, VK; CONWAY, J; JOHNSTON, J; SLEIGHT, P			EFFECTS OF ENDURANCE TRAINING ON BAROREFLEX SENSITIVITY AND BLOOD-PRESSURE IN BORDERLINE HYPERTENSION	LANCET			English	Article							HEART-RATE VARIABILITY; SUDDEN CARDIAC DEATH; MYOCARDIAL-INFARCTION; EXERCISE; ASSOCIATION; PREDICTOR; MORTALITY; DISEASE; RISK; MEN	Physical training offers a potential nonpharmacological strategy for control of mild and borderline hypertension, but its effect on blood pressure is controversial. We investigated the effects of endurance training on waking and sleeping blood pressure and on baroreflex sensitivity in 16 borderline hypertensive patients. First, 8 patients were assessed before and after a 6-month endurance training programme. Then, when it was clear that blood pressures were lower after training, a further 8 patients were studied not only at the end of the training programme but also after 4 months' abstention from exercise (detraining). Measurements were taken of baroreflex sensitivity (response to iv phenylephrine), blood pressure, R-R interval, and blood pressure and R-R variability. Ambulatory blood pressures were measured in 13 patients (7 trained, 6 detrained) and sleep blood pressures in 6 patients (3 trained, 3 detrained). Increased fitness was associated with a decline in resting arterial blood pressure of 9.7 (SE2.0) mm Hg systolic and 6.8 (1.2) mm Hg diastolic, and with a decline in ambulatory blood pressure of 4.8 (1.4) mm Hg and 7.5 (2.1) mm Hg, respectively, both p < 0.05. Baroreflex sensitivity was 14.0 (1.8) ms/mm Hg in the unfit and 17.5 (2.0) ms/mm Hg in the fit; p < 0.05. Sleep blood pressures were not lower in the fit despite longer sleep R-R intervals. These findings indicate that, in some subjects with borderline or mild hypertension, a physical training programme is sufficient to bring the blood pressure within normal limits.	JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND	University of Oxford								ADRAGNA NC, 1985, HYPERTENSION, V7, P132, DOI 10.1161/01.HYP.7.1.132; [Anonymous], 1970, JAMA, V213, P1143; ARMITAGE P, 1966, CLIN SCI, V30, P325; BARNEY JA, 1984, FED PROC, V44, P626; BEDFORD TG, 1987, J APPL PHYSIOL, V63, P1926, DOI 10.1152/jappl.1987.63.5.1926; BEERE PA, 1984, SCIENCE, V226, P180, DOI 10.1126/science.6484569; BILLMAN GE, 1982, CIRCULATION, V66, P874, DOI 10.1161/01.CIR.66.4.874; BILLMAN GE, 1984, CIRCULATION, V69, P1182, DOI 10.1161/01.CIR.69.6.1182; BULPITT CJ, 1974, J CHRON DIS, V27, P309, DOI 10.1016/0021-9681(74)90094-0; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Conway J, 1984, J Hypertens, V2, P203, DOI 10.1097/00004872-198404000-00013; CONWAY J, 1988, J HYPERTENS, V6, P111; EICHNER ER, 1983, AM J MED, V75, P1008, DOI 10.1016/0002-9343(83)90882-3; GILDERS RM, 1989, MED SCI SPORT EXER, V21, P629, DOI 10.1249/00005768-198912000-00001; GOULD BA, 1981, LANCET, V2, P1377; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; ISLEY CD, 1985, BRIT MED J, V290, P1451; JULIUS S, 1990, Journal of the American Medical Association, V264, P354, DOI 10.1001/jama.264.3.354; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LAROVERE MT, 1988, CIRCULATION, V78, P816, DOI 10.1161/01.CIR.78.4.816; Lewis STP, 1980, INT J SPORTS MED, V1, P42, DOI [10.1055/s-2008-1034629, DOI 10.1055/S-2008-1034629]; MANCIA G, 1986, HYPERTENSION, V8, P147, DOI 10.1161/01.HYP.8.2.147; MANCIA G, 1983, LANCET, V2, P695; MANN S, 1980, CLIN SCI, V59, P501; MARK AL, 1982, HYPERTENSION, V4, P39, DOI 10.1161/01.HYP.4.1.39; MARTIN JE, 1990, CIRCULATION, V81, P1560, DOI 10.1161/01.CIR.81.5.1560; MCMAHON M, 1985, MED CLIN N AM, V69, P57, DOI 10.1016/S0025-7125(16)31056-2; MILLARCRAIG MW, 1981, BIOTELEM PAT MON, V8, P56; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAGANI M, 1988, HYPERTENSION, V12, P600, DOI 10.1161/01.HYP.12.6.600; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING TG, 1987, AM HEART J, V114, P925, DOI 10.1016/0002-8703(87)90589-8; RADICE M, 1984, B SOC ITAL, V29, P519; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; SEALS DR, 1989, J APPL PHYSIOL, V66, P1886, DOI 10.1152/jappl.1989.66.4.1886; SEDGWICK AW, 1974, EUR J APPL PHYSIOL O, V33, P307, DOI 10.1007/BF00430238; SMITH ML, 1988, J APPL PHYSIOL, V64, P585, DOI 10.1152/jappl.1988.64.2.585; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; SOMERS VK, 1988, HYPERTENSION, V11, P608, DOI 10.1161/01.HYP.11.6.608; SOMERS VK, 1986, J HYPERTENS, V4, pS657; 1982, PHYSICAL FITNESS; 1985, BRIT MED J, V291, P97	43	151	153	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1991	337	8754					1363	1368		10.1016/0140-6736(91)93056-F	http://dx.doi.org/10.1016/0140-6736(91)93056-F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP870	1674761				2022-12-28	WOS:A1991FP87000001
J	BADWE, RA; GREGORY, WM; CHAUDARY, MA; RICHARDS, MA; BENTLEY, AE; RUBENS, RD; FENTIMAN, IS				BADWE, RA; GREGORY, WM; CHAUDARY, MA; RICHARDS, MA; BENTLEY, AE; RUBENS, RD; FENTIMAN, IS			TIMING OF SURGERY DURING MENSTRUAL-CYCLE AND SURVIVAL OF PREMENOPAUSAL WOMEN WITH OPERABLE BREAST-CANCER	LANCET			English	Article							CLINICAL-TRIALS; SURGICAL CURE; GROWTH; REGRESSION; AUTOCRINE	Timing of operation in relation to menstrual phase might affect outlook in premenopausal women with operable breast cancer. We examined the records of 249 such women treated between 1975 and 1985, and compared overall and recurrence-free survival in those whose operation was 3-12 days after their last menstrual period (LMP) (group 1, n = 75) with those in whom it was 0-2 or 13-32 days after LMP (group 2, n = 174). Overall and recurrence-free survival were greatly reduced in group 1 women (p < 0.001 for both). Actuarial survival at 10 years was 54% in group 1 versus 84% in group 2. This effect was independent of other factors, was of much the same importance as nodal status in multivariate analysis, was largely confined to histologically node-positive cases, seemed to be greater in women with small tumours (less-than-or-equal-to 2 cm), and was seen in patients with oestrogen-receptor positive and negative tumours. Thus phase of menstrual cycle at operation is of great importance for long-term outlook in premenopausal women with breast cancer.	GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust			Fentiman, Ian/AAB-9886-2020; Fentiman, Ian S/I-7644-2019					ANDERSEN PK, 1982, BIOMETRICS, V38, P67, DOI 10.2307/2530289; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1989, CANCER RES, V49, P1996; GELBER RD, 1989, LANCET, V2, P1344; HANNA N, 1982, J IMMUNOL, V130, P974; HISSOM JR, 1987, BIOCHEM BIOPH RES CO, V145, P706, DOI 10.1016/0006-291X(87)91022-9; HOEWITZ KB, 1985, CANCER RES, V45, P167; HRUSHESKY WJM, 1989, LANCET, V2, P949; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MANNI A, 1990, BREAST CANCER RES TR, V15, P73, DOI 10.1007/BF01810779; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWLES TJ, 1989, LANCET, V2, P1343; RATAJCZAK HV, 1988, J EXP MED, V168, P88; RICHARDS MA, 1990, J CLIN ONCOL, V8, P2032, DOI 10.1200/JCO.1990.8.12.2032; ROCHEFORT H, 1988, BIOCHIMIE, V70, P943, DOI 10.1016/0300-9084(88)90236-2; RUBENS RD, 1983, LANCET, V1, P839, DOI 10.1016/S0140-6736(83)91385-5; SENIE R T, 1990, Breast Cancer Research and Treatment, V16, P146; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; VILLE Y, 1990, BREAST CANCER RES TR, V16, P119, DOI 10.1007/BF01809296; YEN S, 1986, REPROD ENDOCRINOLOGY, P126	22	166	166	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1261	1264		10.1016/0140-6736(91)92927-T	http://dx.doi.org/10.1016/0140-6736(91)92927-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674070				2022-12-28	WOS:A1991FN04700011
J	CAFORIO, ALP; WAGNER, R; GILL, JS; BONIFACIO, E; BOSI, E; MILES, A; MCKENNA, WJ; BOTTAZZO, GF				CAFORIO, ALP; WAGNER, R; GILL, JS; BONIFACIO, E; BOSI, E; MILES, A; MCKENNA, WJ; BOTTAZZO, GF			ORGAN-SPECIFIC CARDIAC ANTIBODIES - SEROLOGICAL MARKERS FOR SYSTEMIC HYPERTENSION IN AUTOIMMUNE POLYENDOCRINOPATHY	LANCET			English	Article							DILATED CARDIOMYOPATHY; BLOOD-PRESSURE; AUTOANTIBODIES; VARIANT; CELLS	Circulating organ-specific autoantibodies are serological markers of destruction or impairment of the relevant endocrine tissue cells and may be associated with abnormal hormone levels with or without clinical evidence overt disease. We sought organ-specific cardiac antibodies in patients with autoimmune polyendocrinopathy because of increasing evidence that the heart has endocrine characteristics (secretion of atrial natriuretic peptide [ANP] and other peptide hormones). Serum samples from 166 patients with polyendocrinopathy, 80 with autoimmunity confined to one gland, and 200 healthy blood donors were tested for these antibodies by means of immunofluorescence on human heart. Skeletal muscle was used to identify cross-reacting antibodies. Organ-specific cardiac antibodies were detected in significantly more of the patients with autoimmune polyendocrinopathy (28 [17%]) than of those with autoimmunity confined to one gland (1 [1%]) or of normal subjects (7 [3.5%]; p = 0.0001). Among the patients with autoimmune polyendocrinopathy, the prevalence of systemic hypertension was higher in those with cardiac autoantibodies than in those without (5/28 [18%] vs 2/80 [3%]; p = 0.01); the same was true for a family history of hypertension (11 [42%] vs 5 [7%]; p = 0.0001). There were no significant differences in mean basal or stimulated ANP concentrations between patients with or without antibodies or between patients and controls. 5 of the 22 antibody-positive patients had ANP concentrations outside the normal range, but these disturbances were not associated with systemic hypertension or a family history of the disorder. Patients with autoimmune polyendocrinopathy can have organ-specific cardiac antibodies, which may represent novel serological markers for an autoimmune form of systemic hypertension in the absence of overt cardiac disease.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT DIABET & IMMUNOGENET,LONDON EC1A 7BE,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT IMMUNOL,LONDON,ENGLAND; SAN RAFFAELE HOSP,SCI INST,MILAN,ITALY	St Georges University London; University of London; Queen Mary University London; University of London; University College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			McKenna, William J/C-3243-2008; Bonifacio, Ezio/E-7700-2010; Caforio, Alida/AAC-3223-2019	McKenna, William J/0000-0001-7994-2460; Bonifacio, Ezio/0000-0002-8704-4713; Caforio, Alida Linda Patrizia/0000-0002-4901-5655				BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BOSI E, 1988, ARCH NEUROL-CHICAGO, V45, P246, DOI 10.1001/archneur.1988.00520270016011; BOSI E, IN PRESS DIABETES; BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; BOTTAZZO GF, 1975, LANCET, V2, P97; BOTTAZZO GF, 1985, AUTOIMMUNITY ENDOCRI, P37; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; Claude H, 1908, J PHYSL PATHOL GEN, V10, P469; DONCKIER J, 1985, BRIT MED J, V291, P1648, DOI 10.1136/bmj.291.6509.1648-d; ESPINOSA E, 1969, AM J CARDIOL, V24, P508, DOI 10.1016/0002-9149(69)90493-7; GENEST J, 1988, HYPERTENSION S1, V11, P13; GOETZ KL, 1988, AM J PHYSIOL, V254, pE1, DOI 10.1152/ajpendo.1988.254.1.E1; GREENWALD JE, 1988, J CLIN INVEST, V81, P1036, DOI 10.1172/JCI113414; JENNINGS DB, 1990, CAN J PHYSIOL PHARM, V68, P131, DOI 10.1139/y90-020; KANNEL WB, 1975, ANGIOLOGY, V26, P1, DOI 10.1177/000331977502600101; KAPLAN MH, 1962, J IMMUNOL, V88, P450; KLEIN R, 1979, CLIN EXP IMMUNOL, V58, P283; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NEU N, 1987, J IMMUNOL, V139, P3630; Neufeld M., 1980, POLYGLANDULAR AUTOIM, P357; SCHERBAUM WA, 1983, LANCET, V1, P897; SCHULTHEISS HP, 1985, J MOL CELL CARDIOL, V17, P603, DOI 10.1016/S0022-2828(85)80029-8; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; STREETEN DHP, 1988, HYPERTENSION, V11, P78, DOI 10.1161/01.HYP.11.1.78; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TATEYAMA H, 1990, BIOCHEM BIOPH RES CO, V166, P1080, DOI 10.1016/0006-291X(90)90977-U; TREVISAN R, 1990, DIABETES, V39, P289, DOI 10.2337/diabetes.39.3.289	29	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1111	1115		10.1016/0140-6736(91)92784-Y	http://dx.doi.org/10.1016/0140-6736(91)92784-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674011				2022-12-28	WOS:A1991FL12400001
J	MAGOS, AL; BAUMANN, R; LOCKWOOD, GM; TURNBULL, AC				MAGOS, AL; BAUMANN, R; LOCKWOOD, GM; TURNBULL, AC			EXPERIENCE WITH THE 1ST 250 ENDOMETRIAL RESECTIONS FOR MENORRHAGIA	LANCET			English	Article							ND-YAG LASER; ABLATION; SURGERY	234 patients with menorrhagia were treated hysteroscopically by transcervical resection of the endometrium (TCRE) instead of hysterectomy. 250 procedures were performed under general anaesthesia (63%) or under sedation plus local anaesthesia (38%). The endometrium was excised either totally (91%) or partially (9%) in all but one case, and 56 (22%) of the patients underwent simultaneous resection of submucous fibroids. Surgical time (range 10-100 min) varied with the gynaecologist's experience. 479 ml was the average volume of uterine irrigant absorbed by the patient. Blood loss was usually slight. Operative complications were uncommon, but 4 (2%) women sustained a uterine perforation (without serious sequelae), 7 (3%) absorbed more than 2 litres of fluid, and 1 required tamponade to control postoperative bleeding. Hospital stay was short and full recovery usual by 1-2 weeks. Menstrual symtoms improved in over 90% of the patients throughout the follow-up of up to 2 1/2 years; 27-42% of the women became amenorrhoeic at some time after total TCRE. Results were best in women > 35 years of age, but was not influenced by the presence of fibroids or pretreatment dysmenorrhoea. 10 (4%) women later underwent hysterectomy. Hysteroscopy 3 and 12 months after surgery revealed a small, fibrotic uterine cavity in the majority.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	MAGOS, AL (corresponding author), ROYAL FREE HOSP,ACAD DEPT OBSTET & GYNAECOL,LONDON NW3 2QG,ENGLAND.							ASHERMAN JG, 1950, J OBSTET GYN BRIT EM, V57, P892; BAGGISH MS, 1988, AM J OBSTET GYNECOL, V159, P287, DOI 10.1016/S0002-9378(88)80069-3; BAUMANN R, 1990, BRIT MED J, V300, P304, DOI 10.1136/bmj.300.6720.304; DANIELL JF, 1986, COLP GYNECOL LAS SUR, V2, P43; DAVIS JA, 1989, BRIT J OBSTET GYNAEC, V96, P928, DOI 10.1111/j.1471-0528.1989.tb03347.x; DECHERNEY A, 1983, OBSTET GYNECOL, V61, P392; GIMPELSON RJ, 1988, J REPROD MED, V33, P872; GOLDFARB HA, 1990, OBSTET GYNECOL, V76, P833, DOI 10.1097/00006250-199011000-00022; GOLDRATH MH, 1981, AM J OBSTET GYNECOL, V140, P14, DOI 10.1016/0002-9378(81)90251-9; GOLDRATH MH, 1990, J REPROD MED, V35, P91; GOLDRATH MH, 1986, GYNAECOLOGICAL LASER, P253; GORDON AG, 1989, BAILLIERE CLIN OB GY, V3, P429, DOI 10.1016/S0950-3552(89)80003-3; LOCKWOOD M, 1990, BRIT J OBSTET GYNAEC, V97, P656, DOI 10.1111/j.1471-0528.1990.tb02562.x; LOMANO JM, 1986, J REPROD MED, V31, P148; LOMANO JM, 1988, AM J OBSTET GYNECOL, V159, P152, DOI 10.1016/0002-9378(88)90512-1; MAGOS AL, 1990, LANCET, V335, P44, DOI 10.1016/0140-6736(90)90165-2; MAGOS AL, 1989, LANCET, V2, P925; MAGOS AL, 1989, BRIT MED J, V298, P1209, DOI 10.1136/bmj.298.6682.1209; MAGOS AL, 1990, ADV REP END, V2, P97; NEUWIRTH RS, 1978, AM J OBSTET GYNECOL, V131, P91, DOI 10.1016/0002-9378(78)90481-7; PERRY CP, 1990, J GYNECOL SURG, V6, P199, DOI 10.1089/gyn.1990.6.199; PHIPPS JH, 1990, OBSTET GYNECOL, V76, P876, DOI 10.1097/00006250-199011000-00032; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; TOWNSEND DE, 1990, OBSTET GYNECOL, V76, P310; VANCAILLIE TG, 1989, OBSTET GYNECOL, V74, P425	25	248	253	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1074	1078		10.1016/0140-6736(91)91718-A	http://dx.doi.org/10.1016/0140-6736(91)91718-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673504				2022-12-28	WOS:A1991FK20400015
J	LITTLEWOOD, R				LITTLEWOOD, R			FROM DISEASE TO ILLNESS AND BACK AGAIN	LANCET			English	Article											LITTLEWOOD, R (corresponding author), UNIV LONDON UNIV COLL,CTR MED ANTHROPOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.							CHRISMAN N, 1982, CLIN APPLIED ANTHR; DOUGLAS M, 1985, RISK ACCEPTABILITY S; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; Good Byron J., 1981, SCI CULTURES SOCIOLO, V5; Helman C. G., 1990, CULTURE HLTH ILLNESS; Holden P., 1991, ANTHR NURSING; Kleinman A., 1988, ILLNESS NARRATIVES; Kleinman A., 1980, PATIENTS HEALERS CON; LITTLEWOOD, 1990, BRIT J PSYCHIAT, V156, P308; Littlewood R., 1989, ALIENS ALIENISTS ETH; Littlewood Roland., 1988, PSYCHIATRIC B, V12, P486; MCKEOWN T, 1976, ROLE MED; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207	13	11	11	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1013	1016		10.1016/0140-6736(91)92668-R	http://dx.doi.org/10.1016/0140-6736(91)92668-R			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673174				2022-12-28	WOS:A1991FJ13500012
J	MIZUNO, K; MIYAMOTO, A; SATOMURA, K; KURITA, A; ARAI, T; SAKURADA, M; YANAGIDA, S; NAKAMURA, H				MIZUNO, K; MIYAMOTO, A; SATOMURA, K; KURITA, A; ARAI, T; SAKURADA, M; YANAGIDA, S; NAKAMURA, H			ANGIOSCOPIC CORONARY MACROMORPHOLOGY IN PATIENTS WITH ACUTE CORONARY DISORDERS	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; ANGIOGRAPHIC MORPHOLOGY; ATHEROSCLEROTIC PLAQUES; PATHOGENESIS; THROMBOSIS; PLATELETS; STENOSES; DISEASE; DEATH	To investigate the pathogenesis of acute coronary disorders and to clarify what type of plaque precedes these disorders, percutaneous transluminal coronary angioscopy, by means of a new angioscope, was carried out during catheterisation in 100 consecutive patients anatomically suitable for such investigations. The quality of the angioscopic image was good enough for analysis in 84 patients (14 with acute myocardial infarction [within 8 h of onset], 16 with recent myocardial infarction [3 days-2 months since onset], 24 with old myocardial infarctions, 10 with unstable angina, and 20 with stable angina). Thrombi were observed in most patients with acute coronary disorders (all 14 with acute myocardial infarction, 9 of 10 with unstable angina). Occlusive thrombi were more common in patients with acute myocardial infarction than in those with unstable angina (11 [79%] vs 1 [10%]; p < 0.001), whereas mural (non-occlusive) thrombi were more common in the unstable angina than in the acute myocardial infarction group (8 [80%] vs 3 [21%]; p < 0.001). Xanthomatous ulcerated plaques or ragged irregular surfaces were seen in patients with acute coronary disorders and in those with recent myocardial infarction. Xanthomatous plaques were more common in patients with acute coronary disorders (50%) than in those with stable angina (15%) or old myocardial infarction (8%). By contrast white and smooth plaques were seen in cases of stable angina and old myocardial infarction. Angioscopy could display the intracoronary lumen more precisely than could coronary arteriography. This angioscopic study suggested that, although a thrombus overlying a rupture in the lining of the plaque was common in both unstable angina and acute myocardial infarction, the character of the thrombus may differ between these disorders, and lipid-rich xanthomatous plaque may precede rupture.	NATL DEF MED COLL,DEPT MED ENGN,TOKOROZAWA,SAITAMA 359,JAPAN	National Defense Medical College - Japan	MIZUNO, K (corresponding author), NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN.							AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2; BADIMON L, 1986, ARTERIOSCLEROSIS, V6, P312, DOI 10.1161/01.ATV.6.3.312; CARVALHO AC, 1974, NEW ENGL J MED, V290, P434, DOI 10.1056/NEJM197402212900805; DAVIES MJ, 1990, CIRCULATION, V82, P38; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FREEMAN MR, 1989, CIRCULATION, V80, P17, DOI 10.1161/01.CIR.80.1.17; FUSTER V, 1985, J AM COLL CARDIOL, V5, pB175, DOI 10.1016/S0735-1097(85)80552-0; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; HAFT JI, 1987, CHEST, V92, P609, DOI 10.1378/chest.92.4.609; HOEHER M, 1988, Journal of the American College of Cardiology, V11, p65A; HORIE T, 1978, BRIT HEART J, V40, P153; KUWAKI K, 1987, CIRCULATION, V76, P186; LEVIN DC, 1982, CIRCULATION, V66, P316, DOI 10.1161/01.CIR.66.2.316; LINDOP G, 1985, MUIRS TXB PATHOLOGY; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; POTKIN BN, 1988, AM J CARDIOL, V62, P41, DOI 10.1016/0002-9149(88)91362-8; RAMEE SR, 1991, J AM COLL CARDIOL, V17, P100, DOI 10.1016/0735-1097(91)90710-Q; REHR R, 1989, J AM COLL CARDIOL, V14, P1429, DOI 10.1016/0735-1097(89)90376-8; RICHARDSON PD, 1989, LANCET, V2, P941; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; STUART MJ, 1980, NEW ENGL J MED, V302, P6, DOI 10.1056/NEJM198001033020102; UCHIDA Y, 1987, AM HEART J, V114, P1216, DOI 10.1016/0002-8703(87)90199-2	22	178	188	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					809	812		10.1016/0140-6736(91)92514-3	http://dx.doi.org/10.1016/0140-6736(91)92514-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672912				2022-12-28	WOS:A1991FF22800002
J	KOVACS, A; FREDERICK, T; CHURCH, J; ELLER, A; OXTOBY, M; MASCOLA, L				KOVACS, A; FREDERICK, T; CHURCH, J; ELLER, A; OXTOBY, M; MASCOLA, L			CD4 LYMPHOCYTE-T COUNTS AND PNEUMOCYSTIS-CARINII PNEUMONIA IN PEDIATRIC HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; CHEMOPROPHYLAXIS; RATIO	The relationship between CD4 T-lymphocyte counts and infection with the human immunodeficiency virus (HIV) is retrospectively investigated for 266 HIV-infected and uninfected children who were born to infected women, including 39 with Pneumocystis carinii pneumonia (PCP), in a population-based surveillance study. Of 21 perinatally HIV-infected children with PCP only 10 (48%) had CD4 T-lymphocyte counts that were less than 500 X 10(6) cells/L (500 cells/mm3), compared with all 18 who were infected via blood transfusions or clotting factors. Among 68 children who were 1 year or younger, 18 (90%) of 20 PCP cases had CD4 T-lymphocyte counts that were less than 1500 X 10(6) cells/L (1500 cells/mm3) compared with only five (10%) of 48 children who did not have the acquired immunodeficiency syndrome (odds ratio, 77.4; 95% confidence interval, 19.7 to 313.4). The mean CD4 T-lymphocyte count was lower for the 39 PCP cases when compared with the 188 children who were at different stages of HIV infection and did not have the acquired immunodeficiency syndrome (AIDS) independent of age. The majority of perinatally HIV-infected children with PCP were 6 months or younger and 50% were previously unknown to be infected. Thus, HIV-positive children should be identified early and followed closely. CD4 T-lymphocyte counts may be useful in monitoring HIV-positive children and determining when to begin PCP prophylaxis.	LOS ANGELES CTY DEPT HLTH SERV,PEDIAT AIDS SURVEILLANCE STUDY,LOS ANGELES,CA; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; CTR DIS CONTROL,ATLANTA,GA 30333; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California; Centers for Disease Control & Prevention - USA; University of Southern California	KOVACS, A (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PATHOL,PEDIAT PAVIL,1129 N STATE S,ROOM 3D14,LOS ANGELES,CA 90033, USA.				PHS HHS [U64-CCU903273-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; DENNY TN, 1990, PEDIATR RES, V27, P155; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; HSU H, 1990, 30TH ICAAC ATL; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KOVACS JA, 1989, J INFECT DIS, V160, P882, DOI 10.1093/infdis/160.5.882; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SANDERSLAUFER D, 1990, PEDIATR RES, V27, P183; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VERNON DD, 1988, PEDIATRICS, V82, P223; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1987, MMWR, V36, P225; 1987, MMWR, V36, P235; 1989, MMWR S5, V38, pS1; 1987, MMWR S15, V36, pS1	24	43	43	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1698	1703						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1672169				2022-12-28	WOS:A1991FD65900025
J	PAGE, Y; TARDY, B; ZENI, F; COMTET, C; TERRANA, R; BERTRAND, JC				PAGE, Y; TARDY, B; ZENI, F; COMTET, C; TERRANA, R; BERTRAND, JC			THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO TICLOPIDINE	LANCET			English	Article							PLASMA; METABOLISM; PATIENT; CULTURE; TTP	4 patients had typical features of thrombotic thrombocytopenic purpura (TTP) after 3 to 8 weeks of ticlopidine therapy. In 2 ticlopidine was the only medication taken before TTP; in another, rechallenge with drugs other than ticlopidine that the patient had been taking did not produce relapse. In all patients the delay between start of ticlopidine and TTP was in the same range as the latent period before ticlopidine-induced neutropenia. No relapse occurred in the 4 to 43 months of follow-up in the 3 surviving patients.	HOP BELLEVUE, DEPT EMERGENCY MED, BD PASTEUR, F-42023 ST ETIENNE, FRANCE; HOP ST CHAMOND, DEPT INTENS CARE, ST CHAMOND, FRANCE; HOP BELLEVUE, DEPT INTENS CARE, F-42023 ST ETIENNE, FRANCE	CHU de St Etienne; CHU de St Etienne								ABOUKHALIL WH, 1984, BIOCHEM PHARMACOL, V33, P3893, DOI 10.1016/0006-2952(84)90057-1; AHMED F, 1978, ARCH INTERN MED, V138, P1292, DOI 10.1001/archinte.138.8.1292; AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; BROWN RC, 1973, BRIT MED J, V2, P303, DOI 10.1136/bmj.2.5861.303-a; BUKOWSKI RM, 1982, PROG HEMOST THROMB, V6, P287; Caggiano V, 1983, J Clin Apher, V1, P71, DOI 10.1002/jca.2920010204; Catizone L, 1974, Minerva Nefrol, V21, P439; CLAAS FHJ, 1984, NOUV REV FR HEMATOL, V26, P323; DEGRAMONT A, 1982, NOUV REV FR HEMATOL, V24, P35; DEKKER A, 1974, AM J MED SCI, V267, P243, DOI 10.1097/00000441-197404000-00006; GOODMAN A, 1978, ANN INTERN MED, V89, P501, DOI 10.7326/0003-4819-89-4-501; JACKSON AM, 1984, ANN INTERN MED, V101, P41, DOI 10.7326/0003-4819-101-1-41; KOVACS MJ, 1990, AM J MED, V88, P177, DOI 10.1016/0002-9343(90)90470-X; KWSAAN HC, 1979, SEMIN THROMB HEMOST, V5, P184; LAGARDE M, 1979, PROSTAG LEUKOTR ESS, V2, P433, DOI 10.1016/0161-4630(79)90127-7; LIAN ECY, 1979, BLOOD, V53, P333; METTLER NE, 1969, NEW ENGL J MED, V281, P1023, DOI 10.1056/NEJM196911062811901; NEAME PB, 1980, SEMIN THROMB HEMOST, V6, P416, DOI 10.1055/s-2007-1005113; PARKER JC, 1971, ARCH INTERN MED, V127, P474, DOI 10.1001/archinte.127.3.474; PIOVELLA F, 1984, THROMB RES, V33, P323, DOI 10.1016/0049-3848(84)90167-1; QUAGLINO D, 1982, HAEMATOLOGICA, V67, P940; REMUZZI G, 1978, LANCET, V2, P871; RESEGOTTI L, 1985, NOUV REV FR HEMATOL, V27, P19; ROSE M, 1987, AM J MED, V83, P437, DOI 10.1016/0002-9343(87)90753-4; SACK GH, 1977, MEDICINE, V56, P1, DOI 10.1097/00005792-197756010-00001; TAFT EG, 1979, BLOOD, V54, P842; TARDY B, 1989, EUR J INTERN MED, V1, P145; VESCONI S, 1979, THROMB HAEMOSTASIS, V40, P563; VIANELLI N, 1990, HAEMATOLOGICA, V75, P274; ZACHARSKI LR, 1976, AM J MED, V60, P1061, DOI 10.1016/0002-9343(76)90581-7	30	108	110	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	1991	337	8744					774	776		10.1016/0140-6736(91)91383-6	http://dx.doi.org/10.1016/0140-6736(91)91383-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672401				2022-12-28	WOS:A1991FD88400014
J	FOX, K; DAW, N; SATO, H; CZEPITA, D				FOX, K; DAW, N; SATO, H; CZEPITA, D			DARK-REARING DELAYS THE LOSS OF NMDA-RECEPTOR FUNCTION IN KITTEN VISUAL-CORTEX	NATURE			English	Article							METHYL-D-ASPARTATE; OCULAR DOMINANCE COLUMNS; CAT; PLASTICITY; NEURONS	SOME features of the visual cortex develop postnatally in mammals 1,2. For example, geniculocortical axons that initially overlap throughout cortical layer IV segregate postnatally into two sets of interleaved eye-specific bands 3,4. NMDA (N-methyl-D-aspartate) receptors are necessary for eye-specific axon-segregation in the frog tectum 5, and as NMDA receptors play a greater part in synaptic transmission in early life 6,7 and decrease in function during the period of axon segregation, they may be involved in the segregation of geniculocortical axons: they are well placed to do so as they transduce 8 retinally derived signals essential for segregation 9. Rearing animals in the dark in early life delays segregation 10,11 and prolongs the critical period for plasticity 12. We now report that dark-rearing of kittens also delays the loss of NMDA receptor function in the visual cortex, supporting the view that they play an important part in neuronal development and plasticity.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,MCDONNELL CTR STUDIES HIGHER BRAIN FUNCT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X				BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; CLINE HT, 1990, J NEUROSCI, V10, P1197; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; FLATMAN JA, 1986, BRAIN RES, V363, P62, DOI 10.1016/0006-8993(86)90659-1; FOX K, 1989, J NEUROSCI, V9, P2443; FOX K, 1990, J NEUROPHYSIOL, V64, P1413, DOI 10.1152/jn.1990.64.5.1413; FREEMAN RD, 1979, SCIENCE, V206, P1093, DOI 10.1126/science.493996; GORDON B, 1990, SOC NEUR ABSTR, V17, P986; HAGIHARA K, 1988, EXP BRAIN RES, V69, P407; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Mitchell DE, 1984, HDB PHYSL 1 1, V3, P507; MOWER GD, 1985, J COMP NEUROL, V235, P448, DOI 10.1002/cne.902350404; REYNOLDS IJ, IN PRESS EXPL BRAIN; SHATZ CJ, 1988, CEREB CORTEX, V7, P35; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SWINDALE NV, 1988, J COMP NEUROL, V267, P47; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0	22	105	107	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					342	344		10.1038/350342a0	http://dx.doi.org/10.1038/350342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1672557				2022-12-28	WOS:A1991FD83800093
J	MULKEY, RM; ZUCKER, RS				MULKEY, RM; ZUCKER, RS			ACTION-POTENTIALS MUST ADMIT CALCIUM TO EVOKE TRANSMITTER RELEASE	NATURE			English	Article							NEUROTRANSMITTER RELEASE; NERVE TERMINALS; FACILITATION; DEPOLARIZATION; CRAYFISH; ENTRY; INFLUX	THERE are two hypotheses to explain how neurons release transmitter. The calcium hypothesis proposes that membrane depolarization is necessary only for opening calcium channels and increasing internal calcium concentration ([Ca2+]i) near membrane transmitter-release sites 1-3. These calcium ions trigger a transient release of neurotransmitter 4,5. The calcium-voltage hypothesis postulates that voltage induces a conformational change in a membrane protein rendering it sensitive to calcium such that, in the presence of high [Ca2+]i, depolarization directly triggers transmitter release 6-9. Here we report that when calcium influx is blocked by cobalt or manganese ions in a calcium-free Ringer, as measured with Fura-2, and [Ca2+]i is elevated by liberation from a caged calcium compound, transmitter release at the crayfish neuromuscular junction is unaffected by presynaptic action potentials. These results support the calcium hypothesis.			MULKEY, RM (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Zucker, Robert S/J-9995-2012	Zucker, Robert S/0000-0003-1068-2343				BITTNER GD, 1988, J NEUROBIOL, V20, P386; DELANEY KR, 1990, J PHYSIOL-LONDON, V426, P473, DOI 10.1113/jphysiol.1990.sp018150; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DUDEL J, 1983, PFLUG ARCH EUR J PHY, V399, P1, DOI 10.1007/BF00652515; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HOCHNER B, 1989, NATURE, V342, P433, DOI 10.1038/342433a0; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; Katz B., 1969, RELEASE NEURAL TRANS; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; NARITA K, 1990, BRAIN RES, V510, P289, DOI 10.1016/0006-8993(90)91379-U; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PARNAS I, 1986, PFLUG ARCH EUR J PHY, V406, P131, DOI 10.1007/BF00586673; ZUCKER RS, 1986, J PHYSIOL-PARIS, V81, P237; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1986, SCIENCE, V231, P574, DOI 10.1126/science.2868525; ZUCKER RS, 1988, NATURE, V335, P360, DOI 10.1038/335360a0	20	104	104	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					153	155		10.1038/350153a0	http://dx.doi.org/10.1038/350153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1672444				2022-12-28	WOS:A1991FB64500058
J	GOATE, A; CHARTIERHARLIN, MC; MULLAN, M; BROWN, J; CRAWFORD, F; FIDANI, L; GIUFFRA, L; HAYNES, A; IRVING, N; JAMES, L; MANT, R; NEWTON, P; ROOKE, K; ROQUES, P; TALBOT, C; PERICAKVANCE, M; ROSES, A; WILLIAMSON, R; ROSSOR, M; OWEN, M; HARDY, J				GOATE, A; CHARTIERHARLIN, MC; MULLAN, M; BROWN, J; CRAWFORD, F; FIDANI, L; GIUFFRA, L; HAYNES, A; IRVING, N; JAMES, L; MANT, R; NEWTON, P; ROOKE, K; ROQUES, P; TALBOT, C; PERICAKVANCE, M; ROSES, A; WILLIAMSON, R; ROSSOR, M; OWEN, M; HARDY, J			SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE	NATURE			English	Article							SECONDARY STRUCTURE; LINKAGE; CHROMOSOME-21; CDNA; PREDICTION; MARKERS; DEFECT; LOCUS; DNA	A LOCUS segregating with familial Alzheimer's disease (AD) has been mapped to chromosome 21 (ref. 1), close to the amyloid precursor protein (APP) gene 2-5. Recombinants between the APP gene and the AD locus have been reported 6-8 which seemed to exclude it as the site of the mutation causing familial AD. But recent genetic analysis of a large number of AD families has demonstrated that the disease is heterogeneous 9. Families with late-onset AD do not show linkage to chromosome 21 markers 9,10. Some families with early-onset AD show linkage to chromosome 21 markers, but some do not 8,9,11. This has led to the suggestion that there is non-allelic genetic heterogeneity even within early onset familial AD 8,9. To avoid problems that heterogeneity poses for genetic analysis, we have examined the cosegregation of AD and markers along the long arm of chromosome 21 in a single family with AD confirmed by autopsy. Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene. This mutation causes an amino-acid substitution (Val --> Ile) close to the carboxy terminus of the beta-amyloid peptide. Screening other cases of familial AD revealed a second unrelated family in which this variant occurs. This suggests that some cases of AD could be caused by mutations in the APP gene.	ST MARYS HOSP, SCH MED, DEPT BIOCHEM, ALZHEIMERS DIS RES GRP, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, DEPT NEUROL, LONDON W2 1PG, ENGLAND; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; UNIV COLL CARDIFF, DEPT PSYCHOL MED, CARDIFF CF4 4XN, S GLAM, WALES; UNIV COLL CARDIFF, DEPT MED GENET, CARDIFF CF4 4XN, S GLAM, WALES	Imperial College London; Imperial College London; Yale University; Duke University; Cardiff University; Cardiff University			Rossor, Martin/C-1598-2008; Chartier-Harlin, Marie-Christine/L-4527-2018; Hardy, John/C-2451-2009	Chartier-Harlin, Marie-Christine/0000-0001-6416-6526; Hardy, John/0000-0002-3122-0423; Rossor, Martin/0000-0001-8215-3120; Mullan, Michael/0000-0002-1473-7527; Goate, Alison/0000-0002-0576-2472	NIA NIH HHS [AG-05128] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE AM, 1989, LANCET, V1, P352; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GUO Z, 1990, NUCLEIC ACIDS RES, V18, P4967, DOI 10.1093/nar/18.16.4967-a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEWIS JG, 1990, GENOMICS, V8, P400, DOI 10.1016/0888-7543(90)90300-J; LIM VI, 1974, J MOL BIOL, V88, P857, DOI 10.1016/0022-2836(74)90404-5; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; WARREN AC, 1989, GENOMICS, V4, P579, DOI 10.1016/0888-7543(89)90282-6; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; [No title captured]	30	3714	3899	7	501	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					704	706		10.1038/349704a0	http://dx.doi.org/10.1038/349704a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1671712				2022-12-28	WOS:A1991EY62700050
J	NOLAN, T; DEBELLE, G; OBERKLAID, F; COFFEY, C				NOLAN, T; DEBELLE, G; OBERKLAID, F; COFFEY, C			RANDOMIZED TRIAL OF LAXATIVES IN TREATMENT OF CHILDHOOD ENCOPRESIS	LANCET			English	Article							CHILDREN; BIOFEEDBACK	Primary faecal incontinence (encopresis) in children is usually treated with laxative medication and a behaviour modification programme aimed at promoting regular toileting, but the effectiveness of laxatives has never been adequately investigated. 169 children with encopresis and evidence of stool on plain abdominal radiograph were randomly allocated to receive multimodal (MM) therapy (laxatives plus behaviour modification; n = 83) or behaviour modification alone (BM; n = 86). Mean (SD) follow-up was 55.1 (27.0) weeks and 56.7 (32.0) weeks, respectively. By 12 months' follow-up 42 (51%) of the MM group and 31 (36%) of the BM group (p = 0.079) had achieved remission (at least one 4 week period with no soiling episodes) and 52 (63%) vs 37 (43%) (p = 0.016) had achieved at least partial remission (soiling no more than once a week). MM subjects achieved remission significantly sooner than BM subjects, and the difference in the Kaplan-Meier remission curves was most striking in the first 30 weeks of follow-up (p = 0.012). The patterns of compliance with toileting in the treatment groups were almost identical, although about 1 in 8 children overall did not comply with the sitting programme. After exclusion of the 24 poor compliers, there was no significant difference between BM and MM groups. This study shows a clear advantage overall for the use of laxative medication, although the benefit may not be as great for children who are able to maintain regular toileting.	ROYAL CHILDRENS HOSP,DEPT AMBULATORY PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne			Nolan, Terry/A-2236-2008	Nolan, Terry/0000-0001-6018-3863; Oberklaid, Frank/0000-0002-9024-111X				ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; BARR RG, 1979, CLIN PEDIATR, V18, P674, DOI 10.1177/000992287901801103; BELLMAN M, 1966, ACTA PAEDIATR SC   S, V170, P1; BERG I, 1983, J CHILD PSYCHOL PSYC, V24, P543, DOI 10.1111/j.1469-7610.1983.tb00131.x; DEBELLE G, 1989, AUST PAEDIATR J, V10, P334; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; HALPERN WI, 1977, J AM ACAD CHILD PSY, V16, P478, DOI 10.1016/S0002-7138(09)61602-2; JOLLY H, 1976, P ROY SOC MED, V69, P21, DOI 10.1177/003591577606900112; LAIRD N, 1983, AM STAT, V37, P329, DOI 10.2307/2682785; LEONINGBAUCKE V, 1990, J PEDIATR, V116, P214; LEVINE MD, 1976, PEDIATRICS, V845, P852; LOENINGBAUCKE VA, 1984, PEDIATRICS, V73, P199; LOWERY SP, 1985, J PEDIATR GASTR NUTR, V4, P397, DOI 10.1097/00005176-198506000-00013; PINKERTON P, 1958, ARCH DIS CHILD, V33, P371, DOI 10.1136/adc.33.170.371; RUTTER M, 1970, PSYCHOL MED STUDY CH, P219; SHEPHERD K, 1989, AUST PAEDIATR J, V25, P351; WALD A, 1987, J PEDIATR GASTR NUTR, V6, P554, DOI 10.1097/00005176-198707000-00011; WRIGHT L, 1975, PROF PSYCHOL, V6, P453, DOI 10.1037/0735-7028.6.4.453	19	102	104	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					523	527		10.1016/0140-6736(91)91097-E	http://dx.doi.org/10.1016/0140-6736(91)91097-E			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678797				2022-12-28	WOS:A1991GD00200001
J	KILPI, T; ANTTILA, M; KALLIO, MJT; PELTOLA, H				KILPI, T; ANTTILA, M; KALLIO, MJT; PELTOLA, H			SEVERITY OF CHILDHOOD BACTERIAL-MENINGITIS AND DURATION OF ILLNESS BEFORE DIAGNOSIS	LANCET			English	Article							INFLUENZAE TYPE-B; C-REACTIVE PROTEIN; CEREBROSPINAL-FLUID; PNEUMOCOCCAL MENINGITIS; CHILDREN; INFECTIONS; SEQUELAE; ASSOCIATION; BLOOD	Rapid diagnosis of childhood bacterial meningitis (BM) is generally believed to be essential to avoid poor outcome. To see whether duration of illness before admission to hospital was related to the severity of illness, data from children with BM diagnosed in 18 paediatric hospitals in Finland from 1984 to 1989 were collected prospectively. We divided 286 cases with culture-positive cerebrospinal fluid (CSF) into three groups: BM with a history of up to 24 h (short-history group, n = 141), of more than 24 h and up to 48 h (intermediate-history group, n = 75), and of more than 48 h (long-history group, n = 70). The longer the history, the better the clinical condition of the child. If symptoms or signs of BM lasted 48 h or less, the child did significantly worse, as judged by seven variables, than if the history was longer than 48 h (level of consciousness, p < 0.001; seizures, p < 0.01; CSF protein concentration, p < 0.001; positive CSF gram-stain, p < 0.01; positive blood culture, p < 0.05 in Haemophilus influenzae meningitis, serum C-reactive reactive protein, p < 0.01 between intermediate-history and long-history groups, and urine sodium concentration, p < 0.001 ). The differences were not affected by causative organism, sex, age, or preadmission oral antimicrobial agents. The findings show that if BM follows an insidious pattern of disease, diagnostic delay may be unavoidable, which may have medicolegal implications.	UNIV HELSINKI, CHILDRENS HOSP, STENBACKINKATU 11, SF-00290 HELSINKI 29, FINLAND	University of Helsinki								BAIRD DR, 1976, LANCET, V2, P1344; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; DODGE PR, 1965, NEW ENGL J MED, V272, P1003, DOI 10.1056/NEJM196505132721906; EDWARDS MS, 1981, J PEDIATR-US, V99, P540, DOI 10.1016/S0022-3476(81)80250-8; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; FELDMAN WE, 1982, J PEDIATR-US, V100, P209, DOI 10.1016/S0022-3476(82)80636-7; GARY N, 1989, AM J DIS CHILD, V143, P307, DOI 10.1001/archpedi.1989.02150150061018; JARVIS CW, 1972, CLIN PEDIATR, V11, P201, DOI 10.1177/000992287201100406; KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005; KAPLAN SL, 1978, J PEDIATR-US, V92, P758, DOI 10.1016/S0022-3476(78)80144-9; KAPLAN SL, 1985, BACTERIAL MENINGITIS, P83; KLEIN JO, 1986, PEDIATRICS, V75, P959; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LASCOLEA LJ, 1984, J CLIN MICROBIOL, V19, P187, DOI 10.1128/JCM.19.2.187-190.1984; LAXER RM, 1977, AM J DIS CHILD, V131, P850, DOI 10.1001/archpedi.1977.02120210028004; NIEMOLLER UM, 1989, EUR J CLIN MICROBIOL, V8, P109, DOI 10.1007/BF01963892; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; PELTOLA H, 1988, J PEDIATR-US, V113, P641, DOI 10.1016/S0022-3476(88)80372-X; PELTOLA HO, 1982, LANCET, V1, P980; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; ROMER FK, 1977, LANCET, V2, P345; SMALES ORC, 1979, BMJ-BRIT MED J, V1, P588, DOI 10.1136/bmj.1.6163.588; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; SWARTZ MN, 1965, NEW ENGL J MED, V272, P725, DOI 10.1056/NEJM196504082721406; SYROGIANNOPOULOS GA, 1988, J INFECT DIS, V157, P237, DOI 10.1093/infdis/157.2.237; VALMARI P, 1987, EUR J PEDIATR, V146, P515, DOI 10.1007/BF00441607; VALMARI P, 1987, INFECT MED, V4, P308	27	70	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	1991	338	8764					406	409		10.1016/0140-6736(91)91032-P	http://dx.doi.org/10.1016/0140-6736(91)91032-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678083				2022-12-28	WOS:A1991GB44600004
J	WENGER, JD; PIERCE, R; DEAVER, KA; PLIKAYTIS, BD; FACKLAM, RR; BROOME, CV				WENGER, JD; PIERCE, R; DEAVER, KA; PLIKAYTIS, BD; FACKLAM, RR; BROOME, CV			EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE VACCINE IN UNITED-STATES CHILDREN AGED 18-59 MONTHS	LANCET			English	Article							RISK-FACTORS; BACTERIAL-MENINGITIS; PROTECTIVE EFFICACY; IMMUNOGENICITY; DISEASE; INFANTS; SAFETY; COUNTY	Vaccines prepared from the polyribosylribitol phosphate (PRP) capsule of Haemophilus influenzae b (Hib) have not consistently shown good efficacy in protecting children aged over 18 months from invasive Hib disease. To evaluate the efficacy of conjugate-PRP vaccines in this age-group, and to compare their effect with that of PRP vaccines, a post-marketing case-control study was conducted among 10 400 000 persons. Between Oct 1, 1988, and Feb 28, 1990, 75 patients with Hib disease and 161 control children between 18 and 60 months of age were enrolled. To minimise potentially confounding socioeconomic variables, controls were selected either from among patients' classmates at their day-care centre or from among family acquaintances. 9 of the 75 patients had received the diphtheria toxoid conjugate Hib vaccine more than 2 weeks before onset of illness. After adjusting for age and household crowding, the efficacy of PRP Hib vaccine was 64% (95% Cl = -20, 89) and efficacy of the diphtheria toxoid conjugate Hib vaccine was 74% (95% Cl = 30, 90). The study shows that the protective efficacy of this conjugate vaccine is less than ideal and highlights the need for additional post-licensing studies to confirm and expand understanding of the efficacy of these new products.	CTR DIS CONTROL, RESP DIS BRANCH, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, BIOSTAT & INFORMAT MANAGEMENT BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BERKOWITZ CD, 1987, J PEDIATR-US, V110, P509, DOI 10.1016/S0022-3476(87)80540-1; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; MADORE DV, 1990, PEDIATRICS, V86, P527; MURPHY TV, 1990, CLIN RES, V38, pA183; NOAH ND, 1987, BACTERIAL MENINGITIS, P93; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; REDMOND SR, 1984, JAMA-J AM MED ASSOC, V252, P2581, DOI 10.1001/jama.252.18.2581; SHAPIRO ED, 1989, J INFECT DIS, V160, P1064, DOI 10.1093/infdis/160.6.1064; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; WARD JI, 1988, PEDIATRICS, V81, P887; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	21	40	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 17	1991	338	8764					395	398						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678080				2022-12-28	WOS:A1991GB44600001
J	CRABTREE, JE; TAYLOR, JD; WYATT, JI; HEATLEY, RV; SHALLCROSS, TM; TOMPKINS, DS; RATHBONE, BJ				CRABTREE, JE; TAYLOR, JD; WYATT, JI; HEATLEY, RV; SHALLCROSS, TM; TOMPKINS, DS; RATHBONE, BJ			MUCOSAL IGA RECOGNITION OF HELICOBACTER-PYLORI 120-KDA PROTEIN, PEPTIC-ULCERATION, AND GASTRIC PATHOLOGY	LANCET			English	Article							CAMPYLOBACTER-PYLORIDIS; C-PYLORIDIS; ULCERS; DISEASE	The gastric IgA response to Helicobacter pylori was examined in 100 dyspeptic patients by means of immunoblotting of supernatants from antral biopsy and gastric mononuclear cell cultures. 76 of 78 patients with chronic gastritis, 2 of 8 with reactive gastritis, and 1 of 14 subjects with normal mucosa showed positive responses. Of patients with chronic gastritis, 75%, 83%, 97%, and 76%, respectively, showed responses to the 120 kDa, 90 kDa, 61 kDa, and 31 kDa proteins. None of the 19 patients with chronic gastritis who did not recognise the 120 kDa protein had peptic ulcers, whereas 25 of 57 with positive recognition had peptic ulcers (p < 0.001). Mucosal recognition of the H pylori 120 kDa protein was also positively associated with the activity of gastritis (polymorph infiltration) (p < 0.002) and with the extent of surface degeneration (p < 0.01). These findings suggest that 120-kDa-positive strains of H pylori have pathogenic features associated with active gastritis and peptic ulceration. infection with 120-kDa-negative strains may explain why peptic ulceration develops in only a proportion of subjects infected with H pylori.	BRADFORD ROYAL INFIRM,DEPT MICROBIOL,BRADFORD,ENGLAND; ST JAMES UNIV HOSP,DEPT PATHOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Bradford Royal Infirmary; Saint James's University Hospital	CRABTREE, JE (corresponding author), ST JAMES UNIV HOSP,DEPT MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		Crabtree, Jean E/A-3549-2010					APEL I, 1988, ZBL BAKT-INT J MED M, V268, P271; ARMITAGE P, 1987, STATISTICAL METHODS; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; CRABTREE JE, 1989, GUT, V30, P347, DOI 10.1136/gut.30.3.347; CRABTREE JE, 1991, J CLIN PATHOL, V44, P768, DOI 10.1136/jcp.44.9.768; CRABTREE JE, 1991, DIGEST DIS SCI, V44, P768; CRABTREE JE, 1991, GUT, V44, P768; EIDT S, 1990, HELICOBACTER PYLORI, P228; EMERY AEH, 1976, METHODOLOGY MED GENE, P98; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FIGURA N, 1990, REV ESP ENF DIGES S1, V78, P7; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; HESSEY SJ, 1990, GUT, V31, P134, DOI 10.1136/gut.31.2.134; KALOGEROPOULOS NK, 1988, J CLIN PATHOL, V41, P1093, DOI 10.1136/jcp.41.10.1093; Keenan D.R, 1990, WATSONS BAY LINE SYD; MARSHALL BJ, 1984, LANCET, V1, P1311; MORGAN DR, 1989, CAMPYLOBACTER PYLORI, P115; NEWELL DG, 1987, J GEN MICROBIOL, V133, P163; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; RASKOV H, 1987, SCAND J GASTROENTERO, V22, P568, DOI 10.3109/00365528708991899; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SHALLCROSS TM, 1989, CAMPYLOBACTER PYLORI, P155; SOBALA GM, 1991, LANCET, P94; VONWULFFEN H, 1988, J CLIN PATHOL, V41, P653, DOI 10.1136/jcp.41.6.653; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	27	593	613	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					332	335		10.1016/0140-6736(91)90477-7	http://dx.doi.org/10.1016/0140-6736(91)90477-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677696				2022-12-28	WOS:A1991GA60700002
J	SILVESTRE, L; BOUALI, Y; ULMANN, A				SILVESTRE, L; BOUALI, Y; ULMANN, A			POSTCOITAL CONTRACEPTION - MYTH OR REALITY	LANCET			English	Editorial Material							ETHINYL ESTRADIOL; DL-NORGESTREL; ESTROGENS; DIETHYLSTILBESTROL; INTERCEPTION; COMBINATION; WOMEN		ROUSSEL UCLAF,102 ROUTE NOISY,F-93230 ROMAINVILLE,FRANCE									DIXON GW, 1980, JAMA-J AM MED ASSOC, V244, P1336, DOI 10.1001/jama.244.12.1336; DUBOIS C, 1988, FERTIL STERIL, V50, P593; HASPELS AA, 1976, CONTRACEPTION, V14, P375, DOI 10.1016/S0010-7824(76)80052-2; Haspels DA, 1973, EUR J OBSTET GYNECOL, V3, P113; KUCHERA LK, 1974, CONTRACEPTION, V10, P47, DOI 10.1016/0010-7824(74)90131-0; KUCHERA LK, 1971, J AMER MED ASSOC, V218, P562, DOI 10.1001/jama.218.4.562; PERCIVALSMITH RKL, 1987, CONTRACEPTION, V36, P287, DOI 10.1016/0010-7824(87)90098-9; TIETZE C, 1960, FERTIL STERIL, V11, P485; Tully B, 1983, BRIT J FAM PLANN, V8, P119; VANSANTEN MR, 1985, CONTRACEPTION, V31, P275, DOI 10.1016/0010-7824(85)90097-6; YUZPE AA, 1977, FERTIL STERIL, V28, P932; YUZPE AA, 1982, FERTIL STERIL, V37, P508	12	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1991	338	8758					39	41		10.1016/0140-6736(91)90018-K	http://dx.doi.org/10.1016/0140-6736(91)90018-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV296	1676094				2022-12-28	WOS:A1991FV29600016
J	FIOCCA, R; SOLCIA, E; SANTORO, B				FIOCCA, R; SOLCIA, E; SANTORO, B			DUODENAL-ULCER RELAPSE AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Letter							CAMPYLOBACTER PYLORI		POLICLIN SAN MATTEO,PAVIA,ITALY; GIST BROCADES FARMA,COLOGNO MON,ITALY	IRCCS Fondazione San Matteo	FIOCCA, R (corresponding author), UNIV PAVIA,DEPT HUMAN PATHOL,I-27100 PAVIA,ITALY.		Fiocca, Roberto/K-9705-2016	Fiocca, Roberto/0000-0002-8856-6185				COGHLAN JG, 1987, LANCET, V2, P1109; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P	3	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1614	1614		10.1016/0140-6736(91)93316-2	http://dx.doi.org/10.1016/0140-6736(91)93316-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675746				2022-12-28	WOS:A1991FU55100063
J	ROBERTS, D; OSTRYZNIUK, P; LOEWEN, E; SHANKS, A; WASYLUK, T; PRONGER, L; HASINOFF, I; ROBERTS, E; MCEWEN, TAJ				ROBERTS, D; OSTRYZNIUK, P; LOEWEN, E; SHANKS, A; WASYLUK, T; PRONGER, L; HASINOFF, I; ROBERTS, E; MCEWEN, TAJ			CONTROL OF BLOOD-GAS MEASUREMENTS IN INTENSIVE-CARE UNITS	LANCET			English	Article							ARTERIAL	The frequency of blood gas measurement in two adult intensive-care units was assessed for 7 months before and 12 months after introduction of a protocol of indications for such investigation. Demographic, diagnostic, outcome, and intervention data were collected prospectively. There were no differences in demographic characteristics, severity or type of illness, survival, or frequency of arterial or pulmonary artery catheter use between the two observation periods, but the frequency of blood gas analysis fell by 44% (p < 0.001) after the protocol was introduced.			ROBERTS, D (corresponding author), UNIV MANITOBA,HLTH SCI CTR,DEPT MED,CRIT CARE SECT,ROOM GH-723,820 SHERBROOK ST,WINNIPEG R3A 1R9,MANITOBA,CANADA.							BROWNING J A, 1989, Respiratory Care, V34, P269; CHAPMAN KR, 1983, CHEST, V83, P860; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; HOFFMAN RA, 1989, AM REV RESPIR DIS, V140, P1265, DOI 10.1164/ajrccm/140.5.1265; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARTIN TG, 1982, ANN EMERG MED, V11, P70, DOI 10.1016/S0196-0644(82)80299-0; MIHM FG, 1985, ANESTHESIOLOGY, V62, P85, DOI 10.1097/00000542-198501000-00020; MUAKKASSA FF, 1990, J TRAUMA, V30, P1087, DOI 10.1097/00005373-199009000-00004; PEARSON KS, 1989, ANESTH ANALG, V69, P336; RAFFIN TA, 1986, ANN INTERN MED, V105, P390, DOI 10.7326/0003-4819-105-3-390; SMOLLER BR, 1986, NEW ENGL J MED, V314, P1233, DOI 10.1056/NEJM198605083141906; THORSON SH, 1983, CHEST, V84, P14, DOI 10.1378/chest.84.1.14	12	29	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1580	1582		10.1016/0140-6736(91)93271-A	http://dx.doi.org/10.1016/0140-6736(91)93271-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675718				2022-12-28	WOS:A1991FU55100014
J	PRUSINER, SB				PRUSINER, SB			MOLECULAR-BIOLOGY OF PRION DISEASES	SCIENCE			English	Article							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE-ASSOCIATED FIBRILS; BOVINE SPONGIFORM ENCEPHALOPATHY; ASPARAGINE-LINKED GLYCOSYLATION; NEURO-BLASTOMA CELLS; PROTEIN PRP GENE; INCUBATION PERIOD; SCHEINKER DISEASE; AMYLOID PLAQUES	Prions cause transmissible and genetic neurodegenerative diseases, including scrapie and bovine spongiform encephalopathy of animals and Creutzfeldt-Jakob and Gerstmann-Straussler-Scheinker diseases of humans. Infectious prion particles are composed largely, if not entirely, of an abnormal isoform of the prion protein, which is encoded by a chromosomal gene. A posttranslational process, as yet unidentified, converts the cellular prion protein into an abnormal isoform. Scrapie incubation times, neuropathology, and prion synthesis in transgenic mice are controlled by the prion protein gene. Point mutations in the prion protein genes of animals and humans are genetically linked to development of neurodegeneration. Transgenic mice expressing mutant prion proteins spontaneously develop neurologic dysfunction and spongiform neuropathology. Understanding prion diseases may advance investigations of other neurodegenerative disorders and of the processes by which neurons differentiate, function for decades, and then grow senescent.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PRUSINER, SB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.				NIA NIH HHS [AG02132] Funding Source: Medline; NINDS NIH HHS [NS22786, NS14069] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022786, P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIKEN JM, 1990, J VIROL, V64, P3265, DOI 10.1128/JVI.64.7.3265-3268.1990; AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; AIKEN JM, 1989, J VIROL, V63, P1686, DOI 10.1128/JVI.63.4.1686-1694.1989; AKOWITZ A, 1990, MICROB PATHOGENESIS, V9, P33, DOI 10.1016/0882-4010(90)90038-R; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; ALPER T, 1966, BIOCHEM BIOPH RES CO, V22, P278, DOI 10.1016/0006-291X(66)90478-5; ALPER T, 1978, J GEN VIROL, V41, P503, DOI 10.1099/0022-1317-41-3-503; ALTER M, 1976, SCIENCE, V192, P428, DOI 10.1126/science.192.4238.428-b; BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BEISSON J, 1965, P NATL ACAD SCI USA, V53, P275, DOI 10.1073/pnas.53.2.275; BELLINGERKAWAHARA C, 1987, VIROLOGY, V160, P271, DOI 10.1016/0042-6822(87)90072-9; BELLINGERKAWAHARA C, 1987, J VIROL, V61, P159, DOI 10.1128/JVI.61.1.159-166.1987; BELLINGERKAWAHARA CG, 1988, VIROLOGY, V164, P537, DOI 10.1016/0042-6822(88)90569-7; BENDHEIM PE, 1984, NATURE, V310, P418, DOI 10.1038/310418a0; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BOCKMAN JM, 1987, ANN NEUROL, V21, P589, DOI 10.1002/ana.410210611; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BRAIG HR, 1985, EMBO J, V4, P2309, DOI 10.1002/j.1460-2075.1985.tb03931.x; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHANDLER RL, 1961, LANCET, V1, P1378; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; CHO HJ, 1980, INTERVIROLOGY, V14, P213, DOI 10.1159/000149185; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CZUB M, 1986, J GEN VIROL, V67, P2005, DOI 10.1099/0022-1317-67-9-2005; CZUB M, 1988, J GEN VIROL, V69, P1753, DOI 10.1099/0022-1317-69-7-1753; DEALLER S F, 1990, Food Microbiology (London), V7, P253, DOI 10.1016/0740-0020(90)90032-D; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DICKINSO.AG, 1965, HEREDITY, V20, P485, DOI 10.1038/hdy.1965.64; Dickinson A. G., 1979, Slow transmissible diseases of the nervous system. Volume 1., P367; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; DIEDRICH J, 1987, MICROB PATHOGENESIS, V2, P435, DOI 10.1016/0882-4010(87)90050-7; DIENER TO, 1987, CELL, V49, P719, DOI 10.1016/0092-8674(87)90607-6; DIENER TO, 1982, P NATL ACAD SCI-BIOL, V79, P5220, DOI 10.1073/pnas.79.17.5220; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; DOHURA K, IN PRESS ANN NEUROL; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FARLOW MR, 1989, NEUROLOGY, V39, P1446, DOI 10.1212/WNL.39.11.1446; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; FRANKEL J, 1990, J CELL SCI, V97, P205; GABIZON R, 1990, BIOCHEM J, V266, P1; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GHETTI B, 1989, NEUROLOGY, V39, P1453, DOI 10.1212/WNL.39.11.1453; GIACCONE G, 1990, BRAIN RES, V530, P325, DOI 10.1016/0006-8993(90)91304-Y; GIBBONS RA, 1967, NATURE, V215, P1041, DOI 10.1038/2151041a0; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GIBBS CJ, 1990, BIOMEDICAL ADV AGING, P3; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDFARB LG, 1990, EXP NEUROL, V108, P247, DOI 10.1016/0014-4886(90)90130-K; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P174, DOI 10.1016/0140-6736(90)91693-5; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Gordon W. S., 1946, VET REC, V58, P516; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1989, SOC NEUR ABSTR, V15; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; HECKER R, 1990, 8TH INT C VIR BERL, P284; HERZBERG L, 1974, SCIENCE, V186, P848, DOI 10.1126/science.186.4166.848; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO K, 1989, ANN NEUROL, V26, P137; HSIAO K, UNPUB; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; HUNTER GD, 1969, J COMP PATHOL, V79, P101, DOI 10.1016/0021-9975(69)90033-4; HUNTER GD, 1967, J COMP PATHOL, V77, P301, DOI 10.1016/0021-9975(67)90039-4; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; HUNTER N, 1989, VET REC, V124, P364, DOI 10.1136/vr.124.14.364; JENDROSKA K, IN PRESS NEUROLOGY; KAHANA E, 1974, SCIENCE, V183, P90, DOI 10.1126/science.183.4120.90; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Kimberlin R.H., 1990, SE VIROL, V1, P153; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRETZSCHMAR H, 1991, GENOMICS, V9, P366; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; KRETZSCHMAR HA, 1991, LANCET, V337, P1160, DOI 10.1016/0140-6736(91)92826-N; LAPLANCHE JL, 1990, NUCLEIC ACIDS RES, V18, P6745, DOI 10.1093/nar/18.22.6745; LIAO YCJ, 1986, SCIENCE, V233, P364, DOI 10.1126/science.3014653; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; LOWENSTEIN DH, 1990, MOL CELL BIOL, V10, P1153, DOI 10.1128/MCB.10.3.1153; MANUELIDIS L, 1989, MICROB PATHOGENESIS, V7, P157, DOI 10.1016/0882-4010(89)90051-X; MANUELIDIS L, 1985, P NATL ACAD SCI USA, V82, P4263, DOI 10.1073/pnas.82.12.4263; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MCKINLEY M P, 1990, Journal of Cell Biology, V111, p316A; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCKINLEY MP, 1983, PHOTOCHEM PHOTOBIOL, V37, P539, DOI 10.1111/j.1751-1097.1983.tb04515.x; MCKINLEY MP, 1991, J VIROL, V65, P1440; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MERZ PA, 1987, J VIROL, V61, P42, DOI 10.1128/JVI.61.1.42-49.1987; MERZ PA, 1983, ACTA NEUROPATHOL, V60, P113, DOI 10.1007/BF00685355; MERZ PA, 1984, SCIENCE, V225, P437, DOI 10.1126/science.6377496; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; MILLSON GC, 1971, J COMP PATHOL, V81, P255, DOI 10.1016/0021-9975(71)90100-9; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MURDOCH GH, 1990, J VIROL, V64, P1477, DOI 10.1128/JVI.64.4.1477-1486.1990; NOTCHLIN D, 1989, NEUROLOGY, V39, P910; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1988, CIBA F SYMP, V135, P209; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1989, LANCET, V1, P51; OWEN F, 1990, AM J HUM GENET, V46, P1215; OWEN F, IN PRESS LANCET; PARRY HB, 1962, HEREDITY, V17, P75, DOI 10.1038/hdy.1962.4; PARRY HB, 1983, SCRAPIE DISEASE SHEE; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PATTISON IH, 1966, RES VET SCI, V7, P207; PATTISON IH, 1967, VET REC, V80, P1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1978, BIOCHEMISTRY-US, V17, P4993, DOI 10.1021/bi00616a021; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P6675, DOI 10.1073/pnas.78.11.6675; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; ROBAKIS NK, 1986, BIOCHEM BIOPH RES CO, V140, P758, DOI 10.1016/0006-291X(86)90796-5; ROBERTS GW, 1988, NEUROLOGY, V38, P1534, DOI 10.1212/WNL.38.10.1534; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAFAR J, 1990, P NATL ACAD SCI USA, V87, P6373, DOI 10.1073/pnas.87.16.6373; SAFAR J, 1990, NEUROLOGY, V40, P503, DOI 10.1212/WNL.40.3_Part_1.503; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SCOTT AC, 1990, VET MICROBIOL, V23, P295, DOI 10.1016/0378-1135(90)90160-W; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT M, UNPUB; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SKLAVIADIS T, 1990, ARCH VIROL, V112, P215, DOI 10.1007/BF01323166; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; SOMERVILLE RA, 1989, J GEN VIROL, V70, P25, DOI 10.1099/0022-1317-70-1-25; SPARKES RS, 1986, P NATL ACAD SCI USA, V83, P7358, DOI 10.1073/pnas.83.19.7358; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STAHL N, UNPUB; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TARABOULOS A, 1991, FASEB J, V5, pA1177; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WEITGREFE S, 1985, SCIENCE, V230, P1177; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, IN PRESS NEURON; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WILESMITH JW, 1988, VET REC, V123, P638; WILESMITH JW, IN PRESS CURR TOP MI; WU Y, 1987, NUCLEIC ACIDS RES, V15, P3191, DOI 10.1093/nar/15.7.3191; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	194	1775	1848	13	320	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1515	1522		10.1126/science.1675487	http://dx.doi.org/10.1126/science.1675487			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1675487				2022-12-28	WOS:A1991FR04000038
J	RUPP, RAW; WEINTRAUB, H				RUPP, RAW; WEINTRAUB, H			UBIQUITOUS MYOD TRANSCRIPTION AT THE MIDBLASTULA TRANSITION PRECEDES INDUCTION-DEPENDENT MYOD EXPRESSION IN PRESUMPTIVE MESODERM OF X-LAEVIS	CELL			English	Article							EARLY XENOPUS-EMBRYOS; POLYMERASE CHAIN-REACTION; FIBROBLAST GROWTH-FACTOR; HOMEOBOX GENE XHOX3; MESSENGER-RNA; DNA-BINDING; DEVELOPMENTAL REGULATION; CELLS; FAMILY; EMBRYOGENESIS	We have used a quantitative reverse transcription-polymerase chain reaction assay to detect MyoD mRNA during early embryonic development of Xenopus laevis. We find that during a short period of time following the midblastula transition MyoD becomes transcriptionally activated at a low level ubiquitously throughout the embryo. Restriction of MyoD expression to muscle precursor cells appears as a subsequent event, in which the process of mesoderm induction stabilizes transcription only in the marginal zone of the embryo, the presumptive mesoderm.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	RUPP, RAW (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104, USA.			rupp, ralph/0000-0002-8068-9957				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARVEY RP, 1990, DEVELOPMENT, V108, P669; Holtzer H., 1978, STEM CELLS TISSUE HO, P1; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES EA, 1987, DEVELOPMENT, V101, P557; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LASSAR AB, 1991, TRANSCRIPTIONAL REGU; LEWIN B, 1980, GENE EXPRESSION, V2; MARTINEZSALAS E, 1989, GENE DEV, V3, P1493, DOI 10.1101/gad.3.10.1493; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OCHMAN H, 1988, GENETICS, V120, P621; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1989, DEVELOPMENT, V105, P665; SYMES K, 1987, DEVELOPMENT, V101, P339; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	55	238	238	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					927	937		10.1016/0092-8674(91)90545-A	http://dx.doi.org/10.1016/0092-8674(91)90545-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1675156				2022-12-28	WOS:A1991FR04700004
J	KOURI, YH; SHEPARD, DS; BORRAS, F; SOTOMAYOR, J; GELLERT, GA				KOURI, YH; SHEPARD, DS; BORRAS, F; SOTOMAYOR, J; GELLERT, GA			IMPROVING THE COST-EFFECTIVENESS OF AIDS HEALTH-CARE IN SAN-JUAN, PUERTO-RICO	LANCET			English	Article								In an era of decreasing availability of funds and increasing demand, the AIDS epidemic threatens to overwhelm health-care services in some countries. We describe a comprehensive model for the treatment of AIDS in San Juan, Puerto Rico, and compare it with traditional hospital-based services. Given the existing allocation of funds, the comprehensive model emphasised prevention, education, surveillance, early detection, and outpatient care to reduce hospital care. In 1987, the last year of the traditional system, there were 95 admissions of AIDS patients to hospital, and in 1988, the first year of the comprehensive model, there were 100 admissions. The mean length of stay of AIDS inpatients was reduced from 22.3 days in 1987 to 11.3 days in 1988, a 46.8% reduction (p = 0.001). The annual mean (SE) cost of inpatient care per AIDS patient fell from $15 118 (1699) in 1987 to $3869 (659) in 1988. Savings were used to improve non-hospital services, including outreach, education, emergency and outpatient care, laboratory and epidemiological services, and research, and to introduce an employee incentive scheme. Management strategies that reduce the length of inpatient care and provide less costly treatment alternatives can improve AIDS health care in developing nations.	SAN JUAN CITY DEPT HLTH,SAN JUAN,PR; SAN JUAN AIDS INST,SAN JUAN,PR		KOURI, YH (corresponding author), HARVARD UNIV,HARVARD INST INT DEV,1 ELIOT ST,CAMBRIDGE,MA 02138, USA.							ALAMEDA JL, 1989, 5TH INT C AIDS MONTR, P1049; ARONS RR, 1984, NEW EC HLTH CARE DRG; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; HSIAO WC, 1987, INQUIRY-J HEALTH CAR, V24, P212; KELLY JV, 1989, MED CARE, V27, P1085, DOI 10.1097/00005650-198912000-00001; Scitovsky A A, 1988, Conn Med, V52, P727; SCITOVSKY AA, 1988, AIDS, V2, pS71, DOI 10.1097/00002030-198800001-00011; SHEPARD DS, 1990, EC ASPECTS AIDS HIV, P226; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1989, FED REGISTER, V169, P33155; 1989, MMWR S1S, V36, P3	11	11	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1991	337	8754					1397	1399		10.1016/0140-6736(91)93070-P	http://dx.doi.org/10.1016/0140-6736(91)93070-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP870	1674773				2022-12-28	WOS:A1991FP87000013
J	[Anonymous]				[Anonymous]			DEXFENFLURAMINE	LANCET			English	Editorial Material							OBESE PATIENTS; D-FENFLURAMINE											CAMPBELL DB, 1986, DEV DRUGS MODERN MED, P298; ENZI G, 1988, CLIN NEUROPHARMACOL, V11, pS173; FINER N, 1985, CURR THER RES CLIN E, V38, P847; FINER N, 1987, DIABETES METAB, V13, P598; GARATTINI S, 1988, CLIN NEUROPHARMACOL, V11, pS8; GUYGRAND B, 1989, LANCET, V2, P1142; LEDOUARE.JC, 1966, ARCH INT PHARMACOD T, V161, P206; OROURKE D, 1987, ANN NY ACAD SCI, V499, P329, DOI 10.1111/j.1749-6632.1987.tb36227.x; ROWLAND NE, 1986, PROG NEUROBIOL, V27, P16; SILVERSTONE T, 1986, ADV BIOSCI, V60, P361; TURNER P, 1990, DRUGS, V39, P53, DOI 10.2165/00003495-199000393-00007; WURTMAN J, 1985, INT J EAT DISORDER, V4, P89, DOI 10.1002/1098-108X(198502)4:1<89::AID-EAT2260040110>3.0.CO;2-D; 1991, OBSERV MAGAZINE 0113	13	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1991	337	8753					1315	1316						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674299				2022-12-28	WOS:A1991FP08400006
J	ANAND, P; RUDGE, P; MATHIAS, CJ; SPRINGALL, DR; GHATEI, MA; NAHERNOE, M; SHARIEF, M; MISRA, VP; POLAK, JM; BLOOM, SR; THOMAS, PK				ANAND, P; RUDGE, P; MATHIAS, CJ; SPRINGALL, DR; GHATEI, MA; NAHERNOE, M; SHARIEF, M; MISRA, VP; POLAK, JM; BLOOM, SR; THOMAS, PK			NEW AUTONOMIC AND SENSORY NEUROPATHY WITH LOSS OF ADRENERGIC SYMPATHETIC FUNCTION AND SENSORY NEUROPEPTIDES	LANCET			English	Note							FAILURE; SKIN	A 30-year-old woman with longstanding dizziness was found to have a severe postural fall in blood pressure and a reduced skin axon-reflex flare response. Autonomic tests indicated selective impairment of adrenergic sympathetic function. Plasma noradrenaline, adrenaline, dopamine, and dopamine beta hydroxylase were undetectable. Skin biopsy specimens showed loss of tyrosine hydroxylase and neuropeptide Y (markers of adrenergic sympathetic fibres) and of substance P and calcitonin gene-related peptide (sensory neuropeptides). A sural nerve biopsy specimen showed severe depletion of unmyelinated fibres. The constellation of losses were compatible with nerve growth factor (NGF) deprivation, which was confirmed on assay. This new syndrome may be explained by loss of trophic action of NGF.	HAMMERSMITH HOSP, DEPT HISTOCHEM, LONDON W12 0HS, ENGLAND; HAMMERSMITH HOSP, DEPT MED, LONDON W12 0HS, ENGLAND; TECH UNIV MUNICH, NEUROL KLIN & POLIKLIN, W-8000 MUNICH 2, GERMANY	Imperial College London; Imperial College London; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf	ANAND, P (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROL, QUEEN SQ, LONDON WC1, ENGLAND.							ANAND P, 1988, J NEUROL NEUROSUR PS, V51, P192, DOI 10.1136/jnnp.51.2.192; ANAND P, 1990, NEUROSCI LETT, V118, P61, DOI 10.1016/0304-3940(90)90249-9; GRUNDLER A, 1989, CLIN PHARM, V2, P185; JACOBS JM, 1985, BRAIN, V108, P897, DOI 10.1093/brain/108.4.897; KARANTH SS, 1989, J PATHOL, V157, P15, DOI 10.1002/path.1711570104; LLEWELYN JG, 1986, ACTA NEUROPATHOL, V72, P157, DOI 10.1007/BF00685978; MATHIAS CJ, 1990, Q J MED, V75, P617; NANDA RN, 1977, J NEUROL NEUROSUR PS, V40, P11, DOI 10.1136/jnnp.40.1.11; ROBERTSON D, 1986, NEW ENGL J MED, V314, P1494, DOI 10.1056/NEJM198606053142307; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284	10	23	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1253	1254		10.1016/0140-6736(91)92921-N	http://dx.doi.org/10.1016/0140-6736(91)92921-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674064				2022-12-28	WOS:A1991FN04700005
J	ISBERG, RR				ISBERG, RR			DISCRIMINATION BETWEEN INTRACELLULAR UPTAKE AND SURFACE-ADHESION OF BACTERIAL PATHOGENS	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIBRONECTIN-BINDING PROTEIN; TISSUE-CULTURE CELLS; PSEUDOTUBERCULOSIS INVASIN PROTEIN; BUCCAL EPITHELIAL-CELLS; YERSINIA-ENTEROCOLITICA; RECEPTOR-BINDING; STAPHYLOCOCCUS-AUREUS; PSEUDOMONAS-AERUGINOSA; PLASMA FIBRONECTIN	Most bacterial pathogens initiate infectious diseases by adhering to host cells. Bacterial adherence to nonphagocytic cells usually leads to extracellular colonization; however, many invasive microorganisms enter host cells after binding to the host cell surface. It is unclear why bacterial adherence can result in these two different fates for the microorganism. Analyses of model systems, such as the uptake of enteropathogenic Yersinia into cultured cells, indicate that the particular mammalian cell receptors bound and the nature of the binding event dictate whether the bacterium remains extracellular or enters host cells.			ISBERG, RR (corresponding author), TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA.				NIAID NIH HHS [AI23538, AI29719] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538, R56AI023538, R37AI023538, R01AI029719] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SN, 1983, INFECT IMMUN, V41, P1261, DOI 10.1128/IAI.41.3.1261-1268.1983; BLOCH CA, 1990, INFECT IMMUN, V58, P275, DOI 10.1128/IAI.58.1.275-278.1990; BOCK K, 1985, J BIOL CHEM, V260, P8545; BOVALLIUS A, 1975, CAN J MICROBIOL, V21, P1997, DOI 10.1139/m75-287; BRINTON CC, 1954, BIOCHIM BIOPHYS ACTA, V15, P533, DOI 10.1016/0006-3002(54)90011-6; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CORBI AL, 1988, J BIOL CHEM, V263, P12403; COURTNEY HS, 1986, INFECT IMMUN, V53, P454, DOI 10.1128/IAI.53.3.454-459.1986; COURTNEY HS, 1983, J BACTERIOL, V153, P763, DOI 10.1128/JB.153.2.763-770.1983; DEVENISH JA, 1981, INFECT IMMUN, V32, P48, DOI 10.1128/IAI.32.1.48-55.1981; DOIG P, 1990, INFECT IMMUN, V58, P124, DOI 10.1128/IAI.58.1.124-130.1990; DUGUID JP, 1955, J PATHOL BACTERIOL, V70, P335, DOI 10.1002/path.1700700210; EDEN CS, 1983, PROG ALLERGY, V33, P189; EDEN CS, 1982, INFECTION, V10, P327, DOI 10.1007/BF01640890; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; ESPERSEN F, 1982, INFECT IMMUN, V37, P526, DOI 10.1128/IAI.37.2.526-531.1982; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GEMSKI P, 1980, INFECT IMMUN, V28, P1044; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; GRINNELL F, 1981, J INVEST DERMATOL, V76, P181, DOI 10.1111/1523-1747.ep12525694; GRINNELL F, 1984, J CELL PHYSIOL, V119, P58, DOI 10.1002/jcp.1041190110; GRINNELL F, 1980, J CELL BIOL, V86, P104, DOI 10.1083/jcb.86.1.104; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HEESEMANN J, 1983, J INFECT DIS, V147, P107, DOI 10.1093/infdis/147.1.107; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hook M, 1989, FIBRONECTIN, P295; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IRVIN RT, 1989, INFECT IMMUN, V57, P3720, DOI 10.1128/IAI.57.12.3720-3726.1989; ISBERG RR, 1988, INFECT IMMUN, V56, P2133, DOI 10.1128/IAI.56.8.2133-2138.1988; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; ISBERG RR, 1989, INFECT IMMUN, V57, P1998, DOI 10.1128/IAI.57.7.1998-2005.1989; JACOBS AAC, 1987, J BACTERIOL, V169, P4907, DOI 10.1128/jb.169.11.4907-4911.1987; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KIMURA A, 1990, INFECT IMMUN, V58, P7, DOI 10.1128/IAI.58.1.7-16.1990; KORHONEN TK, 1982, SCAND J INFECT DIS, P26; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; LEE KK, 1989, MOL MICROBIOL, V3, P1493, DOI 10.1111/j.1365-2958.1989.tb00135.x; LEFFLER H, 1982, SCAND J INFECT DIS, P46; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, UNPUB; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDER H, 1988, INFECT IMMUN, V56, P1309, DOI 10.1128/IAI.56.5.1309-1313.1988; LOW D, 1984, INFECT IMMUN, V43, P353, DOI 10.1128/IAI.43.1.353-358.1984; LUND B, 1987, P NATL ACAD SCI USA, V84, P5898, DOI 10.1073/pnas.84.16.5898; LUND B, 1988, MOL MICROBIOL, V2, P255, DOI 10.1111/j.1365-2958.1988.tb00027.x; MANDELL GL, 1973, J CLIN INVEST, V52, P1673, DOI 10.1172/JCI107348; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; MILLER VL, 1989, INFECT IMMUN, V57, P121, DOI 10.1128/IAI.57.1.121-131.1989; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLS JA, 1988, INFECT IMMUN, V56, P2933, DOI 10.1128/IAI.56.11.2933-2941.1988; MOURICOUT M, 1990, INFECT IMMUN, V58, P98, DOI 10.1128/IAI.58.1.98-106.1990; NORMARK S, 1983, INFECT IMMUN, V41, P942, DOI 10.1128/IAI.41.3.942-949.1983; NORMARK S, 1988, A VAN LEEUW J MICROB, V54, P405, DOI 10.1007/BF00461858; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; PAYNE NR, 1987, J EXP MED, V166, P1377, DOI 10.1084/jem.166.5.1377; PETERSON KM, 1983, J EXP MED, V157, P1958, DOI 10.1084/jem.157.6.1958; PIERSON DE, 1990, INFECT IMMUN, V58, P1059, DOI 10.1128/IAI.58.4.1059-1064.1990; PULKKINEN WS, 1991, J BACTERIOL, V173, P86, DOI 10.1128/jb.173.1.86-93.1991; RAJA RH, 1990, INFECT IMMUN, V58, P2593, DOI 10.1128/IAI.58.8.2593-2598.1990; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; SWANSON J, 1983, REV INFECT DIS, V5, pS678; SWITALSKI LM, 1983, INFECT IMMUN, V42, P628, DOI 10.1128/IAI.42.2.628-633.1983; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; THOMAS DD, 1985, J EXP MED, V161, P514, DOI 10.1084/jem.161.3.514; Tuomanen E, 1985, Dev Biol Stand, V61, P197; URISU A, 1986, INFECT IMMUN, V52, P695, DOI 10.1128/IAI.52.3.695-701.1986; VANDEWATER L, 1983, SCIENCE, V220, P201, DOI 10.1126/science.6338594; VANNHIEU GT, UNPUB; VERBRUGH HA, 1981, INFECT IMMUN, V33, P811, DOI 10.1128/IAI.33.3.811-819.1981; WAGNER DD, 1982, EXP CELL RES, V140, P373, DOI 10.1016/0014-4827(82)90126-4; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WRIGHT SD, 1985, REV INFECT DIS, V7, P395; WRIGHT SD, 1986, J EXP MED, V163, P1245, DOI 10.1084/jem.163.5.1245; YOUNG VB, 1990, MOL MICROBIOL, V4, P1119, DOI 10.1111/j.1365-2958.1990.tb00686.x	89	270	279	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1991	252	5008					934	938		10.1126/science.1674624	http://dx.doi.org/10.1126/science.1674624			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1674624				2022-12-28	WOS:A1991FM04000027
J	HELMAN, CG				HELMAN, CG			LIMITS OF BIO-MEDICAL EXPLANATION	LANCET			English	Article							DISORDERS				HELMAN, CG (corresponding author), UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT PRIMARY HLTH CARE, HIGHGATE HILL, LONDON N19 5NF, ENGLAND.							BRABIN L, 1985, AM J EPIDEMIOL, V122, P725, DOI 10.1093/oxfordjournals.aje.a114155; COOPER JE, 1969, AM J PSYCHIAT, V125, P21, DOI 10.1176/ajp.125.10S.21; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; ELLIOTTBINNS CP, 1986, J ROY COLL GEN PRACT, V36, P542; Goffman E, 1961, ENCOUNTERS 2 STUDIES; Good B J, 1977, Cult Med Psychiatry, V1, P25, DOI 10.1007/BF00114809; Greeley A. M., 1978, MED ANTHROPOL, V2, P31, DOI [10.1080/01459740.1978.9986961, DOI 10.1080/01459740.1978.9986961]; Helman C G, 1981, J R Coll Gen Pract, V31, P548; HELMAN C G, 1978, Culture Medicine and Psychiatry, V2, P107, DOI 10.1007/BF00054580; Helman C. G., 1990, CULTURE HLTH ILLNESS; HELMAN CG, 1981, SOC SCI MED-MED ANTH, V15, P521, DOI 10.1016/0160-7987(81)90026-0; HELMAN CG, 1985, CULT MED PSYCHIAT, V9, P1; HELMAN CG, 1988, ANTHR TODAY, V14, P14; Kark S. L., 1981, PRACTICE COMMUNITY O; Keesing R. M., 1981, CULTURAL ANTHR; Kleinman A., 1980, PATIENTS HEALERS CON; Lock M, 1988, BIOMEDICINE EXAMINED; MULL JD, 1988, SOC SCI MED, V27, P53, DOI 10.1016/0277-9536(88)90163-3; OBrien B., 1984, PATTERNS EUROPEAN DI; Payer Lynn, 1989, MED CULTURE; PEACOCK J, 1986, ANTHR LENS; PICHOT P, 1982, PSYCHOL MED, V12, P475, DOI 10.1017/S0033291700055586; SKULTANS V, 1970, MAN, V5, P639, DOI 10.2307/2799108; Stacey M., 1988, SOCIOLOGY HLTH HEALI; VAYDA E, 1982, ARCH SURG-CHICAGO, V117, P846; WEISS MG, 1988, SOC SCI MED, V27, P5, DOI 10.1016/0277-9536(88)90159-1	26	21	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1080	1083		10.1016/0140-6736(91)91720-F	http://dx.doi.org/10.1016/0140-6736(91)91720-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673506				2022-12-28	WOS:A1991FK20400017
J	BRAHAMS, D				BRAHAMS, D			SUDAFED CAPSULES POISONED WITH CYANIDE	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					968	968		10.1016/0140-6736(91)91590-Q	http://dx.doi.org/10.1016/0140-6736(91)91590-Q			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678044				2022-12-28	WOS:A1991FH13100018
J	TREACY, MN; HE, X; ROSENFELD, MG				TREACY, MN; HE, X; ROSENFELD, MG			I-POU - A POU-DOMAIN PROTEIN THAT INHIBITS NEURON-SPECIFIC GENE ACTIVATION	NATURE			English	Article							ACHAETE-SCUTE COMPLEX; DNA-BINDING PROTEINS; DROSOPHILA-MELANOGASTER; TRANSCRIPTION FACTOR; MOLECULAR-GENETICS; GLUCOCORTICOID RECEPTOR; CAENORHABDITIS-ELEGANS; DOPA DECARBOXYLASE; EARLY NEUROGENESIS; SEGMENTATION GENE	A novel, structurally distinct POU-domain protein has been identified that inhibits activation by another positive POU-domain regulator of neuron-specific transcription units. Two Drosophila POU-domain proteins, I-POU and Cf1-a, are coexpressed in overlapping subsets of neurons during development. Because I-POU lacks two basic residues in the N terminus of its homeodomain, it cannot bind DNA, but it does form a stable heterodimeric complex with Cf1-a, preventing Cf1-a from binding to DNA recognition elements and from transactivating the dopa-decarboxylase gene. The inhibition by I-POU provides a potential strategy by which the activation of genes in development is controlled by a homeodomain-containing protein that does not bind DNA.	UNIV CALIF SAN DIEGO, SCH MED, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	TREACY, MN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEALL CJ, 1987, GENE DEV, V1, P510, DOI 10.1101/gad.1.5.510; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNUST E, 1989, BIOESSAYS, V11, P95, DOI 10.1002/bies.950110405; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KONRAD KD, 1987, DEV BIOL, V122, P172, DOI 10.1016/0012-1606(87)90343-5; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOSS J, IN PRESS GENES DEV; WHITE TRF, 1987, ADV GENET, V24, P127; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	64	202	205	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1991	350	6319					577	584		10.1038/350577a0	http://dx.doi.org/10.1038/350577a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1673230				2022-12-28	WOS:A1991FH11200049
J	CONTRERAS, M; BARBARA, JAJ; ANDERSON, CC; RANASINGHE, E; MOORE, C; BRENNAN, MT; HOWELL, DR; ALOYSIUS, S; YARDUMIAN, A				CONTRERAS, M; BARBARA, JAJ; ANDERSON, CC; RANASINGHE, E; MOORE, C; BRENNAN, MT; HOWELL, DR; ALOYSIUS, S; YARDUMIAN, A			LOW INCIDENCE OF NON-A, NON-B POSTTRANSFUSION HEPATITIS IN LONDON CONFIRMED BY HEPATITIS-C VIRUS SEROLOGY	LANCET			English	Article							SERUM ALANINE AMINOTRANSFERASE; BLOOD-TRANSFUSION; DONORS	To see whether the introduction of screening tests for post-transfusion non-A, non-B hepatitis (NANBH) in the UK would be worth while, the incidence of such hepatitis was assessed among patients receiving blood during operations at five hospitals served by the North London Blood Transfusion Centre. 387 patients, who each received blood or blood components from an average of 3 donors were followed up prospectively and blood samples were taken every 2 weeks for 3 months and then each month for a further 3 months. 229 patients also provided a sample at 12 months. All available patient and donor samples were tested for alanine aminotransferase concentrations and for antibody to hepatitis C virus (anti-HCV) by ELISA. Repeatedly anti-HCV positive samples were submitted to supplementary HCV assays. 1 of the 387 patients showed biochemical evidence of acute post-transfusion NANBH after exclusion of non-viral causes. Anti-HCV developed in this patient and the seroconversion was confirmed by recombinant immunoblot assay and polymerase chain reaction. Serum from 1 of the 8 donors whose blood he received was positive for anti-HCV by all three methods. In another patient HCV seroconversion was shown by ELISA but alanine aminotransferase concentrations remained normal throughout follow-up. His samples and those of his 2 donors were negative for HCV by the polymerase chain reaction. A third patient showed rises in alanine aminotransferase compatible with post-transfusion NANBH, but serology and polymerase chain reaction assays for HCV were negative for her samples and those of her donors. Anti-HCV reactivity likely to be false positive (negative by both confirmatory tests and no adverse effects in recipients) was seen in 6 of 1283 donors. This study, despite its being carried out in the part of the UK with the highest frequency of infectious markers in blood donations, has shown a very low incidence of post-transfusion NANBH.			CONTRERAS, M (corresponding author), N LONDON BLOOD TRANSFUS CTR,COLINDALE AVE,LONDON NW9 5BG,ENGLAND.							AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1988, VIRAL HEPATITIS LIVE, P537; ANDERSON CC, 1987, LANCET, V1, P912; BELLOBUONO A, 1990, LANCET, V336, P309, DOI 10.1016/0140-6736(90)91840-7; COLLINS JD, 1983, BRIT MED J, V287, P1422, DOI 10.1136/bmj.287.6403.1422; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MIJOVIC V, 1987, J CLIN PATHOL, V40, P1340, DOI 10.1136/jcp.40.11.1340; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SKIDMORE SJ, 1990, J MED VIROL, V30, P50, DOI 10.1002/jmv.1890300111; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; WATANABE J, 1990, VOX SANG, V59, P86, DOI 10.1111/j.1423-0410.1990.tb05015.x; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WILLIAMS KM, 1986, TRANSFUSION, V26, P552; WOOD GM, 1989, PUBLIC HEALTH, V103, P105, DOI 10.1016/S0033-3506(89)80024-1; 1974, J HYG CAMB, V73, P173; 1988, LANCET, V2, P814	21	67	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					753	757		10.1016/0140-6736(91)91370-A	http://dx.doi.org/10.1016/0140-6736(91)91370-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672391				2022-12-28	WOS:A1991FD88400003
J	WHITTLE, HC; INSKIP, H; HALL, AJ; MENDY, M; DOWNES, R; HOARE, S				WHITTLE, HC; INSKIP, H; HALL, AJ; MENDY, M; DOWNES, R; HOARE, S			VACCINATION AGAINST HEPATITIS-B AND PROTECTION AGAINST CHRONIC VIRAL CARRIAGE IN THE GAMBIA	LANCET			English	Article								358 children in the Gambian villages of Keneba and Manduar, where hepatitis B virus (HBV) infection is endemic, were vaccinated with plasma-derived vaccine against HBV according to one of four regimens and followed for up to 4 years. Two regimens by which vaccine was injected intradermally into children between 0 and 4 years old led to peak geometric mean (95% Cl) concentrations of antibody against HBV surface antigen of 270 (202-358) and 555 (418-748) mIU/ml. The third regimen-intramuscular vaccination of children aged between 0 and 4 years-gave geometric mean peak antibody concentrations of 926 (765-1122) mIU/ml. A fourth regimen was intramuscular vaccination of children between 1 and 9 months old, which gave geometric mean antibody concentrations of 5431 (3903-75 456) mIU/ml. Despite these widely divergent responses and a 89% decay in antibody over the first 2 years, vaccination against HBV was 97% effective in preventing chronic infection. Vaccination was less effective in preventing uncomplicated infection: 5.3% of 264 vaccinees in Keneba and 19.1% of 94 vaccinees in Manduar tested positive for antibody to HBV core antigen. These "breakthrough infections" did not differ in frequency between regimens, and were associated with low initial antibody responses and chronic maternal carriage of HBV.	INT AGCY RES CANC,FAJARA,SENEGAMBIA; DUNN NUTR UNIT,KENEBA,SENEGAMBIA	World Health Organization; International Agency for Research on Cancer (IARC)	WHITTLE, HC (corresponding author), MRC LABS,POB 273,BANJUL,SENEGAMBIA.		Mendy, Maimuna/ABD-5038-2021; Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347; Barin F, 1981, Prog Med Virol, V27, P148; BROWN SE, 1984, LANCET, V2, P184; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; COURSAGET P, 1987, J MED VIROL, V22, P1, DOI 10.1002/jmv.1890220102; COUSAGET P, 1986, LANCET, V2, P1143; GILKS WR, 1989, LANCET, V2, P1273; LOK ASF, 1986, J MED VIROL, V19, P33, DOI 10.1002/jmv.1890190106; MAYANS MV, 1990, LANCET, V336, P1107, DOI 10.1016/0140-6736(90)92580-B; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; WHITTLE HC, 1987, ANN TROP PAEDIATR, V7, P6, DOI 10.1080/02724936.1987.11748464; WHITTLE HC, 1983, LANCET, V1, P1203; WHITTLE HC, 1990, J INFECT DIS, V161, P112; 1989, LANCET, V1, P1057	14	109	114	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					747	750		10.1016/0140-6736(91)91367-4	http://dx.doi.org/10.1016/0140-6736(91)91367-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672389				2022-12-28	WOS:A1991FD88400001
J	HAAHTELA, T; NYBERG, A; LAURIKAINEN, K; SILVASTI, M; VIDGREN, M				HAAHTELA, T; NYBERG, A; LAURIKAINEN, K; SILVASTI, M; VIDGREN, M			DOSE OF INHALED BETA-2-AGONISTS IN ASTHMA	LANCET			English	Letter									ORION PHAMACEUT CO,KUOPIO,FINLAND	Orion Corporation	HAAHTELA, T (corresponding author), HELSINKI UNIV,CENT HOSP,DEPT ALLERG DIS,SF-00250 HELSINKI,FINLAND.							SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P739; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5	3	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					684	684		10.1016/0140-6736(91)92511-Y	http://dx.doi.org/10.1016/0140-6736(91)92511-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1672032				2022-12-28	WOS:A1991FB73000057
J	GARCIA, JF; MCCORMICK, JS				GARCIA, JF; MCCORMICK, JS			BLOOD-PRESSURE CUFFS	LANCET			English	Letter											GARCIA, JF (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH,DUBLIN 2,IRELAND.							PETRIE JC, 1990, BRIT MED J; STOLT M, 1990, AM J HYPERTENS, V3, P697, DOI 10.1093/ajh/3.9.697; 1987, AM NATIONAL STANDARD	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					556	557		10.1016/0140-6736(91)91345-U	http://dx.doi.org/10.1016/0140-6736(91)91345-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671919				2022-12-28	WOS:A1991EZ87400046
J	BRISSONNOEL, A; AZNAR, C; CHUREAU, C; NGUYEN, S; PIERRE, C; BARTOLI, M; BONETE, R; PIALOUX, G; GICQUEL, B; GARRIGUE, G				BRISSONNOEL, A; AZNAR, C; CHUREAU, C; NGUYEN, S; PIERRE, C; BARTOLI, M; BONETE, R; PIALOUX, G; GICQUEL, B; GARRIGUE, G			DIAGNOSIS OF TUBERCULOSIS BY DNA AMPLIFICATION IN CLINICAL-PRACTICE EVALUATION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; IDENTIFICATION; SEQUENCE; COMPLEX; IS6110	Various polymerase chain reaction (PCR) assays have been devised for the rapid identification of mycobacteria in clinical specimens. To assess the value of such assays in routine laboratory work the results obtained by PCR were compared with those obtained by standard microbiological methods for 514 specimens collected for investigation of mycobacterial infection. Specimens were tested for the presence of Mycobacterium tuberculosis complex and atypical mycobacteria in two assays, one based on amplification of the 65 kDa gene and the other on the IS6110 insertion sequence. For the 489 samples that did not contain inhibitors of the amplification reaction PCR findings correlated well with bacteriological and/or clinical data in 476 (97.4%). 6 PCR results turned out to be false negatives, 3 to be false positives and 4 to be mis-identification of strains. Pre-treatment of samples with guanidium thiocyanate reduced the proportion of false-negative results and of samples that contained inhibitors. This study confirms the potential of DNA amplification for early diagnosis of mycobacterial infections.	HOP DESGENETTES,LYONS,FRANCE; HOP LOUIS PASTEUR,PARIS,FRANCE; INST PASTEUR,UNITE GENIE MICROBIOL,CNRS,URA 1300,F-75724 PARIS 15,FRANCE; CTR MED EDOUARD RIST,PARIS,FRANCE; INST PASTEUR,DEV BIOL MED LAB,F-75724 PARIS 15,FRANCE; HOP ST ANNE,TOULON,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BRISSONNOEL, A (corresponding author), DIAGNOST PASTEUR,3 BLVD RAYMOND POINCARE,F-92430 MARNES COQUETTE,FRANCE.							BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRISSONNOEL A, 1989, LANCET, V2, P1069; DEWIT D, 1990, J CLIN MICROBIOL, V28, P2437, DOI 10.1128/JCM.28.11.2437-2441.1990; EISENACH KD, 1990, J INFECT DIS, V161, P977, DOI 10.1093/infdis/161.5.977; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; Maniatis T., 1984, MOL CLONING; MANJUNATH N, 1991, TUBERCLE, V72, P21, DOI 10.1016/0041-3879(91)90020-S; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; PAO CC, 1990, J CLIN MICROBIOL, V28, P1877, DOI 10.1128/JCM.28.9.1877-1880.1990; SHANKAR P, 1990, LANCET, V335, P423, DOI 10.1016/0140-6736(90)90268-A; SJOBRING U, 1990, J CLIN MICROBIOL, V28, P2200; THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668, DOI 10.1128/JCM.28.12.2668-2673.1990; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188	15	273	282	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					364	366		10.1016/0140-6736(91)90492-8	http://dx.doi.org/10.1016/0140-6736(91)90492-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677709				2022-12-28	WOS:A1991GA60700016
J	JOSLYN, G; CARLSON, M; THLIVERIS, A; ALBERTSEN, H; GELBERT, L; SAMOWITZ, W; GRODEN, J; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R				JOSLYN, G; CARLSON, M; THLIVERIS, A; ALBERTSEN, H; GELBERT, L; SAMOWITZ, W; GRODEN, J; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R			IDENTIFICATION OF DELETION MUTATIONS AND 3 NEW GENES AT THE FAMILIAL POLYPOSIS LOCUS	CELL			English	Article							ADENOMATOUS POLYPOSIS; COLORECTAL CANCERS; SHORT ARM; CHROMOSOME-5; LOCALIZATION; FRAGMENTS; RNA	Small (100-260 kb), nested deletions were characterized in DNA from two unrelated patients with familial adenomatous polyposis coli (APC). Three candidate genes located within the deleted region were ascertained and a previous candidate gene, MCC, was shown to be located outside the deleted region. One of the new genes contained sequence identical to SRP19, the gene coding for the 19 kd component of the ribosomal signal recognition particle. The second, provisionally designated DP1 (deleted in polyposis 1), was found to be transcribed in the same orientation as MCC. Two other cDNAs, DP2 and DP3, were found to overlap, forming a single gene, DP2.5, that is transcribed in the same orientation as SRP19.	UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84132; ST MARKS HOSP,SALT LAKE CITY,UT 84117; UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Irvine	JOSLYN, G (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132, USA.		McPherson, John D/D-2633-2017	McPherson, John D/0000-0001-8049-9347; Le Paslier, Denis/0000-0003-4335-9956	NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040886] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHGRI NIH HHS [HG-00320] Funding Source: Medline; NIGMS NIH HHS [R01-GM40886-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; CIRULLO RE, 1983, MOL CELL BIOL, V3, P892, DOI 10.1128/MCB.3.5.892; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GARDINER K, 1986, SOMAT CELL MOLEC GEN, V12, P185, DOI 10.1007/BF01560665; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KINZLER K, 1991, IN PRESS SCIENCE; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P9431, DOI 10.1093/nar/16.20.9431; MANIATIS T, 1982, MOL CLONING LABORATO, P150; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OVERHAUSER J, 1986, AM J HUM GENET, V39, P562; OVERHAUSER J, 1987, NUCLEIC ACIDS RES, V15, P4617, DOI 10.1093/nar/15.11.4617; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	24	685	706	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					601	613		10.1016/0092-8674(81)90022-2	http://dx.doi.org/10.1016/0092-8674(81)90022-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1678319				2022-12-28	WOS:A1991GA94100020
J	BARROS, FC; VAUGHAN, JP; VICTORA, CG; HUTTLY, SRA				BARROS, FC; VAUGHAN, JP; VICTORA, CG; HUTTLY, SRA			EPIDEMIC OF CESAREAN SECTIONS IN BRAZIL	LANCET			English	Article							CESAREAN BIRTH-RATE; PERINATAL-MORTALITY; UNITED-STATES; DELIVERY	Brazil has one of the highest rates of caesarean section in the world. Patterns of caesarean sections were studied in a cohort of 5960 mothers followed from 1982 to 1986 in southern Brazil. Overall, 27.9% were delivered by caesarean section in 1982, this proportion being 30% for nulliparae, 80% for second deliveries when the first was by caesarean, and over 99% for third births when the first two were by caesarean. Socioeconomic status and requests for sterilisation by tubal ligation were important underlying factors. 9.4% of the women were sterilised during a caesarean section (3.7% in the lowest income group and 20.2% in the highest). 31% of women who had had their first child by a caesarean section and who were having a second operative delivery were sterilised. The high rates of caesarean sections and accompanying sterilisations reflect the lack of appropriate reproductive and contraceptive policies in the country.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, MATERNAL & CHILD EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	BARROS, FC (corresponding author), UNIV FED PELOTAS, DEPT SOCIAL MED, CP 464, BR-96001 PELOTAS, RS, BRAZIL.		Victora, Cesar Gomes/Y-2455-2019; Barros, Fernando C/D-4857-2013; Victora, Cesar G/D-4476-2013; Potter, Joseph E/A-3122-2008	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180; 				ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; BARROS F C, 1985, World Health Forum, V6, P322; BARROS FC, 1986, HLTH POLICY PLANNING, V1, P29; BARROS FC, 1990, PAEDIATR PERINAT EP, V4, P267; BARTLEY D, 1983, ONE BIRTH 9 CAESAREA; Berquo E, 1987, Rev Bras Estud Popul, V4, P95; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; FARMAKIDES G, 1987, AM J OBSTET GYNECOL, V156, P565, DOI 10.1016/0002-9378(87)90051-2; FAUNDES A, 1983, FEMINA           NOV, P897; GLEICHER N, 1984, JAMA-J AM MED ASSOC, V252, P3273; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; HUTTLY SRA, 1990, REV SAUDE PUBL, V24, P212, DOI 10.1590/S0034-89101990000300007; JANOWITZ B, 1982, MED CARE, V20, P526, DOI 10.1097/00005650-198205000-00009; JANOWITZ B, 1982, SOC SCI MED, V16, P19, DOI 10.1016/0277-9536(82)90419-1; MOLLOY BG, 1987, BRIT MED J, V294, P1645, DOI 10.1136/bmj.294.6588.1645; NEWCOMBE R, 1977, BRIT MED J, V2, P925, DOI 10.1136/bmj.2.6092.925; NIELSEN TF, 1983, AM J OBSTET GYNECOL, V146, P911, DOI 10.1016/0002-9378(83)90963-8; ODRISCOLL K, 1983, OBSTET GYNECOL, V61, P1; PLACEK PJ, 1983, AM J PUBLIC HEALTH, V73, P861, DOI 10.2105/AJPH.73.8.861; WILLIAMS RL, 1982, NEW ENGL J MED, V306, P207, DOI 10.1056/NEJM198201283060404	21	125	132	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	1991	338	8760					167	169		10.1016/0140-6736(91)90149-J	http://dx.doi.org/10.1016/0140-6736(91)90149-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677075				2022-12-28	WOS:A1991FX42400015
J	WEST, KP; POKHREL, RP; KATZ, J; LECLERQ, SC; KHATRY, SK; SHRESTHA, SR; PRADHAN, EK; TIELSCH, JM; PANDEY, MR; SOMMER, A				WEST, KP; POKHREL, RP; KATZ, J; LECLERQ, SC; KHATRY, SK; SHRESTHA, SR; PRADHAN, EK; TIELSCH, JM; PANDEY, MR; SOMMER, A			EFFICACY OF VITAMIN-A IN REDUCING PRESCHOOL-CHILD MORTALITY IN NEPAL	LANCET			English	Article							MILD VITAMIN; RISK-FACTORS; DEFICIENCY; DIARRHEA; TRIAL; BANGLADESH; MORBIDITY; BLINDNESS; DISEASE; MEASLES	Community trials of the efficacy of vitamin A supplementation in reducing preschool childhood mortality have produced conflicting results. To resolve the question, a randomised, double-masked, placebo-controlled community trial of 28 630 children aged 6-72 months was carried out in rural Nepal, an area representative of the Gangetic flood plain of South Asia. Randomisation was carried out by administrative ward; the vitamin-A-supplemented children received 60 000 retinol equivalents every 4 months and placebo-treated children received identical capsules containing 300 retinol equivalents. After 12 months, the relative risk of death in the vitamin-A-supplemented compared with the control group was 0.70 (95% confidence interval 0.56-0.88), equivalent to a 30% reduction in mortality. The trial, which had been planned to last 2 years, was discontinued. The reduction in mortality was present in both sexes (relative risk for boys 0.77; for girls 0.65), at all ages (range of relative risks 0.83-0.50), and throughout the year (0.76-0.67). The reduction in mortality risk was not affected by acute nutritional status, as measured by arm circumference. Thus, periodic vitamin A delivery in the community can greatly reduce child mortality in developing countries.	NATL SOC PREVENT BLINDNESS,KATMANDU,NEPAL; WHO,PREVENT BLINDNESS PROGRAMME,KATMANDU,NEPAL; MINIST HLTH HIS MAJESTYS GOVT,KATMANDU,NEPAL; JOHNS HOPKINS UNIV,SCH PUBL HLTH,BALTIMORE,MD 21205	World Health Organization; Johns Hopkins University	WEST, KP (corresponding author), JOHNS HOPKINS UNIV,SCH MED,WILMER EYE INST,DANA CTR PREVENT OPHTHALMOL,120 600 N WOLFE ST,BALTIMORE,MD 21205, USA.			Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X	NCRR NIH HHS [RR04060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; BLOEM MW, 1990, AM J EPIDEMIOL, V131, P332, DOI 10.1093/oxfordjournals.aje.a115502; BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375; Fleiss JL, 1981, STAT METHODS RATES P; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KAHN HA, 1989, STATISTICAL METHODS; KATZ J, 1988, INT J EPIDEMIOL, V17, P865, DOI 10.1093/ije/17.4.865; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; MUHILAL PD, 1988, AM J CLIN NUTR, V48, P1271; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; REDDY V, 1991, LANCET, V337, P232; SHAHID NS, 1988, BRIT MED J, V297, P1036, DOI 10.1136/bmj.297.6655.1036; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; SOMMER A, 1983, LANCET, V2, P585; SOMMER A, 1991, LANCET, V337, P925, DOI 10.1016/0140-6736(91)90266-R; STANTON BF, 1986, AM J DIS CHILD, V140, P584, DOI 10.1001/archpedi.1986.02140200094036; STOLL BJ, 1985, J TROP PEDIATRICS, V31, P36, DOI 10.1093/tropej/31.1.36; THURNHAM DI, 1991, LANCET, V337, P232, DOI 10.1016/0140-6736(91)92191-4; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WEST JP, 1984, PERIODIC LARGE DOSES, P25; WEST KP, 1989, ANNU REV NUTR, V9, P63, DOI 10.1146/annurev.nu.09.070189.000431; WEST KP, 1990, 13 P IVACG M KATHM, P11; ZERFAS AJ, 1975, AM J CLIN NUTR, V28, P782, DOI 10.1093/ajcn/28.7.782; 1983, POPULATION STUDIES U, V81; 1988, VITAMIN A SUPPLEMENT	27	284	285	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					67	71		10.1016/0140-6736(91)90070-6	http://dx.doi.org/10.1016/0140-6736(91)90070-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676467	hybrid			2022-12-28	WOS:A1991FW16100001
J	SUMIYA, M; SUPER, M; TABONA, P; LEVINSKY, RJ; ARAI, T; TURNER, MW; SUMMERFIELD, JA				SUMIYA, M; SUPER, M; TABONA, P; LEVINSKY, RJ; ARAI, T; TURNER, MW; SUMMERFIELD, JA			MOLECULAR-BASIS OF OPSONIC DEFECT IN IMMUNODEFICIENT CHILDREN	LANCET			English	Note							MANNOSE-BINDING PROTEINS; HUMAN-SERUM; OPSONIZATION; GENE	Low serum mannose-binding protein (MBP) concentrations are associated with a common opsonic defect. Sequence analysis of the M B P gene in three children with recurrent infections, the opsonic defect and low serum MBP concentrations showed a point mutation at base 230 of exon 1 causing a change of codon 54 from GGC to GAC. The replacement of glycine with an aspartic acid residue disrupts the fifth Gly-Xaa-Yaa repeat in the collagen-like domain of each 32 kD MBP peptide chain and probably prevents the formation of the normal triple helix. Study of sixteen members of the three families showed autosomal dominant coinheritance of the mutation and low serum MBP concentrations.	ST MARYS HOSP,SCH MED,DEPT MED,LONDON W2 1NY,ENGLAND; INST CHILD HLTH,DEPT IMMUNOL,LONDON WC1N 1EH,ENGLAND	Imperial College London; University of London; University College London			Super, Michael/AAW-7952-2021		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; SASTRY K, 1989, J EXP MED, V170, P1175, DOI 10.1084/jem.170.4.1175; SUMMERFIELD JA, 1986, BIOCHIM BIOPHYS ACTA, V883, P197, DOI 10.1016/0304-4165(86)90309-0; SUPER M, 1989, LANCET, V2, P1236; SYKES B, 1989, MOL BIOL MED, V6, P19; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TURNER MW, 1986, IMMUNOLOGY, V58, P111; WILD J, 1983, BIOCHEM J, V210, P167, DOI 10.1042/bj2100167	9	490	521	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1569	1570		10.1016/0140-6736(91)93263-9	http://dx.doi.org/10.1016/0140-6736(91)93263-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675710				2022-12-28	WOS:A1991FU55100006
J	HAHM, JO; LANGDON, RB; SUR, M				HAHM, JO; LANGDON, RB; SUR, M			DISRUPTION OF RETINOGENICULATE AFFERENT SEGREGATION BY ANTAGONISTS TO NMDA RECEPTORS	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; VISUAL-CORTEX; CAT; INFUSION; FERRET; TETRODOTOXIN; PROJECTION; POTENTIALS; CELLS; FIELD	AFFERENT activity has an important role in the formation of connections in the developing mammalian visual system 1,2. But the extent to which the activity of target neurons shapes patterns of afferent termination and synaptic contact is not known. In the ferret's visual pathway, retinal ganglion cell axons from each eye segregate early in development into eye-specific laminae in the lateral geniculate nucleus (LGN)3. The dorsal laminae (termed laminae A and A1) then segregate further into inner and outer sublaminae that retain input from on-centre and off-centre retinal axons, respectively 4,5. Thus, individual retinogeniculate axons form terminal arbors within laminae A and A1 that are restricted to one inner or outer sublamina 6. We report here that blockade of N-methyl-D-aspartate (NMDA) receptors on LGN cells with specific antagonists during the period of sublamina formation prevents retinal afferents from segregating into 'On' and 'Off' sublaminae. Retinogeniculate axons have arbors that are not restricted appropriately, or are restricted in size but inappropriately positioned within the eye-specific laminae. NMDA receptor antagonists may specifically disrupt a mechanism by which LGN neurons detect correlated afferent and target activity 7, and have been shown to reduce retinogeniculate transmission more generally 8-10, causing LGN cells to have markedly reduced levels of activity. These results therefore indicate that the activity of postsynaptic cells can significantly influence the patterning of inputs and the structure of presynaptic afferents during development.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BEAR MF, 1990, J NEUROSCI, V10, P909; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1990, J NEUROSCI, V10, P1197; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; ESGUERRA M, 1990, NEUR ABST, V16, P159; ESGUERRA M, 1989, NEUR ABSTR, V15, P175; FOX K, 1989, J NEUROSCI, V9, P2443; HAHM J, 1988, NEUR ABSTR, V14, P460; HEGGELUND P, 1990, J NEUROPHYSIOL, V63, P1347, DOI 10.1152/jn.1990.63.6.1347; KWON YH, IN PRESS J NEUROPHYS; LANGDON RB, 1990, J NEUROPHYSIOL, V64, P1484, DOI 10.1152/jn.1990.64.5.1484; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P477, DOI 10.1146/annurev.ps.32.020181.002401; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROE AW, 1989, J COMP NEUROL, V288, P208, DOI 10.1002/cne.902880203; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHERMAN SM, 1982, PHYSIOL REV, V62, P740; SILLITO AM, 1990, J NEUROPHYSIOL, V63, P347, DOI 10.1152/jn.1990.63.2.347; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STRYKER MP, 1983, J NEUROSCI, V3, P1943; ZAHS KR, 1985, J COMP NEUROL, V241, P210, DOI 10.1002/cne.902410208	24	225	229	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					568	570		10.1038/351568a0	http://dx.doi.org/10.1038/351568a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1675433				2022-12-28	WOS:A1991FR03400059
J	KARLSSON, L; SURH, CD; SPRENT, J; PETERSON, PA				KARLSSON, L; SURH, CD; SPRENT, J; PETERSON, PA			A NOVEL CLASS-II MHC MOLECULE WITH UNUSUAL TISSUE DISTRIBUTION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELLS; E-ALPHA; ANTIGEN; EXPRESSION; MOUSE; GENES; SELECTION; INVIVO	THE repertoire of mature class II-restricted T cells is generated through a complex process of selection whereby early T cells confront class II molecules in the thymus, especially on epithelial cells 1-3. Expression of class II molecules on such cells is prominent both in the cortex and in the medulla 4,5. We have identified a novel class II molecule, H-2O, which is expressed only in epithelial cells of the thymic medulla and in B cells. The unusual tissue distribution and the nonpolymorphic nature of H-2O suggest that its function is different from that of classical class II molecules.			KARLSSON, L (corresponding author), SCRIPPS CLIN & RES FDN,DEPT IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BEGTOVICH AB, 1990, J IMMUNOL, V144, P1957; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; COWAN EP, 1985, MOL IMMUNOL, V22, P135, DOI 10.1016/S0161-5890(85)80007-9; HIROKAWA K, 1986, THYMUS, V8, P349; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; JONES PP, 1980, SELECTED METHODS CEL, P398; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LAWRANCE SK, 1989, CELL, V58, P583, DOI 10.1016/0092-8674(89)90439-X; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RON Y, 1987, J IMMUNOL, V138, P2848; ROUSE RV, 1979, J IMMUNOL, V122, P2508; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; SPENCER JS, 1989, J EXP MED, V169, P625, DOI 10.1084/jem.169.3.625; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; SYMINGTON FW, 1981, J IMMUNOL, V14, P53; TONELLE C, 1985, EMBO J, V4, P2839; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VU TH, 1989, J IMMUNOL, V142, P2936; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0	23	115	115	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					485	488		10.1038/351485a0	http://dx.doi.org/10.1038/351485a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1675431				2022-12-28	WOS:A1991FP75800057
J	[Anonymous]				[Anonymous]			HOW CUBA CONTROLS HIV-INFECTION	LANCET			English	Editorial Material																		PEREZSTABLE EJ, 1991, AM J PUBLIC HEALTH, V81, P563, DOI 10.2105/AJPH.81.5.563	1	0	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1991	337	8753					1340	1341						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674309				2022-12-28	WOS:A1991FP08400024
J	BRAHAMS, D				BRAHAMS, D			MEDICAL CONFIDENTIALITY AND EXPERT EVIDENCE	LANCET			English	Editorial Material																		HODGKINSON T, 1991, LAW SOC GAZ     0424, P26; HODGKINSON T, 1990, EXPERT EVIDENCE	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1276	1277		10.1016/0140-6736(91)92937-W	http://dx.doi.org/10.1016/0140-6736(91)92937-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674074				2022-12-28	WOS:A1991FN04700016
J	NAYLOR, JA; GREEN, PM; MONTANDON, AJ; RIZZA, CR; GIANNELLI, F				NAYLOR, JA; GREEN, PM; MONTANDON, AJ; RIZZA, CR; GIANNELLI, F			DETECTION OF 3 NOVEL MUTATIONS IN 2 HEMOPHILIA-A PATIENTS BY RAPID SCREENING OF WHOLE ESSENTIAL REGION OF FACTOR-VIII GENE	LANCET			English	Article							DNA; SEQUENCE; CDNA	In an attempt to replace the existing, DNA-based, 50% effective, carrier and prenatal diagnoses of haemophilia A with the 100% successful direct detection of defective genes, a new procedure was developed to screen and identify mutations in all the essential regions of the factor VIII gene (putative promoter, coding sequence, and the cleavage and polyadenylation region). Genomic DNA and cDNA obtained by reverse transcription of the "leaky" mRNA found in peripheral lymphocytes were amplified by means of the polymerase chain reaction to yield a set of eight segments comprising the essential gene sequences. The segments were then screened individually for mutations by the amplification mismatch detection method, which detects and locates any type of sequence discrepancy between the test DNA and the control probe by cleavage of the probe at the site of mismatches. Two haemophilia A patients were studied. The first showed two single-base changes: one (substitution of tryptophan 2229 by cysteine in the C2 domain) is the probable cause of the disease, since it affects a conserved residue of factor VIII(a), whereas the other (the conservative substitution of aspartic acid at position 1241 by glutamic acid) occurs in a domain (B) irrelevant to factor VIII activity. The second patient showed a complete failure of pre-mRNA splicing due to a single-base substitution that changes the obligatory AG acceptor splice site of intron 5 to GG. The method characterises the gene defect in 10 days or less and should lead to the rapid accumulation of information on the molecular biology of haemophilia A.	UNITED MED SCH GUYS & ST THOMASS HOSP, GUYS HOSP, DIV MED & MOLEC GENET, PAEDIAT RES UNIT, LONDON SE1 9RT, ENGLAND; CHURCHILL HOSP, CTR HAEMOPHILIA, OXFORD OX3 7LJ, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford								ABRAMS ES, 1990, GENOMICS, V7, P463, DOI 10.1016/0888-7543(90)90188-Z; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BERG LP, 1990, HUM GENET, V85, P655; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GIANNELLI F, 1990, NUCLEIC ACIDS RES, V18, P4053, DOI 10.1093/nar/18.14.4053; GITSCHIER J, 1985, NATURE, V315, P427, DOI 10.1038/315427a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GITSCHIER J, 1988, BLOOD, V72, P1022; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P3227, DOI 10.1093/nar/18.11.3227; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; GREEN PM, IN PRESS BR J HAEMAT; HIGUCHI M, 1990, GENOMICS, V6, P65, DOI 10.1016/0888-7543(90)90448-4; HOLDING C, 1989, LANCET, V2, P532; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KOGAN S, 1990, P NATL ACAD SCI USA, V87, P2092, DOI 10.1073/pnas.87.6.2092; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEVINSON B, 1990, AM J HUM GENET, V46, P53; MONTANDON AJ, 1990, HUM GENET, V85, P200; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRAYSTMAN MD, 1990, GENOMICS, V6, P293, DOI 10.1016/0888-7543(90)90569-G; TUDDENHAM EGD, MOL BIOL COAGULATION, V2, P849; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	31	110	113	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	1991	337	8742					635	639		10.1016/0140-6736(91)92450-G	http://dx.doi.org/10.1016/0140-6736(91)92450-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671991				2022-12-28	WOS:A1991FB73000003
J	BALDESSARINI, RJ; FRANKENBURG, FR				BALDESSARINI, RJ; FRANKENBURG, FR			DRUG-THERAPY - CLOZAPINE - A NOVEL ANTIPSYCHOTIC AGENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NEUROLEPTIC MALIGNANT SYNDROME; LONG-TERM TREATMENT; SCHIZOPHRENIC-PATIENTS; TARDIVE-DYSKINESIA; INDUCED AGRANULOCYTOSIS; PSYCHOTROPIC-DRUGS; CENTRAL DOPAMINE; RAT STRIATUM; D2 DOPAMINE; HUMAN-BRAIN		HARVARD UNIV, SCH MED, NEUROSCI PROGRAM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MCLEAN DIV, PSYCHOT DISORDERS PROGRAM, BELMONT, MA USA; MASSACHUSETTS GEN HOSP, MCLEAN DIV, PSYCHIAT RES LABS, BELMONT, MA USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	BALDESSARINI, RJ (corresponding author), HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH031154] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-47370, MH-36420, MH-31154] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKENHEIL M, 1989, PSYCHOPHARMACOLOGY, V99, pS32, DOI 10.1007/BF00442556; ANDERMAN B, 1977, EUR J CLIN PHARMACOL, V11, P199, DOI 10.1007/BF00606410; ANDERSEN PH, 1986, J NEUROCHEM, V47, P1822, DOI 10.1111/j.1471-4159.1986.tb13094.x; ANDERSON GD, 1988, BIOL PSYCHIAT, V23, P497, DOI 10.1016/0006-3223(88)90022-4; Angst J., 1971, PHARRNACKOPSYCHIATRI, V4, P192; BAILEY P, 1990, LEPONEX CLOZARIL PRO, P1; BALDESSARINI R J, 1990, P383; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; BALDESSARINI RJ, 1985, CHEMOTHERAPY PSYCHIA, P14; BARTHOLINI G, 1976, J PHARM PHARMACOL, V28, P429, DOI 10.1111/j.2042-7158.1976.tb04648.x; BLACKBURN JR, 1989, PSYCHOPHARMACOLOGY, V98, P453, DOI 10.1007/BF00441941; BLUM A, 1972, PHARMAKOPSYCH NEURO, V5, P155, DOI 10.1055/s-0028-1094343; BONDESSON U, 1988, PSYCHOPHARMACOLOGY, V95, P472; BOYSON SJ, 1988, J PHARMACOL EXP THER, V244, P987; BURKI HR, 1975, PHARMAKOPSYCH NEURO, V8, P115; CAMPBELL A, IN PRESS PSYCHOPHARM; CHAKRABARTI JK, 1989, J MED CHEM, V32, P2573, DOI 10.1021/jm00132a012; CHENG YF, 1988, EUR J CLIN PHARMACOL, V34, P445, DOI 10.1007/BF01046700; CHIODO LA, 1985, J NEUROSCI, V5, P2539; CHIPKIN RE, 1987, EUR J PHARMACOL, V136, P371, DOI 10.1016/0014-2999(87)90310-4; CHIU E, 1976, AUST NZ J PSYCHIAT, V10, P343, DOI 10.3109/00048677609159524; CHOC MG, 1987, PHARMACEUT RES, V4, P402, DOI 10.1023/A:1016434312388; CLAGHORN J, 1987, J CLIN PSYCHOPHARM, V7, P377; COHEN BM, 1979, PSYCHIAT RES, V1, P199, DOI 10.1016/0165-1781(79)90062-3; COHEN BM, 1986, LIFE SCI, V39, P2571, DOI 10.1016/0024-3205(86)90111-6; COHEN BM, 1991, ADV NEUROPSYCHIATRY, V1, P227; COHEN S, 1990, AM J PSYCHIAT, V147, P503; COMPTON DR, 1989, J PHARMACOL EXP THER, V248, P521; COSTALL B, 1976, EUR J PHARMACOL, V40, P9, DOI 10.1016/0014-2999(76)90348-4; COWARD DM, 1989, PSYCHOPHARMACOLOGY, V99, pS6, DOI 10.1007/BF00442552; DAVIS DA, 1990, J MED CHEM, V33, P809, DOI 10.1021/jm00164a053; DEBELLEROCHE JS, 1982, NEUROPHARMACOLOGY, V21, P529, DOI 10.1016/0028-3908(82)90043-0; DEKEYSER J, 1988, NEUROSCI LETT, V91, P142, DOI 10.1016/0304-3940(88)90758-6; EKBLOM B, 1974, CURR THER RES CLIN E, V16, P945; FARDE L, 1989, PSYCHOPHARMACOLOGY, V99, pS28, DOI 10.1007/BF00442555; FISCHER-CORNELSSEN K A, 1976, Psychopharmacology Bulletin, V12, P34; FISCHERC.K, 1974, ARZNEIMITTEL-FORSCH, V24, P1706; FRIEDMAN JH, 1989, NEUROLOGY, V39, P1219, DOI 10.1212/WNL.39.9.1219; FULLER RW, 1986, RES COMMUN CHEM PATH, V54, P23; GELBARD HA, 1989, DEV BRAIN RES, V49, P123, DOI 10.1016/0165-3806(89)90065-5; GELENBERG AJ, 1979, J CLIN PSYCHIAT, V40, P238; GELENBERG AJ, 1989, BIOL THER PSYCHIATRY, V12, P2; Gerbino C, 1980, TARDIVE DYSKINESIA R, P475; GERLACH J, 1978, PSYCHOPHARMACOLOGY, V59, P105, DOI 10.1007/BF00427742; GERLACH J, 1974, ACTA PSYCHIAT SCAND, V50, P410, DOI 10.1111/j.1600-0447.1974.tb09706.x; GERLACH J, 1989, PSYCHOPHARMACOLOGY, V99, pS92, DOI 10.1007/BF00442569; Goldberg ME, 1977, PHARM BIOCH PROPERTI, V1, P1; GOLDSTEIN JM, 1989, J PHARMACOL EXP THER, V249, P673; GROHMANN R, 1989, PSYCHOPHARMACOLOGY, V99, pS101, DOI 10.1007/BF00442571; GUDELSKY GA, 1989, PSYCHOPHARMACOLOGY, V99, pS13, DOI 10.1007/BF00442553; GUDELSKY GA, 1989, PSYCHOPHARMACOLOGY S, V99; GUIRGUIS E, 1977, CURR THER RES CLIN E, V21, P707; HAND TH, 1987, BRAIN RES, V415, P257, DOI 10.1016/0006-8993(87)90207-1; HARING C, 1989, PSYCHOPHARMACOLOGY, V99, pS38, DOI 10.1007/BF00442557; HARTVIG P, 1986, PSYCHOPHARMACOLOGY, V89, P248, DOI 10.1007/BF00310638; HAUSER D, 1978, LIFE SCI, V23, P557; HUNZIKER F, 1963, HELV CHIM ACTA, V46, P2337, DOI 10.1002/hlca.19630460652; HUNZIKER F, 1981, EUR J MED CHEM, V16, P391; ICHIKAWA J, 1990, EUR J PHARMACOL, V176, P371, DOI 10.1016/0014-2999(90)90033-3; IDANPAANHEIKKILA J, 1977, EUR J CLIN PHARMACOL, V11, P193, DOI 10.1007/BF00606409; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KRUPP P, 1989, PSYCHOPHARMACOLOGY, V99, pS118, DOI 10.1007/BF00442575; Kuha S, 1986, NORD PSYCHIATR TIDSK, V40, P225; LIEBERMAN JA, 1988, J CLIN PSYCHIAT, V49, P271; LINDGREN S, 1987, J NEURAL TRANSM, V69, P47, DOI 10.1007/BF01244096; LINDSTROM LH, 1988, ACTA PSYCHIAT SCAND, V77, P524, DOI 10.1111/j.1600-0447.1988.tb05164.x; MAIDMENT NT, 1987, EUR J PHARMACOL, V136, P141, DOI 10.1016/0014-2999(87)90705-9; MANN K, 1987, PHARMACOPSYCHIATRY, V20, P155, DOI 10.1055/s-2007-1017094; MCELROY SL, 1988, USE ANTICONVULSANTS; MELTZER H Y, 1989, Acta Psychiatrica Scandinavica Supplementum, V80, P24; MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238; MULLER T, 1988, LANCET, V2, P1500; NEMEROFF CB, 1991, NEUROPSYCHOPHARMACOL, V4, P27; NIGHTINGALE SL, 1990, JAMA-J AM MED ASSOC, V263, P202; NYLANDER I, 1986, BRAIN RES, V380, P34, DOI 10.1016/0006-8993(86)91426-5; OCONNOR WT, 1989, NEUROSCI LETT, V98, P211, DOI 10.1016/0304-3940(89)90512-0; PAKKENBERG H, 1986, ACTA NEUROL SCAND, V73, P295; PANTELEEVA GP, 1987, CLIN THER, V10, P57; POPE HG, 1986, J NERV MENT DIS, V174, P493, DOI 10.1097/00005053-198608000-00010; POVLSEN UJ, 1985, ACTA PSYCHIAT SCAND, V71, P176, DOI 10.1111/j.1600-0447.1985.tb01268.x; RICHELSON E, 1984, EUR J PHARMACOL, V103, P197, DOI 10.1016/0014-2999(84)90478-3; ROUBICEK J, 1977, BIOL PSYCHIAT, V12, P613; RUPNIAK NMJ, 1985, BIOCHEM PHARMACOL, V34, P2755, DOI 10.1016/0006-2952(85)90577-5; SALETU B, 1987, PHARMACOPSYCHIATRY, V20, P12, DOI 10.1055/s-2007-1017125; SALLER CF, 1989, LIFE SCI, V45, P917, DOI 10.1016/0024-3205(89)90206-3; SAYERS AC, 1976, PSYCHOPHARMACOLOGY, V51, P15, DOI 10.1007/BF00426315; Schmutz J., 1982, CHRONICLES DRUG DISC, V1, P39; SCHOLZ E, 1985, EUR ARCH PSY CLIN N, V235, P60, DOI 10.1007/BF00380972; SCHREMMER C, 1990, PSYCHOPHARMACOLOGY, V100, P399, DOI 10.1007/BF02244614; SCHUSTER P, 1977, CLIN TOXICOL, V10, P437, DOI 10.3109/15563657709046281; SHOPSIN B, 1979, ARCH GEN PSYCHIAT, V36, P657; SIMPSON GM, 1978, PSYCHOPHARMACOLOGY, V56, P75, DOI 10.1007/BF00571412; SINGER K, 1974, J INT MED RES, V2, P433; SMALL JG, 1987, J CLIN PSYCHIAT, V48, P263; THORUP M, 1977, ACTA PSYCHIAT SCAND, V55, P123, DOI 10.1111/j.1600-0447.1977.tb00148.x; VANPRAAG HM, 1976, BRIT J PSYCHIAT, V129, P547, DOI 10.1192/bjp.129.6.547; VANPUTTEN T, 1987, J CLIN PSYCHIAT, V48, P13; Vencovsky E, 1975, Cesk Psychiatr, V71, P21; WALKER JM, 1988, NEUROLOGY, V38, P961, DOI 10.1212/WNL.38.6.961; WINSLOW R, 1990, WALL STREET J   0514, pA18	100	678	682	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					746	754						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1671793				2022-12-28	WOS:A1991FB55600007
J	CARTWRIGHT, KAV; JONES, DM; SMITH, AJ; STUART, JM; KACZMARSKI, EB; PALMER, SR				CARTWRIGHT, KAV; JONES, DM; SMITH, AJ; STUART, JM; KACZMARSKI, EB; PALMER, SR			INFLUENZA-A AND MENINGOCOCCAL DISEASE	LANCET			English	Article							NEISSERIA-MENINGITIDIS; INFECTIONS; EPIDEMIC; VIRUSES	There are several anecdotal accounts of the association between outbreaks of influenza and meningococcal disease. The exceptional increase in the number of cases of meningococcal infection 2 weeks after an influenza A outbreak in England and Wales during November and December, 1989, provided an opportunity to investigate the relation between the two events. Patients with meningococcal disease in December, 1989, were more likely than age-matched controls to show serological evidence of recent influenza A infection (odds ratio 3.9, 95% CI 1.2-13.9). The most likely explanation for the association is immune suppression induced by influenza A, though a lowering of mucosal resistance to meningococcal invasion may also be a factor. Public health authorities should be aware of the association and should be prepared to alert medical practitioners and the public to the increased risk of meningococcal disease when influenza A outbreaks occur.	WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND; ST LUKES HOSP,PUBL HLTH LAB,GUILDFORD,ENGLAND; GLOUCESTER HLTH AUTHOR,DEPT PUBL HLTH MED,GLOUCESTER,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR WELSH UNIT,CARDIFF,WALES		CARTWRIGHT, KAV (corresponding author), GLOUCESTER ROYAL HOSP,PUBL HLTH LAB,GREAT WESTERN RD,GLOUCESTER GL1 3NN,ENGLAND.		Smith, Ashley/GZB-0298-2022					ABRAMSON JS, 1988, PERSPECT BIOL MED, V32, P63; ARTENSTEIN MS, 1967, J AMER MED ASSOC, V201, P1004; BLAKEBROUGH IS, 1982, J INFECT DIS, V146, P626, DOI 10.1093/infdis/146.5.626; CAMBRIDGE G, 1976, INFECT IMMUN, V13, P36, DOI 10.1128/IAI.13.1.36-43.1976; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; DEWALS P, 1983, J INFECTION, V6, P147, DOI 10.1016/S0163-4453(83)92756-1; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FIJEN CAP, 1989, LANCET, V2, P585; Fleming D M, 1985, Health Trends, V17, P13; FLEMING DM, 1990, BRIT J GEN PRACT, V40, P495; FLEMING DM, 1988, J ROY COLL GEN PRACT, V38, P159; KLEINERMAN ES, 1975, LANCET, V2, P1063; LAL H B, 1963, J Indian Med Assoc, V40, P113; LARSON HE, 1976, LANCET, V1, P283, DOI 10.1016/S0140-6736(76)91407-0; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; OXFORD JS, 1990, TOPLEY WILSONS PRINC, V4, P305; PALMER DF, 1975, ADV LABORATORY TECHN, P44; PARKER MT, 1979, J INFECT S2, V1, P9; PETHER JVS, 1982, LANCET, V1, P804; SCHUBIGER G, 1986, SCHWEIZ MED WSCHR, V116, P1172; SWEET C, 1990, TOPLEY WILSONS PRINC, V4, P105; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1990, IMMUNISATION INFECTI, P90; 1988, LANCET, V1, P95	25	159	160	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					554	557		10.1016/0140-6736(91)91112-8	http://dx.doi.org/10.1016/0140-6736(91)91112-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678811				2022-12-28	WOS:A1991GD00200015
J	GOSSEYE, S; VANOBBERGH, L; WEYNAND, B; SCHEIFF, JM; MOULIN, D; DEGOYET, JD; OTTE, JB				GOSSEYE, S; VANOBBERGH, L; WEYNAND, B; SCHEIFF, JM; MOULIN, D; DEGOYET, JD; OTTE, JB			PLATELET AGGREGATES IN SMALL LUNG VESSELS AND DEATH DURING LIVER-TRANSPLANTATION	LANCET			English	Article							SCREEN FILTRATION; BLOOD FILTRATION; PREVENTION; TRANSFUSION	10 children who died suddenly during liver transplantation were found at necropsy to have extensive obstruction of small lung vessels by platelet aggregates. In 7 of these patients pulmonary artery pressure changes before death were consistent with acute obstruction of the pulmonary vascular bed. Platelet aggregates were not strikingly increased in blood vessels in other tissues. No single obvious cause for these unusual histological findings could be identified, although the presence of intravascular catheters, perioperative blood and platelet concentrate transfusions, and cellular debris from the liver forced into the circulation during surgery might predispose to platelet aggregation.	CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT INTENS CARE,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT PAEDIAT SURG,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT ANAESTHESIOL,B-1200 BRUSSELS,BELGIUM; CATHOLIC UNIV LOUVAIN,ST LUC UNIV HOSP,DEPT HAEMATOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc			Goyet, Jean de Ville de/I-6913-2019; Weynand, Birgit/H-9587-2019; Goyet, Jean de Ville de/A-1708-2014	Goyet, Jean de Ville de/0000-0001-7681-6178; Goyet, Jean de Ville de/0000-0001-7681-6178				BARRETT J, 1978, ARCH SURG-CHICAGO, V113, P947; CARLIER M, 1987, TRANSPLANT P, V19, P3333; DERIAN CK, 1990, THROMB RES, V57, P393, DOI 10.1016/0049-3848(90)90255-B; DURTSCHI MB, 1979, AM J SURG, V138, P8, DOI 10.1016/0002-9610(79)90235-6; ELMER O, 1988, AM J SURG, V155, P289, DOI 10.1016/S0002-9610(88)80716-5; GRIFFITH EM, 1977, LANCET, V1, P1010; HARKER LA, 1977, ANN SURG, V186, P594, DOI 10.1097/00000658-197711000-00009; HOAR PF, 1978, ANESTHESIOLOGY, V48, P445, DOI 10.1097/00000542-197806000-00014; MCNAMARA JJ, 1978, SURG GYNECOL OBSTET, V147, P507; MILLER RD, 1990, ANESTHESIA, P1467; MOSELEY RV, 1970, ANN SURG, V171, P329, DOI 10.1097/00000658-197003000-00002; REUL GJ, 1973, ARCH SURG-CHICAGO, V106, P386; REUL GJ, 1974, CHEST, V66, P4, DOI 10.1378/chest.66.1.4; SNYDER EL, 1983, TRANSFUSION, V23, P460, DOI 10.1046/j.1537-2995.1983.23684074264.x	14	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					532	534		10.1016/0140-6736(91)91099-G	http://dx.doi.org/10.1016/0140-6736(91)91099-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678799				2022-12-28	WOS:A1991GD00200003
J	BARKER, JNWN				BARKER, JNWN			THE PATHOPHYSIOLOGY OF PSORIASIS	LANCET			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TUMOR NECROSIS FACTOR; GROWTH FACTOR-ALPHA; EPIDERMAL-CELLS; SKIN; KERATINOCYTES; EXPRESSION; INTERFERON; LESIONS; GAMMA				BARKER, JNWN (corresponding author), GUYS HOSP,DEPT DERMATOL,LONDON SE1 9RT,ENGLAND.			Barker, Jonathan/0000-0002-9030-183X				BAADSGAARD O, 1990, J INVEST DERMATOL, V95, P275, DOI 10.1111/1523-1747.ep12484908; BAADSGAARD O, 1989, J INVEST DERMATOL, V92, P190, DOI 10.1111/1523-1747.ep12276718; BARKER J N W N, 1991, Journal of Dermatological Science, V2, P106, DOI 10.1016/0923-1811(91)90019-T; BARKER JNW, 1991, LANCET, P211; BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; BRAIN SD, 1984, BRIT J PHARMACOL, V83, P313, DOI 10.1111/j.1476-5381.1984.tb10148.x; BRANDRUP F, 1978, ARCH DERMATOL, V114, P874, DOI 10.1001/archderm.114.6.874; COOPER KD, 1990, J IMMUNOL, V144, P4593; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; DUVIC M, 1987, LANCET, V2, P627; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FIERLBECK G, 1990, ARCH DERMATOL, V126, P355; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; GROVES RW, 1991, BRIT J DERMATOL, V124, P117, DOI 10.1111/j.1365-2133.1991.tb00419.x; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; HORN F, 1987, J INVEST DERMATOL, V88, P220, DOI 10.1111/1523-1747.ep12525380; JOHNSON TM, 1985, NEW ENGL J MED, V313, P1415; MACDONALDHULL S, 1989, J INVEST DERMATOL, V92, P782; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PIGUET PF, 1990, AM J PATHOL, V136, P103; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; SCHRODER JM, 1986, J INVEST DERMATOL, V87, P53, DOI 10.1111/1523-1747.ep12523566; SWERLICK RA, 1986, J INVEST DERMATOL, V87, P367, DOI 10.1111/1523-1747.ep12524838; TIILIKAINEN A, 1980, BRIT J DERMATOL, V102, P179, DOI 10.1111/j.1365-2133.1980.tb05690.x; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	27	190	207	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1991	338	8761					227	230		10.1016/0140-6736(91)90357-U	http://dx.doi.org/10.1016/0140-6736(91)90357-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY504	1676787				2022-12-28	WOS:A1991FY50400012
J	HANY, M; RYAN, A; WEBSTER, ADB				HANY, M; RYAN, A; WEBSTER, ADB			LONG-TERM SAFETY AND TOLERABILITY OF INTRAVENOUS IMMUNOGLOBULIN	LANCET			English	Letter											HANY, M (corresponding author), MRC,CLIN RECH INST,IMMUNE DEFICIENCY RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.							Cunningham-Rundles C., 1988, IMMUNODEFICIENCY DIS, P43; Imbach P., 1991, IMMUNOTHERAPY INTRAV; QUINTI K, 1991, PROGR IMMUNODEFICIEN, V3, P150; WILLIAMS PE, 1989, VOX SANG, V57, P15, DOI 10.1111/j.1423-0410.1989.tb04977.x; 1986, CLIN EXP IMMUNOL, V65, P683	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					194	195		10.1016/0140-6736(91)90191-Q	http://dx.doi.org/10.1016/0140-6736(91)90191-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677099				2022-12-28	WOS:A1991FX42400057
J	JONSSON, A; CASSUTO, J; HANSON, B				JONSSON, A; CASSUTO, J; HANSON, B			INHIBITION OF BURN PAIN BY INTRAVENOUS LIGNOCAINE INFUSION	LANCET			English	Note							AMIDE LOCAL-ANESTHETICS; LIDOCAINE	Patients with burns often suffer severe pain, especially during dressing of wounds, but there are no established alternatives to potent opiate analgesics, with their various side-effects. Intravenous lignocaine infusion strikingly reduced self-assessed pain scores in 7 patients during the first 3 days after second-degree burns, without need for supplementary opiate analgesia.	CENT HOSP MOLNDAL,DEPT ANAESTHESIA,S-43180 MOLNDAL,SWEDEN; CENT HOSP MOLNDAL,INTENS CARE UNIT,S-43180 MOLNDAL,SWEDEN; CENT HOSP MOLNDAL,DEPT SURG,S-43180 MOLNDAL,SWEDEN									ARTURSON G, 1990, ENDOCRINOLOGY THERMA, P238; CASSUTO J, 1990, ANESTHESIOLOGY, V72, P302, DOI 10.1097/00000542-199002000-00016; CASSUTO J, 1985, ANESTH ANALG, V64, P971; Choiniere M., 1989, TXB PAIN, P402; Garfield JM, 1987, LOCAL ANESTHETICS, P253; HORROBIN DF, 1977, MED HYPOTHESES, V3, P71, DOI 10.1016/0306-9877(77)90057-3; PECK SL, 1985, J PHARMACOL EXP THER, V235, P418; RIMBACK G, 1988, ANESTHESIOLOGY, V69, P881, DOI 10.1097/00000542-198812000-00013; THOREN P, 1981, ACTA PHYSIOL SCAND, V111, P51, DOI 10.1111/j.1748-1716.1981.tb06704.x; WOOLF CJ, 1985, PAIN, V23, P361, DOI 10.1016/0304-3959(85)90006-5	10	43	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					151	152						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677068				2022-12-28	WOS:A1991FX42400007
J	BRAHAMS, D				BRAHAMS, D			RESPONSIBILITY FOR DEATH ASSOCIATED WITH NEGLIGENT MEDICAL-TREATMENT OF WOUNDS	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					110	110		10.1016/0140-6736(91)90096-8	http://dx.doi.org/10.1016/0140-6736(91)90096-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676436				2022-12-28	WOS:A1991FW16100018
J	POPMA, JJ; TOPOL, EJ				POPMA, JJ; TOPOL, EJ			ADJUNCTS TO THROMBOLYSIS FOR MYOCARDIAL REPERFUSION	ANNALS OF INTERNAL MEDICINE			English	Review						MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; ASPIRIN; HEPARIN; BETA BLOCKING AGENTS	TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; RANDOMIZED CONTROLLED TRIAL; INTRAVENOUS STREPTOKINASE; CORONARY THROMBOLYSIS; PLATELET-AGGREGATION; MULTICENTER TRIAL; MONOCLONAL-ANTIBODY; THROMBIN INHIBITION; CANINE PREPARATION	Objective: To discuss adjunctive pharmacologic agents for acute myocardial infarction, to critique their initial effects in clinical trials, and to review their potential for improving the clinical conditions of patients with acute myocardial infarction. Data Sources: Relevant studies reported from January 1985 to December 1990 were identified through a MEDLINE search of the English-language literature and through a manual search of the bibliographies of all identified articles. Study Selection: Peer-reviewed experimental and clinical studies evaluating the role of pharmacologic adjuncts to thrombolytic therapy in experimental models of coronary occlusion and clinical trials of patients with acute myocardial infarction were selected for review. Data Extraction and Synthesis: The data presented were abstracted by the investigators. Differences with a univariate P value of less than 0.05 were considered to be statistically significant. Conclusions: Current clinical data suggest that adjunctive pharmacologic therapy to thrombolytic agents should include aspirin, at least 160 mg administered as soon as possible after the onset of symptoms; intravenous heparin; and, in selected patients without contraindications, intravenous beta-blockading agents.	CLEVELAND CLIN FDN, DEPT CARDIOL, 1 CLIN CTR, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48109 USA	Cleveland Clinic Foundation; University of Michigan System; University of Michigan								[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1986, LANCET, V2, P57; BABBITT DG, 1989, CIRCULATION, V80, P1388, DOI 10.1161/01.CIR.80.5.1388; BADIMON L, 1988, CIRCULATION S2, V78, P119; BAJAJ AK, 1989, CIRCULATION, V79, P645, DOI 10.1161/01.CIR.79.3.645; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BECKER RC, 1990, AM HEART J, V119, P1254, DOI 10.1016/S0002-8703(05)80172-3; BLEICH SD, 1989, CIRCULATION S2, V80, P113; BRANAGAN JP, 1986, EUR HEART J, V7, P859, DOI 10.1093/oxfordjournals.eurheartj.a061972; BUSH LR, 1989, CIRCULATION, V80, P23; CADROY X, 1989, CIRCULATION S2, V80, P24; CALIFF RM, 1990, CIRCULATION, V82, P1847, DOI 10.1161/01.CIR.82.5.1847; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAO BH, 1989, P NATL ACAD SCI USA, V86, P8050, DOI 10.1073/pnas.86.20.8050; COLLER BS, 1989, CIRCULATION, V80, P1766, DOI 10.1161/01.CIR.80.6.1766; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; COOK JJ, 1989, AM J PHYSIOL, V256, pH1038, DOI 10.1152/ajpheart.1989.256.4.H1038; DATA JL, 1981, CIRCULATION, V64, P4, DOI 10.1161/01.CIR.64.1.4; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; ELLIS SG, 1990, CIRCULATION, V82, P755; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; ENGLER RL, 1986, AM J PHYSIOL, V251, pH314, DOI 10.1152/ajpheart.1986.251.2.H314; ERBEL R, 1988, AM HEART J, V115, P529, DOI 10.1016/0002-8703(88)90800-9; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; GOLD HK, 1988, CIRCULATION, V77, P670, DOI 10.1161/01.CIR.77.3.670; GOLD HK, 1989, CIRCULATION S2, V80, P267; GOLINO P, 1989, CIRCULATION, V79, P911, DOI 10.1161/01.CIR.79.4.911; GOLINO P, 1988, CIRCULATION, V77, P678, DOI 10.1161/01.CIR.77.3.678; GRINES CL, 1989, J AM COLL CARDIOL, V14, P573, DOI 10.1016/0735-1097(89)90095-8; HANSEN JF, 1984, EUR HEART J, V5, P516; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HASKEL EJ, 1989, CIRCULATION, V80, P1775, DOI 10.1161/01.CIR.80.6.1775; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HJALMARSON A, 1983, CIRCULATION, V67, P26; HOGG KJ, 1988, BRIT HEART J, V60, P275; HSAI J, 1990, NEW ENGL J MED, V323, P1433; JANG IK, 1990, CIRCULATION, V81, P219, DOI 10.1161/01.CIR.81.1.219; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; JEREMY RW, 1989, J AM COLL CARDIOL, V13, P304, DOI 10.1016/0735-1097(89)90503-2; KELLY AB, 1988, CIRCULATION S2, V78, P311; KERINS DM, 1989, CLIN RES, V37, pA4; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARAS P, 1986, EUR HEART J, V7, P23; MAURI F, 1987, F ITAL CARDIOL, V1171, P37; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; MELLOT MJ, 1989, CIRCULATION S2, V80, P216; MIRSHAHI M, 1989, BLOOD, V74, P1025; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; NABEL EG, 1989, CIRCULATION S2, V80, P112; NICOLINI FA, 1990, CIRCULATION, V81, P1115, DOI 10.1161/01.CIR.81.3.1115; NORRIS RM, 1988, LANCET, V1, P104; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; OPIE LH, 1989, CIRCULATION, V80, P1049, DOI 10.1161/01.CIR.80.4.1049; OWEN J, 1988, BLOOD, V72, P616; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PENG CF, 1989, AM HEART J, V117, P515, DOI 10.1016/0002-8703(89)90723-0; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PREWITT RM, 1991, IN PRESS CHEST; PULEO PR, 1987, CIRCULATION, V75, P1162, DOI 10.1161/01.CIR.75.6.1162; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; RICHARDSON SG, 1989, BRIT HEART J, V61, P390; ROMSON JL, 1982, CIRCULATION, V66, P1002, DOI 10.1161/01.CIR.66.5.1002; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHAUB RG, 1989, CIRCULATION S2, V80, P217; SHARMA B, 1986, AM J CARDIOL, V58, P1161, DOI 10.1016/0002-9149(86)90375-9; SHARPE N, 1988, LANCET, V1, P255; SHEBUSKI RJ, 1989, THROMB HAEMOSTASIS, V61, P183; SHEBUSKI RJ, 1990, CIRCULATION, V82, P169, DOI 10.1161/01.CIR.82.1.169; SIMPSON PJ, 1990, CIRCULATION, V81, P226, DOI 10.1161/01.CIR.81.1.226; SIRNES PA, 1984, CIRCULATION, V70, P638, DOI 10.1161/01.CIR.70.4.638; SMALLING RW, 1990, J AM COLL CARDIOL, V15, P915, DOI 10.1016/0735-1097(90)90216-C; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; SWEDBERG K, 1987, EUR HEART J, V8, P362, DOI 10.1093/oxfordjournals.eurheartj.a062287; TAVAZZI L, 1989, LANCET, V2, P182; THOMPSON PL, 1988, LANCET, V1, P203; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOPOL EJ, 1989, J AM COLL CARDIOL, V14, P877, DOI 10.1016/0735-1097(89)90458-0; TSCHOPP TB, 1977, THROMB RES, V11, P619, DOI 10.1016/0049-3848(77)90020-2; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1989, LANCET, V1, P1367; WARREN SE, 1988, J AM COLL CARDIOL, V11, P12, DOI 10.1016/0735-1097(88)90159-3; WEISMAN HF, 1988, CIRCULATION, V78, P186, DOI 10.1161/01.CIR.78.1.186; WERNS S, 1989, CIRCULATION S2, V80, P113; WHITE CW, 1987, CIRCULATION, V76, P400; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; YAMAZAKI S, 1986, J AM COLL CARDIOL, V7, P564, DOI 10.1016/S0735-1097(86)80466-1; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446; YUSUF S, 1990, CIRCULATION, V82, P117; 1989, CIRCULATION S2, V80, P114	102	32	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					34	44		10.7326/0003-4819-115-1-34	http://dx.doi.org/10.7326/0003-4819-115-1-34			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1675557				2022-12-28	WOS:A1991FT93700008
J	SYKES, NP				SYKES, NP			ORAL NALOXONE IN OPIOID-ASSOCIATED CONSTIPATION	LANCET			English	Letter									ST GEMMAS HOSPICE,LEEDS,ENGLAND		SYKES, NP (corresponding author), UNIV LEEDS,DEPT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.							BASILISCO G, 1987, DIGEST DIS SCI, V32, P829, DOI 10.1007/BF01296704; FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575; METZ G, 1976, CLIN SCI MOL MED, V50, P237, DOI 10.1042/cs0500237; Twycross RG, 1986, CONTROL ALIMENTARY S, P173	4	48	72	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1475	1475		10.1016/0140-6736(91)93162-3	http://dx.doi.org/10.1016/0140-6736(91)93162-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675336				2022-12-28	WOS:A1991FR06000030
J	BRAHAMS, D				BRAHAMS, D			MEDICINE AND EUROPEAN-COMMISSION PROPOSALS ON SERVICES LIABILITY	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1214	1215		10.1016/0140-6736(91)92876-4	http://dx.doi.org/10.1016/0140-6736(91)92876-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673750				2022-12-28	WOS:A1991FM26100016
J	CLAY, TM; BIDWELL, JL; HOWARD, MR; BRADLEY, BA				CLAY, TM; BIDWELL, JL; HOWARD, MR; BRADLEY, BA			PCR-FINGERPRINTING FOR SELECTION OF HLA MATCHED UNRELATED MARROW DONORS	LANCET			English	Article							DR-BETA-GENES	HLA typing contributes to the delays that occur in the search for HLA-matched unrelated marrow donors, and that result in poor patient survival. A new DNA technique for testing DR match between patient and unrelated marrow donors has been assessed. The technique is based on the formation of heteroduplexes between heterologous amplified coding and non-coding DNA sequences during the final annealing stage of the polymerase chain reaction (PCR), and different HLA-DR/Dw types give unique banding patterns ("PCR fingerprints") on non-denaturing polyacrylamide gel electrophoresis. HLA-DR matching is by visual comparison of patients' with donors' fingerprints. Identity can be confirmed by mixing donor and recipient DNA before the final stage of the PCR ("DNA crossmatching"). In an assessment of the technique in 53 unrelated HLA-A and HLA-B matched patient-donor pairs, 42 pairs gave the same results with PCR fingerprinting as with DNA-RFLP analysis. In the 11 other pairs DR/Dw mismatches were detected by PCR fingerprinting but not by the standard DNA-RFLP method; PCR-SSO typing with selected sequence-specific oligonucleotides (SSO) confirmed that mismatches were due to different subtypes of DR4. PCR fingerprinting might thus accelerate the selection of unrelated marrow donors by simplifying the logistics of the donor search.	UK TRANSPLANT SERV,SOUTHMEAD RD,BRISTOL BS10 5ND,ENGLAND									ANDERSSON G, 1987, J BIOL CHEM, V262, P8748; BACH F, 1964, SCIENCE, V143, P813, DOI 10.1126/science.143.3608.813; BIDWELL J L, 1990, Technique (Philadelphia), V2, P93; BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; BOHME J, 1985, J IMMUNOL, V135, P2149; BRADLEY BA, 1989, BONE MARROW TRANS S2, V4, P44; CLAY TM, 1991, EUR J IMMUNOGENET, V18, P97, DOI 10.1111/j.1744-313X.1991.tb00009.x; HOWARD MR, 1990, TRANSPLANTATION, V49, P547, DOI 10.1097/00007890-199003000-00015; HOWS JM, 1990, BRIT J HAEMATOL, V76, P1, DOI 10.1111/j.1365-2141.1990.tb07828.x; MIDDLETON D, 1988, TRANSPLANT INT, V1, P161, DOI 10.1007/BF00348840; Miller S. A., 1998, NUCLEIC ACIDS RES, V16, P215, DOI DOI 10.1093/NAR/16.3.1215; MYTILINEOS J, 1990, TRANSPLANTATION, V50, P870, DOI 10.1097/00007890-199011000-00024; RUUTU T, 1990, BONE MARROW TRANSPL, V5, P273; SAMBROCK J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; SCHARF SJ, 1988, HUM IMMUNOL, V22, P61, DOI 10.1016/0198-8859(88)90052-3; URYU N, 1990, TISSUE ANTIGENS, V35, P20, DOI 10.1111/j.1399-0039.1990.tb01751.x; WOOD N, 1990, TRANSPLANT P, V22, P2287; WOOD NAP, 1991, EUR J IMMUNOGENET, V18, P147, DOI 10.1111/j.1744-313X.1991.tb00014.x	19	81	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1049	1052		10.1016/0140-6736(91)91704-X	http://dx.doi.org/10.1016/0140-6736(91)91704-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673490				2022-12-28	WOS:A1991FK20400001
J	FUNGLEUNG, WP; SCHILHAM, MW; RAHEMTULLA, A; KUNDIG, TM; VOLLENWEIDER, M; POTTER, J; VANEWIJK, W; MAK, TW				FUNGLEUNG, WP; SCHILHAM, MW; RAHEMTULLA, A; KUNDIG, TM; VOLLENWEIDER, M; POTTER, J; VANEWIJK, W; MAK, TW			CD8 IS NEEDED FOR DEVELOPMENT OF CYTOTOXIC T-CELLS BUT NOT HELPER T-CELLS	CELL			English	Article							MLSA-ENCODED ANTIGENS; STEM-CELLS; HOMOLOGOUS RECOMBINATION; TYROSINE PHOSPHORYLATION; PLURIPOTENTIAL CELLS; SURFACE EXPRESSION; TRANSGENIC MICE; KINASE P56LCK; MOUSE EMBRYOS; LYMPHOCYTES-T	A mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface has been generated by disrupting the Lyt-2 gene using embryonic stem cell technology. In these mice, CD8+ T lymphocytes are not present in peripheral lymphoid organs, but the CD4+ T lymphocyte population seems to be unaltered. Cytotoxic response of T lymphocytes from these mice against alloantigens and viral antigens is dramatically decreased. Proliferative response against alloantigens and in vivo help to B lymphocytes, however, are not affected. These data suggest that CD8 is necessary for the maturation and positive selection of class I MHC restricted cytotoxic T lymphocytes but is not required on any of the intermediate thymocyte populations (CD8+CD4-TcR- or CD4+CD8+TcR(low)) during the development of functional class II MHC restricted helper T cells.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ZURICH, INST PATHOL, CH-8006 ZURICH, SWITZERLAND; ERASMUS UNIV, DEPT IMMUNOL, 3000 DR ROTTERDAM, NETHERLANDS	University of Toronto; University of Toronto; University of Zurich; Erasmus University Rotterdam	FUNGLEUNG, WP (corresponding author), UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA.		Schilham, Marco W./AAL-7223-2021	Schilham, Marco W./0000-0003-4391-6003; Fung-Leung, Wai-Ping/0000-0001-7013-8855				BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BLANC D, 1988, EUR J IMMUNOL, V18, P613, DOI 10.1002/eji.1830180419; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BRADLEY A, 1987, PRODUCTION ANALCHIMA; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HIRSCH MS, 1968, J EXP MED, V128, P121, DOI 10.1084/jem.128.1.121; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOSZINOWSKI U, 1975, EUR J IMMUNOL, V5, P245, DOI 10.1002/eji.1830050405; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LIAW CW, 1986, J IMMUNOL, V137, P1037; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; NAKAUCHI H, 1987, P NATL ACAD SCI USA, V84, P4210, DOI 10.1073/pnas.84.12.4210; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SCHILHAM MW, 1986, J IMMUNOL, V137, P2748; SCHMIDTULLRICH R, 1990, INT IMMUNOL, V2, P247, DOI 10.1093/intimm/2.3.247; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCOTT DW, 1970, CLIN EXP IMMUNOL, V6, P313; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WALKER ID, 1984, IMMUNOL REV, V82, P47, DOI 10.1111/j.1600-065X.1984.tb01117.x; WALKER ID, 1984, EUR J IMMUNOL, V14, P906, DOI 10.1002/eji.1830141009; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	51	482	499	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					443	449		10.1016/0092-8674(91)90462-8	http://dx.doi.org/10.1016/0092-8674(91)90462-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1673361				2022-12-28	WOS:A1991FK18200011
J	SCHATTENKERK, JKME; VANGOOL, T; VANKETEL, RJ; BARTELSMAN, JFWM; KUIKEN, CL; TERPSTRA, WJ; REISS, P				SCHATTENKERK, JKME; VANGOOL, T; VANKETEL, RJ; BARTELSMAN, JFWM; KUIKEN, CL; TERPSTRA, WJ; REISS, P			CLINICAL-SIGNIFICANCE OF SMALL-INTESTINAL MICROSPORIDIOSIS IN HIV-1-INFECTED INDIVIDUALS	LANCET			English	Article							AIDS; PATIENT	To assess the importance of microsporidiosis of the small intestine in the pathogenesis of chronic diarrhoea in HIV-1-infected individuals, duodenal biopsy samples from the following three patient groups were prospectively evaluated for bacterial, viral, and parasitic pathogens by standard methods, and for microsporidia by light microscopy: 55 consecutive HIV-1-antibody-positive subjects with unexplained diarrhoea of at least 3 weeks duration (group A); 38 HIV-1-seropositive subjects without diarrhoea (group B) who consecutively underwent upper gastrointestinal endoscopy for various reasons; and 7 patients without known risk factors for HIV infection with chronic unexplained diarrhoea (group C). In groups A and B most subjects had had previous AIDS-defining opportunistic infections and the median peripheral blood CD4 lymphocyte count was less than 0.1 X 10(9)/l. Microsporidia were detected as the single pathogen in 15 of the group A compared with 1 (in whom diarrhoea subsequently developed) of the group B patients (p = 0.001) and none of the group C patients. With the exception of 4 of the group A patients, no other intestinal pathogens were identified in any of the patients. The median peripheral blood CD4 count was significantly lower in patients with detectable microsporidia than in those without microsporidiosis (0.03 X 10(9)/l vs 0.06 X 10(9)/l; p = 0.03); in all patients with microsporidiosis, the CD4 count was equal to or less than 0.1 X 10(9)/l. 13 patients with microsporidiosis were treated with metronidazole, in 10 of whom treatment led to a substantial improvement or disappearance of diarrhoea within days of starting therapy, but did not result in eradication of the parasite in the 5 patients who underwent repeat biopsy. The findings suggest that small-intestinal microsporidiosis is an important cause of chronic unexplained diarrhoea in HIV-1-infected individuals with pronounced cellular immune deficiency. This infection should therefore be added to the list of AIDS-defining opportunistic infections.	ROYAL TROP INST,DEPT INTERNAL MED,AMSTERDAM,NETHERLANDS; ROYAL TROP INST,NH SWELLENGREBEL LAB TROP HYG,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT MED MICROBIOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,NATL AIDS THERAPY EVALUAT CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam			Van Gool, Tom/H-6750-2012					Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CROWE S, 1990, 6TH INT C AIDS SAN F, V3, P217; CURRY A, 1988, J CLIN PATHOL, V41, P477, DOI 10.1136/jcp.41.4.477-b; DESPORTES I, 1985, J PROTOZOOL, V32, P250; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; OIRENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN J, 1990, 6TH INT C AIDS SAN F, V1, P252; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; Soave R., 1990, Principles and practice of infectious diseases., P2122; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; Van Reken DE, 1990, PRINCIPLES PRACTICE, P398; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; 1990, MMWR, V39, P188; 1987, MMWR S1, V36, pS3	18	158	159	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					895	898		10.1016/0140-6736(91)90215-B	http://dx.doi.org/10.1016/0140-6736(91)90215-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672978				2022-12-28	WOS:A1991FG04800013
J	HOPKINS, KD; JONES, RH; SONKSEN, PH				HOPKINS, KD; JONES, RH; SONKSEN, PH			THE ACROMEGALIC ROSARY	LANCET			English	Letter							INSULIN				HOPKINS, KD (corresponding author), ST THOMAS HOSP,DEPT MED,LONDON SE1 7EH,ENGLAND.							HODGKINSON SC, 1989, J ENDOCRINOL, V120, P429, DOI 10.1677/joe.0.1200429; HOLLY JMP, 1988, CLIN ENDOCRINOL, V29, P667, DOI 10.1111/j.1365-2265.1988.tb03715.x; IBBERTSON, 1991, LANCET, V337, P154; ROELFSEMA F, 1985, CLIN ENDOCRINOL, V22, P531, DOI 10.1111/j.1365-2265.1985.tb00153.x; TAYLOR AM, 1990, CLIN ENDOCRINOL, V32, P229, DOI 10.1111/j.1365-2265.1990.tb00859.x	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					860	861		10.1016/0140-6736(91)92576-N	http://dx.doi.org/10.1016/0140-6736(91)92576-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672956				2022-12-28	WOS:A1991FF22800058
J	PATRICK, AW; BODMER, CW; TIESZEN, KL; WHITE, MC; WILLIAMS, G				PATRICK, AW; BODMER, CW; TIESZEN, KL; WHITE, MC; WILLIAMS, G			HUMAN INSULIN AND AWARENESS OF ACUTE HYPOGLYCEMIC SYMPTOMS IN INSULIN-DEPENDENT DIABETES	LANCET			English	Article							PORCINE INSULIN; INDUCED HYPOGLYCEMIA; RECOMBINANT DNA; PORK INSULIN; COUNTERREGULATORY RESPONSES; MELLITUS; THERAPY	Some insulin-dependent diabetic patients who have clear symptoms of hypoglycaemia during animal insulin treatment have reported loss of these symptoms when human insulin preparations are introduced. A survey of Mersey Region, UK, identified eleven patients whose awareness of hypoglycaemia was lost after introduction of human insulin but returned with animal insulin treatment; seven took part in the study. Acute hypoglycaemia was induced in these patients on two occasions by intravenous infusion of porcine or human soluble insulin (2.5 mU. kg-1, min-1) in random order. There was no significant difference between procine and soluble insulin in the plasma glucose profile; mean (SEM) plasma glucose fell from 7.1 (0.4) mmol/l to a nadir of 1.5 (0.1) mmol/l with porcine insulin and from 7.1 (0.5) mmol/l to 1.6 (0.2) mmol/l with human insulin. An acute autonomic reaction occurred in all seven patients, at a similar plasma glucose concentration (1.9 [0.1] mmol/l with procine insulin; 2.0 [0.2] mmol/l with human insulin). There were no significant differences in the frequency of symptoms or signs of hypoglycaemia between the two insulin species, nor any consistent differences in plasma glucagon, cortisol, growth hormone, adrenaline, or noradrenaline responses to hypoglycaemia. Symptomatic and hormonal responses to acute hypoglycaemia induced by porcine and human soluble insulins therefore seem to be almost indistinguishable, even in patients carefully selected for their apparent loss of hypoglycaemia awareness with human insulin.	HOPE HOSP,DEPT CHEM PATHOL,SALFORD M6 8HD,LANCS,ENGLAND									AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BOULOUX P, 1985, ANN CLIN BIOCHEM, V22, P194, DOI 10.1177/000456328502200217; FISHER BM, 1988, DIABETES RES CLIN EX, V8, P1; GALE EAM, 1989, LANCET, V2, P1264; GALLOWAY JA, 1981, DIABETES CARE, V4, P183, DOI 10.2337/diacare.4.2.183; HANNING I, 1985, DIABETOLOGIA, V28, P831, DOI 10.1007/BF00291073; HEINE RJ, 1989, LANCET, V2, P946; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; HOME PD, 1982, CLIN ENDOCRINOL META, V11, P453, DOI 10.1016/S0300-595X(82)80024-8; KERN W, 1990, DIABETES, V39, P1091, DOI 10.2337/diabetes.39.9.1091; KERR D, 1989, LANCET, V2, P836; LAGER I, 1986, DIABETIC MED, V3, P322, DOI 10.1111/j.1464-5491.1986.tb00772.x; Lawrence RD, 1941, LANCET, V2, P602; OWENS DR, 1984, DIABETOLOGIA, V26, P261; OWENS DR, 1988, DIABETES RES CLIN EX, V8, P17; PICKUP J, 1989, BRIT MED J, V299, P991, DOI 10.1136/bmj.299.6706.991; PICKUP JC, 1982, DIABETES CARE, V5, P29, DOI 10.2337/diacare.5.2.S29; REDMOND S, 1988, BALANCE          AUG, P66; SCHLUTER KJ, 1982, DIABETES CARE, V5, P78, DOI 10.2337/diacare.5.2.S78; SIMONSON DC, 1985, ANN INTERN MED, V103, P184, DOI 10.7326/0003-4819-103-2-184; SJOBOM NC, 1990, DIABETIC MED, V7, P775; SKYLER JS, 1982, DIABETES CARE, V5, P181, DOI 10.2337/diacare.5.2.S181; SUSSMAN KE, 1963, DIABETES, V12, P38, DOI 10.2337/diab.12.1.38; TEUSCHER A, 1987, LANCET, V2, P382	27	38	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					528	532		10.1016/0140-6736(91)91098-F	http://dx.doi.org/10.1016/0140-6736(91)91098-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678798				2022-12-28	WOS:A1991GD00200002
J	LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST				LANG, DM; ALPERN, MB; VISINTAINER, PF; SMITH, ST			INCREASED RISK FOR ANAPHYLACTOID REACTION FROM CONTRAST-MEDIA IN PATIENTS ON BETA-ADRENERGIC BLOCKERS OR WITH ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE REACTIONS; BLOCKADE; IMMUNOTHERAPY; ANTAGONISTS; HISTAMINE; HYPERSENSITIVITY; EPINEPHRINE; EXERCISE; RELEASE; AGENTS	Objective: To determine whether greater risk for anaphylactoid reaction from intravenous urographic contrast media exists in patients receiving beta-adrenergic blockers or in asthmatic patients. Design: Case-control study. Setting: Tertiary care, referral-based medical center. Patients: Of 28 978 intravenous urographic contrast media procedures done from July 1987 to June 1988, 49 patients experienced moderate to severe anaphylactoid reaction. Medical records from these 49 reactors were compared with those from a control group matched for gender, age, and date and type of contrast study who received intravenous urographic contrast media without adverse reaction. Main Results: Patients exposed to beta-adrenergic blockers or with asthma comprised 39% (19 of 49) of reactors, compared to 16% (13 of 83) of matched controls (odds ratio, 3.43; 95% Cl, 1.45 to 8.15; P = 0.005). Exposure to beta-blockers was 27% among reactors and 12% in matched controls (odds ratio, 2.67; Cl, 1.01 to 7.05; P = 0.036). Asthma was found in 12% of reactors and 4% of controls; after correction for beta-blocker use, asthma was also associated with increased risk for anaphylactoid reaction (odds ratio, 4.54; Cl, 1.03 to 20.05; P = 0.046). Compared with nonasthmatic patients not taking beta-blockers, asthmatic patients were at greater risk for anaphylactoid reaction with bronchospasm (P = 0.02). Five of 13 reactors receiving beta-blockers became hypotensive, and three needed hospitalization. Compared with nonasthmatic patients not taking beta-blockers, patients exposed to beta-blocking drugs were almost nine times (odds ratio, 8.7; Cl, 0.81 to 93.5; P = 0.075) more likely to be hospitalized after an anaphylactoid reaction. Conclusion: Increased risk for moderate to severe anaphylactoid reaction from intravenous urographic contrast media exists in patients receiving beta-adrenergic blockers or with asthma. These patients are appropriate target populations for efforts to reduce risk before intravenous urographic contrast media are administered.	HENRY FORD HOSP, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital				Visintainer, Paul/0000-0002-2491-1242				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; AWAI LE, 1984, ANN ALLERGY, V53, P48; BARRETTBEE K, 1978, BIOCHEM BIOPH RES CO, V84, P998, DOI 10.1016/0006-291X(78)91682-0; BENITAH E, 1986, THERAPIE, V41, P139; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CAPELLIER G, 1989, PRESSE MED, V18, P181; CORNAILLE G, 1985, PRESSE MED, V14, P790; DAVIS PB, 1986, J ALLERGY CLIN IMMUN, V77, P667, DOI 10.1016/0091-6749(86)90406-9; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FRISHMAN WH, 1988, MED CLIN N AM, V72, P37, DOI 10.1016/S0025-7125(16)30786-6; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V80, P698, DOI 10.1016/0091-6749(87)90290-9; HAAS F, 1988, AM REV RESPIR DIS, V137, P833, DOI 10.1164/ajrccm/137.4.833; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HIATT WR, 1985, CLIN PHARMACOL THER, V37, P2, DOI 10.1038/clpt.1985.2; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; JACOBSON PD, 1988, JAMA-J AM MED ASSOC, V260, P1586, DOI 10.1001/jama.260.11.1586; KALIMO K, 1980, ANN ALLERGY, V45, P253; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1984, INVEST RADIOL, V19, P116, DOI 10.1097/00004424-198403000-00007; KAPLAN AP, 1989, J ALLERGY CLIN IMMUN, V84, P129, DOI 10.1016/0091-6749(89)90186-3; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KING BF, 1989, MAYO CLIN PROC, V64, P976, DOI 10.1016/S0025-6196(12)61226-9; KLEINBAUM DG, 1982, LIFETIME LEARNING PU, V53, P379; LARSSON K, 1985, EUR J RESPIR DIS, V66, P1; LASSER EC, 1977, RADIOLOGY, V125, P1; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; LIEBERMAN P, 1986, CLIN REV ALLERG, V4, P229; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; ROSENFIELD AT, 1977, INVEST RADIOL, V12, P295, DOI 10.1097/00004424-197705000-00016; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; SULLIVAN TJ, 1988, CURRENT THERAPY ALLE, V3, P91; SVENTIVANYI A, 1968, J ALLERGY, V42, P203; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929; TUNG R, 1982, J IMMUNOL, V128, P2067; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P823, DOI 10.1056/NEJM198503283121304; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65; 1988, FDA DRUG B       NOV, P30	53	129	134	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					270	276		10.7326/0003-4819-115-4-270	http://dx.doi.org/10.7326/0003-4819-115-4-270			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1677239				2022-12-28	WOS:A1991GA76400005
J	SAMUEL, BU; CHERIAN, T; SRIDHARAN, G; MUKUNDAN, P; JOHN, TJ				SAMUEL, BU; CHERIAN, T; SRIDHARAN, G; MUKUNDAN, P; JOHN, TJ			IMMUNE-RESPONSE TO INTRADERMALLY INJECTED INACTIVATED POLIOVIRUS VACCINE	LANCET			English	Note							POLIOMYELITIS; IMMUNIZATION	Immune response to intradermal inoculation of a fractional dose of inactivated poliovirus vaccine (IPV) was measured in 8 adults and 10 children who were previously immune. A striking 4-fold to 1024-fold antibody booster response to all 3 poliovirus serotypes was found in 15 subjects and a similar response to 2 poliovirus serotypes occurred in the other 3 children. Induration and erythema of 3 mm diameter or above, indicative of a cell-mediated immune response, was seen in 12 subjects. Intradermal inoculation of IPV may be a useful technique for secondary immunisation programmes against polio and its use for primary immunisation merits investigation.	CHRISTIAN MED COLL & HOSP,INDIAN COUNCIL MED RES,CTR VIROL,VELLORE 632004,TAMIL NADU,INDIA	Christian Medical College & Hospital (CMCH) Vellore; Indian Council of Medical Research (ICMR)								BEALE AJ, 1990, LANCET, V335, P839, DOI 10.1016/0140-6736(90)90945-2; MCBEAN AM, 1987, PEDIATR INFECT DIS J, V6, P881, DOI 10.1097/00006454-198710000-00001; SULEKHA C, 1990, INT J EPIDEMIOL, V19, P177, DOI 10.1093/ije/19.1.177; TURK JL, 1980, RES MONOGRAPHS IMMUN, V1, P45	4	38	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					343	344		10.1016/0140-6736(91)90480-D	http://dx.doi.org/10.1016/0140-6736(91)90480-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677699				2022-12-28	WOS:A1991GA60700005
J	YARCHOAN, R; VENZON, DJ; PLUDA, JM; LIETZAU, J; WYVILL, KM; TSIATIS, AA; STEINBERG, SM; BRODER, S				YARCHOAN, R; VENZON, DJ; PLUDA, JM; LIETZAU, J; WYVILL, KM; TSIATIS, AA; STEINBERG, SM; BRODER, S			CD4 COUNT AND THE RISK FOR DEATH IN PATIENTS INFECTED WITH HIV RECEIVING ANTIRETROVIRAL THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; AIDS-RELATED COMPLEX; KAPOSIS SARCOMA; HOMOSEXUAL MEN; MONONUCLEAR PHAGOCYTES; NATURAL-HISTORY; ZIDOVUDINE AZT; HTLV-III; PREDICTORS	Objective: To investigate the relation between CD4 count and the immediate hazard of dying in patients receiving zidovudine (azidothymidine [AZT])-based antiretroviral therapy. Setting: A research hospital that recruits patients from the entire United States. Design: Retrospective analysis of a cohort of patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex participating in long-term zidovudine-based antiretroviral protocols. Patients: Fifty-five patients with human immunodeficiency virus (HIV) infection and either AIDS or severe AIDS-related complex who were followed for as many as 4 years while they received antiretroviral therapy. Measurements: CD4 counts were measured. Main Results: Ten patients are known to be alive and 1 was lost to follow-up. Of the 44 patients who are known to have died, the CD4 range was known within 6 months of death in 41. All but 1 of these 41 assessable deaths occurred in patients whose CD4 counts were known to have fallen below 50 CD4 cells/mm3 (p < 10(-10)). The hazard of dying in the cohort ranged from 0 deaths/patient-month (95% Cl, 0 to 0.008 deaths/patient-month) in patients with 200 or more CD4 cells/mm3 to 0.07 deaths/patient-month (Cl, 0.050 to 0.094 deaths/patient-month) in patients with fewer than 50 CD4 cells/mm3. For the patients who died and whose cases were assessable, the mean of the last three CD4 counts obtained before death was 7.7 CD4 cells/mm3 (Cl, 0.9 to 63.3 cells/mm3). The median survival of patients once their CD4 counts fell below 50 CD4 cells/mm3 was 12.1 months (Cl, 7.2 to 19.4 months). Conclusions: In a carefully followed cohort treated with zidovudine-based antiretroviral therapy, nearly all deaths occurred in patients with fewer than 50 CD4 cells/mm3. These findings may have implications in the monitoring of patients with AIDS and in the use of CD4 count as a clinical trials end point for the antiretroviral therapy of HIV infection.	HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	YARCHOAN, R (corresponding author), NCI, BLDG 10, ROOM 13N248, BETHESDA, MD 20892 USA.		Venzon, David J/B-3078-2008		NIAID NIH HHS [AI-24643] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024643, R37AI024643] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHIRMULE N, 1990, BLOOD, V75, P152; COX DR, 1974, THEORETICAL STATISTI, P218; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GOTTLIEB MS, 1983, ANN INTERN MED, V99, P208, DOI 10.7326/0003-4819-99-2-208; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MITSUYASU RT, 1986, CANCER, V57, P1657, DOI 10.1002/1097-0142(19860415)57:8+<1657::AID-CNCR2820571304>3.0.CO;2-N; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PHILLIPS AN, 1991, LANCET, V337, P389; Pizzo P A, 1984, Cancer, V54, P2649, DOI 10.1002/1097-0142(19841201)54:2+<2649::AID-CNCR2820541409>3.0.CO;2-6; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROTHMAN KJ, 1978, J CHRON DIS, V31, P557, DOI 10.1016/0021-9681(78)90043-7; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; STAHL RE, 1982, AM J MED, V73, P171, DOI 10.1016/0002-9343(82)90174-7; SURBONE A, 1988, ANN INTERN MED, V108, P534, DOI 10.7326/0003-4819-108-4-534; VADHANRAJ S, 1986, CANCER RES, V46, P417; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; 1989, MMWR S5, V38, P1	37	170	171	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1991	115	3					184	189		10.7326/0003-4819-115-3-184	http://dx.doi.org/10.7326/0003-4819-115-3-184			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY152	1676252				2022-12-28	WOS:A1991FY15200004
J	CHEN, ZM; GODFREY, R				CHEN, ZM; GODFREY, R			BECOMING A DOCTOR IN CHINA	LANCET			English	Article									SOUTHAMPTON UNIV HOSP,SOUTHAMPTON OX2 6HE,ENGLAND	University of Southampton	CHEN, ZM (corresponding author), RADCLIFFE INFIRM,CLIN TRIAL SERV UNIT,OXFORD OX2 6HE,ENGLAND.							GU XY, 1982, AM J PUBLIC HEALTH, V72, P19, DOI 10.2105/AJPH.72.9_Suppl.19; HILLIER S, 1990, LANCET, V335, P414, DOI 10.1016/0140-6736(90)90250-9; LI MC, 1983, MANAGEMENT CHINESE H, P401; MACKAY J, 1991, THORAX, V46, P153, DOI 10.1136/thx.46.3.153; PETO R, 1987, LANCET, V2, P211; YEN IQ, 1957, CHINESE J PUBL HLTH, V6, P329; YOULONG G, 1982, AM J PUBLIC HEALTH, V72, P59; YU JJ, 1990, JAMA-J AM MED ASSOC, V264, P1575, DOI 10.1001/jama.264.12.1575; 1988, CHINESE HLTH STATIST; 1984, CHINA HLTH SECTOR WO; IN PRESS CHINA LONG; 1989, WORLD HLTH STATISTIC	12	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					169	172		10.1016/0140-6736(91)90150-N	http://dx.doi.org/10.1016/0140-6736(91)90150-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677076				2022-12-28	WOS:A1991FX42400016
J	NAROD, SA; FEUNTEUN, J; LYNCH, HT; WATSON, P; CONWAY, T; LYNCH, J; LENOIR, GM				NAROD, SA; FEUNTEUN, J; LYNCH, HT; WATSON, P; CONWAY, T; LYNCH, J; LENOIR, GM			FAMILIAL BREAST-OVARIAN CANCER LOCUS ON CHROMOSOME-17Q12-Q23	LANCET			English	Note							LINKAGE ANALYSIS	Familial breast cancer has been linked to the D17S74 locus on chromosome 17q. To confirm this finding and to investigate whether ovarian cancer is also linked to this locus, five large families with a hereditary predisposition to cancer of the breast and ovary were investigated. Three families were positive for linkage. For the largest family the lod score was 2.72. These findings suggest that the chromosomal region 17q12-q23, previously shown to contain a gene for early-onset breast cancer, is also associated with a proportion of hereditary ovarian cancers.	INT AGCY RES CANC,150 COURS ALBERT THOMAS,F-69372 LYONS,FRANCE; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED,OMAHA,NE 68178; MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3G 1A4,QUEBEC,CANADA; INST GUSTAVE ROUSSY,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC); McGill University; McGill University; Creighton University; McGill University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Feunteun, Jean/AAZ-1267-2020; Narod, Steven A/AAA-6112-2022	Feunteun, Jean/0000-0003-1212-9189				BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LYNCH HT, 1981, GENETICS BREAST CANC; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; NAROD SA, 1989, HUM GENET, V83, P353, DOI 10.1007/BF00291380; OTT J, 1985, ANAL HUMAN GENETIC L; ROBERTSON M, 1989, NATURE, V342, P222, DOI 10.1038/342222a0	10	523	536	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					82	83						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676470				2022-12-28	WOS:A1991FW16100005
J	HUTCHINSON, CM; WILSON, C; REICHART, CA; MARSIGLIA, VC; ZENILMAN, JM; HOOK, EW				HUTCHINSON, CM; WILSON, C; REICHART, CA; MARSIGLIA, VC; ZENILMAN, JM; HOOK, EW			LYMPHOCYTE-CD4 CONCENTRATIONS IN PATIENTS WITH NEWLY IDENTIFIED HIV-INFECTION ATTENDING STD CLINICS - POTENTIAL IMPACT ON PUBLICLY FUNDED HEALTH-CARE RESOURCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HOMOSEXUAL MEN; SEXUAL-BEHAVIOR; UNITED-STATES; MEDICAL-CARE; AIDS; COHORT; ANTIBODY; COSTS	Since January 1990, human immunodeficiency virus (HIV)-infected patients attending two sexually transmitted disease clinics in Baltimore, Md, have been offered T-lymphocyte subset evaluations. From January through September, CD4+ lymphocyte concentrations were measured in 223 newly diagnosed HIV-infected patients; 50% had fewer than 500 CD4+ T cells and 12% had fewer than 200 CD4+ T cells per cubic millimeter. Most patients were asymptomatic, and, even among patients with fewer than 200 CD4+ T cells, 54% had no symptoms or signs suggestive of advanced HIV infection. Homosexually active men had significantly lower mean CD4+ lymphocyte concentrations than intravenous drug users. Given the substantial numbers of patients with CD4+ concentrations that qualified them for zidovudine therapy, we also assessed their mechanisms of paying for health care. Only 24% of HIV-infected patients had private insurance. Seventy-two percent of patients with fewer than 200 CD4+ T cells either had no insurance or relied on public assistance for health care. Thus, although 50% of asymptomatic individuals identified by routine voluntary HIV screening in an inner-city sexually transmitted disease clinic may benefit from therapy for their disease, 75% of those qualifying for presently recommended therapy either depend on publicly funded health care or have no means of payment for care.	JOHNS HOPKINS UNIV HOSP,DEPT MED,600 N WOLFE ST,BALTIMORE,MD 21205; BALTIMORE MARYLAND CITY HLTH DEPT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BUCHANAN RJ, 1988, AM J PUBLIC HEALTH, V78, P462; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; CHEUNG TW, 1990, JAMA-J AM MED ASSOC, V263, P1067, DOI 10.1001/jama.1990.03440080039013; COATES T, 1988, AIDS S1, V2, P239; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FOX R, 1987, AIDS, V1, P241; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GIORGI JV, 1989, CLIN IMMUNOL IMMUNOP, V52, P10, DOI 10.1016/0090-1229(89)90188-8; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GOEDERT JJ, 1984, LANCET, V2, P711; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; LO B, 1989, ANN INTERN MED, V110, P727; MAKADON HJ, 1990, J ACQ IMMUN DEF SYND, V3, P123; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RANGO NA, 1990, NEW YORK STATE J MED, V90, P116; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; ROGERS MF, 1983, ANN INTERN MED, V99, P151, DOI 10.7326/0003-4819-99-2-151; SCHECHTER MT, 1988, AM J PUBLIC HEALTH, V78, P1535, DOI 10.2105/AJPH.78.12.1535; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SCITOVSKY AA, 1990, J ACQ IMMUN DEF SYND, V3, P904; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; VANGRIENSVEN GJP, 1988, AM J PUBLIC HEALTH, V78, P1575, DOI 10.2105/AJPH.78.12.1575; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZENILMAN JM, 1990, 30TH INT C ANT AG CH; 1990, AM J MED, V89, P335; 1990, MMWR, V39, P137; 1989, MMWR, V381, P1; [No title captured]; 1990, MMWR, V39, P1	41	27	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					253	256		10.1001/jama.266.2.253	http://dx.doi.org/10.1001/jama.266.2.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU896	1676076				2022-12-28	WOS:A1991FU89600035
J	HATANO, M; ROBERTS, CWM; MINDEN, M; CRIST, WM; KORSMEYER, SJ				HATANO, M; ROBERTS, CWM; MINDEN, M; CRIST, WM; KORSMEYER, SJ			DEREGULATION OF A HOMEOBOX GENE, HOX11, BY THE T(10-14) IN T-CELL LEUKEMIA	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; PROTEINS; SEQUENCE; DROSOPHILA; REGION; HELIX; BREAKPOINTS	Molecular cloning of the t(10;14)(q24;q11) recurrent breakpoint of T cell acute lymphoblastic leukemia has demonstrated a transcript for the candidate gene TCL3. Characterization of this gene from chromosome segment l0q24 revealed it to be a new homeobox, HOX11. The HOX11 homeodomain is most similar to that of the murine gene Hlx and possesses a markedly glycine-rich variable region and an acidic carboxyl terminus. HOX11, while expressed in liver, was not detected in normal thymus or T cells. This lineage-restricted homeobox gene is deregulated upon translocation into the T cell receptor locus where it may act as an oncogene.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; PEDIAT ONCOL GRP, ST LOUIS, MO USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896	NATIONAL CANCER INSTITUTE [U10CA030969, P01CA049712, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 30969, CA 21765, 1 PO1 CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; BAKHSHI A, 1985, CELL, V41, P89; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBE ID, 1986, BLOOD, V67, P1181; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANES S, 1990, CELL, V57, P1275; HATANO M, UNPUB; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MAUILIO F, 1986, NATURE, V324, P664; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAIMONDI SC, 1988, BLOOD, V72, P1560; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VISVADER J, 1991, ONCOGENE, V6, P187; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	43	392	397	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1991	253	5015					79	82		10.1126/science.1676542	http://dx.doi.org/10.1126/science.1676542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1676542				2022-12-28	WOS:A1991FV17700039
J	KUKUMBERG, P				KUKUMBERG, P			SIDE-SPECIFIC ELECTROMYOGRAPHIC DIFFERENCES IN TETANY	LANCET			English	Letter							HYPERVENTILATION				KUKUMBERG, P (corresponding author), DERER HOSP & POLICLIN, NEUROL CLIN, CS-83305 BRATISLAVA, CZECH REPUBLIC.							BLAU JN, 1983, BRIT MED J, V286, P1108, DOI 10.1136/bmj.286.6371.1108; BRODTKORB E, 1990, ACTA NEUROL SCAND, V81, P307; GORMAN JM, 1984, AM J PSYCHIAT, V141, P857; Kukumberg P, 1986, Cesk Neurol Neurochir, V49, P255; MORTON ET, 1964, JAMA-J AM MED ASSOC, V187, P301; NEVSIMAL O, 1963, TETANIE ZENTRALNERVE	6	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 29	1991	337	8757					1607	1607		10.1016/0140-6736(91)93302-P	http://dx.doi.org/10.1016/0140-6736(91)93302-P			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675733				2022-12-28	WOS:A1991FU55100048
J	TAPPIN, DM; GIRDWOOD, RWA; FOLLETT, EAC; KENNEDY, R; BROWN, AJ; COCKBURN, F				TAPPIN, DM; GIRDWOOD, RWA; FOLLETT, EAC; KENNEDY, R; BROWN, AJ; COCKBURN, F			PREVALENCE OF MATERNAL HIV-INFECTION IN SCOTLAND BASED ON UNLINKED ANONYMOUS TESTING OF NEWBORN BABIES	LANCET			English	Article							ANTIBODIES; ASSAYS	Dried blood spot samples from newborn babies have been successfully tested for HIV-1 antibody by the particle agglutination method to assess the prevalence of infection in the mothers. In January, 1990, unlinked anonymous testing of Guthrie cards for HIV antibody was begun in Scotland. 99.6% of Scottish births were tested. 9 mothers spontaneously refused to allow testing of their baby's blood. Samples were coded by district postcodes. Eluates of 65 773 dried blood spots were initially tested for HIV-1 antibody with the Fujirebio technique. Of the 31 positive samples l9 were confirmed to be positive by enzyme-linked radioimmunoassay and western blot (seroprevalence 0.29 per 1000). All these samples came from large metropolitan areas on the east coast. Prevalences were 2.5 per 1000 for Edinburgh city, 1.4 per 1000 for Dundee, and 0.7 per 1 000 for Aberdeen. We identified as HIV-positive all babies known to be so in named testing programmes. HIV testing of Guthrie cards can be used to monitor HIV status in mothers who have just given birth. The use of district postcode data in sample identification will allow accurate targetting of prevention strategies and early detection of spread of infection by geographic area.	STOBHILL GEN HOSP,SCOTTISH INBORN ERRORS SCREENING LAB,GLASGOW G21 3UW,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND		TAPPIN, DM (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,SCOTLAND.							ADES A E, 1991, Lancet, V337, P253; BARBARA JAJ, 1989, MED LAB SCI, V46, P135; CONNELL JA, 1990, LANCET, V335, P1366, DOI 10.1016/0140-6736(90)91245-6; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; NORVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; PECKHAM CS, 1990, LANCET, V335, P516, DOI 10.1016/0140-6736(90)90746-R; PEUTHERER JF, 1985, LANCET, V2, P1129; SCRIMGEOUR JB, 1990, 6 P INT C AIDS SAN F; Urquhart G. E. D., 1987, Communicable Diseases in Scotland, V21, P5; 1989, MMWR, V38	11	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1565	1567						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675708				2022-12-28	WOS:A1991FU55100004
J	PRICE, M; LEMAISTRE, M; PISCHETOLA, M; DILAURO, R; DUBOULE, D				PRICE, M; LEMAISTRE, M; PISCHETOLA, M; DILAURO, R; DUBOULE, D			A MOUSE GENE RELATED TO DISTAL-LESS SHOWS A RESTRICTED EXPRESSION IN THE DEVELOPING FOREBRAIN	NATURE			English	Article							LIMB DEVELOPMENT; DROSOPHILA; MURINE; HOMEODOMAIN; EMBRYOGENESIS; ORGANIZATION; HINDBRAIN; PATTERN; EN-1	MANY genes known to be involved in embryogenesis and morphogenesis of the fruitfly Drosophila melanogaster encode proteins with a highly conserved region of 60 amino acids called the homeodomain 1. Mammalian counterparts for most of these genes have been identified, including those homologous to the Drosophila homeotic genes 2,3 or to genes such as evenskipped 4, engrailed 5,6 or caudal 7. We have isolated a murine homeobox gene that encodes a homeodomain similar to that encoded by the Drosophila Distalless (Dll) gene 8. Dll has a crucial role in Drosophila limb morphogenesis, partially specifying pattern along the proximo-distal axis of the limb 8,9. The murine counterpart is expressed in a restricted region of the developing brain, within the diencephalon and the adjacent telencephalic regions.			PRICE, M (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; duboule, denis/0000-0001-9961-2960				BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GLOVER DM, 1989, DNA CLONING PRACTICA; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LUMSDEN A, 1990, TRENDS NEUROSCI, V8, P335; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; Niimi K, 1962, TOKUSHIMA J EXP MED, V8, P203; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RUGH R, 1968, MOUSE ITS REPRODUCTI; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; WILKINSON DG, 1990, TRENDS NEUROSCI, V13, P335, DOI 10.1016/0166-2236(90)90145-Z; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	22	276	286	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					748	751		10.1038/351748a0	http://dx.doi.org/10.1038/351748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1676488				2022-12-28	WOS:A1991FU20100065
J	POYNARD, T; CALES, P; PASTA, L; IDEO, G; PASCAL, JP; PAGLIARO, L; LEBREC, D				POYNARD, T; CALES, P; PASTA, L; IDEO, G; PASCAL, JP; PAGLIARO, L; LEBREC, D			BETA-ADRENERGIC ANTAGONIST DRUGS IN THE PREVENTION OF GASTROINTESTINAL-BLEEDING IN PATIENTS WITH CIRRHOSIS AND ESOPHAGEAL-VARICES - AN ANALYSIS OF DATA AND PROGNOSTIC FACTORS IN 589 PATIENTS FROM 4 RANDOMIZED CLINICAL-TRIALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PORTAL-HYPERTENSION; PROPRANOLOL; NADOLOL; HEMORRHAGE; CIRRHOTICS	Background. The value of beta-adrenergic-antagonist drug therapy for the prevention of initial episodes of gastrointestinal bleeding in patients with cirrhosis and esophageal varices is uncertain, both positive and negative study results having been reported. Methods. In this study, we analyzed data on individual patients from four randomized, controlled trials to assess the efficacy of this treatment. Of the 589 patients studied, 286 received a beta-adrenergic-antagonist drug (propranolol in 203 and nadolol in 83) and 303 received placebo. Results. After two years, the mean (+/- SE) percentage of patients who had had no upper gastrointestinal bleeding was 78 +/- 3 percent in the beta-adrenergic-antagonist treatment group and 65 +/- 3 percent in the control group (P = 0.002). The percentage of patients without fatal bleeding was 90 +/- 2 percent in the treatment group and 82 +/- 3 percent in the control group (P = 0.01). The percentage of patients surviving after two years was 71 +/- 3 percent in the treatment group and 68 +/- 3 percent in the control group (P = 0.34). After age and severity of cirrhosis were taken into account, the survival rate was better in the treatment group (P = 0.09). The percentage of surviving patients who had had no bleeding after two years was 62 +/- 3 percent in the treatment group and 53 +/- 3 percent in the control group (P = 0.04). Both propranolol and nadolol prevented a first episode of bleeding. Severe cirrhosis and especially the presence of ascites were associated with bleeding (P < 0.001) and death (P < 0.001) in both groups. The efficacy of beta-adrenergic-antagonist therapy in the prevention of bleeding (P < 0.001) and of fatal bleeding (P = 0.004) and in the prevention of bleeding or death (P = 0.005) was the same after adjustment for cause and severity of cirrhosis, ascites, and size of varices. Conclusions. Propranolol and nadolol are effective in preventing first bleeding and reducing the mortality rate associated with gastrointestinal bleeding in patients with cirrhosis, regardless of severity.			POYNARD, T (corresponding author), HOP ANTOINE BECLERE,F-92141 CLAMART,FRANCE.		CALES, Paul/AFN-9693-2022; Poynard, Thierry/C-1355-2010	CALES, Paul/0000-0003-4866-5274; Poynard, Thierry/0000-0002-3726-7230; Cottone, Mario/0000-0003-1523-7556; Poynard, Thierry/0000-0002-2050-640X				BURROUGHS AK, 1986, HEPATOLOGY, V6, P1407, DOI 10.1002/hep.1840060631; GATTA A, 1984, AM HEART J, V108, P1167, DOI 10.1016/0002-8703(84)90602-1; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; IDEO G, 1988, HEPATOLOGY, V8, P6, DOI 10.1002/hep.1840080103; LEBREC D, 1980, LANCET, V2, P180; LEBREC D, 1982, HEPATOLOGY, V2, P523; LEBREC D, 1988, J HEPATOL, V7, P118, DOI 10.1016/S0168-8278(88)80515-4; MILLS PR, 1984, GUT, V25, P73, DOI 10.1136/gut.25.1.73; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PASCAL JP, 1987, NEW ENGL J MED, V317, P856, DOI 10.1056/NEJM198710013171403; POYNARD T, 1987, HEPATOLOGY, V7, P447, DOI 10.1002/hep.1840070306; 1989, J HEPATOL, V9, P75	12	371	376	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1532	1538		10.1056/NEJM199105303242202	http://dx.doi.org/10.1056/NEJM199105303242202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	1674104				2022-12-28	WOS:A1991FN05100002
J	MALLOLAS, J; ZAMORA, L; GATELL, JM; MIRO, JM; SORIANO, E				MALLOLAS, J; ZAMORA, L; GATELL, JM; MIRO, JM; SORIANO, E			LOW-DOSE COTRIMOXAZOLE, AEROSOLIZED PENTAMIDINE, OR DAPSONE PLUS PYRIMETHAMINE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA	LANCET			English	Letter							CHEMOPROPHYLAXIS				MALLOLAS, J (corresponding author), UNIV BARCELONA HOSP CLIN,INFECT DIS UNIT,E-08036 BARCELONA,SPAIN.		Gatell, Jose M/ABC-3607-2020	Mallolas Masferrer, Josep/0000-0002-8365-141X				FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; RUSKIN, 1991, LANCET, V337, P468	3	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1162	1163		10.1016/0140-6736(91)92829-Q	http://dx.doi.org/10.1016/0140-6736(91)92829-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674036				2022-12-28	WOS:A1991FL12400039
J	[Anonymous]				[Anonymous]			HIV IN CHILDREN	LANCET			English	Editorial Material																		HONIGSBAUM N, 1991, HIV AIDS CHILDREN; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1991, LANCET, V337, P253	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1030	1030						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673180				2022-12-28	WOS:A1991FJ13500019
J	LAM, KMC; SYED, N; WHITTLE, H; CRAWFORD, DH				LAM, KMC; SYED, N; WHITTLE, H; CRAWFORD, DH			CIRCULATING EPSTEIN-BARR VIRUS-CARRYING B-CELLS IN ACUTE MALARIA	LANCET			English	Article							RENAL-ALLOGRAFT RECIPIENTS; ANTIBODIES; LYMPHOMA; CYCLOSPORIN; REACTIVITY; INFECTION; IMMUNITY; MITOGEN; EBV	Epstein-Barr virus (EBV) infection and Plasmodium falciparum malaria are two known cofactors in the aetiology of endemic Burkitt's lymphoma. To assess the relation between these factors, limiting dilution analysis was used to assess the number of EBV-carrying B cells in the circulation of Gambian children during and after acute malaria. Numbers of virus-carrying cells were five times higher in acute malaria patients and in UK patients with infectious mononucleosis than in convalescent malaria patients and in healthy control adults from the UK. Spontaneous outgrowth in limiting dilution cultures from acute malaria samples was inhibited by acyclovir, a viral DNA polymerase inhibitor. The mechanism of outgrowth, therefore, was virus release from the in-vivo infected cell, which led to infection and immortalisation of co-cultured normal B cells. The findings provide evidence that acute malaria is associated with an increase in the number of EBV-carrying B cells in the circulation. Because of this increase, there is a greater chance of a cytogenetic abnormality occurring in such a cell, with consequent evolution of Burkitt's lymphoma.	MRC LABS,BANJUL,SENEGAMBIA		LAM, KMC (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BERZINS K, 1983, CLIN EXP IMMUNOL, V54, P313; BIGGAR RJ, 1978, INT J CANCER, V22, P239, DOI 10.1002/ijc.2910220304; BURKITT DP, 1983, CANCER, V51, P1777, DOI 10.1002/1097-0142(19830515)51:10<1777::AID-CNCR2820511003>3.0.CO;2-E; COLBY BM, 1980, J VIROL, V34, P560, DOI 10.1128/JVI.34.2.560-568.1980; CRAWFORD DH, 1981, LANCET, V1, P10; GREENWOOD BM, 1974, LANCET, V1, P435; GREENWOOD BM, 1975, NATURE, V257, P592, DOI 10.1038/257592a0; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HENLE W, 1970, SCIENCE, V169, P188, DOI 10.1126/science.169.3941.188; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; LEWIN N, 1987, INT J CANCER, V39, P472, DOI 10.1002/ijc.2910390411; NAGINGTON J, 1980, LANCET, V1, P536; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RAGONA G, 1986, CLIN EXP IMMUNOL, V66, P17; RICKINSON AB, 1974, INT J CANCER, V14, P704, DOI 10.1002/ijc.2910140603; RICKINSON AB, 1977, INT J CANCER, V20, P561; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; STRAUCH B, 1974, LANCET, V1, P234; WEIDANZ WP, 1982, BRIT MED BULL, V38, P167, DOI 10.1093/oxfordjournals.bmb.a071754; WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YAO QY, 1985, INT J CANCER, V35, P43, DOI 10.1002/ijc.2910350108	24	91	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					876	878		10.1016/0140-6736(91)90203-2	http://dx.doi.org/10.1016/0140-6736(91)90203-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672968				2022-12-28	WOS:A1991FG04800003
J	RUBO, J; WAHN, V				RUBO, J; WAHN, V			HIGH-DOSE INTRAVENOUS GAMMA-GLOBULIN IN RHESUS-HEMOLYTIC DISEASE	LANCET			English	Letter							NEONATAL ISOIMMUNE THROMBOCYTOPENIA; IMMUNOGLOBULIN				RUBO, J (corresponding author), UNIV DUSSELDORF,DEPT PAEDIAT,GERMAN RHESUS ALLOIMMUNISAT STUDY GRP,W-4000 DUSSELDORF 1,GERMANY.							DERYCKE M, 1985, ARCH DIS CHILD, V60, P667, DOI 10.1136/adc.60.7.667; MASSEY GV, 1987, J PEDIATR-US, V111, P133, DOI 10.1016/S0022-3476(87)80360-8; Polacek K, 1984, PADIATR PRAX, V29, P1; RUBO J, 1990, MONATSSCHR KINDERH, V138, P216	4	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					914	914		10.1016/0140-6736(91)90243-I	http://dx.doi.org/10.1016/0140-6736(91)90243-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672989				2022-12-28	WOS:A1991FG04800036
J	MELTON, DA				MELTON, DA			PATTERN-FORMATION DURING ANIMAL DEVELOPMENT	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; CHICK LIMB BUD; HISTOSPECIFIC ACETYLCHOLINESTERASE DEVELOPMENT; MESODERM-INDUCING FACTORS; FIBROBLAST GROWTH-FACTOR; RETINOIC ACID RECEPTOR; EARLY XENOPUS EMBRYO; ASCIDIAN EMBRYOS; BICOID PROTEIN; DROSOPHILA EMBRYO	At the beginning of this century, embryologists defined the central problems of developmental biology that remain today. These questions include how differentiated cells arise and form tissues and organs and how pattern is generated. In short, how does an egg give rise to an adult? In recent years, the application of molecular biology to embryological problems has led to significant advances and recast old problems in molecular and cellular terms. Although not necessarily comprehensive, this idiosyncratic review is intended to highlight selected findings and indicate where there are important gaps in our knowledge for those less than familiar with developmental biology.			MELTON, DA (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AKAM M, 1987, DEVELOPMENT, V101, P1; ALTABA ARI, 1990, TRENDS GENET, V6, P57; ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; BROWN NA, 1990, DEVELOPMENT, V109, P1; CHO K, 1989, DEVELOPMENT, V107, P275; CHRISTIAN J, IN PRESS DEVELOPMENT; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; COOKE J, 1989, DEVELOPMENT, V107, P229; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DAVIDSON E, 1986, GENE ACTIVITY EARLY, P411; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENO T, 1985, BIOL BULL, V168, P239, DOI 10.2307/1541237; DEROBERTIS EM, 1989, CELL, V57, P189, DOI 10.1016/0092-8674(89)90954-9; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DRESSLER GR, 1988, TRENDS GENET, V4, P214, DOI 10.1016/S0168-9525(88)80003-9; Driesch H, 1900, ARCH ENTWICKLUNG ORG, V10, P361, DOI 10.1007/BF02156642; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; FREEMAN G, 1976, DEV BIOL, V49, P143, DOI 10.1016/0012-1606(76)90264-5; FREEMAN G, 1982, ROUX ARCH DEV BIOL, V191, P69, DOI 10.1007/BF00848443; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART JC, 1984, PHILOS T R SOC B, V307, P319, DOI 10.1098/rstb.1984.0134; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREENWALD I, 1989, TRENDS GENET, V5, P237, DOI 10.1016/0168-9525(89)90094-2; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Horstadius S, 1973, EXPT EMBRYOLOGY ECHI; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JONES EA, 1987, DEVELOPMENT, V101, P557; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KNOCHEL W, 1989, BLUT, V59, P207, DOI 10.1007/BF00320849; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MADEN M, 1986, J EMBRYOL EXP MORPH, V97, P239; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MARTINEZARIAS A, 1990, NATURE, V6, P287; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; MITRANI E, 1981, NATURE, V289, P800, DOI 10.1038/289800a0; MOWRYK, UNPUB; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NIAZI I A, 1978, Folia Biologica (Cracow), V26, P3; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NISHIKATA T, 1987, DEVELOPMENT, V99, P163; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; PANGANIBAN G, IN PRESS DEVELOPMENT; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Ptashne M., 1986, A GENETIC SWITCH; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REUTER R, IN PRESS DEVELOPMENT; Roberts AB, 1990, GROWTH FACTORS, V3, P277, DOI 10.3109/08977199009003670; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Ruiz i Altaba A, 1989, Nature, V341, P33; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SARGENT MG, 1990, DEVELOPMENT, V109, P967; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SAXEN L, 1989, International Journal of Developmental Biology, V33, P21; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK J, 1983, EGG EMBRYO, P165; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, UNPUB; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TABIN CJ, 1989, DEVELOPMENT, V105, P813; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMS SD, 1984, DEV BIOL, V103, P319, DOI 10.1016/0012-1606(84)90320-8; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VANDENEIJNDENVA.AJ, 1990, ROUX ARCH DEV BIOL, V198, P330; WEDDEN SE, 1989, DEVELOPMENT, V105, P639; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WHITTAKER J, 1979, DETERMINANTS SPATIAL, V29; WHITTAKER JR, 1982, DEV BIOL, V93, P463, DOI 10.1016/0012-1606(82)90134-8; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WOODLAND HR, 1989, CELL, V59, P767, DOI 10.1016/0092-8674(89)90596-5; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WYLIE CC, 1985, J EMBRYOL EXP MORPH, V89, P1; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	149	170	171	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1991	252	5003					234	241		10.1126/science.1672778	http://dx.doi.org/10.1126/science.1672778			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG036	1672778				2022-12-28	WOS:A1991FG03600036
J	POLTERA, AA; ZEAFLORES, G; GUDERIAN, R; BELTRANENA, F; PROANA, R; MORAN, M; ZAK, F; STRIEBEL, HP				POLTERA, AA; ZEAFLORES, G; GUDERIAN, R; BELTRANENA, F; PROANA, R; MORAN, M; ZAK, F; STRIEBEL, HP			ONCHOCERCACIDAL EFFECTS OF AMOCARZINE (CGP-6140) IN LATIN-AMERICA	LANCET			English	Note								An open clinical trial of amocarzine was carried out in onchocerciasis patients in Ecuador and Guatemala. Administration after food was more effective than that during fasting. The most effective and best tolerated regimen, 3 mg/kg twice daily after food for 3 days (in 312 patients), killed 73% of 1477 female worms at nodulectomy 4 months after treatment. The mean microfilarial skin count was greatly reduced within a week (6-11% of day 0 value on day 8) and it remained low for at least 6 months (14-18% on day 180). Follow-up of a higher dose 3 day regimen taken while fasting showed microfilaridermia of 7-9% of the day 0 value 2 years after treatment.	MINIST HLTH,DEPT ONCHOCERCIASIS,GUATEMALA CITY,GUATEMALA; MINIST HLTH,ONCHOCERCIASIS CONTROL PROJECT,QUITO,ECUADOR; RODOLFO ROBLES HOSP,DEPT OPHTHALMOL,GUATEMALA CITY,GUATEMALA; HOSP VOZANDES,DEPT OPHTHALMOL,QUITO,ECUADOR		POLTERA, AA (corresponding author), CIBA GEIGY AG,K-121302,CH-4002 BASEL,SWITZERLAND.							DESOLE G, 1990, LANCET, V335, P1106, DOI 10.1016/0140-6736(90)92687-D; GUDERIAN RH, 1990, T ROY SOC TROP MED H, V84, P109, DOI 10.1016/0035-9203(90)90396-V; LECAILLON JB, 1990, BRIT J CLIN PHARMACO, V30, P629, DOI 10.1111/j.1365-2125.1990.tb03825.x; LECAILLON JB, 1990, BRIT J CLIN PHARMACO, V30, P625, DOI 10.1111/j.1365-2125.1990.tb03824.x; Poltera A A, 1988, Trop Med Parasitol, V39 Suppl 4, P349; POLTERA AA, 1987, LANCET, V1, P505; POLTERA AA, 1989, 12TH INT C TROP MED, P341; POLTERA AA, 1990, B SOC FRANCAISE P S2, V8, P1062; SOULA G, 1989, LANCET, V1, P726	9	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					583	584		10.1016/0140-6736(91)91642-8	http://dx.doi.org/10.1016/0140-6736(91)91642-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671945				2022-12-28	WOS:A1991FA70200006
J	PROUDFOOT, N				PROUDFOOT, N			POLY(A) SIGNALS	CELL			English	Review							YEAST TRANSCRIPTIONAL TERMINATOR; POLYADENYLATION SIGNALS; MUTATIONAL ANALYSIS; GENE-EXPRESSION; SITE; SEQUENCES; UPSTREAM; CELLS				PROUDFOOT, N (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND.			Proudfoot, Nicholas/0000-0001-8646-3222				ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; AHMED YF, 1991, CELL, V64; ANDERGLON CW, 1991, IN PRESS GENES DEV; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248, DOI 10.1128/MCB.9.10.4248; DEZAZZO JD, 1989, MOL CELL BIOL, V9, P4951, DOI 10.1128/MCB.9.11.4951; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HUNT AG, 1987, PLANT MOL BIOL, V8, P23, DOI 10.1007/BF00016431; IWASAKI K, 1990, GENE DEV, V4, P2299, DOI 10.1101/gad.4.12b.2299; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; JU G, 1985, ADV VIRUS RES, V30, P179, DOI 10.1016/S0065-3527(08)60451-0; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; OSBORNE BI, 1989, P NATL ACAD SCI USA, V86, P4097, DOI 10.1073/pnas.86.11.4097; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RUSSO P, 1991, IN PRESS EMBO J; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SANFACON H, 1990, NATURE, V346, P81, DOI 10.1038/346081a0; SANFACON H, 1991, GENE DEV, V5, P141, DOI 10.1101/gad.5.1.141; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARET KS, 1984, J MOL BIOL, V176, P107	26	417	625	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					671	674		10.1016/0092-8674(91)90495-K	http://dx.doi.org/10.1016/0092-8674(91)90495-K			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1671760				2022-12-28	WOS:A1991EZ47800002
J	HUNTER, JO				HUNTER, JO			FOOD ALLERGY - OR ENTEROMETABOLIC DISORDER	LANCET			English	Note							IRRITABLE BOWEL SYNDROME; CONTROLLED TRIAL; DIET; INTOLERANCE; MIGRAINE; DISEASE				HUNTER, JO (corresponding author), ADDENBROOKES HOSP,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.							ATHERTON DJ, 1978, LANCET, V1, P401; Bayliss C E, 1986, Ann Ist Super Sanita, V22, P959; BENTLEY SJ, 1983, LANCET, V2, P295; BOND JH, 1980, GASTROENTEROLOGY, V78, P444; BURKE DA, 1988, BMJ-BRIT MED J, V297, P102, DOI 10.1136/bmj.297.6641.102; DARLINGTON LG, 1986, LANCET, V1, P236; EBRINGER RW, 1979, ANN RHEUM DIS, V37, P145; EGGER J, 1985, LANCET, V1, P540; EGGER J, 1983, LANCET, V2, P865; Hanington E., 1983, Clinical reactions to food, P155; HYAMS JS, 1983, GASTROENTEROLOGY, V84, P30; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; Jones V. A., 1985, Food and the gut, P208; JONES VA, 1982, LANCET, V2, P1115; JONES VA, 1985, LANCET, V2, P177; LESSOF MH, 1980, Q J MED, V195, P259; LITTLEWOOD J, 1982, LANCET, V1, P983; RAVICH WJ, 1983, GASTROENTEROLOGY, V84, P26; SANDLER M, 1970, BACKGROUND MIGRAINE; SHEPPACH W, 1988, GASTROENTEROLOGY, V95, P1549; VANDERWAAIJ D, 1983, ANTIBIOTIC CHOICE IM; 1984, J R COLL PHYSICIANS, V18	23	33	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1991	338	8765					495	496		10.1016/0140-6736(91)90557-6	http://dx.doi.org/10.1016/0140-6736(91)90557-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC153	1678455				2022-12-28	WOS:A1991GC15300017
J	KLAHR, S				KLAHR, S			CHRONIC-RENAL-FAILURE - MANAGEMENT	LANCET			English	Article							CONVERTING ENZYME-INHIBITION; DIABETIC NEPHROPATHY; KIDNEY-FUNCTION; PROGRESSION; DISEASE; THERAPY; INSUFFICIENCY; HYPERTENSION				KLAHR, S (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007126, R01DK040321, P01DK009976] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40321, DK-07126, DK-09976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN DS, PROGR NATURE RENAL D, P81; BEDOGNA V, 1990, KIDNEY INT, V38, P101, DOI 10.1038/ki.1990.173; BERGSTROM J, 1987, NEPHROLOGY, V2, P1192; BJORCK S, 1986, BMJ-BRIT MED J, V293, P471, DOI 10.1136/bmj.293.6545.471; BOHLE A, 1987, AM J NEPHROL, V7, P421, DOI 10.1159/000167514; Cappelli P, 1988, Scand J Urol Nephrol Suppl, V108, P25; DIAMOND JR, 1989, AM J PHYSIOL, V257, pF798, DOI 10.1152/ajprenal.1989.257.5.F798; DONADIO JV, 1984, NEW ENGL J MED, V310, P1421, DOI 10.1056/NEJM198405313102203; ELIAHOU HE, 1988, AM J NEPHROL, V8, P285, DOI 10.1159/000167602; GIMENEZ LF, 1987, KIDNEY INT, V31, P93, DOI 10.1038/ki.1987.14; GRUNDY SM, 1990, KIDNEY INT, V37, P847, DOI 10.1038/ki.1990.57; HUNSICKER LG, 1989, SEMIN NEPHROL, V9, P380; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; KAJIWARA N, 1975, JPN CIRC J, V39, P779, DOI 10.1253/jcj.39.779; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; MARRE M, 1987, BMJ-BRIT MED J, V294, P1448, DOI 10.1136/bmj.294.6585.1448; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; PARVING HH, 1983, LANCET, V1, P1175; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; RUILOPE LM, 1989, AM J KIDNEY DIS, V13, P120, DOI 10.1016/S0272-6386(89)80129-5; WARDLE EN, 1986, NEPHRON, V44, P81; WILLIAMS PS, 1988, Q J MED, V67, P343; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	26	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					423	427		10.1016/0140-6736(91)91043-T	http://dx.doi.org/10.1016/0140-6736(91)91043-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678093				2022-12-28	WOS:A1991GB44600014
J	VANDERVEN, AJAM; KOOPMANS, PP; VREE, TB; VANDERMEER, JWM				VANDERVEN, AJAM; KOOPMANS, PP; VREE, TB; VANDERMEER, JWM			ADVERSE REACTIONS TO COTRIMOXAZOLE IN HIV-INFECTION	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; CUTANEOUS REACTIONS; PLASMA; METABOLISM; DAPSONE; AIDS	The origin of the increased frequency of side-effects to co-trimoxazole in HIV-positive patients is unknown. Data on plasma concentrations of the parent compounds are inconclusive. Evidence points to the hydroxylamine derivatives of sulphamethoxazole as the reactive metabolites that cause adverse reactions to co-trimoxazole. HIV-positive individuals have a systemic glutathione deficiency, and therefore a reduced capacity to scavenge such metabolites. This process would lead to an increased exposure to toxic intermediates and would explain the high frequency of adverse reactions to co-trimoxazole in these patients.	CATHOLIC UNIV NIJMEGEN,HOSP ST RADMOUD,DEPT CLIN PHARM,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	VANDERVEN, AJAM (corresponding author), CATHOLIC UNIV NIJMEGEN,HOSP ST RADMOUD,DEPT INTERNAL MED,DIV GEN INTERNAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Koopmans, Peter/O-9276-2015; van der Meer, Jos W.M./C-8521-2013; van der Ven, A.J.A.M./H-8102-2014	van der Meer, Jos W.M./0000-0001-5120-3690; van der Ven, A.J.A.M./0000-0003-1833-3391				BOWDEN FJ, 1986, LANCET, V2, P853; BUHL R, 1989, LANCET, V2, P1294; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; DEHOVITZ JA, 1985, ANN INTERN MED, V103, P479, DOI 10.7326/0003-4819-103-3-479_2; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; JAFFE HS, 1983, LANCET, V2, P1109; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; OUTWATER E, 1985, 1ST INT C AIDS ATL; REFSUM H, 1990, TRENDS PHARMACOL SCI, V11, P411, DOI 10.1016/0165-6147(90)90148-2; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SMALL CB, 1985, ARCH INTERN MED, V145, P837, DOI 10.1001/archinte.145.5.837; 1986, LANCET, V2, P958	20	128	133	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1991	338	8764					431	433		10.1016/0140-6736(91)91046-W	http://dx.doi.org/10.1016/0140-6736(91)91046-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB446	1678095	Green Submitted			2022-12-28	WOS:A1991GB44600016
J	ECK, HP; STAHLHENNIG, C; HUNSMANN, G; DROGE, W				ECK, HP; STAHLHENNIG, C; HUNSMANN, G; DROGE, W			METABOLIC DISORDER AS EARLY CONSEQUENCE OF SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS MACAQUES	LANCET			English	Note							GLUTAMATE CONCENTRATION; MACROPHAGES; CYSTEINE; PLASMA	To establish whether the high plasma glutamate and low acid-soluble thiol (mainly cysteine) concentrations previously found in patients with HIV-1 infection are a consequence of the infection or a risk factor for its development, a closely related animal model, rhesus and fascicularis macaques infected with simian immunodeficiency virus (SIV(mac251)), was studied. The 23 infected macaques had significantly lower mean plasma thiol and higher glutamate concentrations than 18 uninfected controls (p < 0.001). The changes were apparent by 1 week after infection. Thus, abnormal plasma glutamate and thiol concentrations are, at least in this model, a direct and early consequence of the retroviral infection.	GERMAN PRIMATE CTR,DEPT VIROL & IMMUNOL,GOTTINGEN,GERMANY	Deutsches Primatenzentrum (DPZ)	ECK, HP (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.							BUHL R, 1989, LANCET, V2, P1294; CRANAGE MP, 1990, ANIMAL MODELS AIDS, P103; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DROGE W, 1988, BIOL CHEM H-S, V369, P143, DOI 10.1515/bchm3.1988.369.1.143; DROGE W, 1988, J CANCER RES CLIN, V114, P124, DOI 10.1007/BF00417824; ECK HP, 1989, BIOL CHEM H-S, V370, P109, DOI 10.1515/bchm3.1989.370.1.109; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; FENDRICH C, 1989, AIDS, V3, P305, DOI 10.1097/00002030-198905000-00010; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628	10	59	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1991	338	8763					346	347		10.1016/0140-6736(91)90482-5	http://dx.doi.org/10.1016/0140-6736(91)90482-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677701				2022-12-28	WOS:A1991GA60700007
J	UZAN, S; BEAUFILS, M; BREART, G; BAZIN, B; CAPITANT, C; PARIS, J				UZAN, S; BEAUFILS, M; BREART, G; BAZIN, B; CAPITANT, C; PARIS, J			PREVENTION OF FETAL GROWTH-RETARDATION WITH LOW-DOSE ASPIRIN - FINDINGS OF THE EPREDA TRIAL	LANCET			English	Article							PREGNANCY-INDUCED HYPERTENSION; PRE-ECLAMPSIA; PLACENTAL INSUFFICIENCY; GESTATIONAL AGE; PROSTACYCLIN; THROMBOXANE; PREECLAMPSIA; PLATELETS; THERAPY; DIPYRIDAMOLE	The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial. A secondary aim was to find out whether dipyridamole improves the efficacy of aspirin. 323 women at 15-18 weeks' amenorrhoea were selected at twenty-five participating centres on the basis of fetal growth retardation and/or fetal death or abruptio placentae in at least one previous pregnancy. They were randomly allocated to groups receiving placebo, 150 mg/day aspirin, or 150 mg/day aspirin plus 225 mg/day dipyridamole, for the remainder of the pregnancy. In the first phase of the trial all actively treated patients (n = 156) were compared with the placebo group (n = 73). Mean birthweight was significantly higher in the treated than in the placebo group (2751 [SD 670] vs 2526 [848] g; difference 225 g [95% Cl 129-321 g], p = 0.029) and the frequency of fetal growth retardation in the placebo group was twice that in the treated group (19 [26%] vs 20 [13%]; p < 0.02). The frequencies of stillbirth (4 [5%] vs 2 [1%]) and abruptio placentae (6 [8%] vs 7 [5%]) were also higher in the placebo than in the treated group. The benefits of aspirin treatment were greater in patients with two or more previous poor outcomes than in those with only one. In the second analysis, of aspirin only (n = 127) vs aspirin plus dipyridamole (n = 119), no significant differences were found. There was no excess of maternal or neonatal side-effects in the aspirin-treated patients. Lancet 1 991; 337: 1427-31.	HOP TENON,SERV MED INTERNE A,4 RUE CHINE,F-75970 PARIS 20,FRANCE; HOP TENON,SERV GYNECOL OBSTET,F-75970 PARIS 20,FRANCE; INSERM,U149,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)								BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; CAPETTA P, 1986, LANCET, V1, P919; FITZGERALD GA, 1987, NEW ENGL J MED, V316, P1247; HACHICHA J, 1989, PRESSE MED, V18, P767; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; LUBCHENCO LO, 1972, J PEDIATR-US, V81, P814, DOI 10.1016/S0022-3476(72)80114-8; MARCUS AJ, 1983, NEW ENGL J MED, V309, P1515, DOI 10.1056/NEJM198312153092410; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; NELSON DM, 1989, AM J OBSTET GYNECOL, V161, P1593; RAMOS LS, 1987, AM J OBSTET GYNECOL, V156, P193; REDMAN CWG, 1990, NEW ENGL J MED, V323, P478, DOI 10.1056/NEJM199008163230710; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; RUMACK CM, 1981, OBSTET GYNECOL, V58, pS52; SALZMAN EW, 1982, NEW ENGL J MED, V307, P113, DOI 10.1056/NEJM198207083070209; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SIBAI BM, 1989, OBSTET GYNECOL, V74, P551; SPITZ B, 1988, AM J OBSTET GYNECOL, V159, P1035, DOI 10.1016/0002-9378(88)90406-1; STUART MJ, 1982, NEW ENGL J MED, V307, P909, DOI 10.1056/NEJM198210073071502; THORP JA, 1988, AM J OBSTET GYNECOL, V159, P1381, DOI 10.1016/0002-9378(88)90560-1; TRUDINGER BJ, 1988, AM J OBSTET GYNECOL, V159, P681, DOI 10.1016/S0002-9378(88)80034-6; WALLENBURG HCS, 1987, AM J OBSTET GYNECOL, V157, P1230, DOI 10.1016/S0002-9378(87)80300-9; WALLENBURG HCS, 1986, LANCET, V1, P1; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; WERLER MM, 1989, NEW ENGL J MED, V321, P1639, DOI 10.1056/NEJM198912143212404; YLIKORKALA O, 1986, AM J OBSTET GYNECOL, V155, P345, DOI 10.1016/0002-9378(86)90823-9	26	152	152	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1427	1431		10.1016/0140-6736(91)93124-R	http://dx.doi.org/10.1016/0140-6736(91)93124-R			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675315				2022-12-28	WOS:A1991FR06000001
J	WAKABAYASHI, A; BRENNER, M; KAYALEH, RA; BERNS, MW; BARKER, SJ; RICE, SJ; TADIR, Y; DELLABELLA, L; WILSON, AF				WAKABAYASHI, A; BRENNER, M; KAYALEH, RA; BERNS, MW; BARKER, SJ; RICE, SJ; TADIR, Y; DELLABELLA, L; WILSON, AF			THORACOSCOPIC CARBON-DIOXIDE LASER TREATMENT OF BULLOUS EMPHYSEMA	LANCET			English	Note							DRAINAGE; BULLAE	A new technique of thoracoscopic laser ablation of pulmonary bullae suitable for patients with multiple bullae and diffuse emphysema was developed and assessed in 22 patients. 20 of 22 patients survived. Pre-operative and postoperative functional evaluation is available for the 11 patients followed up for more than a month; at 1 to 3 months postoperatively there were increases in FVC (mean 2.0 litres pre-operatively to 2.7 litres postoperatively, p < 0.001), in FEV1 (0.74 to 1.06 litres, p = 0.01), and in maximum exercise treadmill times (5.4 min to 8.0 min, p < 0.01). Postoperative air leaks lasted a mean of 13 days and usually resolved spontaneously. Other complications were bleeding (1 patient) and unilateral acute lung injury (1 patient). These early results suggest that selected patients with diffuse emphysema and pulmonary bullae may benefit from thoracoscopic carbon dioxide laser ablation.	UNIV CALIF IRVINE,IRVINE MED CTR,DEPT SURG,DIV PULM & CRIT CARE MED,101 CITY DR S,ORANGE,CA 92668; BECKMAN LASER INST & MED CLIN,IRVINE,CA; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT PULM & CRIT CARE MED,ORANGE,CA 92668; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT RADIOL,ORANGE,CA 92668; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT ANESTHESIA,ORANGE,CA 92668	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine				Berns, Michael/0000-0002-9640-2885				BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; FITZGERALD MX, 1974, J THORAC CARDIOV SUR, V68, P566; Gaensler E A, 1986, J Thorac Imaging, V1, P75, DOI 10.1097/00005382-198603000-00009; GUNSTENSEN J, 1973, J THORAC CARDIOV SUR, V65, P920; HEAD JR, 1948, J THORAC CARDIOVASC, V40, P443; LAROS CD, 1986, J THORAC CARDIOV SUR, V91, P63; MACARTHUR AM, 1977, THORAX, V32, P668, DOI 10.1136/thx.32.6.668; OBRIEN CJ, 1986, AUST NZ J SURG, V56, P241, DOI 10.1111/j.1445-2197.1986.tb06142.x; VENN GE, 1988, THORAX, V43, P998, DOI 10.1136/thx.43.12.998; WAKABAYASHI A, 1990, ANN THORAC SURG, V50, P786	10	120	122	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					881	883		10.1016/0140-6736(91)90206-5	http://dx.doi.org/10.1016/0140-6736(91)90206-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672970	Green Submitted			2022-12-28	WOS:A1991FG04800005
J	REMUZZI, G; ROSSINI, M; IMBERTI, O; PERICO, N				REMUZZI, G; ROSSINI, M; IMBERTI, O; PERICO, N			KIDNEY GRAFT-SURVIVAL IN RATS WITHOUT IMMUNOSUPPRESSANTS AFTER INTRATHYMIC GLOMERULAR TRANSPLANTATION	LANCET			English	Article							SELF-TOLERANCE; CYCLOSPORINE; THERAPY; THYMUS	Isolated glomeruli from Brown-Norway (RT1n) rat kidney were inoculated into the thymus of 6 incompatible Lewis (RT1(1)) rats pretreated for 2 days with 40 mg/kg oral cyclosporin daily and given 2.5 mg/kg subcutaneous dexamethasone at inoculation. 10 days later the left kidney from the Brown-Norway donor used to prepare glomeruli was transplanted orthotopically to the Lewis (RT1(1)) rat that had received intrathymic glomeruli. Donor-specific unresponsiveness allowed the renal allograft to survive indefinitely without further immunosuppression. 6 control Lewis rats treated as above except that medium alone was injected intrathymically rejected a renal allograft within 7-9 days.	OSPED RIUNITI BERGAMO,DIV NEPHROL,I-24100 BERGAMO,ITALY	Ospedali Riuniti di Bergamo	REMUZZI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,VIA GAVAZZENI 11,I-24100 BERGAMO,ITALY.		Perico, Norberto/ABH-3222-2020; Remuzzi, Giuseppe/V-9766-2017	Perico, Norberto/0000-0002-3147-4327; Remuzzi, Giuseppe/0000-0002-6194-3446				BONSNES RW, 1945, J BIOL CHEM, V158, P581; Burnet FM, 1949, PRODUCTION ANTIBODIE, P102; CARPENTER CB, 1990, NEW ENGL J MED, V322, P1224, DOI 10.1056/NEJM199004263221709; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; FILO RS, 1980, TRANSPLANTATION, V30, P445, DOI 10.1097/00007890-198012000-00012; FRYD DS, 1980, TRANSPLANTATION, V30, P436, DOI 10.1097/00007890-198012000-00010; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; LANCE EM, 1973, ADV IMMUNOL, V17, P1; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; MYERS BD, 1986, KIDNEY INT, V30, P964, DOI 10.1038/ki.1986.280; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; REMUZZI G, 1985, J CLIN INVEST, V75, P94, DOI 10.1172/JCI111703; Rossini M, 1990, CIRCULATION S1, V81, P161; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; WALKER RG, 1988, KIDNEY TRANSPLANTATI, P319	20	153	164	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					750	752		10.1016/0140-6736(91)91368-5	http://dx.doi.org/10.1016/0140-6736(91)91368-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672390				2022-12-28	WOS:A1991FD88400002
J	HERSH, EM; BREWTON, G; ABRAMS, D; BARTLETT, J; GALPIN, J; GILL, P; GORTER, R; GOTTLIEB, M; JONIKAS, JJ; LANDESMAN, S; LEVINE, A; MARCEL, A; PETERSEN, EA; WHITESIDE, M; ZAHRADNIK, J; NEGRON, C; BOUTITIE, F; CARAUX, J; DUPUY, JM; SALMI, LR				HERSH, EM; BREWTON, G; ABRAMS, D; BARTLETT, J; GALPIN, J; GILL, P; GORTER, R; GOTTLIEB, M; JONIKAS, JJ; LANDESMAN, S; LEVINE, A; MARCEL, A; PETERSEN, EA; WHITESIDE, M; ZAHRADNIK, J; NEGRON, C; BOUTITIE, F; CARAUX, J; DUPUY, JM; SALMI, LR			DITIOCARB SODIUM (DIETHYLDITHIOCARBAMATE) THERAPY IN PATIENTS WITH SYMPTOMATIC HIV-INFECTION AND AIDS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE-DEFICIENCY SYNDROME; CONTROLLED TRIAL; COMPLEX; GLUTATHIONE; PROTECTION; TOXICITY; CELLS	We randomized 389 symptomatic patients with human immunodeficiency virus (HIV) infection to ditiocarb sodium (400 mg/m2 orally for 24 weeks) or a placebo. Patients were well balanced according to Centers for Disease Control (CDC) group, CD4+ cell number, and duration of disease prior to entry. Ten new acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections occurred in the treated patients and 21 in the controls. Reduction of new opportunistic infections in the ditiocarb group was significant in all patients (relative risk [RR], 0.44) and in patients with AIDS (CDC groups IV-C1 and IV-D) (RR, 0.12). The size of the effect of ditiocarb was maintained when data were reanalyzed after exclusion of a patient who progressed to Pneumocystis carinii pneumonia who was not strictly CDC-defined (RR, 0.46), or when considering as new opportunistic infections three events, which were clinically active at entry, but for which the definitive diagnosis was made during study (RR, 0.49). The administration of ditiocarb did not induce any major adverse clinical or biological reactions. We conclude that, in this study, ditiocarb was safe and reduced the incidence of opportunistic infections in patients with symptomatic HIV infection.	SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110; DUKE UNIV,MED CTR,DURHAM,NC 27710; PORTON MED GRP,SHERMAN OAKS,CA; UNIV SO CALIF,HEMATOL RES CTR,LOS ANGELES,CA 90089; PASTEUR MERIEUX SERUMS & VACCINS,LYONS,FRANCE; FLORIDA KEYS MEM HOSP,KEY WEST,FL; MERIEUX INST INC,MIAMI,FL; SUNY HLTH SCI CTR,BROOKLYN,NY	San Francisco General Hospital Medical Center; Duke University; University of Southern California; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	HERSH, EM (corresponding author), UNIV ARIZONA,ARIZONA CANC CTR,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.		Salmi, Louis-Rachid/T-1982-2019					ANDERSON S, 1980, STATISTICAL METHODS; BREWTON GW, 1989, LIFE SCI, V45, P2509, DOI 10.1016/0024-3205(89)90234-8; COX DR, 1972, J R STAT SOC B, V34, P187; DENEKE SM, 1980, BIOCHEM PHARMACOL, V29, P1367, DOI 10.1016/0006-2952(80)90432-3; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GALE GR, 1982, ANN CLIN LAB SCI, V12, P345; GROOPMAN JE, 1987, SEMIN ONCOL, V14, P1; HERSH EM, IN PRESS AIDS RES HU; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN LD, 1987, JAMA-J AM MED ASSOC, V257, P1367; KROWN SE, 1987, SEMIN ONCOL, V14, P27; LANG JM, 1985, LANCET, V2, P1066; LANG JM, 1988, LANCET, V2, P702; LUTZ LM, 1973, BIOCHEM PHARMACOL, V22, P1729, DOI 10.1016/0006-2952(73)90386-9; MANSOUR H, 1986, J PHARMACOL EXP THER, V236, P476; MOSSALAI MD, 1989, 5TH INT C AIDS MONTR; PERCHELLET EM, 1987, J CELL PHYSIOL, V131, P64, DOI 10.1002/jcp.1041310111; PERCHELLET JP, 1987, CANCER RES, V47, P6302; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C; RENOUX G, 1982, IMMUNOMODULATORY DRU, P113; SUNDERMAN FW, 1967, AM J MED SCI, V254, P46; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; 1986, NEW ENGL J MED, V314, P801; [No title captured]; 1988, MMWR, V37, P286	26	89	93	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1538	1544		10.1001/jama.265.12.1538	http://dx.doi.org/10.1001/jama.265.12.1538			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1671884				2022-12-28	WOS:A1991FC60400028
J	BRAHAMS, D				BRAHAMS, D			HAIRLINE FRACTURE AND UNDIAGNOSED MENINGITIS	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					605	606		10.1016/0140-6736(91)91659-I	http://dx.doi.org/10.1016/0140-6736(91)91659-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671955				2022-12-28	WOS:A1991FA70200017
J	ARNAUDO, E; DALAKAS, M; SHANSKE, S; MORAES, CT; DIMAURO, S; SCHON, EA				ARNAUDO, E; DALAKAS, M; SHANSKE, S; MORAES, CT; DIMAURO, S; SCHON, EA			DEPLETION OF MUSCLE MITOCHONDRIAL-DNA IN AIDS PATIENTS WITH ZIDOVUDINE-INDUCED MYOPATHY	LANCET			English	Article							CELLS; DELETIONS; FRAGMENTS	Long-term zidovudine therapy in patients with human immunodeficiency virus (HIV) infection can cause a destructive mitochondrial myopathy with histological features of ragged-red fibres (RRF) and proliferation of abnormal mitochondria. In 9 zidovudine-treated patients with this myopathy we found severely reduced amounts (up to 78% reduction vs normal adult controls) of mitochondrial DNA (mtDNA) in muscle biopsy specimens by means of Southern blotting. In 2 HIV-positive patients who had not received zidovudine, muscle mtDNA content did not differ from that in the 4 controls. Depletion of mtDNA seems to be reversible, since 1 patient showed a substantial reduction in RRF and a concomitant pronounced increase in muscle mtDNA content after zidovudine therapy was discontinued. Depletion of muscle mtDNA is probably due to zidovudine-induced inhibition of mtDNA replication by DNA polymerase gamma and is not a secondary effect of HIV infection.	COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NINCDS,NEUROMUSCULAR DIS UNIT,BETHESDA,MD 20892	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Moraes, Carlos/AAT-3818-2021		NINDS NIH HHS [NS11766] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, P50NS011766] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BYARS N, 1975, BIOCHEMISTRY-US, V14, P3159, DOI 10.1021/bi00685a019; CHEN CH, 1989, J BIOL CHEM, V264, P11934; DALAKAS M, 1989, Neurology, V39, P152; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALAKAS MC, 1988, ANN NEUROL S, V23, P38; DAVIS LG, 1986, BASIC METHODS MOL BI, P47; ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; KADENBACH B, 1969, BIOCHIM BIOPHYS ACTA, V186, P399, DOI 10.1016/0005-2787(69)90021-5; PALVA TK, 1985, FEBS LETT, V192, P267, DOI 10.1016/0014-5793(85)80122-8; ROTIG A, 1989, LANCET, V1, P902; SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZIMMERMANN W, 1980, J BIOL CHEM, V255, P1847; 1990, 44 PHYS DESK REF, P799	20	438	447	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					508	510		10.1016/0140-6736(91)91294-5	http://dx.doi.org/10.1016/0140-6736(91)91294-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671889	hybrid			2022-12-28	WOS:A1991EZ87400002
J	MARCELLIN, P; MARTINOTPEIGNOUX, M; BOYER, N; POUTEAU, M; AUMONT, P; ERLINGER, S; BENHAMOU, JP				MARCELLIN, P; MARTINOTPEIGNOUX, M; BOYER, N; POUTEAU, M; AUMONT, P; ERLINGER, S; BENHAMOU, JP			2ND GENERATION (RIBA) TEST IN DIAGNOSIS OF CHRONIC HEPATITIS-C	LANCET			English	Letter									HOP BEAUJON,INSERM,U24,F-92100 CLICHY,FRANCE; ORTHO DIAGNOST SYST INC,POISSY,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	MARCELLIN, P (corresponding author), HOP BEAUJON,HEPATOL SERV,F-92100 CLICHY,FRANCE.							KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MARCELLIN P, 1990, J HEPATOL, V11, P77, DOI 10.1016/0168-8278(90)90275-V	2	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					551	552		10.1016/0140-6736(91)91335-R	http://dx.doi.org/10.1016/0140-6736(91)91335-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671910				2022-12-28	WOS:A1991EZ87400035
J	ELLENBERG, SS				ELLENBERG, SS			SURROGATE END-POINTS IN CLINICAL-TRIALS - GETTING CLOSER TO IDENTIFYING MARKERS FOR SURVIVAL IN AIDS	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ENDPOINTS				ELLENBERG, SS (corresponding author), NIAID, DIV AIDS, BIOSTAT RES BRANCH, BETHESDA, MD 20892 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; ELLENBERG SS, 1989, STAT MED, V8, P405, DOI 10.1002/sim.4780080404; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; HILLIS A, 1989, STAT MED, V8, P427, DOI 10.1002/sim.4780080406; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Weiss R., 1990, SURROGATE ENDPOINTS; WITTES J, 1989, STAT MED, V8, P415, DOI 10.1002/sim.4780080405	9	23	23	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					63	64		10.1136/bmj.302.6768.63	http://dx.doi.org/10.1136/bmj.302.6768.63			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671650	Bronze, Green Published			2022-12-28	WOS:A1991ER95100003
J	KOMIYAMA, K; MORO, I; MASTUDA, Y; MORSHED, SA; NISHIOKA, M; HAYASHI, N; SHIKATA, T				KOMIYAMA, K; MORO, I; MASTUDA, Y; MORSHED, SA; NISHIOKA, M; HAYASHI, N; SHIKATA, T			HCV IN SALIVA OF CHRONIC HEPATITIS PATIENTS HAVING DENTAL TREATMENT	LANCET			English	Letter									KAGAWA MED COLL,DEPT INTERNAL MED 3,KAGAWA,JAPAN; NIHON UNIV,SCH MED,DEPT PATHOL 1,TOKYO 101,JAPAN	Kagawa University; Nihon University	KOMIYAMA, K (corresponding author), NIHON UNIV,SCH DENT,DEPT PATHOL,1-8-13 KANDA SURUGADAI,CHIYODA KU,TOKYO 101,JAPAN.							ABE K, 1991, LANCET, V337, P248, DOI 10.1016/0140-6736(91)92222-N; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I	3	34	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					572	573		10.1016/0140-6736(91)91137-J	http://dx.doi.org/10.1016/0140-6736(91)91137-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678825				2022-12-28	WOS:A1991GD00200034
J	ZEVIANI, M; GELLERA, C; ANTOZZI, C; RIMOLDI, M; MORANDI, L; VILLANI, F; TIRANTI, V; DIDONATO, S				ZEVIANI, M; GELLERA, C; ANTOZZI, C; RIMOLDI, M; MORANDI, L; VILLANI, F; TIRANTI, V; DIDONATO, S			MATERNALLY INHERITED MYOPATHY AND CARDIOMYOPATHY - ASSOCIATION WITH MUTATION IN MITOCHONDRIAL-DNA TRANSFER RNALEU(UUR)	LANCET			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; GENE; ENCEPHALOMYOPATHIES; CARDIOMYOCYTES; EXERCISE; HEART	Different point mutations of the mitochondrial genome, which all affect the ability of mitochondria to translate their own genes and lead to partial defects of mtDNA-dependent respiratory complexes, are related to distinct clinical mitochondrial disorders. A new maternally inherited disorder, characterised by a combination of adult-onset myopathy and cardiomyopathy, with no clinical involvement of the nervous system, was found in members of a single large pedigree. A heteroplasmic new mutation was identified in the mtDNA gene specifying tRNA(Leu)(UUR). This mutation segregated specifically with the disorder, and there were significant correlations between the proportion of the mtDNA that was of the mutant form and the activities (normalised for citrate synthase activity) of the two mtDNA-dependent respiratory enzymes (complex I, r = -0.71, p < 0.005: complex IV r = - 0.77, p < 0.005) and the maximum oxygen consumption (r = -0.82, p < 0.005), a physiological index of aerobic metabolism. These findings strongly suggest that the tRNA(Leu)(UUR) mutation is the genetic cause of this disorder, and that lesions of mtDNA should be considered in the differential diagnosis of the hereditary cardiomyopathies.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	ZEVIANI, M (corresponding author), IST NEUROCHIRURG C BESTA,DIV BIOCHIM GENET,VIA CELORIA 11,I-20133 MILAN,ITALY.		Gellera, Cinzia/J-7887-2016; Antozzi, Carlo/AAB-8787-2019; Tiranti, Valeria/J-8233-2016; Di Donato, Stefano/B-9717-2012; Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021	Gellera, Cinzia/0000-0002-3582-665X; Antozzi, Carlo/0000-0001-9270-5224; Tiranti, Valeria/0000-0002-3584-7338; Zeviani, Massimo/0000-0002-9067-5508				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; Darley-Usmar V. M., 1987, MITOCHONDRIA PRACTIC; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; LOMBES A, 1989, REV NEUROL-FRANCE, V145, P671; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wasserman K., 1987, PRINCIPLES EXERCISE; ZEVIANI M, 1991, AM J HUM GENET, V48, P203	18	355	360	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					143	147		10.1016/0140-6736(91)90136-D	http://dx.doi.org/10.1016/0140-6736(91)90136-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677065				2022-12-28	WOS:A1991FX42400004
J	KHOURY, AF; KAPLAN, NM				KHOURY, AF; KAPLAN, NM			ALPHA-BLOCKER THERAPY OF HYPERTENSION - AN UNFULFILLED PROMISE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE; PRAZOSIN THERAPY; ANTIHYPERTENSIVE THERAPY; MODERATE HYPERTENSION; PROSTATIC OBSTRUCTION; INSULIN SENSITIVITY; HEART-FAILURE; SERUM-LIPIDS; DOUBLE-BLIND	For various reasons, the alpha-1-receptor blocker prazosin has been used infrequently as initial therapy for hypertension. The introduction of additional agents of this class with properties different from prazosin provides slower onset of action, which should reduce the degree of first-dose and postural hypotension and a longer duration of action, which allows for once-a-day dosage. A summary of the published data on efficacy, side effects, and special properties of this class of agents indicates that they will probably be used more extensively, particularly because of their ability to improve lipid and glucose-insulin metabolism.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AMES RP, 1989, AM J CARDIOL, V64, P203, DOI 10.1016/0002-9149(89)90458-X; AMES RP, 1989, J CLIN PHARMACOL, V29, P123, DOI 10.1002/j.1552-4604.1989.tb03299.x; ANDERTON JL, 1990, J HUM HYPERTENS, V4, P52; BATEY DM, 1989, AM J MED, V86, P74, DOI 10.1016/0002-9343(89)90136-8; BAUER JH, 1984, ARCH INTERN MED, V144, P1196, DOI 10.1001/archinte.144.6.1196; COLUCCI WS, 1982, ANN INTERN MED, V97, P67, DOI 10.7326/0003-4819-97-1-67; CORRAL JL, 1991, AM HEART J, V121, P352, DOI 10.1016/0002-8703(91)90871-E; COX DA, 1986, BRIT J CLIN PHARMACO, V21, pS83, DOI 10.1111/j.1365-2125.1986.tb02858.x; CUBEDDU LX, 1988, AM HEART J, V116, P133, DOI 10.1016/0002-8703(88)90261-X; CUBEDDU LX, 1988, AM J HYPERTENS, V1, P158, DOI 10.1093/ajh/1.2.158; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DAUER AD, 1986, AM J MED, V80, P29, DOI 10.1016/0002-9343(86)90849-1; DETER G, 1986, AM J MED S5B, V80, P62; FEHER MD, 1990, J HUM HYPERTENS, V4, P571; FRISHMAN WH, 1988, MED CLIN N AM, V72, P427, DOI 10.1016/S0025-7125(16)30777-5; Grimm R. H., 1989, HYPERTENSION S1, V13, P131; HAYDUK K, 1987, AM J CARDIOL, V59, pG95, DOI 10.1016/0002-9149(87)90166-4; HEDLUND H, 1983, J UROLOGY, V130, P275, DOI 10.1016/S0022-5347(17)51106-4; HUMPHREYS JE, 1989, J CLIN PHARM THER, V14, P263, DOI 10.1111/j.1365-2710.1989.tb00248.x; IZZO JL, 1981, CLIN PHARMACOL THER, V29, P7, DOI 10.1038/clpt.1981.2; JULIUS S, 1990, EUR J CLIN PHARMACOL, V38, pS125, DOI 10.1007/BF01409481; KAPLAN NM, 1990, CLIN HYPERTENSION; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; KOSHY MC, 1977, CIRCULATION, V55, P533, DOI 10.1161/01.CIR.55.3.533; LARDINOIS CK, 1988, ARCH INTERN MED, V148, P1280, DOI 10.1001/archinte.148.6.1280; LAROCHELLE P, 1982, HYPERTENSION, V4, P93, DOI 10.1161/01.HYP.4.1.93; LEREN TP, 1985, ACTA PHARMACOL TOX, V56, P269; LUTHER RR, 1990, J HUM HYPERTENS, V4, P151; LUTHER RR, 1989, AM HEART J, V117, P842, DOI 10.1016/0002-8703(89)90621-2; MCNAIR A, 1980, ACTA MED SCAND, V207, P413; MEREDITH PA, 1985, J CARDIOVASC PHARM, V7, P532, DOI 10.1097/00005344-198505000-00019; MICHEL MC, 1990, HYPERTENSION, V16, P107, DOI 10.1161/01.HYP.16.2.107; MROCZEK WJ, 1974, CURR THER RES CLIN E, V16, P769; MULVIHILLWILSON J, 1979, J CARDIOVASC PHARM, V1, pS1, DOI 10.1097/00005344-197900011-00001; NICHOLSON JP, 1985, AM J MED, V78, P241, DOI 10.1016/0002-9343(85)90433-4; POLLARE T, 1989, J HYPERTENS, V7, P551, DOI 10.1097/00004872-198907000-00006; POLLARE T, 1988, DIABETOLOGIA, V31, P415, DOI 10.1007/BF00271585; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RAM CVS, 1989, AM J MED, V86, P66, DOI 10.1016/0002-9343(89)90134-4; RAMSAY LE, 1987, POSTGRAD MED J, V63, P99, DOI 10.1136/pgmj.63.736.99; RUBBA P, 1989, J ENDOCRINOL INVEST, V12, P119, DOI 10.1007/BF03349937; SCHAFERS RF, 1989, NEW THERAPEUTIC STRA, P51; SCHEEN AJ, 1989, CURR THER RES CLIN E, V46, P200; SCOTT PJW, 1988, EUR J CLIN PHARMACOL, V34, P119, DOI 10.1007/BF00614546; SHEU WHH, 1990, AM J HYPERTENS, V3, P762; SHIONOIRI H, 1986, CURR THER RES CLIN E, V40, P171; SMYTH P, 1988, EUR J CLIN PHARMACOL, V34, P613, DOI 10.1007/BF00615226; STANASZEK WF, 1983, DRUGS, V25, P339, DOI 10.2165/00003495-198325040-00002; STOKES GS, 1974, BRIT MED J, V2, P298, DOI 10.1136/bmj.2.5914.298; STOKES GS, 1977, BRIT MED J, V1, P1507, DOI 10.1136/bmj.1.6075.1507; TALSETH T, 1990, J HUM HYPERTENS, V4, P39; THOMPSON PD, 1989, AM J MED, V86, P104, DOI 10.1016/0002-9343(89)90143-5; TOMADA F, 1989, AM J HYPERTENS, V2, P834; TORVIK D, 1986, BRIT J CLIN PHARMACO, V21, pS69, DOI 10.1111/j.1365-2125.1986.tb02856.x; WALKER RG, 1981, MED J AUSTRALIA, V2, P146, DOI 10.5694/j.1326-5377.1981.tb100840.x; WEBB DJ, 1987, J HUM HYPERTENS, V1, P195; WEBER MA, 1987, AM J MED, V82, P50, DOI 10.1016/0002-9343(87)90144-6; YASUMOTO K, 1990, J HUM HYPERTENS, V4, P13; 1980, N Z MED J, V92, P341; 1988, ARCH INTERN MED, V148, P1023; 1989, LANCET, V1, P1055	61	45	46	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					394	398		10.1001/jama.266.3.394	http://dx.doi.org/10.1001/jama.266.3.394			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	1676077				2022-12-28	WOS:A1991FV96000030
J	BAUM, M; HOUGHTON, J; RILEY, D				BAUM, M; HOUGHTON, J; RILEY, D			TAMOXIFEN TO PREVENT BREAST-CANCER	LANCET			English	Letter											BAUM, M (corresponding author), KINGS COLL,SCH MED & DENT,RAYNE INST,CANC RES CAMPAIGN,CTR CLIN TRIALS,LONDON SE5 9NU,ENGLAND.							1991, LANCET, V337, P1414	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					114	114		10.1016/0140-6736(91)90104-W	http://dx.doi.org/10.1016/0140-6736(91)90104-W			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676439				2022-12-28	WOS:A1991FW16100025
J	LIGHT, DW				LIGHT, DW			EMBEDDED INEFFICIENCIES IN HEALTH-CARE	LANCET			English	Editorial Material											LIGHT, DW (corresponding author), UNIV MED & DENT NEW JERSEY,DIV BEHAV & SOCIAL MED,CAMDEN,NJ 08103, USA.								0	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1991	338	8759					102	104		10.1016/0140-6736(91)90088-7	http://dx.doi.org/10.1016/0140-6736(91)90088-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW161	1676434				2022-12-28	WOS:A1991FW16100016
J	MCLACHLAN, DRC; DALTON, AJ; KRUCK, TPA; BELL, MY; SMITH, WL; KALOW, W; ANDREWS, DF				MCLACHLAN, DRC; DALTON, AJ; KRUCK, TPA; BELL, MY; SMITH, WL; KALOW, W; ANDREWS, DF			INTRAMUSCULAR DESFERRIOXAMINE IN PATIENTS WITH ALZHEIMERS-DISEASE	LANCET			English	Article							ALUMINUM; IRON; DEFEROXAMINE; DIALYSIS; REMOVAL	Although epidemiological and biochemical evidence suggests that aluminium may be associated with Alzheimer's disease (AD), there is no convincing proof of a causal link for aluminium in disease progression. We have completed a two year, single-blind study to investigate whether the progression of dementia could be slowed by the trivalent ion chelator, desferrioxamine. 48 patients with probable AD were randomly assigned to receive desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months), oral placebo (lecithin), or no treatment. No significant differences in baseline measures of intelligence, memory, or speech ability existed between groups. Activities of daily living were assessed and videorecorded at 6, 12, 18, and 24 month intervals. There were no differences in the rate of deterioration of patients receiving either placebo or no treatment. Desferrioxamine treatment led to significant reduction in the rate of decline of daily living skills as assessed by both group means (p = 0.03) and variances (p < 0.04). The mean rate of decline was twice as rapid for the no-treatment group. Appetite (n = 4) and weight (n = 1) loss were the only reported side-effects. We conclude that sustained administration of desferrioxamine may slow the clinical progression of the dementia associated with AD.	SURREY PLACE CTR,BEHAV RES PROGRAM,TORONTO,ONTARIO,CANADA; QUEEN ST MENTAL HLTH CTR,DEPT PSYCHOL,TORONTO,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT STAT,TORONTO M5S 1A8,ONTARIO,CANADA; NEW YORK STATE INST BASIC RES DEV DISABILITIES,STATEN ISL,NY 10314	University of Toronto; University of Toronto; University of Toronto; Institute for Basic Research in Developmental Disabilities	MCLACHLAN, DRC (corresponding author), UNIV TORONTO,CTR RES NEURODEGENERAT DIS,DEPT PHYSIOL,ROOM 226,TORONTO M5S 1A8,ONTARIO,CANADA.							BLAKE DR, 1983, ANN RHEUM DIS, V42, P89, DOI 10.1136/ard.42.1.89; CHANG TMS, 1983, LANCET, V2, P1051; CRAPPER DR, 1980, ACTA NEUROPATHOL, V50, P19, DOI 10.1007/BF00688530; EDWARDSON JA, 1989, ANN MED, V21, P95, DOI 10.3109/07853898909149192; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Hirschelmann R, 1986, Free Radic Res Commun, V2, P125, DOI 10.3109/10715768609088063; KAZDIN AE, 1984, BEHAV MODIF, P71; KRUCK TPA, 1988, J CHROMATOGR-BIOMED, V433, P207, DOI 10.1016/S0378-4347(00)80599-X; KRUCK TPA, 1990, CLIN PHARMACOL THER, V48, P439, DOI 10.1038/clpt.1990.173; KRUCK TPA, 1985, J CHROMATOGR, V34, P123; MARTYN CN, 1989, LANCET, V1, P59; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORGAN A, 1986, IRCS MED SCI-BIOCHEM, V14, P399; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; PENGLOAN J, 1987, NEPHRON, V46, P211, DOI 10.1159/000184345; PIGA A, 1988, EUR J HAEMATOL, V40, P380; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; SEDGWICK AD, 1984, EUR J RHEUMATOL INFL, V7, P87; SENATOR GB, 1968, ANN RHEUM DIS, V27, P38; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler DLB, 1945, WECHSLER MEMORY SCAL	21	609	623	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1304	1308		10.1016/0140-6736(91)92978-B	http://dx.doi.org/10.1016/0140-6736(91)92978-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674295				2022-12-28	WOS:A1991FP08400002
J	SHIELD, MJ				SHIELD, MJ			NSAIDS, MISOPROSTOL, AND GASTROINTESTINAL-BLEEDING	LANCET			English	Letter											SHIELD, MJ (corresponding author), GD SEARLE & CO LTD,DEPT CLIN & MED RES,HIGH WYCOMBE HP12 4HL,BUCKS,ENGLAND.							BANNWARTH, 1991, LANCET, V337, P973; LEVI S, 1990, LANCET, V336, P840, DOI 10.1016/0140-6736(90)92341-E; ROBINSON GC, 1991, GUT S, pT108; SHIELD MJ, 1990, BR J RHEUMATOL S15, V29	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1221	1222		10.1016/0140-6736(91)92890-E	http://dx.doi.org/10.1016/0140-6736(91)92890-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673756				2022-12-28	WOS:A1991FM26100035
J	VENTO, S; GAROFANO, T; DIPERRI, G; DOLCI, L; CONCIA, E; BASSETTI, D				VENTO, S; GAROFANO, T; DIPERRI, G; DOLCI, L; CONCIA, E; BASSETTI, D			IDENTIFICATION OF HEPATITIS-A VIRUS AS A TRIGGER FOR AUTOIMMUNE CHRONIC HEPATITIS TYPE-1 IN SUSCEPTIBLE INDIVIDUALS	LANCET			English	Article							CHRONIC ACTIVE HEPATITIS; ASIALOGLYCOPROTEIN RECEPTOR PROTEIN; AUTOANTIBODIES; LYMPHOCYTES; AUTOREACTIVITY; ANTIBODIES; ANTIGENS; MEASLES; LECTIN	To identify factors contributing to the pathogenesis of autoimmune chronic active hepatitis (CAH) healthy relatives of 13 patients with the disorder were followed prospectively for 4 years. 58 relatives were monitored for various serological markers and for T-lymphocyte migration inhibitory activity every 2 months. 3 cases of subclinical acute hepatitis A occurred during the study. In 2 of the 3 subjects, before hepatitis A virus (HAV) infection, there was a defect in suppressor-inducer T lymphocytes specifically controlling immune responses to the asialoglycoprotein receptor, an antigen expressed on the hepatocyte surface. In these 2 subjects, specific helper T cells and antibodies to the asialoglycoprotein receptor persisted and increased after acute hepatitis A, and autoimmune CAH type 1 developed within 5 months. Thus, in susceptible individuals HAV is a trigger for autoimmune CAH.	BORGO TRENTO CITY HOSP,DEPT MICROBIOL,VERONA,ITALY; UNIV VERONA,BORGO TRENTO HOSP,DEPT INFECT DIS,I-37100 VERONA,ITALY	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	VENTO, S (corresponding author), A PUGLIESE HOSP,INFECT DIS UNIT,I-88100 CATANZARO,ITALY.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062				ALLISON AC, 1971, LANCET, V2, P135; ESTEBAN JI, 1989, LANCET, V2, P294; FENZI G, 1978, J ENDOCRINOL INVEST, V1, P17, DOI 10.1007/BF03346766; HARFORD J, 1981, P NATL ACAD SCI-BIOL, V78, P1557, DOI 10.1073/pnas.78.3.1557; HARFORD J, 1984, GLYCOCONJUGATES, V4, P27; JOHNSON AH, 1980, 8TH INT HIST TEST WO, P285; LONGO A, 1980, 8TH INT HIST TEST WO, P283; MACKAY IR, 1962, Q J MED, V31, P485; MCFARLANE BM, 1985, J IMMUNOL METHODS, V77, P219, DOI 10.1016/0022-1759(85)90034-1; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1984, CLIN EXP IMMUNOL, V55, P347; MIELI VERGANI G., 1979, Clinical and Experimental Immunology, V38, P16; MIELIVERGANI G, 1989, LANCET, V2, P688; OBRIEN CJ, 1986, LANCET, V1, P350; ROBERTSON DAF, 1987, LANCET, V2, P9; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TERASAKI PI, 1974, DHEW NIH75545 PUBL, P67; TREICHEL U, 1990, HEPATOLOGY, V11, P606, DOI 10.1002/hep.1840110413; TREICHEL U, 1989, HEPATOLOGY, V10, P637; VALLBRACHT A, 1986, HEPATOLOGY, V6, P1308, DOI 10.1002/hep.1840060614; VENTO S, 1986, GASTROENTEROLOGY, V91, P810, DOI 10.1016/0016-5085(86)90680-3; VENTO S, 1987, LANCET, V1, P886; Vento S, 1990, Prog Liver Dis, V9, P335; VENTO S, 1988, J CLIN LAB IMMUNOL, V25, P1; VENTO S, 1984, LANCET, V1, P1200; VENTO S, 1988, J AUTOIMMUN, V1, P299, DOI 10.1016/0896-8411(88)90034-0	26	199	204	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1183	1187		10.1016/0140-6736(91)92858-Y	http://dx.doi.org/10.1016/0140-6736(91)92858-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673738				2022-12-28	WOS:A1991FM26100003
J	NOSTEN, F; TERKUILE, F; CHONGSUPHAJAISIDDHI, T; LUXEMBURGER, C; WEBSTER, HK; EDSTEIN, M; PHAIPUN, L; THEW, KL; WHITE, NJ				NOSTEN, F; TERKUILE, F; CHONGSUPHAJAISIDDHI, T; LUXEMBURGER, C; WEBSTER, HK; EDSTEIN, M; PHAIPUN, L; THEW, KL; WHITE, NJ			MEFLOQUINE-RESISTANT FALCIPARUM-MALARIA ON THE THAI-BURMESE BORDER	LANCET			English	Article							PLASMODIUM-FALCIPARUM; CLINICAL-TRIAL; PHARMACOKINETICS; HALOFANTRINE; CHILDREN	Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1.5 mg/kg, respectively, has been used in Thailand for the past 6 years. In 1985-86, MSP cured over 98% of 5192 patients with falciparum malaria on the Thai-Burmese border. 4 years later we studied the efficacy of MSP in 395 patients at the same location. The cure rate at 28 days was 70.8% (95% Cl 67-77.2%). The proportion of early treatment failures (in whom parasitaemia did not clear) had risen from 0.27 to 3.7% (p < 0.0001). Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p < 0.001). Patients with early treatment failure were retreated with 25 mg/kg mefloquine, but 27% had a further recrudescence of infection within 28 days. The mean (95% Cl) serum mefloquine concentration at the time of first recrudescence was 638 (546-730) ng/ml, a value previously associated with successful treatment. Mefloquine concentrations were no lower in those with recrudescent infections than in age-matched successfully treated patients, suggesting that pharmacokinetic factors were not responsible for the high treatment-failure rate. Plasmodium falciparum has developed resistance to mefloquine rapidly, despite the addition of sulphadoxine and pyrimethamine and strict control of drug administration. The MSP combination should now be abandoned.	MAHIDOL UNIV,FAC TROP MED,420-6 RAJVITHI RD,BANGKOK 10400,THAILAND; UNIV AMSTERDAM,ACAD MED CTR,INFECT DIS & TROP MED UNIT,1105 AZ AMSTERDAM,NETHERLANDS; MED SAN FRONTIERES,PARIS,FRANCE; ARMED FORCES RES INST MED SCI,USA MED COMPONENT,BANGKOK,THAILAND; SHOKLO MALARIA RES UNIT,MAE SOD,THAILAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	Mahidol University; University of Amsterdam; Academic Medical Center Amsterdam; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Mahidol University; University of Oxford			White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012; Kuile, Feiko ter/ABD-6681-2020; Nosten, Francois/AAC-5509-2019	White, Nick/0000-0002-1897-1978; Kuile, Feiko ter/0000-0003-3663-5617; Nosten, Francois/0000-0002-7951-0745	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHONGSUPHAJAISIDDHI T, 1987, B WORLD HEALTH ORGAN, V65, P223; EDSTEIN MD, IN PRESS THER DRUG M; HARINASUTA T, 1983, B WORLD HEALTH ORGAN, V61, P299; KARBWANG J, 1990, CLIN PHARMACOKINET, V19, P264, DOI 10.2165/00003088-199019040-00002; KARBWANG J, 1988, EUR J CLIN PHARMACOL, V35, P677, DOI 10.1007/BF00637607; MAURICE J, 1987, TROPICAL DISEASE RES, P23; MERKLI R, 1980, ANN TROP MED PARASIT, V74, P1; NOSTEN F, 1987, B WORLD HEALTH ORGAN, V65, P891; NOSTEN F, IN PRESS BT J CLIN P; SLUTSKER LM, 1990, B WORLD HEALTH ORGAN, V68, P53; SUEBSAENG L, 1986, B WORLD HEALTH ORGAN, V64, P759; WATKINS WM, 1988, LANCET, V2, P247; WEBSTER HK, 1985, AM J TROP MED HYG, V34, P228, DOI 10.4269/ajtmh.1985.34.228; WEBSTER HK, 1982, LANCET, V2, P1335; WHITE NJ, 1988, EUR J CLIN PHARMACOL, V34, P1, DOI 10.1007/BF01061409; WHITE NJ, 1987, LANCET, V1, P680; WIRIMA J, 1988, LANCET, V2, P250	17	216	220	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1140	1143		10.1016/0140-6736(91)92798-7	http://dx.doi.org/10.1016/0140-6736(91)92798-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674024				2022-12-28	WOS:A1991FL12400015
J	MAURER, J; JANSSEN, JWG; THIEL, E; VANDENDEREN, J; LUDWIG, WD; AYDEMIR, U; HEINZE, B; FONATSCH, C; HARBOTT, J; REITER, A; RIEHM, H; HOELZER, D; BARTRAM, CR				MAURER, J; JANSSEN, JWG; THIEL, E; VANDENDEREN, J; LUDWIG, WD; AYDEMIR, U; HEINZE, B; FONATSCH, C; HARBOTT, J; REITER, A; RIEHM, H; HOELZER, D; BARTRAM, CR			DETECTION OF CHIMERIC BCR-ABL GENES IN ACUTE LYMPHOBLASTIC-LEUKEMIA BY THE POLYMERASE CHAIN-REACTION	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ABNORMALITIES	Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL) is most common in adults and is associated with poor prognosis. Since karyotypic identification of the Philadelphia translocation has been hampered by technical difficulties, we used the polymerase chain reaction (PCR) to look for the BCR-ABL rearrangement in stored samples from a selected group of 314 German ALL patients. BCR-ABL transcripts were found in 77 of 179 adults and were restricted to those with B-precursor leukaemias. 55% of adult common ALL patients had BCR-ABL and its presence correlated with poor overall survival and remission duration. Of 135 children with common ALL, 5 (6%) primary cases and 8 (17%) with recurrent neoplasias were PCR-positive. We recommend prospective evaluation of BCR-ABL analysis with PCR in patients with a B-precursor leukaemia.	UNIV ULM,DEPT PAEDIAT 2,MOLEC BIOL SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY; FREE UNIV BERLIN,DEPT INTERNAL MED HAEMATOL ONCOL,W-1000 BERLIN 33,GERMANY; UNIV ULM,INST OCCUPAT & SOCIAL MED,W-7900 ULM,GERMANY; ERASMUS UNIV,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS; BIOMETR CTR THERAPEUT STUDIES,MUNICH,GERMANY; UNIV LUBECK,SCH MED,INST HUMAN GENET,LUBECK,GERMANY; UNIV GIESSEN,DEPT PAEDIAT,W-6300 GIESSEN,GERMANY; HANOVER MED SCH,DEPT PAEDIAT,HANNOVER,GERMANY; UNIV FRANKFURT,DEPT HAEMATOL INTERNAL MED,W-6000 FRANKFURT 1,GERMANY	Ulm University; Free University of Berlin; Ulm University; Erasmus University Rotterdam; University of Lubeck; Justus Liebig University Giessen; Hannover Medical School; Goethe University Frankfurt								BERGER R, 1990, CANCER GENET CYTOGEN, V44, P143, DOI 10.1016/0165-4608(90)90041-8; BLOOMFIELD CD, 1986, BLOOD, V67, P415; CRIST W, 1990, BLOOD, V76, P489; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1986, BLOOD, V68, P1369; GALE RP, 1988, LEUKEMIA, V2, P321; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1988, LEUKEMIA, V2, P628; HOELZER D, 1988, BLOOD, V71, P123, DOI 10.1182/blood.V71.1.123.123; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEE MS, 1989, BLOOD, V73, P2165; LUDWIG WD, 1988, BLOOD, V71, P1518; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; NOWELL PC, 1960, SCIENCE, V132, P1497; RIEHM H, 1987, KLIN PADIATR, V199, P151, DOI 10.1055/s-2008-1026781; RIEHM H, 1990, ACUTE LEUKEMIAS, V2, P439; SECKERWALKER LM, 1988, BLOOD, V72, P784; THIEL E, 1989, BLOOD, V73, P1247; VANDENDEREN J, 1990, BLOOD, V76, P136; WILLIAMS DL, 1986, BLOOD, V68, P205; WILLIAMS DL, 1985, NEW ENGL J MED, V313, P640	23	247	248	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1055	1058		10.1016/0140-6736(91)91706-Z	http://dx.doi.org/10.1016/0140-6736(91)91706-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673492				2022-12-28	WOS:A1991FK20400003
J	DOE, CQ; CHULAGRAFF, Q; WRIGHT, DM; SCOTT, MP				DOE, CQ; CHULAGRAFF, Q; WRIGHT, DM; SCOTT, MP			THE PROSPERO GENE SPECIFIES CELL FATES IN THE DROSOPHILA CENTRAL-NERVOUS-SYSTEM	CELL			English	Article							ACHAETE-SCUTE COMPLEX; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; GLIAL PATHWAYS; AXON PATHWAYS; GROWTH CONES; PROTEIN; NEUROGENESIS; EXPRESSION; LOCALIZATION	The molecular mechanisms used to generate neuronal diversity are largely unknown. To identify genes controlling cell fate in the Drosophila central nervous system, we screened for mutations that alter expression of homeobox genes in the developing central nervous system (indicating changes in cell fates). We also screened "enhancer trap" lines to identify genes expressed in neuronal stem cells (neuroblasts). The prospero gene was discovered in both screens. Prospero is expressed in a subset of neuroblasts, sensory neuron precursors, and identified glial precursors. It is not expressed in neurons. Neuroblasts lacking prospero function generate abnormal cell lineages, producing incorrectly specified progeny that differentiate into neurons showing axon pathfinding defects. Prospero is therefore a novel type of gene expressed in neuroblasts and known to specify neuronal fate.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	DOE, CQ (corresponding author), UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801, USA.				PHS HHS [27056, 18163] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1991, IN PRESS ANN REV NEU, V14; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Doe C Q, 1990, Semin Cell Biol, V1, P211; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOE CQ, 1991, IN PRESS DETERMINANT; ENGELS WR, 1986, FOCUS, V8, P6; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUFF R, 1989, DEV BIOL, V134, P146, DOI 10.1016/0012-1606(89)90085-7; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1989, J NEUROSCI, V9, P2421; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROBERTSON HM, 1988, GENETICS, V118, P461; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; Sambrook J, 1989, MOL CLONING LABORATO; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5	49	393	398	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					451	464		10.1016/0092-8674(91)90463-9	http://dx.doi.org/10.1016/0092-8674(91)90463-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1673362				2022-12-28	WOS:A1991FK18200012
J	MORRIS, AJ; MADHOK, R; STURROCK, RD; CAPELL, HA; MACKENZIE, JF				MORRIS, AJ; MADHOK, R; STURROCK, RD; CAPELL, HA; MACKENZIE, JF			ENTEROSCOPIC DIAGNOSIS OF SMALL-BOWEL ULCERATION IN PATIENTS RECEIVING NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Note								15 patients with rheumatoid arthritis who were receiving non-steroidal anti-inflammatory drugs (NSAIDs) and who had chronic occult gastrointestinal bleeding underwent extended small bowel examination with a Sonde enteroscope. 7 patients (47%) were found to have jejunal or ileal ulceration. Small bowel enteroscopy may be a valuable technique for the investigation of undiagnosed gastrointestinal bleeding.	GLASGOW ROYAL INFIRM,GASTROINTESTINAL INVEST UNIT,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,CTR RHEUMAT DIS,GLASGOW G4 0SF,SCOTLAND	University of Glasgow; University of Glasgow								Bjarnason I., 1988, RECENT ADV GASTROENT, P23; KENT TH, 1969, AM J PATHOL, V54, P237; LEWIS BS, 1988, GASTROENTEROLOGY, V94, P1117, DOI 10.1016/0016-5085(88)90001-7; MADHOK R, 1986, Q J MED, V255, P53; UPADHYAY R, 1990, ANN RHEUM DIS, V49, P359, DOI 10.1136/ard.49.6.359	5	131	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					520	520		10.1016/0140-6736(91)91300-J	http://dx.doi.org/10.1016/0140-6736(91)91300-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671893				2022-12-28	WOS:A1991EZ87400007
J	SCHIFFERLI, J; LESKI, M; FAVRE, H; IMBACH, P; NYDEGGER, U; DAVIES, K				SCHIFFERLI, J; LESKI, M; FAVRE, H; IMBACH, P; NYDEGGER, U; DAVIES, K			HIGH-DOSE INTRAVENOUS IGG TREATMENT AND RENAL-FUNCTION	LANCET			English	Note							LUPUS	In an open trial of high dose intravenous IgG (IVIG) treatment in nephrotic patients with glomerulonephritis, the first six patients so far studied showed a transient rise in plasma creatinine. This increase was not associated with any symptoms and the urinary deposit remained unchanged. Two other patients with pre-existing renal impairment but without nephrotic syndrome had a transient and reversible rise in plasma creatinine immediately after IVIG. These observations suggest that high-dose IVIG infusion can produce short-lived disturbances in renal function in patients with kidney diseases.	SWISS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,CH-3000 BERN 22,SWITZERLAND; INSELSPITAL BERN,HAEMATOL LAB,CH-3010 BERN,SWITZERLAND; HAMMERSMITH HOSP,DEPT MED,LONDON W12 0HS,ENGLAND	University of Bern; University Hospital of Bern; Imperial College London	SCHIFFERLI, J (corresponding author), HOP CANTONAL GENEVA,DEPT MED,DIV NEPHROL,CH-1211 GENEVA 4,SWITZERLAND.							JORDAN SC, 1989, CLIN IMMUNOL IMMUNOP, V53, pS164, DOI 10.1016/0090-1229(89)90082-2; Kassirer JP, 1988, DIS KIDNEY, P393; KIDA H, 1987, 10 INT C NEPHR LOND, P70; LIN CY, 1989, NEPHRON, V53, P303, DOI 10.1159/000185772; PETRI M, 1988, KIDNEY INT, V34, P832, DOI 10.1038/ki.1988.257; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; STIEHM ER, 1987, ANN INTERN MED, V107, P367, DOI 10.7326/0003-4819-107-2-367; SUZUKI Y, 1984, CLIN EXP IMMUNOL, V58, P663	8	101	101	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					457	458		10.1016/0140-6736(91)93395-P	http://dx.doi.org/10.1016/0140-6736(91)93395-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671473				2022-12-28	WOS:A1991EY88700006
J	BRAHAMS, D				BRAHAMS, D			CONSENT FOR TREATMENT OF MINORS IN WARDSHIP	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1991	338	8766					564	565		10.1016/0140-6736(91)91119-F	http://dx.doi.org/10.1016/0140-6736(91)91119-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD002	1678814				2022-12-28	WOS:A1991GD00200018
J	AUERBACH, PS				AUERBACH, PS			MARINE ENVENOMATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POISON CENTER; JELLYFISH; VERAPAMIL; PHYSALIA; STINGS; WAR		VANDERBILT UNIV,MED CTR,SCH MED,DEPT SURG,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University								AUERBACH PS, 1987, TOXICON, V25, P1350, DOI 10.1016/0041-0101(87)90014-6; AUERBACH PS, 1987, ANN EMERG MED, V16, P643, DOI 10.1016/S0196-0644(87)80061-6; BARSS P, 1984, MED J AUSTRALIA, V141, P854, DOI 10.5694/j.1326-5377.1984.tb132970.x; BURNETT JW, 1987, TOXICON, V25, P581, DOI 10.1016/0041-0101(87)90105-X; BURNETT JW, 1989, TOXICON, V27, P823, DOI 10.1016/0041-0101(89)90050-0; BURNETT JW, 1990, TOXICON, V28, P242, DOI 10.1016/0041-0101(90)90420-C; BURNETT JW, 1983, MED J AUSTRALIA, V2, P192, DOI 10.5694/j.1326-5377.1983.tb122404.x; CROSS TB, 1976, MED J AUSTRALIA, V2, P947, DOI 10.5694/j.1326-5377.1976.tb115533.x; EXTON DR, 1989, MED J AUSTRALIA, V151, P625, DOI 10.5694/j.1326-5377.1989.tb139632.x; FENNER PJ, 1989, MED J AUSTRALIA, V151, P621, DOI 10.5694/j.1326-5377.1989.tb139631.x; FULGHUM DD, 1986, SOUTHERN MED J, V79, P1434, DOI 10.1097/00007611-198611000-00027; GOETZ CG, 1982, CLIN NEUROPHARMACOL, V5, P231, DOI 10.1097/00002826-198205020-00005; GRAINGER CR, 1980, T ROY SOC TROP MED H, V74, P408, DOI 10.1016/0035-9203(80)90115-7; GRAINGER CR, 1985, T ROY SOC TROP MED H, V79, P443, DOI 10.1016/0035-9203(85)90055-0; JANDA J M, 1988, Clinical Microbiology Reviews, V1, P245; KIZER KW, 1985, JAMA-J AM MED ASSOC, V253, P807, DOI 10.1001/jama.253.6.807; LOTZ MJ, 1983, ANN CLIN LAB SCI, V13, P45; MARETIC Z, 1982, TOXICON, V20, P345, DOI 10.1016/0041-0101(82)90241-0; SIMS JK, 1979, HAWAII MED J, V38, P263; STEIN MR, 1989, ANN EMERG MED, V18, P312, DOI 10.1016/S0196-0644(89)80421-4; TOGIAS AG, 1985, J ALLERGY CLIN IMMUN, V75, P672, DOI 10.1016/0091-6749(85)90092-2; TRESTRAIL JH, 1989, VET HUM TOXICOL, V31, P173; TU AT, 1987, ANN EMERG MED, V16, P1023, DOI 10.1016/S0196-0644(87)80752-7; WRIGHT AC, 1981, INFECT IMMUN, V34, P503, DOI 10.1128/IAI.34.2.503-507.1981	24	94	99	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					486	493						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1677161				2022-12-28	WOS:A1991GA76300007
J	MAKI, DG; RINGER, M; ALVARADO, CJ				MAKI, DG; RINGER, M; ALVARADO, CJ			PROSPECTIVE RANDOMIZED TRIAL OF POVIDONE-IODINE, ALCOHOL, AND CHLORHEXIDINE FOR PREVENTION OF INFECTION ASSOCIATED WITH CENTRAL VENOUS AND ARTERIAL CATHETERS	LANCET			English	Article							NOSOCOMIAL INFECTIONS; SKIN; ANTISEPTICS	More than 90% of all intravascular device-related septicaemias are due to central venous or arterial catheters. To assess the efficacy of cutaneous antisepsis to prevent catheter-associated infection, we prospectively studied three antiseptics for disinfection of patients' central venous and arterial catheter insertion sites in a surgical intensive care unit. 668 catheters were randomised to 10% povidone-iodine, 70% alcohol, or 2% aqueous chlorhexidine disinfection of the site before insertion and for site care every other day thereafter. Chlorhexidine was associated with the lowest incidence of local catheter-related infection (2.3 per 100 catheters vs 7.1 and 9.3 for alcohol and povidone-iodine, respectively, p = 0 02) and catheter-related bacteraemia (0.5 vs 2.3 and 2.6). Of the 14 infusion-related bacteraemias (4 due to contaminated infusate or catheter hub, 10 due to infected catheters), 1 was in the chlorhexidine group and 13 were in the other two groups (odds ratio 0.16, p = 0.04). We conclude that use of 2% chlorhexidine, rather than 10% povidone-iodine or 70% alcohol, for cutaneous disinfection before insertion of an intravascular device and for post-insertion site care can substantially reduce the incidence of device-related infection.	UNIV WISCONSIN, DEPT MED, INFECT DIS SECT, MADISON, WI 53706 USA; UNIV WISCONSIN HOSP & CLIN, DEPT INFECT CONTROL, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MAKI, DG (corresponding author), UNIV WISCONSIN HOSP & CLIN, CTR TRAUMA & LIFE SUPPORT, DEPT MED, H4-574, MADISON, WI 53792 USA.							ALY R, 1976, APPL ENVIRON MICROB, V31, P931, DOI 10.1128/AEM.31.6.931-935.1976; AYLIFFE GAJ, 1988, J HOSP INFECT, V11, P226, DOI 10.1016/0195-6701(88)90101-6; BABB JR, 1977, BURNS, V3, P65, DOI 10.1016/0305-4179(77)90011-0; BASTABLE JRG, 1977, BRIT J UROL, V49, P689, DOI 10.1111/j.1464-410X.1977.tb04554.x; Case DE, 1976, SPECIAL PROBLEMS CHE, P367; CHAMPAGNE S, 1984, INFECT CONTROL, V25, P489; CHRISTENSEN KK, 1985, EUR J OBSTET GYN R B, V19, P231, DOI 10.1016/0028-2243(85)90034-6; FABBRI L, 1982, DIALYSIS TRANSPLANT, V11, P483; FRENEY J, 1988, ANTIMICROB AGENTS CH, V32, P873, DOI 10.1128/AAC.32.6.873; GOLDBLUM SE, 1983, AM J KIDNEY DIS, V2, P548, DOI 10.1016/S0272-6386(83)80098-5; HALEY RW, 1981, AM J MED, V70, P947, DOI 10.1016/0002-9343(81)90561-1; KAHAN A, 1983, J INFECTION, V7, P256, DOI 10.1016/S0163-4453(83)97196-7; LILLY HA, 1979, J HYG-CAMBRIDGE, V82, P89, DOI 10.1017/S002217240002550X; LOE H, 1970, Journal of Periodontal Research, V5, P79, DOI 10.1111/j.1600-0765.1970.tb00696.x; LOWBURY EJL, 1974, BRIT J SURG, V61, P19, DOI 10.1002/bjs.1800610106; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1989, INFECTIONS ASS INDWE, P161; MAKI DG, 1982, 22ND INT C ANT AG CH, P699; MAKI DG, 1980, CURRENT CHEMOTHERAPY, P1089; MARRIE TJ, 1981, APPL ENVIRON MICROB, V42, P1093, DOI 10.1128/AEM.42.6.1093-1102.1981; MASSANARI RM, 1984, AM J INFECT CONTROL, V12, P247; NYSTROM B, 1983, J HOSP INFECT, V4, P338, DOI 10.1016/0195-6701(83)90004-X; OBRIEN MS, 1984, DEVIANT BEHAV, V5, P141, DOI 10.1080/01639625.1984.9967638; OKANO M, 1989, ARCH DERMATOL, V125, P50, DOI 10.1001/archderm.125.1.50; SMALLMAN L, 1980, BRIT J SURG, V67, P861, DOI 10.1002/bjs.1800671208; SMERDELY P, 1989, LANCET, V2, P661; SNYDMAN DR, 1982, LANCET, V2, P1385; STANLEY G, 1989, 29TH INT C ANT AG CH, P662; STICKLER DJ, 1983, BRIT J CLIN PRACT, V25, P23	30	552	571	1	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1991	338	8763					339	343		10.1016/0140-6736(91)90479-9	http://dx.doi.org/10.1016/0140-6736(91)90479-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA607	1677698				2022-12-28	WOS:A1991GA60700004
J	PUTKONEN, P; THORSTENSSON, R; GHAVAMZADEH, L; ALBERT, J; HILD, K; BIBERFELD, G; NORRBY, E				PUTKONEN, P; THORSTENSSON, R; GHAVAMZADEH, L; ALBERT, J; HILD, K; BIBERFELD, G; NORRBY, E			PREVENTION OF HIV-2 AND SIVSM INFECTION BY PASSIVE-IMMUNIZATION IN CYNOMOLGUS MONKEYS	NATURE			English	Article							MACACA-FASCICULARIS; IMMUNODEFICIENCY; VIRUS; GLYCOPROTEIN; PROTECTION; CHIMPANZEES; MACAQUES; LEUKEMIA; GP71	INFECTION of macaques with simian immunodeficiency virus (SIV) 1,2 and human immunodeficiency virus type 2 (HIV-2) 3,4 are useful models for studies of immunotherapy and vaccination against HIV as well as for testing of antiviral drugs. Vaccine research showing protective immunity in immunized monkeys 4-10 has indicated that it will be possible to develop a vaccine for prevention of human HIV infection, although many hurdles remain. The design of an HIV vaccine would be helped if the basis of the protective immunity could be elucidated. Passive immune prophylaxis offers a means to determine the relative role of antibodies in protection against infection. We have studied whether a transfer of antibodies can prevent HIV-2 and SIV(sm) (SIV of sooty mangabey origin) infection in cynomolgus monkeys. Sera with high antibody titres were collected, heat-treated and injected into naive animals 6 h before challenge with 10-100 monkey-infectious doses of live homologous virus. All control animals treated with normal monkey serum (n = 6) or no serum (n = 39) became infected by the challenge virus, whereas five out of seven animals pretreated with antibody-containing serum at a dose of 9 ml kg-1 resisted infection. Thus passively transferred antibodies can protect against a low-dose lentivirus challenge in a nonhuman primate.	NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet	PUTKONEN, P (corresponding author), NATL BACTERIOL LAB,DEPT IMMUNOL,S-10521 STOCKHOLM,SWEDEN.							ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; ALBERT J, 1990, AIDS, V4, P291, DOI 10.1097/00002030-199004000-00002; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BIBERFELD G, 1988, AIDS, V2, P195; BJORLING E, IN PRESS P NATN ACAD; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; DENORONHA F, 1978, VIROLOGY, V85, P617, DOI 10.1016/0042-6822(78)90467-1; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; HUNSMANN G, 1975, VIROLOGY, V66, P327, DOI 10.1016/0042-6822(75)90203-2; KATAOKA R, 1990, BLOOD, V76, P1657; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NORRBY E, 1991, AIDS RES HUM RETROV, V7, P279, DOI 10.1089/aid.1991.7.279; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; PUTKONEN P, 1991, AIDS RES HUM RETROV, V7, P271, DOI 10.1089/aid.1991.7.271; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P359; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; THORSTENSSON R, 1991, J ACQ IMMUN DEF SYND, V4, P374	20	203	210	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					436	438		10.1038/352436a0	http://dx.doi.org/10.1038/352436a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1677743				2022-12-28	WOS:A1991FZ34600067
J	OTTO, G; THIES, J; KRAUS, T; MANNER, M; HERFARTH, C; HOFMANN, WJ; SCHLAG, H; MEUER, S				OTTO, G; THIES, J; KRAUS, T; MANNER, M; HERFARTH, C; HOFMANN, WJ; SCHLAG, H; MEUER, S			MONOCLONAL ANTI-CD25 FOR ACUTE REJECTION AFTER LIVER-TRANSPLANTATION	LANCET			English	Letter							RABBIT ANTITHYMOCYTE GLOBULIN; INTERLEUKIN-2 RECEPTOR; IL-2 RECEPTOR; ANTIBODY; PROPHYLAXIS; 33B3.1; TRIAL		UNIV HEIDELBERG,INST PATHOL,W-6900 HEIDELBERG,GERMANY; BIOTEST PHARMA GMBH,DREIEICH,GERMANY; GERMAN CANC RES CTR,DEPT IMMUNOL,W-6900 HEIDELBERG 1,GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	OTTO, G (corresponding author), UNIV HEIDELBERG,CHIRURG KLIN,W-6900 HEIDELBERG,GERMANY.							CANTAROVICH D, 1989, TRANSPLANT P, V21, P1769; CARPENTER CB, 1989, AM J KIDNEY DIS, V14, P54; HERVE P, 1988, LANCET, V2, P1072; KEMNITZ J, 1989, HUM PATHOL, V20, P132, DOI 10.1016/0046-8177(89)90177-9; OTTO G, 1990, LANCET, V335, P1596, DOI 10.1016/0140-6736(90)91430-I; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702	6	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					195	195		10.1016/0140-6736(91)90192-R	http://dx.doi.org/10.1016/0140-6736(91)90192-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677101				2022-12-28	WOS:A1991FX42400058
J	SOWDEN, JM; BERTHJONES, J; ROSS, JS; MOTLEY, RJ; MARKS, R; FINLAY, AY; SALEK, MS; GRAHAMBROWN, RAC; ALLEN, BR; CAMP, RDR				SOWDEN, JM; BERTHJONES, J; ROSS, JS; MOTLEY, RJ; MARKS, R; FINLAY, AY; SALEK, MS; GRAHAMBROWN, RAC; ALLEN, BR; CAMP, RDR			DOUBLE-BLIND, CONTROLLED, CROSSOVER STUDY OF CYCLOSPORINE IN ADULTS WITH SEVERE REFRACTORY ATOPIC-DERMATITIS	LANCET			English	Article							EFFICACY	A few patients remain severely affected by atopic dermatitis into adult life despite treatment with systemic steroids, azathioprine, and photochemotherapy. 33 patients took part in a double- blind, placebo-controlled, crossover study to assess the efficacy and safety of cyclosporin (5 mg/kg per day) in adults with severe refractory atopic dermatitis. Treatments were given for eight weeks each with one group (n = 16) receiving placebo followed by cyclosporin and another (n = 17) receiving cyclosporin and then placebo. Disease activity, extent of disease, sleep and itch, topical steroid use, and adverse events were assessed every two weeks. Both extent and activity of dermatitis were significantly improved (p < 0.001 ) as were subjective measures of disease. 20 patients receiving cyclosporin reported adverse events compared with 8 taking placebo, although no patient required withdrawal from the study. Cyclosporin therapy led to an increase in the mean serum urea, creatinine, and bilirubin concentrations, although only the rise in bilirubin was significant (p = 0.001 ). Our results confirm that cyclosporin is a safe and effective short-term treatment for severe, refractory atopic dermatitis.	LEICESTER ROYAL INFIRM,DEPT DERMATOL,LEICESTER LE2 7LX,ENGLAND; ST THOMAS HOSP,INST DERMATOL,LONDON SE1 7EH,ENGLAND; UNIV WALES COLL MED,DEPT DERMATOL,CARDIFF CF4 4XN,S GLAM,WALES	University of Leicester; Guy's & St Thomas' NHS Foundation Trust; Cardiff University	SOWDEN, JM (corresponding author), UNIV NOTTINGHAM HOSP,DEPT DERMATOL,NOTTINGHAM NG7 2UH,ENGLAND.							CLARK RAF, 1989, ARCH DERMATOL, V125, P413, DOI 10.1001/archderm.125.3.413; FRADIN MS, 1990, BRIT J DERMATOL, V122, P21, DOI 10.1111/j.1365-2133.1990.tb02878.x; GOLD MH, 1989, INT J DERMATOL, V28, P481, DOI 10.1111/j.1365-4362.1989.tb02521.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; LOGAN RA, 1988, J ROY SOC MED, V81, P417, DOI 10.1177/014107688808100720; MOTLEY RJ, 1989, CLIN EXP DERMATOL, V14, P243, DOI 10.1111/j.1365-2230.1989.tb00943.x; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; ROSS JS, 1990, BRIT J DERMATOL, V122, P41, DOI 10.1111/j.1365-2133.1990.tb02881.x; TAYLOR RS, 1989, J AM ACAD DERMATOL, V21, P580; THOMSON AW, 1991, BRIT MED J, V302, P4, DOI 10.1136/bmj.302.6767.4; VANJOOST T, 1987, ARCH DERMATOL, V123, P166, DOI 10.1001/archderm.123.2.166	11	318	321	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1991	338	8760					137	140		10.1016/0140-6736(91)90134-B	http://dx.doi.org/10.1016/0140-6736(91)90134-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX424	1677063				2022-12-28	WOS:A1991FX42400002
J	ADES, AE; PARKER, S; BERRY, T; HOLLAND, FJ; DAVISON, CF; CUBITT, D; HJELM, M; WILCOX, AH; HUDSON, CN; BRIGGS, M; TEDDER, RS; PECKHAM, CS				ADES, AE; PARKER, S; BERRY, T; HOLLAND, FJ; DAVISON, CF; CUBITT, D; HJELM, M; WILCOX, AH; HUDSON, CN; BRIGGS, M; TEDDER, RS; PECKHAM, CS			PREVALENCE OF MATERNAL HIV-1 INFECTION IN THAMES REGIONS - RESULTS FROM ANONYMOUS UNLINKED NEONATAL TESTING	LANCET			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NEWBORNS; WOMEN; SEROPREVALENCE; SURVEILLANCE	To monitor the spread of human immunodeficiency virus (HIV) in the heterosexual population, residues of blood samples collected routinely on absorbent paper for neonatal screening (Guthrie cards) in NE, NW, and SW Thames Regions in England have been tested for antibodies to HIV-1 since June, 1988. 323 369 dried blood spots were analysed to end March, 1991. Prevalence of anti-HIV-1 in newborn babies has remained stable in outer London and non-metropolitan districts whereas prevalence in inner London has increased from 1 in 2000 in the 12 months beginning June, 1988, to 1 in 500 in the first 3 months of 1991. Either exponential or linear growth in the numbers of new seropositives could account for the results. That obstetricians were aware of maternal HIV infection in only 20% of infected pregnancies, indicates the extent to which HIV infection goes unrecognised in the heterosexual community.	UNIV COLL & MIDDLESEX SCH MED,SCH PATHOL,DEPT MED MICROBIOL,VIROL SECT,LONDON,ENGLAND; ST HELIER HOSP,DEPT CHEM PATHOL,CARSHALTON SM5 1AA,SURREY,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT OBSTET & GYNAECOL,LONDON EC1A 7BE,ENGLAND; INST CHILD HLTH,DEPT VIROL,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,DEPT CLIN BIOCHEM,LONDON WC1N 1EH,ENGLAND; HOSP SICK CHILDREN,LONDON WC1N 3JH,ENGLAND	University of London; University College London; St Helier Hospital; University of London; Queen Mary University London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	ADES, AE (corresponding author), INST CHILD HLTH,DIV PUBL HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							[Anonymous], 1990, MMWR, V39; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BERRY TJ, 1990, BRIT MED J, V301, P1274, DOI 10.1136/bmj.301.6763.1274; DAVISON CF, 1989, LANCET, V2, P1442; DOWNS AM, 1990, AIDS, V4, P1117, DOI 10.1097/00002030-199011000-00010; DUNN D, 1991, LANCET, V337, P1218; HALL SM, 1990, ARCH DIS CHILD, V65, P807, DOI 10.1136/adc.65.7.807; HANKINS CA, 1990, CAN MED ASSOC J, V143, P885; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; IPPOLITO G, 1990, JAMA-J AM MED ASSOC, V263, P36, DOI 10.1001/jama.1990.03440010034017; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; MCLAWS ML, 1990, MED J AUSTRALIA, V153, P383, DOI 10.5694/j.1326-5377.1990.tb125494.x; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; PECKHAM CS, 1990, LANCET, V335, P516, DOI 10.1016/0140-6736(90)90746-R; SHERR L, 1990, AIDS Care, V2, P235, DOI 10.1080/09540129008257736; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; 1990, ACQUIRED IMMUNE DEFI; 1991, LANCET, V337, P253; 1989, NATIONAL HIV SEROPRE	20	83	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1991	337	8757					1562	1565		10.1016/0140-6736(91)93260-G	http://dx.doi.org/10.1016/0140-6736(91)93260-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU551	1675707				2022-12-28	WOS:A1991FU55100003
J	ROEP, BO; KALLAN, AA; HAZENBOS, WLW; BRUINING, GJ; BAILYES, EM; ARDEN, SD; HUTTON, JC; DEVRIES, RRP				ROEP, BO; KALLAN, AA; HAZENBOS, WLW; BRUINING, GJ; BAILYES, EM; ARDEN, SD; HUTTON, JC; DEVRIES, RRP			T-CELL REACTIVITY TO 38-KD INSULIN-SECRETORY-GRANULE PROTEIN IN PATIENTS WITH RECENT-ONSET TYPE-1 DIABETES	LANCET			English	Article							BETA-CELLS; MELLITUS; STIMULATION; EXPRESSION; ANTIBODIES; PANCREAS; CLONES; RATS	Type 1 diabetes seems to be an autoimmune disease in which T cells have a substantial role. A possible target antigen was suggested by the proliferation of CD4 T cells from a newly diagnosed patient in response to a 38 kD polypeptide of the insulin-secretory-granule membrane. To see whether this reactivity is widespread at disease onset, we have generated T-cell lines in vitro from peripheral blood mononuclear cells of nineteen children of caucasoid origin with newly diagnosed type 1 diabetes and sixteen healthy controls matched for age and HLA antigens. The procedure involved two cycles of incubation with a rat beta-cell tumour subcellular fraction enriched in secretory granules and plasma membrane components, followed by a proliferation assay. Fourteen (74% [95% confidence interval 49-91%]) of the patients' cell lines showed a positive proliferative response on subsequent exposure to the islet-cell antigen preparation compared with only two (13% [2-38%]) of the controls (p = 3 x 10(-4); difference 61% [44-87%]). Two subjects who had high titres of islet-cell autoantibodies (ICA) without clinical diabetes produced responsive T-cell lines. Reactivity towards the 38 kD fraction of insulin-secretory-granule membranes was found only in patients (eight of ten responders tested; 95% Cl 44-98%) and one ICA-positive non-diabetic subject. Detection of an ongoing autoimmune T-cell response might be useful diagnostically and could lead to prevention of diabetes through specific immunotherapy.	ERASMUS UNIV,ACAD HOSP,DEPT PAEDIAT,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,SOPHIA CHILDRENS HOSP,3000 DR ROTTERDAM,NETHERLANDS; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QQ,ENGLAND	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	ROEP, BO (corresponding author), UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL & BLOOD BANK,BLDG 1,E3-Q,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Roep, Bart/AAD-7609-2021		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BOTTAZZO GF, 1985, NEW ENGL J MED, V313, P353, DOI 10.1056/NEJM198508083130604; BRUINING GJ, 1989, LANCET, V1, P1100; BUSCHARD K, 1990, LANCET, V335, P134, DOI 10.1016/0140-6736(90)90004-O; DEBERARDINIS P, 1988, LANCET, V2, P823; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; GUEST PC, 1989, BIOCHEM J, V264, P503, DOI 10.1042/bj2640503; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; JANEWAY CA, 1989, NATURE, V341, P482, DOI 10.1038/341482a0; KAMPE O, 1989, DIABETES, V38, P1326, DOI 10.2337/diabetes.38.10.1326; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; SIBLEY RK, 1985, LAB INVEST, V53, P132; VANVLIET E, 1989, EUR J IMMUNOL, V19, P213	16	130	134	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1991	337	8755					1439	1441		10.1016/0140-6736(91)93127-U	http://dx.doi.org/10.1016/0140-6736(91)93127-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR060	1675318				2022-12-28	WOS:A1991FR06000004
J	DETRUCHIS, P; SALMON, D; MATHERON, S; JELASKO, P; ROZENBAUM, W; LEPORT, C				DETRUCHIS, P; SALMON, D; MATHERON, S; JELASKO, P; ROZENBAUM, W; LEPORT, C			HALF-DOSE ZIDOVUDINE	LANCET			English	Letter							AIDS-RELATED COMPLEX		HOP BICHAT CLAUDE BERNARD,DEPT TROP DIS,F-75018 PARIS,FRANCE; INSERM,U13,F-75018 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	DETRUCHIS, P (corresponding author), HOP BICHAT CLAUDE BERNARD,DEPT INFECT DIS,F-75018 PARIS,FRANCE.		Matheron, Sophie/D-7420-2017	Matheron, Sophie/0000-0001-7879-6553; Rozenbaum, Willy/0000-0003-1975-3566				DOURNON E, 1988, LANCET, V2, P1297; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1109	1109		10.1016/0140-6736(91)91766-N	http://dx.doi.org/10.1016/0140-6736(91)91766-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673539				2022-12-28	WOS:A1991FK20400069
J	LAMMIE, PJ; HITCH, WL; ALLEN, EMW; HIGHTOWER, W; EBERHARD, ML				LAMMIE, PJ; HITCH, WL; ALLEN, EMW; HIGHTOWER, W; EBERHARD, ML			MATERNAL FILARIAL INFECTION AS RISK FACTOR FOR INFECTION IN CHILDREN	LANCET			English	Note							BRUGIA-PAHANGI; ANTIGENS; RESPONSES; PARASITE; JIRDS	Familial clustering of filarial infection was investigated through random house-to-house surveys of 643 individuals in Leogane, Haiti, an area with endemic Bancroftian filariasis. Children of infected mothers were 2.4 to 2.9 times more likely to be infected than were those of amicrofilaraemic mothers. Filarial-specific cellular responsiveness in amicrofilaraemic children born to infected mothers was lower than that in amicrofilaraemic children born to amicrofilaraemic mothers. No effect of paternal infection status was seen. The findings show that maternal infection is a risk factor for filarial infection in children and is associated with altered parasite-specific immune reactivity.			LAMMIE, PJ (corresponding author), CTR DIS CONTROL, CTR INFECT DIS,DIV PARASIT DIS,PARASIT DIS BRANCH, F13, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.				PHS HHS [YO2-00005-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		FRANKENBURG S, 1988, J IMMUNOL METHODS, V112, P177, DOI 10.1016/0022-1759(88)90355-9; KLEI TR, 1986, T ROY SOC TROP MED H, V80, P214, DOI 10.1016/0035-9203(86)90014-3; LAMMIE PJ, 1988, AM J TROP MED HYG, V38, P125, DOI 10.4269/ajtmh.1988.38.125; LAMMIE PJ, 1983, J IMMUNOL, V130, P1386; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; Ottesen E A, 1984, Trans R Soc Trop Med Hyg, V78 Suppl, P9, DOI 10.1016/0035-9203(84)90309-2; OTTESEN EA, 1981, ACTA TROP, V38, P205; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; RACCURT CP, 1988, T ROY SOC TROP MED H, V82, P721, DOI 10.1016/0035-9203(88)90214-3; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862	10	94	94	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1991	337	8748					1005	1006		10.1016/0140-6736(91)92661-K	http://dx.doi.org/10.1016/0140-6736(91)92661-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673168				2022-12-28	WOS:A1991FJ13500005
J	KROON, C; DEBOER, A; KROON, JM; SCHOENMAKER, HC; VANDERMEER, FJM; COHEN, AF				KROON, C; DEBOER, A; KROON, JM; SCHOENMAKER, HC; VANDERMEER, FJM; COHEN, AF			INFLUENCE OF SKINFOLD THICKNESS ON HEPARIN ABSORPTION	LANCET			English	Note							PHARMACOKINETICS	The absorption of high and low molecular fractions of heparin from the subcutaneous compartment was evaluated in eight healthy males. They were given an intravenous infusion of 4000 U calcium heparin in 4 hours and on another occasion a subcutaneous injection of 12 500 U calcium heparin (washout period of 1 week). Anticoagulation was monitored by anti-Xa, antithrombin activity, and activated partial thromboplastin time. To evaluate factors that might influence absorption, body weight, body fat, and abdominal skinfold thickness were recorded. There was a pronounced inter-individual variability in absorption but the absorption of the two fractions of heparin was similar. The highly variable absorption was related to the abdominal skinfold thickness, and this could have implications for therapeutic and prophylactic heparin regimens.	UNIV HOSP LEIDEN,CTR HUMAN DRUG RES,2300 RC LEIDEN,NETHERLANDS; STATE UNIV LEIDEN HOSP,DEPT HAEMATOL,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)			Cohen, Adam/G-3756-2010	Schoemaker, Rik/0000-0002-7538-3005				[Anonymous], 1990, Lancet, V336, P65; BARA L, 1985, THROMB RES, V39, P631, DOI 10.1016/0049-3848(85)90244-0; BARROWCLIFFE TW, 1979, BRIT J HAEMATOL, V41, P573, DOI 10.1111/j.1365-2141.1979.tb05894.x; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; HARENBERG J, 1986, THROMB RES, V44, P549, DOI 10.1016/0049-3848(86)90333-6; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; STIEKEMA JCJ, 1989, BRIT J CLIN PHARMACO, V27, P39, DOI 10.1111/j.1365-2125.1989.tb05333.x; THOW J, 1990, BRIT MED J, V301, P3, DOI 10.1136/bmj.301.6742.3; VITOUX JF, 1988, THROMB HAEMOSTASIS, V59, P120	9	28	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					945	946		10.1016/0140-6736(91)91573-D	http://dx.doi.org/10.1016/0140-6736(91)91573-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678033				2022-12-28	WOS:A1991FH13100006
J	RUCKNAGEL, DL; KALINYAK, KA; GELFAND, MJ				RUCKNAGEL, DL; KALINYAK, KA; GELFAND, MJ			RIB INFARCTS AND ACUTE CHEST SYNDROME IN SICKLE-CELL DISEASES	LANCET			English	Article							CHILDREN; ANEMIA	In the absence of evidence for pneumonia or pulmonary embolus, primary pulmonary infarction has been assumed to be the cause of the syndrome of chest pain, fever, and pulmonary infiltrate on chest X-ray that commonly complicates sickle cell anaemia. To find out whether the syndrome might be due to rib infarction, 99mTc-diphosphonate bone scans were done. In the eleven episodes thus investigated (10 patients) the scans showed segmental areas of increased radionuclide uptake in ribs, indicative of bone infarction. A possible sequence of events is that the rib infarcts are primary and cause bone pain, followed by soft tissue reaction, pleuritis, and splinting. The resultant hypoventilation leads to atelectasis and subsequent development of the radiographic changes of the acute chest syndrome. Prevention of hypoventilation and treatment of bone pain are important therapeutic goals.	CHILDRENS HOSP MED CTR,DIV RADIOL,CINCINNATI,OH 45229; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48104; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48104; UNIV CINCINNATI,DEPT RADIOL,RADIOISOTOPE LAB,CINCINNATI,OH 45221	Cincinnati Children's Hospital Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Cincinnati	RUCKNAGEL, DL (corresponding author), CHILDRENS HOSP MED CTR,CTR COMPREHENS SICKLE CELL,ELLAND & BETHESDA AVES,CINCINNATI,OH 45229, USA.				NHLBI NIH HHS [HL-16008, HL-15996] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015996, P60HL016008] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1971, AM REV RESPIR DIS, V104, P159; BARRETTCONNOR E, 1973, JAMA-J AM MED ASSOC, V24, P997; BROMBERG PA, 1974, ARCH INTERN MED, V133, P652, DOI 10.1001/archinte.1974.00320160146013; BROMBERG PA, 1967, AM REV RESPIR DIS, V96, P400; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1979, ARCH INTERN MED, V139, P67, DOI 10.1001/archinte.139.1.67; COLE TB, 1986, AM J DIS CHILD, V140, P1255, DOI 10.1001/archpedi.1986.02140260057025; Diggs LMAH., 1973, SICKLE CELL DIS DIAG; GELFAND MJ, 1978, J NUCL MED, V19, P698; MILNER PF, 1982, BLOOD, V60, P1410; OPPENHEI.EH, 1971, AM REV RESPIR DIS, V103, P858; Palmer J, 1983, BLOOD, V62, p59a; PONCZ M, 1985, J PEDIATR-US, V107, P861, DOI 10.1016/S0022-3476(85)80176-1; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; RUCKNAGEL DL, 1988, BLOOD, V72, pA71; Sain A, 1978, Clin Nucl Med, V3, P85, DOI 10.1097/00003072-197803000-00003; SMITH EW, 1954, B JOHNS HOPKINS HOSP, V94, P289; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; Steinberg B, 1930, ARCH PATHOL, V9, P876; THOMAS AN, 1982, BRIT MED J, V285, P633, DOI 10.1136/bmj.285.6342.633	20	64	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					831	833		10.1016/0140-6736(91)92525-7	http://dx.doi.org/10.1016/0140-6736(91)92525-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672922	Green Submitted			2022-12-28	WOS:A1991FF22800013
J	LIGHT, DW				LIGHT, DW			PERESTROIKA FOR BRITAIN NHS	LANCET			English	Editorial Material											LIGHT, DW (corresponding author), UNIV MED & DENT NEW JERSEY,DIV BEHAV & SOCIAL MED,CAMDEN,NJ 08103, USA.							LIGHT DW, 1990, HLTH SERVICE J  1025, P1604; LIGHT DW, 1990, HLTH SERVICE J  1018, P1552	2	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					778	779		10.1016/0140-6736(91)91385-8	http://dx.doi.org/10.1016/0140-6736(91)91385-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672402				2022-12-28	WOS:A1991FD88400016
J	HIBBS, ML; XU, H; STACKER, SA; SPRINGER, TA				HIBBS, ML; XU, H; STACKER, SA; SPRINGER, TA			REGULATION OF ADHESION TO ICAM-1 BY THE CYTOPLASMIC DOMAIN OF LFA-1 INTEGRIN BETA-SUBUNIT	SCIENCE			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; CLONING; CD2; HOMOLOGY; FAMILY; CHAIN	Interactions between cytotoxic lymphocytes and their targets require the T cell antigen receptor (TCR) and the integrin lymphocyte function-associated molecule-1 (LFA-1, CD11a/CD18). LFA-1 is not constitutively avid for its counterreceptors, intercellular adhesion molecules (ICAMs)-1 and -2. Cross-linking of the TCR transiently converts LFA-1 to a high avidity state and thus provides a mechanism for regulating cellular adhesion and de-adhesion in an antigen-specific manner. Truncation of the cytoplasmic domain of the beta, but not the alpha, subunit of LFA-1 eliminated binding to ICAM-1 and sensitivity to phorbol esters. Thus, LFA-1 binding to ICAM-1 was found to be regulated by the cytoplasmic domain of the beta-subunit of LFA-1.	HARVARD UNIV, SCH MED, CTR BLOOD RES, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School			Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273	NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HIBBS ML, UNPUB; KAUFMANN Y, UNPUB; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WILSON RW, 1989, NUCLEIC ACIDS RES, V17, P5397, DOI 10.1093/nar/17.13.5397	25	255	256	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1611	1613		10.1126/science.1672776	http://dx.doi.org/10.1126/science.1672776			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1672776				2022-12-28	WOS:A1991FD89000038
J	VISCO, G; BOUMIS, E; NOTO, P; COMANDINI, UV				VISCO, G; BOUMIS, E; NOTO, P; COMANDINI, UV			PREVENTION OF SIDE-EFFECTS OF INTERFERON	LANCET			English	Letter											VISCO, G (corresponding author), L SPALLANZANI HOSP INFECT DIS,LIVER UNIT,I-00149 ROME,ITALY.							ABDI EA, 1988, EUR J CANCER CLIN ON, V24, P723, DOI 10.1016/0277-5379(88)90305-7; DIANZANI F, 1990, IL SISTEMA INTERFERO, P54; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; FOSSA SD, 1990, CANCER, V65, P2451, DOI 10.1002/1097-0142(19900601)65:11<2451::AID-CNCR2820651108>3.0.CO;2-3; WON SJ, 1988, AM J PHYSIOL, V254, pR499, DOI 10.1152/ajpregu.1988.254.3.R499	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					741	741		10.1016/0140-6736(91)90333-K	http://dx.doi.org/10.1016/0140-6736(91)90333-K			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672212				2022-12-28	WOS:A1991FD36700060
J	BROWN, PH; TEELUCKSINGH, S; MATUSIEWICZ, SP; GREENING, AP; CROMPTON, GK; EDWARDS, CRW				BROWN, PH; TEELUCKSINGH, S; MATUSIEWICZ, SP; GREENING, AP; CROMPTON, GK; EDWARDS, CRW			CUTANEOUS VASOCONSTRICTOR RESPONSE TO GLUCOCORTICOIDS IN ASTHMA	LANCET			English	Article							BECLOMETHASONE DIPROPIONATE; TOPICAL STEROIDS; RESISTANCE; POTENCIES; ASSAY; SKIN	The aim of the study was to find out whether asthma patients whose airways obstruction is sensitive (CS) or resistant (CR) to corticosteroid treatment also differ in their cutaneous vasoconstrictor response to a potent topical glucocorticoid. Corticosteroid resistance was defined by failure of forced expiratory volume in 1 s (FEV1) and peak expiratory flow rate to improve by at least 15% after a 2-week trial of corticosteroids (prednisolone 20 mg daily for 1 week, then 40 mg daily for 1 week) despite more than 15% improvement with inhaled beta agonists. Beclomethasone dipropionate in concentrations of 3-mu-g/ml, 10-mu-g/ml, 30-mu-g/ml, and 100-mu-g/ml was applied to forearm skin; the site was occluded under plastic and the degree of blanching assessed after 18 h. CS asthmatic subjects (n = 31), asthma patients with mild airways obstruction (n = 26), asthma patients taking long-term prednisolone (n = 13), and healthy volunteers showed similar vasoconstrictor responses. In CR asthmatic subjects (n = 15), the response (expressed in terms of either blanching intensity or the proportion of patients showing a positive response) was significantly lower than that in the CS group at concentrations of 3-mu-g/ml (p < 0.01), 10-mu-g/ml (p < 0.01), and 30-mu-g/ml (p < 0.05), but not at 100-mu-g/ml. This resistance to glucocorticoids in the skin, together with reported evidence of glucocorticoid resistance in peripheral blood leucocytes, suggests a general defect in the ability of tissues to respond to glucocorticoids in CR asthma.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	BROWN, PH (corresponding author), NO GEN HOSP,DEPT MED,RESP UNIT,FERRY RD,EDINBURGH EH5 2DQ,MIDLOTHIAN,SCOTLAND.							BARRY BW, 1978, J CLIN PHARMACY, V3, P43, DOI 10.1111/j.1365-2710.1978.tb00102.x; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; BURDICK KH, 1974, ARCH DERMATOL, V110, P238, DOI 10.1001/archderm.110.2.238; BUSSE WW, 1990, CLIN EXP ALLERGY, V20, P125, DOI 10.1111/j.1365-2222.1990.tb02655.x; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CORNELL RC, 1985, ARCH DERMATOL, V121, P63, DOI 10.1001/archderm.121.1.63; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; GAILLARD RC, 1985, J CLIN ENDOCR METAB, V61, P1009, DOI 10.1210/jcem-61-6-1009; GIBSON JR, 1986, BRIT J DERMATOL, V114, P638, DOI 10.1111/j.1365-2133.1986.tb04077.x; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; HARRIS DM, 1975, POSTGRAD MED J, V51, P20; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; KAY AB, 1981, CLIN EXP IMMUNOL, V44, P576; MARKS R, 1986, ARCH DERMATOL, V122, P881, DOI 10.1001/archderm.122.8.881; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P608, DOI 10.1001/archderm.1962.01590110044005; PEERS SH, 1990, AM REV RESPIR DIS, V141, pS18; PLACE VA, 1970, ARCH DERMATOL, V101, P305; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; POZNANSKY MC, 1984, CLIN SCI, V67, P639, DOI 10.1042/cs0670639; RASCHER W, 1980, EUR J PHARMACOL, V68, P267, DOI 10.1016/0014-2999(80)90524-5; SHAH VP, 1989, ARCH DERMATOL, V125, P1558, DOI 10.1001/archderm.125.11.1558; WILKINSON J R, 1990, American Review of Respiratory Disease, V141, pA876; WILKINSON JRW, 1990, CLIN EXP ALLERGY, V20, P189, DOI 10.1111/j.1365-2222.1990.tb02666.x; WILKINSON JRW, 1989, J CLIN INVEST, V84, P1930, DOI 10.1172/JCI114381	24	98	100	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					576	580		10.1016/0140-6736(91)91639-C	http://dx.doi.org/10.1016/0140-6736(91)91639-C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671942				2022-12-28	WOS:A1991FA70200003
